PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HECHT, SS; CARMELLA, SG; MURPHY, SE; AKERKAR, S; BRUNNEMANN, KD; HOFFMANN, D				HECHT, SS; CARMELLA, SG; MURPHY, SE; AKERKAR, S; BRUNNEMANN, KD; HOFFMANN, D			A TOBACCO-SPECIFIC LUNG CARCINOGEN IN THE URINE OF MEN EXPOSED TO CIGARETTE-SMOKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							N-NITROSAMINES; NICOTINE; CANCER	Background. Environmental tobacco smoke has been classified by the Environmental Protection Agency as a carcinogen causally associated with lung cancer in adults, but there have been no reports of lung carcinogens or their metabolites in the body fluids or tissues of nonsmokers exposed to environmental tobacco smoke. Methods. Five male nonsmokers were exposed to sidestream cigarette smoke generated by machine smoking of reference cigarettes tor 180 minutes on each of two days, six months apart. Sidestream smoke is the smoke that originates from the smoldering end of a cigarette between puffs. Twenty-four-hour urine samples were collected before and after exposure. The urine samples were analyzed for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronide, which are metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a powerful lung carcinogen in rodents. NNAL is also a lung carcinogen in rodents. Results. The urinary excretion of the metabolites increased after exposure to sidestream smoke in all the men. The mean (+/-SD) amount of NNAL and NNAL glucuronide was significantly higher after exposure than at base line (33.9+/-20.0 vs. 8.4+/-11.2 ng per 24 hours [127+/-74 vs. 31+/-41 pmol per day], P<0.001) and was correlated with urinary cotinine excretion (r = 0.89, P<0.001). The nicotine concentrations in the air to which the men were exposed were comparable to those in a heavily smoke-polluted bar. Conclusions. Nonsmokers exposed to sidestream cigarette smoke take up and metabolize a lung carcinogen, which provides experimental support for the proposal that environmental tobacco smoke can cause lung cancer.			HECHT, SS (corresponding author), AMER HLTH FDN,VALHALLA,NY 10595, USA.			Hecht, Stephen/0000-0001-7228-1356	PHS HHS [29580] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRUNNEMANN KD, 1992, CARCINOGENESIS, V13, P2415, DOI 10.1093/carcin/13.12.2415; BRUNNEMANN KD, 1990, OCT P CORESTA S KALL, P100; BRUNNEMANN KD, 1993, IARC SCI PUBL, V109, P275; CARMELLA SG, 1993, CANCER RES, V53, P721; CASTONGUAY A, 1983, CANCER RES, V43, P1223; EATOUGH DJ, 1989, ENVIRON INT, V15, P19, DOI 10.1016/0160-4120(89)90005-6; FOILES PG, 1991, CHEM RES TOXICOL, V4, P364, DOI 10.1021/tx00021a017; FONTHAM ETH, 1991, CANCER EPIDEM BIOMAR, V1, P35; GUERIN MR, 1992, CHEM ENV TOBACCO SMO, P229; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HAMMOND SK, 1993, J NATL CANCER I, V85, P474, DOI 10.1093/jnci/85.6.474; HECHT SS, 1993, CARCINOGENESIS, V14, P229, DOI 10.1093/carcin/14.2.229; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; HECHT SS, 1989, CANCER SURV, V8, P273; HECHT SS, 1991, ORIGINS OF HUMAN CANCER, P745; HOFFMANN D, 1985, CANCER RES, V45, P935; HOFFMANN D, 1990, HDB EXPT PHARM, V94, P63; MUSTONEN R, 1993, CARCINOGENESIS, V14, P151, DOI 10.1093/carcin/14.1.151; RIVENSON A, 1988, CANCER RES, V48, P6912; THOMPSON CV, 1989, ENVIRON SCI TECHNOL, V23, P429, DOI 10.1021/es00181a007; 1992, RESPIRATORY HLTH EFF, P1; 1992, RESPIRATORY HLTH EFF, P3	22	172	177	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1543	1546		10.1056/NEJM199311183292105	http://dx.doi.org/10.1056/NEJM199311183292105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8413477	Bronze			2022-12-28	WOS:A1993MG18800005
J	JAYES, RL; ZIMMERMAN, JE; WAGNER, DP; DRAPER, EA; KNAUS, WA				JAYES, RL; ZIMMERMAN, JE; WAGNER, DP; DRAPER, EA; KNAUS, WA			DO-NOT-RESUSCITATE ORDERS IN INTENSIVE-CARE UNITS - CURRENT PRACTICES AND RECENT CHANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIOPULMONARY RESUSCITATION; ADVANCE DIRECTIVES; LIFE SUPPORT; SYSTEM; DNR; PREDICTION; MORTALITY; OUTCOMES; SEVERITY; FAILURE	Objectives.-To describe the characteristics of patients with do-not-resuscitate (DNR) orders and the frequency and timing of these orders in a representative sample of intensive care units (ICUs) and to compare practices from 1980 to 1990. Design.-Prospective inception cohort. Setting.-A total of 42 ICUs in 40 US hospitals with 200 or more beds; 26 randomly selected hospitals and 14 large, tertiary care hospitals that volunteered to be studied. Participants.-A consecutive sample of 17 440 ICU admissions from 1988 to 1990. Measurements.-Patient demographic characteristics, comorbid conditions, disease, and physiological abnormalities. Main Outcome Measures.-Frequency and timing of DN R orders; ICU resource use before and after DNR orders; and patients' hospital and ICU discharge status. Results.-Physicians wrote DNR orders for 1577 ICU admissions (9%) (hospital range, 1.5% to 22%). Patients with ICU DNR orders were older, more functionally impaired, had more comorbid illness, a higher severity of illness, and required the usp of more ICU resources compared with patients without DNR orders. Compared with data from a similar survey from 1979 to 1982, ICU DNR orders were more frequent in 1988 to 1990 (9% vs 5.4%; P<.001) and preceded 60% of all in-unit deaths compared with only 39% in 1979 to 1982 (P<.001). Do-not-resuscitate orders were written sooner (for 3.6% vs 2.0% of patients on day 1 in the ICU) and patients with DNR orders remained in the ICU longer in 1988 to 1990 (2.8 vs 1.4 days) than in 1979 to 1982, and had lower ICU and hospital mortality rates (64% vs 74%, P<.001; and 85% vs 94%, P<.001). Conclusions.-Over the last decade physicians and patients' families set limits earlier and more frequently in cases likely to have poor outcomes. We attribute this change to a greater dialogue about setting limits to care and a greater knowledge of treatment outcomes among physicians and families. These changes in practice preceded implementation of the Patient Self-determination Act, designed to ensure patient autonomy for decisions about life-sustaining therapy.	GEORGE WASHINGTON UNIV, MED CTR, ICU RES UNIT, 2300 K ST NW, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT ANESTHESIOL, WASHINGTON, DC 20037 USA; APACHE MED SYST INC, WASHINGTON, DC USA	George Washington University; George Washington University; George Washington University			Knaus, William/AAX-2138-2020		AHRQ HHS [HSO 5787] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 1974, JAMA-J AM MED ASSOC, V227, P864; [Anonymous], 1991, ANN INTERN MED, V115, P478; AREEN J, 1987, JAMA-J AM MED ASSOC, V258, P229, DOI 10.1001/jama.258.2.229; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; CHANG RWS, 1989, LANCET, V2, P143; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DENARDO SJ, 1989, CRIT CARE MED, V17, P4, DOI 10.1097/00003246-198901000-00002; DONNELLY WJ, 1987, ARCH INTERN MED, V147, P37, DOI 10.1001/archinte.147.1.37; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; FOWLER MDM, 1989, HEART LUNG, V18, P424; FRIED C, 1976, NEW ENGL J MED, V295, P390, DOI 10.1056/NEJM197608122950711; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HOLTZMAN J, 1992, CLIN RES, V40, pA584; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1981, JAMA-J AM MED ASSOC, V246, P2711, DOI 10.1001/jama.246.23.2711; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LO B, 1983, ARCH INTERN MED, V143, P1561, DOI 10.1001/archinte.143.8.1561; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; MUPRHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pR5; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; PINZANI M, 1987, INTENS CARE MED, V13, P148; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHRAM RB, 1978, NEW ENGL J MED, V299, P875, DOI 10.1056/NEJM197810192991608; STERN SG, 1992, CRIT CARE MED, V20, P1263, DOI 10.1097/00003246-199209000-00013; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; WEBSTER GC, 1991, CAN J ANAESTH, V38, P553, DOI 10.1007/BF03008184; WOOG RH, 1987, ANAESTH INTENS CARE, V15, P193, DOI 10.1177/0310057X8701500213; YOUNGNER S J, 1985, Journal of the American Medical Association, V253, P54, DOI 10.1001/jama.253.1.54; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1990, EFFECTIVE DNA POLICI; 1987, LIFE SUSTAINING TREA; 1992, CRIT CARE MED, V20, P320	50	107	110	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2213	2217		10.1001/jama.270.18.2213	http://dx.doi.org/10.1001/jama.270.18.2213			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411606				2022-12-28	WOS:A1993ME81600034
J	PUTNEY, JW; BIRD, GS				PUTNEY, JW; BIRD, GS			THE SIGNAL FOR CAPACITATIVE CALCIUM-ENTRY	CELL			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; RECEPTOR; RELEASE; CELLS; LOCALIZATION; THAPSIGARGIN				PUTNEY, JW (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748				BERLIN RD, 1993, NATURE, V361, P315; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, IN PRESS J BIOL CHEM; FASOLATO C, 1993, IN PRESS J BIOL CHEM; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PUTNEY JW, 1981, PHILOS T ROY SOC B, V296, P37, DOI 10.1098/rstb.1981.0169; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; PUTNEY JW, 1993, IN PRESS ENDOCR REV; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186	17	419	432	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					199	201		10.1016/0092-8674(93)80061-I	http://dx.doi.org/10.1016/0092-8674(93)80061-I			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402906				2022-12-28	WOS:A1993MD88500001
J	KELLERMANN, AL; HACKMAN, BB; SOMES, G; KRETH, TK; NAIL, L; DOBYNS, P				KELLERMANN, AL; HACKMAN, BB; SOMES, G; KRETH, TK; NAIL, L; DOBYNS, P			IMPACT OF 1ST-RESPONDER DEFIBRILLATION IN AN URBAN EMERGENCY MEDICAL-SERVICES SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIAC-ARREST; AUTOMATIC EXTERNAL DEFIBRILLATOR; AMERICAN-HEART-ASSOCIATION; RAPID DEFIBRILLATION; IMPROVING SURVIVAL; TECHNICIANS; EXPERIENCE; MANAGEMENT; RESUSCITATION; PACEMAKER	Objective.-To evaluate the impact of adding first-responder defibrillation by fire-fighters to an existing advanced life-support emergency medical services system. Design.-Nonrandomized, controlled clinical trial with periodic crossover. Setting.-Memphis, Tenn, a city of 610337 people, which is served by a fire department-based emergency medical services system. All city ambulances provide advanced life support. Patients.-Adult victims of out-of-hospital cardiac arrest due to heart disease. Intervention.-Twenty of 40 participating engine companies were equipped with an automated external defibrillator and ordered to apply it immediately in all cases of cardiac arrest. The other 20 companies were ordered to start cardiopulmonary resuscitation (CPR) immediately and wait for paramedics to arrive. Every 75 days, group roles were reversed. Care otherwise proceeded according to 1986 American Heart Association guidelines. Main Outcome Measures.-Return of spontaneous circulation in the field, survival to hospital admission, survival to hospital discharge, and neurological status at discharge. Results.-During the 39-month study interval, 879 patients were treated by a project engine company. Four hundred thirty-one (49%) of these were found in ventricular fibrillation. Bystander CPR was started in only 12% of cases. Overall, firefighters reached the scene a mean of 2.5 minutes faster than simultaneously dispatched paramedics. Although our automated external defibrillators proved to be reliable and efficacious for terminating ventricular fibrillation and pulseless ventricular tachycardia, patients treated by an automated external defibrillator-equipped engine company were no more likely than CPR-treated controls to be resuscitated (32% vs 34%, respectively), to survive to hospital admission (31% vs 29%), or to survive to hospital discharge (14% vs 10%). Neurological outcomes were also, similar in the two treatment groups. Conclusions.-In a fast-response, urban emergency medical services system served by paramedics, the impact of adding first-responder defibrillation appears to be small. Early defibrillation alone cannot overcome low community rates of by-stander CPR. Careful attention to every link in the ''chain of survival'' is needed to achieve optimal rates of survival after cardiac arrest.	UNIV TENNESSEE CTR HLTH SCI,DIV EMERGENCY MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT INTERNAL MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOSTAT & EPIDEMIOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center					AHRQ HHS [HS 06094-02] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1986, Lancet, V1, P397; CAMPBELL JC, 1991, ANN EMERG MED, V20, P433; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1984, LANCET, V2, P318; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CUMMINS RO, 1990, ANN EMERG MED, V19, P1245, DOI 10.1016/S0196-0644(05)82282-6; CUMMINS RO, 1989, ANN EMERG MED, V12, P1269; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH; Fleiss JL, 1981, STAT METHODS RATES P; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; JAGGARAO NSV, 1982, LANCET, V2, P73; KELLERMANN AL, 1993, ANN EMERG MED, V22, P47, DOI 10.1016/S0196-0644(05)80249-5; KELLERMANN AL, 1993, ANN EMERG MED, V22, P1269, DOI 10.1016/S0196-0644(05)80105-2; KERBER RE, 1991, STATEMENT EARLY DEFI; MURPHY DM, 1987, J EMERG MED SERV, V12, P67; NEWMAN MM, 1987, J EMERG MED SERV, V12, P40; ORNATO JP, 1984, ANN EMERG MED, V13, P1096, DOI 10.1016/S0196-0644(84)80331-5; ROZKOVEC A, 1983, CLIN CARDIOL, V7, P527; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; VALENZUELA TD, 1990, ANN EMERG MED, V19, P1407, DOI 10.1016/S0196-0644(05)82609-5; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1986, JAMA-J AM MED ASSOC, V255, P2841; 1990, INSTRUCTORS MANNUAL; 1990, ASTM F125590 AM SOC; 1988, LANCET, V1, P350; 1984, JAMA-J AM MED ASSOC, V251, P351; 1992, JAMA-J AM MED ASSOC, V268, P2172; 1991, CURR EMERG CARDIAC C, V2, P1	38	111	112	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1708	1713		10.1001/jama.270.14.1708	http://dx.doi.org/10.1001/jama.270.14.1708			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411501				2022-12-28	WOS:A1993MA29400027
J	GOUT, I; DHAND, R; HILES, ID; FRY, MJ; PANAYOTOU, G; DAS, P; TRUONG, O; TOTTY, NF; HSUAN, J; BOOKER, GW; CAMPBELL, ID; WATERFIELD, MD				GOUT, I; DHAND, R; HILES, ID; FRY, MJ; PANAYOTOU, G; DAS, P; TRUONG, O; TOTTY, NF; HSUAN, J; BOOKER, GW; CAMPBELL, ID; WATERFIELD, MD			THE GTPASE DYNAMIN BINDS TO AND IS ACTIVATED BY A SUBSET OF SH3 DOMAINS	CELL			English	Article							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; MECHANOCHEMICAL ENZYME; MOLECULAR-CLONING; LIGAND-BINDING; PROTEIN; GENE; IDENTIFICATION; GAP; RAS	Src homology 3 (SH3) domains have been implicated in mediating protein-protein interactions in receptor signaling processes; however, the precise role of this domain remains unclear. In this report, affinity purification techniques were used to identity the GTPase dynamin as an SH3 domain-binding protein. Selective binding to a subset of 15 different recombinant SH3 domains occurs through proline-rich sequence motifs similar to those that mediate the interaction of the SH3 domains of Grb2 and Abl proteins to the guanine nucleotide exchange protein, Sos, and to the 3BP1 protein, respectively. Dynamin GTPase activity is stimulated by several of the bound SH3 domains, suggesting that the function of the SH3 module is not restricted to protein-protein interactions but may also include the interactive regulation of GTP-binding proteins.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	University of Oxford; University of London; University College London	GOUT, I (corresponding author), LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND.		Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Fry, Michael/0000-0001-8518-1370				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MASUR SK, 1990, J NEUROGENET, V6, P191, DOI 10.3109/01677069009107110; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, IN PRESS J CELL BIOL; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	57	556	580	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					25	36		10.1016/0092-8674(93)90676-H	http://dx.doi.org/10.1016/0092-8674(93)90676-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402898				2022-12-28	WOS:A1993MB66700005
J	MARTIN, JL; BARDWELL, JCA; KURIYAN, J				MARTIN, JL; BARDWELL, JCA; KURIYAN, J			CRYSTAL-STRUCTURE OF THE DSBA PROTEIN REQUIRED FOR DISULFIDE BOND FORMATION IN-VIVO	NATURE			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; MACROMOLECULAR STRUCTURES; 3-DIMENSIONAL STRUCTURE; DISULFIDE-ISOMERASE; THIOREDOXIN; RESOLUTION; IDENTIFICATION; CRYSTALLOGRAPHY; REFINEMENT; SEQUENCE	PROTEINS that contain disulphide bonds are often slow to fold in vitro because the oxidation and correct pairing of the cysteine residues is rate limiting1,2. The folding of such proteins is greatly accelerated in Escherichia coli by DsbA3,4, but the mechanism of this rate enhancement is not well understood. Here we report the crystal structure of oxidized DsbA and show that it resembles closely the ubiquitous redox protein thioredoxin5, despite very low sequence similarity. An important difference, however, is the presence of another domain which forms a cap over the thioredoxin-like active site of DsbA. The redox-active disulphide bond, which is responsible for the oxidation of substrates, is thus at a domain interface and is surrounded by grooves and exposed hydrophobic side chains. These features suggest that DsbA might act by binding to partially folded polypeptide chains before oxidation of cysteine residues.	ROCKEFELLER UNIV,NEW YORK,NY 10021; HOWARD HUGHES MED INST,NEW YORK,NY 10021; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Rockefeller University; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Martin, Jennifer L./A-6039-2010	Martin, Jennifer L./0000-0002-9225-8863				BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROWN LR, 1993, J MOL BIOL, V231, P800, DOI 10.1006/jmbi.1993.1327; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLIS LBM, 1992, BIOCHEMISTRY-US, V31, P4882, DOI 10.1021/bi00135a020; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MARTIN JL, 1993, J MOL BIOL, V230, P1097, DOI 10.1006/jmbi.1993.1226; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SODANO P, 1991, J MOL BIOL, V221, P1311; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOMB JF, 1992, P NATL ACAD SCI USA, V89, P10252, DOI 10.1073/pnas.89.21.10252; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WILSON KS, 1978, ACTA CRYSTALLOGR B, V34, P1599, DOI 10.1107/S0567740878006135; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, IN PRESS J MOL BIOL; XIA TH, 1992, PROTEIN SCI, V1, P310; ZAPUN A, IN PRESS BIOCH; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	35	356	372	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					464	468		10.1038/365464a0	http://dx.doi.org/10.1038/365464a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413591				2022-12-28	WOS:A1993LZ63300064
J	HENSHAW, RC; NAJI, SA; RUSSELL, IT; TEMPLETON, AA				HENSHAW, RC; NAJI, SA; RUSSELL, IT; TEMPLETON, AA			COMPARISON OF MEDICAL ABORTION WITH SURGICAL VACUUM ASPIRATION - WOMENS PREFERENCES AND ACCEPTABILITY OF TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIALS; EARLY-PREGNANCY; PATIENT PREFERENCES; TERMINATION; COMPLICATIONS; ANALOG	Objectives-To assess women's preferences for, and the acceptability of, medical abortion and vacuum aspiration in the early first trimester. Design-Patient centred, partially randomised trial. Medical abortion was performed with mifepristone 600 mg followed 48 hours later by gemeprost 1 mg vaginal pessary. Vacuum aspiration was performed under general anaesthesia. Setting-Teaching hospital in Scotland. Patients-363 women undergoing legal induced abortion at less than nine weeks' gestation. Main outcome measures-Women's preferences for method of abortion before abortion; acceptability judged two weeks after abortion by recording the method women would opt to undergo in future and by semantic differential rating technique. Results-73 (20%) women preferred to undergo medical abortion, and 95 (26%) vacuum aspiration; 195 (54%) were willing to undergo either method, and were allocated at random. Both procedures were highly acceptable to women with preferences. Gestation had a definite effect on acceptability in randomised women; at less than 50 days there were no differences, but between 50 and 63 days vacuum aspiration was significantly more acceptable. Conclusions-Women who wish to use a particular method should be allowed their choice, regardless of gestation. Women of 50-63 days' gestation without preferences for a particular method are likely to find vacuum aspiration more acceptable. A patient centred, partially randomised trial design may be a useful tool in pragmatic research.	DEPT PUBL HLTH,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	HENSHAW, RC (corresponding author), ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.		Russell, Ian T/H-1181-2012					BACHELOT A, 1992, CONTRACEPTION, V45, P547, DOI 10.1016/0010-7824(92)90106-4; Botting Beverley, 1991, Popul Trends, V64, P19; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Casagrande J. T., 1978, APPLIED STATISTICS, V27, P176; CASTADOT RG, 1986, FERTIL STERIL, V45, P5; CHARLSON ME, 1984, BRIT MED J, V289, P1281, DOI 10.1136/bmj.289.6454.1281; DUDLEY HAF, 1983, BMJ-BRIT MED J, V287, P957, DOI 10.1136/bmj.287.6397.957; HARVEY I, 1989, BRIT MED J, V299, P684; HEARD M, 1992, BRIT MED J, V304, P195, DOI 10.1136/bmj.304.6821.195; HILL NCW, 1990, AM J OBSTET GYNECOL, V162, P414, DOI 10.1016/0002-9378(90)90398-Q; MARSHALL JF, 1977, PREV MED, V6, P65, DOI 10.1016/0091-7435(77)90005-6; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; ROSEN AS, 1984, CONTRACEPTION, V29, P423, DOI 10.1016/0010-7824(84)90016-7; ROSEN AS, 1979, CONTRACEPTION, V19, P107, DOI 10.1016/S0010-7824(79)80023-2; Russell I T, 1992, Qual Health Care, V1, P51, DOI 10.1136/qshc.1.1.51; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; TANG GWK, 1991, CONTRACEPTION, V44, P523, DOI 10.1016/0010-7824(91)90154-8; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; URQUHART DR, 1991, BRIT J OBSTET GYNAEC, V98, P396, DOI 10.1111/j.1471-0528.1991.tb13431.x; 1990, BRIT J OBSTET GYNAEC, V97, P480; 1985, J R COLL GEN PRACT, V35, P175	22	191	192	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					714	717		10.1136/bmj.307.6906.714	http://dx.doi.org/10.1136/bmj.307.6906.714			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401094	Bronze, Green Published			2022-12-28	WOS:A1993LY29200021
J	KUO, CC; BEAN, BP				KUO, CC; BEAN, BP			G-PROTEIN MODULATION OF ION PERMEATION THROUGH N-TYPE CALCIUM CHANNELS	NATURE			English	Article							CHICK SENSORY NEURONS; GTP-BINDING PROTEIN; SYMPATHETIC NEURONS; HIPPOCAMPAL-NEURONS; INHIBITION; CURRENTS; RECEPTOR; CONDUCTANCE; MECHANISM	N-TYPE calcium channels in cell membranes are inhibited by neurotransmitters such as noradrenaline1-4, luteinizing hormone-releasing (LHRH)5-7, gamma-aminobutyric acid (GABA)8,9 and glutamate10,11. Although GTP-binding proteins (G proteins) are probably the common mediators of such inhibition6,11-14, it is unclear exactly bow G proteins alter the operation of the channel. Various experiments have shown changes in channel gating2-6,15,16. Here we show that inward current carried by Na+ through N-type channels was far less inhibited by LHRH or by internal GTP-gammaS than was current carried by Ba2+. With external Ba2+ and internal Cs+, LHRH inhibited the Ba2+-carried inward limb of the instantaneous current-voltage curve much more than the Cs+-carried outward limb. Noise analysis showed that LHRH or GTP-gammaS decrease single-channel current carried by Ba2+. These results suggest that alteration of the ion permeation pathway contributes significantly to G-protein inhibition of N-type Ca2+ channels.			KUO, CC (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Kuo, Chung-Chin/0000-0001-8208-6829				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BLEY KR, 1990, NEURON, V2, P379; BOLAND LM, 1993, J NEUROSCI, V13, P516; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DOLPHIN AC, 1986, BRIT J PHARMACOL, V88, P213, DOI 10.1111/j.1476-5381.1986.tb09489.x; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; JONES S, 1992, NEUROSCI LETT, V145, P153, DOI 10.1016/0304-3940(92)90009-V; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; KUO CC, 1993, J PHYSIOL-LONDON, V466, P683; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; POLLO A, 1992, PFLUG ARCH EUR J PHY, V422, P75; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V444, P669, DOI 10.1113/jphysiol.1991.sp018900; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SIGWORTH FJ, 1980, NATURE, V283, P293, DOI 10.1038/283293a0; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358	26	68	68	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					258	262		10.1038/365258a0	http://dx.doi.org/10.1038/365258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396731				2022-12-28	WOS:A1993LX47100056
J	GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D				GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D			FORTNIGHTLY REVIEW - GUIDELINES FOR RESUSCITATION AND TRANSFER OF PATIENTS WITH SERIOUS HEAD-INJURY	BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN INJURY; CRITICALLY ILL PATIENTS; HEMATOMA		WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; LAW HOSP,CARLUKE ML8 5ER,LANARK,SCOTLAND	University of Edinburgh	GENTLEMAN, D (corresponding author), DUNDEE ROYAL INFIRM,DUNDEE DD1 9ND,SCOTLAND.							ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GENTLEMAN D, 1992, INT SURG, V77, P297; GENTLEMAN D, 1990, LANCET, V335, P327; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LAMBERT SM, 1993, INJURY, V24, P333, DOI 10.1016/0020-1383(93)90058-E; McLaren C A, 1983, J R Coll Surg Edinb, V28, P399; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUNRO HM, 1993, BR J INTENSIVE CARE, V3, P210; REEVE WG, 1990, BRIT MED J, V300, P85, DOI 10.1136/bmj.300.6717.85; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; RUNCIE CJ, 1992, ANAESTHESIA, V47, P327, DOI 10.1111/j.1365-2044.1992.tb02175.x; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; VYVYAN HAL, 1991, ANAESTHESIA, V46, P395; 1988, RECOMMENDATIONS STAN; 1984, BMJ, V288, P983; 1993, ATLS COURSE MANUAL	25	66	66	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					547	552		10.1136/bmj.307.6903.547	http://dx.doi.org/10.1136/bmj.307.6903.547			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400978	Bronze, Green Published			2022-12-28	WOS:A1993LV18000025
J	LLEDO, PM; VERNIER, P; VINCENT, JD; MASON, WT; ZOREC, R				LLEDO, PM; VERNIER, P; VINCENT, JD; MASON, WT; ZOREC, R			INHIBITION OF RAB3B EXPRESSION ATTENUATES CA2+-DEPENDENT EXOCYTOSIS IN RAT ANTERIOR-PITUITARY-CELLS	NATURE			English	Article							GTP-BINDING PROTEIN; MEMBRANE CAPACITANCE; BOVINE LACTOTROPHS; SYNTHETIC PEPTIDES; ENDOCYTIC PATHWAY; CHROMAFFIN CELLS; SECRETION; BRAIN; DOMAIN; MELANOTROPHS	LOW-MOLECULAR-WEIGHT GTP-binding proteins (small G proteins) of the Rab family have been proposed to act as central regulators of vesicular traffic1,2, and proteins of the Rab3 subfamily (Rab3A, B, C and D)3-6 are thought to be,associated with membrane vesicles or granules undergoing exocytotic fusion with the plasma membrane7-10. Rab3A is highly expressed in brain11, whereas Rab3B is the major form found in rat anterior pituitary gland. We report here that antisense oligonucleotides against Rab3B, introduced into pituitary cells using the whole-cell patch clamp technique, specifically and reversibly block expression of Rab3B. We find that calcium-dependent exocytosis is inhibited without affecting endocytosis. Antisense oligonucleotides directed against Rab3A have no effect. Our results indicate that Rab3B is likely to be a key intracellular signalling molecule which can control exocytosis downstream of other calcium-dependent processes in anterior pituitary cells.	INST A FESSARD,CNRS,F-91198 GIF SUR YVETTE,FRANCE; UNIV LJUBLJANA FAC MED,INST PATHOPHYSIOL,61105 LJUBLJANA,SLOVENIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Ljubljana	LLEDO, PM (corresponding author), AFRC,BABRAHAM INST,DEPT NEUROBIOL,CAMBRIDGE CB2 4AT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AYALA J, 1989, J NEUROSCI RES, V22, P241, DOI 10.1002/jnr.490220303; BAERTSCHI AJ, 1992, MOL ENDOCRINOL, V6, P2257, DOI 10.1210/me.6.12.2257; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Marty A., 1983, SINGLE CHANNEL RECOR, P107; Mason W T, 1986, Methods Enzymol, V124, P207; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PUSH M, 1988, PFLUGERS ARCH, V411, P204; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RUPNIK M, 1992, FEBS LETT, V303, P221, DOI 10.1016/0014-5793(92)80524-K; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SIKDAR SK, 1989, FEBS LETT, V253, P88, DOI 10.1016/0014-5793(89)80936-6; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TARASKEVICH PS, 1984, FED PROC, V43, P2373; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473; ZOREC R, 1991, METHODS NEUROSCI, V4, P194, DOI DOI 10.1016/B978-0-12-185257-3.50018-5	36	185	186	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					540	544		10.1038/364540a0	http://dx.doi.org/10.1038/364540a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393147				2022-12-28	WOS:A1993LQ66700059
J	MICHALEK, MT; GRANT, EP; GRAMM, C; GOLDBERG, AL; ROCK, KL				MICHALEK, MT; GRANT, EP; GRAMM, C; GOLDBERG, AL; ROCK, KL			A ROLE FOR THE UBIQUITIN-DEPENDENT PROTEOLYTIC PATHWAY IN MHC CLASS I-RESTRICTED ANTIGEN PRESENTATION	NATURE			English	Article							TOXIC LYMPHOCYTES-T; ACTIVATING ENZYME; MOLECULES; EXPRESSION; DEGRADATION; PROTEIN; ICAM-1; CELLS; GENE; E1	THE degradation of most cellular proteins starts with their covalent conjugation with ubiquitin1,2. This labels the proteins for rapid hydrolysis to oligopeptides by a (26S) proteolytic complex containing a (20S) degradative particle called the proteasome3,4. Some system in the cytosol also generates antigenic peptides from endogenously synthesized cellular and viral proteins5-10. These peptides bind to newly synthesized class I major histocompatibility complex molecules in the endoplasmic reticulum and peptide/class I complexes are then transported to the cell surface for presentation to cytotoxic T cells11,12. How these peptides are produced is unknown, although a modification that promotes ubiquitin-dependent degradation of a viral protein enhances its presentation with class I13 and indirect evidence suggests a role for proteolytic particles closely resembling and perhaps identical to the proteasome4,12,14,15. Using cells that exhibit a temperature-sensitive defect in ubiquitin conjugation, we report here that nonpermissive temperature inhibited class I-restricted presentation of ovalbumin introduced into the cytosol, but did not affect presentation of an ovalbumin peptide synthesized from a minigene. These results implicate the ubiquitin-dependent proteolytic pathway in the production of antigenic peptides.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	MICHALEK, MT (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA.							ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DANG LH, 1990, J IMMUNOL, V144, P4082; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MICHALEK MT, 1991, J IMMUNOL, V146, P449; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; Moss B, 1991, CURRENT PROTOCOLS MO; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1992, P NATL ACAD SCI USA, V89, P8918, DOI 10.1073/pnas.89.19.8918; SIU G, 1989, J IMMUNOL, V143, P3813; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; WILEY HS, 1987, METHOD ENZYMOL, V146, P402; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	37	310	324	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					552	554		10.1038/363552a0	http://dx.doi.org/10.1038/363552a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8389422	Bronze			2022-12-28	WOS:A1993LF93900053
J	ISOJARVI, JIT; LAATIKAINEN, TJ; PAKARINEN, AJ; JUNTUNEN, KTS; MYLLYLA, VV				ISOJARVI, JIT; LAATIKAINEN, TJ; PAKARINEN, AJ; JUNTUNEN, KTS; MYLLYLA, VV			POLYCYSTIC OVARIES AND HYPERANDROGENISM IN WOMEN TAKING VALPROATE FOR EPILEPSY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REPRODUCTIVE ENDOCRINE DISORDERS; COMPLEX PARTIAL SEIZURES; TEMPORAL-LOBE ORIGIN; CARBAMAZEPINE THERAPY; PITUITARY-FUNCTION; HORMONES; SECRETION	Background. Reproductive endocrine disorders are more common among women with epilepsy than among normal women. These disorders have been attributed to epilepsy itself, but could be related to antiepileptic-drug therapy. Methods. We studied 238 women with epilepsy who were seen regularly at the Outpatient Department of the University Hospital, Oulu, Finland. Their mean age was 33 years (range, 18 to 45), and the mean duration of therapy was 9 years (range, 0 to 31). Twenty-nine (12 percent) were treated with valproate, 120 (50 percent) with carbamazepine, 12 (5 percent) with valproate and carbamazepine, and 62 (26 percent) with other medications; 15 (6 percent) were untreated. Vaginal ultrasonography was performed to determine ovarian size, and serum sex-hormone concentrations were measured in 41 women with epilepsy and menstrual disturbances, 57 women with epilepsy and regular menstrual cycles, and 51 normal women. Results. Menstrual disturbances were present in 13 of the women receiving valproate alone (45 percent), 3 of the women receiving valproate in combination with carbamazepine (25 percent), 23 of the women receiving carbamazepine (19 percent), and 8 of those receiving other medications (13 percent). Forty-three percent of the women receiving valproate had polycystic ovaries, and 17 percent had elevated serum testosterone concentrations without polycystic ovaries; 50 percent of the women receiving valproate and carbamazepine had polycystic ovaries, and 38 percent had elevated serum testosterone concentrations without polycystic ovaries. Eighty percent of the women treated with valproate before the age of 20 years had polycystic ovaries or hyperandrogenism. Conclusions. Menstrual disturbances, polycystic ovaries, and hyperandrogenism are often encountered in women taking valproate for epilepsy.	UNIV OULU, DEPT OBSTET & GYNECOL, SF-90220 OULU, FINLAND; UNIV OULU, DEPT CLIN CHEM, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu	ISOJARVI, JIT (corresponding author), UNIV OULU, DEPT NEUROL, SF-90220 OULU, FINLAND.							ABEAL JL, 1991, CLIN ENDOCRINOL, V35, P477, DOI 10.1111/j.1365-2265.1991.tb00931.x; [Anonymous], 1981, Epilepsia, V22, P489; BILO L, 1988, EPILEPSIA, V29, P612, DOI 10.1111/j.1528-1157.1988.tb03770.x; ELIAS AN, 1982, AM J OBSTET GYNECOL, V144, P72, DOI 10.1016/0002-9378(82)90397-0; Everitt B.J., 1986, NEUROENDOCRINOLOGY, P472; HERZOG AG, 1986, ARCH NEUROL-CHICAGO, V43, P347, DOI 10.1001/archneur.1986.00520040035015; HERZOG AG, 1986, ARCH NEUROL-CHICAGO, V43, P341, DOI 10.1001/archneur.1986.00520040029014; ISOJARVI JIT, 1990, ARCH NEUROL-CHICAGO, V47, P670, DOI 10.1001/archneur.1990.00530060082023; ISOJARVI JIT, 1990, EPILEPSIA, V31, P438, DOI 10.1111/j.1528-1157.1990.tb05500.x; ISOJARVI JIT, 1991, EPILEPSY RES, V9, P139, DOI 10.1016/0920-1211(91)90025-B; KIDDY DS, 1990, CLIN ENDOCRINOL, V32, P213, DOI 10.1111/j.1365-2265.1990.tb00857.x; MARGRAF JW, 1981, NEUROLOGY S159, V31; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1983, EPILEPSY DIAGNOSIS M, P225; MELIS GB, 1986, ADV BIOCHEM PSYCHOPH, V42, P219; MOLAIE M, 1986, EPILEPSIA, V27, P724, DOI 10.1111/j.1528-1157.1986.tb03601.x; NOBELS F, 1992, FERTIL STERIL, V58, P655; POLSON DW, 1988, LANCET, V1, P870; PRITCHARD PB, 1983, ANN NEUROL, V14, P27, DOI 10.1002/ana.410140105; SWANSON M, 1981, J CLIN ULTRASOUND, V9, P219, DOI 10.1002/jcu.1870090504; TRIMBLE MR, 1984, ADV EPILEPTOL, P201; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	22	502	519	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1383	1388		10.1056/NEJM199311043291904	http://dx.doi.org/10.1056/NEJM199311043291904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413434				2022-12-28	WOS:A1993MD94900004
J	PHELPS, CE				PHELPS, CE			THE METHODOLOGIC FOUNDATIONS OF STUDIES OF THE APPROPRIATENESS OF MEDICAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INAPPROPRIATE USE; TECHNOLOGY-ASSESSMENT; PRACTICE GUIDELINES; ERROR RATES; SERVICES; DISEASE				PHELPS, CE (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT COMMUNITY & PREVENT MED,601 ELMWOOD AVE,BOX 644,ROCHESTER,NY 14642, USA.				PHS HHS [R01-5477] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BEGG CB, 1990, MED DECIS MAKING, V10, P149; BEGG CB, 1990, MED DECIS MAKING, V10, P29, DOI 10.1177/0272989X9001000106; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BROOK RH, 1988, LANCET, V1, P750; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; GLOOR JE, 1993, PEDIATRICS, V91, P70; HAVENS PL, 1993, AM J PUBLIC HEALTH, V83, P379, DOI 10.2105/AJPH.83.3.379; HENKELMAN RM, 1990, MED DECIS MAKING, V10, P24, DOI 10.1177/0272989X9001000105; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; HUI SL, 1980, BIOMETRICS, V36, P167, DOI 10.2307/2530508; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MERRICK NJ, 1986, R32046 RAND REP; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PHELPS CE, 1988, MED DECIS MAKING, V8, P279, DOI 10.1177/0272989X8800800409; PHELPS CE, 1990, MED CARE, V28, P703, DOI 10.1097/00005650-199008000-00004; PHELPS CE, 1992, MED CARE, V30, P744, DOI 10.1097/00005650-199208000-00006; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; Swets J., 1982, EVALUATION DIAGNOSTI; WALTER SD, 1988, J CLIN EPIDEMIOL, V41, P923, DOI 10.1016/0895-4356(88)90110-2; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505	25	177	179	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1241	1245		10.1056/NEJM199310213291707	http://dx.doi.org/10.1056/NEJM199310213291707			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8413392				2022-12-28	WOS:A1993MB98800007
J	GARFIN, SR; COHEN, MS				GARFIN, SR; COHEN, MS			SCAPULOTHORACIC PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									INDIANA HAND CTR,INDIANAPOLIS,IN		GARFIN, SR (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.							EMERY RJH, 1991, J BONE JOINT SURG AM, V73A, P1526, DOI 10.2106/00004623-199173100-00010; MILCH H, 1961, Clin Orthop, V20, P139; RICHARDS RR, 1989, CLIN ORTHOPAEDICS, V247, P111	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1867	1867						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411532				2022-12-28	WOS:A1993MB46400034
J	FIELD, MJ; GROSSMAN, JH; LEWIN, M				FIELD, MJ; GROSSMAN, JH; LEWIN, M			ISSUES IN DESIGNING BENEFITS FOR HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									INST MED,HLTH POLICY FELLOWSHIPS PROGRAM,WASHINGTON,DC 20418; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111	Tufts Medical Center	FIELD, MJ (corresponding author), INST MED,DIV HLTH CARE SERV,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1674	1674		10.1001/jama.270.14.1674	http://dx.doi.org/10.1001/jama.270.14.1674			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MA294	8411486				2022-12-28	WOS:A1993MA29400008
J	SUDHOF, TC; DECAMILLI, P; NIEMANN, H; JAHN, R				SUDHOF, TC; DECAMILLI, P; NIEMANN, H; JAHN, R			MEMBRANE-FUSION MACHINERY - INSIGHTS FROM SYNAPTIC PROTEINS	CELL			English	Review							VESICLES; SYNAPTOPHYSIN; COMPONENTS; FAMILY		UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; FED RES CTR VIRUS DIS ANIM,D-72076 TUBINGEN,GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yale University; Yale University; Howard Hughes Medical Institute; Yale University	SUDHOF, TC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Jahn, Reinhard/0000-0003-1542-3498				AALTO MK, 1993, P NATL ACAD SCI USA, V90, P2559; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, IN PRESS EMBO J; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FYKSE EM, 1993, IN PRESS J NEUROCHEM; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; LINK E, 1993, J BIOL CHEM, V268, P18423; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LINSTEDT AF, 1992, J CELL BIOL, V117, P849; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; PELHAM RB, 1993, CELL, V73, P425; PETERS JM, 1990, EMBO J, V9, P1157; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALCHSOLIMENA C, 1993, IN PRESS J NEUROSC; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	24	251	253	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					1	4						4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402889				2022-12-28	WOS:A1993MB66700001
J	FORTINI, ME; REBAY, I; CARON, LA; ARTAVANISTSAKONAS, S				FORTINI, ME; REBAY, I; CARON, LA; ARTAVANISTSAKONAS, S			AN ACTIVATED NOTCH RECEPTOR BLOCKS CELL-FATE COMMITMENT IN THE DEVELOPING DROSOPHILA EYE	NATURE			English	Article							SEVENLESS PROTEIN; TYROSINE KINASE; GENE-PRODUCT; LOCUS; MELANOGASTER; EXPRESSION; HOMOLOG; PHOTORECEPTOR; SEQUENCE; ENHANCER	THE Notch locus of Drosophila melanogaster encodes a 2,703-amino-acid transmembrane protein required for a variety of developmental processes, including neurogenesis, oogenesis and ommatidial assembly1,2. The Notch protein contains a large extracellular domain of 36 epidermal growth factor-like repeats as well as three Notch/Lin-12 repeats and an intracellular domain with 6 Cdc10/ankyrin repeats, motifs that are highly conserved in several vertebrate Notch homologues3-9. Truncation of the extracellular domain of the Drosophila Notch protein produces an activated receptor, as judged by its ability to cause phenotypes similar to gain-of-function alleles or duplications of the Notch locus10. Equivalent truncations of vertebrate Notch-related proteins have been associated with malignant neoplasms and other developmental abnormalities8,11-13. We present here an analysis of activated Notch function at single-cell resolution in the Drosophila compound eye. We find that overexpression of full-length Notch in defined cell types has no apparent effects but that overexpression of activated Notch in the same cells transiently blocks their proper cell-fate commitment, causing them either to adopt incorrect cell fates or to differentiate incompletely. Moreover, an activated Notch protein lacking the transmembrane domain is translocated to the nucleus, raising the possibility that Notch may participate directly in nuclear events.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06536; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536	Yale University; Howard Hughes Medical Institute; Yale University	FORTINI, ME (corresponding author), YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06536, USA.							ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DELIDAKIS C, 1991, GENETICS, V129, P803; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	30	276	285	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					555	557		10.1038/365555a0	http://dx.doi.org/10.1038/365555a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413612				2022-12-28	WOS:A1993MA66100057
J	DUNN, RB; LEWIS, PA				DUNN, RB; LEWIS, PA			COMPLIANCE WITH STANDARDIZED ASSESSMENT SCALES FOR ELDERLY PEOPLE AMONG CONSULTANT GERIATRICIANS IN WESSEX	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED,DEPT MED COMP & STAT,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	DUNN, RB (corresponding author), ST MARTINS HOSP,BATH BA2 5RP,ENGLAND.							DIXON N, 1991, MED AUDIT PRIMER; LEWIS PA, 1992, BRIT J HLTH CARE COM, V9, P36; RODGERS H, 1993, AGE AGEING, V22, P161, DOI 10.1093/ageing/22.3.161; 1992, STANDARDISED ASSESSM	4	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					606	606		10.1136/bmj.307.6904.606	http://dx.doi.org/10.1136/bmj.307.6904.606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401019	Green Published, Bronze			2022-12-28	WOS:A1993LW14900020
J	GREEN, JM				GREEN, JM			THE VIEWS OF SINGLEHANDED GENERAL-PRACTITIONERS - A QUALITATIVE STUDY	BRITISH MEDICAL JOURNAL			English	Article							SATISFACTION	Objectives-To examine the concerns of single-handed general practitioners working in an inner London area and to compare the views of general practitioners in partnerships. Design-Qualitative analysis of semistructured interviews with a random sample of single-handed general practitioners and a sample of general practitioners from partnerships matched for age and sex. Setting-The area covered by Lambeth, Southwark, and Lewisham Family Health Services Authority. Results-The singlehanded general practitioners were more likely to be older, male, and first qualified abroad than general practitioners in partnerships. Their major concerns were inadequate premises, maintaining their singlehanded status, and coping with recent changes to their contract. Most were very satisfied with their solo status and did not see the provision of 24 hour care as stressful. Conclusion-Single handed general practitioners saw themselves as providing a unique service for patients, and their status as an alternative for general practitioners who were unhappy in partnerships. Such practices are unlikely to wither away as a pattern of provision. Any comprehensive development of primary care must take their needs into account.			GREEN, JM (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,LONDON SE5 6SP,ENGLAND.			Green, Judith/0000-0002-2315-5326				BAIN J, 1991, BRIT MED J, V302, P1183, DOI 10.1136/bmj.302.6786.1183; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; FRY J, 1983, PRESENT STATE FUTURE; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; MAKIN PJ, 1988, J ROY COLL GEN PRACT, V38, P303; Morley V., 1991, CASE STUDY DEV PRIMA; MURPHY E, 1992, FAM PRACT, V9, P85, DOI 10.1093/fampra/9.1.85; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; Strauss AL., 1987, QUALITATIVE ANAL SOC, Vxv, P319; Tomlinson B., 1992, REPORT INQUIRY LONDO; WILKIN D, 1987, ANATOMY URBAN GENERA; WILLIAMS SJ, 1991, FAM PRACT, V8, P237, DOI 10.1093/fampra/8.3.237; ZOLTIE N, 1991, BRIT MED J, V302, P941, DOI 10.1136/bmj.302.6782.941; 1992, HLTH PERSONAL SOCIAL; 1991, YOUR CHOICES FUTURE; 1981, PRIMARY HLTH CARE IN	17	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					607	610		10.1136/bmj.307.6904.607	http://dx.doi.org/10.1136/bmj.307.6904.607			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401020	Bronze, Green Published			2022-12-28	WOS:A1993LW14900021
J	SUELING, HM; JOHNSTON, D; MARTIN, IG; DIXON, MF; LANSDOWN, MRJ; MCMAHON, MJ; AXON, ATR				SUELING, HM; JOHNSTON, D; MARTIN, IG; DIXON, MF; LANSDOWN, MRJ; MCMAHON, MJ; AXON, ATR			GASTRIC-CANCER - A CURABLE DISEASE IN BRITAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; ADJUVANT CHEMOTHERAPY; MULTIVARIATE-ANALYSIS; SURGICAL-MANAGEMENT; PROGNOSTIC FACTORS; STOMACH; CARCINOMA; ADENOCARCINOMA; SURVIVAL; EXPERIENCE	Objective-To determine whether more vigorous efforts aimed at earlier diagnosis allied to radical surgical resection lead to improved survival of patients with gastric cancer. Design-Prospective audit of all cases of gastric cancer treated during 1970-89. Setting-Department of surgery, general hospital. Subjects-493 consecutive patients with gastric adenocarcinoma. Main outcome measures-Operative mortality, postoperative morbidity, and five year survival after radical potentially curative resection. Results-207 (42%) patients underwent potentially curative resection. The proportion of all patients in whom this was possible increased significantly (p < 0.01) from 31% in the first five year period to 53% in the last five year period. The proportion of patients who had early gastric cancer rose from 1% to 15% (p < 0.01) and stage I disease rose from 4% to 26% (p < 0.001). After potentially curative resection, mortality 30 days after operation was 6%. Operative mortality decreased from 9% in the 1970s to 5% in the 1980s. Likewise, the incidence of serious postoperative complications decreased from 33% in the 1970s to 17% in the 1980s (p < 0.01). Five year survival was 60% in patients who underwent curative resection, 98% in patients with early gastric cancer, and 93%, 69%, and 28% in stage I, II, and III disease respectively. By the late 1980s five year survival after operation was about 70%. Conclusions-These findings suggest that an increasing proportion of patients with gastric cancer could be diagnosed at a relatively early pathological stage when about two thirds are curable by means of radical surgery.	GEN INFIRM, CTR DIGEST DIS, ACAD UNIT PATHOL, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND; GEN INFIRM, CTR DIGEST DIS, DEPT GASTROENTEROL, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds	SUELING, HM (corresponding author), GEN INFIRM, CTR DIGEST DIS, ACAD UNIT SURG, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND.							ADASHEK K, 1979, ANN SURG, V189, P6, DOI 10.1097/00000658-197901000-00002; AKOH JA, 1991, BRIT J SURG, V78, P349, DOI 10.1002/bjs.1800780325; ALLUM WH, 1989, BRIT J SURG, V76, P535, DOI 10.1002/bjs.1800760604; BUCHHOLTZ TW, 1978, ANN SURG, V188, P711, DOI 10.1097/00000658-197812000-00001; CASSELL P, 1976, BRIT J SURG, V63, P603, DOI 10.1002/bjs.1800630811; COSTELLO CB, 1977, BRIT J SURG, V64, P47, DOI 10.1002/bjs.1800640112; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM D, 1987, BRIT J SURG, V74, P715, DOI 10.1002/bjs.1800740822; CUSCHIERI A, 1986, BRIT J SURG, V73, P513; DAY NE, 1989, WORLD J SURG, V13, P3, DOI 10.1007/BF01671147; DESMOND AM, 1976, P ROY SOC MED, V69, P257; ESTAPE J, 1991, ANN SURG, V213, P219, DOI 10.1097/00000658-199103000-00006; Gear M W, 1980, Br Med J, V280, P1135; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HARTLEY LC, 1987, AUST NZ J SURG, V57, P5, DOI 10.1111/j.1445-2197.1987.tb01230.x; HAWLEY PR, 1970, BRIT J SURG, V57, P862; HISAMICHI S, 1984, JPN J CLIN ONCOL, V14, P211; INBERG MV, 1972, ACTA CHIR SCAND, V138, P195; INOKUCHI K, 1984, JPN J SURG, V14, P351, DOI 10.1007/BF02469540; IRVIN TT, 1988, BRIT J SURG, V75, P106, DOI 10.1002/bjs.1800750205; ITOH H, 1989, AM J SURG, V158, P14, DOI 10.1016/0002-9610(89)90305-X; KAIBARA N, 1990, AM J SURG, V159, P218, DOI 10.1016/S0002-9610(05)80265-X; KAJITANI T, 1981, JPN J SURG, V11, P127; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY BJ, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709091007; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; KIM JP, 1987, WORLD J SURG, V11, P465, DOI 10.1007/BF01655811; Kodama Y, 1981, World J Surg, V5, P241; LINDAHL AK, 1988, EUR J SURG ONCOL, V14, P55; MARUYAMA K, 1987, SCAND J GASTROENTERO, V22, P63, DOI 10.3109/00365528709091021; MARUYAMA K, 1987, WORLD J SURG, V11, P418, DOI 10.1007/BF01655804; MEYERS WC, 1987, ANN SURG, V205, P1, DOI 10.1097/00000658-198701000-00001; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MSIKA S, 1989, WORLD J SURG, V13, P118, DOI 10.1007/BF01671171; Murakami T, 1979, World J Surg, V3, P685; NAKAJIMA T, 1978, INT J CLIN PHARM BI, V16, P209; NAKAJIMA T, 1989, HEPATO-GASTROENTEROL, V36, P79; Nielsen S A, 1974, Acta Chir Scand, V140, P313; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SHIU MH, 1980, ANN SURG, V192, P730, DOI 10.1097/00000658-198012000-00007; SHIU MH, 1989, HEPATO-GASTROENTEROL, V36, P7; SIEWERT JR, 1993, BRIT J SURG, V80, P1015, DOI 10.1002/bjs.1800800829; SJOSTEDT S, 1986, ACTA CHIR SCAND, P25; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; SUELING HM, 1993, GUT               S1, V34, pS15; SVENNEVIG JL, 1976, ACTA CHIR SCAND, V142, P78; YAN CJ, 1985, AM J SURG, V149, P771, DOI 10.1016/S0002-9610(85)80183-5; 1989, MORTALITY STATISTICS	48	204	211	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	1993	307	6904					591	596		10.1136/bmj.307.6904.591	http://dx.doi.org/10.1136/bmj.307.6904.591			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401015	Bronze, Green Published			2022-12-28	WOS:A1993LW14900015
J	RICHARDSON, GE; TUCKER, MA; VENZON, DJ; LINNOILA, RI; PHELPS, R; PHARES, JC; EDISON, M; IHDE, DC; JOHNSON, BE				RICHARDSON, GE; TUCKER, MA; VENZON, DJ; LINNOILA, RI; PHELPS, R; PHARES, JC; EDISON, M; IHDE, DC; JOHNSON, BE			SMOKING CESSATION AFTER SUCCESSFUL TREATMENT OF SMALL-CELL LUNG-CANCER IS ASSOCIATED WITH FEWER SMOKING-RELATED 2ND PRIMARY CANCERS	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING CESSATION; CARCINOMA, OAT CELL; LUNG NEOPLASMS; NEOPLASMS, 2ND PRIMARY; SMOKING	ACUTE NONLYMPHOCYTIC LEUKEMIA; COMBINED MODALITY THERAPY; LONG-TERM SURVIVORS; HODGKINS-DISEASE; COMBINATION CHEMOTHERAPY; BRONCHOGENIC-CARCINOMA; PROGNOSTIC FACTORS; NECK-CANCER; FOLLOW-UP; 10-YEAR EXPERIENCE	Objective: To determine the incidence of second primary cancers developing in patients surviving free of cancer for 2 or more years after treatment for small-cell lung cancer and to assess the potential effect of smoking cessation. Design: Retrospective review of 540 patients from a single institution with a median follow-up of 6.1 years. Setting. A single government institution (the National Cancer Institute). Patients: Consecutive sample of 540 patients with histologically confirmed small-cell lung cancer treated from 1973 through 1989 on therapeutic clinical trials. Measurements: The relative risk for second primary cancers and death were calculated in patients who remained free of cancer for 2 years after initiation of therapy. The relation of these end points to smoking history was also determined. Results: Fifty-five patients (10%) were free of cancer 2 years after initiation of therapy. Eighteen of these patients developed one or more second primary cancers, including 13 who developed second primary non-small-cell lung cancer. The risk for any second primary cancer compared with that in the general population was increased four times (relative risk, 4.4; 95% CI, 2.5-7.2), with a relative risk of a second primary non-small-cell lung cancer of 16 (CI, 8.4-27). Forty-three patients discontinued smoking within 6 months of starting treatment for small-cell lung cancer, and 12 continued to smoke. In those who stopped smoking at time of diagnosis, the relative risk of a second lung cancer was 11 (CI, 4.4 to 23), whereas, in those who continued to smoke, it was 32 (CI, 12 to 69). Conclusions: Patients with small-cell lung cancer who survive cancer-free for more than 2 years have a significantly increased risk for development of a second primary smoking-related cancer. Cigarette smoking cessation after successful therapy is associated with a decrease in risk for a second smoking-related primary cancer.	NATL NAVAL MED CTR, NCI, NAVY MED ONCOL BRANCH, BLDG 8, ROOM 4101, BETHESDA, MD 20899 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA			Richardson, Gary/AAB-1728-2019; Venzon, David J/B-3078-2008; Tucker, Margaret A/B-4297-2015					BOICE JD, 1991, NIH913180 PUBL; BOIVIN JF, 1988, CANCER, V61, P2541, DOI 10.1002/1097-0142(19880615)61:12<2541::AID-CNCR2820611225>3.0.CO;2-G; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BROWER M, 1983, AM J MED, V75, P993, DOI 10.1016/0002-9343(83)90880-X; CASTIGLIANO SG, 1968, J AM DENT ASSOC, V77, P580, DOI 10.14219/jada.archive.1968.0275; CHAK LY, 1984, J CLIN ONCOL, V2, P385, DOI 10.1200/JCO.1984.2.5.385; CIMINO G, 1991, J CLIN ONCOL, V9, P432, DOI 10.1200/JCO.1991.9.3.432; COHEN MH, 1977, CANCER TREAT REP, V61, P349; COHEN MH, 1979, CANCER TREAT REP, V63, P163; COOPER JS, 1989, INT J RADIAT ONCOL, V17, P449, DOI 10.1016/0360-3016(89)90094-1; CORTESE DA, 1983, J THORAC CARDIOV SUR, V86, P373; CULLEN JW, 1989, CANCER PRINCIPLES PR, P181; DAVIS S, 1985, J CLIN ONCOL, V3, P80, DOI 10.1200/JCO.1985.3.1.80; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; GILLIS TM, 1983, AM J SURG, V146, P512, DOI 10.1016/0002-9610(83)90243-X; GLUCKMAN JL, 1983, LARYNGOSCOPE, V93, P71; GOULD VE, 1983, LAB INVEST, V49, P519; HELLQUIST H, 1982, CLIN OTOLARYNGOL, V7, P11, DOI 10.1111/j.1365-2273.1982.tb01557.x; HEYNE KH, 1992, J CLIN ONCOL, V10, P1519, DOI 10.1200/JCO.1992.10.10.1519; HONG WK, 1985, CANCER-AM CANCER SOC, V56, P1242, DOI 10.1002/1097-0142(19850915)56:6<1242::AID-CNCR2820560603>3.0.CO;2-Z; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HONG WK, 1983, NEW ENGL J MED, V308, P75, DOI 10.1056/NEJM198301133080204; IHDE DC, 1986, J CLIN ONCOL, V4, P1443, DOI 10.1200/JCO.1986.4.10.1443; IHDE DC, 1991, P AN M AM SOC CLIN, V10, P240; JACOBS RH, 1986, CANCER, V58, P2177, DOI 10.1002/1097-0142(19861115)58:10<2177::AID-CNCR2820581003>3.0.CO;2-O; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; JOHNSON BE, 1986, AM J MED, V80, P1103, DOI 10.1016/0002-9343(86)90672-8; JOHNSON BE, 1990, J CLIN ONCOL, V8, P396, DOI 10.1200/JCO.1990.8.3.396; JOHNSON BE, 1988, AM J MED, V85, P194; JOHNSON BE, 1985, ANN INTERN MED, V103, P430, DOI 10.7326/0003-4819-103-3-430; JOHNSON DH, 1986, AM J MED, V81, P962, DOI 10.1016/0002-9343(86)90388-8; LEQUAGLIE C, 1991, CHEST, V100, P1053, DOI 10.1378/chest.100.4.1053; LICCIARDELLO JTW, 1989, INT J RADIAT ONCOL, V17, P467, DOI 10.1016/0360-3016(89)90096-5; LIPPMAN SM, 1989, INT J RADIAT ONCOL, V17, P691, DOI 10.1016/0360-3016(89)90126-0; LIST AF, 1985, J CLIN ONCOL, V3, P215, DOI 10.1200/JCO.1985.3.2.215; LIVINGSTON RB, 1984, AM J MED, V77, P415, DOI 10.1016/0002-9343(84)90095-0; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; MASON MK, 1982, THORAX, V37, P453, DOI 10.1136/thx.37.6.453; MATTHEWS MJ, 1988, LUNG CANCER COMPREHE, P5; MCDONALD S, 1989, INT J RADIAT ONCOL, V17, P457, DOI 10.1016/0360-3016(89)90095-3; MEMOLI VA, 1986, LUNG CANCER, V2, P56; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MOORE C, 1971, J AMER MED ASSOC, V218, P553, DOI 10.1001/jama.218.4.553; OSHITA F, 1991, EUR J CANCER, V27, P427, DOI 10.1016/0277-5379(91)90378-Q; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1044, DOI 10.1200/JCO.1986.4.7.1044; OSTERLIND K, 1986, CANCER RES, V46, P4189; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1307, DOI 10.1200/JCO.1986.4.9.1307; PASTORINO U, 1991, LUNG CANCER, V7, P133; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PEREZSTABLE EJ, 1992, AM REV RESPIR DIS, V145, P53, DOI 10.1164/ajrccm/145.1.53; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; RATAIN MJ, 1987, BLOOD, V70, P1412; REYNOLDS RD, 1978, CANCER, V42, P2887, DOI 10.1002/1097-0142(197812)42:6<2887::AID-CNCR2820420651>3.0.CO;2-9; ROSTI G, 1991, P AN M AM SOC CLIN, V10, P268; SAGMAN U, 1992, J CLIN ONCOL, V10, P1525, DOI 10.1200/JCO.1992.10.10.1525; SHIELDS TW, 1978, J THORAC CARDIOV SUR, V76, P439; SILVERMAN S, 1984, CANCER, V53, P563; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Smith R A, 1976, Thorax, V31, P507, DOI 10.1136/thx.31.5.507; SOUHAMI RL, 1990, BRIT J CANCER, V61, P584, DOI 10.1038/bjc.1990.131; SOUHAMI RL, 1985, CANCER RES, V45, P2878; SPIEGELMAN D, 1989, J CLIN ONCOL, V7, P344, DOI 10.1200/JCO.1989.7.3.344; THOMAS P, 1990, ANN THORAC SURG, V49, P242, DOI 10.1016/0003-4975(90)90145-V; THOMPSON SG, 1990, THORAX, V45, P356, DOI 10.1136/thx.45.5.356; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1980, BRIT MED J, V280, P216, DOI 10.1136/bmj.280.6209.216; VANBODEGOM PC, 1989, THORAX, V44, P788, DOI 10.1136/thx.44.10.788; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VINCENT MD, 1987, EUR J CANCER CLIN ON, V23, P1589, DOI 10.1016/0277-5379(87)90436-6; VOGELSANG GB, 1985, AM J MED, V79, P49, DOI 10.1016/0002-9343(85)90545-5; WARREN WH, 1990, CANCER, V65, P1003, DOI 10.1002/1097-0142(19900215)65:4<1003::AID-CNCR2820650427>3.0.CO;2-Y; WILLERS S, 1992, ARCH ENVIRON HEALTH, V47, P357, DOI 10.1080/00039896.1992.9938375; WYNDER EL, 1977, CANCER, V40, P1872, DOI 10.1002/1097-0142(197710)40:4+<1872::AID-CNCR2820400817>3.0.CO;2-#; WYNDER EL, 1969, CANCER, V24, P730, DOI 10.1002/1097-0142(196910)24:4<730::AID-CNCR2820240411>3.0.CO;2-L	77	176	177	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					383	390		10.7326/0003-4819-119-5-199309010-00006	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8393311				2022-12-28	WOS:A1993LZ47600006
J	SCHMIEDER, RE; GATZKA, C; SCHACHINGER, H; SCHOBEL, H; RUDDEL, H				SCHMIEDER, RE; GATZKA, C; SCHACHINGER, H; SCHOBEL, H; RUDDEL, H			OBESITY AS A DETERMINANT FOR RESPONSE TO ANTIHYPERTENSIVE TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							CALCIUM ENTRY BLOCKERS; BLOOD-PRESSURE; ARTERIAL-HYPERTENSION; PLASMA-RENIN; WEIGHT-LOSS; REDUCTIONS; DIURETICS; DISEASE	Objective-To test the hypothesis that beta blockers lower blood pressure more effectively than calcium entry blockers in obese hypertensive patients and that calcium entry blockers are more effective in lean patients. Design-Double blind, randomised controlled trial of treatment over six weeks. Setting-Tertiary referral centre. Subjects-42 white men with uncomplicated mild to moderate essential hypertension (World Health Organisation stage I or II); 36 completed the study. Intervention-Patients were randomised to metoprolol 50-100 mg twice daily or isradipine 2.5-5.0 mg twice daily for six weeks after a two week run in phase. Main outcome measure-Blood pressure after six weeks of treatment. Results-When stratified according to treatment and presence of obesity (body mass index < or greater-than-or-equal-to 27 kg/m2), the mean (SD) fall in blood pressure in the beta blocker group was 24 (13)/18 (10) mm Hg in obese patients and 18 (19)/12 (13) mm Hg in lean patients. In the calcium entry blocker group, the fall in blood pressure was 21 (15)/17 (6) mm Hg in lean patients and 18 (11)/8 (10) mm Hg in obese patients. After taking age and blood pressure before treatment into account there was a significant interaction between obesity and drug therapy (p=0.019) with a better diastolic blood pressure response to calcium entry blockers in lean patients and to beta blockers in obese hypertensive patients. Conclusion-Obesity affects the efficacy of metoprolol and isradipine in reducing blood pressure.	ST FRANZISKA STIFT,DEPT PSYCHOSOMAT MED,W-6550 BAD KREUZNACH,GERMANY		SCHMIEDER, RE (corresponding author), UNIV ERLANGEN NURNBERG,DEPT MED 4,D-90429 NURNBERG,GERMANY.			Schachinger, Hartmut/0000-0003-0690-8864				BUHLER FR, 1988, DRUGS, V35, P495; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; ERNE P, 1983, HYPERTENSION, V5, P97; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; FREIS ED, 1988, HYPERTENSION, V12, P244, DOI 10.1161/01.HYP.12.3.244; FROHLICH ED, 1992, HYPERTENSION S1, V19, P119; Inc S. P. S. S., 1988, SPSS X USERS GUIDE; JESPERSEN LT, 1989, AM J MED, V86, P57; JULIUS S, 1990, EUR J CLIN PHARMACOL, V38, pS125, DOI 10.1007/BF01409481; KAPLAN NM, 1989, JAMA-J AM MED ASSOC, V262, P817, DOI 10.1001/jama.262.6.817; KOREN MJ, 1990, AM J HYPERTENS, V3, pA13; KUSAKA M, 1991, AM J HYPERTENS, V4, P735, DOI 10.1093/ajh/4.9.735; MANINTVELD AJ, 1982, BRIT J COIN PHARM S2, V13, P2455; MESSERLI F H, 1988, American Journal of Medicine, V84, P8, DOI 10.1016/0002-9343(88)90181-7; MESSERLI FH, 1986, NEW ENGL J MED, V314, P378, DOI 10.1056/NEJM198602063140608; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1983, AM J MED, V74, P808, DOI 10.1016/0002-9343(83)91071-9; MESSERLI FH, 1990, CARDIOVASCULR DRUG T; NICHOLSON JP, 1987, ANN INTERN MED, V107, P329, DOI 10.7326/0003-4819-107-2-329; REISIN E, 1991, HYPERTENSION, V17, P405; SCHMIEDER RE, 1987, AM J MED, V82, P11, DOI 10.1016/0002-9343(87)90370-6; SCHULTE W, IN PRESS EUR HEART J; SOWERS JR, 1982, J CLIN ENDOCR METAB, V54, P1181, DOI 10.1210/jcem-54-6-1181; TUCK ML, 1983, ACTA ENDOCRINOL-COP, V102, P252, DOI 10.1530/acta.0.1020252; TUCK ML, 1992, HYPERTENSION, V19, pI67, DOI 10.1161/01.HYP.19.1_Suppl.I67; 1971, HYPERTENSION ADULTS; 1984, STAT B METROP INSUR, V64, P2; 1988, ARCH INTERN MED, V148, P1023	28	45	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					537	540		10.1136/bmj.307.6903.537	http://dx.doi.org/10.1136/bmj.307.6903.537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400973	Bronze, Green Published			2022-12-28	WOS:A1993LV18000016
J	INGRAMS, GJ; MORGAN, FB				INGRAMS, GJ; MORGAN, FB			TRANSCUTANEOUS OVERDOSE OF TERBUTALINE	BRITISH MEDICAL JOURNAL			English	Letter									AYLMER LODGE SURG,KIDDERMINSTER,ENGLAND		INGRAMS, GJ (corresponding author), KIDDERMINSTER GEN HOSP,KIDDERMINSTER DY11 6RJ,ENGLAND.							BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BURLEY PGJ, 1986, LANCET, V2, P323; EEDY DJ, 1988, POSTGRAD MED J, V64, P306, DOI 10.1136/pgmj.64.750.306; JARVIE DR, 1987, CLIN CHIM ACTA, V168, P313, DOI 10.1016/0009-8981(87)90007-6; JEPPSSON AB, 1991, PULM PHARMACOL, V4, P73, DOI 10.1016/0952-0600(91)90055-8	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					484	484		10.1136/bmj.307.6902.484-c	http://dx.doi.org/10.1136/bmj.307.6902.484-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400938	Green Published, Bronze			2022-12-28	WOS:A1993LU59000028
J	LINCOFF, NS; ODEL, JG; HIRANO, M				LINCOFF, NS; ODEL, JG; HIRANO, M			OUTBREAK OF OPTIC AND PERIPHERAL NEUROPATHY IN CUBA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									COLUMBIA PRESBYTERIAN MED CTR,DEPT NEUROL,P&S 4-431,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OPHTHALMOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; Columbia University				Hirano, Michio/0000-0002-7070-7402	NINDS NIH HHS [1K08NS01617-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001617] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARROLL F. D., 1944, American Journal of Ophthalmology, V27, P713, DOI 10.1016/S0002-9394(44)91780-0; CARROLL FD, 1966, ARCH OPHTHALMOL-CHIC, V76, P406; DENNYBROWN D, 1947, MEDICINE, V26, P41, DOI 10.1097/00005792-194702000-00002; FISHER CM, 1955, CAN SERV MED J, V11, P157; FRENCH HW, 1993, NY TIMES        1210, pA4; GLASER JS, 1990, NEUROOPTHALMOLOGY, P129; GRANDE F, 1941, AVITAMINOSIS SISTEMA; HARDY LH, 1957, AO H R R PSEUDOISOCH; Osuntokun B O, 1981, World Rev Nutr Diet, V36, P141; RIVLIN RS, 1993, CECIL TXB MED, V1, P170; Schaumburg HH, 1980, EXPT CLIN NEUROTOXIC, P395; SPILLANE JD, 1947, NUTRITIONAL DISORDER; Strachan H., 1897, PRACTITIONER, V59, P477; VICTOR M, 1960, Arch Ophthalmol, V64, P1; Victor M., 1989, WERNICKE KORSAKOFF S, V2nd	15	39	39	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					511	518		10.1001/jama.270.4.511	http://dx.doi.org/10.1001/jama.270.4.511			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8391588				2022-12-28	WOS:A1993LN42600037
J	AISNER, J				AISNER, J			BREAST-CANCER THERAPY IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											AISNER, J (corresponding author), UNIV MARYLAND,CTR CANC,BALTIMORE,MD 21201, USA.							Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; 1992, LANCET, V339, P71	3	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					391	391		10.1001/jama.270.3.391	http://dx.doi.org/10.1001/jama.270.3.391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8391087				2022-12-28	WOS:A1993LM43500041
J	BASHIR, ZI; BORTOLOTTO, ZA; DAVIES, CH; BERRETTA, N; IRVING, AJ; SEAL, AJ; HENLEY, JM; JANE, DE; WATKINS, JC; COLLINGRIDGE, GL				BASHIR, ZI; BORTOLOTTO, ZA; DAVIES, CH; BERRETTA, N; IRVING, AJ; SEAL, AJ; HENLEY, JM; JANE, DE; WATKINS, JC; COLLINGRIDGE, GL			INDUCTION OF LTP IN THE HIPPOCAMPUS NEEDS SYNAPTIC ACTIVATION OF GLUTAMATE METABOTROPIC RECEPTORS	NATURE			English	Article							LONG-TERM POTENTIATION; PROTEIN KINASE-C; RAT HIPPOCAMPUS; BLOCKS INDUCTION; STRIATAL NEURONS; AREA CA1; ACID; TRANSMISSION; MAINTENANCE; STIMULATION	UNDERSTANDING the mechanisms of long-term potentiation (LTP) should provide insights into the molecular basis of learning and memory in vertebrates. Ionotropic glutamate receptors play a central role in LTP; AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) receptors and NMDA (N-methyl-D-aspartate) receptors mediate synaptic responses that are enhanced in LTP and, in addition, NMDA receptors are necessary for the induction of LTP in most pathways1. There is also circumstantial evidence that metabotropic glutamate receptors (mGluRs) may be involved in LTP because the specific mGluR agonist aminocyclopentane dicarboxylate can augment tetanus-induced LTP2 and, under certain circumstances, can itself induce a slow-onset potentiation3,4. But the absence of any effective mGluR antagonist has prevented the determination of whether mGluRs are involved in the induction of tetanus-induced LTP. We report here that (RS)-alpha-methyl-4-carboxyphenylglycine is a specific mGluR antagonist in the hippocampus and have used this compound to examine the nature of the involvement of mGluRs in LTP. We show that synaptic activation of mGluRs is necessary for the induction of both NMDA receptor-dependent and NMDA receptor-independent forms of LTP in the hippocampus.	UNIV BRISTOL,SCH MED SCI,DEPT PHARMACOL,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	BASHIR, ZI (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Berretta, Nicola/K-5667-2016; collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; Seal, Andrew/C-8550-2014; Henley, Jeremy M/A-2776-2009	Berretta, Nicola/0000-0001-8097-6238; Collingridge, Graham L/0000-0002-9572-5359; Seal, Andrew/0000-0003-3656-4054; Bashir, Zafar/0000-0003-3650-2136; Henley, Jeremy/0000-0003-3589-8335	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BEHNISCH T, 1991, NEUROREPORT, V2, P386, DOI 10.1097/00001756-199107000-00008; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; BRAMHAM CR, 1992, NEUROCHEM INT, V20, P441, DOI 10.1016/0197-0186(92)90021-I; CHARPAK S, 1991, P ROY SOC B-BIOL SCI, V243, P221, DOI 10.1098/rspb.1991.0035; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; DERRICK BE, 1992, J PHARMACOL EXP THER, V263, P725; DESAI MA, 1992, SYNAPSE, V12, P206, DOI 10.1002/syn.890120305; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARVEY J, 1991, BRIT J PHARMACOL, V104, pC79; HU GY, 1992, ACTA PHYSIOL SCAND, V145, P187, DOI 10.1111/j.1748-1716.1992.tb09354.x; IRVING AJ, 1992, CELL CALCIUM, V13, P293, DOI 10.1016/0143-4160(92)90064-Y; IRVING AJ, 1990, EUR J PHARMACOL, V186, P363, DOI 10.1016/0014-2999(90)90462-F; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; IZUMI Y, 1991, NEUROSCI LETT, V122, P187, DOI 10.1016/0304-3940(91)90854-M; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTIN MR, 1983, NEUROPEPTIDES, V4, P45, DOI 10.1016/0143-4179(83)90007-0; MCGUINNESS N, 1991, EUR J PHARMACOL, V197, P231, DOI 10.1016/0014-2999(91)90529-Y; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; REYMANN KG, 1989, NEUROSCI LETT, V98, P166, DOI 10.1016/0304-3940(89)90504-1; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; STANTON PK, 1991, NEUROSCI LETT, V127, P61, DOI 10.1016/0304-3940(91)90895-Z; STRATTON KR, 1990, EUR J PHARMACOL, V186, P357, DOI 10.1016/0014-2999(90)90461-E; STRATTON KR, 1989, EUR J PHARMACOL, V173, P235, DOI 10.1016/0014-2999(89)90529-3; ZHENG F, 1992, NEURON, V9, P163, DOI 10.1016/0896-6273(92)90231-2	36	660	683	2	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					347	350		10.1038/363347a0	http://dx.doi.org/10.1038/363347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8388549				2022-12-28	WOS:A1993LD91700052
J	GYORKE, S; FILL, M				GYORKE, S; FILL, M			RYANODINE RECEPTOR ADAPTATION - CONTROL MECHANISM OF CA2+-INDUCED CA2+ RELEASE IN HEART	SCIENCE			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; SKELETAL-MUSCLE; INOSITOL 1,4,5-TRISPHOSPHATE; CA-2+ RELEASE; CHANNEL; ACTIVATION; CELLS; INACTIVATION; CONTRACTION	Adaptation of single cardiac ryanodine receptor (RyR) channels was demonstrated by application of the caged calcium ion (Ca2+) methodology. In contrast to conventional desensitization found in surface membrane ligand-gated channels, single cardiac RyR channels adapted to maintained Ca2+ stimuli, preserving their ability to respond to a second (larger) Ca2+ stimulus. RyR adaptation may represent a molecular control mechanism for smoothly graded Ca2+-induced Ca2+ release in heart and may be a fundamental feature of channels, including the inositol trisphosphate receptor, that are involved in intracellular Ca2+ signaling in many cell types.	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029640] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29-AR41197] Funding Source: Medline; NINDS NIH HHS [R01-NS29640] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], [No title captured]; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CHU A, 1991, Biophysical Journal, V59, p102A; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; FABIATO A, 1979, NATURE, V281, P146, DOI 10.1038/281146a0; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FILL M, 1990, BIOPHYS J, V50, P471; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GYORKE S, 1992, J PHYSIOL-LONDON, V456, P443; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LAI FA, 1988, BIOCHEM BIOPH RES CO, V151, P441, DOI 10.1016/0006-291X(88)90613-4; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; SWILLENS S, 1992, MOL PHARMACOL, V41, P110; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TATE CA, 1985, J BIOL CHEM, V260, P9618; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189	34	292	295	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					807	809		10.1126/science.8387229	http://dx.doi.org/10.1126/science.8387229			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8387229				2022-12-28	WOS:A1993LA74400030
J	ZAHLER, AM; NEUGEBAUER, KM; LANE, WS; ROTH, MB				ZAHLER, AM; NEUGEBAUER, KM; LANE, WS; ROTH, MB			DISTINCT FUNCTIONS OF SR PROTEINS IN ALTERNATIVE PREMESSENGER RNA SPLICING	SCIENCE			English	Article							BINDING PROTEINS; POLYMERASE-II; INVITRO; REGULATORS; TRANSCRIPTION; EXPRESSION; SITES; ASF	Alternative splicing of precursor messenger RNAs (pre-mRNAs) is a common mechanism of regulating gene expression. SR proteins are a family of pre-mRNA splicing factors that are structurally related and evolutionarily conserved. Any member of the SR family can complement a splicing-deficient extract that lacks the entire family of SR proteins. Here it is demonstrated that particular SR proteins have distinct functions in alternative pre-mRNA splicing in vitro. In addition, SR proteins are differentially expressed in a variety of tissues. These results suggest a fundamental role for SR proteins in the regulation of alternative splicing.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138	Fred Hutchinson Cancer Center; Harvard University				Zahler, Alan/0000-0003-0027-1647	PHS HHS [42786-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARDY CT, 1990, J CLIN MICROBIOL, V28, P2534, DOI 10.1128/JCM.28.11.2534-2538.1990; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, UNPUB	20	360	364	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					219	222		10.1126/science.8385799	http://dx.doi.org/10.1126/science.8385799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8385799				2022-12-28	WOS:A1993KW45200040
J	TSE, A; TSE, FW; ALMERS, W; HILLE, B				TSE, A; TSE, FW; ALMERS, W; HILLE, B			RHYTHMIC EXOCYTOSIS STIMULATED BY GNRH-INDUCED CALCIUM OSCILLATIONS IN RAT GONADOTROPES	SCIENCE			English	Article							LUTEINIZING-HORMONE SECRETION; MEMBRANE CAPACITANCE; CELLS; PITUITARY; CA-2+; RELEASE	In pituitary gonadotropes, gonadotropin-releasing hormone (GnRH) induces the rhythmic release of Ca2+ from an inositol 1,4,5-trisphosphate (IP3)-sensitive store. Simultaneous measurement of the concentration of cytosolic free Ca2+ ([Ca2+]i) and exocytosis in single identified gonadotropes showed that each elevation of [Ca2+]i induced a burst of exocytosis. These phenomena were largely suppressed by buffering of [Ca2+]i but persisted in the absence of extracellular Ca2+. Activation of voltage-gated Ca2+ channels by brief depolarizations seldom supplied enough Ca2+ for exocytosis, but [Ca2+]i elevations induced by photolysis of caged IP3 did trigger exocytosis, confirming that GnRH-stimulated gonadotropic hormone secretion is closely coupled to intracellular Ca2+ release. Agonist-induced oscillations of [Ca2+]i in secretory cells may be a mechanism to optimize the secretory output while avoiding the toxic effects of sustained elevation of [Ca2+]i.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SJ-40,SEATTLE,WA 98195; MAX PLANCK INST MED RES,W-6900 HEIDELBERG 1,GERMANY	University of Washington; University of Washington Seattle; Max Planck Society			Tse, Frederick/C-3449-2013; Tse, Amy/C-3142-2013	Tse, Amy/0000-0002-0847-7466				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; CHANG JP, 1988, ENDOCRINOLOGY, V123, P87, DOI 10.1210/endo-123-1-87; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; LEONG DA, 1991, J BIOL CHEM, V266, P9016; LEVINE JE, 1982, ENDOCRINOLOGY, V111, P1439, DOI 10.1210/endo-111-5-1439; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MOENTER SM, 1992, ENDOCRINOLOGY, V130, P503, DOI 10.1210/en.130.1.503; MORIARTY GC, 1975, ENDOCRINOLOGY, V97, P1215, DOI 10.1210/endo-97-5-1215; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PENNER R, 1989, TRENDS NEUROSCI, V12, P159, DOI 10.1016/0166-2236(89)90059-3; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, IN PRESS ENDOCRINOLO; TSE A, IN PRESS PULSATILITY; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473	32	225	227	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					82	84		10.1126/science.8385366	http://dx.doi.org/10.1126/science.8385366			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8385366				2022-12-28	WOS:A1993KV42300032
J	PRYOR, DB; SHAW, L; MCCANTS, CB; LEE, KL; MARK, DB; HARRELL, FE; MUHLBAIER, LH; CALIFF, RM				PRYOR, DB; SHAW, L; MCCANTS, CB; LEE, KL; MARK, DB; HARRELL, FE; MUHLBAIER, LH; CALIFF, RM			VALUE OF THE HISTORY AND PHYSICAL IN IDENTIFYING PATIENTS AT INCREASED RISK FOR CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION; HEART CATHETERIZATION	SURVIVAL; MODELS	Objective: To determine whether information from the physician's initial evaluation of patients with suspected coronary artery disease predicts coronary anatomy at catheterization and 3-year survival. Design: Prospective validation of regression model estimates in an outpatient cohort. Setting: University medical center. Patients: A total of 1030 consecutive outpatients referred for noninvasive testing for suspected coronary artery disease; 168 of these patients subsequently underwent catheterization within 90 days. Measurements: Information from the initial history, physical examination, electrocardiogram, and chest radiograph was used to predict coronary anatomy (the likelihood of any significant coronary disease, severe disease [left main or three-vessel], and significant left main disease) among 168 catheterized patients and to estimate 3-year survival among all patients. These estimates were compared with those based on treadmill testing. Cardiovascular testing charges were calculated for all patients. Results: Predicted coronary anatomy and survival closely corresponded to actual findings. Compared with the treadmill exercise test, initial evaluation was slightly better able to distinguish patients with or without any coronary disease and was similar in the ability to identify patients at increased risk for dying or with anatomically severe disease. Based on arbitrary definitions, 37% to 66% of patients were at low risk and responsible for 31% to 56% of the charges for cardiovascular testing. Conclusions: The physician's initial evaluation, despite the subjective nature of much of the information gathered, can be used to identify patients likely to benefit from further testing. The development of strategies for cost-conscious quality care must begin with the history, physical examination, and simple laboratory testing.			PRYOR, DB (corresponding author), DUKE UNIV, MED CTR, BOX 3531, DURHAM, NC 27710 USA.			Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS004873, R18HS005635] Funding Source: NIH RePORTER; AHRQ HHS [HS-04873, HS-05635, HS-06503] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLUNDEN PB, 1989, AM ASS MED SYSTEMS I, P135; BOSWICK JM, 1987, 11TH P ANN S COMP AP, P162; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; COX DR, 1972, J R STAT SOC B, V34, P187; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HARRELL FE, 1988, SUGI SUPPLEMENTAL LI, V1, P15; HARRIS PJ, 1980, CIRCULATION, V62, P718, DOI 10.1161/01.CIR.62.4.718; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KONG DF, 1989, ARCH INTERN MED, V149, P1177, DOI 10.1001/archinte.149.5.1177; LEE JC, 1990, J AM COLL CARDIOL, V15, P378, DOI 10.1016/S0735-1097(10)80066-X; LEE KL, 1986, AM J MED, V80, P553, DOI 10.1016/0002-9343(86)90807-7; MARK DB, 1987, ANN INTERN MED, V106, P53, DOI 10.7326/0003-4819-106-1-53; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1987, CIRCULATION, V76, P13; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SOX HC, 1990, AM J MED, V89, P7, DOI 10.1016/0002-9343(90)90090-Z	22	388	396	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					81	90		10.7326/0003-4819-118-2-199301150-00001	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416322				2022-12-28	WOS:A1993KF91800001
J	STAMM, WE; HOOTON, TM				STAMM, WE; HOOTON, TM			MANAGEMENT OF URINARY-TRACT INFECTIONS IN ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SPINAL-CORD INJURY; TRIMETHOPRIM-SULFAMETHOXAZOLE; ASYMPTOMATIC BACTERIURIA; RANDOMIZED TRIAL; NATURAL-HISTORY; RISK-FACTORS; ACUTE PYELONEPHRITIS; ACUTE DYSURIA; DOUBLE-BLIND; WOMEN		UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	STAMM, WE (corresponding author), UNIV WASHINGTON, DEPT MED, DIV INFECT DIS, 325 9TH AVE, SEATTLE, WA 98104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040045] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40045] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRIOLE VT, 1991, MED CLIN N AM, V75, P359, DOI 10.1016/S0025-7125(16)30459-X; BAILEY RR, 1983, SINGLE DOSE THERAPY, P1; BALDASSARRE JS, 1991, MED CLIN N AM, V75, P375, DOI 10.1016/S0025-7125(16)30460-6; BARNES RC, 1986, LANCET, V1, P171; BOSCIA JA, 1987, ANN INTERN MED, V106, P764, DOI 10.7326/0003-4819-106-5-764; CARLSON KJ, 1985, ANN INTERN MED, V102, P244, DOI 10.7326/0003-4819-102-2-244; DONOVAN WH, 1978, ARCH PHYS MED REHAB, V59, P351; EDEN CS, 1988, J INFECT DIS, V157, P421, DOI 10.1093/infdis/157.3.421; FALCK G, 1988, SCAND J INFECT DIS, V20, P619, DOI 10.3109/00365548809035662; FIHN SD, 1988, ANN INTERN MED, V108, P350, DOI 10.7326/0003-4819-108-3-350; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FOWLER JE, 1981, NEW ENGL J MED, V304, P462, DOI 10.1056/NEJM198102193040805; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HARDING GKM, 1991, ANN INTERN MED, V114, P713, DOI 10.7326/0003-4819-114-9-713; HARDING GKM, 1982, REV INFECT DIS, V4, P438; HOEPELMAN AIM, 1992, AIDS, V6, P179, DOI 10.1097/00002030-199202000-00006; HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64; HOOTON TM, 1991, MED CLIN N AM, V75, P339, DOI 10.1016/S0025-7125(16)30458-8; HOOTON TM, 1991, ANTIMICROB AGENTS CH, V35, P1479, DOI 10.1128/AAC.35.7.1479; HOOTON TM, 1991, 31ST INT C ANT AG CH, P260; Johnson J R, 1987, Infect Dis Clin North Am, V1, P773; JOHNSON JR, 1991, J INFECT DIS, V163, P325, DOI 10.1093/infdis/163.2.325; JOHNSON JR, 1989, ANN INTERN MED, V111, P906, DOI 10.7326/0003-4819-111-11-906; JOHNSON JR, 1992, CLIN INFECT DIS, V14, P15, DOI 10.1093/clinids/14.1.15; JOHNSON JR, 1990, INFECT DIS CLIN N AM, V4, pR12; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; KUHLEMEIER KV, 1985, J UROLOGY, V134, P514, DOI 10.1016/S0022-5347(17)47268-5; LIPSKY BA, 1989, ANN INTERN MED, V110, P138, DOI 10.7326/0003-4819-110-2-138; NABER KG, 1989, REV INFECT DIS, V11, pS1321; NICKEL JC, 1985, CAN J SURG, V28, P50; NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619; Nicolle L E, 1987, Infect Dis Clin North Am, V1, P793; NICOLLE LE, 1988, J INFECT DIS, V157, P1239, DOI 10.1093/infdis/157.6.1239; NORRBY SR, 1990, REV INFECT DIS, V12, P458; PAPPAS PG, 1991, MED CLIN N AM, V75, P313, DOI 10.1016/S0025-7125(16)30456-4; PATTON JP, 1991, MED CLIN N AM, V75, P495, DOI 10.1016/S0025-7125(16)30466-7; PFAU A, 1983, J UROLOGY, V129, P1153, DOI 10.1016/S0022-5347(17)52617-8; PLATT R, 1986, AM J EPIDEMIOL, V124, P977, DOI 10.1093/oxfordjournals.aje.a114487; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; REMIS RS, 1987, AM J EPIDEMIOL, V126, P685, DOI 10.1093/oxfordjournals.aje.a114708; RONALD AR, 1976, JAMA-J AM MED ASSOC, V235, P1854, DOI 10.1001/jama.235.17.1854; RONALD AR, 1992, INFECTION, V20, pS164, DOI 10.1007/BF01704364; RONALD AR, 1991, MED CLIN N AM, V75, P299, DOI 10.1016/S0025-7125(16)30455-2; RUBIN RH, 1992, CLIN INFECT DIS, V15, pS216, DOI 10.1093/clind/15.Supplement_1.S216; SHEINFELD J, 1989, NEW ENGL J MED, V320, P773, DOI 10.1056/NEJM198903233201205; SPACH DH, 1992, JAMA-J AM MED ASSOC, V267, P679, DOI 10.1001/jama.267.5.679; STAMM WE, 1991, AM J MED, V91, pS65, DOI 10.1016/0002-9343(91)90345-X; STAMM WE, 1991, REV INFECT DIS, V13, P77; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAMM WE, 1987, ANN INTERN MED, V106, P341, DOI 10.7326/0003-4819-106-3-341; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STAPLETON A, 1990, JAMA-J AM MED ASSOC, V264, P703, DOI 10.1001/jama.264.6.703; STARK RP, 1984, NEW ENGL J MED, V311, P560, DOI 10.1056/NEJM198408303110903; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; Warren J W, 1987, Infect Dis Clin North Am, V1, P823; WARREN JW, 1982, J INFECT DIS, V146, P719, DOI 10.1093/infdis/146.6.719; WARREN JW, 1982, JAMA-J AM MED ASSOC, V248, P454; WOLFSON JS, 1989, ANTIMICROB AGENTS CH, V33, P1655, DOI 10.1128/AAC.33.10.1655; WONG ES, 1983, JAMA-J AM MED ASSOC, V250, P3087, DOI 10.1001/jama.250.22.3087; WONG ES, 1985, ANN INTERN MED, V102, P302, DOI 10.7326/0003-4819-102-3-302; ZHANEL GG, 1990, ARCH INTERN MED, V150, P1389, DOI 10.1001/archinte.150.7.1389	61	562	581	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1328	1334						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413414				2022-12-28	WOS:A1993MD55700008
J	UCKUN, FM; KERSEY, JH; HAAKE, R; WEISDORF, D; NESBIT, ME; RAMSAY, NKC				UCKUN, FM; KERSEY, JH; HAAKE, R; WEISDORF, D; NESBIT, ME; RAMSAY, NKC			PRETRANSPLANTATION BURDEN OF LEUKEMIC PROGENITOR CELLS AS A PREDICTOR OF RELAPSE AFTER BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REMISSION; 4-HYDROPEROXYCYCLOPHOSPHAMIDE; DISEASE	Background. We developed a test to discern small numbers of residual leukemic progenitor cells in the bone marrow of patients with acute lymphoblastic leukemia (ALL) in remission. Preliminary studies revealed that before undergoing bone marrow transplantation such patients differed in their burden of leukemic progenitor cells. These observations suggested that the burden of these cells might influence the risk of relapse after transplantation. Methods. The number of residual leukemic progenitor cells before bone marrow transplantation was determined for 83 patients with high-risk ALL. We combined multiparameter flow cytometry and cell sorting with assays for leukemic progenitor cells in a quantitative method for the detection of minimal residual disease. Results. The count of leukemic progenitor cells in bone marrow specimens from patients in remission varied markedly between patients, ranging from 0 to 12,546 cells per million mononuclear cells, or from 0 to 1.255 percent (median, 51 leukemic progenitor cells per million mononuclear cells, or 0.005 percent). Patients whose count of leukemic progenitor cells exceeded the median value had a higher likelihood of relapse than did patients with values below the median (relapse rate at one year, 100 percent vs. 41 percent; P<0.001). There was a statistically significant inverse relation between the leukemic progenitor-cell content of bone marrow before transplantation and the duration of remission after transplantation (P<0.001). The estimated risk of relapse for patients with greater-than-or-equal-to 51 leukemic progenitor cells per million mononuclear cells was more than 3.5 times the risk for patients with lower counts, after adjustment for the effects of other covariates (P = 0.005). Conclusions. The count of residual leukemic progenitor cells is a powerful predictor of relapse after autologous bone marrow transplantation, particularly among male patients. Its measurement may be useful for analyzing and improving the treatment of patients with high-risk ALL in remission.	UNIV MINNESOTA, HLTH SCI CTR, BONE MARROW TRANSPLANT PROGRAM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, HLTH SCI CTR, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, HLTH SCI CTR, DEPT THERAPEUT RADIOL RADIAT ONCOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, HLTH SCI CTR, DEPT MED, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [CA 42111, CA 42633, CA 21737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA042111, R01CA042633, R01CA042111, P01CA021737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAMPLIN R, 1989, BLOOD, V73, P2051; COX DR, 1972, J R STAT SOC B, V34, P187; ESTROV Z, 1986, NEW ENGL J MED, V315, P538, DOI 10.1056/NEJM198608283150902; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERSEY JH, 1987, NEW ENGL J MED, V317, P461, DOI 10.1056/NEJM198708203170801; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER CB, 1991, BLOOD, V78, P1125; NEGRIN RS, 1991, BLOOD, V78, P255; UCKUN FM, 1990, BLOOD, V76, P1723; UCKUN FM, 1992, BLOOD, V79, P1094; WRIGHT JJ, 1987, J CLIN ONCOL, V5, P735, DOI 10.1200/JCO.1987.5.5.735	11	92	92	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1296	1301		10.1056/NEJM199310283291802	http://dx.doi.org/10.1056/NEJM199310283291802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413410				2022-12-28	WOS:A1993MD55700002
J	PARMA, J; DUPREZ, L; VANSANDE, J; COCHAUX, P; GERVY, C; MOCKEL, J; DUMONT, J; VASSART, G				PARMA, J; DUPREZ, L; VANSANDE, J; COCHAUX, P; GERVY, C; MOCKEL, J; DUMONT, J; VASSART, G			SOMATIC MUTATIONS IN THE THYROTROPIN RECEPTOR GENE CAUSE HYPERFUNCTIONING THYROID ADENOMAS	NATURE			English	Article							G-PROTEIN; TSH RECEPTOR; ALPHA-1B-ADRENERGIC RECEPTOR; CELL-PROLIFERATION; CYCLIC-AMP; AUTOANTIBODIES; NODULES; TUMORS; BINDING; REGION	THE pituitary hormone thyrotropin stimulates the function, expression of differentiation and growth of thyrocytes by cyclic AMP-dependent mechanisms1-3. Tissue hyperplasia and hyperthyroidism are therefore expected to result when activation of the adenylyl cyclase-cAMP cascade is unregulated. This is observed in several situations4,5, including when somatic mutations impair the GTPase activity of the G protein G(salpha) (refs 6, 7). Such a mechanism is probably responsible for the development of a minority, of monoclonal hyperfunctioning thyroid adenomas6,8,9. Here we identify somatic mutations in the carboxy-terminal portion of the third cytoplasmic loop of the thyrotropin receptor in three out of eleven hyperfunctioning thyroid adenomas. These mutations are restricted to tumour tissue and involve two different residues (aspartic acid at position 619 to glycine in two cases, and alanine at position 623 to isoleucine in one case). The mutant receptors confer constitutive activation of adenylyl cyclase when tested by transfection in COS cells. This shows that G-protein-coupled receptors are susceptible to constitutive activation by spontaneous somatic mutations10,11 and may thus behave as proto-oncogenes.	UNIV LIBRE BRUXELLES,FAC MED,SERV GENET MED,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles	PARMA, J (corresponding author), UNIV LIBRE BRUXELLES,FAC MED,INST RECH INTERDISCIPLINAIRE,CAMPUS ERASME,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.							ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHRISTOPHE D, 1989, MOL CELL ENDOCRINOL, V64, P5, DOI 10.1016/0303-7207(89)90060-9; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUMONT JE, 1989, METABOLIC BASIS INHE, P1843; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; RUVKUN G, 1992, NATURE, V360, P711, DOI 10.1038/360711a0; Sambrook J, 1989, MOL CLONING LABORATO; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SUAREZ HG, 1991, ONCOGENE, V6, P677; THOMAS GA, 1989, AM J PATHOL, V134, P141; VANSANDE J, 1980, J CLIN ENDOCR METAB, V50, P776, DOI 10.1210/jcem-50-4-776; VANSANDE J, 1988, J CLIN ENDOCR METAB, V66, P570, DOI 10.1210/jcem-66-3-570; VASSART G, 1987, SCIENCE, V235, P683, DOI 10.1126/science.2880398; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEINTRAUB BD, 1981, ANN INTERN MED, V95, P339, DOI 10.7326/0003-4819-95-3-339; ZAKARIJA M, 1991, EXP CLIN ENDOCRINOL, V97, P165, DOI 10.1055/s-0029-1211057	26	824	862	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					649	651		10.1038/365649a0	http://dx.doi.org/10.1038/365649a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413627				2022-12-28	WOS:A1993MB84600059
J	SMITH, TJ				SMITH, TJ			WHICH HAT DO I WEAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BONE-MARROW TRANSPLANTATION; METASTATIC BREAST-CANCER; PATIENT-RELATIONSHIP; COST-EFFECTIVENESS											Coates Alan S., 1992, INTRO NEW TREATMENTS, P447; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HOLDER AM, 1978, MED MALPRACTICE; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; Percy Walker, 1971, LOVE RUINS; SMITH TJ, 1993, JNCI-J NATL CANCER I, V85, P1460, DOI 10.1093/jnci/85.18.1460; SMITH TJ, 1992, HIGH DOSE CANCER THE; SMITH TJ, 1993, P AM SOC CLIN ONCOL, V12, pA63; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; WEISEMAN T, 1991, ONCOL ISSUES, V6, P7	14	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1657	1659		10.1001/jama.270.14.1657	http://dx.doi.org/10.1001/jama.270.14.1657			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411481				2022-12-28	WOS:A1993MA29400001
J	RADANOV, BP; STURZENEGGER, M; DISTEFANO, G; SCHNIDRIG, A; ALJINOVIC, M				RADANOV, BP; STURZENEGGER, M; DISTEFANO, G; SCHNIDRIG, A; ALJINOVIC, M			FACTORS INFLUENCING RECOVERY FROM HEADACHE AFTER COMMON WHIPLASH	BRITISH MEDICAL JOURNAL			English	Article							CERVICAL-SPINE; INJURIES; NECK; SPRAIN	Objective-To assess the relation between pretraumatic and trauma related headache in patients suffering from whiplash. Design-Follow up study of patients examined a mean (SD) of 7.4 (4.2) days after trauma and again at three and six months. Setting-Patients referred from primary care. Subjects-117 patients (mean age 30.8 (9.5) years. Main outcome measures-Prevalence of trauma related headache and the predictive relation by multiple logistic regression between different somatic and psychological variables and trauma related headache at each examination. Results-Prevalence of trauma related headache decreased from 57% to 27%. History of pretraumatic headache proved a significant risk factor for presenting with trauma related headache. A significant relation between trauma related headache and the following variables was found: at seven days the initial wellbeing score, early onset of neck pain, depression scale from the personality inventory, and the initial intensity of neck pain; at three months, intensity of neck pain, and history of pretraumatic headache; and at six months neck pain, pain intensity, and history of pretraumatic headache. Conclusions-History of pretraumatic headache significantly increases the likelihood of presenting with trauma related headache but only in combination with findings indicative of clinically important injury to the cervical spine.	UNIV BERN,INSELSPITAL,DEPT NEUROL,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern	RADANOV, BP (corresponding author), UNIV BERN,DEPT PSYCHIAT,CONSULTAT SERV MURTENSTR 21,CH-3010 BERN,SWITZERLAND.							ARENA JG, 1984, J PSYCHOSOM RES, V28, P79, DOI 10.1016/0022-3999(84)90043-6; BALLA J, 1988, HEADACHE PROBLEMS DI, P241; BELLAVANCE A, 1989, NEUROLOGY, V39, P1269, DOI 10.1212/WNL.39.9.1269; BOQUET J, 1989, CEPHALALGIA, V9, P15, DOI 10.1046/j.1468-2982.1989.0901015.x; DEANS GT, 1987, INJURY, V18, P10, DOI 10.1016/0020-1383(87)90375-5; DVORAK J, 1987, ORTHOPADE, V16, P2; EDMEADS J, 1988, NEUROLOGY, V38, P1874, DOI 10.1212/WNL.38.12.1874; Fahrenberg J, 1984, FREIBURGER PERSONLIC; HIRSCH SA, 1988, ORTHOP CLIN N AM, V19, P791; KELLY R, 1988, HEADACHE PROBLEMS DI, P217; LANCE JW, 1988, AUST NZ J MED, V18, P311, DOI 10.1111/j.1445-5994.1988.tb02043.x; MAIMARIS C, 1988, INJURY, V19, P393, DOI 10.1016/0020-1383(88)90131-3; MARTIN PR, 1988, BEHAV RES THER, V26, P353, DOI 10.1016/0005-7967(88)90090-3; MARTIN PR, 1992, J PSYCHOSOM RES, V36, P137, DOI 10.1016/0022-3999(92)90022-T; MERSKEY H, 1984, CAN MED ASSOC J, V130, P1119; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608, DOI 10.1302/0301-620X.65B5.6643566; NORUSIS MJ, 1990, SPSS ADV STATISTICS, P44; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; VONZERSSEN D, 1983, METHODOLOGY EVALUATI, P183; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; 1988, CEPHALALGIA S, V7, P8	22	55	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					652	655		10.1136/bmj.307.6905.652	http://dx.doi.org/10.1136/bmj.307.6905.652			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LX470	8401050	Bronze, Green Published			2022-12-28	WOS:A1993LX47000016
J	ROBINSON, R				ROBINSON, R			ECONOMIC-EVALUATION AND HEALTH-CARE .1. WHAT DOES IT MEAN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS	Ever since the concept of value for money in health care was introduced into the NHS, economic terms and jargon have become part of our everyday lives-but do we understand what the different types of economic evaluation all mean, particularly those that sound similar to the uninitiated? This article introduces readers to the purpose of economic evaluation, and briefly explains the differences between cost-minimisation analysis (used when the outcomes of the procedures being compared are the same); cost-effectiveness analysis (used when the outcomes may vary, but can be expressed in common natural units, such as mm Hg for treatments of hypertension); cost-utility analysis (used when outcomes do vary-for example, quality of life scales); and cost-benefit analysis (used when a monetary value is being placed on services received). articles will deal with each one in more detail.			ROBINSON, R (corresponding author), UNIV SOUTHAMPTON, INST HLTH POLICY STUDIES, SOUTHAMPTON SO9 5NH, HANTS, ENGLAND.							Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; HULL R, 1981, NEW ENGL J MED, V304, P1561, DOI 10.1056/NEJM198106253042602; LUDBROOK A, 1981, APPL ECON, V13, P337, DOI 10.1080/00036848100000004; SINTONEN H, 1990, J HEALTH ECON, V9, P85, DOI 10.1016/0167-6296(90)90042-2; Teeling-Smith G, 1988, MEASURING HLTH PRACT; THOMPSON MS, 1986, AM J PUBLIC HEALTH, V76, P392, DOI 10.2105/AJPH.76.4.392	6	118	124	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	1993	307	6905					670	673		10.1136/bmj.307.6905.670	http://dx.doi.org/10.1136/bmj.307.6905.670			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401057	Bronze, Green Published			2022-12-28	WOS:A1993LX47000024
J	SULLIVAN, KMC; BUSA, WB; WILSON, KL				SULLIVAN, KMC; BUSA, WB; WILSON, KL			CALCIUM MOBILIZATION IS REQUIRED FOR NUCLEAR VESICLE FUSION IN-VITRO - IMPLICATIONS FOR MEMBRANE TRAFFIC AND IP(3) RECEPTOR FUNCTION	CELL			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RAT-LIVER NUCLEI; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; GOLGI-APPARATUS; XENOPUS OOCYTES; RELEASE; CA-2+; CELL; TRISPHOSPHATE	We studied the fusion of nuclear vesicles bound to chromatin in Xenopus egg extracts. Fusion was inhibited by 5 mM BAPTA, a Ca2+ buffer that suppresses cytosolic [Ca2+] gradients. The BAPTA-inhibited step in fusion was biochemically distinct from, and occurred later than, the GTPgammaS-sensitive step mediated by the monomeric GTPase, ADP-ribosylation factor. Exogenous inositol 1,4,5-trisphosphate (IP3), which triggers Ca2+ release from lumenal stores via IP3 receptors, stimulated fusion in the presence of BAPTA. This rescue was specific, because inositol 1,3,4-trisphosphate had no effect. Heparin, a potent antagonist of IP3 receptors, independently blocked fusion in an IP3-reversible manner. We suggest that phosphoinositide signaling may regulate nuclear vesicle fusion.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	SULLIVAN, KMC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.							ALBRITTON NL, 1992, SCIENCE, V258, P1812; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1992, CELL CALCIUM, V13, P313, DOI 10.1016/0143-4160(92)90066-2; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; Ferris Christopher D., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P95; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILLESPIE JI, 1983, J PHYSIOL-LONDON, V344, P359, DOI 10.1113/jphysiol.1983.sp014945; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; IVORRA I, 1991, BIOCHEM J, V273, P317, DOI 10.1042/bj2730317; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Lino Masamitsu, 1992, Nature (London), V360, P76; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LOHKA MJ, 1988, CELL BIOL INT REP, V12, P833, DOI 10.1016/0309-1651(88)90091-4; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MATTER N, 1993, J BIOL CHEM, V268, P732; Meldolesi Jacopo, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P187; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, J PHYSIOL-LONDON, V433, P207, DOI 10.1113/jphysiol.1991.sp018422; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RANDAZZO PA, 1993, IN PRESS J BIOL CHEM; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sztul Elizabeth S., 1992, Trends in Cell Biology, V2, P381, DOI 10.1016/0962-8924(92)90051-N; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WIESE C, 1993, IN PRESS CURR OPIN C, V5; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	80	130	131	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1411	1422		10.1016/0092-8674(93)90366-X	http://dx.doi.org/10.1016/0092-8674(93)90366-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391933	Bronze			2022-12-28	WOS:A1993LL20900015
J	YALCINKAYA, TM; SIITERI, PK; VIGNE, JL; LICHT, P; PAVGI, S; FRANK, LG; GLICKMAN, SE				YALCINKAYA, TM; SIITERI, PK; VIGNE, JL; LICHT, P; PAVGI, S; FRANK, LG; GLICKMAN, SE			A MECHANISM FOR VIRILIZATION OF FEMALE SPOTTED HYENAS INUTERO	SCIENCE			English	Article							CROCUTA-CROCUTA; SEX-DIFFERENCES; TESTOSTERONE; DEFICIENCY	Female spotted hyenas exhibit male-like genitalia and dominance over males. Hyena ovarian tissues incubated in vitro produced large quantities of the steroid hormone precursor androstenedione. The activity of aromatase, which converts androstenedione to estrogen, was one-twentieth as great in hyena versus human placental homogenates. In comparison, the activity of 17beta-hydroxysteroid dehydrogenase, which converts androstenedione to testosterone, was equal in the two homogenates. The limited aromatase activity may allow the hyena placenta to convert high circulating concentrations of androstenedione to testosterone, which results in virilization of the fetal external genitalia and possibly destruction of fetal ovarian follicles. Androstenedione production by residual ovarian stromal cells during reproductive life accounts for the epigenetic transmission of virilization in female spotted hyenas.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT ZOOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT PSYCHOL, BERKELEY, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley					NCI NIH HHS [CA-39825] Funding Source: Medline; NIMH NIH HHS [MH-39917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARISTOTLE, 1965, HIST ANIMAIUM; BEATTY WW, 1979, HORM BEHAV, V12, P112, DOI 10.1016/0018-506X(79)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS D. DWIGHT, 1949, FIELDIANA ZOOL, V31, P277; FRANK LG, 1989, SYM ZOOL S, V61, P127; GIVENS J, 1992, CURRENT ISSUES ENDOC, P3; GLICKMAN SE, 1987, P NATL ACAD SCI USA, V84, P3444, DOI 10.1073/pnas.84.10.3444; GLICKMAN SE, 1992, J REPROD FERTIL, V95, P451; HARADA N, 1992, J BIOL CHEM, V267, P4781; HILLIER SG, 1979, BIOL REPROD, V20, P261, DOI 10.1095/biolreprod20.2.261; HORIE K, 1992, HUM REPROD, V7, P184, DOI 10.1093/oxfordjournals.humrep.a137614; JOST A, 1985, HDB BEHAVIORAL NEURO, V7, P3; KRUUK H, 1972, SPOTTED HYENA; LICHT P, 1992, J REPROD FERTIL, V95, P463; LINDEQUE M, 1982, J REPROD FERTIL, V65, P405; MATTHEWS L. HARRISON, 1939, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V230, P1; MIYAIRI S, 1985, J BIOL CHEM, V260, P320; NEAVES WB, 1980, J REPROD FERTIL, V59, P509; NEW MI, 1986, ENDOCR REV, V7, P331, DOI 10.1210/edrv-7-3-331; PANG S, 1985, J CLIN ENDOCR METAB, V60, P428, DOI 10.1210/jcem-60-3-428; PAYNE RW, 1956, ENDOCRINOLOGY, V59, P306, DOI 10.1210/endo-59-3-306; PEDERSEN JM, 1990, HORM BEHAV, V24, P403, DOI 10.1016/0018-506X(90)90018-S; PHOENIX CH, 1959, ENDOCRINOLOGY, V65, P369, DOI 10.1210/endo-65-3-369; SCHREIBER JR, 1976, ENDOCRINOLOGY, V99, P590, DOI 10.1210/endo-99-2-590; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SIEGEL S, 1956, NONPARAMETRIC STAT, P108; SIITERI PK, 1966, J CLIN ENDOCR METAB, V26, P751, DOI 10.1210/jcem-26-7-751; SIITERI PK, 1974, J CLIN ENDOCR METAB, V38, P113, DOI 10.1210/jcem-38-1-113; SIMPSON JL, 1992, CURRENT ISSUES ENDOC, P59; THOMSON ML, 1992, J ENDOCRINOL, V132, P148; WYNN RM, 1964, AM J ANAT, V115, P327, DOI 10.1002/aja.1001150208	31	91	92	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1993	260	5116					1929	1931		10.1126/science.8391165	http://dx.doi.org/10.1126/science.8391165			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8391165				2022-12-28	WOS:A1993LJ34900039
J	LANGECARTER, CA; PLEIMAN, CM; GARDNER, AM; BLUMER, KJ; JOHNSON, GL				LANGECARTER, CA; PLEIMAN, CM; GARDNER, AM; BLUMER, KJ; JOHNSON, GL			A DIVERGENCE IN THE MAP KINASE REGULATORY NETWORK DEFINED BY MEK KINASE AND RAF	SCIENCE			English	Article							PROTEIN-KINASE; SIGNAL TRANSDUCTION; GENE; TYROSINE; INSULIN; DOMAINS; FAMILY; YEAST; ERKS	Mitogen-activated protein kinases (MAPKs) are rapidly phosphorylated and activated in response to various extracellular stimuli in many different cell types. Such regulation of MAPK results from sequential activation of a series of protein kinases. The kinases that phosphorylate MAPKs, the MAP kinase kinases (MEKs) are also activated by phosphorylation. MEKs are related in sequence to the yeast protein kinases Byr1 (from Schizosaccharomyces pombe) and Ste7 (from Saccharomyces cerevisiae), which function in the pheromone-induced signaling pathway that results in mating. Byr1 and Ste7 are in turn regulated by the protein kinases Byr2 and Ste11. The amino acid sequence of the mouse homolog of Byr2 and Ste11, denoted MEKK (MEK kinase), was elucidated from a complementary DNA sequence encoding a protein of 672 amino acid residues (73 kilodaltons). MEKK was expressed in all mouse tissues tested, and it phosphorylated and activated MEK. Phosphorylation and activation of MEK by MEKK was independent of Raf, a growth factor-regulated protein kinase that also phosphorylates MEK. Thus, MEKK and Raf converge at MEK in the protein kinase network mediating the activation of MAPKs by hormones, growth factors, and neurotransmitters.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	LANGECARTER, CA (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.		Blumer, Kendall J/C-5268-2012	Gardner, Anne/0000-0001-7095-772X; Lange, Carol/0000-0003-2751-3976	NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NCI NIH HHS [CA58187] Funding Source: Medline; NIDDK NIH HHS [DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER C, UNPUB; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; QIAN NX, IN PRESS P NATL ACAD; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SEGER R, 1992, J BIOL CHEM, V267, P25628; SETH A, 1991, J BIOL CHEM, V266, P23521; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173	36	1041	1074	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					315	319		10.1126/science.8385802	http://dx.doi.org/10.1126/science.8385802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8385802				2022-12-28	WOS:A1993KX80000026
J	CHATTHA, G; ARIEFF, AI; CUMMINGS, C; TIERNEY, LM				CHATTHA, G; ARIEFF, AI; CUMMINGS, C; TIERNEY, LM			LACTIC-ACIDOSIS COMPLICATING THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Note						ACIDOSIS, LACTIC; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANOXIA; HUMAN IMMUNODEFICIENCY VIRUS; REYES SYNDROME		Lactic acidosis has been reported in patients with the acquired immunodeficiency syndrome (AIDS) only in association with tissue hypoxia. From 1989 to 1991, seven patients with human immunodeficiency virus (HIV) infection who had lactic acidosis without obvious cause were evaluated. Nine normovolemic patients without acidosis or hypoxia served as controls. Findings in the patients included the following: pH, 7.22 +/- 0.07; bicarbonate, 7.0 +/- 2.4 mmol/L and lactate, 14.3 +/- 2.6 mmol/L. Patients and controls did not differ regarding cardiac index, P(O2) oxygen extraction ratio, and systemic oxygen delivery or utilization. Four patients with AIDS died of overwhelming metabolic acidosis, but the three other patients were discharged from the hospital. Autopsy in the four patients who died showed no obvious cause for lactic acidosis. The normal oxygen delivery, utilization, and extraction suggest that increased hyperlactatemia occurred for reasons other than hypoxia. Thus, patients with AIDS but without hypoxia can develop severe lactic acidosis that is not necessarily fatal.	UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								Aiyathurai J E, 1983, Ann Acad Med Singap, V12, P115; ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; ARIEFF AI, 1987, AM J PHYSIOL, V253, pE271, DOI 10.1152/ajpendo.1987.253.3.E271; BERSIN RM, 1989, AM J MED, V87, P7, DOI 10.1016/S0002-9343(89)80476-0; COHEN RD, 1990, METABOLIC MOL BASIS, P981; GANZ W, 1971, AM J CARDIOL, V27, P392, DOI 10.1016/0002-9149(71)90436-X; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; MADIAS NE, 1986, KIDNEY INT, V29, P752, DOI 10.1038/ki.1986.62; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; PERETZ DI, 1965, ANN NY ACAD SCI, V119, P1133, DOI 10.1111/j.1749-6632.1965.tb47467.x	10	119	119	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					37	39		10.7326/0003-4819-118-1-199301010-00007	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416156				2022-12-28	WOS:A1993KE60500007
J	QUEZADO, ZMN; WILSON, WH; CUNNION, RE; PARKER, MM; REDA, D; BRYANT, G; OGNIBENE, FP				QUEZADO, ZMN; WILSON, WH; CUNNION, RE; PARKER, MM; REDA, D; BRYANT, G; OGNIBENE, FP			HIGH-DOSE IFOSFAMIDE IS ASSOCIATED WITH SEVERE, REVERSIBLE CARDIAC DYSFUNCTION	ANNALS OF INTERNAL MEDICINE			English	Article						IFOSFAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; SHOCK CARDIOGENIC; ARRHYTHMIA	ISOPHOSPHAMIDE NSC-109724; CYCLOPHOSPHAMIDE; CARDIOTOXICITY; NEPHROTOXICITY; PHARMACOKINETICS; GLUTATHIONE; THERAPY; CANCER; MESNA	Objective: To determine the incidence and characterize the occurrence of cardiac toxicity with high-dose ifosfamide. Design: Retrospective chart review. Setting: Biomedical research referral center. Patients: Fifty-two consecutive patients with advanced lymphoma or carcinoma enrolled in phase I trials of high-dose ifosfamide as part of combination chemotherapy with autologous bone marrow transplantation. Interventions: Patients were given escalating doses (10 to 18 g/m2) of ifosfamide in combination with carboplatin and etoposide or with lomustine and vinblastine. Measurements: The chart review focused on clinical, radiographic, or electrocardiographic evidence of cardiovascular dysfunction. Data from invasive hemodynamic monitoring, radionuclide cineangiography, and echocardiography were also reviewed. Results: Nine of the patients treated with ifosfamide developed congestive heart failure (17%; 95% CI, 8% to 30%). Eight of these patients, experiencing dyspnea, tachycardia, weight gain, and signs of pulmonary edema, required admission to an intensive care unit. Left ventricular contractility was found to be depressed when evaluated by radionuclide cineangiography, echocardiography, or both. Most patients responded to diuretic, vasodilator, and inotropic therapies. Two patients developed malignant ventricular arrhythmias. One patient died of intractable cardiogenic shock. Five patients died of multiorgan failure, despite showing improvement in left ventricular ejection fraction. Three patients survived and regained baseline left ventricular ejection fraction. Conclusions: High-dose ifosfamide is associated with severe but usually reversible myocardial depression and malignant arrhythmias.	NCI, BETHESDA, MD 20892 USA; WARREN G MAGNUSON CLIN CTR, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Quezado, Zenaide/O-4860-2016	Quezado, Zenaide/0000-0001-9793-4368				ALLEN LM, 1976, CANCER TREAT REP, V60, P451; ANTMAN KH, 1990, SEMIN ONCOL, V17, P7; BURK CD, 1990, J PEDIATR-US, V117, P331, DOI 10.1016/S0022-3476(05)80557-8; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; CABANILLAS F, 1987, CONTR ONCOL, V26, P394; CAZIN B, 1986, CANCER, V57, P2061, DOI 10.1002/1097-0142(19860515)57:10<2061::AID-CNCR2820571031>3.0.CO;2-H; CHRESTA CM, 1990, CANCER RES, V50, P4067; Davies S M, 1989, Cancer Chemother Pharmacol, V24 Suppl 1, pS8; DEFRONZO RA, 1974, CANCER CHEMOTH REP 1, V58, P375; ELIAS AD, 1990, J CLIN ONCOL, V8, P170, DOI 10.1200/JCO.1990.8.1.170; FRIEDMAN HS, 1990, CANCER RES, V50, P2455; GOREN MP, 1987, CANCER RES, V47, P1457; GOTTDIENER JS, 1981, ARCH INTERN MED, V141, P758, DOI 10.1001/archinte.141.6.758; HAVEMANN K, 1989, SEMIN ONCOL, V16, P9; KANDYLIS K, 1989, CANCER CHEMOTH PHARM, V24, P395; NELSON RL, 1976, CLIN PHARMACOL THER, V19, P365; OCONNELL TX, 1974, CANCER RES, V34, P1586; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; PATTERSON WP, 1989, CANCER, V63, P649, DOI 10.1002/1097-0142(19890215)63:4<649::AID-CNCR2820630408>3.0.CO;2-Z; RITCHIE JL, 1980, CANCER, V46, P1109, DOI 10.1002/1097-0142(19800901)46:5<1109::AID-CNCR2820460506>3.0.CO;2-B; SAROSY G, 1989, SEMIN ONCOL, V16, P2; SCHECHTER JP, 1979, CANCER CHEMOTH REP, V58, P887; SCHMIDBAUR H, 1987, ANGEW CHEM INT EDIT, V26, P234, DOI 10.1002/anie.198702341; SCHMOLL H, 1982, CANCER TREAT REV, V9, P21, DOI 10.1016/S0305-7372(82)80074-1; SCHOENIKE SE, 1990, CLIN PHARMACY, V9, P179; SKINNER R, 1990, ARCH DIS CHILD, V65, P732, DOI 10.1136/adc.65.7.732; SMEITINK J, 1988, EUR J PEDIATR, V148, P164, DOI 10.1007/BF00445929; STEINHERZ LJ, 1981, MED PEDIATR ONCOL, V9, P417, DOI 10.1002/mpo.2950090502; TODOROVIC V, 1989, 8TH P ANN M AM ASS C, P567; TORTI FM, 1989, CANCER PRINCIPLES PR, P2153; VOGELZANG NJ, 1980, CANCER TREAT REP, V64, P1159; WILSON WH, 1990, BLOOD S, V76, pA573; WILSON WH, 1991, 27TH P ANN M AM SOC, P286; YATES F, 1948, BIOMETRIKA, V35, P176, DOI 10.1093/biomet/35.1-2.176	34	106	112	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					31	36		10.7326/0003-4819-118-1-199301010-00006	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416155				2022-12-28	WOS:A1993KE60500006
J	LEVINSKY, NG				LEVINSKY, NG			THE ORGANIZATION OF MEDICAL-CARE - LESSONS FROM THE MEDICARE END-STAGE RENAL-DISEASE PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE		BOSTON CITY HOSP, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, BOSTON, MA 02118 USA	Boston Medical Center	LEVINSKY, NG (corresponding author), BOSTON UNIV, MED CTR, DEPT MED, 88 E NEWTON ST, BOSTON, MA 02118 USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; ABRAM HS, 1972, PSYCHIAT MED, V3, P51, DOI 10.2190/GKBB-DKN0-AD5M-RBBY; EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HALPER T, 1985, MILBANK FUND Q, V63, P52, DOI 10.2307/3349898; MURRAY JS, 1962, T AM SOC ART INT ORG, V8, P315; NISSENSON AR, 1993, KIDNEY INT, V43, pS120; Reiser SJ., 1991, BIOMEDICAL POLITICS, P212; Rettig RA, 1991, BIOMEDICAL POLITICS, P176; RETTING RA, 1991, KIDNEY FAILURE FEDER; SANDERS D, 1968, UCLA LAW REV, V15, P357; SCHUPAK E, 1965, ANN INTERN MED, V62, P509, DOI 10.7326/0003-4819-62-3-509; SHERMAN RA, 1993, AM J KIDNEY DIS, V21, P632, DOI 10.1016/S0272-6386(12)80036-9; Tokars J I, 1993, ASAIO J, V39, P71, DOI 10.1097/00002480-199301000-00016; 1967, GPO933491 PUBL; 1992, USRDS SPECIAL STUDY	17	47	47	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1395	1399		10.1056/NEJM199311043291907	http://dx.doi.org/10.1056/NEJM199311043291907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413437				2022-12-28	WOS:A1993MD94900007
J	TRUOG, RD; BRENNAN, TA				TRUOG, RD; BRENNAN, TA			PARTICIPATION OF PHYSICIANS IN CAPITAL-PUNISHMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEATH-PENALTY; EXECUTION; ETHICS		HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	TRUOG, RD (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P1096, DOI 10.2105/AJPH.75.9.1096; Annas GJ, 1990, AM HLTH LAW; BONNIE RJ, 1990, HASTINGS CENT REP, V20, P12, DOI 10.2307/3563155; BRENNAN T, 1991, DOCTORING MED ETHICS; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CORNMAN S, 1984, CRIM JUSTICE J, V7, P363; CURRAN WJ, 1980, NEW ENGL J MED, V302, P226, DOI 10.1056/NEJM198001243020410; DEVLIN P, 1962, ENFORCEMENT MORALS; DRIMMER F, 1990, YOU ARE DEAD BOOK EX, P87; DUBLER NN, 1979, HASTINGS CENT REP, V9, P7, DOI 10.2307/3561512; Frady Marshall, 1993, NEW YORKER      0222, P105; HANSON MJ, 1992, HASTINGS CENT REP, V22, P2; HEILBRUN K, 1992, AM J PSYCHIAT, V149, P596; HINSON S, 1992, ROLE PHYSICIANS EXEC; Hsieh D S, 1989, JAMA, V261, P132; KEERDOJA E, 1984, NEWSWEEK        0409, P106; Lifton R. J., 1986, NAZI DOCTORS MED KIL; LODDER L, 1992, AM MED NEWS     1109, P37; LODDER L, 1993, AM MED  NEWS    0301, P11; MARLETTE M, 1992, CORRECT COMPEND, V17, P1; MCBRIDE K, 1992, SPOKESMAN SPOKA 1214, P1; MERZ B, 1990, AM MED NEWS     0921, P32; ROSNER F, 1991, NEW YORK STATE J MED, V91, P15; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SKOLNICK AA, 1993, JAMA-J AM MED ASSOC, V269, P721, DOI 10.1001/jama.269.6.721; THORBURN KM, 1987, WESTERN J MED, V146, P638; TRUOG RD, 1992, NEW ENGL J MED, V326, P1506; Walzer M., 1984, SPHERES JUSTICE; WEINER DB, 1972, J AMER MED ASSOC, V220, P85, DOI 10.1001/jama.220.1.85; Weisberg Jacob, 1991, NEW REPUBLIC, P23; WEST LJ, 1975, AM J ORTHOPSYCHIAT, V45, P689, DOI 10.1111/j.1939-0025.1975.tb01195.x; Wikler Daniel, 1993, Kennedy Institute of Ethics Journal, V3, P39; 1992, ANN INTTERN MED, V117, P947; 1992, COUNCIL ETHICAL JUDI, P5; 1989, STATE KILLS DEATH PE, P71; 1991, NY STATE J MED, V91, P271; 1993, LANCET, V341, P209; 1993, JAMA-J AM MED ASSOC, V270, P365; 1993, FED REGISTER, V58, P4898; 1992, PRINCIPLES MED ETHIC; 1981, WORLD MED J, V28, P81; 1985, NATIONS HLTH, V15, P20; 1990, AM MED NEWS     1130, P31	43	32	32	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1346	1350		10.1056/NEJM199310283291812	http://dx.doi.org/10.1056/NEJM199310283291812			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MD557	8413417				2022-12-28	WOS:A1993MD55700012
J	PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ				PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ			TEMPORAL CHANGES IN THE CARE AND OUTCOMES OF ELDERLY PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION, 1987 THROUGH 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; THROMBOLYTIC THERAPY; GENDER BIAS; SELECTION	Objective.-To investigate changes between 1987 and 1990 in the care and outcomes associated with acute myocardial infarction (AMI) in elderly patients. Design.-Retrospective cohort study using a longitudinal database created from Medicare administrative files. Patients.-Cohorts comprising a total of 856 847 AMI patients insured by Medicare between 1987 and 1990. Main Outcome Measures.-Annual rates of mortality at 30 days and 1 year following AMI, and the use of coronary angiography, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty during the first 90 days after a new AMI. Results.-Between 1987 and 1990, mortality rates decreased 10% overall from 26% to 23% at 30 days (P<.001) and from 40% to 36% at 1 year following AMI (P<.001). Declines in mortality and adjusted risks of 1-year mortality were similar in men and women and in blacks and whites, but mortality declines were more evident in those younger than 85 years. Meanwhile, the proportion of elderly AMI patients having angiography within the first 90 days after their index admission increased from 24% to 33% (P<.001); proportions increased for both genders and all races. The proportion of patients undergoing revascularization procedures increased from 13% to 21 %; while rates of bypass surgery increased from 8% to 11%, rates of angioplasty doubled from 5% to 10% (all P<.001). Conclusions.-Between 1987 and 1990, survival of elderly patients following AMI improved significantly. While changes in patient treatment may be responsible, the increased use of thrombolytic therapy appears to be only a partial explanation. Also, while the use of coronary angiography and revascularization procedures increased dramatically, the degree to which it caused the improvement in survival could not be determined.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, JOHN F KENNEDY SCH GOVT, CAMBRIDGE, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	PASHOS, CL (corresponding author), HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, 25 SHATTUCK ST, PARCEL B, BOSTON, MA 02115 USA.		Newhouse, Joseph/AGJ-5632-2022		AHRQ HHS [HS-06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1988, LANCET, V2, P349; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WILCOX RG, 1988, LANCET, V2, P525; 1993, MONTHLY VITAL STATIS, V41, P18; 1989, INT CLASSIFICATION D; 1991, PHYSICIANS CURRENT P; 1990, 1990 HCFA STATISTICS	22	93	96	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1832	1836		10.1001/jama.270.15.1832	http://dx.doi.org/10.1001/jama.270.15.1832			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411527				2022-12-28	WOS:A1993MB46400026
J	KIM, JL; NIKOLOV, DB; BURLEY, SK				KIM, JL; NIKOLOV, DB; BURLEY, SK			CO-CRYSTAL STRUCTURE OF TBP RECOGNIZING THE MINOR-GROOVE OF A TATA ELEMENT	NATURE			English	Article							RNA POLYMERASE-II; NUCLEIC-ACID INTERACTION; BINDING-PROTEIN; TRANSCRIPTION FACTOR; TFIID BINDS; DNA; YEAST; COMPLEX; BOX; INITIATION	The three-dimensional structure of a TATA-box binding polypeptide complexed with the TATA element of the adenovirus major late promoter ha's been determined by X-ray crystallography at 2.25 angstrom resolution. Binding of the saddle-shaped protein induces a conformational change in the DNA, inducing sharp kinks at either end of the sequence TATAAAAG. Between the kinks, the right-handed double helix is smoothly curved and partially unwound, presenting a widened minor groove to TBP's concave, antiparallel beta-sheet. Side-chain/base interactions are restricted to the minor groove, and include hydrogen bonds, van der Waals contacts and phenylalanine-base stacking interactions.	ROCKEFELLER UNIV, MOLEC BIOPHYS LABS, 1230 YORK AVE, NEW YORK, NY 10021 USA	Rockefeller University				Burley, Stephen K./0000-0002-2487-9713				ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, XPLOR MANUAL; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLL M, 1989, BIOCHEMISTRY-US, V28, P310, DOI 10.1021/bi00427a042; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FLORES O, 1988, J BIOL CHEM, V263, P10812; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LORCH Y, 1993, MOL CELL BIOL, V13, P1872, DOI 10.1128/MCB.13.3.1872; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WOLBERGER C, 1993, CURR OPIN STRUC BIOL, V3, P3, DOI 10.1016/0959-440X(93)90194-P; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841; ZIFF EB, 1978, CELL, V15, P1463, DOI 10.1016/0092-8674(78)90070-3	56	1014	1025	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1993	365	6446					520	527		10.1038/365520a0	http://dx.doi.org/10.1038/365520a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413605				2022-12-28	WOS:A1993MA66100045
J	LAOR, A; COHEN, L; DANON, YL				LAOR, A; COHEN, L; DANON, YL			EFFECTS OF TIME, SEX, ETHNIC-ORIGIN, AND AREA OF RESIDENCE ON PREVALENCE OF ASTHMA IN ISRAELI ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERRESPONSIVENESS; NATURAL-HISTORY; UNITED-STATES; CHILDREN; SYMPTOMS; SCHOOLCHILDREN; CHILDHOOD; HEALTH; SAMPLE	Objectives-To study effects of time, sex, ethnic origin, and area of residence on prevalence of asthma in Israeli adolescents. Design-Retrospective survey of asthma from computerised medical draft records of conscripts examined up to the end of 1989. Setting-Five regional centres in Israel. Subjects-443186 conscripts (262836 males and 180350 females) aged 17-18 who were born over a nine year period. Main outcome measures-Asthma determined by medical history, physical examination, and lung function tests at rest and after exercise. Results-Asthma was more prevalent in males than females (26.5/1000 v 21.4/1000, relative risk 1.25 (95% confidence interval 1.19 to 1.32)). Subjects were split into three groups according to year of birth, and prevalence of asthma increased over time from 18/1000 to 24/1000 to 36/1000 (risk of asthma 0.56 (0.54 to 0.59) for first birth group relative to last birth group and 0.69 (0.66 to 0.72) for second group relative to last group). Risk of asthma was also affected by ethnic origin (highest for Western origin and lowest for north African origin, relative risk 1.63 (1.56 to 1.71)) and area of residence (highest in the central coastal region-risk of 1.24 (1.19 to 1.30) relative to the north coastal region-and lowest in inland areas-risk of 0.67 (0.64 to 0.70) relative to north coastal region). Conclusions-Prevalence of asthma in Israel is increasing and is higher in males, in people of Western origin, and in those living in the most industrialised coastal region.	CHILDRENS MED CTR ISRAEL,KIPPER INST CHILD IMMUNOL,IL-42600 PETAH TIQWA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,HAIFA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	LAOR, A (corresponding author), LADY DAVIES CARMEL HOSP,DEPT INTERNAL MED B,IL-34362 HAIFA,ISRAEL.							ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; AURBACH I, 1993, THORAX, V48, P139; BROOK U, 1991, Harefuah, V120, P539; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURR ML, 1987, J EPIDEMIOL COMMUN H, V41, P185, DOI 10.1136/jech.41.3.185; CHARPIN D, 1988, ALLERGY, V43, P481, DOI 10.1111/j.1398-9995.1988.tb01624.x; DIPEDE C, 1991, CHEST, V99, P916, DOI 10.1378/chest.99.4.916; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GERSTMAN BB, 1989, J ALLERGY CLIN IMMUN, V83, P1032, DOI 10.1016/0091-6749(89)90444-2; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HORNE SL, 1989, CHEST, V95, P992, DOI 10.1378/chest.95.5.992; HORNE SL, 1990, CLIN INVEST MED, V13, P333; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; KAPLAN BA, 1988, J ASTHMA, V25, P125, DOI 10.3109/02770908809073199; KARK JD, 1986, ISRAEL J MED SCI, V22, P318; MCCULLAGH P, 1985, GENERALIZED LINEAR M; MCFADDEN ER, 1991, HARRISONS PRINCIPLES, P1047; MITCHELL EA, 1991, SOC SCI MED, V32, P831, DOI 10.1016/0277-9536(91)90309-Z; PATTEMORE PK, 1989, THORAX, V44, P168, DOI 10.1136/thx.44.3.168; PEDERSEN PA, 1987, CHEST, V91, pS107, DOI 10.1378/chest.91.6.107S; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWARTZ YA, 1990, ANN ALLERGY, V65, P105; WITZMAN M, 1990, AM J DIS CHILD, V144, P1189; 1990, P200 SAS I TECHN REP	32	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					841	844		10.1136/bmj.307.6908.841	http://dx.doi.org/10.1136/bmj.307.6908.841			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401126	Green Published, Bronze			2022-12-28	WOS:A1993MA29300021
J	VENABLES, PJW				VENABLES, PJW			FORTNIGHTLY REVIEW - DIAGNOSIS AND TREATMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREDNISONE; NEPHRITIS; CYCLOPHOSPHAMIDE; AUTOANTIBODIES; DISEASE				VENABLES, PJW (corresponding author), MATHILDA & TERENCE INST RHEUMATOL, LONDON W6 7DW, ENGLAND.							BARRON KS, 1982, J PEDIATR-US, V101, P137, DOI 10.1016/S0022-3476(82)80203-5; EDWARDS JCW, 1987, ANN RHEUM DIS, V46, P773, DOI 10.1136/ard.46.10.773; Ginzler Ellen M., 1992, Current Opinion in Rheumatology, V4, P672; Gladman Dafna D., 1992, Current Opinion in Rheumatology, V4, P681; HAHN BH, 1993, TXB RHEUMATOLOGY, P1043; HARLEY JB, 1988, RHEUM DIS CLIN N AM, V14, P43; KIMBERLY RP, 1988, RHEUM DIS CLIN N AM, V14, P203; LEVEY AS, 1992, ANN INTERN MED, V116, P114, DOI 10.7326/0003-4819-116-2-114; LIEBERMAN JD, 1988, RHEUM DIS CLIN N AM, V14, P223; LUBBE WF, 1983, LANCET, V1, P1361; MARGUERIE C, 1990, Q J MED, V77, P1019, DOI 10.1093/qjmed/77.1.1019; MCCUNE WJ, 1988, RHEUM DIS CLIN N AM, V14, P149; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; Miller Michael L., 1992, Current Opinion in Rheumatology, V4, P693; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P988, DOI 10.1136/ard.47.12.988; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VENABLES PJW, IN PRESS RHEUMATOLOG; VYSE TJ, 1993, BRIT J HOSP MED, V50, P121; WILKE WS, 1991, CLIN EXP RHEUMATOL, V9, P581; 1981, J RHEUMATOL, V8, P783	21	12	14	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	1993	307	6905					663	666		10.1136/bmj.307.6905.663	http://dx.doi.org/10.1136/bmj.307.6905.663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401055	Green Published, Bronze			2022-12-28	WOS:A1993LX47000022
J	KIM, H; JACOBSON, EL; JACOBSON, MK				KIM, H; JACOBSON, EL; JACOBSON, MK			SYNTHESIS AND DEGRADATION OF CYCLIC ADP RIBOSE BY NAD GLYCOHYDROLASES	SCIENCE			English	Article							EGG-SPECIFIC NADASE; 2ND-MESSENGER ENZYME; CALCIUM RELEASE; CA-2+ RELEASE; MECHANISM; METABOLITE; MICROSOMES; MODULATION; TISSUES; ADENINE	Cyclic adenosine diphosphoribose (cADPR), a recently discovered metabolite of nicotinamide adenine dinucleotide (NAD), is a potent calcium-releasing agent postulated to be a new second messenger. An enzyme that catalyzes the synthesis of cADPR from NAD and the hydrolysis of cADPR to ADP-ribose (ADPR) was purified to homogeneity from canine spleen microsomes. The net conversion of NAD to ADPR categorizes this enzyme as an NAD glycohydrolase. NAD glycohydrolases are ubiquitous membrane-bound enzymes that have been known for many years but whose function has not been identified. The results presented here suggest that these enzymes may function in the regulation of calcium homeostasis by the ability to synthesize and degrade cADPR.	UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536; UNIV N TEXAS,HLTH SCI CTR,DEPT MED,FT WORTH,TX 76107; UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,FT WORTH,TX 76107; UNIV KENTUCKY,LUCILLE PARKER MARKEY CANC CTR,LEXINGTON,KY 40536; UNIV KENTUCKY,COLL ALLIED HLTH PROFESS,DEPT CLIN SCI,LEXINGTON,KY 40536	University of Kentucky; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; University of Kentucky; University of Kentucky					NCI NIH HHS [CA43894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZGONZALEZ R, 1983, ANAL BIOCHEM, V135, P69, DOI 10.1016/0003-2697(83)90732-7; BERRIDGE MJ, 1989, NATURE, V341, P167; BULL HG, 1978, J BIOL CHEM, V253, P5186; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Handler P, 1942, J BIOL CHEM, V143, P49; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; JACOBSON MK, 1990, ADP RIBOSYLATING TOX, P479; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; KAPLAN NO, 1956, J BIOL CHEM, V221, P823; Kim H.-J., UNPUB; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; MULERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; PASCAL M, 1976, FEBS LETT, V66, P107, DOI 10.1016/0014-5793(76)80596-0; PRICE SR, 1987, PYRIDINE NUCLEOTIDE, P513; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SCHUBER F, 1976, EUR J BIOCHEM, V69, P593, DOI 10.1111/j.1432-1033.1976.tb10945.x; SCHUBER F, 1979, BIOORG CHEM, V8, P83, DOI 10.1016/0045-2068(79)90039-7; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TARNUS C, 1979, BIOORG CHEM, V16, P38; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WILLIAMSON KC, 1989, ADP RIBOSYLATING TOX, P493; YOST DA, 1981, J BIOL CHEM, V256, P3647	31	238	239	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1330	1333		10.1126/science.8395705	http://dx.doi.org/10.1126/science.8395705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8395705				2022-12-28	WOS:A1993LV65600031
J	BOWEN, JRC; SAHI, S				BOWEN, JRC; SAHI, S			CYCLOSPORINE-INDUCED COLITIS	BRITISH MEDICAL JOURNAL			English	Letter											BOWEN, JRC (corresponding author), BMH RINTELN,BFPO 29,RINTELN,GERMANY.							INNES A, 1988, LANCET, V2, P957; 1991, LANCET, V338, P389	2	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					484	484		10.1136/bmj.307.6902.484-b	http://dx.doi.org/10.1136/bmj.307.6902.484-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400936	Green Published, Bronze			2022-12-28	WOS:A1993LU59000027
J	KERANEN, T; RIEKKINEN, PJ				KERANEN, T; RIEKKINEN, PJ			REMISSION OF SEIZURES IN UNTREATED EPILEPSY	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE		UNIV HOSP KUOPIO,DEPT NEUROL,SF-70210 KUOPIO,FINLAND	Kuopio University Hospital; University of Eastern Finland								BERAN R G, 1982, Neuroepidemiology, V1, P201, DOI 10.1159/000110703; Gowers WR, 1881, EPILEPSY OTHER CHRON; HAERER AF, 1986, EPILEPSIA, V27, P66, DOI 10.1111/j.1528-1157.1986.tb03503.x; KERANEN T, 1989, EPILEPSIA, V30, P413, DOI 10.1111/j.1528-1157.1989.tb05320.x; ZIELINSKI JJ, 1974, EPILEPSIA, V15, P203, DOI 10.1111/j.1528-1157.1974.tb04942.x	5	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					483	483		10.1136/bmj.307.6902.483	http://dx.doi.org/10.1136/bmj.307.6902.483			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400934	Green Published, Bronze			2022-12-28	WOS:A1993LU59000024
J	HASTY, P; BRADLEY, A; MORRIS, JH; EDMONDSON, DG; VENUTI, JM; OLSON, EN; KLEIN, WH				HASTY, P; BRADLEY, A; MORRIS, JH; EDMONDSON, DG; VENUTI, JM; OLSON, EN; KLEIN, WH			MUSCLE DEFICIENCY AND NEONATAL DEATH IN MICE WITH A TARGETED MUTATION IN THE MYOGENIN GENE	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; REGULATORY GENE; MESSENGER-RNA; MOUSE EMBRYO; EXPRESSION; REGION; CDNA; SUBUNIT; MYOD; DIFFERENTIATION	Myogenin is a muscle-specific transcription factor that can induce myogenesis in a variety of cell types in tissue culture. To test myogenin's role in vivo, mice homozygous for a targeted mutation in the myogenin gene were generated. These mice survive fetal development but die immediately after birth and show a severe reduction of all skeletal muscle. Myogenin-mutant mice differ from mice carrying mutations in genes for the related myogenic factors Myf5 and MyoD, which have no muscle defects. Myogenin is therefore essential for the development of functional skeletal muscle.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center	HASTY, P (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030, USA.			Hasty, Paul/0000-0003-3046-0131; Bradley, Allan/0000-0002-2349-8839; Edmondson, Diane/0000-0003-3702-9715				BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRUNETTI A, 1990, MOL ENDOCRINOL, V4, P880, DOI 10.1210/mend-4-6-880; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHEN JM, 1953, J ANAT, V87, P130; CHEN JM, 1952, J ANAT, V86, P373; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEDFORD RM, 1980, P NATL ACAD SCI-BIOL, V77, P5749, DOI 10.1073/pnas.77.10.5749; OLSON E, 1990, GENOMICS, V8, P427, DOI 10.1016/0888-7543(90)90028-S; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUCNICKI MA, 1992, CELL, V71, P383; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539	36	1041	1098	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					501	506		10.1038/364501a0	http://dx.doi.org/10.1038/364501a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393145				2022-12-28	WOS:A1993LQ66700044
J	PEUNOVA, N; ENIKOLOPOV, G				PEUNOVA, N; ENIKOLOPOV, G			AMPLIFICATION OF CALCIUM-INDUCED GENE-TRANSCRIPTION BY NITRIC-OXIDE IN NEURONAL CELLS	NATURE			English	Article							LONG-TERM POTENTIATION; CYCLIC-AMP; C-FOS; NERVOUS-SYSTEM; FACTOR CREB; BINDING-PROTEIN; PHOSPHORYLATION; MESSENGER; SEQUENCE; KINASES	NITRIC oxide (NO) is a short-lived, highly reactive gas, which has been identified as a mediator in vasodilation, an active agent in macrophage cytotoxicity and neurotoxicity, and a neurotransmitter in the central and peripheral nervous systems1-5. Production of NO by neurons is critical for facilitated synaptic transmission in models of synaptic plasticity such as long-term potentiation and long-term depression, suggesting a role for NO as a retrograde messenger that could complete a hypothetical feed-back loop by strengthening the connection between postsynaptic and presynaptic cells6-10. We report here that although alone NO has no evident effect on transcription, it can act as an amplifier of calcium signals in neuronal cells. NO and Ca2+ action have to coincide in time for amplification to occur. Experiments with a series of simplified reporter genes in combination with specific recombinant protein kinase inhibitors suggest that induction of gene activity following NO-amplified calcium action involves protein kinase A-dependent activation of the transcription factor CREB.	COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory			Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BONHOEFFER T, 1990, COLD SH Q B, V55, P137; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Curran T, 1988, ONCOGENE HDB, P307; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Schulman H, 1991, Curr Opin Neurobiol, V1, P43, DOI 10.1016/0959-4388(91)90009-V; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; WALSH DA, 1991, METHOD ENZYMOL, V201, P304	29	282	297	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1993	364	6436					450	453		10.1038/364450a0	http://dx.doi.org/10.1038/364450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8392663				2022-12-28	WOS:A1993LP64000057
J	VONKROSIGK, M; BAL, T; MCCORMICK, DA				VONKROSIGK, M; BAL, T; MCCORMICK, DA			CELLULAR MECHANISMS OF A SYNCHRONIZED OSCILLATION IN THE THALAMUS	SCIENCE			English	Article							NUCLEUS RETICULARIS THALAMI; LATERAL GENICULATE-NUCLEUS; NEURONS; CAT; RAT; INVITRO	Spindle waves are a prototypical example of synchronized oscillations, a common feature of neuronal activity in thalamic and cortical systems in sleeping and waking animals. Spontaneous spindle waves recorded from slices of the ferret lateral geniculate nucleus were generated by rebound burst firing in relay cells. This rebound burst firing resulted from inhibitory postsynaptic potentials arriving from the perigeniculate nucleus, the cells of which were activated by burst firing in relay neurons. Reduction of gamma-aminobutyric acid(A) (GABA(A)) receptor-mediated inhibition markedly enhanced GABA(B) inhibitory postsynaptic potentials in relay cells and subsequently generated a slowed and rhythmic population activity resembling that which occurs during an absence seizure. Pharmacological block of GABA(B) receptors abolished this seizure-like activity but not normal spindle waves, suggesting that GABA(B) antagonists may be useful in the treatment of absence seizures.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510	Yale University			McCormick, David A/J-2649-2015; Kobelt, Liza/F-5926-2011	McCormick, David A/0000-0002-9803-8335; 				[Anonymous], [No title captured]; AVANZINI G, 1989, J PHYSIOL-LONDON, V416, P111, DOI 10.1113/jphysiol.1989.sp017752; AVOLI M., 1990, GENERALIZED EPILEPSY; BAL T, IN PRESS J PHYSL LON; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; BUZSAKI G, 1988, J NEUROSCI, V8, P4007; CUCCHIARO J, 1991, J COMP NEUROL, V31, P316; DOSSI RC, 1992, J PHYSIOL-LONDON, V447, P215, DOI 10.1113/jphysiol.1992.sp018999; FITZPATRICK D, 1984, J NEUROSCI, V4, P1809; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HOUSER CR, 1980, BRAIN RES, V200, P341, DOI 10.1016/0006-8993(80)90925-7; HUGUENARD JR, 1992, J NEUROPHYSIOL, V68, P373; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; KING GA, 1979, NEUROPHARMACOLOGY, V18, P47, DOI 10.1016/0028-3908(79)90008-X; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; MCCORMICK DA, 1988, NATURE, V334, P246, DOI 10.1038/334246a0; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; Steriade M., 1990, THALAMIC OSCILLATION	23	613	621	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					361	364		10.1126/science.8392750	http://dx.doi.org/10.1126/science.8392750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8392750				2022-12-28	WOS:A1993LM67800039
J	JENKINS, DJA; WOLEVER, TMS; RAO, AV; HEGELE, RA; MITCHELL, SJ; RANSOM, TPP; BOCTOR, DL; SPADAFORA, PJ; JENKINS, AL; MEHLING, C; RELLE, LK; CONNELLY, PW; STORY, JA; FURUMOTO, EJ; COREY, P; WURSCH, P				JENKINS, DJA; WOLEVER, TMS; RAO, AV; HEGELE, RA; MITCHELL, SJ; RANSOM, TPP; BOCTOR, DL; SPADAFORA, PJ; JENKINS, AL; MEHLING, C; RELLE, LK; CONNELLY, PW; STORY, JA; FURUMOTO, EJ; COREY, P; WURSCH, P			EFFECT ON BLOOD-LIPIDS OF VERY HIGH INTAKES OF FIBER IN DIETS LOW IN SATURATED FAT AND CHOLESTEROL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CORONARY HEART-DISEASE; COMBINED HYPERLIPIDEMIA; PLASMA-CHOLESTEROL; OAT-BRAN; SERUM; MEN; ASSOCIATION; FOODS; ACIDS	Background. It is known that soluble fiber in the diet can lower blood lipid levels. It is less certain, however, that eating foods with soluble fiber will further lower blood lipids when the intake of saturated fat and cholesterol has already been reduced to very low levels. Furthermore, the mechanism of the lipid-lowering effect of fiber has not been elucidated. Methods. To address these questions, we studied 43 volunteers with hyperlipidemia in a crossover study involving two four-month dietary periods. The two metabolic diets contained foods high in either soluble or insoluble fiber and were separated by a two-month National Cholesterol Education Program Step 2 diet. The metabolic diets were low in saturated fat (<4 percent of total calories) and cholesterol (<25 mg per 1 000 kcal), high in carbohydrate (greater-than-or-equal-to 60 percent of total calories), and very high in fiber (>24 g per 1000 kcal). Results. Blood lipids fell to their lowest levels by week 4 of both study diets. When the soluble-fiber period was compared with the insoluble-fiber period, the subjects' total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels were found to be lower by a mean (+/-SE) of 4.9+/-0.9 percent (P<0.001), 4.8+/-1.3 percent (P<0.001), and 3.4+/-1.3 percent (P = 0.014), respectively. In contrast, the ratio of total to HDL cholesterol was not significantly different during the two dietary periods. The loss of fecal bile acids was 83+/-14 percent greater during the soluble-fiber period than during the insoluble-fiber period (P<0.001) and was related to the differences in total and LDL cholesterol and apolipoprotein B levels (r = 0.42, P = 0.005; r = 0.49, P<0.001; and r = 0.33, P = 0.035, respectively). The difference in serum cholesterol levels between the two dietary periods was greater among the men (7.5+/-1.2 percent, P<0.001) than among the women (3.4+/-1.2 percent, P = 0.008). Conclusions. Very high intakes of foods rich in soluble fiber lower blood cholesterol levels even when the main dietary modifiers of blood lipids - namely, saturated fat and cholesterol - are greatly reduced.	UNIV TORONTO,FAC MED,DEPT NUTR SCI,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,FAC MED,DEPT PREVENT MED & BIOSTAT,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,ST MICHAELS HOSP,DIV ENDOCRINOL & METAB,TORONTO M5B 1W8,ONTARIO,CANADA; PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907; NESTLE RES CTR,DIV CARBOHYDRATE RES,LAUSANNE,SWITZERLAND	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Nestle SA	JENKINS, DJA (corresponding author), UNIV TORONTO,ST MICHAELS HOSP,CTR CLIN NUTR & RISK FACTOR MODIFICAT,61 QUEEN ST E,TORONTO M5C 2T2,ON,CANADA.		Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020; Jenkins, David JA/A-1992-2009; Wolever, Thomas/AAC-8066-2022; Connelly, Philip W/B-7583-2012	Hegele, Robert/0000-0003-2861-5325; Connelly, Philip W/0000-0001-7244-6843; Boctor, Dana/0000-0002-0493-4594	NHLBI NIH HHS [R01 HL 39689] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL139689, R01HL039689] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JW, 1988, AM J CLIN NUTR, V47, P440, DOI 10.1093/ajcn/47.3.440; ANDERSON JW, 1984, AM J CLIN NUTR, V40, P1146, DOI 10.1093/ajcn/40.6.1146; ANDERSON JW, IN PRESS VAHOUNY FIB; BELL LP, 1989, JAMA-J AM MED ASSOC, V261, P3419, DOI 10.1001/jama.261.23.3419; BLANKENHORN DH, 1990, JAMA-J AM MED ASSOC, V263, P1646, DOI 10.1001/jama.263.12.1646; BROWN WV, 1989, 2ND INT C PREV CARD; CLARK LC, 1977, OXYGEN SUPPLY, P120; CUNNANE SC, 1990, J NUTR, V120, P338, DOI 10.1093/jn/120.4.338; FINK PC, 1989, J CLIN CHEM CLIN BIO, V27, P261; GINSBERG HN, 1990, NEW ENGL J MED, V322, P574, DOI 10.1056/NEJM199003013220902; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; GUERRANT GO, 1982, J CLIN MICROBIOL, V16, P355, DOI 10.1128/JCM.16.2.355-360.1982; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HIXSON JE, 1990, J LIPID RES, V31, P545; Horwitz W, 1980, AOAC OFFICIAL METHOD; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KRITCHEVSKY D, 1974, J NUTR, V104, P458, DOI 10.1093/jn/104.4.458; KUZUYA T, 1976, DIABETOLOGIA, V12, P511, DOI 10.1007/BF01219516; LEVY RI, 1984, CIRCULATION, V69, P325, DOI 10.1161/01.CIR.69.2.325; NEWMAN RK, 1989, NUTR REP INT, V39, P749; NIERENBERG DW, 1985, J CHROMATOGR, V345, P275, DOI 10.1016/0378-4347(85)80165-1; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; SCHAEFER EJ, 1981, AM J CLIN NUTR, V34, P1758, DOI 10.1093/ajcn/34.9.1758; SNIDERMAN AD, 1982, ANN INTERN MED, V97, P833, DOI 10.7326/0003-4819-97-6-833; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; TURLEY SD, 1991, METABOLISM, V40, P1063, DOI 10.1016/0026-0495(91)90131-F; VANHORN L, 1991, AM J PUBLIC HEALTH, V81, P183, DOI 10.2105/AJPH.81.2.183; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; 1990, NIH903046 PUBL; 1988, DDHS PHS8850210 PUBL; 1987, PHYSL EFFECTS HLTH C; 1982, NIH822014 PUBL; 1974, DHEW NIH75628 PUBL; 1984, JAMA-J AM MED ASSOC, V251, P365; [No title captured]; 1991, FOOD LABELLING HLTH; 1985, SAS STAT USSERS GUID	40	233	238	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					21	26		10.1056/NEJM199307013290104	http://dx.doi.org/10.1056/NEJM199307013290104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8389421				2022-12-28	WOS:A1993LJ33800004
J	EBNER, R; CHEN, RH; SHUM, L; LAWLER, S; ZIONCHECK, TF; LEE, A; LOPEZ, AR; DERYNCK, R				EBNER, R; CHEN, RH; SHUM, L; LAWLER, S; ZIONCHECK, TF; LEE, A; LOPEZ, AR; DERYNCK, R			CLONING OF A TYPE-I TGF-BETA RECEPTOR AND ITS EFFECT OF TGF-BETA BINDING TO THE TYPE-II RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR-BETA; EXPRESSION CLONING; PROTEIN-KINASE; PURIFICATION	Transforming growth factor-beta (TGF-beta) affects cellular proliferation, differentiation, and interaction with the extracellular matrix primarily through interaction with the type I and type II TGF-beta receptors. The type II receptors for TGF-beta and activin contain putative serine-threonine kinase domains. A murine serine-threonine kinase receptor, Tsk 7L, was cloned that shared a conserved extracellular domain with the type II TGF-beta receptor. Overexpression of Tsk 7L alone did not increase cell surface binding of TGF-beta, but coexpression with the type II TGF-beta receptor caused TGF-beta to bind to Tsk 7L, which had the size of the type I TGF-beta receptor. Overexpression of Tsk 7L inhibited binding of TGF-beta to the type II receptor in a dominant negative fashion. Combinatorial interactions and stoichiometric ratios between the type I and II receptors may therefore determine the extent of TGF-beta binding and the resulting biological activities.	UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, VET ADM MED CTR, HEMATOL ONCOL SECT 111H, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT IMMUNOL, STANFORD, CA 94305 USA	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University			Chen, Ruey-Hwa/G-6121-2019; Lopez, Andrea/GQQ-3059-2022	Chen, Ruey-Hwa/0000-0001-8124-5832; 				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BAIRACH A, 1991, PROSITE DICT PROTEIN; BOYD FT, 1990, J CELL SCI, P131; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; EBNER R, UNPUB; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAWLER S, UNPUB; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1068; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LOPEZ A, UNPUB; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Scott J D, 1992, Curr Opin Neurobiol, V2, P289, DOI 10.1016/0959-4388(92)90117-4; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; Smith A J, 1980, Methods Enzymol, V65, P560; ULLRICH A, 1990, CELL, V61, P243; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	35	413	453	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1344	1348		10.1126/science.8388127	http://dx.doi.org/10.1126/science.8388127			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8388127				2022-12-28	WOS:A1993LE02500048
J	BANNER, DW; DARCY, A; JANES, W; GENTZ, R; SCHOENFELD, HJ; BROGER, C; LOETSCHER, H; LESSLAUER, W				BANNER, DW; DARCY, A; JANES, W; GENTZ, R; SCHOENFELD, HJ; BROGER, C; LOETSCHER, H; LESSLAUER, W			CRYSTAL-STRUCTURE OF THE SOLUBLE HUMAN 55 KD TNF RECEPTOR-HUMAN TNF-BETA COMPLEX - IMPLICATIONS FOR TNF RECEPTOR ACTIVATION	CELL			English	Article							TUMOR-NECROSIS-FACTOR; ELECTRON-DENSITY MAPS; MUTATIONAL ANALYSIS; PROTEIN STRUCTURES; MOLECULAR-CLONING; FACTOR-ALPHA; BINDING; RESOLUTION; LOCALIZATION; PURIFICATION	The X-ray crystal structure of the complex of the extracellular domain of the human 55 kd tumor necrosis factor (TNF) receptor with human TNFbeta has been determined at 2.85 angstrom resolution. The complex has three receptor molecules bound symmetrically to one TNFbeta trimer. The receptor fragment, a very elongated end to end assembly of four similar folding domains, binds in the groove between two adjacent TNFbeta subunits. The structure of the complex defines the orientation of the ligand with respect to the cell membrane and provides a model for TNF receptor activation. The novel fold of the TNF receptor structure is likely to be representative of the nerve growth factor (NGF)/TNF receptor family as a whole.			BANNER, DW (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND.							BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Cooley W.B., 1893, AM J MED SCI, V105, P487, DOI [10.1097/00000441-189305000-00001, DOI 10.1097/00000441-189305000-00001]; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DARCY A, 1993, J MOL BIOL, V229, P555, DOI 10.1006/jmbi.1993.1055; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEHR G, 1992, J IMMUNOL, V149, P911; GOH CR, 1991, PROTEIN ENG, V4, P785; GREER J, 1974, J MOL BIOL, V82, P279, DOI 10.1016/0022-2836(74)90591-9; HAKOSHIMA T, 1988, J MOL BIOL, V201, P455, DOI 10.1016/0022-2836(88)90153-2; HELLER RA, 1992, CELL, V70, P47; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LATTMAN EE, 1972, ACTA CRYSTALLOGR B, V26, P1854; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Loetscher H, 1991, Oxf Surv Eukaryot Genes, V7, P119; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; McPherson A Jr, 1976, Methods Biochem Anal, V23, P249, DOI 10.1002/9780470110430.ch4; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SECKINGER P, 1990, EUR J IMMUNOL, V20, P1167, DOI 10.1002/eji.1830200533; Shear MJ, 1943, J NATL CANCER I, V4, P81; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STUART D, 1985, ACTA CRYSTALLOGR A, V40, P713; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713	61	968	1091	2	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					431	445		10.1016/0092-8674(93)90132-A	http://dx.doi.org/10.1016/0092-8674(93)90132-A			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387891				2022-12-28	WOS:A1993LA74300006
J	KUME, S; MUTO, A; ARUGA, J; NAKAGAWA, T; MICHIKAWA, T; FURUICHI, T; NAKADE, S; OKANO, H; MIKOSHIBA, K				KUME, S; MUTO, A; ARUGA, J; NAKAGAWA, T; MICHIKAWA, T; FURUICHI, T; NAKADE, S; OKANO, H; MIKOSHIBA, K			THE XENOPUS IP(3) RECEPTOR - STRUCTURE, FUNCTION, AND LOCALIZATION IN OOCYTES AND EGGS	CELL			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SEA-URCHIN EGGS; CORTICAL GRANULE EXOCYTOSIS; RECONSTITUTED LIPID VESICLES; CEREBELLAR PURKINJE-CELLS; PROTO-ONCOGENE PRODUCT; GOLDEN-HAMSTER EGGS; CALCIUM RELEASE; MESSENGER-RNA; MOUSE CEREBELLUM	To study the role of the IP3 receptor (IP3R) upon egg activation, cDNA clones encoding IP3R expressed in the Xenopus oocytes were isolated. By analyses of the primary structure and functional expression of the cDNA, Xenopus IP3R (XIP3R) was shown to have an IP3-binding domain and a putative Ca2+ channel region. Immunocytochemical studies revealed polarized distribution of XIP3R in the cytoplasm of the animal hemisphere in a well-organized endoplasmic reticulum-like structure and intensive localization in the perinuclear region of stage VI immature oocytes. In ovulated unfertilized eggs, XIP3R was densely enriched in the cortical region of both hemispheres in addition to its polarized localization. After fertilization, XIP3R showed a drastic change in its distribution in the cortical region. These results imply the predominant role of the XIP3R in both the formation and propagation of Ca2+ waves at fertilization.	OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN; RIKEN, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI 305, JAPAN	Osaka University; RIKEN	KUME, S (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOLEC NEUROBIOL, 4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN.		Okano, Hideyuki/I-7584-2019; Aruga, Jun/H-5837-2011; Mikoshiba, Katsuhiko/N-7943-2015; Furuichi, Teiichi/B-5086-2014; Kume, Shoen/M-4356-2016; Muto, Akira/E-2580-2015	Aruga, Jun/0000-0001-7936-1375; Furuichi, Teiichi/0000-0002-9676-1888; Kume, Shoen/0000-0002-4292-205X; Muto, Akira/0000-0003-4276-1775; Nakagawa, Toshiyuki/0000-0001-8415-4119				BAKER C, 1990, NUCLEIC ACIDS RES, V18, P3537, DOI 10.1093/nar/18.12.3537; BEMENT WM, 1989, J CELL BIOL, V108, P885, DOI 10.1083/jcb.108.3.885; BEMENT WM, 1989, CELL TISSUE RES, V255, P183; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUCK WR, 1992, EXP CELL RES, V202, P59, DOI 10.1016/0014-4827(92)90404-V; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; BUSA WB, 1988, PHILOS T ROY SOC B, V320, P415, DOI 10.1098/rstb.1988.0085; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CAMPANELLA C, 1984, J EXP ZOOL, V229, P283, DOI 10.1002/jez.1402290214; CHARBONNEAU M, 1984, DEV BIOL, V102, P90, DOI 10.1016/0012-1606(84)90177-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CUTHBERTSON KSR, 1981, NATURE, V294, P754, DOI 10.1038/294754a0; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EISEN A, 1984, J CELL BIOL, V99, P1878, DOI 10.1083/jcb.99.5.1878; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; ELINSON RP, 1975, DEV BIOL, V47, P257, DOI 10.1016/0012-1606(75)90281-X; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUJIWARA A, 1990, DEV GROWTH DIFFER, V32, P303; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; GARDINER DM, 1983, J CELL BIOL, V96, P1159, DOI 10.1083/jcb.96.4.1159; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDENBERG M, 1980, DEV GROWTH DIFFER, V22, P345; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; HARA K, 1979, ROUX ARCH DEV BIOL, V186, P91, DOI 10.1007/BF00848113; HOEY T, 1989, CURR PROTOCOLS MOL S, V2; HOLLINGER TG, 1980, GAMETE RES, V3, P45, DOI 10.1002/mrd.1120030106; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; IWAMATSU T, 1989, DEV GROWTH DIFFER, V31, P39; JAFFE LA, 1988, REGULATORY MECHANISM, P15; JAFFE LF, 1983, DEV BIOL, V99, P265, DOI 10.1016/0012-1606(83)90276-2; KLINE D, 1988, SCIENCE, V241, P464, DOI 10.1126/science.3134693; KLINE D, 1991, DEV BIOL, V143, P218, DOI 10.1016/0012-1606(91)90072-B; KLINE D, 1988, DEV BIOL, V126, P346, DOI 10.1016/0012-1606(88)90145-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARABELL C, 1992, DEV BIOL, V153, P347, DOI 10.1016/0012-1606(92)90119-2; LARABELL CA, 1988, CELL TISSUE RES, V251, P129, DOI 10.1007/BF00215457; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKAGAWA T, 1991, J NEUROCHEM, V57, P1807, DOI 10.1111/j.1471-4159.1991.tb06385.x; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NIEUWKOOP PD, 1967, NORMAL DEV TABLE XEN; ORON Y, 1988, P NATL ACAD SCI USA, V85, P3820, DOI 10.1073/pnas.85.11.3820; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETER AB, 1991, J CELL BIOL, V114, P455, DOI 10.1083/jcb.114.3.455; PICARD A, 1985, FEBS LETT, V182, P446, DOI 10.1016/0014-5793(85)80351-3; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBERG K, 1990, SCIENCE, V249, P298, DOI 10.1126/science.2374929; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1992, DEV GROWTH DIFFER, V34, P37; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RC, 1990, DEVELOPMENT, V110, P769; STEINHARDT R, 1977, DEV BIOL, V58, P185, DOI 10.1016/0012-1606(77)90084-7; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STRICKER SA, 1992, DEV BIOL, V149, P370, DOI 10.1016/0012-1606(92)90292-O; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; TURNER PR, 1987, DEV BIOL, V120, P577, DOI 10.1016/0012-1606(87)90260-0; TURNER PR, 1986, J CELL BIOL, V102, P70, DOI 10.1083/jcb.102.1.70; VINCENT JP, 1987, DEV BIOL, V123, P526, DOI 10.1016/0012-1606(87)90411-8; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WINKLER MM, 1980, NATURE, V287, P558, DOI 10.1038/287558a0; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; YOSHIMOTO Y, 1986, DEV GROWTH DIFFER, V28, P583	106	213	214	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					555	570		10.1016/0092-8674(93)90142-D	http://dx.doi.org/10.1016/0092-8674(93)90142-D			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387895				2022-12-28	WOS:A1993LA74300016
J	GROOTHUIS, JR; SIMOES, EAF; LEVIN, MJ; HALL, CB; LONG, CE; RODRIGUEZ, WJ; ARROBIO, J; MEISSNER, HC; FULTON, DR; WELLIVER, RC; TRISTRAM, DA; SIBER, GR; PRINCE, GA; VANRADEN, M; HEMMING, VG				GROOTHUIS, JR; SIMOES, EAF; LEVIN, MJ; HALL, CB; LONG, CE; RODRIGUEZ, WJ; ARROBIO, J; MEISSNER, HC; FULTON, DR; WELLIVER, RC; TRISTRAM, DA; SIBER, GR; PRINCE, GA; VANRADEN, M; HEMMING, VG			PROPHYLACTIC ADMINISTRATION OF RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN TO HIGH-RISK INFANTS AND YOUNG-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS GAMMA-GLOBULIN; COTTON RATS; MATERNAL ANTIBODY; VIRAL-INFECTION; PULMONARY PATHOLOGY; EPIDEMIOLOGY; WASHINGTON; DISEASE; HOSPITALIZATION; IMMUNOTHERAPY	Background. Infants with cardiac disease or prematurity are at risk for severe illness caused by respiratory syncytial virus. Immune globulin with a high titer of antibodies against respiratory syncytial virus may offer infants and young children at risk protection from this serious, common respiratory illness. Methods. We studied 249 infants and young children (mean age, eight months) who had bronchopulmonary dysplasia due to prematurity (n = 102), congenital heart disease (n = 87), or prematurity alone (n = 60). Respiratory syncytial virus immune globulin was given monthly to some of these children in either a high dose (750 mg per kilogram of body weight; n = 81) or a low dose (150 mg per kilogram; n = 79); 89 controls received no immune globulin. Group assignments were random. Assessments of respiratory illness and management were conducted without knowledge of the children's group assignments. Results. There were 64 episodes of respiratory syncytial virus infection: 19 in the high-dose group, 16 in the low-dose group, and 29 in the control group. In the high-dose group there were fewer lower respiratory tract infections (7, vs. 20 in the control group; P = 0.01), fewer hospitalizations (6, vs. 18 in the control group; P = 0.02), fewer hospital days (43, vs. 128 in the control group; P = 0.02), fewer days in the intensive care unit (P = 0.05), and less use of ribavirin (P = 0.05). In the low-dose group there was a significant reduction only in the number of days in the intensive care unit (P = 0.03). Adverse events during the 580 infusions were generally mild and included fluid overload (in five children), oxygen desaturation (eight), and fever (six). Six children died: three in the high-dose group, three in the low-dose group, and none in the control group (P = 0.15), but no death was attributed to the use of immune globulin or to illness caused by respiratory syncytial virus. Conclusions. Administration of high doses of respiratory syncytial virus immune globulin is a safe and effective means of preventing lower respiratory tract infection in infants and young children at high risk for this disease.	UNIV COLORADO,SCH MED,DEPT PEDIAT,DIV NEONATOL,DENVER,CO 80202; UNIV COLORADO,SCH MED,DEPT PEDIAT,DIV INFECT DIS,DENVER,CO 80202; UNIV COLORADO,SCH MED,DEPT PEDIAT,DIV CARDIOL,DENVER,CO 80202; STRONG MEM HOSP,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,ROCHESTER,NY 14627; CHILDRENS HOSP,NATL MED CTR,WASHINGTON,DC 20010; TUFTS UNIV,FLOATING HOSP INFANTS & CHILDREN,DIV CARDIOL,BOSTON,MA 02111; TUFTS UNIV,FLOATING HOSP INFANTS & CHILDREN,DIV INFECT DIS,BOSTON,MA 02111; SUNY BUFFALO,CHILDRENS HOSP,MED CTR,DIV INFECT DIS,BUFFALO,NY 14260; MASSACHUSETTS PUBL HLTH BIOL LABS,BOSTON,MA; VIRION SYST,ROCKVILLE,MD; NIAID,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,F EDWARD HEBERT SCH MED,DEPT PEDIAT,BETHESDA,MD 20814	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Rochester; University of Rochester; Children's National Health System; Floating Hospital For Children; Tufts University; Floating Hospital For Children; Tufts University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Uniformed Services University of the Health Sciences - USA	GROOTHUIS, JR (corresponding author), CHILDRENS HOSP,1056 E 19TH AVE,B070,DENVER,CO 80218, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-00044, RR-69] Funding Source: Medline; PHS HHS [N01-A1-82520] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABMAN SH, 1988, J PEDIATR-US, V113, P826, DOI 10.1016/S0022-3476(88)80008-8; APPENDIX N, 1985, NEW VACCINE DEV ESTA, V1, P397; BAKER CJ, 1992, NEW ENGL J MED, V327, P213, DOI 10.1056/NEJM199207233270401; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; BRUHN FW, 1977, J PEDIATR-US, V90, P382, DOI 10.1016/S0022-3476(77)80697-5; BRUHN FW, 1977, AM J DIS CHILD, V131, P145, DOI 10.1001/archpedi.1977.02120150027004; CHANOCK RM, 1965, PEDIATRICS, V36, P21; CONNORS M, 1992, VACCINE, V10, P475, DOI 10.1016/0264-410X(92)90397-3; DESIERRA TM, 1993, J PEDIATR-US, V122, P787, DOI 10.1016/S0022-3476(06)80027-2; EEISMAN LE, 1992, J PEDIATR, V121, P434; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007; GROOTHUIS JR, 1991, ANTIMICROB AGENTS CH, V35, P1469, DOI 10.1128/AAC.35.7.1469; GROOTHUIS JR, 1990, J PEDIATR-US, V117, P792, DOI 10.1016/S0022-3476(05)83347-5; GROOTHUIS JR, 1988, PEDIATRICS, V82, P199; GROOTHUIS JR, 1990, AM J DIS CHILD, V144, P346, DOI 10.1001/archpedi.1990.02150270096033; HALL CB, 1979, NEW ENGL J MED, V300, P393, DOI 10.1056/NEJM197902223000803; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; LAMPRECHT CL, 1976, J INFECT DIS, V134, P211, DOI 10.1093/infdis/134.3.211; LAUER BA, 1985, J CLIN MICROBIOL, V22, P782, DOI 10.1128/JCM.22.5.782-785.1985; LODA FA, 1968, J PEDIATR-US, V72, P161, DOI 10.1016/S0022-3476(68)80305-1; MACDONALD NE, 1982, NEW ENGL J MED, V307, P397, DOI 10.1056/NEJM198208123070702; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCMILLAN JA, 1988, PEDIATRICS, V81, P22; MURPHY BR, 1990, VACCINE, V8, P497, DOI 10.1016/0264-410X(90)90253-I; NAVAS L, 1992, J PEDIATR-US, V121, P348, DOI 10.1016/S0022-3476(05)90000-0; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; OGILVIE MM, 1981, J MED VIROL, V7, P263, DOI 10.1002/jmv.1890070403; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; PRINCE GA, 1985, VIRUS RES, V3, P193, DOI 10.1016/0168-1702(85)90045-0; PRINCE GA, 1987, J VIROL, V61, P1851, DOI 10.1128/JVI.61.6.1851-1854.1987; PRINCE GA, 1985, J VIROL, V55, P517, DOI 10.1128/JVI.55.3.517-520.1985; PRINCE GA, 1986, J VIROL, V57, P721, DOI 10.1128/JVI.57.3.721-728.1986; PRINCE GA, 1978, AM J PATHOL, V93, P771; PRINCE GA, 1983, INFECT IMMUN, V42, P81, DOI 10.1128/IAI.42.1.81-87.1983; PRINCE GA, 1986, J VIROL, V59, P193; SIBER GR, 1992, J INFECT DIS, V165, P456, DOI 10.1093/infdis/165.3.456; SIMOES EAF, 1993, AM J DIS CHILD, V147, P303, DOI 10.1001/archpedi.1993.02160270065020; Simoes Eric A. F., 1993, Pediatric Research, V33, p183A; SUFFIN SC, 1979, J IMMUNOL, V123, P10; TAYLOR G, 1983, LANCET, V2, P976; WARD KA, 1983, J GEN VIROL, V64, P1867, DOI 10.1099/0022-1317-64-9-1867; WELLIVER R C, 1988, Clinical Microbiology Reviews, V1, P27	45	565	600	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1524	1530		10.1056/NEJM199311183292102	http://dx.doi.org/10.1056/NEJM199311183292102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8413475				2022-12-28	WOS:A1993MG18800002
J	IKEDA, RM; KONDRACKI, SF; DRABKIN, PD; BIRKHEAD, GS; MORSE, DL				IKEDA, RM; KONDRACKI, SF; DRABKIN, PD; BIRKHEAD, GS; MORSE, DL			PLEURODYNIA AMONG FOOTBALL PLAYERS AT A HIGH-SCHOOL - AN OUTBREAK ASSOCIATED WITH COXSACKIEVIRUS-B1	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ASEPTIC-MENINGITIS	Objective.-Enteroviral outbreaks involving athletic teams have been described, although the mode of transmission has been unclear. In September 1991, an out-break of pleurodynia among high school football players provided an opportunity to identify possible modes of transmission. Design.-Retrospective cohort outbreak investigation. Setting.-Public high school in upstate New York. Results.-Illness was reported by 17 (20%) of the football players. Behaviors involving contact with common water containers were associated with illness, including eating ice cubes from the team ice chest (relative risk [RR], 9.2; 95% confidence interval [CI], 1.3 to 65.5) and drinking water f rom the team cooler (RR, 6.3; 95% CI, 1.5 to 25.7). Coxsackievirus B1 was isolated in four (50%) of the eight stool specimens collected. Conclusions.-Contamination of common water containers by an infected player may have contributed to or initiated the outbreak. In addition to discouraging direct oral contact with common drinking containers, use of individual water containers and ice packs for injuries was recommended.	NEW YORK STATE DEPT HLTH,BUR COMMUNICABLE DIS CONTROL,ALBANY,NY 12201	State University of New York (SUNY) System	IKEDA, RM (corresponding author), CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,4770 BUFORD HWY NE,ATLANTA,GA 30341, USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560				ALEXANDER JP, 1993, J INFECT DIS, V167, P1201, DOI 10.1093/infdis/167.5.1201; BARON RC, 1982, JAMA-J AM MED ASSOC, V248, P1724, DOI 10.1001/jama.248.14.1724; CHONG AYH, 1975, TROP GEOGR MED, V27, P151; EVANS AS, 1931, VIRAL INFECTIONS HUM; HORSTMANN DM, 1950, JAMA-J AM MED ASSOC, V142, P236, DOI 10.1001/jama.1950.02910220016004; MOORE M, 1983, JAMA-J AM MED ASSOC, V249, P2039, DOI 10.1001/jama.249.15.2039; RUSSELL W R, 1949, Br Med J, V1, P465; RUSSELL WR, 1947, BRIT MED J, V2, P1023, DOI 10.1136/bmj.2.4538.1023; SCHOUB BD, 1985, J HYG-CAMBRIDGE, V95, P447, DOI 10.1017/S0022172400062872; Sylvesr E, 1934, EPIDEMIC MYALGIA BOR; THOMAS JC, 1990, J SCHOOL HEALTH, V60, P395	11	16	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2205	2206		10.1001/jama.270.18.2205	http://dx.doi.org/10.1001/jama.270.18.2205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411604				2022-12-28	WOS:A1993ME81600032
J	OXMAN, AD; SACKETT, DL; GUYATT, GH				OXMAN, AD; SACKETT, DL; GUYATT, GH			USERS GUIDES TO THE MEDICAL LITERATURE .1. HOW TO GET STARTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE; INFORMATION; ACCESS		MCMASTER UNIV, HLTH SCI CTR,DEPT CLIN EPIDEMIOL,1200 MAIN ST W, ROOM 2C12, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOSTAT, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT FAMILY MED, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT MED, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; McMaster University			Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; CHALMERS I, 1989, EFFECTIVE CARE PREGN, P3; CHALMERS I, 1992, OXFORD DATABASE PERI; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; Ehrenkranz R.A., 1992, EFFECTIVE CARE NEWBO; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HAYNES RB, 1986, ANN INTERN MED, V105, P810, DOI 10.7326/0003-4819-105-5-810; LINDBERG DAB, 1993, JAMA-J AM MED ASSOC, V269, P3124, DOI 10.1001/jama.269.24.3124; MANNING PR, 1992, JAMA-J AM MED ASSOC, V268, P1135; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; RUBENSTEIN E, 1993, CARE SURGICAL PATIEN; STROSS JK, 1979, JAMA-J AM MED ASSOC, V241, P2622, DOI 10.1001/jama.241.24.2622; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151	15	429	449	1	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2093	2095						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411577				2022-12-28	WOS:A1993MD88200031
J	BACHMAN, JW; HEISE, RH; NAESSENS, JM; TIMMERMAN, MG				BACHMAN, JW; HEISE, RH; NAESSENS, JM; TIMMERMAN, MG			A STUDY OF VARIOUS TESTS TO DETECT ASYMPTOMATIC URINARY-TRACT INFECTIONS IN AN OBSTETRIC POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTERIURIA; PREGNANCY; URINALYSIS; CULTURE; NITRITE; RISK	Objective.-To compare rapid screening techniques for detecting asymptomatic urinary tract infections (AUTIs) in pregnant women. Design.-Comparison of results of the screening tests of urinalysis, urine dipstick, and Gram's staining with the results of standard urine culture at an initial prenatal visit. In follow-up visits, urine dipstick testing was compared with urinalysis. Setting.-Departments of Family Medicine and Obstetrics and Gynecology, Mayo Clinic, Rochester, Minn. Patients.-Pregnant women (1 047) from the local community were screened for AUTI on initial and follow-up visits. Methods.-Initial prenatal urine was tested by using urine dipstick testing, urinalysis, Gram's staining, and urine culture. At each follow-up visit, urine specimens were tested by using urine dipstick and urinalysis. Main Outcome Measures.-Sensitivity and specificity, incremental patient costs, and clinical outcomes were used to assess the effectiveness of the techniques. Results.-On initial visits, rapid screening tests for AUTI in pregnant women revealed the following: Gram's staining identified 22 of 24 patients with AUTI (sensitivity, 91.7%; specificity, 89.2%); urine dipstick, 12 of 24 (sensitivity, 50.0%; specificity, 96.9%); and urinalysis with presence of leukocytes, six of 24 (sensitivity, 25.0%; specificity, 99.0%). In follow-up visits, urine dipstick tests detected 19 infections and urinalysis, three (positive predictive value, 5% compared with 3%). Conclusions.-Urine dipstick testing for nitrites identified half of all patients with urinary tract infections and was superior to urinalysis on follow-up visits. Although Gram's staining is more expensive, it was more accurate for AUTI than urinalysis or urine dipstick test for nitrites. Urinalysis was never the test of choice because it was more expensive and detected fewer positive cultures. Leukocyte measurement correlated poorly with AUTI.	MAYO CLIN & MAYO FDN, DEPT OBSTET & GYNECOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic	BACHMAN, JW (corresponding author), MAYO CLIN & MAYO FDN, DEPT FAMILY MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ABYAD A, 1991, J FAM PRACTICE, V33, P471; ANDRIOLE VT, 1991, MED CLIN N AM, V75, P359, DOI 10.1016/S0025-7125(16)30459-X; ARCHBALD FJ, 1984, J REPROD MED, V29, P272; CAMPBELLBROWN M, 1987, BRIT MED J, V294, P1579, DOI 10.1136/bmj.294.6587.1579; CZERWINSKI AW, 1971, AM J OBSTET GYNECOL, V110, P42, DOI 10.1016/0002-9378(71)90211-0; GOLAN A, 1989, EUR J OBSTET GYN R B, V33, P101, DOI 10.1016/0028-2243(89)90202-5; GORDON M C, 1989, Comprehensive Therapy, V15, P52; HARRIS RE, 1979, OBSTET GYNECOL, V53, P71; IRAVANI A, 1991, UROLOGY, V37, P503, DOI 10.1016/0090-4295(91)80312-U; LENKE RR, 1981, AM J OBSTET GYNECOL, V140, P427, DOI 10.1016/0002-9378(81)90039-9; LUCAS AR, 1988, MAYO CLIN PROC, V63, P433, DOI 10.1016/S0025-6196(12)65638-9; MCNEELEY SG, 1987, OBSTET GYNECOL, V69, P550; NORDEN CW, 1968, ANNU REV MED, V19, P431, DOI 10.1146/annurev.me.19.020168.002243; North D H, 1990, J Miss State Med Assoc, V31, P331; PLAUCHE WC, 1981, SOUTHERN MED J, V74, P1227, DOI 10.1097/00007611-198110000-00020; ROBERTSON AW, 1988, OBSTET GYNECOL, V71, P878; SOISSON AP, 1985, J REPROD MED, V30, P588; STENQVIST K, 1989, AM J EPIDEMIOL, V129, P372, DOI 10.1093/oxfordjournals.aje.a115140; TURCK M, 1962, NEW ENGL J MED, V266, P857, DOI 10.1056/NEJM196204262661703; 1989, GUIDE CLIN PREVENTIV, P155; 1979, CAN MED ASS J, V121, P1193	21	80	91	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1971	1974		10.1001/jama.270.16.1971	http://dx.doi.org/10.1001/jama.270.16.1971			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8411555				2022-12-28	WOS:A1993MC51300030
J	SCHEJTER, ED; WIESCHAUS, E				SCHEJTER, ED; WIESCHAUS, E			BOTTLENECK ACTS AS A REGULATOR OF THE MICROFILAMENT NETWORK GOVERNING CELLULARIZATION OF THE DROSOPHILA EMBRYO	CELL			English	Article							SEQUENCE-ANALYSIS; GENE ACTIVITY; MELANOGASTER; EMBRYOGENESIS; BLASTODERM; MYOSIN; CYTOKINESIS; TAILLESS; SET; EXPRESSION	A dynamic network of cortical microfilaments is associated with the cleavage furrow membranes during cellularization of the Drosophila embryo. A specific set of structural rearrangements in this network is required for orchestration and execution of its mechanistic roles. We describe the characterization of the gene bottleneck (bnk), mutations in which disturb the proper sequence of rearrangements of the microfilament network, leading to a variety of morphological defects during cellularization. bnk, whose expression is restricted to the blastoderm stages of Drosophila embryogenesis, encodes a novel, exceptionally basic protein that specifically colocalizes with the microfilament network. The expression pattern and mutant phenotype of bnk suggest a direct role for this element in regulation of the dynamic restructuring of the actin-based cytoskeleton of cellularizing Drosophila embryos.			SCHEJTER, ED (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.				NICHD NIH HHS [5R01HD15587] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015587] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CAVANER DR, 1987, NUCLEIC ACIDS RES, V15, P1353; CROZATIER M, 1992, GENETICS, V131, P905; DELOZANNE A, 1987, SCIENCE, V236, P1081; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1993, IN PRESS DEV DROSOPH; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FULLILOVE SL, 1971, DEV BIOL, V26, P560, DOI 10.1016/0012-1606(71)90141-2; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KATOH K, 1989, PROTOPLASMA, V150, P83, DOI 10.1007/BF01403663; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P663; KIEHART DP, 1991, CURR TOP MEMBR, V38, P79; LEVY LS, 1982, DEV BIOL, V94, P451, DOI 10.1016/0012-1606(82)90362-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; MAHOWALD AP, 1963, EXP CELL RES, V32, P457, DOI 10.1016/0014-4827(63)90186-1; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIGNONI F, 1992, DEVELOPMENT, V115, P239; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PLANQUES V, 1991, EXP CELL RES, V192, P557, DOI 10.1016/0014-4827(91)90076-7; POLLARD TD, 1990, ANN NY ACAD SCI, V582, P120; Poodry C.A., 1992, P143; RICKOLL WL, 1976, DEV BIOL, V49, P304, DOI 10.1016/0012-1606(76)90278-5; ROSE LS, 1992, GENE DEV, V6, P1255, DOI 10.1101/gad.6.7.1255; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SCHEJTER ED, 1992, COLD SPRING HARB SYM, V57, P653, DOI 10.1101/SQB.1992.057.01.071; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cellbio.9.1.67; SCHROEDER TE, 1990, ANN NY ACAD SCI, V582, P78; SCHWALM FE, 1988, INSECT MORPHOGENESIS, P136; SCHWEISGUTH F, 1990, GENE DEV, V4, P922, DOI 10.1101/gad.4.6.922; SIMPSON L, 1990, DEVELOPMENT, V110, P851; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TURNER FR, 1976, DEV BIOL, V50, P95, DOI 10.1016/0012-1606(76)90070-1; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; VINCENT A, 1985, J MOL BIOL, V186, P149, DOI 10.1016/0022-2836(85)90265-7; WARN RM, 1986, EXP CELL RES, V163, P201, DOI 10.1016/0014-4827(86)90573-2; WARN RM, 1990, J CELL SCI, V96, P35; WARN RM, 1980, J EMBRYOL EXP MORPH, V57, P167; WARN RM, 1986, J CELL SCI, P311; WARN RM, 1983, EXP CELL RES, V143, P103, DOI 10.1016/0014-4827(83)90113-1; WIESCHAUS E, 1988, DEVELOPMENT, V104, P483; Wieschaus E., 1986, P199; WOLF N, 1988, DEVELOPMENT, V102, P311; WONG YC, 1981, NUCLEIC ACIDS RES, V9, P6749, DOI 10.1093/nar/9.24.6749; YONEMURA S, 1991, J CELL SCI, V100, P73; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; ZIPURSKY SL, 1985, P NATL ACAD SCI USA, V82, P1855, DOI 10.1073/pnas.82.6.1855	67	74	75	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					373	385		10.1016/0092-8674(93)80078-S	http://dx.doi.org/10.1016/0092-8674(93)80078-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402919				2022-12-28	WOS:A1993MD88500018
J	MOORE, EDW; ETTER, EF; PHILIPSON, KD; CARRINGTON, WA; FOGARTY, KE; LIFSHITZ, LM; FAY, FS				MOORE, EDW; ETTER, EF; PHILIPSON, KD; CARRINGTON, WA; FOGARTY, KE; LIFSHITZ, LM; FAY, FS			COUPLING OF THE NA+/CA2+ EXCHANGER, NA+/K+ PUMP AND SARCOPLASMIC-RETICULUM IN SMOOTH-MUSCLE	NATURE			English	Article							SODIUM CALCIUM EXCHANGE; ENDOPLASMIC-RETICULUM; CELLS; ACTIVATION; RELEASE; CALSEQUESTRIN; CONTRACTION; MECHANISM; PROTEIN	THE Na+/Ca2+ exchanger, driven by a transmembrane Na+ gradient, plays a key role in regulating Ca2+ concentration in many cells1,2. Although the exchanger influences Ca2+ concentration, its activity in smooth muscle appears to be closely coupled to Ca2+ availability from intracellular stores3. This linkage might result if the exchanger were positioned close to Ca2+ storage sites within the sarcoplasmic reticulum. To test this hypothesis we have developed methods to assess the relative three-dimensional distribution of proteins involved in Na+/K+ pumping, Na+/Ca2+ exchange, Ca2+ storage within the sarcoplasmic reticulum, and attachment of contractile filaments to the membrane in smooth muscle. Here we report that the Na+/Ca2+ exchanger is largely co-distributed with the Na+/K+ pump on unique regions, of the plasma membrane in register with, and close to, calsequestrin-containing regions of the sarcoplasmic reticulum in sites distinct from the sites where contractile filaments attach to the membrane. This molecular organization suggests that the plasma membrane is divided into at least two functional domains, and appear to provide a mechanism for the strong linkage seen in smooth muscle between Na+/K+ pumping and Na+/Ca2+ exchange, and between Na+/Ca2+ exchange and Ca2+ release from the sarcoplasmic reticulum4-7.	UNIV MASSACHUSETTS, SCH MED, BIOMED IMAGING GRP, WORCESTER, MA 01605 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, CARDIOVASC RES LAB, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, CARDIOVASC RES LAB, LOS ANGELES, CA 90024 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	MOORE, EDW (corresponding author), UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.			Moore, Edwin DW/0000-0001-7519-5592				ASHIDA T, 1987, J PHYSIOL-LONDON, V392, P617, DOI 10.1113/jphysiol.1987.sp016800; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BRADING AF, 1980, BRIT J PHARMACOL, V70, P229, DOI 10.1111/j.1476-5381.1980.tb07928.x; CARRINGTON WA, 1990, SPIE P, V1205, P72; CARRINGTON WA, 1990, MODERN CELL BIOL, V9, P53; ETTER E F, 1989, Journal of Cell Biology, V109, p169A; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FAY F S, 1992, Biophysical Journal, V61, pA389; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; FAY FS, 1982, METHOD ENZYMOL, V85, P284; GABELLA G, 1973, PHILOS T R SOC B, V265, P7, DOI 10.1098/rstb.1973.0004; GABELLA G, 1978, CELL TISSUE RES, V190, P255; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GIRARDET M, 1983, BIOCHEMISTRY-US, V22, P2296, DOI 10.1021/bi00278a037; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIFSHITZ LM, 1992, SOC PHOTOOPT INSTR E, V1808, P521; LYNCH RM, 1991, J CELL BIOL, V112, P385, DOI 10.1083/jcb.112.3.385; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; REUTER H, 1973, PHILOS T R SOC B, V265, P87, DOI 10.1098/rstb.1973.0011; REUTER H, 1991, NATURE, V349, P567, DOI 10.1038/349567a0; SCHEID CR, 1979, NATURE, V277, P32, DOI 10.1038/277032a0; SOMLYO AP, 1971, J CELL BIOL, V51, P722, DOI 10.1083/jcb.51.3.722; STEHNOBITTEL L, 1992, J PHYSIOL-LONDON, V451, P49, DOI 10.1113/jphysiol.1992.sp019153; VANBREEMEN C, 1977, J PHYSIOL-LONDON, V272, P317, DOI 10.1113/jphysiol.1977.sp012046; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; WILLIAMS DA, 1986, AM J PHYSIOL, V250, pC779, DOI 10.1152/ajpcell.1986.250.5.C779; WUYTACK F, 1987, BIOCHIM BIOPHYS ACTA, V899, P151, DOI 10.1016/0005-2736(87)90395-6	32	203	203	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					657	660		10.1038/365657a0	http://dx.doi.org/10.1038/365657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413629				2022-12-28	WOS:A1993MB84600062
J	MOORE, MS; BLOBEL, G				MOORE, MS; BLOBEL, G			THE GTP-BINDING PROTEIN RAN/TC4 IS REQUIRED FOR PROTEIN IMPORT INTO THE NUCLEUS	NATURE			English	Article							PREMATURE CHROMOSOME CONDENSATION; SACCHAROMYCES-CEREVISIAE; GENE RCC1; REGULATOR; INHIBITION; CELLS; DNA; TRANSLOCATION; MUTATION; MITOSIS	Two cytosolic fractions (A and B) from Xenopus oocytes are sufficient to support protein import into the nuclei of digitonin-permeabilized cells1. Fraction A recognizes the nuclear localization sequence (NLS) and binds the import substrate to the nuclear envelope, whereas fraction B mediates the subsequent passage of the bound substrate into the nucleus. Here we report that two interacting components are required for full fraction-B activity, purify one of these components to homogeneity, and show that it is the highly abundant GTP-binding protein Ran (Ras-related nuclear protein)/TC4.			MOORE, MS (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORRESTER W, 1992, GENE DEV, V2, P754; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	26	689	694	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					661	663		10.1038/365661a0	http://dx.doi.org/10.1038/365661a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413630				2022-12-28	WOS:A1993MB84600063
J	BITTNER V; WEINER, DH; YUSUF, S; ROGERS, WJ; MCINTYRE, KM; BANGDIWALA, SI; KRONENBERG, MW; KOSTIS, JB; KOHN, RM; GUILLOTTE, M; GREENBERG, B; WOODS, PA; BOURASSA, MG				BITTNER, V; WEINER, DH; YUSUF, S; ROGERS, WJ; MCINTYRE, KM; BANGDIWALA, SI; KRONENBERG, MW; KOSTIS, JB; KOHN, RM; GUILLOTTE, M; GREENBERG, B; WOODS, PA; BOURASSA, MG			PREDICTION OF MORTALITY AND MORBIDITY WITH A 6-MINUTE WALK TEST IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE-HEART-FAILURE; EXERCISE CAPACITY; ISOSORBIDE DINITRATE; FUNCTIONAL-CAPACITY; PROGNOSTIC VALUE; PERFORMANCE; DISEASE; DETERMINANTS; HYDRALAZINE; VARIABLES	Objective.-To study the potential usefulness of the 6-minute walk test, a self-paced submaximal exercise test, as a prognostic indicator in patients with left ventricular dysfunction. Design.-Data were collected during a prospective cohort study, the Studies of Left Ventricular Dysfunction (SOLVD) Registry Substudy. Setting.-Twenty tertiary care hospitals in the United States, Canada, and Belgium. Participants.-A stratified random sample of 898 patients from the SOLVD Registry who had either radiological evidence of congestive heart failure and/or an ejection fraction of 0.45 or less were enrolled in the substudy and underwent a detailed clinical evaluation including a 6-minute walk test. Patients were followed up for a mean of 242 days. Outcome Measures.-Mortality and hospitalization. Results.-During follow-up, 52 walk-test participants (6.2%) died and 252 (30.3%) were hospitalized. Hospitalization for congestive heart failure occurred in 78 participants (9.4%), and the combined endpoint of death or hospitalization for congestive heart failure occurred in 114 walk-test participants (13.7%). Compared with the highest performance level, patients in the lowest performance level had a significantly greater chance of dying (10.23% vs 2.99%; P=.01), of being hospitalized (40.91% vs 19.90%; P=.002), and of being hospitalized for heart failure (22.16% vs 1.990/o; P<.0001). In a logistic regression model, ejection fraction and distance walked were equally strong and independent predictors of mortality and heart failure hospitalization rates during follow-up. Conclusion.-The 6-minute walk test is a safe and simple clinical tool that strongly and independently predicts morbidity and mortality in patients with left ventricular dysfunction.	OREGON HLTH SCI UNIV, DEPT MED, PORTLAND, OR 97201 USA; UNIV N CAROLINA, DEPT BIOSTAT, COLLABORAT STUDIES COORDINATING CTR, CHAPEL HILL, NC 27514 USA; VET AFFAIRS MED CTR, BOSTON, MA USA; UNIV MED & DENT NEW JERSEY, DEPT MED & PHARMACOL, NEW BRUNSWICK, NJ USA; SUNY Buffalo, DEPT MED, BUFFALO, NY 14260 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; MONTREAL HEART INST, RES CTR, MONTREAL H1T 1C8, QUEBEC, CANADA; SUNY Buffalo, DEPT RES, BUFFALO, NY 14260 USA; VET AFFAIRS MED CTR, MANCHESTER, NH USA; NIH, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20892 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RES, BOSTON, MA 02115 USA	Oregon Health & Science University; University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rutgers State University New Brunswick; Rutgers State University Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Harvard Medical School; Vanderbilt University; Universite de Montreal; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	BITTNER V (corresponding author), UNIV ALABAMA, DEPT MED, DIV CARDIOVASC DIS, THT 328 UAB STN, BIRMINGHAM, AL 35294 USA.			Bourassa, Martial G./0000-0002-4439-8650; Yusuf, Salim/0000-0003-4776-5601	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055001] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01 HC55001] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER BJ, 1986, AM HEART J, V111, P697, DOI 10.1016/0002-8703(86)90102-X; BANGDIWALA SI, 1992, AM J CARDIOL, V70, P347, DOI 10.1016/0002-9149(92)90617-8; BRAUNWALD E, 1992, HEART DIS TXB CARDIO, P11; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; COHN JN, 1987, CIRCULATION, V75, P49; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; COHN JN, 1990, CIRCULATION, V81, P48; DUNSELMAN PHJM, 1988, AM HEART J, V116, P1475, DOI 10.1016/0002-8703(88)90731-4; FRANCIOSA JA, 1987, CIRCULATION, V75, P20; FRANCIOSA JA, 1979, AM J MED, V67, P460, DOI 10.1016/0002-9343(79)90794-0; FRANCIOSA JA, 1981, AM J CARDIOL, V47, P33, DOI 10.1016/0002-9149(81)90286-1; GIBBS JSR, 1990, J AM COLL CARDIOL, V15, P52, DOI 10.1016/0735-1097(90)90174-N; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; GRIFFIN BP, 1991, AM J CARDIOL, V67, P848, DOI 10.1016/0002-9149(91)90618-U; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; JAFRI SM, 1986, AM HEART J, V112, P194, DOI 10.1016/0002-8703(86)90706-4; KANNEL WB, 1991, AM HEART J, V121, P951, DOI 10.1016/0002-8703(91)90225-7; KNOX AJ, 1988, THORAX, V43, P388, DOI 10.1136/thx.43.5.388; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; MEILER SEL, 1987, AM HEART J, V113, P1207, DOI 10.1016/0002-8703(87)90935-5; ROZKOVEC A, 1989, EUR HEART J, V10, P63, DOI 10.1093/oxfordjournals.eurheartj.a059382; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; WILLENS HJ, 1987, AM HEART J, V114, P377, DOI 10.1016/0002-8703(87)90506-0; 1990, AM J CARDIOL, V66, P315; 1991, NEW ENGL J MED, V325, P293	28	629	689	3	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1702	1707		10.1001/jama.270.14.1702	http://dx.doi.org/10.1001/jama.270.14.1702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411500				2022-12-28	WOS:A1993MA29400026
J	BRECHNER, RJ; COWIE, CC; HOWIE, LJ; HERMAN, WH; WILL, JC; HARRIS, MI				BRECHNER, RJ; COWIE, CC; HOWIE, LJ; HERMAN, WH; WILL, JC; HARRIS, MI			OPHTHALMIC EXAMINATION AMONG ADULTS WITH DIAGNOSED DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETINOPATHY; PREVALENCE; RISK; CARE; AGE; YR	Objective.-To assess whether adults with diagnosed diabetes in the United States are receiving recommended eye examinations for detection of diabetic retinopathy and what factors are associated with receiving them. Design, Setting, and Participants.-The design was a cross-sectional survey of the civilian, noninstitutionalized US population 18 years of age or older, based on the 1989 National Health Interview Survey. A multistage probability sampling strategy was used to identify a representative sample of 84 572 persons. A questionnaire on diabetes was administered to all subjects with diagnosed diabetes (n=2405). Main Outcome Measure.-A dilated eye examination in the past year. Main Results.-Of all adults with diagnosed diabetes in the United States, only 49% had a dilated eye examination in the past year. This included 57% of people with insulin-dependent diabetes mellitus (IDDM), 55% with insulin-treated noninsulin-dependent diabetes mellitus (NIDDM), and 44% with NIDDM not treated with insulin. Even among diabetics at high risk of vision loss because of retinopathy or long duration of diabetes, the proportion with a dilated eye examination was only 61% and 57%, respectively. By logistic regression, the probability of a dilated eye examination among persons with NIDDM increased with older age, higher socioeconomic status, and having attended a diabetes education class. The probability of a dilated eye examination was not independently related to race, duration of diabetes, frequency of physician visits for diabetes, or health insurance. Conclusions.-About half of adults with diabetes in the United States are not receiving timely and recommended eye care to detect and treat retinopathy. Wide-spread interventions, including patient and professional education, are needed to ensure that diabetic patients who are not receiving appropriate eye care have an annual dilated eye examination to detect retinopathy and prevent vision loss.	NIDDKD, NATL DIABET DATA GRP, WESTWOOD BLDG, ROOM 620, BETHESDA, MD 20892 USA; CTR DIS CONTROL & PREVENT, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, DIV DIABET TRANSLAT, ATLANTA, GA USA; SCI SYST INC, BETHESDA, MD USA; NATL CTR HLTH STAT, DIV HLTH INTERVIEW STAT, HYATTSVILLE, MD 20782 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								[Anonymous], 1978, Ophthalmology, V85, P82; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1976, Am J Ophthalmol, V81, P383; AWH CC, 1991, ARCH INTERN MED, V151, P1405, DOI 10.1001/archinte.151.7.1405; BERGER W, 1986, DIABETOLOGIA, V29, pA517; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; Cochran WG, 1977, SAMPLING TECHNIQUES, P319; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1985, NIH851468 PUBL, pCH13; KLEIN R, 1985, DIABETES MELLITUS MA, P101; KOONS DA, 1973, VITAL HLTH STAT   54, V2; KOVAR MG, 1985, VITAL HLTH STAT   18, V1; LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1; MASSEY JT, 1989, VITAL HLTH STAT  110, V2; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, SURVEY DATA ANAL SOF; SINGER DE, 1992, ANN INTERN MED, V116, P683; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SPRAFKA JM, 1990, ARCH INTERN MED, V150, P857, DOI 10.1001/archinte.150.4.857; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; 1992, DIABETES CARE S2, V15, P16; 1988, PHYSICIANS GUIDE INS, P109; 1980, VISION PROBLEMS US, P1; 1988, DIABETES CARE, V11, P745; 1990, VITAL HLTH STAT 176, V10; 1991, PREVENTION TREATMENT, P5; 1988, PHYSICIANS GUIDE NON, P69; 1989, DIABETIC RETINOPATHY	38	210	215	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1714	1718		10.1001/jama.270.14.1714	http://dx.doi.org/10.1001/jama.270.14.1714			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411502				2022-12-28	WOS:A1993MA29400028
J	TITUS, MA				TITUS, MA			FROM FAT YEAST AND NERVOUS MICE TO BRAIN MYOSIN-V	CELL			English	Review							GENE; DICTYOSTELIUM; LOCALIZATION; PROTEINS; ENCODES; DOMAINS; LOCUS				TITUS, MA (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.							BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; CHENEY RE, 1993, CELL, V75; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KNIGHT AE, 1993, J MOL BIOL, V231, P148, DOI 10.1006/jmbi.1993.1266; LARSON RE, 1990, J NEUROCHEM, V54, P1288, DOI 10.1111/j.1471-4159.1990.tb01961.x; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MOORE KJ, 1988, GENETICS, V119, P933; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RINCHICK EM, 1979, TRENDS GENET, V1, P170; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SANDERS G, 1992, FEBS LETT, V311, P295, DOI 10.1016/0014-5793(92)81123-4; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613	22	12	12	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					9	11						3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402904				2022-12-28	WOS:A1993MB66700003
J	GORDON, NLM; DAWSON, AA; BENNETT, B; INNES, G; EREMIN, O; JONES, PF				GORDON, NLM; DAWSON, AA; BENNETT, B; INNES, G; EREMIN, O; JONES, PF			OUTCOME IN COLORECTAL ADENOCARCINOMA - 2 7-YEAR STUDIES OF A POPULATION	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; HEPATIC METASTASES; CANCER; CARCINOMA; PERFUSION; SURGERY	Objective-To record every patient with proved colorectal adenocarcinoma presenting from a defined population over two years in 1968-9 and during 1980-2, and to compare treatment and outcome over seven years. Design-Retrospective in 1968-9 and prospective in 1980-2. Setting-Aberdeen general hospitals. Subjects-Every patient presenting to the four general surgical units with histological proof of colorectal adenocarcinoma. Main findings-On average, one new patient presented each week per 100000 population. The proportion of patients aged 65 and over rose from 67% to 71%. An operation was performed on 385 patients in 1968-9 and on 399 during 1980-2. At laparotomy the proportion of patients who seemed to be curable and had a radical operation rose slightly, from 56% to 61%, and operative mortality fell from 9% to 5%. In all there were 421 survivors of curative surgery, and seven years later three quarters were either alive (51%) or had died without recurrence (25%). In both studies some 40% of patients were considered incurable when they presented, but the number who had a palliative resection rose from 59% to 85%. Conclusions-The contribution of radical surgery to the treatment of colorectal adenocarcinoma is substantial, with three quarters of patients so treated showing no evidence of recurrence after seven years. Operative mortality in an elderly population is now low, and improvement in late outcome is more likely to come from developments in adjuvant therapy than in operative technique. A continuing problem is that 40% of patients are not curable when they present, although palliative resection can now be offered to over 80%.	UNIV ABERDEEN,DEPT MED,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 1FX,SCOTLAND; UNIV ABERDEEN,DEPT SURG,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen; University of Aberdeen; University of Aberdeen								ARCHER SG, 1989, BRIT J SURG, V76, P545, DOI 10.1002/bjs.1800760607; BEART RW, 1983, DIS COLON RECTUM, V26, P393, DOI 10.1007/BF02553382; BROWN SCW, 1988, BRIT J SURG, V75, P645, DOI 10.1002/bjs.1800750708; CALLAGHAN J, 1990, AM J SURG, V159, P277, DOI 10.1016/S0002-9610(05)81216-4; CLARKE DN, 1980, BMJ-BRIT MED J, V280, P431, DOI 10.1136/bmj.280.6212.431; COLLINS REC, 1993, ANN R COLL SURG ENGL, V75, pS33; DARBY CR, 1992, BRIT J SURG, V79, P206, DOI 10.1002/bjs.1800790305; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; FIELDING LP, 1993, LANCET, V341, P471, DOI 10.1016/0140-6736(93)90217-5; FIELDING LP, 1992, LANCET, V340, P502, DOI 10.1016/0140-6736(92)91708-G; FINLAY IG, 1988, BRIT J SURG, V75, P641, DOI 10.1002/bjs.1800750707; FINLAY IG, 1986, BRIT J SURG, V73, P732, DOI 10.1002/bjs.1800730918; GRAY R, 1991, BRIT J CANCER, V63, P841, DOI 10.1038/bjc.1991.187; HARDCASTLE JD, 1989, LANCET, V1, P1160; JACKSON BT, 1992, ANN R COLL SURG ENGL, V74, pS63; KEE F, 1992, BRIT MED J, V305, P158, DOI 10.1136/bmj.305.6846.158; MCARDLE CS, 1990, BRIT J SURG, V77, P280, DOI 10.1002/bjs.1800770314; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; TAYLOR I, 1985, BRIT J SURG, V72, P359, DOI 10.1002/bjs.1800720509; 1990, BRIT J SURG, V77, P1063; 1993, ORG GENERAL SURGICAL; 1983, 1982 REG GEN SCOTL A	22	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					707	710		10.1136/bmj.307.6906.707	http://dx.doi.org/10.1136/bmj.307.6906.707			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401092	Green Published, Bronze			2022-12-28	WOS:A1993LY29200019
J	HEALY, B				HEALY, B			THE DINGELL HEARINGS ON SCIENTIFIC MISCONDUCT - BLUNT INSTRUMENTS INDEED	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											HEALY, B (corresponding author), CLEVELAND CLIN,CLEVELAND,OH 44195, USA.							DINGELL JD, 1993, NEW ENGL J MED, V328, P1610, DOI 10.1056/NEJM199306033282207	1	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					725	727		10.1056/NEJM199309023291010	http://dx.doi.org/10.1056/NEJM199309023291010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8393964				2022-12-28	WOS:A1993LU58300010
J	BEKKERS, JM				BEKKERS, JM			ENHANCEMENT BY HISTAMINE OF NMDA-MEDIATED SYNAPTIC TRANSMISSION IN THE HIPPOCAMPUS	SCIENCE			English	Article							RAT HIPPOCAMPUS; PYRAMIDAL CELLS; BRAIN; CURRENTS; NEURONS; MECHANISMS; IMPAIRMENT; RECEPTORS; FIBERS	Histamine is a neuromodulator in the brain, and the hippocampus is one of the regions of the brain that is innervated by histaminergic neurons. When applied to cultured hippocampal neurons, histamine selectively increased by up to tenfold the amplitude of the component of synaptic transmission that was mediated by N-methyl-D-aspartate (NMDA) receptors. Spontaneous miniature synaptic currents and the current elicited by applied NMDA also were enhanced, indicating that the histamine effect was expressed primarily postsynaptically. These results suggest that histamine may modulate processes involving NMDA receptors, such as the induction of long-term potentiation.			BEKKERS, JM (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV NEUROSCI, CANBERRA, ACT 2601, AUSTRALIA.			Bekkers, John/0000-0001-8619-5512				BARBIN G, 1976, J NEUROCHEM, V26, P259, DOI 10.1111/j.1471-4159.1976.tb04474.x; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DEALMEIDA MAMR, 1986, ARCH INT PHARMACOD T, V283, P193; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; HAAS HL, 1983, NATURE, V302, P432, DOI 10.1038/302432a0; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; INAGAKI N, 1988, J COMP NEUROL, V273, P283, DOI 10.1002/cne.902730302; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KATZ B, 1967, J PHYSIOL-LONDON, V189, P535, DOI 10.1113/jphysiol.1967.sp008183; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCCORMICK DA, 1991, J NEUROSCI, V11, P3188; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; PANULA P, 1989, NEUROSCIENCE, V28, P585, DOI 10.1016/0306-4522(89)90007-9; PELLMAR TC, 1986, J NEUROPHYSIOL, V55, P727, DOI 10.1152/jn.1986.55.4.727; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V435, P373, DOI 10.1113/jphysiol.1991.sp018515; SCHWARTZ JC, 1986, TRENDS PHARMACOL SCI, V7, P24, DOI 10.1016/0165-6147(86)90236-1; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SEGAL M, 1981, BRAIN RES, V213, P443, DOI 10.1016/0006-8993(81)90251-1; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; SPRINGFIELD SA, 1988, CELL MOL NEUROBIOL, V8, P431, DOI 10.1007/BF00711227; TONKISS J, 1992, EXP BRAIN RES, V90, P572; WADA H, 1991, TRENDS NEUROSCI, V14, P415, DOI 10.1016/0166-2236(91)90034-R; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	31	133	143	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					104	106		10.1126/science.8391168	http://dx.doi.org/10.1126/science.8391168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8391168				2022-12-28	WOS:A1993LK43400043
J	FEKETY, R; SHAH, AB				FEKETY, R; SHAH, AB			DIAGNOSIS AND TREATMENT OF CLOSTRIDIUM-DIFFICILE COLITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIBIOTIC-ASSOCIATED DIARRHEA; PSEUDOMEMBRANOUS COLITIS; SACCHAROMYCES-BOULARDII; COMPUTED-TOMOGRAPHY; TOXIN-A; VANCOMYCIN; HAMSTERS; DISEASE; THERAPY; TRIAL	Pseudomembranous colitis associated with antibiotic therapy is almost always due to an overgrowth of Clostridium difficile. If untreated, pseudomembranous colitis can lead to severe diarrhea, hypovolemic shock, toxic dilatation of the colon, cecal perforation, hemorrhage, and death. However, C difficile-associated colitis can mimic the more common ''benign'' antibiotic-associated diarrhea that is not caused by C difficile. An algorithm for diagnosis management of hospitalized patients with antibiotic diarrhea and C difficile colitis is presented in this review. Diagnosis depends on sigmoidoscopy and/or stool tests for C difficile toxins in all patients with antibiotic-associated diarrhea. If the results of these tests are positive, either metronidazole or vancomycin is recommended for treatment of mild illness, and vancomycin is recommended for treatment of severe illness. Oral therapy is always preferred because it is more reliable. In patients with recurrent or relapsing colitis, treatment with either metronidazole or vancomycin is effective for that episode, but novel approaches, such as the oral or rectal introduction of competing nonpathogenic organisms, may prove to be more successful in prevention of relapses.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,ANN ARBOR,MI 48109; LOYOLA UNIV,HINES VET AFFAIRS HOSP,DIV INFECT DIS,MAYWOOD,IL 60153	University of Michigan System; University of Michigan; Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital								BARTLETT JG, 1984, DM-DIS MON, V30, P1; BATTS DH, 1980, CURRENT CHEMOTHERAPY, V2, P944; BURBIGE EJ, 1975, JAMA-J AM MED ASSOC, V231, P1157, DOI 10.1001/jama.231.11.1157; CHURCH JM, 1986, DIS COLON RECTUM, V29, P804, DOI 10.1007/BF02555349; CUDMORE MA, 1982, ARCH INTERN MED, V142, P333, DOI 10.1001/archinte.142.2.333; DRAPKIN MS, 1985, ARCH SURG-CHICAGO, V120, P1321; DUDLEY MN, 1986, ARCH INTERN MED, V146, P1101, DOI 10.1001/archinte.146.6.1101; DZINK J, 1980, ANTIMICROB AGENTS CH, V17, P695, DOI 10.1128/AAC.17.4.695; ELMER GW, 1987, ANTIMICROB AGENTS CH, V31, P129, DOI 10.1128/AAC.31.1.129; EVALDSON G, 1982, SCAND J INFECT DIS S, V35, P9; FEKETY R, 1979, REV INFECT DIS, V1, P386; FEKETY R, 1989, AM J MED, V86, P15, DOI 10.1016/0002-9343(89)90223-4; FEKETY R, 1990, PRINCIPLES PRACTICE, P863; FREIMAN JP, 1989, JAMA-J AM MED ASSOC, V262, P902, DOI 10.1001/jama.1989.03430070050023; GARNER DC, 1991, 31ST INT C ANT AG CH, P12; GEBHARD RL, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90460-7; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERACI JE, 1956, P STAFF M MAYO CLIN, V31, P564; GORBACH SL, 1987, LANCET, V2, P1519; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; JOHNSON S, 1992, ANN INTERN MED, V117, P297, DOI 10.7326/0003-4819-117-4-297; LAUGHON BE, 1984, J INFECT DIS, V149, P781, DOI 10.1093/infdis/149.5.781; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; LYERLY DM, 1983, J CLIN MICROBIOL, V17, P72, DOI 10.1128/JCM.17.1.72-78.1983; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MEGIBOW AJ, 1984, J COMPUT ASSIST TOMO, V8, P281; MILES BL, 1988, J CLIN MICROBIOL, V26, P2452, DOI 10.1128/JCM.26.11.2452-2455.1988; MUKAI JK, 1987, J CAN ASSOC RADIOL, V38, P62; ROLFE RD, 1981, J INFECT DIS, V143, P470, DOI 10.1093/infdis/143.3.470; SCHWAN A, 1984, SCAND J INFECT DIS, V16, P211, DOI 10.3109/00365548409087145; SEAL D, 1987, EUR J CLIN MICROBIOL, V6, P51, DOI 10.1007/BF02097191; SURAWICZ CM, 1989, AM J GASTROENTEROL, V84, P1285; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; TEASLEY DG, 1983, LANCET, V2, P1043; TEDESCO FJ, 1985, AM J GASTROENTEROL, V80, P867; TEDESCO FJ, 1982, GASTROENTEROLOGY, V83, P1259; TVEDE M, 1989, LANCET, V1, P1156	37	271	293	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					71	75		10.1001/jama.269.1.71	http://dx.doi.org/10.1001/jama.269.1.71			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416409				2022-12-28	WOS:A1993KF02600030
J	IGLEHART, JK				IGLEHART, JK			HEALTH-CARE REFORM - THE LABYRINTH OF CONGRESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SYSTEM											BALZ D, 1993, WASHINGTON POST 1010, pA4; BIRNBAUM JH, 1987, SHODOWN GUCCI GULCH; BRODER DS, 1993, WASHINGTON POST 0725, pA16; DINGELL JD, 1993, NEW ENGL J MED, V328, P1610, DOI 10.1056/NEJM199306033282207; Ehrenhalt A, 1992, US AMBITION POLITICI; FELDSTEIN MS, 1993, WALL ST J       0929, pA18; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1992, NEW ENGL J MED, V327, P1467, DOI 10.1056/NEJM199211123272027; IGLEHART JK, 1993, NEW ENGL J MED, V328, P896, DOI 10.1056/NEJM199303253281226; JACKSON B, 1988, HONEST GRAFT BIG MON; KASSIRER JP, 1993, NEW ENGL J MED, V328, P1634, DOI 10.1056/NEJM199306033282212; PEAR R, 1993, NY TIMES        0806, pA18; REDBURN T, 1993, NY TIMES        1105, pA1; 1993, PRESIDENTS HLTH SECU; 1993, POLITICS AM 1994	15	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1593	1596		10.1056/NEJM199311183292129	http://dx.doi.org/10.1056/NEJM199311183292129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8413495				2022-12-28	WOS:A1993MG18800040
J	GROVER, SA; BARKUN, AN; SACKETT, DL				GROVER, SA; BARKUN, AN; SACKETT, DL			DOES THIS PATIENT HAVE SPLENOMEGALY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPLENIC ENLARGEMENT; SPLEEN SIZE; LIVER; PREDICTION		MONTREAL GEN HOSP,DIV GASTROENTEROL,MONTREAL H3G 1A4,QUEBEC,CANADA; MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3A 2T5,QUEBEC,CANADA; MCMASTER UNIV,DEPT MED,DIV GEN INTERNAL MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA; HENDERSON GEN HOSP,HAMILTON L8V 1C3,ONTARIO,CANADA	McGill University; McGill University; McGill University; McGill University; McMaster University; McMaster University; McMaster University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,DIV GEN INTERNAL MED,1650 AVE CEDAR,MONTREAL H3G 1A4,QUEBEC,CANADA.							BARKUN AN, 1989, AM J MED, V87, P562; BARKUN AN, 1991, AM J MED, V91, P512, DOI 10.1016/0002-9343(91)90188-4; BERRIS B, 1966, CAN MED ASSOC J, V95, P1318; BLENDIS LM, 1970, BMJ-BRIT MED J, V1, P727, DOI 10.1136/bmj.1.5698.727; CASTELL DO, 1967, ANN INTERN MED, V67, P1265, DOI 10.7326/0003-4819-67-6-1265; EBAUGH FG, 1979, ANN INTERN MED, V90, P130, DOI 10.7326/0003-4819-90-1-130_2; ESPINOZA P, 1987, DIGEST DIS SCI, V32, P244, DOI 10.1007/BF01297048; HALPERN S, 1974, ARCH INTERN MED, V134, P123, DOI 10.1001/archinte.134.1.123; INGEBERG S, 1983, ACTA HAEMATOL-BASEL, V69, P243, DOI 10.1159/000206899; KOGA T, 1975, RADIOLOGY, V115, P157, DOI 10.1148/115.1.157; LARSON SM, 1971, J NUCL MED, V12, P123; MCINTYRE OR, 1967, ANN INTERN MED, V66, P301, DOI 10.7326/0003-4819-66-2-301; MYERS J, 1974, ARCH PATHOL, V98, P33; NIEDERAU C, 1983, RADIOLOGY, V149, P537, DOI 10.1148/radiology.149.2.6622701; NIXON RK, 1954, NEW ENGL J MED, V250, P166, DOI 10.1056/NEJM195401282500407; RIEMENSCHNEIDER PA, 1965, AMER J ROENTGENOL RA, V94, P462; SHAW MT, 1973, LANCET, V1, P317; SULLIVAN S, 1976, BRIT MED J, V2, P1043, DOI 10.1136/bmj.2.6043.1043; TALBOTT JE, 1970, BIOGRAPHICAL HIST ME, P594; WESTIN J, 1972, ACTA MED SCAND, V191, P263; ZHANG B, 1987, J CLIN PATHOL, V40, P508, DOI 10.1136/jcp.40.5.508	21	51	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2218	2221		10.1001/jama.270.18.2218	http://dx.doi.org/10.1001/jama.270.18.2218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411607				2022-12-28	WOS:A1993ME81600035
J	KUNDROTAS, L				KUNDROTAS, L			STING OF THE FIRE ANT (SOLENOPSIS)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KUNDROTAS, L (corresponding author), WILFORD HALL USAF MED CTR,LACKLAND AFB,TX 78236, USA.								0	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1317	1317						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413412				2022-12-28	WOS:A1993MD55700006
J	MAIZELS, RM; BUNDY, DAP; SELKIRK, ME; SMITH, DF; ANDERSON, RM				MAIZELS, RM; BUNDY, DAP; SELKIRK, ME; SMITH, DF; ANDERSON, RM			IMMUNOLOGICAL MODULATION AND EVASION BY HELMINTH-PARASITES IN HUMAN-POPULATIONS	NATURE			English	Review								Helminth parasites are highly prevalent in human communities in developing countries. In an endemic area an infected individual may harbour parasitic worms for most of his or her life, and the ability of these infections to survive immunological attack has long been a puzzle. But new techniques are starting to expose the diverse mechanisms by which these agents modulate or evade their hosts' defences, creating a dynamic interaction between the human immune system and the parasite population.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,WELLCOME RES CTR PARASIT INFECT,DEPT BIOCHEM,LONDON SW7 2BB,ENGLAND	Imperial College London	MAIZELS, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,WELLCOME RES CTR PARASIT INFECT,DEPT BIOL,LONDON SW7 2BB,ENGLAND.			Selkirk, Murray/0000-0002-6274-6014; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	450	464	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					797	805		10.1038/365797a0	http://dx.doi.org/10.1038/365797a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413664	Bronze			2022-12-28	WOS:A1993MD95100039
J	SEKIDO, N; MUKAIDA, N; HARADA, A; NAKANISHI, I; WATANABE, Y; MATSUSHIMA, K				SEKIDO, N; MUKAIDA, N; HARADA, A; NAKANISHI, I; WATANABE, Y; MATSUSHIMA, K			PREVENTION OF LUNG REPERFUSION INJURY IN RABBITS BY A MONOCLONAL-ANTIBODY AGAINST INTERLEUKIN-8	NATURE			English	Article							ISCHEMIA-REPERFUSION; VASCULAR INJURY; LYMPHOCYTES-T; NEUTROPHIL; LEUKOTRIENE-B4; PURIFICATION; DEPLETION; PEPTIDE; BINDING; MODEL	RE-ESTABLISHING blood flow to ischaemic tissues causes greater injury than that induced during the ischaemic period1,2. This type of tissue injury, reperfusion injury, is involved in frostbite, multiple organ failure after hypovolaemia and in myocardial infarction1. Depletion of neutrophils alleviates reperfusion injury, implying a causal role of neutrophil infiltration3,4. Among members of the recently discovered family of chemotactic cytokines (chemokines)5-8, interleukin-8 (IL-8)5,9-13 is a major neutrophil chemotactic and activating factor produced by various types of human cells. We investigated its pathophysiological role in a rabbit model of a lung reperfusion injury. Reperfusion of ischaemic lung caused neutrophil infiltration and destruction of pulmonary structure, as well as local production of IL-8. Furthermore, the administration of a neutralizing monoclonal antibody against IL-8 prevented neutrophil infiltration and tissue injury, proving a causal role of locally produced IL-8 in this model.	KANAZAWA UNIV,SCH MED,CANC RES INST,DEPT PHARMACOL,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT PATHOL 1,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT HYG,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT SURG 1,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ABE Y, IN PRESS BR HEART J; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; EGAN JW, 1989, PROSTAGLANDINS, V37, P597, DOI 10.1016/0090-6980(89)90075-0; FURIE MB, 1984, J CELL BIOL, V98, P1033, DOI 10.1083/jcb.98.3.1033; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HILL J, 1992, SURGERY, V112, P166; HORGAN MJ, 1990, AM J PHYSIOL, V259, pL315, DOI 10.1152/ajplung.1990.259.4.L315; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; KORTHUIS RJ, 1988, AM J PHYSIOL, V254, pH823, DOI 10.1152/ajpheart.1988.254.5.H823; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEFER AM, 1991, BRIT J PHARMACOL, V103, P1153, DOI 10.1111/j.1476-5381.1991.tb12316.x; LEHR HA, 1991, J CLIN INVEST, V87, P2036, DOI 10.1172/JCI115233; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; MENTIKO AP, 1992, J CLIN INVEST, V90, P791; OGATA K, 1983, J IMMUNOL METHODS, V65, P75, DOI 10.1016/0022-1759(83)90305-8; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; WELBOURN CRB, 1991, BRIT J SURG, V78, P651, DOI 10.1002/bjs.1800780607; WELBOURN R, 1990, J IMMUNOL, V145, P1906; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; ZIMMERMAN BJ, 1990, GASTROENTEROLOGY, V99, P1358, DOI 10.1016/0016-5085(90)91162-Y	31	465	559	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					654	657		10.1038/365654a0	http://dx.doi.org/10.1038/365654a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413628				2022-12-28	WOS:A1993MB84600061
J	SADOWSKI, HB; SHUAI, K; DARNELL, JE; GILMAN, MZ				SADOWSKI, HB; SHUAI, K; DARNELL, JE; GILMAN, MZ			A COMMON NUCLEAR SIGNAL-TRANSDUCTION PATHWAY ACTIVATED BY GROWTH-FACTOR AND CYTOKINE RECEPTORS	SCIENCE			English	Article							SERUM RESPONSE ELEMENT; PROTEIN-TYROSINE KINASES; C-FOS PROMOTER; INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATOR; TERNARY COMPLEX; GENE-EXPRESSION; SH3 DOMAINS; BINDING; ISGF3	Growth factors and cytokines act through cell surface receptors with different biochemical properties. Yet each type of receptor can elicit similar as well as distinct biological responses in target cells, suggesting that distinct classes of receptors activate common gene sets. Epidermal growth factor, interferon-gamma interleukin-6 all activated, through direct tyrosine phosphorylation, latent cytoplasmic transcription factors that recognized similar DNA elements. However, different ligands activated different patterns of factors with distinct DNA-binding specificities in the same and in different cells. Thus, unrelated receptors may activate a common nuclear signal transduction pathway that, through differential use of latent cytoplasmic proteins, permits these receptors to regulate both common and unique sets of genes.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA	Cold Spring Harbor Laboratory; Rockefeller University					NATIONAL CANCER INSTITUTE [T32CA009311, R01CA045642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NCI NIH HHS [CA09311, CA45642] Funding Source: Medline; NIAID NIH HHS [AI32489] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BERNARDS A, 1991, ONCOGENE, V6, P1185; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MULLER M, IN PRESS EMBO J; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, UNPUB; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; TREISMAN R, 1992, TRANSCRIPTIONAL REGU, P881; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAN YJY, 1988, J INTERFERON RES, V8, P105, DOI 10.1089/jir.1988.8.105; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	45	701	726	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1739	1744		10.1126/science.8397445	http://dx.doi.org/10.1126/science.8397445			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8397445				2022-12-28	WOS:A1993LY58400028
J	ALLEN, J; WILSON, A; FRASER, R; GRAY, DP				ALLEN, J; WILSON, A; FRASER, R; GRAY, DP			THE ACADEMIC BASE FOR GENERAL-PRACTICE - THE CASE FOR CHANGE	BRITISH MEDICAL JOURNAL			English	Article								University departments of general practice and the postgraduate education system for general practice have developed separately over the past 30 years. This separation is now impeding the academic development of the discipline and causes difficulties with recruitment and career progression. These problems could be eased by the creation of integrated departments. This would establish a critical mass for research and educational development, allow human and other resources to be used more flexibly and effectively, and provide a strong base for undergraduate education, vocational training, higher professional training, and continuing education. It could encourage collaborative ventures with other disciplines and also lead to higher standards of patient care.	UNIV EXETER,POSTGRAD MED SCH,EXETER EX4 4RJ,DEVON,ENGLAND; UNIV LEICESTER,DEPT GEN PRACTICE,LEICESTER LE1 7RH,ENGLAND	University of Exeter; University of Leicester	ALLEN, J (corresponding author), COUNTESTHORPE HLTH CTR,LEICESTER LE8 3QJ,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				FRASER RC, 1988, 4RCGP42 OCC PAP; GRAY DJP, 1981, TRAINING GENERAL PRA; GRAY DP, 1991, BRIT MED J, V302, P1380, DOI 10.1136/bmj.302.6789.1380; HOWIE JGR, 1986, 198MACKENZIE REORT G; WILLIAMS WO, 1991, BR J GEN PRACT, V40, P491; 1985, RECOMMENDATIONS REGI; 1990, RCGP49 ROYAL COLL GE; 1972, HM7275 DEP HLTH SOC; 1991, COURSE ORG WORKLOAD; 1979, NATIONAL HTLH SERVIC; 1991, REMIT RESPONSIBILITI	11	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					719	722		10.1136/bmj.307.6906.719	http://dx.doi.org/10.1136/bmj.307.6906.719			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401096	Green Published, Bronze			2022-12-28	WOS:A1993LY29200023
J	SOMMER, T; JENTSCH, S				SOMMER, T; JENTSCH, S			A PROTEIN TRANSLOCATION DEFECT LINKED TO UBIQUITIN CONJUGATION AT THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							YEAST; DEGRADATION; MEMBRANE; ENZYME; ENCODES; GENE; POLYPEPTIDES; INSERTION; PATHWAY; COMPLEX	UBIQUITIN-Conjugating enzymes function in selective proteolysis pathways and catalyse the covalent attachment of ubiquitin to proteolytic substrates1-4. Here we report the identification of an integral membrane ubiquitin-conjugating enzyme. This enzyme, UBC6, localizes to the endoplasmic reticulum (ER), with the catalytic domain facing the cytosol. ubc6 loss-of-function mutants suppress the protein translocation defect caused by a mutation in SEC61, which encodes a key component of a multisubunit protein translocation apparatus of the ER5-11. The expression of the sec61 mutant phenotype requires both the activity of UBC6 and its localization at the ER membrane. This suggests that UBC6 may mediate selective degradation of ER membrane proteins and that the protein translocation defect of sec61 may be caused by proteolysis of components of a structurally distorted mutant translocation apparatus.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINLEY D, 1986, REV CELL BIOL, V7, P25; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Guthrie C, 1991, GUIDE YEAST GENETICS; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	30	271	276	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					176	179		10.1038/365176a0	http://dx.doi.org/10.1038/365176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8396728				2022-12-28	WOS:A1993LW44200052
J	STAHL, N; YANCOPOULOS, GD				STAHL, N; YANCOPOULOS, GD			THE ALPHAS, BETAS, AND KINASES OF CYTOKINE RECEPTOR COMPLEXES	CELL			English	Review							IL-6 SIGNAL TRANSDUCER; HUMAN GROWTH-HORMONE; ERYTHROPOIETIN RECEPTOR; GP130; INTERLEUKIN-6; PROTEIN; DESIGN				STAHL, N (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.							ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1993, J BIOL CHEM, V268, P7628; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XY, 1993, J BIOL CHEM, V268, P3573; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YATAWA H, 1993, EMBO J, V12, P1705; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	30	423	449	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					587	590		10.1016/0092-8674(93)90506-L	http://dx.doi.org/10.1016/0092-8674(93)90506-L			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395346				2022-12-28	WOS:A1993LU59200002
J	COOK, M; FERNER, RE				COOK, M; FERNER, RE			ADVERSE DRUG-REACTIONS - WHO IS TO KNOW	BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND					Ferner, Robin/0000-0003-3769-1346				DAVIES DM, 1991, TXB ADVERSE DRUG REA; HASLMAN R, 1988, ADVERSE DRUG REACT, V3, P133; KARCH FE, 1976, CLIN PHARMACOL THER, V19, P489; 1992, BRIT NATIONAL FORMUL	4	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					480	481		10.1136/bmj.307.6902.480	http://dx.doi.org/10.1136/bmj.307.6902.480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400931	Bronze, Green Published			2022-12-28	WOS:A1993LU59000021
J	MANNHEIMER, C; ELIASSON, T; ANDERSSON, B; BERGH, CH; AUGUSTINSSON, LE; EMANUELSSON, H; WAAGSTEIN, F				MANNHEIMER, C; ELIASSON, T; ANDERSSON, B; BERGH, CH; AUGUSTINSSON, LE; EMANUELSSON, H; WAAGSTEIN, F			EFFECTS OF SPINAL-CORD STIMULATION IN ANGINA-PECTORIS INDUCED BY PACING AND POSSIBLE MECHANISMS OF ACTION	BRITISH MEDICAL JOURNAL			English	Article							ELECTRICAL NERVE-STIMULATION; CORONARY BLOOD-FLOW; OXYGEN-CONSUMPTION; BETA-BLOCKADE; METABOLISM; LACTATE; DISEASE; REPRODUCIBILITY; IMPROVEMENT; ADENOSINE	Objective-To investigate the effects of spinal cord stimulation on myocardial ischaemia, coronary blood flow, and myocardial oxygen consumption in angina pectoris induced by atrial pacing. Design-The heart was paced to angina during a control phase and treatment with spinal cord stimulation. Blood samples were drawn from a peripheral artery and the coronary sinus. Setting-Multidisciplinary pain centre, department of medicine, Ostra Hospital, and Wallenberg Research Laboratory, Sahlgrenska Hospital, Gothenburg, Sweden. Subjects-Twenty patients with intractable angina pectoris, all with a spinal cord stimulator implanted before the study. Results-Spinal cord stimulation increased patients' tolerance to pacing (p<0.001). At the pacing rate comparable to that producing angina during the control recording, myocardial lactate production during control session turned into extraction (p=0.003) and, on the electrocardiogram, ST segment depression decreased, time to ST depression increased, and time to recovery from ST depression decreased (p=0.01; p<0.05, and p <0.05, respectively). Spinal cord stimulation also reduced coronary sinus blood flow (p=0.01) and myocardial oxygen consumption (p=0.02). At the maximum pacing rate during treatment, all patients experienced anginal pain. Myocardial lactate extraction reverted to production (p<0.01) and the magnitude and duration of ST segment depression increased to the same values as during control pacing, indicating that myocardial ischaemia during treatment with spinal cord stimulation gives rise to anginal pain. Conclusions-Spinal cord stimulation has an antianginal and anti-ischaemic effect in severe coronary artery disease. These effects seem to be secondary to a decrease in myocardial oxygen consumption. Furthermore, myocardial ischaemia during treatment gives rise to anginal pain. Thus, spinal cord stimulation does not deprive the patient of a warning signal.	SAHLGRENS UNIV HOSP,DIV CARDIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT NEUROSURG,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital	MANNHEIMER, C (corresponding author), OSTRA HOSP,CTR MULTIDISCIPLINARY PAIN,DEPT MED,S-41685 GOTHENBURG,SWEDEN.							AUGUSTINSSON LE, 1985, ANN SURG, V202, P104, DOI 10.1097/00000658-198507000-00017; BLOMBERG S, 1989, EUR HEART J, V10, P437, DOI 10.1093/oxfordjournals.eurheartj.a059507; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; CHANDLER MJ, 1993, EUR HEART J, V14, P96, DOI 10.1093/eurheartj/14.1.96; COHEN LS, 1966, AM J CARDIOL, V17, P153, DOI 10.1016/0002-9149(66)90347-X; COOK AW, 1976, NEW YORK STATE J MED, V76, P366; DELANDSHEERE C, 1992, AM J CARDIOL, V69, P1143, DOI 10.1016/0002-9149(92)90926-P; EMANUELSSON H, 1987, AM HEART J, V114, P1360, DOI 10.1016/0002-8703(87)90537-0; FEIGL EO, 1983, PHYSIOL REV, V63, P1, DOI 10.1152/physrev.1983.63.1.1; FORRESTE.JS, 1971, AM J CARDIOL, V27, P237, DOI 10.1016/0002-9149(71)90296-7; GANZ W, 1971, CIRCULATION, V44, P181, DOI 10.1161/01.CIR.44.2.181; GERTZ EW, 1980, CIRCULATION, V61, P256, DOI 10.1161/01.CIR.61.2.256; Gybels J, 1987, Acta Neurochir Suppl (Wien), V38, P64; HOSOBUCHI Y, 1985, APPL NEUROPHYSIOL, V48, P372, DOI 10.1159/000101161; IHLEN H, 1983, CARDIOLOGY, V70, P177, DOI 10.1159/000173591; JACKSON G, 1977, BRIT HEART J, V39, P829; JACOBS MJHM, 1990, J VASC SURG, V12, P354, DOI 10.1067/mva.1990.22787; KNABB RM, 1983, CIRC RES, V53, P33, DOI 10.1161/01.RES.53.1.33; KROGER K, 1989, EUR HEART J, V10, P179, DOI 10.1093/eurheartj/10.suppl_F.179; LEHMANN EL, 1986, TESTING STATISTICAL, P233; LUNDEBERG T, 1988, LANCET, V2, P712; MANNHEIMER C, 1989, BRIT HEART J, V62, P36; MANNHEIMER C, 1988, BRIT HEART J, V59, P56; MANNHEIMER C, 1985, CIRCULATION, V71, P308, DOI 10.1161/01.CIR.71.2.308; MILLER WL, 1979, CIRC RES, V45, P708, DOI 10.1161/01.RES.45.6.708; MOSHER P, 1964, CIRC RES, V14, P250, DOI 10.1161/01.RES.14.3.250; NEILL WA, 1974, J LAB CLIN MED, V83, P428; ODEN A, 1975, ANN STAT, V3, P518, DOI 10.1214/aos/1176343082; REMME WJ, 1992, EUR HEART J S, V13, pP1963; ROBERTSON RM, 1983, AM HEART J, V105, P901, DOI 10.1016/0002-8703(83)90387-3; SANDERSON JE, 1992, EUR HEART J, V13, P628, DOI 10.1093/oxfordjournals.eurheartj.a060226; SIEGFRIED J, 1982, APPL NEUROPHYSIOL, V45, P201; SOWTON G. E., 1967, CARDIOVASC RES, V1, P301, DOI 10.1093/cvr/1.4.301; THADANI U, 1979, CIRCULATION, V60, P1036, DOI 10.1161/01.CIR.60.5.1036	34	149	156	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					477	480		10.1136/bmj.307.6902.477	http://dx.doi.org/10.1136/bmj.307.6902.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400930	Green Published, Bronze			2022-12-28	WOS:A1993LU59000020
J	MULKEY, RM; HERRON, CE; MALENKA, RC				MULKEY, RM; HERRON, CE; MALENKA, RC			AN ESSENTIAL ROLE FOR PROTEIN PHOSPHATASES IN HIPPOCAMPAL LONG-TERM DEPRESSION	SCIENCE			English	Article							POTENTIATED SYNAPTIC RESPONSES; OKADAIC ACID; AREA CA1; KINASE ACTIVITY; MICROCYSTIN-LR; CALYCULIN-A; MOUSE SKIN; STIMULATION; CALMODULIN; INDUCTION	The effectiveness of long-term potentiation (LTP) as a mechanism for information storage would be severely limited if processes that decrease synaptic strength did not also exist. In area CA1 of the rat hippocampus, prolonged periods of low-frequency afferent stimulation elicit a long-term depression (LTD) that is specific to the stimulated input. The induction of LTD was blocked by the extracellular application of okadaic acid or calyculin A, two inhibitors of protein phosphatases 1 and 2A. The loading of CA1 cells with microcystin LR, a membrane-impermeable protein phosphatase inhibitor, or calmodulin antagonists also blocked or attenuated LTD. The application of calyculin A after the induction of LTD reversed the synaptic depression, suggesting that phosphatase activity is required for the maintenance of LTD. These findings indicate that the synaptic activation of protein phosphatases plays an important role in the regulation of synaptic transmission.	UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH045334, F32MH010306] Funding Source: NIH RePORTER; NIMH NIH HHS [MH10306, MH00942, MH45334] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTOLA A, IN PRESS TRENDS NEUR; BARRIONUEVO G, 1980, LIFE SCI, V27, P2385, DOI 10.1016/0024-3205(80)90509-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLINO A, 1992, J NEUROSCI, V12, P180; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HERRON CE, UNPUB; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KLANN E, 1991, J BIOL CHEM, V266, P24253; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPHO, V23, P1; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; SUGANUMA M, 1990, CANCER RES, V50, P3521; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	37	530	541	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1051	1055		10.1126/science.8394601	http://dx.doi.org/10.1126/science.8394601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8394601				2022-12-28	WOS:A1993LT74700036
J	NAKATSU, Y; TYNDALE, RF; DELOREY, TM; DURHAMPIERRE, D; GARDNER, JM; MCDANEL, HJ; NGUYEN, Q; WAGSTAFF, J; LALANDE, M; SIKELA, JM; OLSEN, RW; TOBIN, AJ; BRILLIANT, MH				NAKATSU, Y; TYNDALE, RF; DELOREY, TM; DURHAMPIERRE, D; GARDNER, JM; MCDANEL, HJ; NGUYEN, Q; WAGSTAFF, J; LALANDE, M; SIKELA, JM; OLSEN, RW; TOBIN, AJ; BRILLIANT, MH			A CLUSTER OF 3 GABA(A) RECEPTOR SUBUNIT GENES IS DELETED IN A NEUROLOGICAL MUTANT OF THE MOUSE P-LOCUS	NATURE			English	Article							PRADER-WILLI SYNDROME; ANGELMAN SYNDROMES; REGION; LOCALIZATION; BENZODIAZEPINE; CHROMOSOME-7; EXPRESSION; BETA-3; ALPHA; MODEL	THE mouse pink-eyed cleft-palate (p(cp)) mutation is characterized by hypopigmentation associated with cleft palate, neurological disorders and runting1,2. Most p(cp) homozygotes are born with cleft palate and die shortly after birth, presumably as a result of feeding problems3. A few exceptional p(cp) mutants live beyond this stage but display tremor and jerky gait2. We report here that the genes encoding the gamma-aminobutyric acid type A (GABA(A)) receptor subunits alpha5 (originally described as alpha4; ref. 4), beta3 and gamma3 are disrupted by a deletion in p(cp) mice. We also show that the alpha5 and gamma3 genes are located between the p and beta3 genes on mouse chromosome 7. The p(cp) deletion leads to alterations of binding properties of the GABA(A) receptors in the brain, providing an in vivo model system for studying GABA(A) receptor function. The human homologue of the region deleted in p(cp) mice is associated with Angelman syndrome5-9. Thus, p(cp) mice may be useful in defining the region containing the gene(s) for this syndrome.	FOX CHASE CANC CTR,INST CANC RES,7701 BURHOLME AVE,PHILADELPHIA,PA 19111; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; CHILDRENS HOSP MED CTR,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	Fox Chase Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Nakatsu, Yoshimichi/0000-0001-7408-7071; Tyndale, Rachel/0000-0003-1297-2053				ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; BRILLIANT MH, 1992, MAMM GENOME, V3, P187, DOI 10.1007/BF00355717; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; CULIAT CT, 1993, P NATL ACAD SCI USA, V90, P5105, DOI 10.1073/pnas.90.11.5105; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; HAMABE J, 1991, AM J MED GENET, V41, P54, DOI 10.1002/ajmg.1320410116; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KNOLL JHM, 1993, HUM MOL GENET, V2, P183, DOI 10.1093/hmg/2.2.183; KORPI ER, 1993, NATURE, V361, P356, DOI 10.1038/361356a0; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LYON MF, 1992, P NATL ACAD SCI USA, V89, P6968, DOI 10.1073/pnas.89.15.6968; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; NAKATSU Y, 1992, MAMM GENOME, V2, P69, DOI 10.1007/BF00570442; NICHOLLS RD, 1989, MOUSE NEWS LETT, V84, P87; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P59; PHILLIPS RJS, 1977, MOUSE NEWSLETTER, V56, P18; POULTER MO, 1992, J NEUROSCI, V12, P2888, DOI 10.1523/JNEUROSCI.12-08-02888.1992; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REIS A, 1993, LANCET, V341, P122, DOI 10.1016/0140-6736(93)92606-T; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SILVERS WK, 1979, COAT COLORS MICE, P90; SINNETT D, 1993, AM J HUM GENET, V52, P1216; WAGSTAFF J, 1991, AM J HUM GENET, V49, P330; WAGSTAFF J, 1991, GENOMICS, V11, P1071, DOI 10.1016/0888-7543(91)90034-C; WILCOX AS, 1992, P NATL ACAD SCI USA, V89, P5857, DOI 10.1073/pnas.89.13.5857; WILSONSHAW D, 1991, FEBS LETT, V284, P211, DOI 10.1016/0014-5793(91)80687-X; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; ZHANG JH, 1991, J COMP NEUROL, V308, P586, DOI 10.1002/cne.903080407	32	94	95	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					448	450		10.1038/364448a0	http://dx.doi.org/10.1038/364448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8392662				2022-12-28	WOS:A1993LP64000056
J	SMITH, CA; GRUSS, HJ; DAVIS, T; ANDERSON, D; FARRAH, T; BAKER, E; SUTHERLAND, GR; BRANNAN, CI; COPELAND, NG; JENKINS, NA; GRABSTEIN, KH; GLINIAK, B; MCALISTER, IB; FANSLOW, W; ALDERSON, M; FALK, B; GIMPEL, S; GILLIS, S; DIN, WS; GOODWIN, RG; ARMITAGE, RJ				SMITH, CA; GRUSS, HJ; DAVIS, T; ANDERSON, D; FARRAH, T; BAKER, E; SUTHERLAND, GR; BRANNAN, CI; COPELAND, NG; JENKINS, NA; GRABSTEIN, KH; GLINIAK, B; MCALISTER, IB; FANSLOW, W; ALDERSON, M; FALK, B; GIMPEL, S; GILLIS, S; DIN, WS; GOODWIN, RG; ARMITAGE, RJ			CD30 ANTIGEN, A MARKER FOR HODGKINS LYMPHOMA, IS A RECEPTOR WHOSE LIGAND DEFINES AN EMERGING FAMILY OF CYTOKINES WITH HOMOLOGY TO TNF	CELL			English	Article							TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; STERNBERG-REED CELLS; GENETIC-LINKAGE MAP; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; MOLECULAR-CLONING; IL-1 RECEPTOR; SURFACE; DISEASE	CD30 is a surface marker for neoplastic cells of Hodgkin's lymphoma and shows sequence homology to members of the tumor necrosis factor (TNF) receptor superfamily. Using a chimeric probe consisting of the extracellular domain of CD30 fused to truncated immunoglobulin heavy chains, we expression cloned the cDNA cognate from the murine T cell clone 7B9. The encoded protein is a 239 amino acid type II membrane protein whose C-terminal domain shows significant homology to TNFalpha, TNFbeta, and the CD40L. Cross-hybridization to an induced peripheral blood T cell cDNA library yielded the human homolog, which is 72% identical at the amino acid level. The recombinant human ligand enhances the proliferation of CD3-activated T cells yet induces differential responses, including cell death, in several CD30+ lymphoma-derived clones. The human and murine genes map to 9q33 and the proximal region of chromosome 4, respectively.	ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SMITH, CA (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.		Sutherland, Grant Robert/D-2606-2012		NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREESEN R, 1984, BLOOD, V63, P1299; ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BROWNING JL, 1991, J IMMUNOL, V147, P1230; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CARDE P, 1990, EUR J CANCER, V26, P474, DOI 10.1016/0277-5379(90)90019-P; CARRIER A, 1992, GENE, V116, P173, DOI 10.1016/0378-1119(92)90513-O; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CLARK EA, 1990, TISSUE ANTIGENS, V36, P33, DOI 10.1111/j.1399-0039.1990.tb01795.x; CLARK SP, 1992, COMPUT APPL BIOSCI, V8, P535; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DIEHL V, 1992, 2ND INT S HODGK DIS, V3; DREXLER HG, 1986, LEUKEMIA RES, V10, P487, DOI 10.1016/0145-2126(86)90084-6; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; FISCHER P, 1988, BLOOD, V72, P234; FONATSCH C, 1992, GENOMICS, V14, P825, DOI 10.1016/S0888-7543(05)80203-4; FROESE P, 1987, J IMMUNOL, V139, P2081; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; Green EL, 1981, GENETICS PROBABILITY, P77; GRUSS HJ, 1992, CANCER RES, V52, P3353; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES EY, 1990, PROG CLIN BIOL RES, V349, P321; KLEIN G, 1992, BLOOD, V80, P299; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KWON BS, 1989, CELL IMMUNOL, V121, P414, DOI 10.1016/0008-8749(89)90040-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSELY B, 1989, CELL, V59, P335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFREUNDSCHUH M, 1989, ONKOLOGIE, V12, P30, DOI 10.1159/000216681; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SELBY MJ, 1987, MOL CELL BIOL, V7, P3057, DOI 10.1128/MCB.7.9.3057; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; URDAL DL, 1988, J BIOL CHEM, V263, P2870; WARE CF, 1992, J IMMUNOL, V149, P3881; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; 1991, PROGRAM MANUAL GCG P, V7	62	507	543	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1349	1360		10.1016/0092-8674(93)90361-S	http://dx.doi.org/10.1016/0092-8674(93)90361-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391931				2022-12-28	WOS:A1993LL20900010
J	DUFFNER, PK; HOROWITZ, ME; KRISCHER, JP; FRIEDMAN, HS; BURGER, PC; COHEN, ME; SANFORD, RA; MULHERN, RK; JAMES, HE; FREEMAN, CR; SEIDEL, FG; KUN, LE				DUFFNER, PK; HOROWITZ, ME; KRISCHER, JP; FRIEDMAN, HS; BURGER, PC; COHEN, ME; SANFORD, RA; MULHERN, RK; JAMES, HE; FREEMAN, CR; SEIDEL, FG; KUN, LE			POSTOPERATIVE CHEMOTHERAPY AND DELAYED RADIATION IN CHILDREN LESS-THAN 3 YEARS OF AGE WITH MALIGNANT BRAIN-TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; PHASE-II; IRRADIATION; SURVIVAL; VINCRISTINE; THERAPY; GROWTH	Background. Among patients with malignant brain tumors, infants and very young children have the worst prognosis and the most severe treatment-related neurotoxic effects. Therefore, in 1986, the Pediatric Oncology Group began a study in which postoperative chemotherapy was given in order to permit a delay in the delivery of radiation to the developing brain. Methods. Children under 36 months of age with biopsy-proved malignant brain tumors were treated postoperatively with two 28-day cycles of cyclophosphamide plus vincristine, followed by one 28-day cycle of cisplatin plus etoposide. This sequence was repeated until the disease progressed or for two years in 132 children under 24 months of age at diagnosis and for one year in 66 children 24 to 36 months of age at diagnosis. After this, the patients received radiation therapy. The response to the first two cycles of chemotherapy was measured in 102 patients with residual postoperative disease. Results. The first two cycles of cyclophosphamide and vincristine produced complete or partial responses in 39 percent of the 102 patients who could be evaluated. The response rates were highest among patients with medulloblastomas, malignant gliomas, or ependymomas. Patients with brain-stem gliomas or embryonal tumors (primitive neuroectodermal tumors) had little or no response. The progression-free survival rate was 41 percent at one year for children who were 24 to 36 months old at diagnosis and 39 percent at two years for those under 24 months of age at diagnosis. Multivariate analysis identified embryonal tumors as a significant adverse prognostic feature (relative risk, 2.2; 95 percent confidence interval, 1.4 to 3.4) and complete resection as a favorable feature (relative risk, 0.33; 95 percent confidence interval, 0.20 to 0.54). Complete responses to chemotherapy were associated with a progression-free survival rate approaching that achieved with gross total resection. A comparison of cognitive evaluations obtained at base line and after one year of chemotherapy revealed no evidence of deterioration in cognitive function. Conclusions. Chemotherapy appears to be an effective primary postoperative treatment for many malignant brain tumors in young children. Disease control for one or two years in a large minority of patients permitted a delay in the delivery of radiation and, on the basis of preliminary results, a reduction in neurotoxicity. For patients who had undergone total surgical resection or who had a complete response to chemotherapy, the results are sufficiently encouraging to suggest that radiation therapy may not be needed in this subgroup of children after at least one year of chemotherapy.	SUNY Buffalo, SCH MED & BIOMED SCI, BUFFALO, NY 14260 USA; ROSWELL PK CANC INST, BUFFALO, NY USA; UNIV FLORIDA, PEDIAT ONCOL GRP STAT OFF, GAINESVILLE, FL 32611 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; NCI, PEDIAT BRANCH, BETHESDA, MD 20892 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; CHILDRENS MERCY HOSP, KANSAS CITY, MO 64108 USA; UNIV CALIF SAN DIEGO, MED CTR, SAN DIEGO, CA 92103 USA; MONTREAL GEN HOSP, MONTREAL H3G 1A4, QUEBEC, CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute; State University System of Florida; University of Florida; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital; Children's Mercy Hospital; University of California System; University of California San Diego; McGill University			Krischer, Jeffrey P/I-5004-2012					ALLEN JC, 1981, J NEUROSURG, V55, P749, DOI 10.3171/jns.1981.55.5.0749; ALLEN JC, 1983, CANCER, V52, P2001, DOI 10.1002/1097-0142(19831201)52:11<2001::AID-CNCR2820521105>3.0.CO;2-D; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BERTOLONE SJ, 1983, P AN M AM SOC CLIN, V2, P72; BLOOM HJG, 1990, INT J RADIAT ONCOL, V18, P723, DOI 10.1016/0360-3016(90)90392-W; BLOOM HJG, 1990, INT J RADIAT ONCOL, V19, P829; BURGER PC, 1991, SURGICAL PATHOLOGY N; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS PC, 1986, AM J ROENTGENOL, V147, P587, DOI 10.2214/ajr.147.3.587; DEUTSCH M, 1991, P AN M AM SOC CLIN, V10, P124; DUFFNER PK, 1986, NEUROLOGY, V36, P597, DOI 10.1212/WNL.36.5.597; DUFFNER PK, 1986, ANN NEUROL, V20, P424; ELLENBERG L, 1987, NEUROSURGERY, V21, P638, DOI 10.1227/00006123-198711000-00006; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FINLAY J, 1991, P AN M AM SOC CLIN, V10, P308; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHAN AB, 1982, CANCER TREAT REP, V66, P2013; LAMPKIN BC, 1967, PEDIATRICS, V39, P761; LEFKOWITZ I, 1989, P AN M AM SOC CLIN, V8, P87; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; McCarthy D, 1972, MCCARTHY SCALES CHIL; ROSENSTOCK JG, 1976, J NEUROSURG, V45, P135, DOI 10.3171/jns.1976.45.2.0135; Russell D., 1989, PATHOLOGY TUMORS NER; SHALET SM, 1987, ARCH DIS CHILD, V62, P461, DOI 10.1136/adc.62.5.461; SHRIEVE DC, 1992, INT J RADIAT ONCOL, V24, P599, DOI 10.1016/0360-3016(92)90704-L; SHUSTER JJ, 1988, AM STAT, V42, P234; SKLANSKY BD, 1974, CANCER-AM CANCER SOC, V33, P460, DOI 10.1002/1097-0142(197402)33:2<460::AID-CNCR2820330222>3.0.CO;2-5; SNEDECOR GW, 1981, STATISTICAL METHODS, P228; SPOSTO R, 1989, J NEURO-ONCOL, V7, P165, DOI 10.1007/BF00165101; SPUNBERG JJ, 1981, INT J RADIAT ONCOL, V7, P727, DOI 10.1016/0360-3016(81)90465-X; SUC E, 1990, ACTA NEUROCHIR, V106, P93, DOI 10.1007/BF01809448; TIRELLI U, 1984, J CLIN ONCOL, V2, P432, DOI 10.1200/JCO.1984.2.5.432; WALKER RW, 1983, ANN NEUROL, V14, P371	34	575	582	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1725	1731		10.1056/NEJM199306173282401	http://dx.doi.org/10.1056/NEJM199306173282401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	8388548				2022-12-28	WOS:A1993LG03800001
J	CIGARROA, JE; ISSELBACHER, EM; DESANCTIS, RW; EAGLE, KA				CIGARROA, JE; ISSELBACHER, EM; DESANCTIS, RW; EAGLE, KA			DIAGNOSTIC-IMAGING IN THE EVALUATION OF SUSPECTED AORTIC DISSECTION - OLD STANDARDS AND NEW DIRECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; COMPUTED-TOMOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; THORACIC AORTA; ANEURYSM		MASSACHUSETTS GEN HOSP,CARDIAC UNIT,ACC 469,15 PARKMAN ST,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital								ADACHI H, 1991, CIRCULATION, V84, P14; Adachi H, 1990, CIRCULATION S4, V82, P19; AMPARO EG, 1985, RADIOLOGY, V155, P399, DOI 10.1148/radiology.155.2.3983390; BALLAL RS, 1991, CIRCULATION, V84, P1903, DOI 10.1161/01.CIR.84.5.1903; CAMBRIA RP, 1988, ANN SURG, V208, P619, DOI 10.1097/00000658-198811000-00013; CAPUTO GR, 1990, INVEST RADIOL, V25, P838, DOI 10.1097/00004424-199007000-00017; CHAN KL, 1991, AM HEART J, V122, P495, DOI 10.1016/0002-8703(91)91007-A; Daily P O, 1970, Ann Thorac Surg, V10, P237; DEBAKEY ME, 1965, J THORAC CARDIOV SUR, V49, P130, DOI 10.1016/S0022-5223(19)33323-9; DESANCTIS RW, 1987, NEW ENGL J MED, V317, P1060, DOI 10.1056/NEJM198710223171705; EAGLE KA, 1989, CURR PROB CARDIOLOGY, V14, P225, DOI 10.1016/S0146-2806(89)80010-6; EAGLE KA, 1986, AM J CARDIOL, V57, P322, DOI 10.1016/0002-9149(86)90912-4; EARNEST F, 1979, MAYO CLIN PROC, V54, P43; ERBEL R, 1989, LANCET, V1, P457; ERBEL R, 1987, BRIT HEART J, V58, P45; GEISINGER MA, 1985, RADIOLOGY, V155, P407, DOI 10.1148/radiology.155.2.3983391; GODWIN JD, 1980, RADIOLOGY, V136, P125, DOI 10.1148/radiology.136.1.7384486; GOLDEN A, 1949, AM HEART J, V37, P114, DOI 10.1016/0002-8703(49)91434-9; GOLDMAN AP, 1986, AM HEART J, V111, P970, DOI 10.1016/0002-8703(86)90648-4; GOLDMAN AP, 1986, AM J MED, V80, P1225, DOI 10.1016/0002-9343(86)90693-5; GRANATO JE, 1985, AM J CARDIOL, V56, P123, DOI 10.1016/0002-9149(85)90579-X; GROSS SC, 1980, RADIOLOGY, V136, P135, DOI 10.1148/radiology.136.1.7384487; GUTIERREZ FR, 1980, RADIOLOGY, V135, P759, DOI 10.1148/radiology.135.3.7384468; HAMADA S, 1992, RADIOLOGY, V183, P155, DOI 10.1148/radiology.183.1.1549663; HARRIS RD, 1979, J COMPUT ASSIST TOMO, V3, P81; HART WL, 1963, CIRCULATION, V27, P1140, DOI 10.1161/01.CIR.27.6.1140; HASHIMOTO S, 1989, J AM COLL CARDIOL, V14, P1253, DOI 10.1016/0735-1097(89)90424-5; HAYASHI K, 1974, AM J ROENTGENOL, V122, P769, DOI 10.2214/ajr.122.4.769; HERFKENS RJ, 1983, RADIOLOGY, V147, P749, DOI 10.1148/radiology.147.3.6601813; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; ILICETO S, 1987, CIRCULATION, V75, P748, DOI 10.1161/01.CIR.75.4.748; KERN MJ, 1990, AM HEART J, V119, P143, DOI 10.1016/S0002-8703(05)80094-8; KERSTINGSOMMERHOFF BA, 1988, RADIOLOGY, V166, P651, DOI 10.1148/radiology.166.3.3340758; KIRSCHNER LP, 1968, AMER J ROENTGENOL RA, V102, P349, DOI 10.2214/ajr.102.2.349; MATHEW T, 1984, AM J CARDIOL, V54, P379, DOI 10.1016/0002-9149(84)90201-7; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; OMOTO R, 1992, CIRCULATION, V85, P1237, DOI 10.1161/01.CIR.85.4.1237; PAULIN S, 1987, AM J ROENTGENOL, V148, P665, DOI 10.2214/ajr.148.4.665; PETASNICK JP, 1991, RADIOLOGY, V180, P297, DOI 10.1148/radiology.180.2.2068287; Roelandt J R, 1992, J Am Soc Echocardiogr, V5, P361; SECHTEM U, 1987, AM J ROENTGENOL, V148, P239, DOI 10.2214/ajr.148.2.239; SECHTEM U, 1988, RADIOLOGY, V167, P425, DOI 10.1148/radiology.167.2.3357951; SELDINGER SI, 1953, ACTA RADIOL, V39, P368, DOI 10.3109/00016925309136722; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; SHELLOCK FG, 1991, RADIOLOGY, V180, P541, DOI 10.1148/radiology.180.2.2068325; SHUFORD WH, 1969, NEW ENGL J MED, V280, P225, DOI 10.1056/NEJM196901302800501; SILVEY SV, 1991, AM J CARDIOL, V68, P286, DOI 10.1016/0002-9149(91)90769-H; SIMON P, 1992, J THORAC CARDIOV SUR, V103, P1113; STEIN HL, 1968, AMER J ROENTGENOL RA, V102, P333, DOI 10.2214/ajr.102.2.333; SUCHATO C, 1980, J COMPUT ASSIST TOMO, V4, P115, DOI 10.1097/00004728-198002000-00022; TISNADO J, 1980, AM J ROENTGENOL, V135, P719, DOI 10.2214/ajr.135.4.719; VASILE N, 1986, J COMPUT ASSIST TOMO, V10, P211, DOI 10.1097/00004728-198603000-00008; VICTOR MF, 1981, AM J CARDIOL, V48, P1155, DOI 10.1016/0002-9149(81)90334-9; WHITE RD, 1988, AM J ROENTGENOL, V150, P87, DOI 10.2214/ajr.150.1.87; WHITE RD, 1986, AM J CARDIOL, V57, P282, DOI 10.1016/0002-9149(86)90906-9; WILBERS CRH, 1990, TEX HEART I J, V17, P271	57	276	295	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					35	43		10.1056/NEJM199301073280107	http://dx.doi.org/10.1056/NEJM199301073280107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8416269				2022-12-28	WOS:A1993KF50700007
J	WALLACE, MR; ROSSETTI, RJ; OLSON, PE				WALLACE, MR; ROSSETTI, RJ; OLSON, PE			CATS AND TOXOPLASMOSIS RISK IN HIV-INFECTED ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ENCEPHALITIS; PREVALENCE; GONDII; AIDS	Objective.-To establish the prevalence and incidence of toxoplasmosis in an adult human immunodeficiency virus (HIV) population, and to determine if cat ownership contributes to the risk of toxoplasmosis. Design.-Retrospective record and laboratory review, coupled with a patient survey. Setting.-A tertiary-care military hospital HIV program. Patients.-A total of 723 HIV-infected adults, all former or current US military personnel. Main Outcome Measures.-Prevalence and incidence of serologic evidence of toxoplasmosis infection. Results.-A total of 723 HIV-infected patients had serial Toxoplasma IgG antibody determinations. Seventy patients (9.7%) were positive on their initial screen; the seronegative patients were tested annually for 1 to 5 years (mean duration of follow-up, 2.1 years). Only 13 patients (2.0%) who were initially seronegative acquired antibodies to Toxoplasma gondii. None of the patients who seroconverted developed clinical disease. A pet history was available on 12 of 13 patients who seroconverted; only one (8.3%) had owned or lived in a household with a cat during the period of seroconversion. The calculated attributable risk of cat ownership/exposure for toxoplasmosis seroconversion in this population is -2.9 per 100 persons annually. Conclusion.-Toxoplasma antibody seroconversion in an adult HIV-infected population is unusual and appears unrelated to cat ownership or exposure.	USN HOSP,DEPT CLIN INVEST,SAN DIEGO,CA 92134	United States Department of Defense; United States Navy	WALLACE, MR (corresponding author), USN HOSP,DEPT INTERNAL MED,DIV INFECT DIS,SAN DIEGO,CA 92134, USA.							BEACH PG, 1979, J INFECT DIS, V140, P780, DOI 10.1093/infdis/140.5.780; DANNEMANN BR, 1989, HOSP PRACT, V24, P139; FELDMAN HA, 1965, AM J EPIDEMIOL, V81, P385, DOI 10.1093/oxfordjournals.aje.a120524; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; Israelski D M, 1988, Infect Dis Clin North Am, V2, P429; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P292; LAST JM, 1988, DICT EPIDEMIOLOGY, P170; LUFT BJ, 1990, AIDS, V4, P593, DOI 10.1097/00002030-199006000-00018; McCabe R. E., 1990, Principles and practice of infectious diseases., P2090; PETERSON DR, 1972, AM J EPIDEMIOL, V96, P215, DOI 10.1093/oxfordjournals.aje.a121450; STRAYPEDERSEN B, 1975, SCAND J INFECT DIS, V11, P159; TEUTSCH SM, 1979, NEW ENGL J MED, V300, P695, DOI 10.1056/NEJM197903293001302; ULMANEN I, 1975, SCAND J INFECT DIS, V7, P67, DOI 10.3109/inf.1975.7.issue-1.12	13	66	67	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					76	77		10.1001/jama.269.1.76	http://dx.doi.org/10.1001/jama.269.1.76			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416410				2022-12-28	WOS:A1993KF02600031
J	VANPEENEN, HJ				VANPEENEN, HJ			ARE WE ALWAYS - WHEN DO WE STOP	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIANS; LICENSURE, MEDICAL		A physician reads of a sanction brought by the medical board against a casual friend. His musings lead him to more fundamental questions, such as when does one become a doctor? When, if ever, does one cease to be one?											0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					69	70		10.7326/0003-4819-118-1-199301010-00012	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416160				2022-12-28	WOS:A1993KE60500011
J	WEIDMAN, P; ROTH, R; HEUSER, J				WEIDMAN, P; ROTH, R; HEUSER, J			GOLGI MEMBRANE DYNAMICS IMAGED BY FREEZE-ETCH ELECTRON-MICROSCOPY - VIEWS OF DIFFERENT MEMBRANE COATINGS INVOLVED IN TUBULATION VERSUS VESICULATION	CELL			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; TRANSPORT VESICLES; COATED VESICLES; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; BETA-COP; CLATHRIN; BINDING; STACK	We used high resolution three-dimensional electron microscopy to visualize Golgi cisternal structure and analyze morphological transitions induced by various in vitro incubations. Our images show that Golgi cisternae have two distinct surface coatings with different distributions and apparent functions. The first type, probably a coatomer coat, consists of tightly packed approximately 10 nm surface particles. These are localized exclusively to sites of membrane budding and are as intimately involved in bud formation as clathrin or caveolin coats. When this coating is exaggerated by GTPgammaS, the periphery of all cisternae is partitioned into coated vesicles that remain attached at their sites of formation. A second, much finer coating is evenly distributed over the periphery of cisternae, including tubules enclosing the fenestrae. It appears to stabilize the membrane curvature associated with tubules and edges. These different coatings must be considered in further attempts to unravel Golgi membrane trafficking mechanisms.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)	WEIDMAN, P (corresponding author), ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104, USA.				NIGMS NIH HHS [5R01GM29647] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN V J, 1988, Journal of Cell Biology, V107, p759A; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; Beams H. W., 1968, International Review of Cytology, V23, P209, DOI 10.1016/S0074-7696(08)60273-9; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CLUETT EB, 1993, J CELL BIOL, V120, P709; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MCMORROW I, 1990, J CELL BIOL, V110, P1513, DOI 10.1083/jcb.110.5.1513; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P215; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1992, CELL, V2, P381; Sztul Elizabeth S., 1992, Trends in Cell Biology, V2, P381, DOI 10.1016/0962-8924(92)90051-N; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	44	117	120	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					123	133		10.1016/S0092-8674(05)80089-3	http://dx.doi.org/10.1016/S0092-8674(05)80089-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402891				2022-12-28	WOS:A1993MB66700013
J	BATES, P; YOUNG, JAT; VARMUS, HE				BATES, P; YOUNG, JAT; VARMUS, HE			A RECEPTOR FOR SUBGROUP-A ROUS-SARCOMA VIRUS IS RELATED TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR	CELL			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; APE LEUKEMIA-VIRUS; MUTATIONAL ANALYSIS; GENE ENCODES; HOST RANGE; PROTEIN; INFECTION; SEQUENCE; CD4; DETERMINANTS	Cellular receptors are required for efficient entry of retroviruses into cells. We previously cloned a chicken gene responsible for susceptibility to the retrovirus subgroup A Rous sarcoma virus (RSV(A)). Here we have isolated the quail homolog and generated two alternatively spliced processed genes encoding cellular receptors for RSV(A). Predicted products of the processed genes appear to be small membrane-associated proteins with identical 83 amino acid extracellular domains but different membrane anchors. Within the extracellular domain is a region closely related to the ligand-binding repeat of the low density lipoprotein receptor (LDLR). Expression of either processed gene renders mammalian cells specifically susceptible to RSV(A). Antibodies directed against the receptor block subgroup A infection of avian cells via endogenous receptors and have no effect on entry of other RSV subgroups. Thus, small LDLR-related proteins are cellular receptors for RSV(A).	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Young, John/0000-0003-1824-2561; Bates, Paul/0000-0002-3918-5976	NATIONAL CANCER INSTITUTE [R35CA039832] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BOVA CA, 1988, J VIROL, V62, P75, DOI 10.1128/JVI.62.1.75-83.1988; BOVA CA, 1986, VIROLOGY, V152, P343, DOI 10.1016/0042-6822(86)90137-6; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; ESSER V, 1988, J BIOL CHEM, V263, P13282; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; JOHANN SV, 1992, J VIROL, V66, P1635, DOI 10.1128/JVI.66.3.1635-1640.1992; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOZAK SL, 1990, J VIROL, V64, P3500, DOI 10.1128/JVI.64.7.3500-3508.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENTZ TL, 1990, J GEN VIROL, V71, P751, DOI 10.1099/0022-1317-71-4-751; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOHSE P, 1991, J BIOL CHEM, V266, P10479; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; PAYNE LN, 1966, VIROLOGY, V29, P190, DOI 10.1016/0042-6822(66)90025-0; RUBIN H, 1965, VIROLOGY, V26, P270, DOI 10.1016/0042-6822(65)90274-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOTOHNO K, 1982, NATURE, V299, P265, DOI 10.1038/299265a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SORGE J, 1982, Journal of Molecular and Applied Genetics, V1, P547; STANLEY KK, 1988, CURR TOP MICROBIOL I, V140, P49; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VOGT PK, 1966, VIROLOGY, V30, P368, DOI 10.1016/0042-6822(66)90115-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Weiss R, 1982, RNA TUMOR VIRUSES; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993	37	300	313	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1043	1051		10.1016/0092-8674(93)90726-7	http://dx.doi.org/10.1016/0092-8674(93)90726-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402880				2022-12-28	WOS:A1993LY49300011
J	MASUR, H				MASUR, H			RECOMMENDATIONS ON PROPHYLAXIS AND THERAPY FOR DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX DISEASE IN PATIENTS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMMUNE-DEFICIENCY-SYNDROME; INTRACELLULARE BACTEREMIA; NATURAL-HISTORY; AIDS; CLARITHROMYCIN; CIPROFLOXACIN; ETHAMBUTOL; IDENTIFICATION; EPIDEMIOLOGY; CLOFAZIMINE				MASUR, H (corresponding author), NIH,BETHESDA,MD 20892, USA.							AGINS BD, 1989, J INFECT DIS, V159, P784, DOI 10.1093/infdis/159.4.784; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHAISSON RE, 1992, 32ND INT C ANT AG CH, P891; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; DELALLA F, 1992, ANTIMICROB AGENTS CH, V36, P1567, DOI 10.1128/AAC.36.7.1567; ELLNER JJ, 1991, J INFECT DIS, V163, P1326, DOI 10.1093/infdis/163.6.1326; EVANS KD, 1992, J CLIN MICROBIOL, V30, P2427, DOI 10.1128/JCM.30.9.2427-2431.1992; HAVLIK J, 1992, 92ND GEN M AM SOC MI; HAVLIK JA, 1992, J INFECT DIS, V165, P577, DOI 10.1093/infdis/165.3.577; HAVLIR D, 1993, J CLIN MICROBIOL, V31, P1794, DOI 10.1128/JCM.31.7.1794-1798.1993; HEIFETS LB, 1992, AM REV RESPIR DIS, V145, P856, DOI 10.1164/ajrccm/145.4_Pt_1.856; HEIFETS LB, 1991, AM REV RESPIR DIS, V144, P1; HOPEWELL P, 1992, CLIN INFECT DIS, V15, pS296, DOI 10.1093/clind/15.Supplement_1.S296; HORSBURGH CR, 1992, AIDS, V6, P512; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; HORSBURGH CR, 1993, PEDIATR INFECT DIS J, V12, P219, DOI 10.1097/00006454-199303000-00009; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; HORSBURGH CR, 1991, AM REV RESPIR DIS S, V146, pA115; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; INDERLIED CB, 1993, CLIN MICROBIOL REV, V6, P266, DOI 10.1128/CMR.6.3.266-310.1993; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; KEMPER C, 1992, 8TH INT C AIDS AMST; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; KEMPER CA, 1992, 32ND INT C ANT AG CH, P894; KIRSCHNER RA, 1992, AM REV RESPIR DIS, V145, P271, DOI 10.1164/ajrccm/145.2_Pt_1.271; MASUR H, 1982, JAMA-J AM MED ASSOC, V248, P3013, DOI 10.1001/jama.248.22.3013; NARANG P, 1992, 8TH INT C AIDS AMST; NASSOS PS, 1993, 93RD GEN M AM SOC MI; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W	33	279	282	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					898	904		10.1056/NEJM199309163291228	http://dx.doi.org/10.1056/NEJM199309163291228			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8395019	Bronze			2022-12-28	WOS:A1993LW55100037
J	ARCHIMANDRITIS, AJ; WEETCH, MS				ARCHIMANDRITIS, AJ; WEETCH, MS			KIDNEY GRANULOMA IN CROHNS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									SO GEN HOSP,CTR GASTROINTESTINAL,GLASGOW G51 4TF,SCOTLAND	University of Glasgow								BUCHANAN TM, 1983, HARRISONS PRINCIPLES, P974; COTRAN RS, 1981, KIDNEY, V2, P1633; EADE MN, 1971, SCAND J GASTROENTERO, V6, P199, DOI 10.3109/00365527109180693; MEYER JH, 1973, GASTROINTESTINAL DIS, P1350; Whitehead R, 1980, INFLAMM BOWEL DIS, P296	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					540	541		10.1136/bmj.307.6903.540	http://dx.doi.org/10.1136/bmj.307.6903.540			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400974	Bronze, Green Published			2022-12-28	WOS:A1993LV18000017
J	DIVECHA, N; BANFIC, H; IRVINE, RF				DIVECHA, N; BANFIC, H; IRVINE, RF			INOSITIDES AND THE NUCLEUS AND INOSITIDES IN THE NUCLEUS	CELL			English	Review							PROTEIN-KINASE-C; SWISS 3T3 CELLS; PHOSPHOLIPASE-C; DIACYLGLYCEROL; TRANSLOCATION; RECEPTOR; BETA		UNIV ZAGREB,SCH MED,DEPT PHYSIOL,41000 ZAGREB,CROATIA	University of Zagreb	DIVECHA, N (corresponding author), AFRC,BABRAHAM INST,DEPT DEV & SIGNALLING,CAMBRIDGE CB2 4AT,ENGLAND.			divecha, nullin/0000-0001-9695-6039				BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; CAPITANI S, 1989, FEBS LETT, V245, P194; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; FABRIKANT JI, 1968, J CELL BIOL, V36, P551, DOI 10.1083/jcb.36.3.551; FIELDS AP, 1990, J CELL SCI, V96, P107; GRISHAM J, 1962, CANCER RES, V22, P847; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; LEACH KL, 1992, J BIOL CHEM, V267, P21816; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SASAKI YY, 1993, J BIOL CHEM, V68, P3805; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SMITH CD, 1983, J BIOL CHEM, V258, P9368; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TRUBIANI O, 1990, CELL BIOL INT REP, V14, P559, DOI 10.1016/0309-1651(90)91183-5	20	216	218	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					405	407		10.1016/0092-8674(93)80041-C	http://dx.doi.org/10.1016/0092-8674(93)80041-C			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8394217				2022-12-28	WOS:A1993LT73900001
J	TORRES, BA; GRIGGS, ND; JOHNSON, HM				TORRES, BA; GRIGGS, ND; JOHNSON, HM			BACTERIAL AND RETROVIRAL SUPERANTIGENS SHARE A COMMON BINDING REGION ON CLASS-II MHC ANTIGENS	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-A; MAMMARY-TUMOR VIRUS; HLA-DR; MOLECULES; PEPTIDES; SURFACE; CELLS	STAPHYLOCOCCAL enterotoxin A (SEA), one of the most potent T-cell mitogens known, has been classified as a bacterial superantigen on the basis of ability to stimulate Vbeta-specific T-cell subsets1. SEA interacts with class II major histocompatibility complex (MHC) antigens on antigen-presenting cells and the T-cell antigen receptor (TCR) on T cells2-4, resulting in a ternary complex of MHC-SEA-TCR. Mls antigens are known to be products of mouse mammary tumour virus (MMTV)5,6, and it has been reported that two exogenous strains of MMTV encode retroviral superantigens in the open reading frames of the 3' long terminal repeat of the viral genome7,8; however, no binding of the putative MMTV superantigen to either MHC antigens or TCR has been demonstrated. Here we use synthetic peptides to identify a site on the MMTV-1 superantigen that binds to class II MHC antigens. The site is encompassed by amino-acid residues 76-119 of the MMTV-1 superantigen. Direct binding and competition experiments show that the MMTV superantigen and SEA bind to at least one common region on class II MHC antigens.			TORRES, BA (corresponding author), UNIV FLORIDA,DEPT MICROBIOL & CELL SCI,GAINESVILLE,FL 32611, USA.							ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISCHER H, 1989, J IMMUNOL, V142, P3151; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GRIGGS ND, 1992, J IMMUNOL, V148, P2516; JOHNSON HM, 1991, FASEB J, V5, P2706, DOI 10.1096/fasebj.5.12.1916093; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LEE JM, 1990, J IMMUNOL, V145, P3360; MAGAZINE HI, 1988, P NATL ACAD SCI USA, V85, P1237, DOI 10.1073/pnas.85.4.1237; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PONTZER CH, 1991, P NATL ACAD SCI USA, V88, P125, DOI 10.1073/pnas.88.1.125; PONTZER CH, 1992, P NATL ACAD SCI USA, V89, P7727, DOI 10.1073/pnas.89.16.7727; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; RUSSELL JK, 1990, BIOCHEM BIOPH RES CO, V168, P696, DOI 10.1016/0006-291X(90)92377-C; RUSSELL JK, 1991, P NATL ACAD SCI USA, V88, P7228, DOI 10.1073/pnas.88.16.7228; SETTE A, 1989, J IMMUNOL, V142, P35; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R	22	32	33	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					152	154		10.1038/364152a0	http://dx.doi.org/10.1038/364152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8391645				2022-12-28	WOS:A1993LL36700051
J	PORTER, RK; BRAND, MD				PORTER, RK; BRAND, MD			BODY-MASS DEPENDENCE OF H+ LEAK IN MITOCHONDRIA AND ITS RELEVANCE TO METABOLIC-RATE	NATURE			English	Article							RELATIVE PROTON STOICHIOMETRIES; INNER MEMBRANE; LIVER-MITOCHONDRIA; PERMEABILITY; FORCE; CONDUCTANCE; PUMPS	THE standard metabolic rate of an animal is the rate of heat production under conditions that minimize known extra requirements for energy1,2. In tissues and cells from aerobic organisms, energy expenditure can conveniently be measured as oxygen consumption3,4. Measurements made using isolated rat hepatocytes have shown that a significant contribution to resting oxygen consumption (and hence heat production) is made by a futile cycle of proton pumping and proton leak across the mitochondrial inner membrane5. Two important factors affecting standard metabolic rate, thyroid status and phylogeny, also affect the proton permeability5-10. A third major factor affecting standard metabolic rate is body mass11,12. Here we show that proton leak decreases with increasing body mass in mammals. We suggest that differences in proton leak may partly explain the differences in standard metabolic rate between mammals of different mass.			PORTER, RK (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.		Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153; Porter, Richard/0000-0001-9854-5161				BLAXTER KL, 1989, ENERGY METABOLISM RU; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; BRAND MD, 1990, J THEOR BIOL, V145, P267, DOI 10.1016/S0022-5193(05)80131-6; BRAND MD, 1992, EUR J BIOCHEM, V206, P775, DOI 10.1111/j.1432-1033.1992.tb16984.x; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BRAND MD, 1992, EBEC SHORT REP, V7, P64; BRODY S, 1932, U MISSOURI AGR EXP S, V166, P89; BRODY S, 1951, BIOENERGETICS GROWTH; BROWN GC, 1989, J BIOL CHEM, V264, P14704; BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1059, P55, DOI 10.1016/S0005-2728(05)80187-2; Calder WA., 1984, SIZE FUNCTION LIFE H; ELSE PL, 1985, AM J PHYSIOL, V248, pR415, DOI 10.1152/ajpregu.1985.248.4.R415; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1989, FEBS LETT, V248, P175, DOI 10.1016/0014-5793(89)80455-7; HAFNER RP, 1991, BIOCHEM J, V275, P75, DOI 10.1042/bj2750075; HORRUM MA, 1990, MOL CELL ENDOCRINOL, V68, P137, DOI 10.1016/0303-7207(90)90186-C; Jansky L, 1965, ACTA U CAROL BIOL, V1, P1; Kleiber M, 1941, P SOC EXP BIOL MED, V48, P419, DOI 10.3181/00379727-48-13340; Kleiber M, 1961, FIRE LIFE; KLEIBER MAX, 1932, HILGARDIA, V6, P315; KREBS HA, 1950, BIOCHIM BIOPHYS ACTA, V4, P249, DOI 10.1016/0006-3002(50)90032-1; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; MITCHELL P, 1967, BIOCHEM J, V105, P1147, DOI 10.1042/bj1051147; NOBES CD, 1990, J BIOL CHEM, V265, P12903; SMITH RE, 1955, ANN NY ACAD SCI, V62, P403; [No title captured]	26	211	224	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					628	630		10.1038/362628a0	http://dx.doi.org/10.1038/362628a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8385274				2022-12-28	WOS:A1993KX43800046
J	BURSTIN, HR; JOHNSON, WG; LIPSITZ, SR; BRENNAN, TA				BURSTIN, HR; JOHNSON, WG; LIPSITZ, SR; BRENNAN, TA			DO THE POOR SUE MORE - A CASE-CONTROL STUDY OF MALPRACTICE CLAIMS AND SOCIOECONOMIC-STATUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE EVENTS; NEGLIGENCE	Objective.-To evaluate whether socioeconomic status is associated with risk of malpractice claims, particularly among those who have suffered medical injury. Design.-Case-control study. Setting.-Fifty-one hospitals in New York State. Methods.-The presence and severity of medical injury, defined as disability at the time of discharge or prolongation of the hospitalization caused by medical treatment as opposed to the disease process, were assessed through review of approximately 31 000 hospital records in New York in 1984. These sampled records were then linked to formal malpractice claims. To estimate the risk of malpractice claims by age, gender, race, insurance status, and income, we conducted a case-control study of claimant cases matched with nonclaimant controls. The cases were all those patients who filed malpractice claims referring to alleged malpractice during a sampled hospitalization. Physician reviewers had previously judged the level of disability that resulted from the medical injury. Claimants (n=51) were each matched with five nonclaimant controls on the basis of injury. Noninjured cases were matched with noninjured controls and injured cases were matched with injured controls. Results.-We found that poor patients (odds ratio [OR], 0.2; 95% confidence interval [CI], 0.03 to 0.8) and uninsured patients (OR, 0.1; 95% CI, 0.005 to 0.9) were significantly less likely to file malpractice claims, after controlling for the severity of medical injury. Among patients who suffered medical injury, the elderly (OR, 0.2; 95% CI, 0.03. to 0.9) were also less likely to file claims. Gender and race were not independently associated with risk of malpractice claims. Conclusions.-Poor and uninsured patients are significantly less likely to sue for malpractice, even after controlling for the presence of medical injury. Fear of malpractice risk should not be a significant factor in the decision to serve the poor. Tort reforms that would protect physicians who serve the medically indigent from malpractice suits may not be warranted.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; ARIZONA STATE UNIV,SCH HLTH ADM & POLICY,TEMPE,AZ 85287	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Arizona State University; Arizona State University-Tempe								BOUFFORD JI, 1986, COMMUNITY ORIENTED P; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1992, YALE L POLY REV, V10, P431; Breslow N, 1980, STATISTICAL METHODS, V32; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; BURSTIN HR, 1993, EC ANAL MED MALPRACT; HUGHES D, 1989, MED PROFESSIONAL LIA, V2, P59; LEWISIDEMA D, 1988, INCREASING PROVIDER; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MUSSMAN MG, 1991, JAMA-J AM MED ASSOC, V265, P2992, DOI 10.1001/jama.265.22.2992; SAGER M, 1990, ARCH INTERN MED, V150, P1091, DOI 10.1001/archinte.150.5.1091; SHAVELL S, 1989, JAMA-J AM MED ASSOC, V262, P1391; 1992, DO MEDICAID MEDICARE; 1984, STATEWIDE PLANNING R; 1992, HLTH LAWYERS NEWS RE; 1991, MED LIABILITY REFORM; 1987, MED MALPRACTICE CHAR; 1988, SURVEY PROFESSIONAL; 1984, 1984 SOURCEBOOK ZIP; 1989, MED PROFESSIONAL LIB; 1988, HOSPITAL SURVEY OBST	21	123	123	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1697	1701		10.1001/jama.270.14.1697	http://dx.doi.org/10.1001/jama.270.14.1697			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411499				2022-12-28	WOS:A1993MA29400025
J	GREEN, S				GREEN, S			IMMUNOAUGMENTATIVE THERAPY - AN UNPROVED CANCER-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GREEN, S (corresponding author), ZOL CONSULTANTS INC,340 W 57TH ST,SUITE 8J,NEW YORK,NY 10019, USA.				NCI NIH HHS [NCI 2R-44-CA-41953-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA041953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRY LJ, 1964, BACTERIAL ENDOTOXINS, P151; BURTON, 1980, COMMUNICATION   0518; BURTON L, 1962, T NEW YORK ACAD SCI, V25, P33, DOI 10.1111/j.2164-0947.1962.tb03512.x; BURTON L, 1980, Patent No. 4199497; BURTON L, 1988, L BURTONS IMMUNOAUGM; BURTON L, 1978, Patent No. 4082732; BURTON L, 1978, Patent No. 4082733; BURTON L, 1981, IAT BACKGROUND MATER, V1, P1; BURTON L, 1978, Patent No. 4076701; BURTON LAWRENCE, 1959, TRANS NEW YORK ACAD SCI, V21, P700; CURT GA, 1986, JAMA-J AM MED ASSOC, V255, P505, DOI 10.1001/jama.255.4.505; CURT GA, 1984, NEW ENGL J MED, V311, P859; DAVEY RT, 1992, AIDS ETIOLOGY DIAGNO, P141; FRIEDMAN F, 1962, T NEW YORK ACAD SCI, V25, P29, DOI 10.1111/j.2164-0947.1962.tb03511.x; FRIEDMAN F., 1965, PROC AMER ASS CANCER RES, V6, P20; FRIEDMAN F, 1957, CANCER RES, V17, P208; FRIEDMAN F, 1956, CANCER RES, V16, P1059; FRIEDMAN F, 1957, ANN NY ACAD SCI, V68, P349, DOI 10.1111/j.1749-6632.1957.tb56090.x; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; KASSEL R, 1962, T NEW YORK ACAD SCI, V25, P39, DOI 10.1111/j.2164-0947.1962.tb03513.x; KASSEL R, 1963, ANN NY ACAD SCI, V100, P791, DOI 10.1111/j.1749-6632.1963.tb42890.x; KINLEN LJ, 1982, CANCER EPIDEMIOL, P494; LAWRENCE HS, 1959, CELLULAR HUMORAL  ED, P529; Macfarlane Burnet F., 1970, IMMUNOLOGICAL SURVEI; MITCHELL HK, 1961, SCIENCE, V133, P876, DOI 10.1126/science.133.3456.876; MOSS R, 1993, CANCER CHRONICLES, V4, P7; MULLEREBERHARD HJ, 1970, HARVEY LECT, V66, P75; MULVANY JG, 1969, METHOD MICROBIOL, P205, DOI DOI 10.1016/50580-9517(08)70138-7; ONIGBINDE TA, 1992, CLIN CHEM PRINCIPLES, P104; PURTILO DT, 1983, J CLIN IMMUNOL, V3, P197, DOI 10.1007/BF00915343; STUTMAN O, 1973, ISRAEL J MED SCI, V9, P217; Stutman O., 1978, NUDE MOUSE EXPT CLIN, P411; STUTMAN O, 1989, NAT IMMUN, P479; TANFORD C, 1961, PHYSICAL CHEM MACROM, P89; THOMAS L, CITED INDIRECTLY; WILLETT HP, 1984, ZINSSER MICROBIOLOGY, P233; ZAVERTNIK JJ, 1991, DUBIOUS CANCER TREAT, P63; 1985, MMWR MORB MORTAL WKL, V34, P489; 1985, GUIDELINE STERILE DR; 1990, OTAH405 US C PUBL OF; 1980, MED WORLD NEWS  1124, P24	41	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1719	1723		10.1001/jama.270.14.1719	http://dx.doi.org/10.1001/jama.270.14.1719			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411503				2022-12-28	WOS:A1993MA29400029
J	KLEIN, R; SMEYNE, RJ; WURST, W; LONG, LK; AUERBACH, BA; JOYNER, AL; BARBACID, M				KLEIN, R; SMEYNE, RJ; WURST, W; LONG, LK; AUERBACH, BA; JOYNER, AL; BARBACID, M			TARGETED DISRUPTION OF THE TRKB NEUROTROPHIN RECEPTOR GENE RESULTS IN NERVOUS-SYSTEM LESIONS AND NEONATAL DEATH	CELL			English	Article							TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; EMBRYONIC STEM-CELLS; GROWTH-FACTOR FAMILY; SENSORY NEURONS; PROLIFERATION; MOTONEURONS; EXPRESSION; SURVIVAL; MUTATION	We have generated mice carrying a germline mutation in the tyrosine kinase catalytic domain of the trkB gene. This mutation eliminates expression of gp145trkB, a protein-tyrosine kinase that serves as the signaling receptor for two members of the nerve growth factor family of neurotrophins, brain-derived neurotrophic factor and neurotrophin-4. Mice homozygous for this mutation, trkB(TK) (-/-), develop to birth. However, these animals do not display feeding activity, and most die by P1. Neuroanatomical examination of trkB(TK) (-/-) mice revealed neuronal deficiencies in the central (facial motor nucleus and spinal cord) and peripheral (trigeminal and dorsal root ganglia) nervous systems. These findings illustrate the role of the gp145trkB protein-tyrosine kinase receptor in the ontogeny of the mammalian nervous system.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X5, ON, CANADA	Bristol-Myers Squibb; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Wurst, Wolfgang/0000-0003-4422-7410; Smeyne, Richard/0000-0002-8459-5472				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BARBACID M, 1993, ONCOGENE, V8, P2033; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EASTER SS, 1993, J NEUROSCI, V13, P285; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEDREEN JC, 1985, J HISTOCHEM CYTOCHEM, V33, P134, DOI 10.1177/33.2.2578498; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAMBALLE F, 1993, IN PRESS J NEUROSCI; LAMBALLE F, 1993, IN PRESS EMBO J, V13; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VOGEL KS, 1991, NEURON, V7, P819, DOI 10.1016/0896-6273(91)90284-7; WURST W, 1993, GENE TARGETING PRACT; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	50	579	585	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					113	122		10.1016/0092-8674(93)90683-H	http://dx.doi.org/10.1016/0092-8674(93)90683-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402890				2022-12-28	WOS:A1993MB66700012
J	MATSUYAMA, T; KIMURA, T; KITAGAWA, M; PFEFFER, K; KAWAKAMI, T; WATANABE, N; KUNDIG, TM; AMAKAWA, R; KISHIHARA, K; WAKEHAM, A; POTTER, J; FURLONGER, CL; NARENDRAN, A; SUZUKI, H; OHASHI, PS; PAIGE, CJ; TANIGUCHI, T; MAK, TW				MATSUYAMA, T; KIMURA, T; KITAGAWA, M; PFEFFER, K; KAWAKAMI, T; WATANABE, N; KUNDIG, TM; AMAKAWA, R; KISHIHARA, K; WAKEHAM, A; POTTER, J; FURLONGER, CL; NARENDRAN, A; SUZUKI, H; OHASHI, PS; PAIGE, CJ; TANIGUCHI, T; MAK, TW			TARGETED DISRUPTION OF IRF-1 OR IRF-2 RESULTS IN ABNORMAL TYPE-I IFN GENE INDUCTION AND ABERRANT LYMPHOCYTE DEVELOPMENT	CELL			English	Article							INTERFERON-BETA GENE; REGULATORY FACTOR-I; MEDIATE VIRUS INDUCIBILITY; T-CELLS; TRANSCRIPTIONAL ACTIVATOR; SIGNAL TRANSDUCTION; TRANSGENIC MICE; STEM-CELLS; EXPRESSION; MURINE	Interferon regulatory factor 1 (IRF-1), a transcriptional activator, and its antagonistic repressor, IRF-2, were originally identified as regulators of the type I interferon (IFN) system. We have generated mice deficient in either IRF-1 or IRF-2 by gene targeting in embryonic stem cells. IRF-1-deficient fibroblasts lacked the normally observed type I IFN induction by poly(I):poly(C), while they induced type I IFN to similar levels as the wild type following Newcastle disease virus (NDV) infection. In contrast, IRF-2-deficient fibroblasts showed up-regulated type I IFN induction by NDV infection. A profound reduction of TCRalphabeta+CD4-CD8+ T cells in IRF-1-deficient mice, with a thymocyte developmental defect, reveals a critical role for IRF-1 in T cell development. IRF-2-deficient mice exhibited bone marrow suppression of hematopoiesis and B lymphopoiesis and mortality following lymphocytic choriomeningitis virus infection.	UNIV TORONTO, DEPT IMMUNOL & MED BIOPHYS, ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Osaka University	MATSUYAMA, T (corresponding author), UNIV TORONTO, DEPT IMMUNOL & MED BIOPHYS, AMGEN INST, TORONTO M4X 1K9, ONTARIO, CANADA.		Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X; Ohashi, Pamela S./0000-0003-2915-9317; Kimura, Tohru/0000-0001-9227-0996; Pfeffer, Klaus/0000-0002-5652-6330				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AGUI T, 1991, EUR J IMMUNOL, V21, P2277, DOI 10.1002/eji.1830210942; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; Demaeyer E., 1988, INTERFERONS OTHER RE; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; EVERSON MP, 1990, CELL IMMUNOL, V127, P470, DOI 10.1016/0008-8749(90)90147-J; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FLENNIKEN AM, 1988, J VIROL, V62, P3077, DOI 10.1128/JVI.62.9.3077-3083.1988; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUPTA SC, 1986, P NATL ACAD SCI USA, V83, P2604, DOI 10.1073/pnas.83.8.2604; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HOGAN B, 1986, MANIPULATING MOUSE E; IVANOV V, 1992, INT IMMUNOL, V4, P729, DOI 10.1093/intimm/4.7.729; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEHMANNGRUBE F, 1982, MOUSE BIOMEDICAL RES, V2, P231; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEVY D, 1990, NEW BIOL, V2, P383; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NARENDRAN A, 1992, EUR J IMMUNOL, V22, P1001, DOI 10.1002/eji.1830220419; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P649, DOI 10.1002/eji.1830190412; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PAIGE CJ, 1983, NATURE, V302, P711, DOI 10.1038/302711a0; PAIGE CJ, 1982, J IMMUNOL METHODS, V52, P51, DOI 10.1016/0022-1759(82)90349-0; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; REYES AA, 1982, P NATL ACAD SCI-BIOL, V79, P3270, DOI 10.1073/pnas.79.10.3270; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; STEWART WE, 1971, J VIROL, V7, P792, DOI 10.1128/JVI.7.6.792-801.1971; STEWART WE, 1979, INTERFERON SYSTEM, P233; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VILCEK J, 1990, HDB EXPT PHARM, P3; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; YOSHITAKE I, 1986, NUCLEIC ACIDS RES, V14, P10117; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1992, CURR OPIN IMMUNOL, V4, P408, DOI 10.1016/S0952-7915(06)80031-2	76	568	578	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					83	97		10.1016/S0092-8674(05)80086-8	http://dx.doi.org/10.1016/S0092-8674(05)80086-8			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402903				2022-12-28	WOS:A1993MB66700010
J	LOWEY, S; WALLER, GS; TRYBUS, KM				LOWEY, S; WALLER, GS; TRYBUS, KM			SKELETAL-MUSCLE MYOSIN LIGHT-CHAINS ARE ESSENTIAL FOR PHYSIOLOGICAL SPEEDS OF SHORTENING	NATURE			English	Article							SCALLOP MYOSIN; HEAVY-CHAINS; ACTIN; SUBFRAGMENT-1; MICROSCOPY; ANTIBODIES; VELOCITY; BINDING; INVITRO; FIBERS	IN muscle each myosin head contains a regulatory light chain (LC2) that is wrapped around the head/rod junction, and an alkali light chain that is distal to LC2 (ref. 1). The role of these light chains in vertebrate skeletal muscle myosin has remained obscure2,3. Here we prepare heavy chains that are free of both light chains in order to determine by a motility assay4 whether the light chains are necessary for movement. We find that removal of light chains from myosin reduces the velocity of actin filaments from 8.8 mum s-1 to 0.8 mum s-1 without significantly decreasing the ATPase activity. Reconstitution of myosin with LC2 or alkali light chain increases filament velocity to intermediate rates, and readdition of both classes of light chains fully restores the original sliding velocity. We conclude that even though the light chains are not essential for enzymatic activity, light-chain/heavy-chain interactions play an important part in the conversion of chemical energy into movement.			LOWEY, S (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.							FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; LOWEY S, IN PRESS J BIOL CHEM; MOSS RL, 1982, J BIOL CHEM, V257, P8588; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SIVARAMAKRISHNAN M, 1982, J BIOL CHEM, V257, P1102; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	19	280	284	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					454	456		10.1038/365454a0	http://dx.doi.org/10.1038/365454a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413589				2022-12-28	WOS:A1993LZ63300060
J	FU, XY; ZHANG, JJ				FU, XY; ZHANG, JJ			TRANSCRIPTION FACTOR P91 INTERACTS WITH THE EPIDERMAL GROWTH-FACTOR RECEPTOR AND MEDIATES ACTIVATION OF THE C-FOS GENE PROMOTER	CELL			English	Article							DNA-BINDING PROTEINS; INTERFERON-ALPHA; SH3 DOMAINS; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; STIMULATED TRANSCRIPTION; CYTOPLASMIC ACTIVATION; PROTO-ONCOGENE; JUN ACTIVITY; IFN-GAMMA	Transcription factor p91 contains a SH2 domain and is activated by tyrosine phosphorylation. Here we demonstrate that epidermal growth factor (EGF) induces rapid tyrosine phosphorylation and nuclear translocation of p91. Through its SH2 domain, p91 directly interacts with the EGF receptor in a ligand-dependent manner. p91 is a necessary component of an EGF-induced DNA-binding factor that recognizes a previously identified regulatory element, SIE (c-sis-inducible element), in the c-fos gene promoter. Activated pg1 stimulates SIE-dependent transcription in vitro. Cotransfection of an SIE-containing reporter with a p91 expression vector shows that p91 is a positive transcriptional regulator of the c-fos gene promoter. These studies suggest that EGF uses a direct signaling pathway to control nuclear transcriptional events.			FU, XY (corresponding author), CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029, USA.							BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGANSE, 1993, NATURE, V363, P45; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HONIG H, 1991, NUCLEIC ACIDS RES, V11, P3607; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1990, CANCER BIOL, V1, P47; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	77	303	306	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1135	1145		10.1016/0092-8674(93)90734-8	http://dx.doi.org/10.1016/0092-8674(93)90734-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402883				2022-12-28	WOS:A1993LY49300019
J	TARTAGLIA, LA; AYRES, TM; WONG, GHW; GOEDDEL, DV				TARTAGLIA, LA; AYRES, TM; WONG, GHW; GOEDDEL, DV			A NOVEL DOMAIN WITHIN THE 55 KD TNF RECEPTOR SIGNALS CELL-DEATH	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; MONOCLONAL-ANTIBODIES; EXPRESSION; IDENTIFICATION; ACTIVATION; ANTIGEN; MUTAGENESIS; INDUCTION; APOPTOSIS	Deletion mutagenesis of the intracellular region of the 55 kd TNF receptor (TNF-R1) identified an approximately 80 amino acid domain near the C-terminus responsible for signaling cytotoxicity. This domain shows weak homology with the intracellular domain of Fas antigen, a transmembrane polypeptide that can also initiate a signal for cytotoxicity. Alanine-scanning mutagenesis of TNF-R1 confirmed that many of the amino acids conserved with Fas antigen are critical for the cytotoxic signal. This region of TNF-R1 -Fas homology is therefore likely to define a novel domain (death domain) that signals programed cell death. Mutations within the death domain of TNF-R1 also disrupted its ability to signal anti-viral activity and nitric oxide (NO) synthase induction. In addition, large deletions in the membrane-proximal half of the intracellular domain did not block signaling of cytotoxicity or anti-viral activity but did block induction of NO synthase.	GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	TARTAGLIA, LA (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.		Yang, Chen/G-1379-2010					BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1992, J IMMUNOL, V149, P3550	29	1196	1259	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					845	853		10.1016/0092-8674(93)90464-2	http://dx.doi.org/10.1016/0092-8674(93)90464-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8397073				2022-12-28	WOS:A1993LX29200010
J	NAMBA, T; SUGIMOTO, Y; NEGISHI, M; IRIE, A; USHIKUBI, F; KAKIZUKA, A; ITO, S; ICHIKAWA, A; NARUMIYA, S				NAMBA, T; SUGIMOTO, Y; NEGISHI, M; IRIE, A; USHIKUBI, F; KAKIZUKA, A; ITO, S; ICHIKAWA, A; NARUMIYA, S			ALTERNATIVE SPLICING OF C-TERMINAL TAIL OF PROSTAGLANDIN-E RECEPTOR SUBTYPE-EP3 DETERMINES G-PROTEIN SPECIFICITY	NATURE			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BOVINE ADRENAL-MEDULLA; PERTUSSIS TOXIN; THROMBOXANE-A2 RECEPTOR; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; EXPRESSION; CLONING; REGIONS; CDNA	PEPTIDE hormones, neurotransmitters, and autacoids activate a family of seven-transmembrane-domain receptors1. Each of these receptors specifically couples to one of several G proteins, G(s), G(i), G(o) and G(p), to activate a specific second messenger system2. Cell surface receptors for prostanoids have been characterized pharmacologically3 and the complementary DNAs for thromboxane A2 receptor4,5 and the EP3 subtype of the prostaglandin (PG)E receptor6 reveal that they belong to the seven-transmembrane-domain receptor family. The EP3 receptor mediates the diverse physiological actions of PGE2 (ref. 3). Although most of them occur through coupling of the EP3 receptor to G(i) and inhibition of adenylyl cyclase, the EP3-mediated contraction of uterine muscle can only occur by activation of another second messenger pathway7. In chromaffin cells, two different second messenger pathways are activated by PGE2 binding to an apparently single EP3 receptor class8. Here we show that at least four isoforms of the EP3 receptor, which differ only at their C-terminal tails and are produced by alternative splicing, couple to different G proteins to activate different second messenger systems.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAESTHESIA,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 606,JAPAN; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Kyoto University; Kyoto University; Kyoto University			Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; FONG TM, 1992, MOL PHARMACOL, V41, P24; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GOUREAU O, 1992, AM J PHYSIOL, V263, pC257, DOI 10.1152/ajpcell.1992.263.1.C257; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; ITO S, 1991, J NEUROCHEM, V56, P531, DOI 10.1111/j.1471-4159.1991.tb08182.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W	30	533	544	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					166	170		10.1038/365166a0	http://dx.doi.org/10.1038/365166a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8396726				2022-12-28	WOS:A1993LW44200050
J	WILCOX, M; GARDOSI, J; MONGELLI, M; RAY, C; JOHNSON, I				WILCOX, M; GARDOSI, J; MONGELLI, M; RAY, C; JOHNSON, I			BIRTH-WEIGHT FROM PREGNANCIES DATED BY ULTRASONOGRAPHY IN A MULTICULTURAL BRITISH POPULATION	BRITISH MEDICAL JOURNAL			English	Article							LAST MENSTRUAL PERIOD; GESTATIONAL-AGE; BIPARIETAL DIAMETER; ULTRASOUND; GROWTH	Objective-To produce standard curves of birth weight according to gestational age validated by ultrasonography in the British population, with particular reference to the effects of ethnic origin. Design-Retrospective analysis of computerised obstetric database. Setting-Three large maternity units associated with Nottingham University with over 16 000 deliveries a year. Patients-41718 women with ultrasound dated singleton pregnancies and delivery between 168 and 300 days' gestation. Main outcome measures-Length of gestation, ethnic origin, parity, maternal height and weight at booking, smoking during pregnancy; the effect of these variables on birth weight. Results-Birth weights from ultrasound dated pregnancies have a higher population mean and show less flattening of the birthweight curve at term than those of pregnancies dated from menstrual history. Significant differences were observed in mean birth weights of babies of mothers of European origin (3357 g), of Afro-Carribean origin (3173 g), and from the Indian subcontinent (3096 g). There were also significant interethnic differences in length of gestation, parity, maternal height, booking weight, and smoking habit which affected birth weight. The ethnic differences in birth weight were even greater when the effect of smoking was excluded. Conclusions-Birthweight standards require precise dating of pregnancy and should describe the population from which they were derived. In a heterogeneous maternity population the accurate assessment of an individual baby's weight needs to take the factors which affect birthweight standards into consideration.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				ANDERSON HR, 1990, P S EFFECTS SMOKING; CAMPBELL S, 1971, J OBSTET GYN BR COMM, V78, P513; CAMPBELL S, 1985, OBSTET GYNECOL, V65, P613; CAMPBELL S, 1984, REPORT RCOG WORKING; CARHILL R, 1985, DERIVATION EXPLOITAT; CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1, P48; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; GEIRSSON RT, 1991, ULTRASOUND OBST GYN, V1, P212, DOI 10.1046/j.1469-0705.1991.01030212.x; GEIRSSON RT, 1991, BRIT J OBSTET GYNAEC, V98, P108, DOI 10.1111/j.1471-0528.1991.tb10323.x; GRUNDY MFB, 1978, BRIT J OBSTET GYNAEC, V85, P481, DOI 10.1111/j.1471-0528.1978.tb15618.x; Hall M H, 1990, Paediatr Perinat Epidemiol, V4, P123, DOI 10.1111/j.1365-3016.1990.tb00625.x; HALL MH, 1985, BRIT J OBSTET GYNAEC, V92, P452, DOI 10.1111/j.1471-0528.1985.tb01348.x; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; PERSSON PH, 1983, AM J OBSTET GYNECOL, V146, P942, DOI 10.1016/0002-9378(83)90970-5; PERSSON PH, 1989, FETAL GROWTH, P13; ROBINSON HP, 1975, BRIT J OBSTET GYNAEC, V82, P702, DOI 10.1111/j.1471-0528.1975.tb00710.x; ROEMER VM, 1990, Z GEBURTSH PERINATOL, V194, P241; THOMSON A M, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P903; WALDENSTROM U, 1990, OBSTET GYNECOL, V76, P336; WEINER CP, 1985, OBSTET GYNECOL, V65, P323; WILCOX MA, 1993, BRIT J OBSTET GYNAEC, V100, P342, DOI 10.1111/j.1471-0528.1993.tb12977.x; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5; 1988, STATISTICAL PACKAGE	23	155	157	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					588	591		10.1136/bmj.307.6904.588	http://dx.doi.org/10.1136/bmj.307.6904.588			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401014	Bronze, Green Published			2022-12-28	WOS:A1993LW14900014
J	LI, R; BOTCHAN, MR				LI, R; BOTCHAN, MR			THE ACIDIC TRANSCRIPTIONAL ACTIVATION DOMAINS OF VP16 AND P53 BIND THE CELLULAR REPLICATION PROTEIN-A AND STIMULATE INVITRO BPV-1 DNA-REPLICATION	CELL			English	Article							HERPES-SIMPLEX VIRUS; EMBRYONAL CARCINOMA-CELLS; SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; SV40 ORIGIN; YEAST GAL4; T-ANTIGEN; WILD-TYPE; INITIATION	For papillomavirus DNA replication, the E2 enhancer protein cooperatively assists in binding of the E1 helicase to the origin. We report that, at limiting E1 and E2 levels, the enhancer proteins GAL4-VP16 and GAL4-p53(1-73) stimulate BPV in vitro DNA replication. This cell-free system was used to ascertain whether the acidic activation domains have a cellular target important for replication. Cellular extracts were depleted of replication activity by passage through a VP16 affinity column. The protein depleted was the cellular factor replication protein A. The direct interaction between replication protein A and VP16, as well as the activation of replication by VP16, is dependent upon the C-terminus of the VP16 activation domain. E2 and the activation domain of p53 also interact with replication protein A. We suggest that a link between transcription and replication involves factors that help convert a closed DNA complex to an open complex.			LI, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NCI NIH HHS [CA 42414, CA 30490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030490, R01CA042414, R37CA030490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHANG LS, 1990, J VIROL, V64, P2103, DOI 10.1128/JVI.64.5.2103-2109.1990; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANGMAN WL, 1992, CELL, V71, P3632; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FUJIMURA FK, 1982, P NATL ACAD SCI-BIOL, V79, P1479, DOI 10.1073/pnas.79.5.1479; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HANDA H, 1983, NATURE, V302, P545, DOI 10.1038/302545a0; HEINTZ N H, 1992, Current Opinion in Cell Biology, V4, P459, DOI 10.1016/0955-0674(92)90012-2; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATINKA M, 1981, NATURE, V290, P720, DOI 10.1038/290720a0; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KLESSIG DF, 1979, CELL, V17, P957, DOI 10.1016/0092-8674(79)90335-0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEBOWSKI J, 1985, NATURE, V317, P169; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MULLER WJ, 1988, MOL CELL BIOL, V8, P5000, DOI 10.1128/MCB.8.11.5000; NILSSON M, 1991, NUCLEIC ACIDS RES, V19, P7061, DOI 10.1093/nar/19.25.7061; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKIKAWA K, 1981, P NATL ACAD SCI-BIOL, V78, P1100, DOI 10.1073/pnas.78.2.1100; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SPALHOLZ BA, 1993, VIROLOGY, V193, P201, DOI 10.1006/viro.1993.1116; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEINBERG D, 1991, P NATL ACAD SCI USA, V87, P8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG SW, 1991, J VIROL, V65, P2601, DOI 10.1128/JVI.65.5.2601-2611.1991; YANG L, 1991, COLD SPRING HARB SYM, V56, P335; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	95	322	322	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1207	1221		10.1016/0092-8674(93)90649-B	http://dx.doi.org/10.1016/0092-8674(93)90649-B			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8390328				2022-12-28	WOS:A1993LH54800016
J	BRUGGE, JS				BRUGGE, JS			NEW INTRACELLULAR TARGETS FOR THERAPEUTIC DRUG DESIGN	SCIENCE			English	Article							PROTEINS				BRUGGE, JS (corresponding author), ARIAD PHARMACEUT INC,26 LANDSDOWNE ST,CAMBRIDGE,MA 02139, USA.							BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; JACOBS G, 1990, New Biologist, V2, P583; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	12	102	110	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					918	919		10.1126/science.8388123	http://dx.doi.org/10.1126/science.8388123			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8388123				2022-12-28	WOS:A1993LB79100030
J	LANDWEBER, LF; GILBERT, W				LANDWEBER, LF; GILBERT, W			RNA EDITING AS A SOURCE OF GENETIC-VARIATION	NATURE			English	Article							POLYMERASE CHAIN-REACTION; OXIDASE SUBUNIT-III; SINGLE-STRANDED-DNA; TRYPANOSOMA-BRUCEI; MAXICIRCLE DNA; NUCLEOTIDE-SEQUENCE; NADH DEHYDROGENASE	KINETOPLASTID RNA editing alters mitochondrial RNA transcripts by addition and deletion of uridine residues1, producing open reading frames that may be twice as long as the original RNA2. Although the COIII gene encoding cytochrome c oxidase subunit III in Trypanosoma brucei is edited along its entire length2, the presumably homologous genes in two related trypanosomes, Leishmania tarentolae and Crithidia fasciculata, are only modestly edited at their 5' ends1. We used a comparative approach to investigate the evolution of an edited gene and to determine how well editing creates conserved protein sequences. As RNA editing probably involves the pairing of several guide RNA molecules with the messenger RNA3,4, We expected the edited proteins to be resistant to evolutionary change. Here we report that RNA editing is extensive in the mitochondria of four species of the insect parasite Herpetomonas, which is possibly an evolutionary precursor of T. brucei and L. tarentolae5, and the discovery that RNA editing is a novel source ot frameshift mutations over evolutionary time. The edited proteins accumulate mutations nearly twice as rapidly as the unedited versions.			LANDWEBER, LF (corresponding author), HARVARD UNIV,BIOL LABS,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELACRUZ VF, 1984, J BIOL CHEM, V259, P5136; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; KREITMAN M, 1989, GENE ANAL TECH, V6, P84, DOI 10.1016/0735-0651(89)90021-6; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SLOOF P, 1987, NUCLEIC ACIDS RES, V15, P51, DOI 10.1093/nar/15.1.51; VOLLOCH V, 1991, P NATL ACAD SCI USA, V88, P10671, DOI 10.1073/pnas.88.23.10671; YOUNG IG, 1981, EUR J BIOCHEM, V116, P165, DOI 10.1111/j.1432-1033.1981.tb05314.x	16	51	53	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					179	182		10.1038/363179a0	http://dx.doi.org/10.1038/363179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8387160				2022-12-28	WOS:A1993LB80100053
J	KUNZ, J; HENRIQUEZ, R; SCHNEIDER, U; DEUTERREINHARD, M; MOVVA, NR; HALL, MN				KUNZ, J; HENRIQUEZ, R; SCHNEIDER, U; DEUTERREINHARD, M; MOVVA, NR; HALL, MN			TARGET OF RAPAMYCIN IN YEAST, TOR2, IS AN ESSENTIAL PHOSPHATIDYLINOSITOL KINASE HOMOLOG REQUIRED FOR G(1) PROGRESSION	CELL			English	Article							CELL-CYCLE ARREST; COLONY-STIMULATING FACTOR; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; MACROLIDES FK-506; CATALYTIC SUBUNIT; MATING-PHEROMONE; ESCHERICHIA-COLI	The yeast TOR2 gene encodes an essential 282 kd phosphatidylinositol (PI) 3-kinase homolog. TOR2 is related to the catalytic subunit of bovine PI 3-kinase and to yeast VPS34, a vacuolar sorting protein also shown to have PI 3-kinase activity. The immunosuppressant rapamycin most likely acts by inhibiting PI kinase activity because TOR2 mutations confer resistance to rapamycin and because a TOR1 TOR2 double disruption (TOR1 is a nonessential TOR2 homolog) confers G1 arrest, as does rapamycin. Our results further suggest that 3-phosphorylated phosphoinositides, whose physiological significance has not been determined, are an important signal in cell cycle activation. In yeast, this signal may act in a signal transduction pathway similar to the interleukin-2 signal transduction pathway in T cells.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz	KUNZ, J (corresponding author), UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND.			Hall, Michael N/0000-0002-2998-0757				ARIMA N, 1992, J IMMUNOL, V149, P83; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11149; CARTER BLA, 1980, GENETICS, V96, P561; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOOR F, 1992, NATURE, V360, P682; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO H, 1989, J BIOL CHEM, V264, P3116; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MASLINSKI W, 1992, J BIOL CHEM, V267, P15281; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; THEVELEIN JM, 1992, MOL BIOL SACCHAROMYC, P109; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	91	713	842	1	41	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					585	596		10.1016/0092-8674(93)90144-F	http://dx.doi.org/10.1016/0092-8674(93)90144-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387896				2022-12-28	WOS:A1993LA74300018
J	MARAIS, R; WYNNE, J; TREISMAN, R				MARAIS, R; WYNNE, J; TREISMAN, R			THE SRF ACCESSORY PROTEIN ELK-1 CONTAINS A GROWTH FACTOR-REGULATED TRANSCRIPTIONAL ACTIVATION DOMAIN	CELL			English	Article							SERUM-RESPONSE ELEMENT; C-FOS EXPRESSION; KINASE-C; TERNARY COMPLEX; RAS PROTEIN; CELLS; JUN; PHOSPHORYLATION; SEQUENCE; SIGNALS	The Elk-1 and SRF transcription factors form a ternary complex at the c-fos serum response element (SRE). Growth factor stimulation rapidly induces a reversible change in the electrophoretic mobility of the ternary complex, accompanied by increased phosphorylation of the Elk-1 C-terminal region and by the activation of a 42 kd cellular Elk-1 kinase. Phosphorylation of Elk-1 in vitro by partially purified p42/p44 MAP kinase induces a similar reduction in ternary complex mobility but has little effect on the efficiency of its formation. In vitro, MAP kinase phosphorylates the Elk-1 C-terminal region at multiple sites, which are also phosphorylated following growth factor stimulation in vivo. The Elk-1 C-terminal region functions as a regulated transcriptional activation domain whose activity in vivo is dependent on the integrity of the MAP kinase sites. These findings directly link transcriptional activation by the SRE to the growth factor-regulated phosphorylation of an SRE-binding protein.	IMPERIAL CANC RES FUND, TRANSCRIPT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Treisman, Richard/0000-0002-9658-0067; Marais, Richard/0000-0001-7484-4183				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAURSEN RA, 1989, METHODS PROTEIN SEQU, P61; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PATEL G, 1992, NUCLEIC ACIDS RES, V20, P97, DOI 10.1093/nar/20.1.97; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	57	1189	1212	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					381	393		10.1016/0092-8674(93)90237-K	http://dx.doi.org/10.1016/0092-8674(93)90237-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8386592				2022-12-28	WOS:A1993KY50500018
J	COHEN, RB; ABDALLAH, JM; GRAY, JR; FOSS, F				COHEN, RB; ABDALLAH, JM; GRAY, JR; FOSS, F			REVERSIBLE NEUROLOGIC TOXICITY IN PATIENTS TREATED WITH STANDARD-DOSE FLUDARABINE PHOSPHATE FOR MYCOSIS-FUNGOIDES AND CHRONIC LYMPHOCYTIC-LEUKEMIA	ANNALS OF INTERNAL MEDICINE			English	Note						LEUKEMIA, LYMPHATIC, CHRONIC; MYCOSIS FUNGOIDES; FLUDARABINE PHOSPHATE; CENTRAL NERVOUS SYSTEM DISEASES; NEUROLOGIC MANIFESTATIONS	NERVOUS-SYSTEM TOXICITY; PHASE-I	Fludarabine phosphate is approved for the treatment of advanced B-cell chronic lymphocytic leukemia refractory to alkylating agents. We report two cases of disabling but reversible neurotoxicity in a patient with mycosis fungoides and a patient with chronic lymphocytic leukemia who received standard doses of fludarabine (20 to 25 mg m2 per day for 5 days) every 28 days for 6 to 8 cycles). Serial brain magnetic resonance imaging scans in the patient with mycosis fungoides showed rapid evolution of white-matter changes with subsequent complete resolution.	NCI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COHEN, RB (corresponding author), USN, NATL NAVAL MED CTR, NCI, MED ONCOL BRANCH, BETHESDA, MD 20889 USA.							CHUN HG, 1986, CANCER TREAT REP, V70, P1225; HOCHSTER HS, 1992, J CLIN ONCOL, V10, P28, DOI 10.1200/JCO.1992.10.1.28; KEATING MJ, 1991, J CLIN ONCOL, V9, P44, DOI 10.1200/JCO.1991.9.1.44; MERKEL DE, 1986, CANCER TREAT REP, V70, P1449; PUCCIO CA, 1991, J CLIN ONCOL, V9, P1562, DOI 10.1200/JCO.1991.9.9.1562; SPRIGGS DR, 1986, CANCER RES, V46, P5953; VONHOFF DD, 1990, SEMIN ONCOL, V17, P33; WARRELL RP, 1986, J CLIN ONCOL, V4, P74, DOI 10.1200/JCO.1986.4.1.74; WHELAN JS, 1991, BRIT J CANCER, V64, P120, DOI 10.1038/bjc.1991.253	9	46	47	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					114	116		10.7326/0003-4819-118-2-199301150-00007	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416307				2022-12-28	WOS:A1993KF91800007
J	JANES, CH; LINDOR, KD				JANES, CH; LINDOR, KD			OUTCOME OF PATIENTS HOSPITALIZED FOR COMPLICATIONS AFTER OUTPATIENT LIVER-BIOPSY	ANNALS OF INTERNAL MEDICINE			English	Article						BIOPSY, NEEDLE; AMBULATORY SURGERY; AMBULATORY CARE; LIVER DISEASES; HOSPITALIZATION		Objective: To determine the safety of outpatient liver biopsies by analyzing the outcome of patients hospitalized for complications. Design: Retrospective review. Setting: Large clinic referral center. Patients: All patients admitted after outpatient liver biopsy at the Mayo Clinic from 1 April 1989 to 1 April 1991. Results: During this period, 405 outpatients underwent biopsy. Of the 405 patients, 13 (3.2%) were admitted with complications after biopsy. Five patients (38%) were admitted with persistent localized pain, five (38%) with orthostatic hypotension, one (8%) with both pain and hypotension, one (8%) with peritoneal signs, and one (8%) with lightheadedness but no orthostatic changes. All complications were noted within 3 hours after the biopsy. Bleeding, potentially the most serious complication, was radiographically defined in 5 of the 13 patients (38%) admitted. Only two patients, however, required blood transfusions. No patient required invasive management such as surgery or chest tube placement. The average length of the hospital stay was 1.5 days. Conclusion: Complications after outpatient liver biopsy occur early and rarely require invasive management. Outpatient liver biopsy is safe when done on carefully selected patients in a setting that provides close observation for at least 3 hours after liver biopsy.	MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA	Mayo Clinic								HEGARTY JE, 1984, BRIT MED J, V288, P1254, DOI 10.1136/bmj.288.6426.1254; JACOBS WH, 1989, DIGEST DIS SCI, V34, P322, DOI 10.1007/BF01536249; KNAUER CM, 1978, GASTROENTEROLOGY, V74, P101; MCGILL DB, 1990, GASTROENTEROLOGY, V99, P1396, DOI 10.1016/0016-5085(90)91167-5; PERRAULT J, 1978, GASTROENTEROLOGY, V74, P103; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; TERRY R, 1952, BRIT MED J, V1, P1102, DOI 10.1136/bmj.1.4768.1102; ZAMCHECK N, 1953, NEW ENGL J MED, V249, P1062, DOI 10.1056/NEJM195312242492605; 1990, MEDICARE NATIONAL DA	9	237	245	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					96	98		10.7326/0003-4819-118-2-199301150-00003	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00003			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416324				2022-12-28	WOS:A1993KF91800003
J	RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ				RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ			A PROSPECTIVE-STUDY OF LIPOPROTEIN(A) AND THE RISK OF MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; LP(A) LIPOPROTEIN; ARTERY DISEASE; SERUM LIPOPROTEIN(A); APOLIPOPROTEIN-B; PREDICTIVE VALUE; MEN; ASSOCIATION	Objective.-To assess prospectively the risk of myocardial infarction (MI) associated with elevated levels of lipoprotein(a) (Lp[a]). Design.-Nested case-control study using prospectively collected plasma samples. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 14 916 male physicians aged 40 to 84 years with no prior history of MI or stroke provided plasma samples at baseline and were followed up prospectively for an average period of 60.2 months. Samples from 296 physicians who subsequently developed MI were analyzed for Lp(a) level together with paired controls, matched for smoking status and age. Main Outcome Measure.-Fatal or nonfatal acute MI. Results.-The distribution of Lp(a) level among cases was virtually identical to that of controls (P=.88), and there was no significant difference between groups for median Lp(a) levels (103.0 mg/L vs 102.5 mg/L; P=.73). In analyses controlling for age and smoking status, we found no evidence of association between increasing level of Lp(a) and risk of MI (relative risks from lowest to highest quintiles of Lp(a): 1.00, 0.97, 0.83, 0.88, and 1.07; P for trend=.93) or a threshold effect at any pre-specified cutoff of Lp(a) level (relative risks associated with Lp[a] levels above the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution, respectively: 1.04, 1.00, 1.19, 1.00, and 1.07; all P values nonsignificant). Further adjustment for both lipid and nonlipid cardiovascular risk factors had no material impact. Conclusions.-In this prospective study of predominantly middle-aged white men, we found no evidence of association between Lp(a) level and risk of future MI. These data do not support the use of Lp(a) level as a screening tool to define cardiovascular risk among this population.	BRIGHAM & WOMENS HOSP,DEPT PEDIAT,DIV CARDIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PEDIAT,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DIV AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1977, J LIPID RES, V18, P331; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BERG K, 1974, CLIN GENET, V6, P230; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; CRAIG WY, 1992, ATHEROSCLEROSIS, V93, P261, DOI 10.1016/0021-9150(92)90264-H; DAHLEN G, 1975, CLIN GENET, V7, P334; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DURRINGTON PN, 1988, LANCET, V1, P1070; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; HAFFNER SM, 1992, METABOLISM, V41, P194, DOI 10.1016/0026-0495(92)90152-Z; HEARN JA, 1990, AM J CARDIOL, V66, P1176, DOI 10.1016/0002-9149(90)91094-M; HOEFLER G, 1988, ARTERIOSCLEROSIS, V8, P398, DOI 10.1161/01.ATV.8.4.398; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JAUHIAINEN M, 1990, 55TH M EUR ATH SOC B, P42; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KOSTNER GM, 1992, CLIN CHIM ACTA, V211, P191, DOI 10.1016/0009-8981(92)90196-W; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P671; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MENSINK RP, 1992, J LIPID RES, V33, P1493; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; OLOFSSON BO, 1989, EUR HEART J, V10, P77; PARRA HJ, 1987, CLIN CHIM ACTA, V167, P27; PEARSON T, 1990, CIRCULATION, V82, pA475; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SLUNGA L, 1992, SCAND J CLIN LAB INV, V52, P95, DOI 10.3109/00365519209088771; SRINIVASAN SR, 1991, CIRCULATION, V84, P160, DOI 10.1161/01.CIR.84.1.160; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; [No title captured]; 1971, ISCHEMIC HEART DISEA	37	447	454	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2195	2199		10.1001/jama.270.18.2195	http://dx.doi.org/10.1001/jama.270.18.2195			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411602				2022-12-28	WOS:A1993ME81600030
J	DORIG, RE; MARCIL, A; CHOPRA, A; RICHARDSON, CD				DORIG, RE; MARCIL, A; CHOPRA, A; RICHARDSON, CD			THE HUMAN CD46 MOLECULE IS A RECEPTOR FOR MEASLES-VIRUS (EDMONSTON STRAIN)	CELL			English	Article							MEMBRANE COFACTOR PROTEIN; MONOCLONAL-ANTIBODIES; COMPLEMENT ACTIVATION; FUSION; BINDING; LYMPHOCYTES; REPLICATION; SYSTEM; GENE; MCP	Measles virus normally causes disease in human beings, and the host range of this virus may be determined by a specific receptor on the surface of primate cells. Human-rodent somatic cell hybrids were tested for their ability to bind measles virus, and only cells that contained human chromosome 1 were capable of binding virus. A study of lymphocyte markers suggested that the complement regulator known either as membrane cofactor protein or CD46 was the measles virus receptor. We proved this hypothesis by demonstrating that hamster cell lines that expressed human CD46 could subsequently bind virus. Furthermore, infected CD46+ cells produced syncytia and viral proteins. Finally, polyclonal antisera against CD46 inhibited virus binding and infection. These results prove that human CD46 permits cells both to bind measles virus and to support infection.	MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University	DORIG, RE (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,6100 ROYALM AVE,MONTREAL H4P 2R2,PQ,CANADA.			Marcil, Anne/0000-0002-4111-1781				ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P268; ALBRECHT P, 1980, INFECT IMMUN, V25, P969; ALKHATIB G, 1986, VIROLOGY, V150, P479, DOI 10.1016/0042-6822(86)90312-0; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BELLINI WJ, 1979, J GEN VIROL, V43, P633, DOI 10.1099/0022-1317-43-3-633; BILLETER MA, 1991, PARAMYXOVIRUSES, P323; Blake FG, 1921, J EXP MED, V33, P385, DOI 10.1084/jem.33.3.385; BRINCKMANN UG, 1991, J GEN VIROL, V72, P2491, DOI 10.1099/0022-1317-72-10-2491; CARRIGAN DR, 1986, VIROLOGY, V148, P349, DOI 10.1016/0042-6822(86)90331-4; CHO SW, 1991, CLIN EXP IMMUNOL, V83, P257; ENDERS JF, 1962, AM J DIS CHILD, V103, P335, DOI 10.1001/archpedi.1962.02080020347030; ENDERS JF, 1962, AM J DIS CHILD, V103, P473, DOI 10.1001/archpedi.1962.02080020485066; EY PL, 1986, METHOD ENZYMOL, V121, P497; FONG TM, 1993, NATURE, V362, P350; Fraser K. B., 1978, MEASLES VIRUS ITS BI; GASTEL B, 1973, Journal of the History of Medicine and Allied Sciences, V28, P34; GRAVES MC, 1978, VIROLOGY, V86, P254, DOI 10.1016/0042-6822(78)90025-9; HARROWE G, 1990, J CLIN INVEST, V85, P1324, DOI 10.1172/JCI114571; HARROWE G, 1992, CELL MOL NEUROBIOL, V12, P397, DOI 10.1007/BF00711541; HILLEMAN MR, 1968, J AMER MED ASSOC, V206, P587, DOI 10.1001/jama.206.3.587; HSI BL, 1988, AM J REPROD IMMUNOL, V18, P21; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; JOSEPH BS, 1975, J VIROL, V16, P1638, DOI 10.1128/JVI.16.6.1638-1649.1975; KATZ SL, 1958, P SOC EXP BIOL MED, V97, P23, DOI 10.3181/00379727-97-23637; KNIGHT P, 1972, J VIROL, V10, P995, DOI 10.1128/JVI.10.5.995-1001.1972; KOHNO S, 1968, JPN J MED SCI BIOL, V21, P301, DOI 10.7883/yoken1952.21.301; KORENBERG JR, 1987, AM J HUM GENET, V41, P963; KRAH DL, 1989, VIROLOGY, V172, P386, DOI 10.1016/0042-6822(89)90147-5; KRAH DL, 1988, J VIROL, V62, P1565, DOI 10.1128/JVI.62.5.1565-1572.1988; LEVY JA, 1986, SCIENCE, V232, P998, DOI 10.1126/science.3010461; LIEBERT UG, 1987, J GEN VIROL, V68, P1715, DOI 10.1099/0022-1317-68-6-1715; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LISZEWSKI MK, 1992, CURR TOP MICROBIOL I, V178, P47; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAKINO S, 1970, JPN J MICROBIOL, V14, P501; MARKWELL MAK, 1990, PAROMYXOVIRUSES, P407; MOORE MD, 1991, J VIROL, V65, P3559, DOI 10.1128/JVI.65.7.3559-3565.1991; MORGAN EM, 1977, BACTERIOL REV, V41, P636, DOI 10.1128/MMBR.41.3.636-666.1977; MUSSER SJ, 1962, AM J DIS CHILD, V103, P476, DOI 10.1001/archpedi.1962.02080020488068; NANICHE D, 1993, J GEN VIROL, V74, P1073, DOI 10.1099/0022-1317-74-6-1073; NANICHE D, 1992, J GEN VIROL, V73, P2617, DOI 10.1099/0022-1317-73-10-2617; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; NORRBY E, 1971, VIROLOGY, V44, P594; Norrby E., 1990, VIROLOGY, P1013; NORRBY ERLING, 1962, ARCH GES VIRUSFORSCH, V12, P164, DOI 10.1007/BF01258127; OHUCHI R, 1984, MICROBIOL IMMUNOL, V28, P757, DOI 10.1111/j.1348-0421.1984.tb00731.x; PERIES JR, 1960, CR HEBD ACAD SCI, V251, P820; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; PURCELL DFJ, 1991, IMMUNOGENETICS, V33, P335, DOI 10.1007/BF00216692; RICHARDSON C, 1986, VIROLOGY, V155, P508, DOI 10.1016/0042-6822(86)90212-6; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; ROTA JS, 1992, VIROLOGY, V188, P135, DOI 10.1016/0042-6822(92)90742-8; SCHUMACHER HP, 1972, ARCH GES VIRUSFORSCH, V36, P296, DOI 10.1007/BF01249860; SERGEL T, 1993, VIROLOGY, V193, P717, DOI 10.1006/viro.1993.1180; SEYA T, 1988, EUR J IMMUNOL, V18, P1289, DOI 10.1002/eji.1830180821; SHAVER DOROTHY N., 1964, ARCH GESAMTE VIRUSFORSCH, V14, P487, DOI 10.1007/BF01555080; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; VALDIMARSSON H, 1975, NATURE, V255, P554, DOI 10.1038/255554a0; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WEISS R, 1992, SCIENCE, V258, P546, DOI 10.1126/science.1329205; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILD TF, 1991, J GEN VIROL, V72, P435	63	844	878	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					295	305		10.1016/0092-8674(93)80071-L	http://dx.doi.org/10.1016/0092-8674(93)80071-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402913				2022-12-28	WOS:A1993MD88500011
J	LUO, YL; RAIBLE, D; RAPER, JA				LUO, YL; RAIBLE, D; RAPER, JA			COLLAPSIN - A PROTEIN IN BRAIN THAT INDUCES THE COLLAPSE AND PARALYSIS OF NEURONAL GROWTH CONES	CELL			English	Article							POSTERIOR TECTAL MEMBRANES; PIONEER AXON MIGRATIONS; NEURAL CELL-ADHESION; RAT SPINAL-CORD; IMMUNOGLOBULIN SUPERFAMILY; NEURITE GROWTH; C-ELEGANS; RETINAL AXONS; FASCICLIN-II; GUIDES CELL	Repulsive guidance cues can steer neuronal growth cones during development and prevent mature axons from regenerating. We have identified a 100 kd glycoprotein in the chick brain that is a good candidate for a repulsive cue. Since it induces the collapse and paralysis of neuronal growth cones in vitro, we have named it collapsin. It is effective at concentrations of approximately 10 pM. The C-terminal half of collapsin contains a single immunoglobulin-like domain and an additional highly basic region. The N-terminal half of collapsin shares significant homology with fasciclin IV, a growth cone guidance protein in grasshopper. Recombinant collapsin causes sensory ganglion growth cones to collapse but not retinal ganglion cell growth cones. We propose that collapsin could serve as a ligand that guides specific growth cones by a motility-inhibiting mechanism.			LUO, YL (corresponding author), UNIV PENN, SCH MED, DEPT NEUROSCI, PHILADELPHIA, PA 19104 USA.			Raible, David/0000-0002-5342-5841				Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAWCETT JW, 1989, J CELL SCI, V92, P93; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; IVINS JK, 1991, J NEUROSCI, V11, P1597; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P1595; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; MOORMAN SJ, 1990, J NEUROSCI, V10, P3158; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; RAPER JA, 1990, EXP NEUROL, V109, P70, DOI 10.1016/S0014-4886(05)80009-3; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; Tessier-Lavigne M, 1992, Curr Opin Neurobiol, V2, P60, DOI 10.1016/0959-4388(92)90163-F; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; TSAO MC, 1982, J CELL PHYSIOL, V110, P219, DOI 10.1002/jcp.1041100217; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER J, 1987, DEVELOPMENT, V101, P909; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	54	987	1032	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					217	227		10.1016/0092-8674(93)80064-L	http://dx.doi.org/10.1016/0092-8674(93)80064-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402908	hybrid			2022-12-28	WOS:A1993MD88500004
J	CHAO, NJ; SCHMIDT, GM; NILAND, JC; AMYLON, MD; DAGIS, AC; LONG, GD; NADEMANEE, AP; NEGRIN, RS; ODONNELL, MR; PARKER, PM; SMITH, EP; SNYDER, DS; STEIN, AS; WONG, RM; BLUME, KG; FORMAN, SJ				CHAO, NJ; SCHMIDT, GM; NILAND, JC; AMYLON, MD; DAGIS, AC; LONG, GD; NADEMANEE, AP; NEGRIN, RS; ODONNELL, MR; PARKER, PM; SMITH, EP; SNYDER, DS; STEIN, AS; WONG, RM; BLUME, KG; FORMAN, SJ			CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; TERM FOLLOW-UP; RETROSPECTIVE ANALYSIS; CONTROLLED TRIAL; T-CELLS; LEUKEMIA; PREVENTION; RECIPIENTS; DEPLETION; REGIMEN	Background. Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of GVHD. Methods. One hundred fifty patients with either acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, or lymphoblastic lymphoma in first complete remission were enrolled in the study. All the patients were given fractionated total-body irradiation (1320 cGy) and etoposide (60 mg per kilogram of body weight) in preparation for transplantation, and received bone marrow from genotypically histocompatible donors. To prevent GVHD, they were randomly assigned to prophylactic treatment with either cyclosporine, methotrexate, and prednisone or cyclosporine and prednisone without methotrexate. All the patients received standardized supportive care after transplantation, including intravenous gamma globulin. Results. Patients receiving cyclosporine, methotrexate, and prednisone had a significantly lower incidence of acute GVHD of grades II to IV (9 percent) than those receiving cyclosporine and prednisone (23 percent, P = 0.02). Multivariate regression analysis demonstrated that an increased risk of acute GVHD was associated with an elevated serum creatinine concentration (P = 0.006) and treatment with cyclosporine and prednisone alone (P = 0.02). The lower incidence of acute GVHD was not associated with a higher rate of relapse of leukemia or lymphoma. There was no significant difference in disease-free survival at three years between the two treatment groups (64 percent with the three-drug regimen vs. 59 percent with the two-drug regimen, P = 0.57). Conclusions. The combination of cyclosporine, methotrexate, and prednisone was more effective in preventing acute GVHD of grades II to IV than was the combination of cyclosporine and prednisone without methotrexate.	STANFORD UNIV, BONE MARROW TRANSPLANT PROGRAM, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA; CITY HOPE NATL MED CTR, DEPT HEMATOL & BONE MARROW TRANSPLANTAT, DUARTE, CA 91010 USA; CITY HOPE NATL MED CTR, DEPT BIOSTAT, DUARTE, CA 91010 USA	Stanford University; Stanford University; City of Hope; City of Hope					NATIONAL CANCER INSTITUTE [P01CA030206, P01CA049605] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49605, CA-30206] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTAULTPERES P, 1989, TRANSPLANT P, V21, P904; BLUME, 1987, BLOOD, V69, P1789; BLUME KG, 1993, BLOOD, V81, P2187; BLUME KG, 1987, BLOOD, V69, P1015; CHAO NJ, 1991, BLOOD, V78, P1923; DEEG HJ, 1985, BLOOD, V65, P1325, DOI 10.1182/blood.V65.6.1325.bloodjournal6561325; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MARANINCHI D, 1987, LANCET, V2, P175; MARTIN PJ, 1990, BLOOD, V76, P1464, DOI 10.1182/blood.V76.8.1464.1464; MARTIN PJ, 1991, BLOOD, V77, P1821; MARTIN PJ, 1985, BLOOD, V66, P664; NASH RA, 1992, BLOOD, V80, P1838; OREILLY RJ, 1985, TRANSPLANT P, V17, P455; RAMSAY NKC, 1982, NEW ENGL J MED, V306, P392, DOI 10.1056/NEJM198202183060703; Santos G., 1987, CLIN TRANSPLANT, V1, P21; SANTOS GW, 1985, EXP HEMATOL, V13, P427; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SCHMIDT GM, 1993, TRANSPLANTATION, V55, P551, DOI 10.1097/00007890-199303000-00018; STORB R, 1990, BLOOD, V76, P1037; STORB R, 1985, IMMUNOL REV, V88, P215, DOI 10.1111/j.1600-065X.1985.tb01160.x; STORB R, 1988, BLOOD, V71, P293; STORB R, 1986, BLOOD, V68, P119; STORB R, 1989, BLOOD, V73, P1729; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; TUTSCHKA PJ, 1987, BLOOD, V70, P1382	28	228	228	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1225	1230		10.1056/NEJM199310213291703	http://dx.doi.org/10.1056/NEJM199310213291703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8413388				2022-12-28	WOS:A1993MB98800003
J	NYGAARD, B; HEGEDUS, L; GERVIL, M; HJALGRIM, H; SOEJENSEN, P; HANSEN, JM				NYGAARD, B; HEGEDUS, L; GERVIL, M; HJALGRIM, H; SOEJENSEN, P; HANSEN, JM			RADIOIODINE TREATMENT OF MULTINODULAR NONTOXIC GOITER	BRITISH MEDICAL JOURNAL			English	Article							NONTOXIC GOITER; RADIOACTIVE IODINE; THYROID SIZE; THYROXINE TREATMENT; THERAPY; HYPERTHYROIDISM; NODULES; AGE; SEX	Objective-To investigate the long term effect of radioactive iodine on thyroid function and size in patients with non-toxic multinodular goitre. Design-Consecutive patients with multinodular non-toxic goitre selected for radioactive iodine treatment and followed for a minimum of 12 months (median 48 months) after an intended dose of 3.7 MBq/g thyroid tissue corrected to a 100% uptake of iodine-131 in 24 hours. Patients-69 patients with a growing multinodular non-toxic goitre causing local compression symptoms or cosmetic inconveniences. The treatment was chosen because of a high operative risk, previous thyroidectomy, or refusal to be operated on. Main outcome measurements-Standard thyroid function variables and ultrasonically determined thyroid volume before treatment as well as 1, 2, 3, 6, and 12 months after treatment and then once a year. Results-56 patients were treated with a single dose of I-131, 12 with two doses, and one with four doses. In 45 patients treated with one dose and remaining euthyroid the median thyroid volume was reduced from 73 (interquartile range 50-106) ml to 29 (23-48) ml at 24 months in the 39 patients in whom this was measured during follow up. The median reduction was 40 (22-48) ml (60% reduction, p<0.0001), half of which occurred within three months. Patients treated with two doses as well as those developing hypothyroidism and hyperthyroidism had a significant reduction in thyroid volume. Eleven patients developed hypothyroidism (cumulative five year risk 22%, 95% confidence interval 4.8% to 38.4%). Side effects were few: three cases of hyperthyroidism and two cases of radiation thyroiditis. Only one patient was dissatisfied with the result; she was referred for operation six months after treatment. Conclusions-A substantial reduction in thyroid volume accompanied by a low incidence of hypothyroidism and few side effects makes the use of radioactive iodine an attractive alternative to surgery in selected cases of non-toxic multinodular goitre.	ODENSE UNIV HOSP,DEPT INTERNAL MED & ENDOCRINOL M,DK-5000 ODENSE,DENMARK; HERLEV UNIV HOSP,DEPT INTERNAL MED & ENDOCRINOL,DK-2730 HERLEV,DENMARK; HERLEV UNIV HOSP,DEPT ULTRASOUND,DK-2730 HERLEV,DENMARK	University of Southern Denmark; Odense University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital			Hjalgrim, Henrik/AAG-4973-2021	Nygaard, Birte/0000-0002-9540-4950				AGERBAEK H, 1988, Ugeskrift for Laeger, V150, P533; BEAHRS OH, 1963, SURG GYNECOL OBSTET, V117, P535; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; FARRAR JJ, 1991, CLIN ENDOCRINOL, V35, P207, DOI 10.1111/j.1365-2265.1991.tb03523.x; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; HAAS V, 1988, ACTA ENDOCRINOL-COP, V119, P125, DOI 10.1530/acta.0.1190125; HALL P, 1992, LANCET, V340, P1; HANSEN JM, 1975, ACTA ENDOCRINOL-COP, V79, P60, DOI 10.1530/acta.0.0790060; HEGEDUS L, 1986, LANCET, V2, P339; HEGEDUS L, 1988, BRIT MED J, V297, P661, DOI 10.1136/bmj.297.6649.661; HEGEDUS L, 1986, ACTA ENDOCRINOL-COP, V113, P226, DOI 10.1530/acta.0.1130226; HEGEDUS L, 1987, BRIT MED J, V294, P801, DOI 10.1136/bmj.294.6575.801; HEGEDUS L, 1983, J CLIN ENDOCR METAB, V56, P260, DOI 10.1210/jcem-56-2-260; HEGEDUS L, 1986, AM J OBSTET GYNECOL, V155, P142, DOI 10.1016/0002-9378(86)90098-0; HEGEDUS L, 1986, LANCET, V2, P876; HEGEDUS L, 1991, THYROID S1, V1, P2; HOLLANDER M, 1973, NONPARAMETRIC STAT, P147; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; JARLOV AE, 1992, CLIN ENDOCRINOL, V37, P335, DOI 10.1111/j.1365-2265.1992.tb02334.x; KAY TWH, 1988, AM J MED, V84, P19, DOI 10.1016/0002-9343(88)90003-4; KEIDERLING W, 1964, DEUT MED WOCHENSCHR, V89, P453, DOI 10.1055/s-0028-1111038; KLEIN B, 1989, NUKLEARMED, V28, P129; PERRILD H, 1982, ACTA ENDOCRINOL-COP, V100, P382, DOI 10.1530/acta.0.1000382; VERELST J, 1990, ACTA ENDOCRINOL-COP, V122, P417, DOI 10.1530/acta.0.1220417	25	123	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					828	832		10.1136/bmj.307.6908.828	http://dx.doi.org/10.1136/bmj.307.6908.828			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401123	Green Published, Bronze			2022-12-28	WOS:A1993MA29300018
J	HEYDUK, T; LEE, JC; EBRIGHT, YW; BLATTER, EE; ZHOU, YH; EBRIGHT, RH				HEYDUK, T; LEE, JC; EBRIGHT, YW; BLATTER, EE; ZHOU, YH; EBRIGHT, RH			CAP INTERACTS WITH RNA-POLYMERASE IN SOLUTION IN THE ABSENCE OF PROMOTER DNA	NATURE			English	Article							AMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; LAC PROMOTER; FLUORESCENCE POLARIZATION; RIBOSOMAL-SUBUNITS; BINDING; ACTIVATOR; MUTANTS; REGION	PROTEIN-PROTEIN interactions between transcription activator proteins and RNA polymerase or basal transcription factors have been suggested to be important for transcription activation1-8. Interactions between catabolite gene activator protein (CAP)9,10 and RNA polymerase have been proposed based on face-of-helix-dependent transcription activation by CAP11-13 and based on face-of-helix-dependent cooperative binding of CAP and RNA polymerase to promoter DNA14,15. Mutants of CAP specifically defective in transcription activation have been isolated (mutants defective in transcription activation, but not defective in DNA binding and DNA bending16-19). All such mutants contain amino-acid substitutions within a surface loop consisting of amino acids 152 to 166 of CAP16-19. Here we use the thermodynamically rigorous technique of fluorescence polarization20-23 to show that CAP interacts with RNA polymerase in solution in the absence of promoter DNA (K(D,app) = 2.8 x 10(-7) M), whereas [Ala158]CAP, a mutant of CAP specifically defective in transcription activation, does not.	RUTGERS UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855; RUTGERS UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Texas System; University of Texas Medical Branch Galveston			Ebright, Richard/O-3321-2019; Lee, James C/A-7849-2009	Ebright, Richard/0000-0001-8915-7140; 				BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BENTLEY K L, 1985, Biotechniques, V3, P356; BLAZY B, 1980, MOL BIOL REP, V6, P39, DOI 10.1007/BF00775753; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; FRANCOIS JC, 1989, P NATL ACAD SCI USA, V86, P9702, DOI 10.1073/pnas.86.24.9702; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Ishihama A, 1990, Adv Biophys, V26, P19, DOI 10.1016/0065-227X(90)90005-E; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MANDECKI W, 1984, GENE, V31, P263, DOI 10.1016/0378-1119(84)90219-1; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REN YL, 1988, P NATL ACAD SCI USA, V85, P4138, DOI 10.1073/pnas.85.12.4138; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; WEIEL J, 1982, J BIOL CHEM, V257, P1215; WEIEL J, 1981, BIOCHEMISTRY-US, V20, P5859, DOI 10.1021/bi00523a032; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J	30	75	75	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					548	549		10.1038/364548a0	http://dx.doi.org/10.1038/364548a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393148				2022-12-28	WOS:A1993LQ66700061
J	MARKS, DI; CULLIS, JO; WARD, KN; LACEY, S; SZYDLO, R; HUGHES, TP; SCHWARER, AP; LUTZ, E; BARRETT, AJ; HOWS, JM; BATCHELOR, JR; GOLDMAN, JM				MARKS, DI; CULLIS, JO; WARD, KN; LACEY, S; SZYDLO, R; HUGHES, TP; SCHWARER, AP; LUTZ, E; BARRETT, AJ; HOWS, JM; BATCHELOR, JR; GOLDMAN, JM			ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA USING SIBLING AND VOLUNTEER UNRELATED DONORS - A COMPARISON OF COMPLICATIONS IN THE 1ST 2 YEARS	ANNALS OF INTERNAL MEDICINE			English	Article						TRANSPLANTATION, HOMOLOGOUS; BONE MARROW TRANSPLANTATION; LEUKEMIA, MYELOID, CHRONIC; TISSUE DONORS; HLA ANTIGENS	CHRONIC MYELOGENOUS LEUKEMIA; T-CELL DEPLETION; CHRONIC PHASE; CYTOMEGALOVIRUS-INFECTION; HOST-DISEASE; RELAPSE; GANCICLOVIR; GRAFT; RISK	Objective: To compare the short- and medium-term complications (particularly infection) of bone marrow transplantation for chronic myeloid leukemia in patients with HLA-identical sibling donors or volunteer unrelated donors. Design: Retrospective review of two cohorts of patients. Setting: Tertiary referral center. Patients: One hundred three patients with chronic myeloid leukemia in first chronic phase. Intervention: Patients were treated with bone marrow transplantation using marrow from HLA-identical siblings (n = 57) and volunteer donors (n = 46). Main Results: In total, 68 patients survived a median of 22 months from bone marrow transplant (range, 7 to 81 months). The actuarial probabilities of overall survival and leukemia-free survival at 2 years for the sibling donor group were 73% (95% CI, 60% to 86%) and 72% (CI, 60% to 84%), respectively, and for the volunteer donor group, 47% (CI, 31% to 63%) and 42% (CI, 26% to 58%) (P = 0.07 and 0.05, respectively). However, after adjustment for duration of disease, overall and disease-free survival in the two donor groups did not differ significantly. A major problem was an increased incidence of severe viral infection in the volunteer unrelated donor group (19 episodes in 16 of 46 patients compared with 7 episodes in 7 of 57 sibling donor patients, P = 0.01). The actuarial incidence of chronic graft-versus-host disease (GVHD) was higher in volunteer unrelated donor patients (77% [CI, 63% to 91%] compared with 49% [CI, 35% to 63%]; P = 0.02) but that of acute GVHD was not. The median performance status of the survivors in the volunteer donor group is similar to that in the sibling donor group. The incidence of hematologic relapse in both groups so far is low. Conclusion: Results appear to justify the continued use of volunteer donors in chronic-phase chronic myeloid leukemia, but infection and chronic GVHD are still major problems.	HAMMERSMITH HOSP, LONDON W12 0HS, ENGLAND	Imperial College London			Szydlo, Richard/C-6678-2012; Hughes, Tim/AAO-9975-2021	Szydlo, Richard/0000-0003-1102-8298; 				APPERLEY JF, 1986, BONE MARROW TRANSPL, V1, P53; ARTHUR CK, 1988, BLOOD, V71, P1179; ASH RC, 1990, NEW ENGL J MED, V322, P485, DOI 10.1056/NEJM199002223220801; ATKINSON K, 1991, BRIT J HAEMATOL, V79, P57, DOI 10.1111/j.1365-2141.1991.tb08007.x; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BIDWELL JL, 1988, TRANSPLANTATION, P1049; Breslow N, 1980, STATISTICAL METHODS, V32; COX DR, 1972, J R STAT SOC B, V34, P187; CULLIS JO, 1992, BLOOD, V79, P1379; CULLIS JO, 1992, BRIT J HAEMATOL, V81, P378, DOI 10.1111/j.1365-2141.1992.tb08243.x; CULLIS JO, 1992, BRIT J HAEMATOL, V80, P33, DOI 10.1111/j.1365-2141.1992.tb06397.x; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GOOLDEN AWG, 1983, BRIT J RADIOL, V56, P245, DOI 10.1259/0007-1285-56-664-245; GRIFFITHS PD, 1984, LANCET, V2, P1242; KALBFLEISCH JD, 1976, STATISTICAL ANAL FAI; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MACKINNON S, 1990, EXP HEMATOL, V18, P421; MARKS DI, 1992, BONE MARROW TRANSPL, V10, P463; MARKS DI, 1992, BRIT J HAEMATOL, V81, P383, DOI 10.1111/j.1365-2141.1992.tb08244.x; MCINTOSH K, 1984, AM J DIS CHILD, V138, P305, DOI 10.1001/archpedi.1984.02140410083024; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; VANBEKKUM DW, 1975, EXP HEMATOL, V3, P149; WALDMANN H, 1985, ADV EXP MED BIOL, V186, P869; YANG SY, 1989, IMMUNOBIOLOGY HLA, V1, P332	30	202	206	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					207	214		10.7326/0003-4819-119-3-199308010-00005	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8391772				2022-12-28	WOS:A1993LU90300005
J	GALE, NW; KAPLAN, S; LOWENSTEIN, EJ; SCHLESSINGER, J; BARSAGI, D				GALE, NW; KAPLAN, S; LOWENSTEIN, EJ; SCHLESSINGER, J; BARSAGI, D			GRB2 MEDIATES THE EGF-DEPENDENT ACTIVATION OF GUANINE-NUCLEOTIDE EXCHANGE ON RAS	NATURE			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR; INSULIN; P21RAS; GENE; STIMULATION; MUTATION; PRODUCTS; FAMILY; CELLS	ACTIVATION of receptor tyrosine kinases such as those for epidermal growth factor (EGF), platelet-derived growth factor, or nerve growth factor converts the inactive, GDP-bound form of Ras to the active, GTP-bound form1-4, and a dominant negative mutant of Ras interferes with signalling from such receptors5-8. The mechanisms by which receptor tyrosine kinases and Ras are coupled, however, are not well understood. Many cytoplasmic proteins regulated by such receptors contain Src-homology (SH) 2 and 3 domains, and the SH2- and SH3-containing protein Grb2, like its homologue from Caenorhabditis elegans, Sem-5, appears to play an important role in the control of Ras by receptor tyrosine kinases9-11. Here we show that overexpression of Grb2 potentiates the EGF-induced activation of Ras and mitogen-activated protein kinase by enhancing the rate of guanine nucleotide exchange on Ras. Cellular Grb2 appears to form a complex with a guanine-nucleotide-exchange factor for Ras, which binds to the ligand-activated EGF receptor, allowing the tyrosine kinase to modulate Ras activity.	COLD SPRING HARBOR LAB,1 BUNGTOWN RD,BOX 100,COLD SPRING HARBOR,NY 11724; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Cold Spring Harbor Laboratory; New York University				Bar-Sagi, Dafna/0000-0003-2597-8948				BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; POLAKIS P, 1992, CANCER SURV, V12, P25; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUZAKISADCOCK M, 1992, NATURE, V360, P689; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	30	561	583	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					88	92		10.1038/363088a0	http://dx.doi.org/10.1038/363088a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8386805				2022-12-28	WOS:A1993LA68200067
J	CAMACHO, P; LECHLEITER, JD				CAMACHO, P; LECHLEITER, JD			INCREASED FREQUENCY OF CALCIUM WAVES IN XENOPUS-LAEVIS OOCYTES THAT EXPRESS A CALCIUM-ATPASE	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; CA-2+ ATPASE; RELEASE; OSCILLATIONS; STORES; MUSCLE; PROPAGATION	When inositol 1,4,5-trisphosphate (IP3) receptors are activated, calcium is released from intracellular stores in excitatory propagating waves that annihilate each other upon collision. The annihilation phenomenon suggests the presence of an underlying refractory period that controls excitability. Enhanced calcium-adenosine triphosphatase (ATPase) activity might alter the refractory period of calcium release. Expression of messenger RNA encoding the avian calcium-ATPase (SERCA1) in Xenopus laevis oocytes increased the frequency of IP3-induced calcium waves and narrowed the width of individual calcium waves. The effect of SERCA1 expression on calcium wave frequency was dependent on the concentration of IP3 and was larger at higher (1 muM) than at lower (0.1 muM) concentrations of IP3. The results demonstrate that calcium pump activity can control IP3-mediated calcium signaling.			CAMACHO, P (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA.							ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; DOCKERY JD, 1988, PHYSICA D, V30, P177, DOI 10.1016/0167-2789(88)90105-4; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1992, J BIOL CHEM, V267, P18776; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARKINS AB, 1991, BIOPHYS J, V59, P240; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MILLER RN, 1981, BIOPHYS J, V34, P227, DOI 10.1016/S0006-3495(81)84847-3; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; RAPP PE, 1981, J EXP BIOL, V93, P119; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Winfree A.T., 1987, TIME BREAKS 3 DIMENS; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0	47	147	147	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1993	260	5105					226	229		10.1126/science.8385800	http://dx.doi.org/10.1126/science.8385800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8385800				2022-12-28	WOS:A1993KW45200042
J	PAI, LH				PAI, LH			IMMUNOTOXIN THERAPY FOR CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN OVARIAN-CANCER; RICIN-A CHAIN; PSEUDOMONAS EXOTOXIN; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; DIPHTHERIA-TOXIN; MOUSE MODEL; RECEPTOR; DOMAINS; CELLS				PAI, LH (corresponding author), NCI,MOLEC BIOL LAB,BLDG 37,ROOM 4E16,BETHESDA,MD 20892, USA.							ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1989, P NATL ACAD SCI USA, V86, P8545, DOI 10.1073/pnas.86.21.8545; BLAKEY DC, 1987, CANCER RES, V47, P947; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; FITZGERALD DJ, 1986, P NATL ACAD SCI USA, V83, P6627, DOI 10.1073/pnas.83.17.6627; FRANKEL AE, 1989, IMMUNOTOXINS; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONDO T, 1988, J BIOL CHEM, V263, P9470; OGATA M, 1990, J BIOL CHEM, V265, P20678; OLSNES S, 1985, ENDOCYTOSIS, P195; PAI LH, 1991, P NATL ACAD SCI USA, V88, P3358, DOI 10.1073/pnas.88.8.3358; PAI LH, 1991, J CLIN ONCOL, V9, P2095, DOI 10.1200/JCO.1991.9.12.2095; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1991, CANCER RES, V51, P3781; PASTAN I, 1992, ANN REV BIOCH S, V61, pK31; PIATAK M, 1988, J BIOL CHEM, V263, P4837; THORPE PE, 1988, CANCER RES, V48, P6393; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WILLINGHAM MC, 1987, P NATL ACAD SCI USA, V84, P2474, DOI 10.1073/pnas.84.8.2474	26	52	61	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					78	81		10.1001/jama.269.1.78	http://dx.doi.org/10.1001/jama.269.1.78			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416411				2022-12-28	WOS:A1993KF02600032
J	LEWIS, EJ; HUNSICKER, LG; BAIN, RP; ROHDE, RD				LEWIS, EJ; HUNSICKER, LG; BAIN, RP; ROHDE, RD			THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN-DEPENDENT DIABETICS; TERM ANTIHYPERTENSIVE TREATMENT; KIDNEY-FUNCTION; GLOMERULAR GROWTH; CAPTOPRIL; PROTEINURIA; MICROALBUMINURIA; MACROMOLECULES; HYPERTENSION; PROGRESSION	Background. Renal function declines progressively in patients who have diabetic nephropathy, and the decline may be slowed by antihypertensive drugs. The purpose of this study was to determine whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy. Methods. We performed a randomized, controlled trial comparing captopril with placebo in patients with insulin-dependent diabetes mellitus in whom urinary protein excretion was greater-than-or-equal-to 500 mg per day and the serum creatinine concentration was less-than-or-equal-to 2.5 mg per deciliter (221 mumol per liter). Blood-pressure goals were defined to achieve control during a median follow-up of three years. The primary end point was a doubling of the base-line serum creatinine concentration. Results. Two hundred seven patients received captopril, and 202 placebo. Serum creatinine concentrations doubled in 25 patients in the captopril group, as compared with 43 patients in the placebo group (P = 0.007). The associated reductions in risk of a doubling of the serum creatinine concentration were 48 percent in the captopril group as a whole, 76 percent in the subgroup with a baseline serum creatinine concentration of 2.0 mg per deciliter (177 mumol per liter), 55 percent in the subgroup with a concentration of 1.5 mg per deciliter (133 mumol per liter), and 17 percent in the subgroup with a concentration of 1.0 mg per deciliter (88.4 mumol per liter). The mean (+/- SD) rate of decline in creatinine clearance was 11 +/- 21 percent per year in the captopril group and 17 +/- 20 percent per year in the placebo group (P = 0.03). Among the patients whose base-line serum creatinine concentration was greater-than-or-equal-to 1.5 mg per deciliter, creatinine clearance declined at a rate of 23 +/- 25 percent per year in the captopril group and at a rate of 37 +/- 25 percent per year in the placebo group (P = 0.01). Captopril treatment was associated with a 50 percent reduction in the risk of the combined end points of death, dialysis, and transplantation that was independent of the small disparity in blood pressure between the groups. Conclusions. Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.	UNIV IOWA,DEPT MED,IOWA CITY,IA; GEORGE WASHINGTON UNIV,CTR BIOSTAT,WASHINGTON,DC 20052	University of Iowa; George Washington University	LEWIS, EJ (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,NEPHROL SECT,1653 W CONGRESS PKY,CHICAGO,IL 60612, USA.				NCRR NIH HHS [MO1-RR00030] Funding Source: Medline; NIDDK NIH HHS [5 R01-DK 39908, 5 R01-DK 39826] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039908, R01DK039826] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1989, KIDNEY INT, V36, P526, DOI 10.1038/ki.1989.227; BAIN R, 1992, J AM SOC NEPHROL, V3, pS97; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BJORCK S, 1986, BMJ-BRIT MED J, V293, P471, DOI 10.1136/bmj.293.6545.471; CHRISTLIEB AR, 1981, DIABETES, V30, P90; Cochran W.G, 1957, STAT METHODS, V6th ed; Cox DR., 1970, ANAL BINARY DATA; FOGO A, 1989, SEMIN NEPHROL, V9, P329; FOGO A, 1990, KIDNEY INT, V38, P1068, DOI 10.1038/ki.1990.314; HOMMEL E, 1986, BMJ-BRIT MED J, V293, P467, DOI 10.1136/bmj.293.6545.467; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEHMANN EL, 1975, NONPARAMETRICS; LIN DY, 1991, J AM STAT ASSOC, V86, P725, DOI 10.2307/2290404; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MEHTA C, 1991, STATXACT STATISTICAL; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; PARVING HH, 1985, HYPERTENSION, V7, P114; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1989, BMJ-BRIT MED J, V299, P533, DOI 10.1136/bmj.299.6698.533; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PRAGA M, 1992, AM J KIDNEY DIS, V20, P240, DOI 10.1016/S0272-6386(12)80696-2; REMUZZI A, 1990, J CLIN INVEST, V85, P541, DOI 10.1172/JCI114470; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WEI LJ, 1984, J AM STAT ASSOC, V79, P653, DOI 10.2307/2288413; Wei LJ, 1989, CONTROL CLIN TRIALS, V10, P126; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; 1985, SAS USERS GUIDE STAT	35	4387	4478	2	182	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1456	1462		10.1056/NEJM199311113292004	http://dx.doi.org/10.1056/NEJM199311113292004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413456				2022-12-28	WOS:A1993MF29200004
J	GREENGOLD, NL				GREENGOLD, NL			A VACATION FIT FOR A DOG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2148	2148		10.1001/jama.270.18.2148	http://dx.doi.org/10.1001/jama.270.18.2148			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411583				2022-12-28	WOS:A1993ME81600001
J	KAUFMAN, DS; SHIPLEY, WU; GRIFFIN, PP; HENEY, NM; ALTHAUSEN, AF; EFIRD, JT				KAUFMAN, DS; SHIPLEY, WU; GRIFFIN, PP; HENEY, NM; ALTHAUSEN, AF; EFIRD, JT			SELECTIVE BLADDER PRESERVATION BY COMBINATION TREATMENT OF INVASIVE BLADDER-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSITIONAL CELL-CARCINOMA; ADJUVANT CHEMOTHERAPY; CISPLATIN; RADIOTHERAPY; METHOTREXATE; VINBLASTINE; TRIAL; DOXORUBICIN; IRRADIATION; MANAGEMENT	Background. For patients with invasive bladder cancer the usual recommended treatment is radical cystectomy, although transurethral resection of the tumor, systemic chemotherapy, and radiotherapy are each effective in some patients. We sought to determine whether these treatments in combination might be as effective as radical cystectomy and thus might allow the bladder to be preserved and the cancer cured. Methods. We enrolled 53 consecutive patients with muscle-invading bladder cancer (stages T2 through T4, NXMO) in a trial of transurethral surgery, combination chemotherapy, and irradiation (4000 cGy) with concurrent cisplatin administration. Urologic evaluation of the tumor response directed further therapy: radical cystectomy in the 8 patients who had incomplete responses, additional chemotherapy and radiotherapy (6480 cGy) in the 34 patients who had complete responses or who were unsuited for cystectomy, and alternative care in the 11 patients who could not tolerate either irradiation or chemotherapy. Results. After a median follow-up of 48 months, 24 of the 53 patients (45 percent) were alive and free of detectable tumor. In 31 patients (58 percent) the bladder was free of invasive tumor and functioning well, even though in 9 (17 percent) a superficial tumor recurred and required further transurethral surgery and intravesical drug therapy. Of the 28 patients who had complete responses after initial treatment, 89 percent had functioning tumor-free bladders. Conclusions. Conservative combination treatment may be an acceptable alternative to immediate cystectomy in selected patients with bladder cancer, although a randomized clinical trial that included a group for simultaneous comparison would be required to produce definitive results.	MASSACHUSETTS GEN HOSP, DEPT RADIAT ONCOL, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT UROL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	KAUFMAN, DS (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, DEPT MED ONCOL, FRUIT ST, BOSTON, MA 02114 USA.				NATIONAL CANCER INSTITUTE [R03CA056381] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56381-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOOM HJG, 1982, BRIT J UROL, V54, P136, DOI 10.1111/j.1464-410X.1982.tb13537.x; COPPIN C, 1992, P AN M AM SOC CLIN, V11, P198; COX DR, 1972, J R STAT SOC B, V34, P187; FUNG CY, 1991, J CLIN ONCOL, V9, P1533, DOI 10.1200/JCO.1991.9.9.1533; HALL RR, 1991, EJC SUPPL, V27, pS29; HARKER WG, 1985, J CLIN ONCOL, V3, P1463, DOI 10.1200/JCO.1985.3.11.1463; HENRY K, 1988, J UROLOGY, V140, P964, DOI 10.1016/S0022-5347(17)41899-4; HERR HW, 1987, J UROLOGY, V138, P1162, DOI 10.1016/S0022-5347(17)43535-X; HUG EB, 1992, J UROLOGY, V148, P47, DOI 10.1016/S0022-5347(17)36505-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; LOGOTHETIS C, 1988, P AN M AM SOC CLIN, V7, P134; PROUT GR, 1990, J UROLOGY, V144, P1128, DOI 10.1016/S0022-5347(17)39674-X; PROUT GR, 1979, CANCER-AM CANCER SOC, V43, P2532, DOI 10.1002/1097-0142(197906)43:6<2532::AID-CNCR2820430654>3.0.CO;2-B; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; SAUER R, 1990, INT J RADIAT ONCOL, V19, P687, DOI 10.1016/0360-3016(90)90497-8; SCHER HI, 1993, J CLIN ONCOL, V11, P400, DOI 10.1200/JCO.1993.11.3.400; SELL A, 1991, SCAND J UROL NEPHROL, P193; SHIPLEY WU, 1987, JAMA-J AM MED ASSOC, V258, P931, DOI 10.1001/jama.258.7.931; SHIPLEY WU, 1985, J UROLOGY, V134, P679, DOI 10.1016/S0022-5347(17)47381-2; SKINNER DG, 1991, J UROLOGY, V145, P459, DOI 10.1016/S0022-5347(17)38368-4; SPLINTER TAW, 1990, 1989 P INT WORKSH HE; STERNBERG CN, 1988, J UROLOGY, V139, P461, DOI 10.1016/S0022-5347(17)42494-3; TESTER W, 1991, P AN M AM SOC CLIN, V10, P165	24	174	176	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1377	1382		10.1056/NEJM199311043291903	http://dx.doi.org/10.1056/NEJM199311043291903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413433				2022-12-28	WOS:A1993MD94900003
J	LOHR, KN; GROSSMAN, JH; CASSEL, CK				LOHR, KN; GROSSMAN, JH; CASSEL, CK			ISSUES IN MEASURING AND ASSURING QUALITY OF CARE FOR HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637	Tufts Medical Center; University of Chicago	LOHR, KN (corresponding author), INST MED,DIV HLTH CARE SERV,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							1990, NEW ENGL J MED, V322, P707	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1911	1911		10.1001/jama.270.16.1911	http://dx.doi.org/10.1001/jama.270.16.1911			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC513	8411537				2022-12-28	WOS:A1993MC51300003
J	WHITBY, MC; RYDER, L; LLOYD, RG				WHITBY, MC; RYDER, L; LLOYD, RG			REVERSE BRANCH MIGRATION OF HOLLIDAY JUNCTIONS BY RECG PROTEIN - A NEW MECHANISM FOR RESOLUTION OF INTERMEDIATES IN RECOMBINATION AND DNA-REPAIR	CELL			English	Article							ESCHERICHIA-COLI RECA; RUVC GENE-PRODUCT; CONJUGATIONAL RECOMBINATION; HOMOLOGOUS RECOMBINATION; ATPASE ACTIVITY; RECBCD ENZYME; PURIFICATION; INHIBITION; REQUIRES; MUTANT	The RecG protein of E. coli is a junction-specific DNA helicase involved in recombination and DNA repair. The function of the protein was investigated using an in vitro recombination reaction catalyzed by RecA. We show that RecG counters RecA-driven strand exchange by catalyzing branch migration of the Holliday junction in the reverse direction. This activity represents a new mechanism for resolving recombination intermediates that is independent of junction cleavage. We discuss how reverse branch migration can facilitate DNA repair, promote recombination in conjugational crosses, and confine the distribution of Chi-stimulated cross-overs. We suggest that the RecG mechanism for resolution of junctions is universal and provides a simple system that allows gene conversion without associated crossing over.			WHITBY, MC (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND.			Whitby, Matthew/0000-0003-0951-3374	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; HURST DD, 1972, P NATL ACAD SCI USA, V69, P101, DOI 10.1073/pnas.69.1.101; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; JINGJER L, 1992, MOL MICROBIOL, V6, P2219; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KHIDHIR MA, 1985, MOL GEN GENET, V199, P133, DOI 10.1007/BF00327522; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; LAM ST, 1974, GENETICS, V77, P425; LLOYD RG, 1987, MOL GEN GENET, V209, P135, DOI 10.1007/BF00329848; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LLOYD RG, 1984, MOL GEN GENET, V197, P328, DOI 10.1007/BF00330981; LU C, 1987, J MOL BIOL, V196, P497, DOI 10.1016/0022-2836(87)90027-1; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; MULLER B, 1993, IN PRESS J BIOL CHEM; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RINKEN R, 1992, J BACTERIOL, V174, P1172, DOI 10.1128/jb.174.4.1172-1178.1992; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STAHL FW, 1980, GENETICS, V94, P235; STORM PK, 1971, MUTAT RES, V13, P9, DOI 10.1016/0027-5107(71)90121-7; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKAHASHI NK, 1992, P NATL ACAD SCI USA, V89, P5912, DOI 10.1073/pnas.89.13.5912; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	63	140	140	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					341	350		10.1016/0092-8674(93)80075-P	http://dx.doi.org/10.1016/0092-8674(93)80075-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402917				2022-12-28	WOS:A1993MD88500015
J	LEBWOHL, M; HALPERIN, J; PHELPS, RG				LEBWOHL, M; HALPERIN, J; PHELPS, RG			BRIEF REPORT - OCCULT PSEUDOXANTHOMA ELASTICUM IN PATIENTS WITH PREMATURE CARDIOVASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029; MT SINAI MED CTR,DEPT INTERNAL MED,DIV CARDIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	LEBWOHL, M (corresponding author), MT SINAI MED CTR,DEPT DERMATOL,5 E 98TH ST,BOX 1048,NEW YORK,NY 10029, USA.		Halperin, Jonathan/AAJ-4721-2020	Halperin, Jonathan/0000-0002-8318-5471				BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BEIGHTON P, 1993, MCKUSICKS HERITABLE; CLARKSON JG, 1982, SURV OPHTHALMOL, V26, P235, DOI 10.1016/0039-6257(82)90158-8; LEBWOHL M, 1987, NEW ENGL J MED, V317, P347, DOI 10.1056/NEJM198708063170604; LEBWOHL MG, 1982, NEW ENGL J MED, V307, P228, DOI 10.1056/NEJM198207223070406; NAVARROLOPEZ F, 1980, CHEST, V78, P113, DOI 10.1378/chest.78.1.113; Neldner K H, 1988, Clin Dermatol, V6, P1; POPE FM, 1975, BRIT J DERMATOL, V92, P493; SCHACHNER L, 1974, AM J DIS CHILD, V127, P571, DOI 10.1001/archpedi.1974.02110230117021	9	93	93	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1237	1239		10.1056/NEJM199310213291705	http://dx.doi.org/10.1056/NEJM199310213291705			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8413390				2022-12-28	WOS:A1993MB98800005
J	SVOBODA, K; SCHMIDT, CF; SCHNAPP, BJ; BLOCK, SM				SVOBODA, K; SCHMIDT, CF; SCHNAPP, BJ; BLOCK, SM			DIRECT OBSERVATION OF KINESIN STEPPING BY OPTICAL TRAPPING INTERFEROMETRY	NATURE			English	Article							FORCE GENERATION; INVITRO; MICROTUBULES; MOVEMENT; MOLECULES; ASSAY; SIZE; DISPLACEMENT; ORGANELLE; DENSITIES	Do biological motors move with regular steps? To address this question, we constructed instrumentation with the spatial and temporal sensitivity to resolve movement on a molecular scale. We deposited silica beads carrying single molecules of the motor protein kinesin on microtubules using optical tweezers and analysed their motion under controlled loads by interferometry. We find that kinesin moves with 8-nm steps.	ROWLAND INST SCI INC, 100 EDWIN LAND BLVD, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, COMM BIOPHYS, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School			Schmidt, Christoph F/G-3787-2011	Schmidt, Christoph F/0000-0003-2864-6973				AMOS LA, 1974, J CELL SCI, V14, P523; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BAGSHAW CR, 1982, MUSCLE CONTRACTION; Block S, 1990, NONINVASIVE TECHNIQU, V9, P375; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; DENK W, 1990, APPL OPTICS, V29, P2382, DOI 10.1364/AO.29.002382; GALLAGHER NC, 1981, IEEE T ACOUST SPEECH, V29, P1136, DOI 10.1109/TASSP.1981.1163708; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Glatter O., 1982, SMALL ANGLE XRAY SCA; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Happel J, 1991, LOW REYNOLDS NUMBER, P322; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KAMIMURA S, 1992, J CELL BIOL, V116, P1443, DOI 10.1083/jcb.116.6.1443; KAMIMURA S, 1992, J CELL BIOL, V118, P865, DOI 10.1083/jcb.118.4.865; KAMIMURA S, 1987, APPL OPTICS, V26, P3425, DOI 10.1364/AO.26.003425; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUO SC, 1991, J CELL SCI, P135; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SAKMANN B, 1983, SINGLE CHANNEL RECOR; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SIMMONS R M, 1992, Current Biology, V2, P373, DOI 10.1016/0960-9822(92)90074-K; SIMMONS RM, 1993, ADV EXP MED BIOL, V332, P331; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; SPUDICH JA, 1990, NATURE, V348, P284, DOI 10.1038/348284a0; Squire J, 1981, STRUCTURAL BASIS MUS; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; WANG CW, 1954, SELECTED PAPERS NOIS, P113; WEINGARTEN MD, 1974, BIOCHEMISTRY-US, V13, P5529, DOI 10.1021/bi00724a012; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	49	1530	1575	7	401	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1993	365	6448					721	727		10.1038/365721a0	http://dx.doi.org/10.1038/365721a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413650				2022-12-28	WOS:A1993MC81200052
J	PAREKH, AB; TERLAU, H; STUHMER, W				PAREKH, AB; TERLAU, H; STUHMER, W			DEPLETION OF INSP3 STORES ACTIVATES A CA2+ AND K+ CURRENT BY MEANS OF A PHOSPHATASE AND A DIFFUSIBLE MESSENGER	NATURE			English	Article							XENOPUS OOCYTES; INOSITOL PHOSPHATES; CALCIUM ENTRY; RECEPTOR; PHOSPHORYLATION; RESOLUTION; INJECTION; SEROTONIN; PROTEINS; CHANNEL	IN non-excitable cells, release of Ca2+ from the inositol 1,4,5-trisphosphate (InsP3)-sensitive store can activate Ca2+ entry1-3. Very little is known about the signal mechanism relating store emptying to plasma membrane Ca2+ influx. It has been suggested that the signal may be either a diffusible messenger like an inositol phosphate4, or the InsP3 receptor itself, which, by physically coupling to some component of Ca2+ entry in the plasma membrane, may link store release to Ca2+ entry5. The nature of the Ca2+ entry pathway is also unclear. Only in mast cells has a very selective Ca2+ current been observed after store emptying6. Activation of exogenous 5-hydroxytryptamine (5-HT) receptors expressed in Xenopus oocytes or direct injection of InsP3 evokes Ca2+ entry activated by InsP3 pool depletion7. Here we investigate the nature of this influx pathway and find a current activated by pool depletion. This has an unusual selectivity in that it is more permeable to Ca2+ ions than to other divalent cations (Ba2+, Sr2+ or Mn2+). Moreover, a K+ permeability is also stimulated after pool depletion. The activation of this store depletion current involves both a phosphatase and an unidentified diffusible messenger. Both the Ca2+ entry pathway and the activating factors found here may be relevant to pool-depleted Ca2+ entry in a variety of non-excitable cells.	MAX PLANCK INST EXPTL MED,DEPT MOLEC BIOL NEURONAL SIGNALS,D-37077 GOTTINGEN,GERMANY	Max Planck Society	PAREKH, AB (corresponding author), MAX PLANCK INST BIOPHYS CHEM,DEPT MEMBRANE BIOPHYS,FASSBERG POB 2841,D-37077 GOTTINGEN,GERMANY.		Stuehmer, Walter/A-2176-2009	Stuehmer, Walter/0000-0002-0642-7764				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FOGUET M, 1992, EMBO J, V11, P3481, DOI 10.1002/j.1460-2075.1992.tb05427.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOGH M, 1993, J PHYSL, V465, P359; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KRAMER RH, 1990, NEURON, V2, P335; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LUBBERT H, 1987, J NEUROSCI, V7, P1159; LUPUMEIRI M, 1993, CELL CALCIUM, V14, P101, DOI 10.1016/0143-4160(93)90080-P; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; NOMURA Y, 1987, MOL BRAIN RES, V2, P113, DOI 10.1016/0169-328X(87)90004-0; PAREKH AB, IN PRESS J PHYSL; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WHITE MM, 1990, MOL PHARMACOL, V37, P720; YAO Y, 1992, P R SOC LOND B, V246, P269; ZODROW J, 1984, LIFE SCI, V34, P1967, DOI 10.1016/0024-3205(84)90128-0	28	379	381	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					814	818		10.1038/364814a0	http://dx.doi.org/10.1038/364814a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8395025				2022-12-28	WOS:A1993LU58100059
J	DEAN, C; PHILLIPS, J; GADD, EM; JOSEPH, M; ENGLAND, S				DEAN, C; PHILLIPS, J; GADD, EM; JOSEPH, M; ENGLAND, S			COMPARISON OF COMMUNITY-BASED SERVICE WITH HOSPITAL-BASED SERVICE FOR PEOPLE WITH ACUTE, SEVERE PSYCHIATRIC-ILLNESS	BRITISH MEDICAL JOURNAL			English	Article							TRIAL; HOME; CARE	Objective-To compare the burden on relatives and outcome of people treated for severe acute psychiatric illness by a community service and a traditional hospital based service. Design-Follow up of patients aged 16-65 who required admission to hospital or home treatment for psychiatric illness during january 1990 to February 1991. Setting-Two Birmingham electoral wards, Sparkbrook and Small Heath; Sparkbrook has a community based service and Small Heath a traditional hospital based service. Subjects-69 patients from Sparkbrook and 55 from Small Heath. Main outcome measures-Scores on present state examination, social behaviour assessment schedule, and general health questionnaire. Results-24 (35%) of Sparkbrook patients received some treatment in hospital during the initial episodes. Relatives of Sparkbrook patients were less distressed by their burden at the initial assessment than relatives of Small Heath patients (mean score 0.11 v 0.29, p<0.01). Relatives were also more satisfied with the support they received and the treatment received by patients. More patients from Sparkbrook than Small Heath were in contact with a psychiatrist (81% (95% confidence interval 71% to 91%) v 62% (44% to 68%)) and community nurse (56% (44% to 68%) v 14% (13% to 24%)) one year after the initial episode. Sparkbrook patients spent significantly fewer days in hospital during the initial episode (8 days v 59 days) and the first year (20.6 v 67.9 days). Conclusion-The community based service is as effective as the hospital based service and is preferred by relatives. It is more effective in keeping people in long term contact with psychiatrists.	UNIV BIRMINGHAM,DEPT PSYCHIAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; MAIN ST RESOURCE CTR,BIRMINGHAM,ENGLAND; HIGHCROFT HOSP,BIRMINGHAM,ENGLAND	University of Birmingham								AFFLECK JW, 1984, BRIT J PSYCHIAT, V145, P517, DOI 10.1192/bjp.145.5.517; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; DEAN C, 1990, BRIT MED J, V301, P1021, DOI 10.1136/bmj.301.6759.1021; DEAN C, 1989, B ROYAL COLLEGE PSYC, V13, P667; DEDMAN P, 1993, BRIT MED J, V306, P1359, DOI 10.1136/bmj.306.6889.1359; FENTON FR, 1979, ARCH GEN PSYCHIAT, V36, P1073; Goldberg DP, 1972, DETECTION PSYCHIAT I; GRAD J, 1968, BRIT J PSYCHIAT, V114, P265, DOI 10.1192/bjp.114.508.265; HOULT J, 1984, SOC SCI MED, V18, P1005, DOI 10.1016/0277-9536(84)90272-7; MERSON S, 1992, LANCET, V339, P1311, DOI 10.1016/0140-6736(92)91959-C; MUIJEN M, 1992, BRIT J PSYCHIAT, V160, P379, DOI 10.1192/bjp.160.3.379; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; PAI S, 1983, BRIT J PSYCHIAT, V143, P447, DOI 10.1192/bjp.143.5.447; PLATT S, 1980, SOC PSYCHIATR, V15, P43, DOI 10.1007/BF00577960; Wing J. K. C., 1974, MEASUREMENT CLASSIFI	15	52	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					473	476		10.1136/bmj.307.6902.473	http://dx.doi.org/10.1136/bmj.307.6902.473			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU590	8400929	Green Published			2022-12-28	WOS:A1993LU59000019
J	LEFKOWITZ, RJ				LEFKOWITZ, RJ			G-PROTEIN-COUPLED RECEPTOR KINASES	CELL			English	Review							RHODOPSIN KINASE; FAMILY; DESENSITIZATION; ISOPRENYLATION; SIGNAL		DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute	LEFKOWITZ, RJ (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021					AMBROSE C, 1993, HUM MOL GENET, V1, P6697; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1254; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420	22	435	442	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					409	412		10.1016/0092-8674(93)80042-D	http://dx.doi.org/10.1016/0092-8674(93)80042-D			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8394218				2022-12-28	WOS:A1993LT73900002
J	TAZI, J; KORNSTADT, U; ROSSI, F; JEANTEUR, P; CATHALA, G; BRUNEL, C; LUHRMANN, R				TAZI, J; KORNSTADT, U; ROSSI, F; JEANTEUR, P; CATHALA, G; BRUNEL, C; LUHRMANN, R			THIOPHOSPHORYLATION OF U1-70K PROTEIN INHIBITS PREMESSENGER RNA SPLICING	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; DROSOPHILA ENCODES; BINDING PROTEINS; SNRNP; SPLICEOSOME; POLYPEPTIDE; REGULATORS; YEAST; SITE; U1	THE U1 small nuclear ribonucleoprotein (snRNP) particle is one of the Sm class of snRNPs essential for splicing of precursor messenger RNA1-5. Mammalian U1 snRNP contains a 165-nucleotide long RNA molecule and at least 11 proteins: the U1-specific 70K proteins A and C, and the common U snRNP proteins (B', B, D1, D2, D3, E, F and G). One of the functions of U1 snRNP is recognition of the 5' splice site, an event that requires both U1 RNA and U1 proteins6-10. The 70K protein is the only heavily phosphorylated U1 protein in the cell11,12. Isolated U1 snRNPs are associated with a kinase activity that selectively phosphorylates the 70K protein in vitro in a reaction requiring ATP. Here we investigate the role of phosphorylation of the 70K protein in the splicing of pre-mRNA. The 70K protein on U1 snRNPs was phosphorylated in vitro with either ATP, or with ATP-gammaS, which gave a thiophosphorylated product that was resistant to dephosphorylation by phosphatases. When HeLa nuclear splicing extracts that had been depleted of endogenous U1 snRNPs were complemented with U1 snRNPs possessing normal phosphorylated 70K protein, mature spliceosomes were generated and the splicing activity of the extracts was fully restored. By contrast, if thiophosphorylated U1 snRNPs were used instead, splicing was completely inhibited, although formation of the mature spliceosome was unaffected. Our data show that the state of phosphorylation of the U1-specific 70K protein is critical for its participation in a pre-catalytic step of the splicing reaction.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,W-3550 MARBURG,GERMANY	Philipps University Marburg	TAZI, J (corresponding author), UNIV MONTPELLIER 2,CNRS,UNITE GENET MOLEC 1191,F-34095 MONTPELLIER 5,FRANCE.			Tazi, Jamal/0000-0002-1949-8748				AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BACH M, 1990, METHOD ENZYMOL, V181, P232; BIENCOWE BJ, 1989, CELL, V59, P531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; KHELLIL S, 1991, NUCLEIC ACIDS RES, V19, P877, DOI 10.1093/nar/19.4.877; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LELAYTAHA MN, 1986, J MOL BIOL, V189, P519, DOI 10.1016/0022-2836(86)90321-9; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1992, MOL CELL BIOL YEAST; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TAZI J, 1992, J BIOL CHEM, V267, P4322; TAZI J, IN PRESS MOL CELL BI; TETEI K, 1987, J BIOL CHEM, V262, P11667; WOOLEY JC, 1983, P NATL ACAD SCI-BIOL, V80, P5208, DOI 10.1073/pnas.80.17.5208; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	29	137	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					283	286		10.1038/363283a0	http://dx.doi.org/10.1038/363283a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8387646				2022-12-28	WOS:A1993LC86600059
J	TROUCHE, D; GRIGORIEV, M; LENORMAND, JL; ROBIN, P; LEIBOVITCH, SA; SASSONECORSI, P; HARELBELLAN, A				TROUCHE, D; GRIGORIEV, M; LENORMAND, JL; ROBIN, P; LEIBOVITCH, SA; SASSONECORSI, P; HARELBELLAN, A			REPRESSION OF C-FOS PROMOTER BY MYOD ON MUSCLE-CELL DIFFERENTIATION	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; DNA-BINDING; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; MYOGENIC DIFFERENTIATION; TRANSCRIPTION FACTOR; MYC HOMOLOGY; FIBROBLASTS; EXPRESSION; MYOBLASTS	TERMINAL differentiation and cell proliferation are in many cases, as in muscle cells1, mutually exclusive processes. While differentiating myoblasts are withdrawn from the cell cycle2, myogenesis is inhibited by some mitogens and overexpression of some oncogenes3,4, including proto-oncogene c-fos5 (which expresses a growth-associated protein constituting the regulatory factor AP-1 in conjunction with c-Jun6,7). MyoD, a muscle-specific transcription factor of the basic helix-loop-helix family8,9, acts at both levels because it triggers a muscle differentiation programme in non-muscle cells10-12, and induces a complete block of cell proliferation13,14. Antagonistic interaction between MyoD and c-Jun has been demonstrated15. We here show that c-fos expression greatly decreases upon muscle cell differentiation, concomitant with MyoD-induced activity. We have identified a MyoD-binding site overlapping with the serum-responsive element in the c-fos promoter. We demonstrate that MyoD can act as a negative regulator for c-fos transcription by blocking serum responsiveness through this binding site. These data suggest that the MyoD negative effect on cell growth could be partly mediated by transcriptional inactivation of growth-responsive genes.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Lenormand, Jean-Luc/M-6644-2014; Lenormand, Jean-Luc/ABF-3850-2021; Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015	Lenormand, Jean-Luc/0000-0002-2766-9180; Harel-Bellan, Annick/0000-0002-2339-153X; Trouche, Didier/0000-0003-1398-6481; Grigoriev, Michel/0000-0002-0252-2254				BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSI M, 1991, ONCOGENE, V6, P1767; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; METZ R, 1991, ONCOGENE, V6, P2165; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PINSET C, 1991, EMBO J, V10, P2411, DOI 10.1002/j.1460-2075.1991.tb07780.x; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TROUCHE D, 1991, BLOOD, V77, P55; TROUCHE D, 1991, J IMMUNOL, V147, P2398	31	90	90	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					79	82		10.1038/363079a0	http://dx.doi.org/10.1038/363079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8386804				2022-12-28	WOS:A1993LA68200064
J	RASMUSSEN, MH; ANDERSEN, T; BREUM, L; GOTZSCHE, PC; HILSTED, J				RASMUSSEN, MH; ANDERSEN, T; BREUM, L; GOTZSCHE, PC; HILSTED, J			CIMETIDINE SUSPENSION AS ADJUVANT TO ENERGY RESTRICTED DIET IN TREATING OBESITY	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND	Objective-To study the effect of cimetidine suspension compared with placebo suspension on weight loss in moderately obese patients taking a 5 MJ/day diet supplemented with dietary fibre. To determine the relation between the effectiveness of the blinding and weight loss. Design-Randomised double blind study with an eight week parallel group phase and a subsequent eight week crossover or continuation phase. Setting-Outpatient clinic. Subjects-60 patients (51 women) aged 18-60. Main outcome measure-Weight loss. Results-After eight weeks of treatment the mean weight loss in the cimetidine group (5.7 kg) was similar to that of the placebo group (5.9 kg; p=0.78, 95% confidence interval -2.0 to 1.5 kg). Body mass index, waist and hip measurements, waist-hip ratio, and systolic and diastolic blood pressures decreased similarly in the two groups. No association was found between weight loss and the patients' ability to guess if they were being given drug or placebo. Correct guesses of current drug were more prevalent than expected by chance (25/37 correct, p=0.05 for the parallel group phase; 26/30, p=0.0001 for the crossover phase). Conclusions-Cimetidine had no effect on weight loss in moderately obese patients. The study underlines the potential problem that blinding of patients to treatment can be compromised.	HVIDOVRE UNIV HOSP,DEPT GASTROENTEROL,DK-2650 HVIDOVRE,DENMARK; HVIDOVRE UNIV HOSP,DEPT RHEUMATOL,DK-2650 HVIDOVRE,DENMARK	University of Copenhagen; University of Copenhagen	RASMUSSEN, MH (corresponding author), HVIDOVRE UNIV HOSP,DEPT ENDOCRINOL,DK-2650 HVIDOVRE,DENMARK.							ANDERSEN T, 1992, INT J OBESITY, V16, P35; ARMITAGE P, 1987, STATISTICAL METHODS; BROWNELL KD, 1982, AM J PSYCHIAT, V139, P1487; CROMIE BW, 1963, LANCET, V1, P994; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1989, CONTROLLED CLIN TRIA, V10, P356; HEY H, 1986, CLIN NUTR, V6, P195; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1030; LASAGNA L, 1955, J Chronic Dis, V1, P353, DOI 10.1016/0021-9681(55)90090-4; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; NASH H, 1962, J NERV MENT DIS, V134, P34, DOI 10.1097/00005053-196213410-00004; NASH H, 1959, J NERV MENT DIS, V128, P1239; Seidell J C, 1988, Acta Med Scand Suppl, V723, P189; STOABIRKETVEDT G, 1991, INT J OBESITY S3, V15, P19; 1988, BMJ, V296, P401	15	16	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1093	1096		10.1136/bmj.306.6885.1093	http://dx.doi.org/10.1136/bmj.306.6885.1093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8388286	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500019
J	DALTON, ME; DECHERNEY, AH				DALTON, ME; DECHERNEY, AH			CURRENT CONCEPTS - PRENATAL-DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; CONGENITAL HEART-DISEASE; SERUM ALPHA-FETOPROTEIN; LIMB ABNORMALITIES; UNITED-STATES; FETAL ECHOCARDIOGRAPHY; CHROMOSOME MOSAICISM; PREDICTIVE VALUE; ULTRASOUND; PREGNANCY		TUFTS UNIV,SCH MED,DEPT OBSTET & GYNECOL,BOSTON,MA 02111	Tufts University			DeCherney, Alan H/AAS-2944-2020					ALLAN LD, 1988, CLIN OBSTET GYNECOL, V31, P61, DOI 10.1097/00003081-198803000-00009; [Anonymous], 1991, LANCET, V337, P1491; BAKKETEIG LS, 1984, LANCET, V2, P207; Benacerraf B R, 1989, Clin Diagn Ultrasound, V25, P21; BENNETT MJ, 1982, BRIT J OBSTET GYNAEC, V89, P338, DOI 10.1111/j.1471-0528.1982.tb05074.x; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; BRYNE D, 1991, ULTRASOUND OBSTET GY, V1, P235; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; CHOO V, 1991, LANCET, V338, P750, DOI 10.1016/0140-6736(91)91461-3; COPEL JA, 1988, AM J OBSTET GYNECOL, V158, P409, DOI 10.1016/0002-9378(88)90166-4; COPEL JA, 1986, AM J OBSTET GYNECOL, V154, P1121, DOI 10.1016/0002-9378(86)90773-8; COPEL JA, 1987, AM J OBSTET GYNECOL, V157, P648, DOI 10.1016/S0002-9378(87)80022-4; COWCHOCK S, 1980, AM J MED GENET, V5, P309, DOI 10.1002/ajmg.1320050314; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; DALTON M, 1986, AM J OBSTET GYNECOL, V154, P532, DOI 10.1016/0002-9378(86)90597-1; DIMAIO MS, 1987, NEW ENGL J MED, V317, P342, DOI 10.1056/NEJM198708063170603; EIKNES SH, 1984, LANCET, V1, P1347; EVANS MI, 1991, AM J OBSTET GYNECOL, V165, P728, DOI 10.1016/0002-9378(91)90318-L; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTER UG, 1992, LANCET, V339, P66, DOI 10.1016/0140-6736(92)90198-C; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GOSDEN C, 1988, LANCET, V1, P613; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HILL LM, 1985, AM J OBSTET GYNECOL, V151, P44, DOI 10.1016/0002-9378(85)90421-1; HOOK EB, 1981, OBSTET GYNECOL, V58, P282; HOOK EB, 1983, JAMA-J AM MED ASSOC, V249, P2034, DOI 10.1001/jama.249.15.2034; HSU LYF, 1984, PRENATAL DIAG, V4, P97, DOI 10.1002/pd.1970040708; JACKSON LG, 1991, LANCET, V337, P1423; JACKSON LG, 1992, NEW ENGL J MED, V327, P594, DOI 10.1056/NEJM199208273270903; KALOUSEK DK, 1987, HUM GENET, V77, P163, DOI 10.1007/BF00272385; KLINGER K, 1992, AM J HUM GENET, V51, P55; LEDBETTER DH, 1990, AM J OBSTET GYNECOL, V162, P495, DOI 10.1016/0002-9378(90)90419-8; LIN AE, 1988, J PEDIATR-US, V113, P1105, DOI 10.1016/S0022-3476(88)80591-2; MAHONEY MJ, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93117-R; MANCHESTER DK, 1988, PRENATAL DIAG, V8, P109, DOI 10.1002/pd.1970080205; McKusick VA, 1990, MENDELIAN INHERITANC; MERCER S, 1988, CAN J SURG, V31, P25; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; MONNI G, 1991, LANCET, V337, P1091; NEILSON JP, 1984, BRIT MED J, V289, P1179, DOI 10.1136/bmj.289.6453.1179; NORA JJ, 1988, AM J MED GENET, V29, P137, DOI 10.1002/ajmg.1320290117; PALOMAKI GE, 1988, OBSTET GYNECOL, V71, P906; PLATT LD, 1986, OBSTET GYNECOL, V68, P153; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SABBAGHA RE, 1985, AM J OBSTET GYNECOL, V152, P822, DOI 10.1016/S0002-9378(85)80070-3; SCHLOO R, 1992, AM J MED GENET, V42, P404, DOI 10.1002/ajmg.1320420338; SHULMAN LP, 1990, SEMIN PERINATOL, V14, P456; SIMPSON NE, 1976, CAN MED ASSOC J, V115, P739; STENE J, 1970, HUM HERED, V20, P112, DOI 10.1159/000152301; TABOR A, 1986, LANCET, V1, P1287; VANDENHOF MC, 1990, AM J OBSTET GYNECOL, V162, P322, DOI 10.1016/0002-9378(90)90378-K; WALDENSTROM U, 1988, LANCET, V2, P585; WATSON JD, 1990, SCIENCE, V248, P44, DOI 10.1126/science.2181665; 1984, NATIONAL I HLTH CONS; 1978, BRIT J OBSTET GYN  S, V85, P12; 1987, TECHNICAL B AM COLLE, V108, P1; 1976, JAMA-J AM MED ASSOC, V236, P1471; 1977, LANCET, V1, P1323; 1989, MMWR MORB MORTAL WKL, V38, P633; 1988, TECHNICAL B AM COLLE, V16, P1	62	81	88	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					114	120						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	8416422				2022-12-28	WOS:A1993KG46700008
J	COHEN, PR				COHEN, PR			NEUROFIBROMATOSIS TYPE-1	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											COHEN, PR (corresponding author), UNIV TEXAS,SCH MED,HOUSTON,TX 77025, USA.								0	5	5	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1549	1549						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8413478				2022-12-28	WOS:A1993MG18800007
J	MAGGIONI, AP; MASERI, A; FRESCO, C; FRANZOSI, MG; MAURI, F; SANTORO, E; TOGNONI, G				MAGGIONI, AP; MASERI, A; FRESCO, C; FRANZOSI, MG; MAURI, F; SANTORO, E; TOGNONI, G			AGE-RELATED INCREASE IN MORTALITY AMONG PATIENTS WITH 1ST MYOCARDIAL INFARCTIONS TREATED WITH THROMBOLYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The overall rate of mortality due to ischemic heart disease is known to increase progressively with age. We evaluated the relation between the mortality rate and age in patients with first myocardial infarctions treated with thrombolytic therapy. Methods. We studied 9720 patients with first infarctions who had been enrolled in the GISSI-2 trial. (This trial compared the efficacy of tissue plasminogen activator with that of streptokinase in patients with myocardial infarction.) Of these, only 35 percent had a history of angina. The relation between age and mortality during hospitalization and during the six months after discharge was determined by unadjusted and adjusted analyses. Results. The in-hospital mortality rate was 1.9 percent among patients 40 years old or younger, but it increased to 31.9 percent among those more than 80 years old; however, values for indicators of infarct size did not increase with age. Autopsies were performed in 20 percent of the 772 patients who died in the hospital; the findings showed that the frequency of cardiac rupture increased from 19 percent among patients 60 years old or younger to 86 percent among those more than 70 years old. The mortality rate for the first six months after hospital discharge also increased significantly with age. After adjustment for confounding variables, older age continued to be significantly associated with a higher risk of in-hospital and post-discharge death. When age was introduced into a multivariate model as a continuous variable, the risk of death was estimated to increase by about 6 percent per year for both in-hospital and six-month mortality rates. Conclusions. In patients with first myocardial infarctions who received thrombolytic therapy, age was a powerful independent predictor of both in-hospital and post-discharge mortality rates. The exponential, age-related increase in the mortality rate did not appear to be explained by larger infarcts.			MAGGIONI, AP (corresponding author), GISSI 2, COORDINATING CTR, VIA ERITREA 62, I-20157 MILAN, ITALY.		Fresco, Claudio/M-5203-2015; santoro, eugenio/ABG-7901-2020; Maggioni, Aldo Pietro/AAL-5334-2020	Fresco, Claudio/0000-0001-7123-8153; santoro, eugenio/0000-0002-5719-9896; Maggioni, Aldo Pietro/0000-0003-2764-6779				ACKERMAN RF, 1950, CIRCULATION, V1, P1345, DOI 10.1161/01.CIR.1.6.1345; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V1, P921; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BATES RJ, 1977, AM J CARDIOL, V40, P429, DOI 10.1016/0002-9149(77)90167-9; BOGATY P, 1993, CIRCULATION, V87, P1938, DOI 10.1161/01.CIR.87.6.1938; CAPASSO JM, 1990, AM J PHYSIOL, V259, pH1086, DOI 10.1152/ajpheart.1990.259.4.H1086; DEVITA C, 1990, LANCET, V335, P289, DOI 10.1016/0140-6736(90)90104-D; FOLLAND ED, 1979, CIRCULATION, V60, P760, DOI 10.1161/01.CIR.60.4.760; GERSTENBLITH G, 1977, CIRCULATION, V56, P273, DOI 10.1161/01.CIR.56.2.273; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HUNT D, 1992, LANCET, V339, P753; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; VESTAL RE, 1979, CLIN PHARMACOL THER, V26, P181; WAGNER GS, 1982, CIRCULATION, V65, P342, DOI 10.1161/01.CIR.65.2.342; WHITE NK, 1950, CIRCULATION, V1, P645, DOI 10.1161/01.CIR.1.4.645; 1988, LANCET, V2, P292; 1991, AM J CARDIOL S, V68, pD87; 1992, AM J CARDIOL S, V70, pC62	23	318	330	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1442	1448		10.1056/NEJM199311113292002	http://dx.doi.org/10.1056/NEJM199311113292002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413454	Bronze			2022-12-28	WOS:A1993MF29200002
J	CLINTON, JJ				CLINTON, JJ			SICKLE-CELL DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AHCPR,ROCKVILLE,MD 20852										0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2158	2158		10.1001/jama.270.18.2158	http://dx.doi.org/10.1001/jama.270.18.2158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411588				2022-12-28	WOS:A1993ME81600008
J	GOLDSTEIN, KP; KVIZ, FJ; DAUM, RS				GOLDSTEIN, KP; KVIZ, FJ; DAUM, RS			ACCURACY OF IMMUNIZATION HISTORIES PROVIDED BY ADULTS ACCOMPANYING PRESCHOOL-CHILDREN TO A PEDIATRIC EMERGENCY DEPARTMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-Because some have advocated the use of emergency departments to administer delayed childhood immunizations, we evaluated the accuracy of immunization histories obtained in this setting by comparison with medical records of inner-city health care facilities. Design.-Questionnaires were orally administered to adults accompanying children to the emergency department. Individual medical records were reviewed. Setting.-Pediatric emergency department at Wyler Children's Hospital, University of Chicago and 68 inner-city primary care clinics. Patients.-Children aged 3 to 65 months registering for medical care. Of the sample, 98% were African American; 75% were Medicaid recipients. Main Outcome Measures.-Adults' knowledge of immunization histories, immunization cards, and medical records compared with American Academy of Pediatrics/Immunization Practices Advisory Committee recommendations. Results.-Of the accompanying adults, 64% stated that their child's general immunization status was ''up-to-date''; 65% of these had clinic records confirming that status. Only 8% of specific regimens stated by these adults accurately matched those found in clinic records. Moreover, 45% of adults accompanying children at least 16 months and older provided inaccurate information regarding previous receipt of measles immunization. Conclusion.-Information provided by accompanying adults (from recall or from immunization cards) is inadequate to determine accurately which preschoolers in the pediatric emergency department are delayed in immunizations.	UNIV CHICAGO,DEPT PEDIAT,INFECT DIS SECT,CHICAGO,IL 60637; UNIV ILLINOIS,SCH PUBL HLTH,CHICAGO,IL 60680	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	GOLDSTEIN, KP (corresponding author), UNIV CHICAGO,DEPT PEDIAT,GEN PEDIAT SECT,CHICAGO,IL 60637, USA.							CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; ORENSTEIN WA, 1988, 22ND P IMM C SAN ANT, P121; WINGERT WA, 1968, AM J PUBLIC HEALTH N, V58, P859, DOI 10.2105/AJPH.58.5.859; WINGERT WA, 1969, CALIF MED, V110, P207; 1991, MMWR MORB MORTAL WKL, V40, P369; 1989, MMWR MORB MORTAL WKL, V38, P871; 1989, MMWR MORB MORTAL WKL, V38, P863; 1992, MMWR MORB MORTAL WKL, V41, P103; 1990, MMWR MORB MORTAL WKL, V39, P353; 1991, MMWR MORB MORTAL WKL, V40, P36; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1989, MMWR MORB MORTAL WKL, V38, P210; 1993, JAMA-J AM MED ASSOC, V269, P1817; 1991, MMWR MORB MORTAL WKL, V40, pRR1; 1991, REPORT COMMITTEE INF, P17; 1990, MMWR MORB MORTAL WKL, V39, P361; 1989, MMWR MORB MORTAL WKL, V38, P4	18	107	107	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2190	2194		10.1001/jama.270.18.2190	http://dx.doi.org/10.1001/jama.270.18.2190			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ME816	8411601				2022-12-28	WOS:A1993ME81600029
J	GROETTRUP, M; UNGEWISS, K; AZOGUI, O; PALACIOS, R; OWEN, MJ; HAYDAY, AC; VONBOEHMER, H				GROETTRUP, M; UNGEWISS, K; AZOGUI, O; PALACIOS, R; OWEN, MJ; HAYDAY, AC; VONBOEHMER, H			A NOVEL DISULFIDE-LINKED HETERODIMER ON PRE-T-CELLS CONSISTS OF THE T-CELL RECEPTOR-BETA CHAIN AND A 33 KD GLYCOPROTEIN	CELL			English	Article							ANTIGEN RECEPTOR; TCR-BETA; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; ALPHA-CHAIN; SIGNAL TRANSDUCTION; SURFACE EXPRESSION; LYMPHOCYTES-B; LIGHT-CHAIN; GENE	We describe a novel signal-transducing protein complex, which consists of the T cell receptor (TCR) beta chain that is disulfide linked to a 33 kd glycoprotein and non-covalently associated with proteins of the CD3 complex on the surface of the pre-T cell line SCB.29. This 33 kd glycoprotein, provisionally designated gp33, represents neither of the known TCR chains and has escaped previous detection because it labels poorly by surface iodination. This glycoprotein is absent from the surface of mature T cell lines. A TCR beta complex with identical molecular masses before and after reduction can be immunoprecipitated from surface-iodinated large thymocytes of TCR alpha-deficient mice. The novel gp33-TCR beta complex may be entirely or partly responsible for control of early T cell development exerted by the TCR beta protein.	UNIV PARIS 05,INSERM,U373,F-75015 PARIS,FRANCE; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Cancer Research UK; Yale University	GROETTRUP, M (corresponding author), BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND.							BENOIST C, 1992, CURR OPIN IMMUNOL, V4, P156, DOI 10.1016/0952-7915(92)90005-Y; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BROCKER T, 1993, EUR J IMMUNOL, V23, P1435, DOI 10.1002/eji.1830230705; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, THESIS U BASEL BASEL; HAARS R, 1986, J EXP MED, V164, P1, DOI 10.1084/jem.164.1.1; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KONING F, 1988, J IMMUNOL, V140, P3126; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PEARSE M, 1988, P NATL ACAD SCI USA, V85, P6082, DOI 10.1073/pnas.85.16.6082; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROSLONIEC EF, 1989, J IMMUNOL, V142, P4176; SAITO T, 1987, J IMMUNOL, V139, P625; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1993, CURR OPIN IMMUNOL, V5, P175, DOI 10.1016/0952-7915(93)90001-9; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3	53	303	304	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					283	294		10.1016/0092-8674(93)80070-U	http://dx.doi.org/10.1016/0092-8674(93)80070-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402912				2022-12-28	WOS:A1993MD88500010
J	ZHENG, XF; RUDERMAN, JV				ZHENG, XF; RUDERMAN, JV			FUNCTIONAL-ANALYSIS OF THE P-BOX, A DOMAIN IN CYCLIN-B REQUIRED FOR THE ACTIVATION OF CDC25	CELL			English	Article							MATURATION-PROMOTING FACTOR; P80CDC25 MITOTIC INDUCER; CELL-FREE SYSTEM; PROTEIN-KINASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; DNA-REPLICATION	Cyclin B-cdc2 complexes are kept inactive by inhibitory phosphorylations on Thr-14 and Tyr-15 of cdc2 until they are dephosphorylated at the end of G2 by the phosphatase cdc25. Recent work has suggested that a small region of cyclin B, which we call the P box, may contribute part of a phosphatase-activating domain to cdc25. Individual conservative substitutions at three invariant residues within the P box yield mutant cyclin 8 proteins that bind cdc2 in vitro and then show the predicted cell cycle arrest, with cdc25 remaining in the low activity interphase form and cyclin B-cdc2 complexes remaining phosphorylated and inactive. While the low activity interphase form of cdc25 cannot act on cdc2 complexed with a mutant P box cyclin, the high activity M phase form of cdc25 can. These results demonstrate that the P box domain of cyclin B is required for cdc25 activation and support a two-step mechanism for the cdc25-dependent activation of cyclin B-cdc2.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	ZHENG, XF (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023696] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-23696] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BELLE R, 1992, BIOL CELL, V75, P139, DOI 10.1016/0248-4900(92)90134-M; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAGAN I, 1988, J CELL SCI, V91, P587; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILARSKI KL, 1991, COLD SH Q B, V56, P377; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NISHIMOTO T, 1992, ANN REV CELL BIOL, V2, P174; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NUGENT JHA, 1991, J CELL SCI, V99, P669; OCONNELL MJ, 1992, EMBO J, V11, P2139, DOI 10.1002/j.1460-2075.1992.tb05273.x; OFARRELL P, 1991, COLD SH Q B, V56, P83; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RUDERMAN J, 1991, COLD SH Q B, V56, P495; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sambrook J, 1989, MOL CLONING LABORATO; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SOLOMON MJ, 1991, COLD SH Q B, V56, P427; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUDIER FW, 1990, ANNU REV BIOCHEM, V185, P60; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431	82	71	72	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					155	164		10.1016/S0092-8674(05)80092-3	http://dx.doi.org/10.1016/S0092-8674(05)80092-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402895				2022-12-28	WOS:A1993MB66700016
J	ROBINSON, R				ROBINSON, R			ECONOMIC-EVALUATION AND HEALTH-CARE .2. COSTS AND COST-MINIMIZATION ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article								Whatever kind of economic evaluation you plan to undertake, the costs must be assessed. In health care these are first of all divided into costs borne by the NHS (like drugs), by patients and their families (like travel), and by the rest of society (like health education). Next the costs have to be valued in monetary terms; direct costs, like wages, pose little problem, but indirect costs (like time spent in hospital) have to have values imputed to them. And that is not all: costs must be further subdivided into average, marginal, and joint costs, which help decisions on how much of a service should be provided. Capital costs (investments in plant, buildings, and machinery) are also important, as are discounting and inflation. In this second article in the series Ray Robinson defines the types of costs, their measurement, and how they should be valued in monetary terms.			ROBINSON, R (corresponding author), UNIV SOUTHAMPTON,INST HLTH POLICY STUDIES,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND.							OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; Torrance GW, 1987, METHODS EC EVALUATIO; 1989, 2 DEP TRANSP HIGHW E	3	108	113	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					726	728		10.1136/bmj.307.6906.726	http://dx.doi.org/10.1136/bmj.307.6906.726			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LY292	8401098	Bronze, Green Published			2022-12-28	WOS:A1993LY29200025
J	KAI, J				KAI, J			PARENTS PERCEPTIONS OF TAKING BABIES RECTAL TEMPERATURE	BRITISH MEDICAL JOURNAL			English	Article							SCORING SYSTEM; BABY CHECK; AXILLARY; CHILDREN; ILLNESS; INFANTS	Objective-To explore the attitudes of parents to measuring their babies' rectal temperature. Design-Qualitative study using unstructured interviews of parents given ''Baby Check,'' a scoring system designed to assess severity of illness in babies that includes measurement of rectal temperature. Setting-One inner city general practice in Newcastle upon Tyne. Subjects--42 parents of 34 babies under 6 months old. Results-Parents were reluctant to measure rectal temperature in their babies; 37 parents spontaneously raised concerns. Fifteen did not undertake measurement, 16 did so once only, and 11 did so more than once. Parents' concerns included a fear of hurting their child, anxieties about sexual intimacy and abuse, difficulty in comforting their child, and concern for their child's feelings. Most (33) substituted axillary measurement. Conclusions--Parents' preference for the axillary method of measuring temperature and resistance to using a rectal method in their children was based on several concerns. If parents are to be encouraged to use the rectal method of measuring temperature in sick babies any benefits must be set against the generation of considerable parental anxiety and the resources that would be necessary to negotiate with parents and change their views.			KAI, J (corresponding author), MED SCH NEWCASTLE UPON TYNE,SCH HLTH CARE SCI,DEPT PRIMARY HLTH CARE,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND.			Kai, Joe/0000-0001-9040-9384				CAMPBELL B, 1988, CHILD SEXUAL ABUSE C; CLARKE S, 1992, BMJ, V304, P96; COLE TJ, 1991, J ROY STAT SOC A STA, V154, P287, DOI 10.2307/2983042; Glaser B.G., 1965, AWARENESS DYING; HOBBS CJ, 1986, LANCET, V2, P792; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106, DOI 10.1136/adc.66.1.106; WEISSE ME, 1991, PEDIATR INFECT DIS J, V10, P541, DOI 10.1097/00006454-199107000-00013; WILKIN D, 1987, ANATOMY URBAN GENERA; 1989, BIRTH 5 GUIDE 1ST FI; 1988, REPORT INQUIRY CHILD	14	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					660	662		10.1136/bmj.307.6905.660	http://dx.doi.org/10.1136/bmj.307.6905.660			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401054	Bronze, Green Published			2022-12-28	WOS:A1993LX47000020
J	LI, M; WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA				LI, M; WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA			CONVERGENT REGULATION OF SODIUM-CHANNELS BY PROTEIN-KINASE-C AND CAMP-DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							SOMATIC-CELL LINE; RAT-BRAIN; ALPHA-SUBUNIT; XENOPUS-OOCYTES; FUNCTIONAL EXPRESSION; CLONED CDNA; PHOSPHORYLATION; MODULATION; SITE; MEMBRANE	The function of voltage-gated sodium channels that are responsible for action potential generation in mammalian brain neurons is modulated by phosphorylation by adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (cA-PK) and by protein kinase C (PKC). Reduction of peak sodium currents by cA-PK in intact cells required concurrent activation of PKC and was prevented by blocking phosphorylation of serine 1506, a site in the inactivation gate of the channel that is phosphorylated by PKC but not by cA-PK. Replacement of serine 1506 with negatively charged amino acids mimicked the effect of phosphorylation. Conversion of the consensus sequence surrounding serine 1506 to one more favorable for cA-PK enhanced modulation of sodium currents by cA-PK. Convergent modulation of sodium channels required phosphorylation of serine 1506 by PKC accompanied by phosphorylation of additional sites by cA-PK. This regulatory mechanism may serve to integrate neuronal signals mediated through these parallel signaling pathways.			LI, M (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195, USA.				NIGMS NIH HHS [T32-GM07270] Funding Source: Medline; NINDS NIH HHS [R01-NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; GERSHON E, 1992, J NEUROSCI, V12, P3743; GINTY DD, 1992, J CELL BIOL, V116, P1465, DOI 10.1083/jcb.116.6.1465; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, UNPUB; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; Numann Randal, 1992, Society for Neuroscience Abstracts, V18, P1133; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; Samantha Murphy S, UNPUB; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SMITH RD, 1992, AM J PHYSIOL, V263, pC660, DOI 10.1152/ajpcell.1992.263.3.C660; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; YANG XC, 1992, J NEUROSCI, V12, P268	33	245	247	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1439	1442		10.1126/science.8396273	http://dx.doi.org/10.1126/science.8396273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8396273				2022-12-28	WOS:A1993LW54900030
J	ALLEN, GC; DIXON, NE; KORNBERG, A				ALLEN, GC; DIXON, NE; KORNBERG, A			STRAND SWITCHING OF A REPLICATIVE DNA HELICASE PROMOTED BY THE ESCHERICHIA-COLI PRIMOSOME	CELL			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; PROTEIN ACTION; PHI-X174 DNA; PURIFIED ENZYMES; GENE-PRODUCT; VIRAL-DNA; FACTOR-Y; SEQUENCE; CONVERSION	The E. coli primosome assembles at an origin on a single-stranded DNA, like that of PHIX174, to promote replication of that template. Upon conversion to the duplex form, the primosome can generate a rolling circle product from this template. Rolling circle synthesis implies the transfer of the DnaB helicase from its initial loading site on the viral strand to a displaced complementary strand. Isolated primosomes promote only unit-length synthesis; supplementation with PriC, DnaC, and DnaT is necessary to reconstitute rolling circle synthesis. Rolling circle replication is sensitive to salts, whereas primosome assembly and unit-length synthesis are not. Thus, the primosome promotes two distinct reactions: assembly for first-round synthesis and strand switching for rolling circle synthesis.	AUSTRALIAN NATL UNIV,RES SCH CHEM,CTR MOLEC STRUCT & FUNCT,CANBERRA,ACT 2600,AUSTRALIA	Australian National University	ALLEN, GC (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.		Dixon, Nicholas E/A-1226-2008	Dixon, Nicholas E/0000-0002-5958-6945	NIGMS NIH HHS [GM07851] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P11610; ALLEN GC, 1993, IN PRESS J BIOL CHEM, V268; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5253; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Kornberg A., 1992, DNA REPLICATION; LARK CA, 1978, J BACTERIOL, V136, P1008, DOI 10.1128/JB.136.3.1008-1017.1978; LARK KG, 1978, CSHSQB, V43, P537; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MASAI H, 1990, J BIOL CHEM, V265, P15134; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P2304; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SELZER G, 1982, P NATL ACAD SCI-BIOL, V79, P7082, DOI 10.1073/pnas.79.23.7082; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1981, J BIOL CHEM, V256, P5233; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZECHEL K, 1975, J BIOL CHEM, V250, P4684	37	18	18	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					713	722		10.1016/0092-8674(93)90518-U	http://dx.doi.org/10.1016/0092-8674(93)90518-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395352				2022-12-28	WOS:A1993LU59200014
J	SLESAREV, AI; STETTER, KO; LAKE, JA; GELLERT, M; KRAH, R; KOZYAVKIN, SA				SLESAREV, AI; STETTER, KO; LAKE, JA; GELLERT, M; KRAH, R; KOZYAVKIN, SA			DNA TOPOISOMERASE-V IS A RELATIVE OF EUKARYOTIC TOPOISOMERASE-I FROM A HYPERTHERMOPHILIC PROKARYOTE	NATURE			English	Article							DESULFUROCOCCUS-AMYLOLYTICUS; METHANOPYRUS-KANDLERI; ARCHAEBACTERIA; 110-DEGREES-C; METHANOGENS; ARCHAEA; GENE	THE DNA topoisomerases are ubiquitous enzymes that fulfil vital roles in the replication, transcription and recombination of DNA by carrying out DNA-strand passage reactions1-7. Here we characterize a prokaryotic counterpart to the eukaryotic topoisomerase I in the hyperthermophilic methanogen Methanopyrus kandleri8-10. The new enzyme, called topoisomerase V, has the following properties in common with eukaryotic topoisomerase I, which distinguish it from all other known prokaryotic topoisomerases: (1) its activity is Mg2+-independent; (2) it relaxes both negatively and positively supercoiled DNA; (3) it makes a covalent complex with the 3' end of the broken DNA strand; and (4) it is recognized by antibody raised against human topoisomerase I. Eukaryotic-like enzymes have been discovered in some hyperthermophilic prokaryotes, namely the eocytes11 and the extremely thermophilic archaebacteria12, and hyperthermophilic homologues of eukaryotic DNA polymerase-a, transcription factor IIB and DNA ligase13-15 have all been reported. Thus our findings support the idea that some essential parts of the eukaryotic transcription-translation and replication machineries were in place before the emergence of eukaryotes, and that the closest living relatives of eukaryotes may be hyperthermophiles.	RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA; UKRAINIAN ACAD SCI,RE KAVETSKY INST ONCOL & RADIOBIOL,KIEV 252127,UKRAINE; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,W-8400 REGENSBURG,GERMANY; NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892	Russian Academy of Sciences; National Academy of Sciences Ukraine; University of California System; University of California Los Angeles; University of Regensburg; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	SLESAREV, AI (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.			Kozyavkin, Sergei/0000-0001-5605-5113				BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BURGGRAF S, 1991, SYST APPL MICROBIOL, V14, P346, DOI 10.1016/S0723-2020(11)80308-5; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KORNBERG A, 1992, DNA REPLICATION, P379; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; KURR M, 1991, ARCH MICROBIOL, V156, P239, DOI 10.1007/BF00262992; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P68; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SLESAREV AI, 1991, J BIOL CHEM, V266, P12321; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; TSE YC, 1980, J BIOL CHEM, V255, P5560; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	21	81	84	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					735	736		10.1038/364735a0	http://dx.doi.org/10.1038/364735a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8395022				2022-12-28	WOS:A1993LT67700064
J	NONET, ML; GRUNDAHL, K; MEYER, BJ; RAND, JB				NONET, ML; GRUNDAHL, K; MEYER, BJ; RAND, JB			SYNAPTIC FUNCTION IS IMPAIRED BUT NOT ELIMINATED IN C-ELEGANS MUTANTS LACKING SYNAPTOTAGMIN	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSMITTER RELEASE; SEQUENCE-ANALYSIS; PROTEIN; P65; IDENTIFICATION; EXOCYTOSIS; MUTATIONS; VESICLES; MEMBRANE	Synaptotagmin is an abundant synaptic vesicle-associated protein proposed to be involved in calcium-mediated neurotransmitter release. Our molecular and genetic results demonstrate that, although synaptotagmin is required for the proper function of the presynaptic nerve terminal in C. elegans, some neurotransmitter release persists in synaptogamin mutants. In C. elegans neurons, synaptotagmin is localized to regions known to be rich in synapses and appears to be associated with synaptic vesicles. Mutants defective in the synaptotagmin gene, called snt-1, exhibit severe behavioral abnormalities that are characteristic of deficiencies in synaptic function, including severe locomotion, feeding, and defecation defects. The mutants are defective in exocytosis, since they accumulate acetylcholine, and are resistant to cholinesterase inhibitors, but they nevertheless remain sensitive to cholinergic receptor agonists. In spite of these exocytic defects, snt-1 mutants are capable of coordinated motor movements, indicating that the mutants do not have a complete block of neurotransmitter release.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	University of California System; University of California Berkeley; Oklahoma Medical Research Foundation				Meyer, Barbara/0000-0002-6530-4588				ALFONSO A, 1993, IN PRESS SCIENCE; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRENNER S, 1974, GENETICS, V77, P71; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GIBSON TJ, 1987, GENE, V53, P283, DOI 10.1016/0378-1119(87)90017-5; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERMAN RK, 1978, GENETICS, V88, P49; HERMAN RK, 1980, NEMATODES BIOL MODEL, V1, P227; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HODGKIN J, 1979, GENETICS, V91, P67; HOSONO R, 1989, ZOOL SCI, V6, P697; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; JAHN R, 1991, MARKERS NEURAL ENDOC, P25; JOHNSON CD, 1988, NEURON, V1, P165, DOI 10.1016/0896-6273(88)90201-2; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEWIS JA, 1980, NEUROSCIENCE, V5, P967, DOI 10.1016/0306-4522(80)90180-3; LEWIS JA, 1987, J NEUROSCI, V7, P3059; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCCAMAN RE, 1977, J NEUROCHEM, V28, P669, DOI 10.1111/j.1471-4159.1977.tb10442.x; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MCINTIRE SL, 1993, IN PRESS NATURE; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER L, 1991, THESIS MIT CAMBRIDGE; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; RAND JB, 1985, PSYCHOPHARMACOL BULL, V21, P623; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; Sulston J., 1988, NEMATODE CAENORHABDI, P587; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315	68	477	498	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1291	1305		10.1016/0092-8674(93)90357-V	http://dx.doi.org/10.1016/0092-8674(93)90357-V			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391930	Bronze			2022-12-28	WOS:A1993LL20900006
J	PEREZMARTIN, J; ESPINOSA, M				PEREZMARTIN, J; ESPINOSA, M			PROTEIN-INDUCED BENDING AS A TRANSCRIPTIONAL SWITCH	SCIENCE			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; BACILLUS-SUBTILIS; POSITIVE CONTROL; PLASMID PLS1; DNA; ACTIVATOR; PROMOTER; REPA; INITIATION	The question of whether protein-induced DNA bending can act as a switch factor when placed upstream of an array of promoters located in tandem was investigated in vivo. The catabolite activating protein binding site of the fur operon was replaced by the binding site of the RepA repressor protein, which is able to bend DNA immediately after binding. Appropriately phased induced bending could act as a transcriptional switch factor in vivo.	CSIC,CTR INVEST BIOL,VELAZQUEZ 144,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Espinosa, Manuel/M-5282-2019; Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382				AIBA H, 1981, J BIOL CHEM, V256, P1905; BALLESTER S, 1990, GENE, V86, P71, DOI 10.1016/0378-1119(90)90115-8; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DELORENZO V, 1988, EUR J BIOCHEM, V173, P537; DELSOLAR G, 1992, MOL MICROBIOL, V6, P83; DELSOLAR G, IN PRESS MOL MICROBI; DELSOLAR GH, 1990, J BIOL CHEM, V265, P12569; DELSOLAR GH, 1989, NUCLEIC ACIDS RES, V17, P2405, DOI 10.1093/nar/17.7.2405; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; KUHNKE G, 1989, EMBO J, V8, P1247, DOI 10.1002/j.1460-2075.1989.tb03498.x; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; Miller J.H., 1972, EXPT MOL GENETICS; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; PEREZMARTIN J, 1989, J BIOL CHEM, V264, P21334; PEREZMARTIN J, UNPUB; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; TIMMIS K, IN PRESS METHODS ENZ; TOBIN JF, 1990, J MOL BIOL, V211, P713; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	32	70	70	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					805	807		10.1126/science.8387228	http://dx.doi.org/10.1126/science.8387228			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8387228				2022-12-28	WOS:A1993LA74400029
J	GIARDIELLO, FM; HAMILTON, SR; KRUSH, AJ; PIANTADOSI, S; HYLIND, LM; CELANO, P; BOOKER, SV; ROBINSON, CR; OFFERHAUS, GJA				GIARDIELLO, FM; HAMILTON, SR; KRUSH, AJ; PIANTADOSI, S; HYLIND, LM; CELANO, P; BOOKER, SV; ROBINSON, CR; OFFERHAUS, GJA			TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTESTINAL TUMORS; INDOMETHACIN TREATMENT; CELL-CYCLE; IDENTIFICATION; INHIBITION; GENES; RAT; CHROMOSOME-5Q21; MUTATIONS; THERAPY	Background. Familial adenomatous polyposis is an autosomal dominant disorder characterized by the formation of hundreds of colorectal adenomas and eventual colorectal cancer. Administration of the nonsteroidal antiinflammatory drug sulindac has been followed by regression of polyps in patients with this disorder, but no controlled trial of this drug in patients who have not had surgery has been reported. Methods. We conducted a randomized, double-blind, placebo-controlled study of 22 patients with familial adenomatous polyposis, including 18 who had not undergone colectomy. The patients received sulindac at a dose of 150 mg orally twice a day for nine months or identical-appearing placebo tablets. The number and size of the polyps were evaluated every three months for one year. Results. A statistically significant decrease in the mean number of polyps and their mean diameter occurred in patients treated with sulindac, as compared with those given placebo. When treatment was stopped at nine months, the number of polyps had decreased to 44 percent of base-line values and the diameter of the polyps to 35 percent of base-line values (P = 0.014 and P<0.001, respectively, for the comparison with the changes in the group given placebo). No patient had complete resolution of polyps. Three months after treatment with sulindac was stopped, both the number and the size of the polyps increased in sulindac-treated patients but remained significantly lower than the values at base line. No side effects from sulindac were noted. Conclusions. Sulindac reduces the number and size of colorectal adenomas in patients with familial adenomatous polyposis, but its effect is incomplete, and it is unlikely to replace colectomy as primary therapy.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	GIARDIELLO, FM (corresponding author), JOHNS HOPKINS UNIV HOSP,DIV GASTROENTEROL,BLALOCK 935,600 N WOLFE ST,BALTIMORE,MD 21287, USA.				NCI NIH HHS [CA 53802] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYER BM, 1979, BIOCHEM PHARMACOL, V28, P441, DOI 10.1016/0006-2952(79)90112-6; BAYER BM, 1979, J PHARMACOL EXP THER, V210, P106; BOLAND CR, 1989, GASTROINTESTINAL DIS, P1483; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; DECOSSE JJ, 1989, J NATL CANCER I, V81, P2190; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HIAL V, 1977, J PHARMACOL EXP THER, V202, P446; HIAL V, 1976, EUR J PHARMACOL, V37, P367, DOI 10.1016/0014-2999(76)90044-3; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; NARISAWA T, 1982, GANN, V73, P377; NARISAWA T, 1981, CANCER RES, V41, P1954; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; ROSS DS, 1988, J SURG RES, V45, P249, DOI 10.1016/0022-4804(88)90071-6; VERMA AK, 1980, CANCER RES, V40, P308; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119	25	1435	1482	1	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1313	1316		10.1056/NEJM199305063281805	http://dx.doi.org/10.1056/NEJM199305063281805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	8385741				2022-12-28	WOS:A1993KZ64000005
J	POOLE, CJM; SHAKESPEARE, AT				POOLE, CJM; SHAKESPEARE, AT			SHOULD SEWAGE WORKERS AND CARERS FOR PEOPLE WITH LEARNING-DISABILITIES BE VACCINATED FOR HEPATITIS-A	BRITISH MEDICAL JOURNAL			English	Article											POOLE, CJM (corresponding author), CENT CLIN,DEPT OCCUPAT HLTH,DUDLEY DY2 7BX,ENGLAND.							HEAP BJ, 1991, LANCET, V338, P1152, DOI 10.1016/0140-6736(91)92015-T; SKINHOJ P, 1981, ARCH ENVIRON HEALTH, V36, P139, DOI 10.1080/00039896.1981.10667618; TILZEY AJ, 1992, BMJ-BRIT MED J, V304, P1272, DOI 10.1136/bmj.304.6837.1272; TIMOTHY EM, 1984, COMMUNICAB DIS REP, V3, P3; 1992, LANCET, V339, P1198	5	30	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1102	1102		10.1136/bmj.306.6885.1102	http://dx.doi.org/10.1136/bmj.306.6885.1102			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8388287	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500023
J	BURGER, MPM; HOLLEMA, H; GOUW, ASH; PIETERS, WJLM; QUINT, WGV				BURGER, MPM; HOLLEMA, H; GOUW, ASH; PIETERS, WJLM; QUINT, WGV			CIGARETTE-SMOKING AND HUMAN PAPILLOMAVIRUS IN PATIENTS WITH REPORTED CERVICAL CYTOLOGICAL ABNORMALITY	BRITISH MEDICAL JOURNAL			English	Article							POLYMERASE CHAIN-REACTION; INTRAEPITHELIAL NEOPLASIA; UTERINE CERVIX; CARCINOMA INSITU; CANCER; SCRAPES; MUCUS; DNA	Objective-To assess the relation between two risk factors for cervical neoplasia: smoking and infection with oncogenic human papillomavirus. It has been suggested that smoking causes a local immunological defect, which could facilitate the infection and persistence of human papillomavirus. Design-Cross sectional epidemiological study. Completion of a structured questionnaire by the patients, analysis of cervical scrapes for human papillomavirus, and morphological examination of biopsy specimens. Setting-Outpatient gynaecological clinic. Subjects-181 women with a report of cervical cytological abnormality. Main outcome measures-Prevalence of infection with oncogenic human papillomavirus and smoking habits. Results-Oncogenic human papillomavirus was found in the cervix of 26 (41%) of the 63 women who did not smoke, 22 (58%) of the 38 who smoked 1-10 cigarettes a day, 28 (61%) of the 46 who smoked 11-20 cigarettes a day, and 26 (76%) of the 34 who smoked greater-than-or-equal-to 21 cigarettes a day. The prevalence of the virus thus increased in accordance with the number of cigarettes smoked (p=0.001). This relation remained after adjustment for age at first intercourse and lifetime number of sexual partners. Of the 63 non-smokers, 23 had previously smoked at least 10 cigarettes a day at some time. Of these 23 women, 14 (61%) had oncogenic human papillomavirus in their cervix. Of the 40 women who had never smoked at least 10 cigarettes a day, 12 (30%) had the virus. The prevalence of oncogenic human papillomavirus in non-smokers therefore depended on previous smoking habits (p=0.03). Conclusion-The dose dependent effect of cigarette smoking on the occurrence of oncogenic human papillomavirus favours a causal relation between these risk factors for cervical neoplasia.	UNIV GRONINGEN HOSP,DEPT PATHOL,9713 EZ GRONINGEN,NETHERLANDS; DEPT PATHOL,9675 HJ WINSCHOTEN,NETHERLANDS; DIAGNOST CTR SSDZ,DEPT MOLEC BIOL,2625 AD DELFT,NETHERLANDS	University of Groningen	BURGER, MPM (corresponding author), UNIV GRONINGEN HOSP,DEPT OBSTET & GYNAECOL,9713 EZ GRONINGEN,NETHERLANDS.							BARRASSO R, 1987, GYNECOL ONCOL, V27, P197, DOI 10.1016/0090-8258(87)90293-9; BARTON SE, 1988, LANCET, V2, P652; BRESLOW NE, 1980, IARC SCI PUBL, V32, P146; BRINTON LA, 1986, JAMA-J AM MED ASSOC, V255, P3265, DOI 10.1001/jama.255.23.3265; CAMPION MJ, 1986, LANCET, V2, P237; CLAAS ECJ, 1989, AM J PATHOL, V135, P703; CLARKE EA, 1982, AM J EPIDEMIOL, V115, P59, DOI 10.1093/oxfordjournals.aje.a113279; CORNELISSEN MTE, 1989, J GEN VIROL, V70, P2555, DOI 10.1099/0022-1317-70-10-2555; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; HOLLY EA, 1986, J NATL CANCER I, V76, P983; IKENBERG H, 1990, GENITAL PAPILLOMAVIR, P87; JENSON AB, 1990, PAPILLOMAVIRUSES HUM, P12; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P60; LYON JL, 1983, AM J PUBLIC HEALTH, V73, P558, DOI 10.2105/AJPH.73.5.558; MELCHERS W, 1989, J MED VIROL, V27, P329, DOI 10.1002/jmv.1890270413; RICHART RM, 1990, OBSTET GYNECOL, V75, P131; RICHART RM, 1973, PATHOLOGY ANN 1973, P301; ROHAN T, 1991, INT J CANCER, V49, P856, DOI 10.1002/ijc.2910490609; ROTKIN ID, 1973, CANCER RES, V33, P1353; SAITO K, 1987, CANCER, V59, P2064, DOI 10.1002/1097-0142(19870615)59:12<2064::AID-CNCR2820591217>3.0.CO;2-7; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SYRJANEN K, 1989, ACTA OBSTET GYN SCAN, V68, P613, DOI 10.3109/00016348909013280; TREVATHAN E, 1983, JAMA-J AM MED ASSOC, V250, P499, DOI 10.1001/jama.250.4.499; VANDENBRULE AJC, 1990, INT J CANCER, V45, P644, DOI 10.1002/ijc.2910450412; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; ZURHAUSEN H, 1989, JNCI-J NATL CANCER I, V81, P1680; 1991, DFPHS1990 DUTCH F PU	27	72	77	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					749	752		10.1136/bmj.306.6880.749	http://dx.doi.org/10.1136/bmj.306.6880.749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8387842	Green Published, Bronze			2022-12-28	WOS:A1993KU17300020
J	SPACH, DH; SILVERSTEIN, FE; STAMM, WE				SPACH, DH; SILVERSTEIN, FE; STAMM, WE			TRANSMISSION OF INFECTION BY GASTROINTESTINAL ENDOSCOPY AND BRONCHOSCOPY	ANNALS OF INTERNAL MEDICINE			English	Review						ENDOSCOPY, GASTROINTESTINAL; BRONCHOSCOPY; SALMONELLA; PSEUDOMONAS-AERUGINOSA; MYCOBACTERIUM TUBERCULOSIS	HUMAN-IMMUNODEFICIENCY-VIRUS; RETROGRADE CHOLANGIOPANCREATOGRAPHY ERCP; MYCOBACTERIUM-CHELONEI ISOLATION; CAMPYLOBACTER-PYLORI INFECTION; PSEUDOMONAS-AERUGINOSA SEPSIS; FLEXIBLE FIBEROPTIC ENDOSCOPY; BRONCHOALVEOLAR LAVAGE FLUID; VIRAL HEPATITIS-B; PRACTICAL IMPLICATIONS; SERRATIA-MARCESCENS	Objective: To review reports on the transmission of infections by flexible gastrointestinal endoscopy and bronchoscopy in order to determine common infecting microorganisms, circumstances of transmission, and methods of risk reduction. Data Sources: Relevant English-language articles were identified through prominent review articles and a MEDLINE search (1966 to July 1992); additional references were selected from the bibliographies of identified articles. Study Selection: All selected articles related to transmission of infection by gastrointestinal endoscopy or bronchoscopy; 265 articles were reviewed in detail. Data Synthesis: Two hundred and eighty-one infections were transmitted by gastrointestinal endoscopy, and 96 were transmitted by bronchoscopy. The clinical spectrum of these infections ranged from asymptomatic colonization to death. Salmonella species and Pseudomonas aeruginosa were repeatedly identified as the causative agents of infections transmitted by gastrointestinal endoscopy, and Mycobacterium tuberculosis, atypical mycobacteria, and P. aeruginosa were the most common causes of infections transmitted by bronchoscopy. One case of hepatitis B virus transmission via gastrointestinal endoscopy was documented. Major reasons for transmission were improper cleaning and disinfection procedures; the contamination of endoscopes by automatic washers; and an inability to decontaminate endoscopes, despite the use of standard disinfection techniques, because of their complex channel and valve systems. Conclusions: The most common agents of infection transmitted by endoscopy are Salmonella, Pseudomonas, and Mycobacterium species. To prevent endoscopic transmission of infections, recommended disinfection guidelines must be followed, the effectiveness of automatic washers must be carefully monitored, and improvements in endoscope design are needed to facilitate effective cleaning and disinfection.	UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle								ALLEN JI, 1987, GASTROENTEROLOGY, V92, P759, DOI 10.1016/0016-5085(87)90029-1; ALVARADO CJ, 1991, AM J MED, V91, pS272, DOI 10.1016/0002-9343(91)90381-7; [Anonymous], 1988, GASTROINTEST ENDOSC, V34, p37S; AXON ATR, 1991, J GASTROEN HEPATOL, V6, P23, DOI 10.1111/j.1440-1746.1991.tb01138.x; AYOOLA EA, 1981, GASTROINTEST ENDOSC, V27, P60, DOI 10.1016/S0016-5107(81)73150-X; BAKER JL, 1987, JAMA-J AM MED ASSOC, V257, P2609, DOI 10.1001/jama.257.19.2609; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BEECHAM HJ, 1979, JAMA-J AM MED ASSOC, V241, P1013, DOI 10.1001/jama.241.10.1013; BEST M, 1990, J CLIN MICROBIOL, V28, P2234, DOI 10.1128/JCM.28.10.2234-2239.1990; BILBAO MK, 1976, GASTROENTEROLOGY, V70, P314; BIRNIE GG, 1983, GUT, V24, P171, DOI 10.1136/gut.24.2.171; BOND WW, 1978, GASTROINTEST ENDOSC, V24, P225, DOI 10.1016/S0016-5107(78)73517-0; BOND WW, 1981, LANCET, V1, P550; BOND WW, 1991, DISINFECTION STERILI, P1097; BOTTRILL PM, 1991, J GASTROEN HEPATOL, V6, P45, DOI 10.1111/j.1440-1746.1991.tb01143.x; CHAYT KJ, 1986, JAMA-J AM MED ASSOC, V256, P2356, DOI 10.1001/jama.256.17.2356; CHIARAMONTE M, 1983, HEPATO-GASTROENTEROL, V30, P189; CHMEL H, 1976, AM J MED, V60, P203, DOI 10.1016/0002-9343(76)90429-0; CLASSEN DC, 1988, AM J MED, V84, P590, DOI 10.1016/0002-9343(88)90141-6; CLASSEN M, 1988, ENDOSCOPY, V20, P128, DOI 10.1055/s-2007-1013017; COLINJONES DG, 1978, CLIN GASTROENTEROL, V7, P775; COLLIGNON P, 1989, MED J AUSTRALIA, V151, P269, DOI 10.5694/j.1326-5377.1989.tb101192.x; COLLINS FM, 1976, J CLIN MICROBIOL, V4, P408; CORRADO OJ, 1986, HUM TOXICOL, V5, P325, DOI 10.1177/096032718600500505; CREDLE WF, 1974, AM REV RESPIR DIS, V109, P67; CRYAN EMJ, 1984, J HOSP INFECT, V5, P371, DOI 10.1016/0195-6701(84)90004-5; CWALINA WM, 1988, SOC GASTROINTESTINAL, P100; DAVIDSON PT, 1990, ANN INTERN MED, V112, P393, DOI 10.7326/0003-4819-76-3-112-6-393; DAWSON DJ, 1982, AM REV RESPIR DIS, V126, P1095; DEAN AG, 1977, LANCET, V2, P134; DOHERTY DE, 1982, DIGEST DIS SCI, V27, P169, DOI 10.1007/BF01311712; DURANTE L, 1992, AM J MED, V92, P476, DOI 10.1016/0002-9343(92)90743-U; DWYER DM, 1987, GASTROINTEST ENDOSC, V33, P84, DOI 10.1016/S0016-5107(87)71515-6; EARNSHAW JJ, 1985, J HOSP INFECT, V6, P95, DOI 10.1016/S0195-6701(85)80024-4; ELSON CO, 1975, GASTROENTEROLOGY, V69, P507; Favero M., 1991, DISINFECTION STERILI, P617; FRASER V, 1991, 91ST GEN M AM SOC MI, P425; Fraser V, 1992, GASTROINTEST ENDOSC, V38, P277; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; GOLDSTEIN B, 1985, J HOSP INFECT, V6, P194; GORSE GJ, 1991, INFECT CONT HOSP EP, V12, P289; GRAHAM DY, 1988, AM J GASTROENTEROL, V83, P974; GREENE WH, 1974, GASTROENTEROLOGY, V67, P912; GROGAN JB, 1966, J TRAUM, V6, P639, DOI 10.1097/00005373-196609000-00010; GUBLER JGH, 1992, CHEST, V101, P1245, DOI 10.1378/chest.101.5.1245; HANSON PJV, 1989, LANCET, V2, P86; HANSON PJV, 1991, THORAX, V46, P410, DOI 10.1136/thx.46.6.410; HANSON PJV, 1990, GUT, V31, P657, DOI 10.1136/gut.31.6.657; Hawkey P M, 1981, J Hosp Infect, V2, P373, DOI 10.1016/0195-6701(81)90071-2; HOFFMANN K K, 1989, Infection Control and Hospital Epidemiology, V10, P511, DOI 10.1086/645937; HOLLAND HD, 1990, AM J SCI, V290A, P1; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; HOOFNAGLE JH, 1980, J CLIN GASTROENTEROL, V2, P65, DOI 10.1097/00004836-198003000-00010; HUSSAIN SA, 1978, CHEST, V74, P483, DOI 10.1016/S0012-3692(15)37419-5; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KACZMAREK RG, 1992, AM J MED, V92, P257, DOI 10.1016/0002-9343(92)90074-L; KANE RC, 1975, AM REV RESPIR DIS, V111, P102; KATNER HP, 1988, J FAM PRACTICE, V27, P271; KAYE D, 1967, ANN NY ACAD SCI, V145, P429, DOI 10.1111/j.1749-6632.1967.tb50242.x; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KOBAYASHI H, 1978, MED INSTRUM, V12, P171; KOK ASF, 1987, J GASTROEN HEPATOL, V2, P175; KORETZ RL, 1979, DIGEST DIS SCI, V24, P21, DOI 10.1007/BF01297233; LANGENBERG W, 1990, J INFECT DIS, V161, P507, DOI 10.1093/infdis/161.3.507; LEERS WD, 1980, CAN MED ASSOC J, V123, P275; LOW DE, 1980, ARCH INTERN MED, V140, P1076, DOI 10.1001/archinte.140.8.1076; MAIMAN M, 1988, JAMA-J AM MED ASSOC, V260, P2214, DOI 10.1001/jama.260.15.2214; MANDELSTAM P, 1976, GASTROINTEST ENDOSC, V23, P16, DOI 10.1016/S0016-5107(76)73568-5; MARKOVITZ A, 1979, WESTERN J MED, V131, P550; MCCLELLAND DBL, 1978, BRIT MED J, V1, P23, DOI 10.1136/bmj.1.6104.23; MCDONALD GB, 1976, GASTROINTEST ENDOSC, V22, P168, DOI 10.1016/S0016-5107(76)73735-0; MONCADA RE, 1978, GASTROINTEST ENDOSC, V24, P231, DOI 10.1016/S0016-5107(78)73518-2; MORGAN AG, 1978, BRIT MED J, V1, P369, DOI 10.1136/bmj.1.6109.369; MORRIS IM, 1975, LANCET, V2, P1152; MORRISON AJ, 1984, REV INFECT DIS, V6, pS627; MUSHER DM, 1973, ARCH INTERN MED, V132, P869, DOI 10.1001/archinte.132.6.869; NELSON JA, 1988, LANCET, V1, P259; NELSON KE, 1983, AM REV RESPIR DIS, V127, P97, DOI 10.1164/arrd.1983.127.1.97; Noy M F, 1980, J Hosp Infect, V1, P53, DOI 10.1016/0195-6701(80)90032-8; NYE K, 1990, J HOSP INFECT, V16, P257, DOI 10.1016/0195-6701(90)90114-4; OCONNOR BH, 1982, LANCET, V2, P864; OSMOND D, 1990, AIDS KNOWLEDGE BASE, P1; PAPPAS SA, 1983, AM REV RESPIR DIS, V127, P391; PARKER HW, 1979, GASTROINTEST ENDOSC, V25, P102, DOI 10.1016/S0016-5107(79)73385-2; PEREIRA W, 1975, AM REV RESPIR DIS, V112, P59; PRIGOGINE T, 1988, J HOSP INFECT, V11, P93, DOI 10.1016/0195-6701(88)90047-3; QIZILBASH A, 1986, LAB INVEST, V54, pA51; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; REDEKER AG, 1975, AM J MED SCI, V270, P9, DOI 10.1097/00000441-197507000-00003; REICHERT M, 1991, INFECT CONT HOSP EP, V12, P497; RICHARDSON AJ, 1986, J HOSP INFECT, V7, P208, DOI 10.1016/0195-6701(86)90068-X; ROBINSON WS, 1989, PRINCIPLES PRACTICE, P1204; ROTHSTEIN RI, 1992, GASTROINTEST ENDOSC, V38, P277; RUBBO SD, 1967, J APPL BACTERIOL, V30, P78, DOI 10.1111/j.1365-2672.1967.tb00277.x; RUTALA WA, 1990, AM J INFECT CONTROL, V18, P99, DOI 10.1016/0196-6553(90)90089-B; RUTALA WA, 1991, INFECT CONT HOSP EP, V12, P282; Sammartino M T, 1982, J Hosp Infect, V3, P65, DOI 10.1016/0195-6701(82)90032-9; SATTAR SA, 1991, REV INFECT DIS, V13, P430; SCHLEUPNER CJ, 1980, INFECT CONT HOSP EP, V1, P38, DOI 10.1017/S0195941700052383; SCHLIESSLER KH, 1980, LANCET, V2, P1246; SCHOUSBOE M, 1980, NEW ZEAL MED J, V92, P275; Schoutens-Serruys E, 1981, J Hosp Infect, V2, P392, DOI 10.1016/0195-6701(81)90077-3; SEEFELD U, 1981, ENDOSCOPY, V13, P238, DOI 10.1055/s-2007-1021694; SIEGMANIGRA Y, 1985, J HOSP INFECT, V6, P218; SIEGMANIGRA Y, 1988, J HOSP INFECT, V12, P7, DOI 10.1016/0195-6701(88)90116-8; SILVERSTEIN FE, 1992, GASTROINTEST ENDOSC, V38, P277; SILVIS SE, 1976, JAMA-J AM MED ASSOC, V235, P928, DOI 10.1001/jama.235.9.928; SIMMONS BP, 1983, AM J INFECT CONTROL, V11, P97, DOI 10.1016/0196-6553(83)90122-0; SINGH S, 1989, J HOSP INFECT, V14, P49, DOI 10.1016/0195-6701(89)90133-3; STAFFORD RS, 1991, 7 P INT C AIDS FLOR, P32; STEERE AC, 1979, AM REV RESPIR DIS, V120, P214; STRUELENS MJ, 1990, 3RD P INT C NOS INF; SURATT PM, 1977, CHEST, V71, P52, DOI 10.1378/chest.71.1.52; TUFFNELL PG, 1976, CAN J PUBLIC HEALTH, V67, P141; VANGOSSUM A, 1989, ENDOSCOPY, V21, P247, DOI 10.1055/s-2007-1012962; WAYE JD, 1989, ENDOSCOPY REV, V6, P62; WEBB SF, 1975, CHEST, V68, P703, DOI 10.1378/chest.68.5.703; WEINSTEIN HJ, 1977, AM REV RESPIR DIS, V116, P541, DOI 10.1164/arrd.1977.116.3.541; WEINSTEIN RA, 1977, LANCET, V2, P862; WELLER IVD, 1988, GUT, V29, P1134, DOI 10.1136/gut.29.8.1134; WHEELER PW, 1989, J INFECT DIS, V159, P954, DOI 10.1093/infdis/159.5.954; WOODCOCK A, 1989, LANCET, V2, P270; 1989, A2289 US MARK END EN; 1991, MMWR, V39, P675; 1989, MMWR S4, V38, P1; 1987, ANN INTERN MED, V107, P353; 1985, MMWR, V34, P681; 1978, AORN J, V28, P907; 1977, MMWR, V41, P22; 1990, MMWR, V39, P1; 1990, MMWR, V39, P909	131	352	371	2	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					117	128		10.7326/0003-4819-118-2-199301150-00008	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416308				2022-12-28	WOS:A1993KF91800008
J	MASON, RP; BESDINE, RW				MASON, RP; BESDINE, RW			ALUMINUM IN ALZHEIMERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NEUROFIBRILLARY TANGLES; DRINKING-WATER; PLAQUE CORES; MICROPROBE; ACCUMULATION; ABSENCE				MASON, RP (corresponding author), UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA.							CANDY JM, 1986, LANCET, V1, P354; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; MARTYN CN, 1989, LANCET, V1, P59; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; NERI LC, 1991, LANCET, V338, P390, DOI 10.1016/0140-6736(91)90531-S; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; PETTEGREW JW, 1989, ANN NY ACAD SCI, V568, P5	10	1	1	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1868	1868		10.1001/jama.270.15.1868	http://dx.doi.org/10.1001/jama.270.15.1868			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411534				2022-12-28	WOS:A1993MB46400037
J	LOWE, SW; RULEY, HE; JACKS, T; HOUSMAN, DE				LOWE, SW; RULEY, HE; JACKS, T; HOUSMAN, DE			P53-DEPENDENT APOPTOSIS MODULATES THE CYTOTOXICITY OF ANTICANCER AGENTS	CELL			English	Article							PROGRAMMED CELL-DEATH; ACUTE LYMPHOBLASTIC-LEUKEMIA; P53 GENE-MUTATIONS; WILD-TYPE P53; LUNG-CANCER; E1A PROTEINS; MUTANT P53; C-MYC; DNA; ACTIVATION	Although the primary cellular targets of many anticancer agents have been identified, less is known about the processes leading to the selective cell death of cancer cells or the molecular basis of drug resistance. p53-deficient mouse embryonic fibroblasts were used to examine systematically the requirement for p53 in cellular sensitivity and resistance to a diverse group of anticancer agents. These results demonstrate that an oncogene, specifically the adenovirus E1A gene, can sensitize fibroblasts to apoptosis induced by ionizing radiation, 5-fluorouracil, etoposide, and adriamycin. Furthermore, the p53 tumor suppressor is required for efficient execution of the death program. These data reinforce the notion that the cytotoxic action of many anticancer agents involves processes subsequent to the interaction between drug and cellular target and indicate that divergent stimuli can activate a common cell death program. Consequently, the involvement of p53 in the apoptotic response suggests a mechanism whereby tumor cells can acquire cross-resistance to anticancer agents.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Massachusetts Institute of Technology (MIT); Vanderbilt University	LOWE, SW (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [P01-CA42063, 5R27CA17575, R01CA40602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA017575, P01CA042063, R01CA040602, R01CA017575] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1993, ADV CANCER RES, V60, P157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DAMICO D, 1992, ONCOGENE, V7, P3369; DAVIDOFF AM, 1991, SURGERY, V110, P259; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; HEIMDAL K, 1993, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; ISAACS WB, 1991, CANCER RES, V51, P4716; JAROS E, 1992, BRIT J CANCER, V66, P373, DOI 10.1038/bjc.1992.273; JONVEAUX P, 1991, LEUKEMIA, V5, P839; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1989, CANCER RES, V49, P5870; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NERI A, 1993, BLOOD, V81, P128; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHI YF, 1990, J IMMUNOL, V144, P3326; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STRETCH JR, 1991, CANCER RES, V51, P5976; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THORLACIUS S, 1993, CANCER RES, V53, P1637; VANERP PEJ, 1988, CYTOMETRY, V9, P627, DOI 10.1002/cyto.990090618; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; WALKER GC, 1987, CELLULAR MOL BIOL, P1346; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEARGIN J, 1993, J CLIN INVEST, V91, P211	61	2962	3033	7	246	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					957	967		10.1016/0092-8674(93)90719-7	http://dx.doi.org/10.1016/0092-8674(93)90719-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402885				2022-12-28	WOS:A1993LY49300004
J	MYERS, LC; TERRANOVA, MP; FERENTZ, AE; WAGNER, G; VERDINE, GL				MYERS, LC; TERRANOVA, MP; FERENTZ, AE; WAGNER, G; VERDINE, GL			REPAIR OF DNA METHYLPHOSPHOTRIESTERS THROUGH A METALLOACTIVATED CYSTEINE NUCLEOPHILE	SCIENCE			English	Article							CD-113 NMR; BINDING-PROTEIN; GENE-32 PROTEIN; ZINC ENZYMES; COORDINATION; COMPLEXES; DOMAIN; SPECTROSCOPY; LIGANDS	The Escherichia coli Ada protein repairs methylphosphotriesters in DNA by direct, irreversible methyl transfer to one of its own cysteines. Upon methyl transfer, Ada acquires the ability to bind specific DNA sequences and thereby to induce genes that confer resistance to methylating agents. The amino-terminal domain of Ada, which comprises the methylphosphotriester repair and sequence-specific DNA binding elements, contains a tightly bound zinc ion. Analysis of the zinc binding site by cadmium-113 nuclear magnetic resonance and site-directed mutagenesis revealed that zinc participates in the autocatalytic activation of the active site cysteine and may also function as a conformational switch.	HARVARD UNIV,PROGRAM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Harvard Medical School; Harvard University								BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BOBSEIN BR, 1981, J BIOL CHEM, V256, P5313; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CEDAR H, 1989, CELL, V53, P3; COLEMAN JE, 1971, PROGR BIOORGANIC CHE, V1, P159; COLEMAN JE, 1986, ZINC ENZYMES, P77; COTTON FA, 1988, ADV INORG CHEM RAD, P597; DEMPLE B, 1990, PROTEIN METHYLATION, P285; ELDER RC, 1978, INORG CHEM, V17, P1296, DOI 10.1021/ic50183a039; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; FREY MH, 1985, J AM CHEM SOC, V107, P6847, DOI 10.1021/ja00310a017; GIEDROC DP, 1992, BIOCHEMISTRY-US, V31, P765, DOI 10.1021/bi00118a018; GIEDROC DP, 1989, BIOCHEMISTRY-US, V28, P2410, DOI 10.1021/bi00432a011; JACKOW F, UNPUB; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KUEHN CG, 1980, PROG INORG CHEM, V27, P154; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LINDOY LF, 1974, INORG CHEM, V13, P2494, DOI 10.1021/ic50140a037; LIVE D, 1985, J AM CHEM SOC, V107, P1775, DOI 10.1021/ja00292a062; MYERS LC, 1992, BIOCHEMISTRY-US, V31, P4541, DOI 10.1021/bi00134a002; MYERS LT, UNPUB; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; RAJANIKANTH B, 1984, INDIAN J CHEM B, V23, P1043; Singer B., 1983, MOL BIOL MUTAGENS CA; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; SUMMERS MF, 1988, COORDIN CHEM REV, V86, P43, DOI 10.1016/0010-8545(88)85012-4; TERRANOVA ML, UNPUB; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; WORGOTTER E, 1986, J AM CHEM SOC, V108, P6162	33	180	182	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1164	1167		10.1126/science.8395079	http://dx.doi.org/10.1126/science.8395079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8395079				2022-12-28	WOS:A1993LU58600030
J	PAJUS, I; LESTANG, P; LIOTE, F; DRYLL, A				PAJUS, I; LESTANG, P; LIOTE, F; DRYLL, A			ERYTHRODERMA AFTER CLODRONATE TREATMENT	BRITISH MEDICAL JOURNAL			English	Letter											PAJUS, I (corresponding author), HOP LARIBOISIERE,F-75475 PARIS 10,FRANCE.			Liote, Frederic/0000-0003-4419-0726				BEGAUD B, 1985, THERAPIE, V40, P111; ELLIOTT AT, 1988, BRIT MED J, V297, P592, DOI 10.1136/bmj.297.6648.592-a; MAUTALEN CA, 1984, BRIT MED J, V288, P828, DOI 10.1136/bmj.288.6420.828-a; MIAN M, 1991, INT J CLIN PHARM RES, V1, P107; ROUX C, 1992, CALCIFIED TISSUE INT, V50, P78	5	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					484	484		10.1136/bmj.307.6902.484	http://dx.doi.org/10.1136/bmj.307.6902.484			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400937	Green Published, Bronze			2022-12-28	WOS:A1993LU59000025
J	VISWANATHAN, R; ZASADZINSKI, JA; SCHWARTZ, DK				VISWANATHAN, R; ZASADZINSKI, JA; SCHWARTZ, DK			STRAINED-LAYER VAN-DER-WAALS EPITAXY IN A LANGMUIR-BLODGETT-FILM	SCIENCE			English	Article							ATOMIC FORCE MICROSCOPY; MOLECULAR-RESOLUTION IMAGES; AIR-WATER-INTERFACE; ELECTRON-DIFFRACTION; REENTRANT APPEARANCE; 2 DIMENSIONS; MONOLAYER; ACID; GROWTH; SURFACE	Atomic force microscope images of Langmuir-Blodgett films of lead and manganese fatty acid salts show that these monolayers have long-range order and are oriented with respect to the mica substrate, although the lattice symmetries of the monolayers and substrate are dramatically different. The surface lattice of sequentially thicker films evolves toward the bulk structure while retaining the substrate alignment. This behavior is in distinct contrast to films of cadmium fatty acid salts on mica, or all films on amorphous silicon oxide, in which the monolayer structure is disordered and a three-layer-thick film displays the bulk structure.	UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles			Schwartz, Daniel K/H-5153-2012	Schwartz, Daniel K/0000-0001-5397-7200	NIGMS NIH HHS [GM 47334] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn D.J., 1991, J CHEM PHYS, V95, P8486, DOI 10.1063/1.461278; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BOHM C, 1989, THIN SOLID FILMS, V178, P511, DOI 10.1016/0040-6090(89)90346-5; BONNEROT A, 1985, CHEM PHYS, V97, P365, DOI 10.1016/0301-0104(85)87045-2; BOURDIEU L, 1991, PHYS REV LETT, V67, P2029, DOI 10.1103/PhysRevLett.67.2029; ECKHARDT CJ, 1992, LANGMUIR, V8, P2591, DOI 10.1021/la00047a003; ECKHARDT CJ, 1992, CHEM PHYS LETT, V194, P370, DOI 10.1016/0009-2614(92)86067-R; EGGER M, 1990, J STRUCT BIOL, V103, P89, DOI 10.1016/1047-8477(90)90089-U; GARNAES J, 1992, NATURE, V357, P5; GAROFF S, 1986, J PHYS-PARIS, V47, P701, DOI 10.1051/jphys:01986004704070100; HANSMA HG, 1991, LANGMUIR, V7, P1051, DOI 10.1021/la00054a005; Kitaigorodskii A.I., 1961, ORGANIC CHEM CRYSTAL; KOMA A, 1989, APPL SURF SCI, V41-2, P451, DOI 10.1016/0169-4332(89)90102-5; LEVEILLER F, 1991, SCIENCE, V252, P1532, DOI 10.1126/science.252.5012.1532; MARTI O, 1988, SCIENCE, V239, P50, DOI 10.1126/science.3336773; MEYER E, 1991, NATURE, V349, P398, DOI 10.1038/349398a0; OHUCHI FS, 1990, J APPL PHYS, V68, P2168, DOI 10.1063/1.346574; PRAKASH M, 1986, CHEM PHYS LETT, V128, P354, DOI 10.1016/0009-2614(86)80376-1; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; ROBERTS GG, 1985, ADV PHYS, V34, P475, DOI 10.1080/00018738500101801; SCHLOSSMAN ML, 1991, PHYS REV LETT, V66, P1599, DOI 10.1103/PhysRevLett.66.1599; SCHWARTZ DK, 1992, J PHYS CHEM-US, V96, P10444, DOI 10.1021/j100204a059; SCHWARTZ DK, 1992, J CHEM PHYS, V96, P2356, DOI 10.1063/1.462032; SCHWARTZ DK, 1992, SCIENCE, V257, P508, DOI 10.1126/science.257.5069.508; SCHWARTZ DK, 1993, PHYS REV LETT, V70, P1267, DOI 10.1103/PhysRevLett.70.1267; STEITZ R, 1991, THIN SOLID FILMS, V205, P124, DOI 10.1016/0040-6090(91)90483-E; TIPPMANNKRAYER P, 1992, THIN SOLID FILMS, V210, P577, DOI 10.1016/0040-6090(92)90346-D; UENO K, 1990, J VAC SCI TECHNOL A, V8, P68, DOI 10.1116/1.576983; VISWANATHAN R, 1992, LANGMUIR, V8, P1603, DOI 10.1021/la00042a018; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; YAZDANIAN M, 1990, LANGMUIR, V6, P1093, DOI 10.1021/la00096a012; YAZDANIAN M, 1992, LANGMUIR, V8, P630, DOI 10.1021/la00038a055; ZASADZINSKI JAN, 1991, BIOPHYS J, V59, P755, DOI 10.1016/S0006-3495(91)82288-3	33	65	65	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					449	452		10.1126/science.8392751	http://dx.doi.org/10.1126/science.8392751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392751				2022-12-28	WOS:A1993LN62300029
J	ELLINOR, PT; ZHANG, JF; RANDALL, AD; ZHOU, M; SCHWARZ, TL; TSIEN, RW; HORNE, WA				ELLINOR, PT; ZHANG, JF; RANDALL, AD; ZHOU, M; SCHWARZ, TL; TSIEN, RW; HORNE, WA			FUNCTIONAL EXPRESSION OF A RAPIDLY INACTIVATING NEURONAL CALCIUM-CHANNEL	NATURE			English	Article							CHICK SENSORY NEURONS; ELECTRIC ORGAN; OMEGA-CONOTOXIN; NERVE-TERMINALS; CELLS; RECEPTOR; CURRENTS; BINDING	DIVERSE types of calcium channels in vertebrate neurons are important in linking electrical activity to transmitter release, gene expression and modulation of membrane excitability1. Four classes of Ca2+ channels (T, N, L and P-type) have been distinguished2-6 on the basis of their electrophysiological and pharmacological properties. Most of the recently cloned Ca2+ channels7-16 fit within this functional classification. But one major branch of the Ca2+ channel gene family, including BII (ref. 15) and doe-1 (ref. 16), has not been functionally characterized. We report here the expression of doe-1 and show that it is a high-voltage-activated (HVA) Ca2+ channel that inactivates more rapidly than previously expressed calcium channels. Unlike L-type or P-type channels, doe-1 is not blocked by dihydropyridine antagonists or the peptide toxin omega-Aga-IVA, respectively. In contrast to a previously cloned N-type channel14, doe-I block by omega-CTx-GVIA requires micromolar toxin and is readily reversible. Unlike most HVA channels, doe-1 also shows unusual sensitivity to block by Ni2+. Thus, doe-1 is an HVA Ca2+ channel with novel functional properties. We have identified a Ca2+ channel current in rat cerebellar granule neurons that resembles doe-1 in many kinetic and pharmacological features.	STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Stanford University; Cornell University				Ellinor, Patrick/0000-0002-2067-0533; Randall, Andrew/0000-0001-8852-3671				AHMAD SN, 1988, BRAIN RES, V453, P247; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARLSON SS, 1978, BIOCHEMISTRY-US, V17, P1188, DOI 10.1021/bi00600a009; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; Hille B., 1992, IONIC CHANNELS EXCIT; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HORNE WA, 1991, J BIOL CHEM, V266, P13719; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; KASAI H, 1992, J PHYSIOL-LONDON, V448, P161, DOI 10.1113/jphysiol.1992.sp019035; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, INTRACELLULAR CALCIU, P97; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NARAHASHI T, 1987, J PHYSIOL-LONDON, V383, P231; NGSEE JK, 1991, J BIOL CHEM, V226, P2625; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, J NEUROSCI, V11, P2259; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WANG XM, 1992, J PHYSIOL-LONDON, V445, P181, DOI 10.1113/jphysiol.1992.sp018919; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	33	247	253	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					455	458		10.1038/363455a0	http://dx.doi.org/10.1038/363455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8389006				2022-12-28	WOS:A1993LE93800060
J	ANDERSON, DR; LENSING, AWA; WELLS, PS; LEVINE, MN; WEITZ, JI; HIRSH, J				ANDERSON, DR; LENSING, AWA; WELLS, PS; LEVINE, MN; WEITZ, JI; HIRSH, J			LIMITATIONS OF IMPEDANCE PLETHYSMOGRAPHY IN THE DIAGNOSIS OF CLINICALLY SUSPECTED DEEP-VEIN THROMBOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						PLETHYSMOGRAPHY, IMPEDANCE; PHLEBOGRAPHY; THROMBOPHLEBITIS; ANTICOAGULANTS; THROMBOSIS	VENOUS-THROMBOSIS; OUTPATIENTS; MANAGEMENT; HIP; PHLEBOGRAPHY; REPLACEMENT; VENOGRAPHY; SURGERY	Objective: To re-evaluate the accuracy of impedance plethysmography (IPG) for the detection of proximal deep-vein thrombosis (DVT). Patients: A total of 384 of 390 consecutive outpatients referred with their first episode of clinically suspected deep-vein thrombosis. Setting: University-based tertiary care medical center associated with a cancer clinic. Design: A retrospective analysis of a cohort of patients whose data were recorded and stored prospectively on a computerized data base over a 22-month period. Measurements: Patients were evaluated by a physician and underwent IPG testing. Patients with abnormal IPG tests and those with normal IPG results in whom there was a high clinical suspicion of DVT or in whom follow-up IPG testing was not feasible were referred for venography. Venography and IPG results were interpreted by a panel of independent observers. Two models of the IPG instrument were used (Codman 200 and Electrodiagnostic Instruments 800). Results: Venography (or compression ultrasound) was done in 57 patients with an abnormal IPG test and in 85 patients with normal IPG results. Impedance plethysmography was abnormal in only 37 of 56 patients with confirmed proximal-vein thrombosis (sensitivity, 66%; 95% CI, 52% to 78%). Of the 57 patients with an abnormal IPG result, 37 had DVT (positive predictive value, 65%). The sensitivity for the detection of proximal DVT did not differ between the IPG 200 and 800 instruments (sensitivity, 63% and 71%, respectively; P > 0.2). Of the 19 proximal-vein thrombi not detected by IPG, 12 (63%) were occlusive and 11 (58%) involved at least the popliteal and superficial femoral veins. Conclusions: At our center, IPG has a far lower sensitivity for proximal-vein thrombosis than has been previously reported for symptomatic outpatients. The reason for this low sensitivity is unclear. Our findings indicate that centers using IPG as the initial diagnostic test for suspected DVT should be aware of this potential problem and should consider re-evaluating the sensitivity of their IPG machines by performing venography in a cohort of their patients with normal test results.	HAMILTON CIV HOSP, RES CTR, HAMILTON L8V 1C3, ON, CANADA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University			Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				BETTMANN MA, 1977, RADIOLOGY, V122, P101, DOI 10.1148/122.1.101; BULLER HR, 1991, THROMB HAEMOSTASIS, V66, P133; COOPERMAN M, 1979, AM J SURG, V137, P252, DOI 10.1016/0002-9610(79)90157-0; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KAKKAR VV, 1969, LANCET, V2, P230; LAGERSTEDT CI, 1985, LANCET, V2, P515; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1991, THROMB HAEMOSTASIS, V65, P1730; MCLACHLIN J, 1962, ARCH SURG-CHICAGO, V85, P738; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; PETERS SHA, 1982, THROMB HAEMOSTASIS, V48, P297; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; ROSENDAAL FR, 1991, THROMB HAEMOSTASIS, V65, P1043; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; TAYLOR DW, 1980, THROMB RES, V17, P561, DOI 10.1016/0049-3848(80)90094-8; TOY PTCY, 1978, WESTERN J MED, V129, P89	25	83	84	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					25	30		10.7326/0003-4819-118-1-199301010-00005	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416154				2022-12-28	WOS:A1993KE60500005
J	CASS, OW; FREEMAN, ML; PEINE, CJ; ZERA, RT; ONSTAD, GR				CASS, OW; FREEMAN, ML; PEINE, CJ; ZERA, RT; ONSTAD, GR			OBJECTIVE EVALUATION OF ENDOSCOPY SKILLS DURING TRAINING	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOSCOPY, GASTROINTESTINAL; CLINICAL COMPETENCE; ENDOSCOPY, DIGESTIVE SYSTEM; COLONOSCOPY; CERTIFICATION	UPPER-GASTROINTESTINAL-TRACT; PROCEDURAL SKILLS; COMPLICATIONS; SIGMOIDOSCOPY; PHYSICIANS; COMPETENCE; DIAGNOSIS; TRIAL	Objective: To evaluate the number of supervised gastrointestinal endoscopic procedures required to achieve initial competency using a simple objective grading system. Design: Prospective, cross-sectional study. Setting: A gastroenterology and surgical training program at a large, university-affiliated county hospital. Participants: Seven gastroenterology fellows and five fourth-year surgery residents. Interventions: Trainees were graded postprocedure using a microcomputer program. Grading criteria for esophagogastroduodenoscopy included entering the esophagus (esophageal intubation), traversing the pylorus into the duodenum, and recognizing whether the upper gastrointestinal tract was abnormal. Criteria for colonoscopy were traversing the splenic flexure, intubating the cecum, and recognizing whether the colon was abnormal. Results: When presented with a case mix representative of practice, esophageal intubation did not reach 90% until more than 100 procedures had been done. Cecal intubation remained at only 84% after 100 procedures. Conclusions: More than 100 supervised upper gastrointestinal endoscopies or colonoscopies are necessary to achieve technical competence in gastrointestinal endoscopy.	HENNEPIN CTY MED CTR, DEPT SURG, MINNEAPOLIS, MN 55415 USA	Hennepin County Medical Center	CASS, OW (corresponding author), HENNEPIN CTY MED CTR, DEPT MED, 701 PK AVE S, MINNEAPOLIS, MN 55415 USA.							BAILLIE J, 1991, ENDOSCOPY, V23, P126, DOI 10.1055/s-2007-1010637; BELL GD, 1990, SCAND J GASTROENTERO, V25, P18, DOI 10.3109/00365529009093167; BENDTSEN F, 1990, HEPATOLOGY, V11, P341, DOI 10.1002/hep.1840110302; Benson JA, 1987, GASTROENTEROLOGY, V92, P254, DOI 10.1016/0016-5085(87)90869-9; CONN HO, 1965, NEW ENGL J MED, V272, P830, DOI 10.1056/NEJM196504222721604; GILBERT DA, DIG DIS SCI S, V26, pS55; GJORUP T, 1986, SCAND J GASTROENTERO, V21, P261, DOI 10.3109/00365528609003074; HAWES R, 1986, AM J MED, V80, P465, DOI 10.1016/0002-9343(86)90721-7; KLING PA, 1985, SCAND J GASTROENTERO, V20, P462, DOI 10.3109/00365528509089681; MILLER G, 1987, LEBER MAGEN DARM, V17, P299; NOAR MD, 1992, GASTROINTEST ENDOSC, V38, P280; PARRY BR, 1991, AUST NZ J SURG, V61, P419, DOI 10.1111/j.1445-2197.1991.tb00254.x; PETERSON WL, 1981, NEW ENGL J MED, V304, P925, DOI 10.1056/NEJM198104163041601; REIERTSEN O, 1987, ENDOSCOPY, V19, P1, DOI 10.1055/s-2007-1013011; SILVIS SE, 1976, JAMA-J AM MED ASSOC, V235, P928, DOI 10.1001/jama.235.9.928; WHITE LJ, 1987, ANN INTERN MED, V107, P588, DOI 10.7326/0003-4819-107-4-588; WHITE LJ, 1987, ANN INTERN MED, V107, P937, DOI 10.7326/0003-4819-107-6-937; WHITE LJ, 1987, ANN INTERN MED, V107, P772, DOI 10.7326/0003-4819-107-5-772; WIGTON RS, 1989, ANN INTERN MED, V111, P1023, DOI 10.7326/0003-4819-111-12-1023; WIGTON RS, 1989, ANN INTERN MED, V111, P932, DOI 10.7326/0003-4819-111-11-932; WILLIAMS CB, 1990, GASTROINTEST ENDOSC, V36, P220; 1990, AM BOARD INTERNA SPR, P4; 1991, PRINCIPLES TRAINING, P3; 1991, APPROPRIATE USE GAST, P7	24	196	198	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					40	44		10.7326/0003-4819-118-1-199301010-00008	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416157				2022-12-28	WOS:A1993KE60500008
J	BAKER, MD; BELL, LM; AVNER, JR				BAKER, MD; BELL, LM; AVNER, JR			OUTPATIENT MANAGEMENT WITHOUT ANTIBIOTICS OF FEVER IN SELECTED INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEBRILE INFANTS; OBSERVATION SCALES; SERIOUS ILLNESS; AGE; CEFTRIAXONE; YOUNGER	Background. In many academic centers it is standard practice to hospitalize all febrile infants younger than two months of age, whereas in community settings such infants are often cared for as outpatients. Methods. We conducted a controlled study of 747 consecutive infants 29 through 56 days of age who had temperatures of at least 38.2-degrees-C. After a complete history taking, physical examination, and sepsis workup, the 460 infants with laboratory or clinical findings suggestive of serious bacterial illness were hospitalized and treated with antibiotics. The screening criteria for serious bacterial illness included a white-cell count of at least 15,000 per cubic millimeter, a spun urine specimen that had 10 or more white cells per high-power field or that was positive on bright-field microscopy, cerebrospinal fluid with a white-cell count of 8 or more per cubic millimeter or a positive Gram's stain, or a chest film showing an infiltrate. The 287 infants who had unremarkable examinations and normal laboratory results were assigned to either inpatient observation without antibiotics (n = 148) or outpatient care without antibiotics but with reexaminations after 24 and 48 hours (n = 139). Results. Serious bacterial illness was diagnosed in 65 infants (8.7 percent). Of these 65 infants, 64 were identified by our screening criteria for inpatient care and antibiotic treatment (sensitivity = 98 percent; 95 percent confidence interval, 92 to 100). Of the 287 infants assigned to observation and no antibiotics, 286 (99.7 percent) did not have serious bacterial illness. Only two infants assigned to outpatient observation were subsequently admitted to the hospital; neither was found to have a serious illness. Out-patient care without antibiotics of the febrile infants at low risk for serious illness resulted in a savings of about $3,100 per patient. Conclusions. With the use of strict screening criteria, a substantial number of febrile one-to-two-month-old infants can be cared for safely as outpatients and without antibiotics.	CHILDRENS HOSP PHILADELPHIA,DIV ALLERGY IMMUNOL & INFECT DIS,PHILADELPHIA,PA 19104; UNIV PENN,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	BAKER, MD (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV GEN PEDIAT,EMERGENCY MED SECT,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.		Baker, Mark/N-7720-2019					BAKER MD, 1990, PEDIATRICS, V85, P1040; BARAFF LJ, 1991, PEDIATR INFECT DIS J, V10, P795, DOI 10.1097/00006454-199111000-00001; BASKIN MN, 1992, J PEDIATR-US, V120, P22, DOI 10.1016/S0022-3476(05)80591-8; CASPE WB, 1983, PEDIATR INFECT DIS J, V2, P131, DOI 10.1097/00006454-198303000-00013; DAGAN R, 1988, J PEDIATR-US, V112, P355, DOI 10.1016/S0022-3476(88)80312-3; DEANGELIS C, 1983, AM J DIS CHILD, V137, P1146, DOI 10.1001/archpedi.1983.02140380006003; DEANGELIS C, 1983, AM J DIS CHILD, V137, P1150, DOI 10.1001/archpedi.1983.02140380010004; GREENE JW, 1981, CLIN PEDIATR, V20, P375, DOI 10.1177/000992288102000601; KING JC, 1987, SOUTHERN MED J, V80, P948, DOI 10.1097/00007611-198708000-00004; LIEU TA, 1992, PEDIATRICS, V89, P1135; MCCARTHY P, 1992, PEDIATRICS, V89, P1251; MCCARTHY PL, 1982, PEDIATRICS, V70, P802; PHILIP AGS, 1980, PEDIATRICS, V65, P1036; POWELL KR, 1990, PEDIATR INFECT DIS J, V9, P153, DOI 10.1097/00006454-199003000-00001; WALD ER, 1991, AM J DIS CHILD, V145, P1359, DOI 10.1001/archpedi.1991.02160120027012	15	311	324	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1437	1441		10.1056/NEJM199311113292001	http://dx.doi.org/10.1056/NEJM199311113292001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413453	Bronze			2022-12-28	WOS:A1993MF29200001
J	HARRIS, CC; HOLLSTEIN, M				HARRIS, CC; HOLLSTEIN, M			CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WILD-TYPE P53; BREAST-CANCER PATIENTS; CELL-CYCLE CHECKPOINT; POOR PROGNOSIS; LUNG-CANCER; PROTEIN P53; HEPATOCELLULAR-CARCINOMA; SV40-TRANSFORMED CELLS; MUTATIONAL SPECIFICITY; COLORECTAL-CARCINOMA		INT AGCY RES CANC, WHO, MECHANISMS CARCINOGENESIS UNIT, F-69372 LYON, FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)	HARRIS, CC (corresponding author), NCI, HUMAN CARCINOGENESIS LAB, BLDG 37, RM 2C01, BETHESDA, MD 20892 USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BENNETT WP, 1991, ONCOGENE, V6, P1779; BENNETT WP, 1992, CANCER RES, V52, P6092; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1992, LANCET, V339, P1350; BORRESEN AL, 1992, LANCET, V340, P318; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BRUGGE J, 1991, ORIGINS HUMAN CANCER; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG KC, 1993, ADV CANCER RES, V60, P121; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; FREBOURG T, 1992, CANCER RES, V52, P6976; FRIEDMANN T, 1992, CANCER, V70, P1810, DOI 10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1991, CANCER RES, V51, pS5023; HARRIS CC, 1993, ACCOMPLISHMENTS CANC, P179; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORII A, 1992, CANCER RES, V52, P3231; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISHIOKA C, IN PRESS NAT GENET; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; ITO T, 1992, CANCER RES, V52, P1369; IWAYA K, 1991, JPN J CANCER RES, V82, P835, DOI 10.1111/j.1349-7006.1991.tb02710.x; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES PA, 1991, CANCER RES, V51, P3617; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LEACH FS, 1993, CANCER RES, V53, P2231; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEHMAN TA, IN PRESS IARC MONOGR; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY DD, 1992, CANCER RES, V52, P5668; LI FP, 1990, CURR PROB CANCER, V14, P75; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LILLEBERG SL, 1992, MOL CARCINOGEN, V6, P159, DOI 10.1002/mc.2940060211; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAESAWA C, 1992, JPN J CANCER RES, V83, P1253, DOI 10.1111/j.1349-7006.1992.tb02754.x; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLUMI AF, 1990, CANCER RES, V50, P7081; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PUISIEUX A, 1993, ONCOGENE, V8, P487; QUINLAN DC, 1992, CANCER RES, V52, P4828; RIOU G, 1992, J NATL CANCER I, V84, P1525, DOI 10.1093/jnci/84.19.1525; ROBERTSON M, 1991, NATURE, V353, P300, DOI 10.1038/353300a0; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; ROTTER V, 1991, ADV CANCER RES, V57, P257; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SATO T, 1990, CANCER RES, V50, P7184; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHIMKE RN, 1978, GENETICS CANCER MAN, V18, P26; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SILVESTRINI R, 1993, J NATL CANCER I, V85, P965, DOI 10.1093/jnci/85.12.965; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P223, DOI 10.1007/BF01611179; SOZZI G, 1992, CANCER RES, V52, P6079; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THILLY WG, 1990, ANNU REV PHARMACOL, V30, P369; THOR AD, 1993, J NATL CANCER I, V85, P176, DOI 10.1093/jnci/85.3.176; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TROTTIER Y, 1992, MOL CARCINOGEN, V6, P140, DOI 10.1002/mc.2940060209; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; WANG LD, 1993, CANCER RES, V53, P1783; Watson J. D., 1987, MOL BIOL GENE; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINTER SF, 1992, CANCER RES, V52, P4168; WUWILLIAMS AH, 1992, RISK ANAL, V12, P559, DOI 10.1111/j.1539-6924.1992.tb00712.x; YANUCK M, 1993, CANCER RES, V53, P3257; YAP EPH, 1993, LANCET, V341, P251, DOI 10.1016/0140-6736(93)90124-Y; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	138	1342	1377	2	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1318	1327		10.1056/NEJM199310283291807	http://dx.doi.org/10.1056/NEJM199310283291807			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413413				2022-12-28	WOS:A1993MD55700007
J	BAKER, J; LIU, JP; ROBERTSON, EJ; EFSTRATIADIS, A				BAKER, J; LIU, JP; ROBERTSON, EJ; EFSTRATIADIS, A			ROLE OF INSULIN-LIKE GROWTH-FACTORS IN EMBRYONIC AND POSTNATAL-GROWTH	CELL			English	Article							FACTOR-II GENE; MESSENGER RIBONUCLEIC-ACIDS; GIANT TRANSGENIC MICE; IGF-II; BINDING-PROTEINS; PRENATAL GROWTH; DEVELOPING RAT; MOUSE EMBRYOS; DWARF MICE; ADULT-RAT	A developmental analysis of growth kinetics in mouse embryos carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I), IGF-II, and the type 1 IGF receptor (IGF1R), alone or in combination, defined the onset of mutational effects leading to growth deficiency and indicated that between embryonic days 11.0 and 12.5, IGF1R serves only the in vivo mitogenic signaling of IGF-II. From E13.5 onward, IGF1R interacts with both IGF-I and IGF-II, while IGF-II recognizes an additional unknown receptor (XR). In contrast with the embryo proper, placental growth is served exclusively by an IGF-II-XR interaction. Additional genetic data suggested that the type 2 IGF/mannose 6-phosphate receptor is an unlikely candidate for XR. Postnatal growth curves indicated that surviving Igf-1(-/-) mutants, which are infertile and exhibit delayed bone development, continue to grow with a retarded rate after birth in comparison with wild-type littermates and become 30% of normal weight as adults.			BAKER, J (corresponding author), COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							[Anonymous], 1991, INSULIN LIKE GROWTH; AYERLELIEVRE C, 1991, DEVELOPMENT, V111, P105; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; BECK F, 1987, DEVELOPMENT, V101, P175; Boettiger E, 1938, ENDOCRINOLOGY, V22, P447, DOI 10.1210/endo-22-4-447; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CHARD T, 1989, J ENDOCRINOL, V123, P3, DOI 10.1677/joe.0.1230003; CHENG TC, 1983, ENDOCRINOLOGY, V113, P1669, DOI 10.1210/endo-113-5-1669; COCK AG, 1966, Q REV BIOL, V41, P131, DOI 10.1086/404940; DAUGHADAY WH, 1989, PERSPECT BIOL MED, V32, P194; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DERCOLE AJ, 1980, DEV BIOL, V79, P33, DOI 10.1016/0012-1606(80)90071-8; EICHER EM, 1980, J HERED, V71, P187, DOI 10.1093/oxfordjournals.jhered.a109344; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; ENESCO M, 1962, J EMBRYOL EXP MORPH, V10, P530; FILSON AJ, 1993, DEVELOPMENT, V118, P731; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; GIRARD J, 1989, INTRAUTERINE GROWTH, P23; Gluckman P., 1992, HUMAN GROWTH BASIC C, P253; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GOEDBLOED JF, 1972, ACTA ANAT, V82, P305; GREEN H, 1985, DIFFERENTIATION, V29, P195, DOI 10.1111/j.1432-0436.1985.tb00316.x; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; HOYT EC, 1988, MOL ENDOCRINOL, V2, P1077, DOI 10.1210/mend-2-11-1077; HUGGETT AS, 1951, J PHYSIOL-LONDON, V114, P306, DOI 10.1113/jphysiol.1951.sp004622; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; HYNES MA, 1987, MOL ENDOCRINOL, V1, P233, DOI 10.1210/mend-1-3-233; ISAKSSON OGP, 1991, PEDIATR NEPHROL, V5, P451, DOI 10.1007/BF01453680; JAMES DA, 1967, J REPROD FERTIL, V14, P265, DOI 10.1530/jrf.0.0140265; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; JONAS HA, 1989, BIOCHEM J, V257, P101, DOI 10.1042/bj2570101; KIESS W, 1987, J BIOL CHEM, V262, P12745; KOHLER E, 1972, N-S ARCH PHARMAKOL, V272, P169, DOI 10.1007/BF00508767; LAIRD AK, 1965, GROWTH, V29, P233; LEE JE, 1990, DEVELOPMENT, V110, P151; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LINDAHL A, 1987, J ENDOCRINOL, V115, P263, DOI 10.1677/joe.0.1150263; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LUND PK, 1986, J BIOL CHEM, V261, P4539; MacDowell EC, 1927, J GEN PHYSIOL, V11, P57, DOI 10.1085/jgp.11.1.57; MACNEIL MD, 1983, GROWTH, V47, P371; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MCLAREN A, 1965, J REPROD FERTIL, V9, P79, DOI 10.1530/jrf.0.0090079; MCLAREN A, 1965, J REPROD FERTIL, V9, P343; Medawar PB., 1945, ESSAYS GROWTH FORM, P157; MILNER RDG, 1987, EUR J PEDIATR, V146, P113, DOI 10.1007/BF02343214; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1806, DOI 10.1210/endo-120-5-1806; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; Needham J, 1931, CHEM EMBRYOLOGY; NILSSON A, 1986, SCIENCE, V233, P571, DOI 10.1126/science.3523759; NISSLEY SP, 1980, HORM METAB RES, V12, P158, DOI 10.1055/s-2007-996230; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKA Y, 1985, J BIOL CHEM, V260, P9435; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAYNE PR, 1967, NATURE, V215, P849, DOI 10.1038/215849a0; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; ROBERTS CT, 1986, J BIOL CHEM, V261, P25; ROTWEIN P, 1987, ENDOCRINOLOGY, V121, P2141, DOI 10.1210/endo-121-6-2141; RUGH R, 1990, MOUSE ITS REPRODUCTI; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SENIOR PV, 1990, DEVELOPMENT, V109, P67; SHEA BT, 1987, ENDOCRINOLOGY, V121, P1924, DOI 10.1210/endo-121-6-1924; SHEA BT, 1990, GENET RES, V56, P21, DOI 10.1017/S0016672300028846; SIKOV MR, 1970, GROWTH, V34, P1; Snell GD, 1929, P NATL ACAD SCI USA, V15, P274, DOI 10.1073/pnas.15.3.274; STRECK RD, 1992, ENDOCRINOLOGY, V131, P2030, DOI 10.1210/en.131.4.2030; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; TELFORD NA, 1990, MOL REPROD DEV, V27, P81, DOI 10.1002/mrd.1080270202; VANBUULOFFERS S, 1983, ACTA ENDOCRINOL-COP, V103, P1; von Bertalanffy L., 1960, FUNDAMENTAL ASPECTS, P137, DOI 10.1016/b978-0-408-10638-2.50012-4; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WINICK M, 1965, DEV BIOL, V12, P451, DOI 10.1016/0012-1606(65)90009-6; ZHOU J, 1992, ENDOCRINOLOGY, V131, P1230, DOI 10.1210/en.131.3.1230	82	1963	2031	0	106	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					73	82		10.1016/0092-8674(93)90680-O	http://dx.doi.org/10.1016/0092-8674(93)90680-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402902	hybrid			2022-12-28	WOS:A1993MB66700009
J	ANDERSON, SJ; LEVIN, SD; PERLMUTTER, RM				ANDERSON, SJ; LEVIN, SD; PERLMUTTER, RM			PROTEIN-TYROSINE KINASE P56(LCK) CONTROLS ALLELIC EXCLUSION OF T-CELL RECEPTOR BETA-CHAIN GENES	NATURE			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; THYMOCYTE DEVELOPMENT; SIGNAL TRANSDUCTION; TRANSGENIC MICE; EXPRESSION; P56LCK; ALPHA; LAMBDA-5; SURFACE	DURING T-cell development, site-specific DNA rearrangements mediating assembly of beta- and alpha-chain genes of the T-cell receptor (TCR) are developmentally ordered1,2. In particular, assembly and expression of a complete beta-chain gene blocks further rearrangements at the beta-locus (a process referred to as allelic exclusion)3 and drives the generation and expansion of CD4+8+ cells4,5. Although the mechanism used by TCRbeta chains to deliver such signals is unknown, studies in transgenic animals have suggested that the lymphocyte-specific protein tyrosine kinase p56lck may impinge on a similar signalling pathway6. The hypothesis that TCRbeta chains deliver intracellular signals via p56lck makes an explicit prediction: that interference with p56lck function will mitigate the effects of a simultaneously expressed TCRbeta chain. Here we confirm this prediction through examination of allelic exclusion in mice expressing both a functional TCRbeta chain transgene and a catalytically inactive form of p56lck.	UNIV WASHINGTON,SCH MED SL15,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED SL15,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED SL15,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED SL15,DEPT MED MED GENET,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; CHOU HS, 1987, P NATL ACAD SCI USA, V84, P1992, DOI 10.1073/pnas.84.7.1992; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OWEN JJT, 1988, IMMUNOLOGY, V63, P639; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	28	138	138	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					552	554		10.1038/365552a0	http://dx.doi.org/10.1038/365552a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413611				2022-12-28	WOS:A1993MA66100056
J	JOHNSSON, K; ALLEMANN, RK; WIDMER, H; BENNER, SA				JOHNSSON, K; ALLEMANN, RK; WIDMER, H; BENNER, SA			SYNTHESIS, STRUCTURE AND ACTIVITY OF ARTIFICIAL, RATIONALLY DESIGNED CATALYTIC POLYPEPTIDES	NATURE			English	Article							ALPHA-HELIX DIPOLE; BUNDLE PROTEIN; DECARBOXYLATION; ACID	BIOLOGICAL macromolecules with catalytic activity can be created artificially using two approaches. The first exploits a system that selects a few catalytically active biomolecules from a large pool of randomly generated (and largely inactive) molecules. Catalytic antibodies1 and many catalytic RNA molecules2 are obtained in this way. The second involves rational design of a biomolecule that folds in solution to present to the substrate an array of catalytic functional groups3-8. Here we report the synthesis of rationally designed polypeptides that catalyse the decarboxylation of oxaloacetate via an imine intermediate. We determine the secondary structures of the polypeptides by two-dimensional NMR spectroscopy. We are able to trap and identify intermediates in the catalytic cycle, and to explore the kinetics in detail. The formation of the imine by our artificial oxaloacetate decarboxylases is three to four orders of magnitude faster than can be achieved with simple amine catalysts: this performance rivals that of typical catalytic antibodies.	SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California Berkeley; Novartis; Sandoz			johnsson, kai/P-4222-2014	johnsson, kai/0000-0002-8002-1981				ALLEMANN RK, 1989, THESIS EIDGENOSSISCH; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, TOP STEREOCHEM, P127; BRUICE PY, 1989, J AM CHEM SOC, V111, P962, DOI 10.1021/ja00185a028; CHAKRAVARTY PK, 1973, EXPERIENTIA, V29, P786, DOI 10.1007/BF01946284; EISENBERG D, 1986, Proteins Structure Function and Genetics, V1, P16, DOI 10.1002/prot.340010105; GHADIRI MR, 1992, J AM CHEM SOC, V114, P825, DOI 10.1021/ja00029a004; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; GUTHRIE JP, 1972, J AM CHEM SOC, V94, P9136, DOI 10.1021/ja00781a025; GUTHRIE JP, 1972, J AM CHEM SOC, V94, P9132, DOI 10.1021/ja00781a024; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HAY RW, 1965, AUST J CHEM, V18, P337, DOI 10.1071/CH9650337; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HINE J, 1972, J AM CHEM SOC, V94, P190, DOI 10.1021/ja00756a033; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, V587; JOHNSSON K, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P166; JOHNSSON K, 1992, THESIS EIDGENOSISCHE; KAISER ET, 1988, REDESIGNING MOL LIFE, P25; KAPLAN H, 1971, BIOCHEM J, V124, P289, DOI 10.1042/bj1240289; KOEHLER K, 1964, J AM CHEM SOC, V86, P2413, DOI 10.1021/ja01066a024; LANGEN H, 1989, EUR J BIOCHEM, V182, P727, DOI 10.1111/j.1432-1033.1989.tb14885.x; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEUSSING DL, 1980, J AM CHEM SOC, V102, P5635, DOI 10.1021/ja00537a039; MERRIFIELD RB, 1980, PEPTIDES ANAL SYNTHE, V2, P3; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OLEARY MH, 1968, BIOCHEMISTRY-US, V7, P913, DOI 10.1021/bi00843a005; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; REIMANN JE, 1966, J AM CHEM SOC, V88, P3973, DOI 10.1021/ja00969a016; ROZZELL JD, 1987, METHOD ENZYMOL, V136, P479; ROZZELL JD, 1984, J AM CHEM SOC, V106, P4937, DOI 10.1021/ja00329a051; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SASAKI T, 1989, J AM CHEM SOC, V111, P380, DOI 10.1021/ja00183a065; SELTZER S, 1959, J AM CHEM SOC, V81, P4018, DOI 10.1021/ja01524a051; SHEEHAN JC, 1966, J AM CHEM SOC, V88, P3455, DOI 10.1021/ja00966a065; SPETNAGEL WJ, 1976, J AM CHEM SOC, V98, P8199, DOI 10.1021/ja00441a052; Wada A, 1976, Adv Biophys, P1; WESETHEIMER FH, 1971, P R WELCH FDN C CHEM, V15, P7; Wuthrich K., 1986, NMR PROTEINS NUCL AC	42	200	202	6	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					530	532		10.1038/365530a0	http://dx.doi.org/10.1038/365530a0			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413606				2022-12-28	WOS:A1993MA66100047
J	EASTLEY, RJ; MACPHERSON, R; RICHARDS, H; MIAN, IH				EASTLEY, RJ; MACPHERSON, R; RICHARDS, H; MIAN, IH			ASSAULTS ON PROFESSIONAL CARERS OF ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM CARE		SOUTHMEAD GEN HOSP,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital	EASTLEY, RJ (corresponding author), UNIV BRISTOL,DEPT MENTAL HLTH,BRISTOL BS2 8DZ,ENGLAND.							DONNELLY CM, 1989, INT J GERIATR PSYCH, V4, P299, DOI 10.1002/gps.930040509; FOTTRELL E, 1980, BRIT J PSYCHIAT, V136, P216, DOI 10.1192/bjp.136.3.216; KIRK S, 1989, INT J GERIATR PSYCH, V4, P305, DOI 10.1002/gps.930040510; LAM D, 1989, INT J GERIATR PSYCH, V4, P109, DOI 10.1002/gps.930040209; MANN AH, 1984, AGE AGEING, V13, P257, DOI 10.1093/ageing/13.5.257	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					845	845		10.1136/bmj.307.6908.845	http://dx.doi.org/10.1136/bmj.307.6908.845			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MA293	8401128	Green Published, Bronze			2022-12-28	WOS:A1993MA29300023
J	CLAPHAM, DE; NEER, EJ				CLAPHAM, DE; NEER, EJ			NEW ROLES FOR G-PROTEIN BETA-GAMMA-DIMERS IN TRANSMEMBRANE SIGNALING	NATURE			English	Article							MUSCARINIC K+-CHANNEL; GTP-BINDING PROTEINS; PHOSPHOLIPASE-C; ADENYLYL CYCLASE; REGULATORY PROTEINS; SUBUNIT ACTIVATION; TRANSDUCTION; RECEPTORS; MEMBRANE; KINASE	When a membrane-bound receptor acts on a G protein, the GTP-binding or G(alpha) subunit dissociates from the G(betagamma) dimer. Until recently, the G(alpha) subunit alone was thought to act on the enzymes and ion channels controlled by these proteins. Newer evidence indicates that the G(betagamma) dimer also plays a major part in signal transmission, enhancing the complexity of the possible interactions between the G proteins and their targets.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	CLAPHAM, DE (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHARMACOL, GUGGENHEIM 7, ROCHESTER, MN 55905 USA.		soler, martha maricel m gomez/L-6025-2014; Clapham, David/R-5974-2019	soler, martha maricel m gomez/0000-0002-4412-8108; Clapham, David/0000-0002-4459-9428				ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1987, TRENDS PHARMACOL SCI, V8, P209, DOI 10.1016/0165-6147(87)90064-2; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CLAPHAM DA, IN PRESS REV NEUROSC; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HARTZELL HC, 1992, TRENDS PHARMACOL SCI, V13, P380, DOI 10.1016/0165-6147(92)90117-O; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HILDEBRANDT JD, 1983, J BIOL CHEM, V258, P3141; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; IM MJ, 1987, J RECEPTOR RES, V7, P17, DOI 10.3109/10799898709054977; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INIGUEZLLUHI J, IN PRESS TRENDS CELL; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; JEISEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE E, 1992, J BIOL CHEM, V267, P1212; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MATTERA R, 1987, J BIOL CHEM, V262, P11247; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NAVANATI C, 1990, G PROTEINS SIGNAL TR; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YI F, 1991, J BIOL CHEM, V266, P3900	71	626	641	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1993	365	6445					403	406		10.1038/365403a0	http://dx.doi.org/10.1038/365403a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413584				2022-12-28	WOS:A1993LZ63300045
J	KATZ, JD; WANG, B; HASKINS, K; BENOIST, C; MATHIS, D				KATZ, JD; WANG, B; HASKINS, K; BENOIST, C; MATHIS, D			FOLLOWING A DIABETOGENIC T-CELL FROM GENESIS THROUGH PATHOGENESIS	CELL			English	Article							NONOBESE DIABETIC MICE; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTOR TRANSGENIC MICE; ATHYMIC NUDE-MICE; NOD MICE; MONOCLONAL-ANTIBODY; CLONAL DELETION; LYMPHOCYTE-T; BETA-GENES; ANTIGEN	Nonobese diabetic (NOD) mice spontaneously develop a disease very similar to type 1 diabetes in humans. We have generated a transgenic mouse strain carrying the rearranged T cell receptor genes from a diabetogenic T cell clone derived from a NOD mouse. Self-reactive T cells expressing the transgene-encoded specificity are not tolerized in these animals, resulting in rampant insulitis and eventually diabetes. Features of the disease process emphasize two so-called check-points, recognized previously in the NOD and human diseases but easily misinterpreted. Although NOD mice are protected from insulitis and diabetes by expression of the E molecule encoded in the major histocompatibility complex, the transgenics are not, permitting us to exclude some possible mechanisms of protection.	UNIV COLORADO, HLTH SCI CTR, BARBARA DAVIS CTR DIABET, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KATZ, JD (corresponding author), INST CHIM BIOL, GENET MOLEC EUCARYOTES LAB,CNRS,UNITE BIOL MOLEC, INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.			Katz, Jonathan/0000-0002-9864-2268				ACHAORBEA H, 1985, EUR J IMMUNOL, V15, P31, DOI 10.1002/eji.1830150107; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; Berg L J, 1989, Semin Immunol, V1, P105; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BOHME J, 1990, SCIENCE, V249, P293, DOI 10.1126/science.2115690; BOITARD C, 1989, J EXP MED, V169, P1669, DOI 10.1084/jem.169.5.1669; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BRADLEY BJ, 1992, DIABETES, V41, P1603, DOI 10.2337/diabetes.41.12.1603; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DARDENNE M, 1989, EUR J IMMUNOL, V19, P889, DOI 10.1002/eji.1830190516; DIAZGALLO C, 1992, P NATL ACAD SCI USA, V89, P8656, DOI 10.1073/pnas.89.18.8656; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FOWELL D, 1993, J EXP MED, V177, P627, DOI 10.1084/jem.177.3.627; GARCHON HJ, 1992, CURR OPIN IMMUNOL, V4, P716, DOI 10.1016/0952-7915(92)90051-F; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HARADA M, 1986, EXP ANIM TOKYO, V35, P501, DOI 10.1538/expanim1978.35.4_501; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HASKINS K, 1989, P NATL ACAD SCI USA, V86, P8000, DOI 10.1073/pnas.86.20.8000; HASKINS K, 1988, DIABETES, V37, P1444, DOI 10.2337/diabetes.37.10.1444; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HAYAKAWA M, 1991, DIABETES, V40, P1210, DOI 10.2337/diabetes.40.9.1210; HAYWARD AR, 1989, J IMMUNOL, V143, P1555; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HUTCHINGS P, 1990, NATURE, V348, P639, DOI 10.1038/348639a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOIKE T, 1987, DIABETES, V36, P539, DOI 10.2337/diabetes.36.4.539; KOOP BF, 1992, GENOMICS, V13, P1209, DOI 10.1016/0888-7543(92)90039-U; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEE KU, 1988, DIABETES, V37, P989, DOI 10.2337/diabetes.37.7.989; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MAKINO S, 1986, EXP ANIM TOKYO, V35, P495, DOI 10.1538/expanim1978.35.4_495; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MILLER BJ, 1988, J IMMUNOL, V140, P52; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MIYAZAKI A, 1985, CLIN EXP IMMUNOL, V60, P622; MORI Y, 1986, DIABETOLOGIA, V29, P244, DOI 10.1007/BF00454884; NAGATA M, 1992, DIABETES, V41, P998, DOI 10.2337/diabetes.41.8.998; NAGATA M, 1989, J IMMUNOL, V143, P1155; NAKANO N, 1991, J EXP MED, V173, P1091, DOI 10.1084/jem.173.5.1091; NISHIMOTO H, 1987, NATURE, V328, P432, DOI 10.1038/328432a0; OGAWA M, 1985, BIOMED RES-TOKYO, V6, P103; Ohashi P S, 1989, Semin Immunol, V1, P95; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OREILLY LA, 1991, EUR J IMMUNOL, V21, P1171, DOI 10.1002/eji.1830210512; PANKEWYCZ O, 1991, EUR J IMMUNOL, V21, P873, DOI 10.1002/eji.1830210403; PANKEWYCZ OG, 1992, EUR J IMMUNOL, V22, P2017, DOI 10.1002/eji.1830220810; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; REICHERT RA, 1983, J EXP MED, V157, P813, DOI 10.1084/jem.157.3.813; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SEMPE P, 1991, EUR J IMMUNOL, V21, P1163, DOI 10.1002/eji.1830210511; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437; SIGNORELLI K, 1992, EUR J IMMUNOL, V22, P2487, DOI 10.1002/eji.1830221004; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; THIVOLET C, 1991, J IMMUNOL, V146, P85; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; UEHIRA M, 1989, INT IMMUNOL, V1, P210; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; UNO M, 1992, IMMUNOL LETT, V31, P47, DOI 10.1016/0165-2478(92)90009-D; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WICKER LS, 1992, J EXP MED, V176, P67, DOI 10.1084/jem.176.1.67; YAGI H, 1992, EUR J IMMUNOL, V22, P2387, DOI 10.1002/eji.1830220931; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325	78	601	608	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1089	1100		10.1016/0092-8674(93)90730-E	http://dx.doi.org/10.1016/0092-8674(93)90730-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402882				2022-12-28	WOS:A1993LY49300015
J	GRIGNANI, F; FERRUCCI, PF; TESTA, U; TALAMO, G; FAGIOLI, M; ALCALAY, M; MENCARELLI, A; GRIGNANI, F; PESCHLE, C; NICOLETTI, I; PELICCI, PG				GRIGNANI, F; FERRUCCI, PF; TESTA, U; TALAMO, G; FAGIOLI, M; ALCALAY, M; MENCARELLI, A; GRIGNANI, F; PESCHLE, C; NICOLETTI, I; PELICCI, PG			THE ACUTE PROMYELOCYTIC LEUKEMIA-SPECIFIC PML-RAR-ALPHA FUSION PROTEIN INHIBITS DIFFERENTIATION AND PROMOTES SURVIVAL OF MYELOID PRECURSOR CELLS	CELL			English	Article							RETINOIC ACID RECEPTOR; ADENOSINE 3'-5'-MONOPHOSPHATE-INDUCING AGENTS; GRANULOCYTIC DIFFERENTIATION; T(15-17) TRANSLOCATION; MOLECULAR EVALUATION; RESIDUAL DISEASE; GENE-EXPRESSION; FLOW-CYTOMETRY; C-MYC; APOPTOSIS	Acute promyelocytic leukemia is a clonal expansion of hematopoietic precursors blocked at the promyelocytic stage. The differentiation block can be reversed by retinoic acid, which induces blast maturation both in vitro and in vivo. Acute promyelocytic leukemia is characterized by a 15;17 chromosome translocation with breakpoints within the retinoic acid alpha receptor (RARalpha) gene on 17 and the PML gene, which encodes a putative transcription factor, on 15. A PML-RARalpha fusion protein is formed as a consequence of the translocation. We expressed the PML-RARalpha protein in U937 myeloid precursor cells and showed that they lost the capacity to differentiate under the action of different stimuli (vitamin D3 and transforming growth factor beta1), acquired enhanced sensitivity to retinoic acid, and exhibited a higher growth rate consequent to diminished apoptotic cell death. These results provide evidence of biological activity of PML-RARalpha and recapitulate critical features of the promyelocytic leukemia phenotype.	IST SUPER SANITA,DEPT HAEMATOL & ONCOL,I-00161 ROME,ITALY; THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107	Istituto Superiore di Sanita (ISS); Jefferson University	GRIGNANI, F (corresponding author), UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY.		Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019; Ferrucci, Pier Francesco/AAQ-9002-2020; Testa, Ugo/J-6472-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Testa, Ugo/0000-0001-7900-8942; Ferrucci, Pier Francesco/0000-0001-6255-5851				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BIONDI A, 1991, BLOOD, V77, P1418; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DERMIME S, 1993, IN PRESS BLOOD; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIVERIO D, 1992, BLOOD, V79, P1; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LANOTTE M, 1991, BLOOD, V77, P1080; LOCOCO F, 1991, BLOOD, V77, P1657; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LONGO L, 1993, IN PRESS LEUK LYMPHO; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1991, BLOOD, V77, P909; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MITELMAN F, 1988, CATALOG CHROMOSOME A; MUINDI J, 1992, BLOOD, V79, P299; NERVI C, 1992, CANCER RES, V52, P3687; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLSSON IL, 1982, CANCER RES, V42, P3928; OLSSON IL, 1982, CANCER RES, V42, P3924; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAZA A, 1992, BLOOD, V79, P1037; RAZA A, 1987, BLOOD, V69, P1647; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; TESTA U, 1993, J IMMUNOL, V150, P2418; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	58	552	571	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					423	431		10.1016/0092-8674(93)80044-F	http://dx.doi.org/10.1016/0092-8674(93)80044-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8394219				2022-12-28	WOS:A1993LT73900004
J	WILSON, AC; LAMARCO, K; PETERSON, MG; HERR, W				WILSON, AC; LAMARCO, K; PETERSON, MG; HERR, W			THE VP16 ACCESSORY PROTEIN HCF IS A FAMILY OF POLYPEPTIDES PROCESSED FROM A LARGE PRECURSOR PROTEIN	CELL			English	Article							RNA POLYMERASE-II; TYPE-1 TRANSACTIVATOR VMW65; OCTAMER-BINDING-PROTEIN; HOMEO DOMAIN; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; CELLULAR FACTOR; DNA COMPLEX; OCT-1; PURIFICATION	Upon lytic infection of permissive cells, the herpes simplex virus (HSV) transactivator protein VP16 associates with an accessory protein termed host cell factor (HCF). Binding to HCF activates VP16 for association with the octamer motif-binding protein Oct-1, to form a multiprotein-DNA complex responsible for activating transcription of the HSV immediate early genes. We show that HCF comprises a series of related polypeptides that range from 110 to 300 kd, all of which are encoded by a single gene. Although there is no obvious sequence similarity between HCF and other known proteins, HCF contains eight repeats of a new 26 amino acid motif. cDNAs encoding HCF predict a large open reading frame of 2035 codons. When expressed in human cells, this large open reading frame encodes both the 300 kd and smaller HCF polypeptides, indicating that the smaller polypeptides arise by processing of the 300 kd protein.	TULARIK INC,S SAN FRANCISCO,CA 94080		WILSON, AC (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Wilson, Angus C/AAA-8153-2019; Herr, Winship/E-6491-2012	Wilson, Angus C/0000-0002-5016-4164; Herr, Winship/0000-0002-3606-4546	NCI NIH HHS [CA-13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GODING CR, 1989, VIROLOGY, V173, P363; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; MCLEAN C, 1982, J GEN VIROL, V63, P297, DOI 10.1099/0022-1317-63-2-297; NEVINS JR, 1992, SCIENCE, V258, P424; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; Sambrook J, 1989, MOL CLONING LABORATO; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; WERSTUCK GH, 1993, J BIOL CHEM, V268, P1272; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	40	222	234	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					115	125		10.1016/0092-8674(93)90299-6	http://dx.doi.org/10.1016/0092-8674(93)90299-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8392914				2022-12-28	WOS:A1993LN62500012
J	HUANG, ZJ; EDERY, I; ROSBASH, M				HUANG, ZJ; EDERY, I; ROSBASH, M			PAS IS A DIMERIZATION DOMAIN COMMON TO DROSOPHILA PERIOD AND SEVERAL TRANSCRIPTION FACTORS	NATURE			English	Article							DNA-BINDING; GENE-PRODUCT; PROTEIN; CLOCK; MELANOGASTER; RECEPTOR; MYC	MUTATIONS in the period gene product (PER) can shorten or lengthen the circadian rhythms of Drosophila melanogaster1, but its biochemical activity has not been established. PER contains a motif of approximately 270 amino acids whose function is unknown (termed PAS2) and which is also present in three transcription factors of the basic-helix-loop-helix (bHLH) type, in the D. melanogaster single-minded gene product (SIM)2, and in both subunits of the mammalian dioxin receptor complex3,4,28. We show here that the PER PAS functions in vitro as a novel protein dimerization motif and that it can mediate associations between different members of the PAS protein family. The dimerization efficiency is decreased by several missense mutations in the PAS domain, including the original per(L) mutation, which lengthens circadian periods from 24 h to 29 h (ref. 1). The results indicate that the PAS domain may function as a dimerization domain in both SIM and the dioxin receptor complex, and that PER may regulate circadian gene transcription partly by interacting with the PAS domain of bHLH-PAS-containing transcription factors.	BRANDEIS UNIV, DEPT BIOL, HOWARD HUGHES MED INST, WALTHAM, MA 02254 USA	Brandeis University; Howard Hughes Medical Institute				Huang, Z. Josh/0000-0003-0592-028X				BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1992, J NEUROSCI, V12, P2735; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SMITH RF, 1982, MOL GEN GENET, V185, P30, DOI 10.1007/BF00333786; VANDOREN M, 1991, DEVELOPMENT, V113, P245; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	27	443	453	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1993	364	6434					259	262		10.1038/364259a0	http://dx.doi.org/10.1038/364259a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8391649				2022-12-28	WOS:A1993LM68300064
J	GERACI, JM; ROSEN, AK; ASH, AS; MCNIFF, KJ; MOSKOWITZ, MA				GERACI, JM; ROSEN, AK; ASH, AS; MCNIFF, KJ; MOSKOWITZ, MA			PREDICTING THE OCCURRENCE OF ADVERSE EVENTS AFTER CORONARY-ARTERY BYPASS-SURGERY	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY ARTERY BYPASS; MEDICARE; MYOCARDIAL INFARCTION; HEART FAILURE, CONGESTIVE; WOUND INFECTION	HOSPITAL DEATH RATES; QUALITY; MORTALITY; RISK; COMPLICATIONS; MEDISGROUPS; SEVERITY; ILLNESS; CARE	Objective: To determine whether adverse events occurring after coronary artery bypass surgery in Medicare patients can be predicted from clinical variables representing illness severity at admission. Design: Retrospective analysis of clinical data abstracted from hospital charts, with development and validation using half-samples of the database. A logistic model was developed using illness severity at admission to predict the occurrence of an adverse event after bypass surgery. Setting: Hospitals in seven states. Patients: Random sample of 2213 Medicare patients 65 years of age or more who underwent bypass surgery between January 1985 and June 1986. Outcome Measure: The occurrence of death within 30 days of admission or any of 13 nonfatal postoperative adverse events (for example, myocardial infarction, congestive heart failure, and wound infection). Results: Thirty-three percent of patients had one or more postoperative adverse events or died within 30 days of admission. Mortality within 30 days of admission was 6.6%; each adverse event was associated with increased mortality (range, 7.5% to 66.7%). Admission predictors of the occurrence of an adverse event included a history of bypass surgery, emergent surgery, a history of chronic obstructive pulmonary disease, the presence of an infiltrate on admission chest radiograph, a pulse of 110 beats/min or more, age, blood urea nitrogen of 10.7 mmol/L (30 mg/dL) or more, acute myocardial infarction at admission, and a history of myocardial infarction; the presence of one- or two-vessel disease was negatively associated with the occurrence of an adverse event. The model c-statistic was 0.64. Conclusions: Severity of illness at admission has modest predictive power with respect to adverse-event occurrence in Medicare patients who undergo bypass surgery.	BOSTON UNIV, MED CTR,GEN INTERNAL MED SECT,SUITE 1108, 720 HARRISON AVE, BOSTON, MA 02118 USA; BOSTON UNIV, SCH PUBL HLTH, BOSTON, MA 02215 USA	Boston University; Boston University			Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253				BLUMBERG MS, 1988, HEALTH AFFAIR, V7, P62, DOI 10.1377/hlthaff.7.1.62; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; BROOK RH, 1990, ANN INTERN MED, V113, P747, DOI 10.7326/0003-4819-113-10-747; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DONABEDIAN A, 1985, EXPLORATIONS QUALITY, P257; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; IEZZONI LI, 1991, AM J PUBLIC HEALTH, V81, P74, DOI 10.2105/AJPH.81.1.74; IEZZONI LI, 1988, 18C98556104 BOST U M; IEZZONI LI, 1988, 18C98526105 BOST U M; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1986, JAMA-J AM MED ASSOC, V255, P2780, DOI 10.1001/jama.255.20.2780; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; PARSONNET V, 1989, CIRCULATION, V79, P3; ROSEN AK, 1990, 99C98526106 BOST U M; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SOMERVILLE J, 1991, AM MED NEWS     0218, P39; THOMAS JW, 1989, INQUIRY-J HEALTH CAR, V26, P483; 1987, OTAH387 OFF TECHN AS, P101; 1990, REHOSPITALIZATION GE, V3; 1990, HCFA03301 HLTH CAR F	29	62	62	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					18	24		10.7326/0003-4819-118-1-199301010-00004	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416153				2022-12-28	WOS:A1993KE60500004
J	CHRIVIA, JC; KWOK, RPS; LAMB, N; HAGIWARA, M; MONTMINY, MR; GOODMAN, RH				CHRIVIA, JC; KWOK, RPS; LAMB, N; HAGIWARA, M; MONTMINY, MR; GOODMAN, RH			PHOSPHORYLATED CREB BINDS SPECIFICALLY TO THE NUCLEAR-PROTEIN CBP	NATURE			English	Article								CYCLIC AMP-regulated gene expression frequently involves a DNA element known as the cAMP-regulated enhancer (CRE)1-4. Many transcription factors bind to this element, including the protein CREB5,6, which is activated as a result of phosphorylation by protein kinase A7. This modification stimulates interaction with one or more of the general transcription factors or, alternatively, allows recruitment of a co-activator. Here we report that CREB phosphorylated by protein kinase A binds specifically to a nuclear protein of M(r) 265K which we term CBP (for CREB-binding protein). Fusion of a heterologous DNA-binding domain to the amino terminus of CBP enables the chimaeric protein to function as a protein kinase A-regulated transcriptional activator. We propose that CBP may participate in cAMP-regulated gene expression by interacting with the activated phosphorylated form of CREB.	CNRS,INSERM,CTR RECH BIOCHIM MACROMOLEC,F-34033 MONTPELLIER,FRANCE; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Oregon Health & Science University; Salk Institute								BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HOEFFLER JP, 1988, SCIENCE, V242, P1428; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Reichlin M, 1980, Methods Enzymol, V70, P159; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	18	1763	1810	4	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					855	859		10.1038/365855a0	http://dx.doi.org/10.1038/365855a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413673				2022-12-28	WOS:A1993MD95100056
J	STROBER, W; EHRHARDT, RO				STROBER, W; EHRHARDT, RO			CHRONIC INTESTINAL INFLAMMATION - AN UNEXPECTED OUTCOME IN CYTOKINE OR T-CELL RECEPTOR MUTANT MICE	CELL			English	Article							BOWEL-DISEASE; CROHNS-DISEASE; INTERLEUKIN-2; LYMPHOCYTES; MUCOSA				STROBER, W (corresponding author), NIAID, CLIN INVEST LAB, MUCOSAL IMMUN SECT, BETHESDA, MD 20892 USA.							BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562, DOI 10.1016/0016-5085(89)90406-X; BRYNSKOV J, 1992, GUT, V33, P55, DOI 10.1136/gut.33.1.55; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; FIOCCHI C, 1984, GASTROENTEROLOGY, V86, P734; GURBINDO C, 1993, GASTROENTEROLOGY, V104, P964, DOI 10.1016/0016-5085(93)90262-B; HALSTENSEN TS, 1989, GASTROENTEROLOGY, V97, P10, DOI 10.1016/0016-5085(89)91409-1; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KUSUGAMI K, 1991, GASTROENTEROLOGY, V101, P1594, DOI 10.1016/0016-5085(91)90397-4; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MULLIN GE, 1992, GASTROENTEROLOGY, V102, P1620, DOI 10.1016/0016-5085(92)91722-G; PIRZER U, 1991, LANCET, V338, P1238, DOI 10.1016/0140-6736(91)92104-A; PULLMAN WE, 1992, CLIN EXP IMMUNOL, V88, P132; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; STROBER W, 1985, DIGEST DIS SCI, V30, pS3, DOI 10.1007/BF01296964; STROBER W, 1986, J CLIN IMMUNOL, V6, P415, DOI 10.1007/BF00915248; ZEITZ M, 1988, GASTROENTEROLOGY, V94, P353, DOI 10.1016/0016-5085(88)90422-2	17	167	174	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					203	205		10.1016/0092-8674(93)80062-J	http://dx.doi.org/10.1016/0092-8674(93)80062-J			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402907				2022-12-28	WOS:A1993MD88500002
J	VEIS, DJ; SORENSON, CM; SHUTTER, JR; KORSMEYER, SJ				VEIS, DJ; SORENSON, CM; SHUTTER, JR; KORSMEYER, SJ			BCL-2-DEFICIENT MICE DEMONSTRATE FULMINANT LYMPHOID APOPTOSIS, POLYCYSTIC KIDNEYS, AND HYPOPIGMENTED HAIR	CELL			English	Article							PROGRAMMED CELL-DEATH; C-MYC; B-CELL; CAENORHABDITIS-ELEGANS; FOLLICULAR LYMPHOMA; TRANSGENIC MICE; MESSENGER-RNA; BCL-2; MOUSE; DISEASE	bcl-2 -/- mice complete embryonic development, but display growth retardation and early mortality postnatally. Hematopoiesis including lymphocyte differentiation is initially normal, but thymus and spleen undergo massive apoptotic involution. Thymocytes require an apoptotic signal to manifest accelerated cell death. Renal failure results from severe polycystic kidney disease characterized by dilated proximal and distal tubular segments and hyperproliferation of epithelium and interstitium. bcl-2 -/- mice turn gray with the second hair follicle cycle, implicating a defect in redox-regulated melanin synthesis. The abnormalities in these loss of function mice argue that Bcl-2 is a death repressor molecule functioning in an antioxidant pathway.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT PATHOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	VEIS, DJ (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA.			Novack, Deborah/0000-0001-7101-5582	NATIONAL EYE INSTITUTE [T32EY007108] Funding Source: NIH RePORTER; NEI NIH HHS [5T32 EY 07108-04] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; AVNER ED, 1988, PEDIATR NEPHROL, V2, P210, DOI 10.1007/BF00862593; AVNER ED, 1987, PEDIATR NEPHROL, V1, P587, DOI 10.1007/BF00853593; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOISSY RE, 1988, DERMATOL CLIN, V6, P161, DOI 10.1016/S0733-8635(18)30663-6; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; COLES HSR, 1993, DEVELOPMENT, V118, P777; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN AP, 1978, LAB INVEST, V38, P244; EVAN AP, 1976, LAB INVEST, V35, P93; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GABOW PA, 1993, DIS KIDNEY, P535; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HJELLE JT, 1990, TOXICOLOGY, V60, P211; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKSON IJ, 1990, GENETICS, V126, P451; JOHNSON E, 1958, J ENDOCRINOL, V16, P337, DOI 10.1677/joe.0.0160337; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEBRUN DP, 1993, AM J PATHOL, V142, P743; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIATTELLI M, 1962, TETRAHEDRON, V18, P941, DOI 10.1016/S0040-4020(01)92747-4; PROTA G, 1980, J INVEST DERMATOL, V75, P122, DOI 10.1111/1523-1747.ep12521344; RAHILLY MA, 1992, J PATHOL, V168, P335, DOI 10.1002/path.1711680315; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, J IMMUNOL, V151, P2546; YOHN JJ, 1991, J INVEST DERMATOL, V97, P405, DOI 10.1111/1523-1747.ep12480983; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; ZDARSKY E, 1990, GENETICS, V126, P443	57	1425	1465	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					229	240		10.1016/0092-8674(93)80065-M	http://dx.doi.org/10.1016/0092-8674(93)80065-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402909				2022-12-28	WOS:A1993MD88500005
J	MARS, JS				MARS, JS			DRIVERS WHO DEFY THE LAW	BRITISH MEDICAL JOURNAL			English	Article																		FONDA G, 1989, OPHTHALMOLOGY, V96, P1457; KELLNER JL, 1987, OPHTHALMOLOGY, V94, P1180; KELLNER JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1697; MCCAGHREY GE, 1987, OPTOMETRY TODAY, V27, P178; TAYLOR SP, 1988, OPTICIAN, V196, P14	5	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					844	845		10.1136/bmj.307.6908.844	http://dx.doi.org/10.1136/bmj.307.6908.844			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401127	Green Published, Bronze			2022-12-28	WOS:A1993MA29300022
J	ZHAO, JJG; PICK, L				ZHAO, JJG; PICK, L			GENERATING LOSS-OF-FUNCTION PHENOTYPES OF THE FUSHI-TARAZU GENE WITH A TARGETED RIBOZYME IN DROSOPHILA	NATURE			English	Article							SEGMENTATION GENE; SELF-CLEAVAGE; MESSENGER-RNA; MELANOGASTER; EMBRYOGENESIS; NEUROGENESIS; EXPRESSION; REDUCTION; SEQUENCE; ENZYMES	THE ability to isolate gene sequences and analyse their expression patterns has generated demand for mutations created to assess their biological functions. In Drosophila melanogaster this can be achieved by traditional mutagenesis, but this is time-consuming, labour-intensive and not always successful. Moreover, the functions of genes that are expressed several times during development are often obscured in the later stages because of disruptions caused by the absence of early gene function. Here we propose a new strategy to create conditional knock-out mutations using a targeted heat-inducible ribozyme. Ribozymes are catalytic RNA molecules that specifically cleave RNAs1-11 and are potentially useful for studying gene function during animal development because the expression of critical regulatory genes is usually low and their function is often dosage-dependent. The ribozyme can be delivered to a specific region or at a particular developmental stage using a region-specific or inducible promoter. The Drosophila fushi tarazu (ftz) gene is a good candidate for testing this approach12-17. We generated transgenic flies carrying a ribozyme against the ftz gene. The two developmental phases of ftz function can be distinguished by timed induction of the ribozyme. Activation of the ribozyme in the blastoderm disrupts the ftz seven-stripe pattern and produces ftz-like pair-rule defects in larvae. The involvement of ftz in neurogenesis was verified by activation of the ribozyme during the early phase of formation of the central nervous system.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CARROLL SB, 1985, CELL, V43, P47, DOI 10.1016/0092-8674(85)90011-X; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KARR TL, 1989, DEVELOPMENT, V105, P95; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; STEINECKE P, 1992, EMBO J, V11, P1525, DOI 10.1002/j.1460-2075.1992.tb05197.x; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WEINER AJ, 1984, CELL, V37, P843, DOI 10.1016/0092-8674(84)90419-7; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343; ZHENG X, 1992, J VIROL, V66, P1361	26	79	92	2	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					448	451		10.1038/365448a0	http://dx.doi.org/10.1038/365448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413588				2022-12-28	WOS:A1993LZ63300058
J	MATTER, K; WHITNEY, JA; YAMAMOTO, EM; MELLMAN, I				MATTER, K; WHITNEY, JA; YAMAMOTO, EM; MELLMAN, I			COMMON SIGNALS CONTROL LOW-DENSITY-LIPOPROTEIN RECEPTOR SORTING IN ENDOSOMES AND THE GOLGI-COMPLEX OF MDCK CELLS	CELL			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; PLASMA-MEMBRANE PROTEINS; LYMPHOCYTE FC-RECEPTORS; BREFELDIN-A; CYTOPLASMIC DOMAIN; SELECTIVE-INHIBITION; LYSOSOMAL MEMBRANE; APICAL DOMAIN	The cytoplasmic domain of the LDL receptor bears two tyrosine-containing determinants that can independently target receptors from the Golgi to the basolateral plasma membrane of MDCK cells. We found that these determinants, localized to the membrane-proximal and -distal regions of the receptor's cytoplasmic domain, also control polarized sorting in endosomes. Inactivation of the distal determinant reduced receptors' ability to return to the basolateral domain following endocytosis, resulting instead in receptor transcytosis from basolateral endosomes to the apical plasma membrane. Similarly, receptors internalized from the apical surface were transported from apical endosomes to the basolateral surface, owing to the proximal basolateral targeting determinant. Thus, receptor recycling in endosomes is directed by the same signals as polarized sorting in the Golgi, indicating that sorting on the endocytic and biosynthetic pathways involves similar mechanisms. The observation that brefeldin A interfered with sorting but not transport in both endosomes and the Golgi further supports this.			MATTER, K (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.		Matter, Karl/C-4880-2008; Mellman, Ira/ABG-5896-2020	Matter, Karl/0000-0001-8026-7220; 				BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1991, Semin Cell Biol, V2, P397; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SLOT JW, 1991, J CELL BIOL, V113, P1232; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WAN JS, 1992, J BIOL CHEM, V267, P13446; WANDINGERNESS A, 1990, INTRACELLULAR TRAFFI, P575; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923	54	152	156	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1053	1064		10.1016/0092-8674(93)90727-8	http://dx.doi.org/10.1016/0092-8674(93)90727-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402881				2022-12-28	WOS:A1993LY49300012
J	CARROLL, B; DOW, C; SNASHALL, D; MARSHALL, T; CHIODINI, PL				CARROLL, B; DOW, C; SNASHALL, D; MARSHALL, T; CHIODINI, PL			POST-TROPICAL SCREENING - HOW USEFUL IS IT	BRITISH MEDICAL JOURNAL			English	Article									FCO,DEPT MED & WELF,OLD ADMIRALTY BLDG,MALL,LONDON SW1A 2AF,ENGLAND; HOSP TROP DIS,LONDON NW1 0PE,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine								MOHR E, 1992, J CLIN MICROBIOL, V30, P1572, DOI 10.1128/JCM.30.6.1572-1574.1992	1	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					541	541		10.1136/bmj.307.6903.541	http://dx.doi.org/10.1136/bmj.307.6903.541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400975	Green Published, Bronze			2022-12-28	WOS:A1993LV18000018
J	POSTEL, EH; BERBERICH, SJ; FLINT, SJ; FERRONE, CA				POSTEL, EH; BERBERICH, SJ; FLINT, SJ; FERRONE, CA			HUMAN C-MYC TRANSCRIPTION FACTOR PUF IDENTIFIED AS NM23-H2 NUCLEOSIDE DIPHOSPHATE KINASE, A CANDIDATE SUPPRESSOR OF TUMOR-METASTASIS	SCIENCE			English	Article							MOLECULAR-CLONING; RNA LEVELS; GENE; PROMOTER; PROTEINS; CELLS; DIFFERENTIATION; EXPRESSION; ACTIVATION	A human gene encoding the c-myc purine-binding transcription factor PuF was identified by screening of a cervical carcinoma cell complementary DNA library with a DNA fragment containing PuF binding sites. The 17-kilodalton bacterially produced PuF was shown to have biological activity and properties similar to that of human PuF. DNA sequence analysis of recombinant PuF revealed perfect identity with the human nm23-H2 nucleoside diphosphate kinase gene, a potential negative regulator of cancer metastasis. These results provide a link between nm23 and the c-myc oncogene and suggest that the nm23 protein can function in vitro in the transcriptional regulation of c-myc expression.			POSTEL, EH (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.							BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POSTEL EH, UNPUB; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAHL JA, 1991, CANCER RES, V51, P445; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	29	492	509	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					478	480		10.1126/science.8392752	http://dx.doi.org/10.1126/science.8392752			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392752				2022-12-28	WOS:A1993LN62300038
J	WALSH, CT				WALSH, CT			VANCOMYCIN RESISTANCE - DECODING THE MOLECULAR LOGIC	SCIENCE			English	Editorial Material							VANA		HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	WALSH, CT (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							ARTHUR M, IN PRESS ANTIMICROB; BILLOTKLEIN D, 1992, ANTIMICROB AGENTS CH, V36, P1487, DOI 10.1128/AAC.36.7.1487; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; HANDWERGER S, 1992, J BACTERIOL, V174, P5982, DOI 10.1128/jb.174.18.5982-5984.1992; HOLMAN TR, UNPUB; JACOBY G, 1961, NEW ENGL J MED, V324, P601; JOHNSON AP, 1990, CLIN MICROBIOL REV, V3, P280, DOI 10.1128/CMR.3.3.280-291.1990; Leclercq R., 1988, NEW ENGL J MED, V319, P157; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NICHOLS RL, 1992, CLIN INFECT DIS, V15, P72, DOI 10.1093/clinids/15.1.72; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1992, J BIOL CHEM, V267, P19753; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WILLIAMS DH, 1984, ACCOUNTS CHEM RES, V17, P364, DOI 10.1021/ar00106a004; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006; WRIGHT GD, 1992, ANTIMICROB AGENTS CH, V36, P1514, DOI 10.1128/AAC.36.7.1514	20	178	186	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					308	309		10.1126/science.8392747	http://dx.doi.org/10.1126/science.8392747			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8392747				2022-12-28	WOS:A1993LM67800024
J	GUNZBURG, WH; HEINEMANN, F; WINTERSPERGER, S; MIETHKE, T; WAGNER, H; ERFLE, V; SALMONS, B				GUNZBURG, WH; HEINEMANN, F; WINTERSPERGER, S; MIETHKE, T; WAGNER, H; ERFLE, V; SALMONS, B			ENDOGENOUS SUPERANTIGEN EXPRESSION CONTROLLED BY A NOVEL PROMOTER IN THE MMTV LONG TERMINAL REPEAT	NATURE			English	Article							MAMMARY-TUMOR VIRUS; OPEN READING FRAME; MESSENGER-RNA; ENV GENE; T-CELLS; REGION; IDENTIFICATION; SEQUENCES; SYSTEM; MICE	ENDOGENOUS superantigens are encoded by the open reading frame contained within the mouse mammary tumour virus long terminal repeat (MMTV LTR). Superantigen expression results in T-cell proliferation and, during early ontogeny, T-cell deletion1,2. Here we identify a novel promoter located upstream of the previously described MMTV promoter. Transcripts from this promoter initiate within the U3 region of the MMTV LTR and splice to the acceptor for endogenous superantigen coding region. The novel U3 promoter is active in B lymphocytes, which are cognate antigen-presenting cells for endogenous superantigen, and is able to direct expression of superantigen in the absence of the previously described MMTV promoter.	TECH UNIV MUNICH,INST MED MICROBIOL & HYG,D-81675 MUNICH,GERMANY; LUDWIG MAXIMILIANS UNIV MUNCHEN,INST MOLEC ANIM BREEDING,D-80539 MUNICH,GERMANY	Technical University of Munich; University of Munich	GUNZBURG, WH (corresponding author), GSF RES CTR ENVIRONM & HLTH,INST MOLEC VIROL,D-85758 OBERSCHLEISSHEIM,GERMANY.		Gunzburg, Walter/ABI-6076-2020; Salmons, Brian/E-3001-2010	Gunzburg, Walter/0000-0001-8907-1021; Salmons, Brian/0000-0002-9490-9447				ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CRANDELL RA, 1973, IN VITRO CELL DEV B, V9, P176, DOI 10.1007/BF02618435; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; HORNSBY PJ, 1992, BIOTECHNIQUES, V12, P244; HUBER B T, 1992, Current Biology, V2, P495; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KENNEDY N, 1982, NATURE, V295, P622, DOI 10.1038/295622a0; LIEGLER TJ, 1986, J VIROL, V59, P159, DOI 10.1128/JVI.59.1.159-162.1986; LUND FE, 1991, J EXP MED, V174, P1439, DOI 10.1084/jem.174.6.1439; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; REDMOND SMS, 1983, EMBO J, V2, P125, DOI 10.1002/j.1460-2075.1983.tb01393.x; RINGOLD GM, 1977, CELL, V10, P19, DOI 10.1016/0092-8674(77)90135-0; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SALMONS B, 1985, VIROLOGY, V144, P101, DOI 10.1016/0042-6822(85)90309-5; TSUBURA A, 1988, CANCER RES, V48, P6555; VANOOYEN AJJ, 1983, J VIROL, V46, P362, DOI 10.1128/JVI.46.2.362-370.1983; WHEELER DA, 1983, J VIROL, V46, P42, DOI 10.1128/JVI.46.1.42-49.1983	26	47	49	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					154	158		10.1038/364154a0	http://dx.doi.org/10.1038/364154a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8391646				2022-12-28	WOS:A1993LL36700052
J	MADUKE, M; ROISE, D				MADUKE, M; ROISE, D			IMPORT OF A MITOCHONDRIAL PRESEQUENCE INTO PROTEIN-FREE PHOSPHOLIPID-VESICLES	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; SYNTHETIC PRESEQUENCE; YEAST MITOCHONDRIA; SIGNAL PEPTIDE; TRANSLOCATION; INSERTION; HYPOTHESIS; BILAYERS	A synthetic mitochondrial presequence has been shown to translocate across pure phospholipid bilayers. The presequence was fluorescently labeled so that its association with membranes could be monitored spectroscopically. In the presence of large unilamellar vesicles, the presequence showed time- and potential-dependent protection from reaction with added trypsin and dithionite. The protection was rapidly reversed by treatment of the vesicles with detergent. If the vesicles contained trypsin, the added presequence became sensitive to digestion by,the protease. The results show that a mitochondrial presequence can translocate across phospholipid bilayers that lack a hydrophilic translocation pore.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego				Maduke, Merritt/0000-0001-7787-306X	NIGMS NIH HHS [T32-GM08326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CHEN LB, 1981, COLD SPRING HARB SYM, V46, P141, DOI 10.1101/SQB.1982.046.01.018; DEKROON AIPM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P111, DOI 10.1016/0005-2736(91)90199-I; DUMONT ME, 1984, J BIOL CHEM, V259, P4147; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MADUKE M, UNPUB; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; Penefsky H S, 1979, Methods Enzymol, V56, P527; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	39	81	81	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1993	260	5106					364	367		10.1126/science.8385804	http://dx.doi.org/10.1126/science.8385804			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8385804				2022-12-28	WOS:A1993KX80000042
J	TSAY, YF; FRANK, MJ; PAGE, T; DEAN, C; CRAWFORD, NM				TSAY, YF; FRANK, MJ; PAGE, T; DEAN, C; CRAWFORD, NM			IDENTIFICATION OF A MOBILE ENDOGENOUS TRANSPOSON IN ARABIDOPSIS-THALIANA	SCIENCE			English	Article							NITRATE REDUCTASE; PUTATIVE TRANSPOSASE; ELEMENT FAMILY; DNA; GENE; PROTEIN; MUTANTS; PLANTS; AC; CHLORATE	A mobile endogenous transposable element, Tag1, has been identified in the plant Arabidopsis thaliana. Tag1 was found in the nitrate transporter gene, CHL1, of a chlorate-resistant mutant present in a population of plants containing an active maize Ac transposon. Tag1 excises from the chl1 gene producing chlorate-sensitive revertants with Tag1 or Tag1-related elements at different loci. Tag1 and related elements are present in the Landsberg but not Columbia or Wassilewskija ecotypes of Arabidopsis. Thus, Tag1 provides a tool for the insertional mutagenesis of plant genes essential for biological processes of agronomic importance.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; AFRC,IPSR,JOHN INNES CTR,DEPT MOLEC GENET,NORWICH NR4 7UJ,ENGLAND; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of California System; University of California San Diego			Tsay, Yi-Fang/ABB-3662-2021	Tsay, Yi-Fang/0000-0003-4271-0687	NCI NIH HHS [5T32CA09345-12] Funding Source: Medline; NIGMS NIH HHS [GM 40672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG B, 1947, ANN R AGR COLL SWEDE, V15, P37; ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; Berg DE, 1989, MOBILE DNA; BRAAKSMA FJ, 1982, THEOR APPL GENET, V64, P83, DOI 10.1007/BF00303657; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; Crawford N. M., 1992, Genetic engineering: principles and methods. Volume 14., P89; DEAN C, 1992, PLANT J, V2, P69, DOI 10.1111/j.1365-313X.1992.00069.x; DODDEMA H, 1979, PHYSIOL PLANTARUM, V45, P332, DOI 10.1111/j.1399-3054.1979.tb02593.x; DODDEMA H, 1978, PHYSIOL PLANTARUM, V43, P343, DOI 10.1111/j.1399-3054.1978.tb01592.x; FELDMANN KA, 1989, SCIENCE, V243, P1351, DOI 10.1126/science.243.4896.1351; FELDMANN KA, 1991, PLANT J, V1, P1; FELDMAR S, 1991, EMBO J, V10, P4003, DOI 10.1002/j.1460-2075.1991.tb04975.x; GREVELDING C, 1992, P NATL ACAD SCI USA, V89, P6085, DOI 10.1073/pnas.89.13.6085; KONCZ C, 1990, EMBO J, V9, P1337, DOI 10.1002/j.1460-2075.1990.tb08248.x; KONIECZNY A, 1991, GENETICS, V127, P801; KUNZE R, 1989, EMBO J, V8, P3177, DOI 10.1002/j.1460-2075.1989.tb08476.x; MARKS MD, 1989, PLANT CELL, V1, P1043, DOI 10.1105/tpc.1.11.1043; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; Nelson O, 1988, PLANT TRANSPOSABLE E; PELEMAN J, 1991, P NATL ACAD SCI USA, V88, P3618, DOI 10.1073/pnas.88.9.3618; PESCHKE VM, 1987, SCIENCE, V238, P804, DOI 10.1126/science.238.4828.804; SCHMIDT R, 1989, MOL GEN GENET, V220, P17, DOI 10.1007/BF00260850; SCHOLTEN HJ, 1986, PHYSIOL PLANTARUM, V66, P265, DOI 10.1111/j.1399-3054.1986.tb02418.x; SHIELDS R, 1989, NATURE, V337, P308, DOI 10.1038/337308a0; SWINBURNE J, 1992, PLANT CELL, V4, P583, DOI 10.1105/tpc.4.5.583; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; VANSLUYS MA, 1987, EMBO J, V6, P3881, DOI 10.1002/j.1460-2075.1987.tb02728.x; VOYTAS DF, 1988, NATURE, V336, P242, DOI 10.1038/336242a0; VOYTAS DF, 1990, GENETICS, V126, P713; WALBOT V, 1992, ANNU REV PLANT PHYS, V43, P49, DOI 10.1146/annurev.pp.43.060192.000405; WILKINSON JQ, 1991, PLANT CELL, V3, P461, DOI 10.1105/tpc.3.5.461; Wray J.L., 1989, MOL GENETIC ASPECTS; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	34	89	98	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					342	344		10.1126/science.8385803	http://dx.doi.org/10.1126/science.8385803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8385803				2022-12-28	WOS:A1993KX80000035
J	RIVERA, GK; PINKEL, D; SIMONE, JV; HANCOCK, ML; CRIST, WM				RIVERA, GK; PINKEL, D; SIMONE, JV; HANCOCK, ML; CRIST, WM			TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA - 30 YEARS EXPERIENCE AT ST-JUDE-CHILDRENS-RESEARCH-HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; CENTRAL NERVOUS-SYSTEM; HIGH-DOSE METHOTREXATE; LONG-TERM SURVIVORS; CLINICAL PHARMACODYNAMICS; COMBINATION CHEMOTHERAPY; CHILDHOOD LEUKEMIA; REMISSION DURATION; THERAPY; IRRADIATION	Background. Therapy for childhood lymphoblastic leukemia has evolved during the past three decades, but key questions about what are the least toxic, most effective forms of treatment remain unanswered because of the lack of comprehensive follow-up information. Methods. To assess long-term outcome in the series of clinical trials conducted at St. Jude Hospital, we compared the results of treatment typical of four eras: exploratory combination chemotherapy (era 1, 1962 to 1966; 91 patients), regimens for the control of meningeal leukemia (era 2, 1967 to 1979; 825 patients), limited intensification of therapy (era 3, 1979 to 1983; 428 patients), and extended intensification of therapy (era 4, 1984 to 1988; 358 patients). (''Intensification'' refers to strategies of systemic chemotherapy that are more aggressive than conventional ones.) The major end points were survival and event-free survival; we also calculated the relative risk of treatment failure and the rate of relapse or death after treatment ended (post-treatment failure rate). Results. The probability of event-free survival im proved significantly in each successive era (P<0.001 by the log-rank test), reaching 71 percent in era 4. There was a decrease of approximately 50 percent in the risk of treatment failure from one era to the next in each subgroup of patients defined according to different combinations of the leukocyte count, race, age, and sex. Leukemia appeared to be eradicated in patients who remained in complete remission for three years or more after treatment in era 4. The incidence of death due to nonleukemic causes remained 4 to 6 percent despite the trend toward more intensive treatment. An estimated 765 patients (45 percent) are long-term survivors; most of them (80 percent) have no health problems related to leukemia or its treatment. Conclusions. The development and successful application of preventive therapy for meningeal leukemia, followed by the intensification of systemic chemotherapy, has progressively improved the rate of cure of childhood lymphoblastic leukemia, with relatively few adverse sequelae.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; MD ANDERSON CANC CTR, NEW YORK, NY USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 20180, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUR RJA, 1978, CANCER, V42, P2123, DOI 10.1002/1097-0142(197811)42:5<2123::AID-CNCR2820420507>3.0.CO;2-5; AUR RJA, 1972, CANCER, V29, P381, DOI 10.1002/1097-0142(197202)29:2<381::AID-CNCR2820290219>3.0.CO;2-P; AUR RJA, 1971, BLOOD-J HEMATOL, V37, P272, DOI 10.1182/blood.V37.3.272.272; BLEYER WA, 1985, SEMIN ONCOL, V12, P131; CAMITTA BM, 1980, MED PEDIATR ONCOL, V8, P383, DOI 10.1002/mpo.2950080410; CAMPANA D, 1990, BLOOD, V76, P163, DOI 10.1182/blood.V76.1.163.163; CAMPANA D, 1990, BLOOD, V76, P1901; CHEN W, 1992, P NATL ACAD SCI USA, V89, P1468, DOI 10.1073/pnas.89.4.1468; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; COX DR, 1972, J R STAT SOC B, V34, P187; DAHL GV, 1987, J CLIN ONCOL, V5, P1015, DOI 10.1200/JCO.1987.5.7.1015; EGUIGUREN JM, 1992, BLOOD, V79, P871; EVANS WE, 1988, BLUT, V56, P241, DOI 10.1007/BF00320282; EVANS WE, 1986, NEW ENGL J MED, V314, P471, DOI 10.1056/NEJM198602203140803; GAYNON PS, 1988, LANCET, V2, P921; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; HAMMOND D, 1986, MED PEDIATR ONCOL, V14, P124, DOI 10.1002/mpo.2950140305; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; LOOK AT, 1987, NEW ENGL J MED, V317, P1666; MULHERN RK, 1988, J CLIN ONCOL, V6, P315, DOI 10.1200/JCO.1988.6.2.315; MURPHY SB, 1986, NEW ENGL J MED, V314, P188; NIEMEYER CM, 1991, ANN ONCOL, V2, P745, DOI 10.1093/oxfordjournals.annonc.a057856; NIEMEYER CM, 1991, BLOOD, V78, P2514, DOI 10.1182/blood.V78.10.2514.2514; OCHS J, 1991, J CLIN ONCOL, V9, P145, DOI 10.1200/JCO.1991.9.1.145; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; PINKEL D, 1971, J AMER MED ASSOC, V216, P648, DOI 10.1001/jama.216.4.648; PINKEL D, 1992, LEUKEMIA, V6, P127; PUI CH, 1988, MED PEDIATR ONCOL, V16, P21, DOI 10.1002/mpo.2950160106; PUI CH, 1984, CANCER RES, V44, P3593; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PULLEN J, 1993, J CLIN ONCOL, V11, P839, DOI 10.1200/JCO.1993.11.5.839; Riehm H, 1990, Haematol Blood Transfus, V33, P439; RIVERA G, 1979, BLOOD, V53, P1114; RIVERA GK, 1988, J CLIN ONCOL, V6, P191, DOI 10.1200/JCO.1988.6.2.191; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RIVERA GK, 1988, NEW ENGL J MED, V318, P1541; SCHRIOCK EA, 1991, J CLIN ONCOL, V9, P400, DOI 10.1200/JCO.1991.9.3.400; SIMONE JV, 1976, BRIT J HAEMATOL, V32, P465, DOI 10.1111/j.1365-2141.1976.tb00950.x; SKIPPER HOWARD E., 1965, CANCER CHEMOTHERAP REP, V45, P5; TRUEWORTHY R, 1992, J CLIN ONCOL, V10, P606, DOI 10.1200/JCO.1992.10.4.606	43	249	251	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1289	1295		10.1056/NEJM199310283291801	http://dx.doi.org/10.1056/NEJM199310283291801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413409				2022-12-28	WOS:A1993MD55700001
J	SCHWARTZ, TB				SCHWARTZ, TB			A VIEW FROM OUT THERE - A 2ND LOOK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									RUSH UNIV,RUSH MED COLL,CHICAGO,IL 60612; UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195	Rush University; University of Washington; University of Washington Seattle								SCHWARTZ TB, 1989, JAMA-J AM MED ASSOC, V262, P2730; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; 1991, AMA POLICY COMPENDIU, P95; 1989, CURRENT OPINIONS COU	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1975	1976						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8411556				2022-12-28	WOS:A1993MC51300031
J	BLAKELY, G; MAY, G; MCCULLOCH, R; ARCISZEWSKA, LK; BURKE, M; LOVETT, ST; SHERRATT, DJ				BLAKELY, G; MAY, G; MCCULLOCH, R; ARCISZEWSKA, LK; BURKE, M; LOVETT, ST; SHERRATT, DJ			2 RELATED RECOMBINASES ARE REQUIRED FOR SITE-SPECIFIC RECOMBINATION AT DIF AND CER IN ESCHERICHIA-COLI K12	CELL			English	Article							RECJ CHROMOSOMAL REGION; ESCHERICHIA-COLI; INTEGRASE FAMILY; TYPE-1 FIMBRIAE; PHASE VARIATION; PROTEIN; IDENTIFICATION; CLEAVAGE; TYROSINE; PARTNERS	The stable inheritance of ColE1-related plasmids and the normal partition of the E. coli chromosome require the function of the Xer site-specific recombination system. We show that in addition to the XerC recombinase, whose function has already been implicated in this system, a second chromosomally encoded recombinase, XerD, is required. The XerC and XerD proteins show 37% identity and bind to separate halves of the recombination site. Both proteins act catalytically in the recombination reaction. Recombination site asymmetry and the requirement of two recombinases ensure that only correctly aligned sites are recombined. We predict that normal partition of most circular chromosomes requires the participation of site-specific recombination to convert any multimers (arising by homologous recombination) to monomers.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University	BLAKELY, G (corresponding author), UNIV GLASGOW,INST GENET,GLASGOW G11 5JS,SCOTLAND.		Lovett, Susan/AAC-1810-2021	Lovett, Susan/0000-0003-2792-1857				ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BLAKELY G, 1991, NEW BIOL, V3, P789; BLONFIELD IC, 1993, J BACTERIOL, V175, P27; BOOCOCK MR, 1987, UCLA S MOL CELLULAR, V47, P703; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COLLOMS SD, 1990, J BACTERIOL, V172, P6973, DOI 10.1128/jb.172.12.6973-6980.1990; HATFULL GF, 1988, GENETIC RECOMBINATIO, P857; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KLEMM P, 1986, EMBO J, V5, P1389, DOI 10.1002/j.1460-2075.1986.tb04372.x; Kornberg A., 1992, DNA REPLICATION; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; LOVETT ST, 1985, J BACTERIOL, V162, P280, DOI 10.1128/JB.162.1.280-285.1985; LOVETT ST, 1991, J BACTERIOL, V173, P353, DOI 10.1128/jb.173.1.353-364.1991; MCCLAIN MS, 1991, J BACTERIOL, V173, P5308, DOI 10.1128/jb.173.17.5308-5314.1991; McClintock B, 1932, P NATL ACAD SCI USA, V18, P677, DOI 10.1073/pnas.18.12.677; Murphy E, 1989, MOBILE DNA-UK, P269; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; Sambrook J, 1989, MOL CLONING LABORATO; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; SHERRATT DJ, 1993, CHROMOSOME, P25; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STIRLING CJ, 1989, EMBO J, V8, P1623, DOI 10.1002/j.1460-2075.1989.tb03547.x; STIRLING CJ, 1988, EMBO J, V7, P4389, DOI 10.1002/j.1460-2075.1988.tb03338.x; SUMMERS DK, 1984, CELL, V36, P1097, DOI 10.1016/0092-8674(84)90060-6; SUMMERS DK, 1989, EMBO J, V8, P309, DOI 10.1002/j.1460-2075.1989.tb03378.x; TRIEUCUOT P, 1993, MOL MICROBIOL, V8, P179, DOI 10.1111/j.1365-2958.1993.tb01214.x	37	280	287	2	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					351	361		10.1016/0092-8674(93)80076-Q	http://dx.doi.org/10.1016/0092-8674(93)80076-Q			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402918				2022-12-28	WOS:A1993MD88500016
J	DAMUTH, J				DAMUTH, J			COPES RULE, THE ISLAND RULE AND THE SCALING OF MAMMALIAN POPULATION-DENSITY	NATURE			English	Article							BODY SIZE; ABUNDANCE; BIRDS; EVOLUTION; ANIMALS	COPE'S rule-the generalization that animal taxa tend to evolve toward larger body size suggests that there are widespread net selective advantages to being large1-4. Size-abundance relationships within bird4-7 and desert rodent4 guilds show that larger species usually do control more energy locally, and thus maintain larger populations than expected for their body size, implying that larger individuals are relatively better at obtaining and using local resources. But we report here results that show that this is not generally the case among mammal species. Within dietary groups containing only small species, larger species usually do better, but within those that contain the largest mammals, small species tend to control more energy. This suggests that in mammals there is an optimum body size for energy acquisition at about 1 kg. Thus, net adaptive advantages of large individuals for resource control cannot be used as a general explanation for evolutionary size increase in mammals, although other proposed explanations for Cope's rule are unaffected8-10. Instead, these results suggest a partial explanation for another widespread ecotypic pattern, the 'island rule': that on islands, small mammal species evolve to larger size and large species to smaller size11-13. If on an island a species' usual competitors and predators are absent, it should often tend to evolve toward the optimum body size, and the adaptive advantages of doing so would be greatest for populations starting at body-size extremes.			DAMUTH, J (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106, USA.			Damuth, John/0000-0002-1635-9726				BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; Caughley G., 1977, ANAL VERTEBRATE POPU; COTGREAVE P, 1992, FUNCT ECOL, V6, P248, DOI 10.2307/2389514; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; DAMUTH J, 1987, BIOL J LINN SOC, V31, P193, DOI 10.1111/j.1095-8312.1987.tb01990.x; DAMUTH J, 1991, NATURE, V351, P268, DOI 10.1038/351268a0; DUTOIT JT, 1989, AM NAT, V133, P736, DOI 10.1086/284949; Eisenberg J.F., 1981, MAMMALIAN RAD; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FOSTER JB, 1964, NATURE, V202, P234, DOI 10.1038/202234a0; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; GOULD SJ, 1966, BIOL REV, V41, P587, DOI 10.1111/j.1469-185X.1966.tb01624.x; HEANEY LR, 1978, EVOLUTION, V32, P29, DOI 10.1111/j.1558-5646.1978.tb01096.x; HOFMANN R R, 1972, Mammalia, V36, P226, DOI 10.1515/mamm.1972.36.2.226; JUANES F, 1986, AM NAT, V128, P921, DOI 10.1086/284613; Kleiber M., 1975, FIRE LIFE; KUHRY B, 1977, SYST ZOOL, V26, P201, DOI 10.2307/2412842; LAWTON JH, 1989, OIKOS, V55, P429, DOI 10.2307/3565606; LEWONTIN RC, 1989, AM NAT, V134, P513, DOI 10.1086/284994; LOMOLINO MV, 1985, AM NAT, V125, P310, DOI 10.1086/284343; Maiorana V.C., 1990, P69; MCARDLE BH, 1988, CAN J ZOOL, V66, P2329, DOI 10.1139/z88-348; NAGY KA, 1987, ECOL MONOGR, V57, P111, DOI 10.2307/1942620; NEE S, 1991, NATURE, V351, P312, DOI 10.1038/351312a0; NEWELL ND, 1949, EVOLUTION, V3, P103, DOI 10.2307/2405545; PAGEL MD, 1988, AM NAT, V132, P344, DOI 10.1086/284857; RIDLEY M, 1989, J THEOR BIOL, V136, P361, DOI 10.1016/S0022-5193(89)80171-7; RIGGS DS, 1978, LIFE SCI, V22, P1305, DOI 10.1016/0024-3205(78)90098-X; ROBINSON JG, 1986, AM NAT, V128, P665, DOI 10.1086/284596; Sondaar P.Y., 1977, MAJOR PATTERNS VERTE, P671, DOI DOI 10.1007/978-1-4684-8851-7; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; Van Valen L, 1973, EVOL THEORY, V49, P31, DOI DOI 10.1007/S13398-014-0173-7.2; VANVALEN L, 1975, EVOLUTION, V29, P87, DOI 10.1111/j.1558-5646.1975.tb00816.x; Yablokov A.V, 1974, VARIABILITY MAMMALS	34	185	187	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					748	750		10.1038/365748a0	http://dx.doi.org/10.1038/365748a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413651				2022-12-28	WOS:A1993MC81200061
J	GRECO, PJ; EISENBERG, JM				GRECO, PJ; EISENBERG, JM			CHANGING PHYSICIANS PRACTICES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONTROLLED TRIAL; PRACTICE GUIDELINES; OFFICE PRACTICE; MEDICAL-PRACTICE; HEALTH-CARE; FEEDBACK; COST; EDUCATION; INTERVENTION; IMPROVEMENT				GRECO, PJ (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.				AHRQ HHS [HS06481-02] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; AVORN J, 1988, ARCH INTERN MED, V148, P1720, DOI 10.1001/archinte.148.8.1720; AVORN J, 1983, JAMA-J AM MED ASSOC, V250, P1752, DOI 10.1001/jama.250.13.1752; Berwick D. M, 1990, CURING HLTH CARE NEW; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BERWICK DM, 1986, JAMA-J AM MED ASSOC, V255, P1450, DOI 10.1001/jama.255.11.1450; BILLI JE, 1992, J GEN INTERN MED, V7, P411, DOI 10.1007/BF02599158; COLEMAN RW, 1991, AM J MED, V90, P439; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; EISENBERG J, 1986, DOCTORS DECISIONS CO; EVERITT DE, 1990, INFECT CONT HOSP EP, V11, P578; FINEBERG HV, 1987, B CANCER, V74, P333; FRAZIER LM, 1991, ANN INTERN MED, V115, P116, DOI 10.7326/0003-4819-115-2-116; Gray BH., 1989, CONTROLLING COSTS CH; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; HERSHEY CO, 1988, MED CARE, V26, P88, DOI 10.1097/00005650-198801000-00010; HICKSON GB, 1987, PEDIATRICS, V80, P344; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KLEIN D, 1976, PLANN CHANGE, P117; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; KROENKE LTCK, 1990, J AM GERIATR SOC, V38, P31, DOI 10.1111/j.1532-5415.1990.tb01593.x; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LINDSEY PA, 1990, J HEALTH POLIT POLIC, V15, P543, DOI 10.1215/03616878-15-3-543; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANHEIM LM, 1990, MED CARE, V28, P29, DOI 10.1097/00005650-199001000-00005; MCEACHERN JE, 1991, J OCCUP ENVIRON MED, V33, P364; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MEYER TJ, 1991, J GEN INTERN MED, V6, P133, DOI 10.1007/BF02598309; PARRINO TA, 1989, AM J MED, V86, P442, DOI 10.1016/0002-9343(89)90343-4; RAY WA, 1985, JAMA-J AM MED ASSOC, V253, P1774, DOI 10.1001/jama.253.12.1774; RAY WA, 1986, JAMA-J AM MED ASSOC, V256, P2536, DOI 10.1001/jama.256.18.2536; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SPIEGEL JS, 1989, ARCH INTERN MED, V149, P549, DOI 10.1001/archinte.149.3.549; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; WACHTEL TJ, 1990, J GEN INTERN MED, V5, P335, DOI 10.1007/BF02600402; WHITE CW, 1985, ANN INTERN MED, V102, P686, DOI 10.7326/0003-4819-102-5-686; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001; 1993, JAMA-J AM MED ASSOC, V269, P1018	44	772	779	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1271	1274		10.1056/NEJM199310213291714	http://dx.doi.org/10.1056/NEJM199310213291714			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MB988	8413397				2022-12-28	WOS:A1993MB98800014
J	SOLA, SM; KOHLER, M				SOLA, SM; KOHLER, M			RECENT DISCOVERIES OF DRYOPITHECUS SHED NEW LIGHT ON EVOLUTION OF GREAT APES	NATURE			English	Article							CLADE	THE origin and early evolution of the great ape/human clade (Hominidae) is currently a subject of debate1-3. The controversy is fuelled by the fragmentary nature of the fossils which renders it difficult to determine clearly derived features that permit the recognition of fossil members of this clade. We report here the recent discovery of a facial skeleton and a temporal fragment with the petrosal bone of Dryopithecus laietanus, which provides a way out of an impasse. The lack of the fossa subarcuata is a great ape and human clade synapomorphy, and proves unequivocally that Dryopithecus belongs to this clade. The zygomatic possesses derived characters which reveal that Dryopithecus is related to the Ponginae and not to the African apes/humans, as recently suggested1. The remaining morphological features are plesiomorphic and thus provide a good model of a common ancestor of all Hominidae.			SOLA, SM (corresponding author), ESCOLA IND 23,INST PALEONTOL M CRUSAFONT,E-08201 SABADELL,SPAIN.		Klein, Richard G/B-5910-2009	Kohler, Meike/0000-0002-6816-6651; Moya-Sola, Salvador/0000-0001-8506-1061; Kohler, Meike/0000-0001-9228-3164				Aiello L., 1990, P1; ANDREWS P, 1982, NATURE, V308, P541; ANDREWS P, 1992, SCIENCE, V360, P641; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; BONIS L, 1990, NATURE, V345, P712; DEAN D, 1992, SCIENCE, V359, P676; GROVES CP, 1991, J HUM EVOL, V20, P167, DOI 10.1016/0047-2484(91)90056-2; Lartet E., 1856, CR HEBD ACAD SCI, V43, P219; Napier J. R., 1959, Fossil Mammals of Africa, V16, P1; PILBEAM D, 1990, NATURE, V348, P237, DOI 10.1038/348237a0; SABAN R, 1965, MEM MUS NAT HIST NAT, V29, P1; SCHWARTZ JH, 1990, J HUM EVOL, V19, P591, DOI 10.1016/0047-2484(90)90001-R; SIMONS EL, 1965, FOLIA PRIMATOL, V3, P81, DOI 10.1159/000155026	13	41	41	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					543	545		10.1038/365543a0	http://dx.doi.org/10.1038/365543a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413607				2022-12-28	WOS:A1993MA66100052
J	CARDOSO, MC; LEONHARDT, H; NADALGINARD, B				CARDOSO, MC; LEONHARDT, H; NADALGINARD, B			REVERSAL OF TERMINAL DIFFERENTIATION AND CONTROL OF DNA-REPLICATION - CYCLIN-A AND CDK2 SPECIFICALLY LOCALIZE AT SUBNUCLEAR SITES OF DNA-REPLICATION	CELL			English	Article							TEMPERATURE-SENSITIVE MUTANTS; XENOPUS EGG EXTRACTS; CELL NUCLEAR ANTIGEN; PRE-MESSENGER-RNA; CASEIN KINASE-II; SIMIAN-VIRUS 40; S-PHASE; PROTEIN-A; AUXILIARY PROTEIN; TOPOISOMERASE-II	DNA replication in mammalian cells occurs in discrete nuclear foci. Here we show that terminally differentiated myotubes can be induced to reenter S phase and show the same pattern of replication foci as cycling cells. We used this cellular system to analyze the interaction of cell cycle proteins with these foci in vivo. Cyclin A and cdk2, but not cyclin B1 and cdc2, were specifically localized at nuclear replication foci, just like the replication protein proliferating cell nuclear antigen. A potential target of cyclin A and cdk2 is the 34 kd subunit of replication protein A (RPA34). In contrast with the 70 kd subunit, which localizes to the foci, RPA34 was not detected at these replication sites, which may reflect a transient interaction. The specific localization of cyclin A and cdk2 at nuclear replication foci provides a direct link between cell cycle regulation and DNA replication.	CHILDRENS HOSP MED CTR, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	CARDOSO, MC (corresponding author), CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA.		Leonhardt, Heinrich/B-2791-2014					ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; BALDIN V, 1993, IN PRESS GENES DEV; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CALZA RE, 1984, CELL, V36, P689, DOI 10.1016/0092-8674(84)90349-0; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CARTER KC, 1993, OSCIENCE, V259, P1330; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DANDREA AD, 1983, NUCLEIC ACIDS RES, V11, P4753, DOI 10.1093/nar/11.14.4753; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1991, COLD SH Q B, V56, P315; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EKI T, 1991, J BIOL CHEM, V266, P3087; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Endo T., 1989, CELLULAR MOL BIOL MU, P95; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEY EG, 1986, J CELL SCI, P99; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FOX MH, 1991, J CELL SCI, V99, P247; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALL ZW, 1989, CELL, V59, P771, DOI 10.1016/0092-8674(89)90597-7; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HASTINGS KEM, 1984, RECOMBINANT DNA CELL, P219; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; KENNY MK, 1990, J BIOL CHEM, V265, P769; KONIGSBERG IR, 1960, J BIOPHYS BIOCHEM CY, V8, P333, DOI 10.1083/jcb.8.2.333; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEHNER CF, 1991, COLD SH Q B, V56, P465; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; MILLS AD, 1989, J CELL SCI, V94, P471; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MOSER FG, 1975, J CELL BIOL, V66, P676, DOI 10.1083/jcb.66.3.676; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RAY S, 1992, J VIROL, V66, P6509, DOI 10.1128/JVI.66.11.6509-6516.1992; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; TEGTMEYE.P, 1971, J VIROL, V8, P516, DOI 10.1128/JVI.8.4.516-524.1971; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, 1993, IN PRESS ONCOGENE; VANDIERENDONCK JH, 1989, CYTOMETRY, V10, P143, DOI 10.1002/cyto.990100205; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WEISBLUM B, 1974, CHROMOSOMA, V46, P255; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	83	373	376	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					979	992		10.1016/0092-8674(93)90721-2	http://dx.doi.org/10.1016/0092-8674(93)90721-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402887	Green Submitted			2022-12-28	WOS:A1993LY49300006
J	AYESH, R; MITCHELL, SC; ZHANG, A; SMITH, RL				AYESH, R; MITCHELL, SC; ZHANG, A; SMITH, RL			THE FISH ODOR SYNDROME - BIOCHEMICAL, FAMILIAL, AND CLINICAL ASPECTS	BRITISH MEDICAL JOURNAL			English	Article							GENETIC-POLYMORPHISM; PRIMARY SEQUENCE; N-OXIDATION; TRIMETHYLAMINE; CLONING	Objectives-To study the biochemical, familial, and clinical features of the fish odour among subjects with suspected body malodour. Design-Subjects who responded to a newspaper article were screened for the fish odour syndrome by interview and biochemical tests. Families of subjects with the syndrome were tested if possible. Setting-St Mary's Hospital, London, and some interviews at subjects' homes. Subjects-187 subjects (28 males) with suspected body malodour, of whom 156 (19 males) underwent biochemical tests. Five families of six of the subjects with the fish odour syndrome agreed to further tests. Main outcome measures-Amounts of trimethylamine and trimethylamine N-oxide in urine collected over 24 hours under normal dietary conditions and for eight hours after oral challenge with 600 mg trimethylamine. Results-The fish odour syndrome was diagnosed in 11 subjects: the percentage of total trimethylamine excreted in their urine samples that was oxidised to trimethylamine N-oxide was <55% under normal dietary conditions and <25% after oral challenge with trimethylamine (in normal subjects >80% of trimethylamine was N-oxidised). Parents of six of the subjects with the syndrome were tested: all showed impaired N-oxidation of excreted trimethylamine (< 80%) after oral challenge, indicating that they were heterozygous carriers of the allele for the syndrome. The syndrome was associated with various psychosocial reactions including clinical depression. Conclusions-The fish odour syndrome can be inherited in an autosomal recessive fashion. It should be considered as a possible causative factor in patients complaining of body malodour.	ST MARYS HOSP,IMPERIAL COLL,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON W2 1PG,ENGLAND	Imperial College London								ALWAIZ M, 1987, XENOBIOTICA, V17, P551, DOI 10.3109/00498258709043962; ALWAIZ M, 1987, CLIN PHARMACOL THER, V42, P588, DOI 10.1038/clpt.1987.201; ALWAIZ M, 1989, J INHERIT METAB DIS, V12, P80, DOI 10.1007/BF01805534; ALWAIZ M, 1988, CLIN SCI, V74, P231, DOI 10.1042/cs0740231; AYESH R, 1990, PHARMACOL THERAPEUT, V45, P387, DOI 10.1016/0163-7258(90)90074-C; AYESH R, 1992, PHARMACOGENETICS DRU, P315; DOLPHIN C, 1991, J BIOL CHEM, V266, P12379; DOLPHIN CT, 1992, BIOCHEM J, V287, P261, DOI 10.1042/bj2870261; HUMBERT JR, 1970, LANCET, V1, P770; Willey GR, 1985, EDUC CHEM, V22, P178; ZHANG AQ, 1992, J CHROMATOGR-BIOMED, V584, P141, DOI 10.1016/0378-4347(92)80569-C	11	110	114	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					655	657		10.1136/bmj.307.6905.655	http://dx.doi.org/10.1136/bmj.307.6905.655			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401051	Green Published, Bronze			2022-12-28	WOS:A1993LX47000017
J	HELD, W; WAANDERS, GA; SHAKHOV, AN; SCARPELLINO, L; ACHAORBEA, H; MACDONALD, HR				HELD, W; WAANDERS, GA; SHAKHOV, AN; SCARPELLINO, L; ACHAORBEA, H; MACDONALD, HR			SUPERANTIGEN-INDUCED IMMUNE STIMULATION AMPLIFIES MOUSE MAMMARY-TUMOR VIRUS-INFECTION AND ALLOWS VIRUS TRANSMISSION	CELL			English	Article							T-CELL RECEPTOR; LONG TERMINAL REPEAT; OPEN READING FRAME; TRANSGENIC MICE; GENE-PRODUCTS; ENDOGENOUS SUPERANTIGEN; SERINE PROTEASES; CLONAL DELETION; EXPRESSION; MLS	Endogenous and infectious mouse mammary tumor viruses (MMTVs) encode in their 3' long terminal repeat a protein that exerts superantigen activity; that is, it is able to interact with T cells via the variable domain of the T cell receptor (TCR) beta chain. We show here that transmission of an infectious MMTV is prevented when superantigen-reactive cells are absent through either clonal deletion due to the expression of an endogenous MTV with identical superantigen specificity or exclusion due to expression of a transgenic TCR beta chain that does not interact with the viral superantigen. A strict requirement for superantigen-reactive T cells is also seen for a local immune response following MMTV infection. This immune response locally amplifies the number of MMTV-infected B cells, most likely owing to their clonal expansion. Collectively, our data indicate that a superantigen-induced immune response is critical for the MMTV life cycle.			HELD, W (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.							ABE R, 1989, ANNU REV IMMUNOL, V7, P683, DOI 10.1146/annurev.iy.07.040189.003343; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1992, J EXP MED, V176, P1769, DOI 10.1084/jem.176.6.1769; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; ACHAORBEA H, 1993, IMMUNOL REV, V131, P5, DOI 10.1111/j.1600-065X.1993.tb01527.x; BEUTNER U, 1992, P NATL ACAD SCI USA, V89, P5432, DOI 10.1073/pnas.89.12.5432; Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162; BRANDTCARLSON C, 1993, VIROLOGY, V193, P171, DOI 10.1006/viro.1993.1113; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORRADIN G, 1984, NATURE, V308, P547, DOI 10.1038/308547a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DICKSON C, 1981, J VIROL, V37, P36, DOI 10.1128/JVI.37.1.36-47.1981; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FESTENSTEIN H, 1983, TRANSPLANTATION, V37, P322; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GOODING LR, 1992, CELL, V71, P5; HAINAUT P, 1990, CANCER RES, V50, P3754; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; HELD W, 1992, J EXP MED, V175, P1623, DOI 10.1084/jem.175.6.1623; HELD W, 1990, INT IMMUNOL, V2, P57, DOI 10.1093/intimm/2.1.57; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KATZ ME, 1986, J IMMUNOL, V136, P1; KENNEDY N, 1982, NATURE, V295, P622, DOI 10.1038/295622a0; KNIGHT AM, 1992, EUR J IMMUNOL, V22, P879, DOI 10.1002/eji.1830220339; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LIEGLER TJ, 1986, J VIROL, V59, P159, DOI 10.1128/JVI.59.1.159-162.1986; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1991, NATURE, V349, P525; MOHAN N, 1993, J EXP MED, V177, P351, DOI 10.1084/jem.177.2.351; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; NANDA NK, 1991, P NATL ACAD SCI USA, V88, P9503, DOI 10.1073/pnas.88.21.9503; OKADA CY, 1990, J IMMUNOL, V144, P3473; PAYNE J, 1988, P NATL ACAD SCI USA, V85, P7695, DOI 10.1073/pnas.85.20.7695; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SMITH GH, 1987, J GEN VIROL, V68, P473, DOI 10.1099/0022-1317-68-2-473; SQUARTINI F, 1970, CANCER RES, V30, P2069; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TSUBURA A, 1988, CANCER RES, V48, P6555; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; WAANDERS GA, 1992, EUR J IMMUNOL, V22, P291, DOI 10.1002/eji.1830220144; WAANDERS GA, 1993, J EXP MED, V177, P1359, DOI 10.1084/jem.177.5.1359; Weiss R, 1985, RNA TUMOR VIRUSES; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1991, J EXP MED, V174, P1255, DOI 10.1084/jem.174.5.1255	62	195	195	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					529	540		10.1016/0092-8674(93)80054-I	http://dx.doi.org/10.1016/0092-8674(93)80054-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8394220				2022-12-28	WOS:A1993LT73900014
J	LOPEZCASILLAS, F; WRANA, JL; MASSAGUE, J				LOPEZCASILLAS, F; WRANA, JL; MASSAGUE, J			BETAGLYCAN PRESENTS LIGAND TO THE TGF-BETA SIGNALING RECEPTOR	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; HEMATOPOIETIC PROGENITOR CELLS; FIBROBLAST GROWTH; PROTEOGLYCAN BETAGLYCAN; EXPRESSION CLONING; ENDOTHELIAL-CELLS; TRK PROTOONCOGENE; MOLECULAR-CLONING; HEPARAN-SULFATE; NGF RECEPTOR	Transforming growth factor beta (TGFbeta) signals through a heteromeric protein kinase receptor that has a limited ability to bind ligand. This limitation is overcome by the action of betaglycan (TGFbeta type III receptor), a separate TGFbeta-binding membrane protein of previously unknown function. Betaglycan presents TGFbeta directly to the kinase subunit of the signaling receptor, forming a high affinity ternary complex. Membrane betaglycan increases TGFbeta binding to the signaling receptor, enhances cell responsiveness to TGFbeta, and eliminates marked biological differences between TGFbeta isoforms. Thus, betaglycan is a direct regulator of TGFbeta access to the signaling receptors.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	LOPEZCASILLAS, F (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.		Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHIEFETZ S, 1992, J BIOL CHEM, V267, P19027; CHIEFETZ S, 1990, J BIOL CHEM, V265, P20533; CHIEFETZ S, 1988, J BIOL CHEM, V263, P16984; CHIEFETZ S, 1987, CELL, V48, P409; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; EVAN GI, 1985, MOL CELL BIOL, V5, P360; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MERWIN JR, 1991, AM J PATHOL, V138, P37; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SAUNDERS S, 1989, J CELL BIOL, V108, P547; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SMITH DB, 1990, CURRENT PROTOCOLS MO; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	55	785	828	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1435	1444		10.1016/0092-8674(93)90368-Z	http://dx.doi.org/10.1016/0092-8674(93)90368-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391934	Bronze			2022-12-28	WOS:A1993LL20900017
J	MESZAROS, LG; BAK, J; CHU, A				MESZAROS, LG; BAK, J; CHU, A			CYCLIC ADP-RIBOSE AS AN ENDOGENOUS REGULATOR OF THE NONSKELETAL TYPE RYANODINE RECEPTOR CA2+ CHANNEL	NATURE			English	Article							CA-2+ RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CALCIUM RELEASE; MUSCLE; MEMBRANES; CONDUCTANCE; ACTIVATION; METABOLITE; MECHANISM; BINDING	THE skeletal and cardiac isoforms1 of the ryanodine receptor Ca2+ channel (RyRC) constitute the Ca2+ release pathway in sarcoplasmic reticulum of skeletal and cardiac muscles, respectively2,3. A direct mechanical and a Ca2+-triggered mechanism (Ca2+-induced Ca2+ release) have been respectively proposed to explain the in situ activation of Ca2+ release in skeletal and cardiac muscle4,5. In non-muscle cells, however, where the RyRC also participates in Ca2+ signalling6-11 the mechanism of RyRC activation is unknown. Cyclic adenosine 5'-diphosphoribose (cADPR)12, which is present in many mammalian tissues13, has been reported to induce Ca2+ release from ryanodine-sensitive intracellular Ca2+ stores in sea urchin eggs14. Here we provide evidence that cADPR directly activates the cardiac but not the skeletal isoform of the RyRC. This, together with results on sea urchin eggs14, suggests that cADPR is an endogenous activator of the non-skeletal type of RyRC and may thus have a role similar to inositol 1,4,5-trisphosphate15 in Ca2+ signalling.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine	MESZAROS, LG (corresponding author), MED COLL GEORGIA,DEPT PHYSIOL & ENDOCRINOL,AUGUSTA,GA 30912, USA.							ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; CHU A, 1991, J BIOL CHEM, V266, P7699; CHU A, 1990, MOL PHARMACOL, V37, P735; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; EDELMAN AM, 1985, J NEUROSCI, V5, P2609; FABIATO A, 1989, MOL CELL BIOCHEM, V89, P135; FAOLATO C, 1991, J BIOL CHEM, V266, P20159; FILL M, 1990, BIOPHYS J, V50, P471; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LAI FA, 1990, ADV EXP MED BIOL, V269, P73; LEE HC, 1989, J BIOL CHEM, V264, P1608; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MESZAROS LG, 1991, AM J PHYSIOL, V261, pC1048, DOI 10.1152/ajpcell.1991.261.6.C1048; MESZAROS LG, 1985, J BIOL CHEM, V260, P6076; OTSU K, 1990, J BIOL CHEM, V265, P13472; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SHOSHANBARMATZ V, 1991, BIOCHEM J, V276, P41, DOI 10.1042/bj2760041; SUMIDA M, 1978, J BIOL CHEM, V253, P8772; WASETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113	29	337	341	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					76	79		10.1038/364076a0	http://dx.doi.org/10.1038/364076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8391127				2022-12-28	WOS:A1993LK81800062
J	TARTAGLIA, LA; ROTHE, M; HU, YF; GOEDDEL, DV				TARTAGLIA, LA; ROTHE, M; HU, YF; GOEDDEL, DV			TUMOR NECROSIS FACTORS CYTOTOXIC ACTIVITY IS SIGNALED BY THE P55 TNF RECEPTOR	CELL			English	Note							ANTIBODIES; RESPONSES				TARTAGLIA, LA (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GEHR G, 1992, J IMMUNOL, V149, P911; HELLER RA, 1992, CELL, V70, P47; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; PENNICA D, 1992, J BIOL CHEM, V267, P21172; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1992, MOL BIOL FREE RADICA, P69	16	330	346	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					213	216		10.1016/0092-8674(93)90222-C	http://dx.doi.org/10.1016/0092-8674(93)90222-C			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8386591				2022-12-28	WOS:A1993KY50500003
J	NARULA, J; KHAW, BA; DEC, GW; PALACIOS, IF; SOUTHERN, JF; FALLON, JT; STRAUSS, HW; HABER, E; YASUDA, T				NARULA, J; KHAW, BA; DEC, GW; PALACIOS, IF; SOUTHERN, JF; FALLON, JT; STRAUSS, HW; HABER, E; YASUDA, T			RECOGNITION OF ACUTE MYOCARDITIS MASQUERADING AS ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ANTIMYOSIN ANTIBODY; DIAGNOSIS; BIOPSY		MASSACHUSETTS GEN HOSP,CARDIAC UNIT,TILTON 2,32 FRUIT ST,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DIV NUCL MED,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NORTHEASTERN UNIV,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Northeastern University; Harvard University; Harvard T.H. Chan School of Public Health				Fallon, John/0000-0002-7677-4868				Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; BRAAT SH, 1987, AM J CARDIOL, V60, P725, DOI 10.1016/0002-9149(87)90391-2; COSTANZONORDIN MR, 1985, BRIT HEART J, V53, P25; DEC GW, 1990, J AM COLL CARDIOL, V16, P97, DOI 10.1016/0735-1097(90)90463-Y; DEC GW, 1992, J AM COLL CARDIOL, V20, P85, DOI 10.1016/0735-1097(92)90141-9; DEC GW, 1990, J AM COLL CARDIOL, V15, P283, DOI 10.1016/S0735-1097(10)80050-6; GILLIS JG, 1954, AM HEART J, V47, P117, DOI 10.1016/0002-8703(54)90220-3; GOLDMAN AM, 1962, DIS CHEST, V41, P61, DOI 10.1378/chest.41.1.61; JOHNSON LL, 1989, J AM COLL CARDIOL, V13, P27, DOI 10.1016/0735-1097(89)90544-5; KHAW BA, 1986, CIRCULATION, V74, P501, DOI 10.1161/01.CIR.74.3.501; KHAW BA, 1987, J NUCL MED, V28, P1671; KHAW BA, 1982, SCIENCE, V217, P1050, DOI 10.1126/science.7051286; LIMAS CJ, 1971, SOUTHERN MED J, V64, P1534, DOI 10.1097/00007611-197112000-00027; MASON JW, 1978, AM J CARDIOL, V41, P887, DOI 10.1016/0002-9149(78)90729-4; MIKLOZEK CL, 1988, AM HEART J, V115, P768, DOI 10.1016/0002-8703(88)90877-0; PAILLARD F, 1990, CIRCULATION, V82, P118; SAFFITZ J, 1983, AM J CARDIOL, V52, P646; SAFFITZ JE, 1983, AM J CARDIOL, V52, P644, DOI 10.1016/0002-9149(83)90046-2; SPODICK DH, 1986, AM J MED, V81, P661, DOI 10.1016/0002-9343(86)90554-1; VOLPINI M, 1989, AM J CARDIOL, V63, P7, DOI 10.1016/0002-9149(89)91066-7; YASUDA T, 1987, CIRCULATION, V76, P306, DOI 10.1161/01.CIR.76.2.306	21	95	101	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					100	104		10.1056/NEJM199301143280205	http://dx.doi.org/10.1056/NEJM199301143280205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	8416421				2022-12-28	WOS:A1993KG46700005
J	LIPPMAN, SM; BATSAKIS, JG; TOTH, BB; WEBER, RS; LEE, JJ; MARTIN, JW; HAYS, GL; GOEPFERT, H; HONG, WK				LIPPMAN, SM; BATSAKIS, JG; TOTH, BB; WEBER, RS; LEE, JJ; MARTIN, JW; HAYS, GL; GOEPFERT, H; HONG, WK			COMPARISON OF LOW-DOSE ISOTRETINOIN WITH BETA-CAROTENE TO PREVENT ORAL CARCINOGENESIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; THERAPEUTIC ANTICANCER AGENTS; NECK-CANCER; VITAMIN-A; 13-CIS-RETINOIC ACID; ANALOGS RETINOIDS; HEAD; CHEMOPREVENTION; LEUKOPLAKIA; EXPRESSION	Background. High-dose isotretinoin therapy has been determined to be an effective treatment for leukoplakia. However, a high rate of relapses and toxic reactions led us to conduct a trial of a much lower dose of isotretinoin in the hope of maintaining a response and limiting toxicity. Methods. In the first phase of the study, 70 patients with leukoplakia underwent induction therapy with a high dose of isotretinoin (1.5 mg per kilogram of body weight per day) for three months; in the second phase, patients with responses or stable lesions were randomly assigned to maintenance therapy with either beta carotene (30 mg per day) or a low dose of isotretinoin (0.5 mg per kilogram per day) for nine months. Results. In the first phase, the rate of response to high-dose induction therapy in the 66 patients who could be evaluated was 55 percent (36 patients). The lesions of seven patients progressed, and therefore they did not participate in the second phase of the trial. Of the 59 patients included in the second phase, 33 were assigned to beta carotene therapy and 26 to low-dose isotretinoin therapy; these two groups did not differ significantly in prognostic factors. Of the 53 patients who could be evaluated, 22 in the low-dose isotretinoin group and 13 in the beta carotene group responded to maintenance therapy or continued to have stable lesions (92 percent vs. 45 percent, P<0.001). In situ carcinoma developed in one patient in each group, and invasive squamous-cell carcinoma in five patients in the beta carotene group. Toxicity was generally mild, though greater in the group given low-dose isotretinoin therapy. Conclusions. When preceded by high-dose induction therapy, low-dose isotretinoin therapy was significantly more active against leukoplakia than beta carotene and was easily tolerated.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT DENT ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DENT BRANCH,DEPT ORAL DIAGNOST SCI,HOUSTON,TX 77225	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	LIPPMAN, SM (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,BOX 80,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Lee, Jack/P-7331-2019; Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019	Lee, Jack/0000-0002-4584-929X; Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214	NCI NIH HHS [CA-46303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA046303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJANI JA, 1990, CANCER INVEST, V8, P147, DOI 10.3109/07357909009017560; BAND PR, 1986, CANCER DETECT PREV, V9, P157; Batsakis G.J, 1979, TUMORS HEAD NECK CLI, V2nd ed., P334; BOLLAG W, 1983, LANCET, V1, P860; COOPER JS, 1989, INT J RADIAT ONCOL, V17, P449, DOI 10.1016/0360-3016(89)90094-1; DECKER J, 1982, NEW ENGL J MED, V306, P1151, DOI 10.1056/NEJM198205133061905; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; GUDAS LJ, 1990, AM J RESP CELL MOL, V2, P319, DOI 10.1165/ajrcmb/2.4.319; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HU L, 1991, CANCER RES, V51, P3972; Hyams VJ, 1988, ATLAS TUMOR PATHOLOG; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; KRAMER I R H, 1978, Oral Surgery Oral Medicine Oral Pathology, V46, P518; Lippman S M, 1992, Important Adv Oncol, P93; LIPPMAN SM, 1989, INT J RADIAT ONCOL, V17, P691, DOI 10.1016/0360-3016(89)90126-0; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; MEYSKENS FL, 1985, CRC CR REV ONCOL-HEM, V3, P75, DOI 10.1016/S1040-8428(85)80040-8; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; SHIN DM, 1990, CANCER RES, V50, P2505; SILVERMAN S, 1984, CANCER, V53, P563; SILVERMAN S, 1990, ORAL CANCER; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SPORN MB, 1976, CANCER RES, V36, P2699; SPORN MB, 1976, FED PROC, V35, P1332; TEPPERMAN BS, 1981, LANCET, V2, P547; VIKRAM B, 1984, ARCH OTOLARYNGOL, V110, P564; WINN DM, 1984, CANCER RES, V44, P1216; Wolf G, 1992, CANCER MED, P1211; Woolson R. F, 1987, STATISTICAL METHODS	36	325	335	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					15	20		10.1056/NEJM199301073280103	http://dx.doi.org/10.1056/NEJM199301073280103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8416267				2022-12-28	WOS:A1993KF50700003
J	GIUGLIANO, D; MARFELLA, R; QUATRARO, A; DEROSA, N; SALVATORE, T; COZZOLINO, D; CERIELLO, A; TORELLA, R				GIUGLIANO, D; MARFELLA, R; QUATRARO, A; DEROSA, N; SALVATORE, T; COZZOLINO, D; CERIELLO, A; TORELLA, R			TOLRESTAT FOR MILD DIABETIC NEUROPATHY - A 52-WEEK, RANDOMIZED, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						TOLRESTAT; DIABETIC NEUROPATHIES; AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETES-MELLITUS; ALDEHYDE REDUCTASE	ALDOSE-REDUCTASE INHIBITOR; HEART-RATE; AUTONOMIC NEUROPATHY; NERVE FUNCTION; COMPLICATIONS; NORMOGLYCEMIA; PATHOGENESIS; SORBINIL; MELLITUS; PAIN	Objective: To evaluate the effectiveness and safety of tolrestat, an aldose-reductase inhibitor, in patients with mild diabetic autonomic and peripheral neuropathy. Design: Randomized, placebo-controlled, double-blind 52-week trial. Setting: University hospital clinic. Patients: Forty-five diabetic patients with asymptomatic autonomic neuropathy identified by at least one pathologic cardiovascular reflex test result. Interventions: All patients were given placebo during a 4-week run-in period (single-blind). Twenty patients were randomly assigned to continue to receive placebo, and 25 were assigned to treatment with tolrestat (200 mg/d given in the morning). Measurements and Results: At 12 months, improvements in nerve functions occurred in patients receiving tolrestat. Compared with baseline values, postural hypotension decreased by a value of 5.9 mm Hg (95% CI, 1.6 to 8.7); deep-breathing, maximum/minimum heart rate (expiration/inspiration ratio) increased by a value of 0.026 (CI, 0.015 to 0.036); and lying-to-standing heart rate ratio (30:15 ratio) increased by a value of 0.032 (CI, 0.027 to 0.052). In the placebo group, all test results except postural hypotension deteriorated. Vibration perception threshold at the malleolus and great toe of the dominant leg improved in the tolrestat group (- 1.4; CI, - 3.69 to - 1.09) but tended to worsen in the placebo group during the study period. No important side effects were detected in either group. Conclusions: The progression of mild diabetic autonomic and peripheral neuropathy may be halted or even reversed by pharmacologic intervention with the aldose-reductase inhibitor tolrestat.	NAPLES UNIV, I-80138 NAPLES, ITALY	University of Naples Federico II			Marfella, Raffaele/C-6899-2012	Marfella, Raffaele/0000-0003-3960-9270; Giugliano, Dario/0000-0002-9377-873X; salvatore, teresa/0000-0002-6532-7122; Ceriello, Antonio/0000-0001-8122-3203				AGARDH CD, 1983, ACTA MED SCAND, V213, P283; BLOOM SR, 1984, BRIT MED J, V228, P1973; BOULTON AJM, 1986, CLIN ENDOCRINOL META, V15, P917, DOI 10.1016/S0300-595X(86)80080-9; BOULTON AJM, 1990, DIABETOLOGIA, V33, P431, DOI 10.1007/BF00404095; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DAHLJORGENSEN K, 1986, BRIT MED J, V293, P1195, DOI 10.1136/bmj.293.6556.1195; DYCK PJ, 1986, ANN NEUROL, V19, P288, DOI 10.1002/ana.410190311; EWING DJ, 1978, BRIT MED J, V1, P145, DOI 10.1136/bmj.1.6106.145; FAGIUS J, 1985, DIABETOLOGIA, V28, P323; GILL JS, 1990, DIABETES METAB, V16, P296; GREENE DA, 1987, NEW ENGL J MED, V316, P599; JASPAN J, 1983, LANCET, V2, P758; JOHNSON PC, 1986, ANN NEUROL, V19, P450, DOI 10.1002/ana.410190505; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; OBRIEN IAD, 1986, BRIT HEART J, V55, P348; PIRART J, 1977, DIABETES METAB, V3, P97; RASKIN P, 1987, AM J MED, V83, P298, DOI 10.1016/0002-9343(87)90702-9; RYDER S, 1987, DRUG DEVELOP RES, V11, P131, DOI 10.1002/ddr.430110208; SERVICE FJ, 1985, DIABETOLOGIA, V28, P722; SIMA AAF, 1988, NEW ENGL J MED, V319, P548, DOI 10.1056/NEJM198809013190905; WATKINS PJ, 1990, NEW ENGL J MED, V322, P1078, DOI 10.1056/NEJM199004123221511; WIELING W, 1982, DIABETOLOGIA, V22, P163, DOI 10.1007/BF00283745; YOUNG RJ, 1983, DIABETES, V32, P938, DOI 10.2337/diabetes.32.10.938; 1987, DIABETES CARE, V13, P427	25	55	58	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					7	11		10.7326/0003-4819-118-1-199301010-00002	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416161				2022-12-28	WOS:A1993KE60500002
J	LINDEGREN, ML; ATKINSON, WL; FARIZO, KM; STEHRGREEN, PA				LINDEGREN, ML; ATKINSON, WL; FARIZO, KM; STEHRGREEN, PA			MEASLES VACCINATION IN PEDIATRIC EMERGENCY DEPARTMENTS DURING A MEASLES OUTBREAK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MEDICAL SETTINGS; IMMUNIZATION; TRANSMISSION; CHILDREN; OPPORTUNITIES; INFANTS; HEALTH; CARE	Objective.-To determine the proportion of preschool-aged patients attending two inner-city hospital pediatric emergency departments (EDs) who were eligible for measles vaccination, to describe their demographic and clinical characteristics, and to assess the performance of the ED immunization programs that were implemented during a measles outbreak in vaccinating eligible children. Design.-Cross-sectional study. Setting.-Pediatric EDs of two urban hospitals in Chicago, Ill, in 1989. Participants.-Children 6 months to 5 years of age seen in the EDs. Intervention.-None. Main Outcome Measures.-The proportion of preschool-aged patients attending the two EDs who were eligible for measles vaccination and the proportion of vaccine-eligible children who were given measles vaccine. Results.-508 ED patients at hospital A and 255 patients at hospital B, 18% and 29%, respectively, were considered to be vaccine eligible. The most common discharge diagnoses of eligible patients were viral syndrome, otitis media, and minor trauma. Of vaccine-eligible patients, 59% at hospitals A and B were not vaccinated in the ED. At hospital B, patients with an infectious or respiratory disease diagnosis were less likely to be vaccinated than those with other diagnoses (P<.05). Conclusions.-Many children seen in these EDs were eligible for measles vaccination, and many eligible patients were not vaccinated. During community outbreaks of measles, optimal vaccination programs in pediatric EDs could increase vaccination coverage among inner-city preschool-aged children who may have limited access to health care.	CTR DIS CONTROL & PREVENT,DIV IMMUNIZAT,MAILSTOP EO5,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								[Anonymous], 1989, MMWR-MORBID MORTAL W, V38, P49; ATKINSON W, 1992, 32ND P INT C ANT AG; ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; ATKINSON WL, 1991, SEMIN PEDIATR INFECT, V2, P100; BELL LM, 1992, AJDC, V146, P474; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DALES LG, 1985, WESTERN J MED, V142, P415; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295; FARIZO KM, 1991, PEDIATRICS, V87, P74; FARIZO KM, 1992, PEDIATRICS, V89, P589; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HOEKELMAN RA, 1976, CLIN PEDIATR, V15, P261, DOI 10.1177/000992287601500305; HUTCHINS SS, 1993, AM J PUBLIC HEALTH, V83, P862, DOI 10.2105/AJPH.83.6.862; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; ISTRE GR, 1987, PEDIATRICS, V79, P356; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; LINDEGREN ML, 1991, 31ST P INT C ANT AG; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; NDIKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448, DOI 10.1093/ije/17.2.448; PETER G, 1991, JAMA-J AM MED ASSOC, V265, P2111, DOI 10.1001/jama.265.16.2111; POLIS MA, 1987, ARCH INTERN MED, V147, P1999, DOI 10.1001/archinte.147.11.1999; RODEWALD LE, 1993, PEDIATRICS, V91, P605; SCOTT RM, 1984, PEDIATRICS, V73, P777; WOOD DL, 1990, PEDIATRICS, V86, P666; 1991, MMWR MORB MORTAL WKL, V40, P369; 1991, REPORT COMMITTEE INF, P7; 1992, MMWR CDC SURVEILL SU, V41, P1; 1990, MMWR MORB MORTAL WKL, V39, P317; 1989, MMWR MORB MORTAL WKL, V38, P57; 1990, MMWR MORB MORTAL WKL, V39, P325; 1989, MMWR MORB MORTAL WKL, V38, P219; 1989, MMWR MORB MORTAL WKL, V38, P205; 1992, MMWR MORB MORTAL WKL, V41, P103; 1941, MMWR MORB MORTAL WKL, V40, P305; 1990, MMWR MORB MORTAL WKL, V39, P353; 1991, MMWR MORB MORTAL WKL, V40, P36; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1989, MMWR MORB MORTAL WKL, V38, P1; 1990, MMWR MORB MORTAL WKL, V39, P361; 1993, MMWR MORB MORTAL WKL, V42, P1	41	20	20	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2185	2189		10.1001/jama.270.18.2185	http://dx.doi.org/10.1001/jama.270.18.2185			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411600				2022-12-28	WOS:A1993ME81600028
J	SCHUTT, CE; MYSLIK, JC; ROZYCKI, MD; GOONESEKERE, NCW; LINDBERG, U				SCHUTT, CE; MYSLIK, JC; ROZYCKI, MD; GOONESEKERE, NCW; LINDBERG, U			THE STRUCTURE OF CRYSTALLINE PROFILIN BETA-ACTIN	NATURE			English	Article								The three-dimensional structure of bovine profilin-beta-actin has been solved to 2.55 angstrom resolution by X-ray crystallography. There are several significant local changes in the structure of beta-actin compared with alpha-actin as well as an overall 5-degrees rotation between its two major domains. Actin molecules in the crystal are organized into ribbons through intermolecular contacts like those found in oligomeric protein assemblies. Profilin forms two extensive contacts with the actin ribbon, one of which appears to correspond to the solution contact in vitro.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,WGI,DEPT ZOOL CELL BIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	SCHUTT, CE (corresponding author), PRINCETON UNIV,HENRY H HOYT LAB,DEPT CHEM,PRINCETON,NJ 08544, USA.							AMPE C, 1988, FEBS LETT, V228, P17, DOI 10.1016/0014-5793(88)80575-1; ASPENSTROM P, 1993, FEBS LETT, V329, P163, DOI 10.1016/0014-5793(93)80215-G; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BJORKEGREN C, IN PRESS FEBS LETT; BRAY D, 1976, J MOL BIOL, V105, P527, DOI 10.1016/0022-2836(76)90233-3; BRUNGER AT, 1992, XPLOR V 30 MANUAL; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CARLSSON L, 1979, THESIS UPPSALA U SWE; FINZEL BC, 1990, CRYSTALLOGRAPHIC MOD, P175; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LINDBERG U, 1966, J BIOL CHEM, V241, P1246; MALM B, 1983, J MUSCLE RES CELL M, V4, P569, DOI 10.1007/BF00712116; MARKEY F, 1981, CELL, V23, P145, DOI 10.1016/0092-8674(81)90279-8; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MYSLIK JC, 1992, THESIS PRINCETON U U; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PROBST E, 1972, BIOCHIM BIOPHYS ACTA, V278, P577, DOI 10.1016/0005-2795(72)90017-7; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RODGERS DW, 1987, P NATL ACAD SCI USA, V84, P6157, DOI 10.1073/pnas.84.17.6157; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SEGURA M, 1984, J BIOL CHEM, V259, P3949; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TIRION MM, 1993, J MOL BIOL, V230, P186, DOI 10.1006/jmbi.1993.1135; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WINKLER FK, 1979, ACTA CRYSTALLOGR A, V35, P901, DOI 10.1107/S0567739479002035; YU FX, 1992, J BIOL CHEM, V267, P14616; 1979, CCP4 DAR LAB PACK	51	612	627	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					810	816		10.1038/365810a0	http://dx.doi.org/10.1038/365810a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413665				2022-12-28	WOS:A1993MD95100041
J	JELLINEK, MS; NURCOMBE, B				JELLINEK, MS; NURCOMBE, B			2 WRONGS DONT MAKE A RIGHT - MANAGED CARE, MENTAL-HEALTH, AND THE MARKETPLACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA 02115; VANDERBILT UNIV,MED CTR,SCH MED,DIV CHILD & ADOLESCENT PSYCHIAT,NASHVILLE,TN 37232	Harvard University; Harvard Medical School; Vanderbilt University	JELLINEK, MS (corresponding author), MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,15 PARKMAN ST,ACC 725,BOSTON,MA 02114, USA.							Andersen TF., 1990, CHALLENGES MED PRACT; BURTON TM, 1992, WALL STREET J   0728, pA1; HENDRICKS B, 1991, SAN ANTONIO EXP 1010, P17; KERR P, 1993, NY TIMES        0101, pD3; KOSLOWE PA, 1991, MENTAL HLTH STATISTI, V201, P16; MCCUE M, 1992, AM J PSYCHIAT, V150, P77; MILAZZOSAYRE LJ, 1986, MENTAL HLTH STATISTI, V175, P16; MULLEY AG, 1988, JAMA-J AM MED ASSOC, V260, P540, DOI 10.1001/jama.260.4.540; NURCOMBE B, IN PRESS MENTAL HLTH; OSS M, 1991, OPEN MINDS, P2; RUNDLE RL, 1993, WALL STREET J   0526, pB1; SEDERER LI, 1992, AM J PSYCHIAT, V149, P1157; SHARFSTEIN SS, 1991, AM J PSYCHIAT, V150, P7; WEITHORN LA, 1988, STANFORD LAW REV, V40, P773, DOI 10.2307/1228816; WESTERMEYER J, 1991, HOSP COMMUNITY PSYCH, V42, P1221; 1992, GROUP HLTH ASS AM S, P13; 1992, OPENP MINDS; 1992, FINANCING MENTAL HLT	18	68	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1737	1739		10.1001/jama.270.14.1737	http://dx.doi.org/10.1001/jama.270.14.1737			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MA294	8411506				2022-12-28	WOS:A1993MA29400032
J	KASHLEV, M; NUDLER, E; GOLDFARB, A; WHITE, T; KUTTER, E				KASHLEV, M; NUDLER, E; GOLDFARB, A; WHITE, T; KUTTER, E			BACTERIOPHAGE-T4 ALC PROTEIN - A TRANSCRIPTION TERMINATION FACTOR SENSING LOCAL MODIFICATION OF DNA	CELL			English	Article							COLI RNA-POLYMERASE; STRUCTURAL-ANALYSIS; TERNARY COMPLEXES; GENE-PRODUCT; BETA-SUBUNIT; MUTATION	Bacteriophage T4 Alc protein Participates in shutting off host transcription after infection of E. coli. It is demonstrated that Alc acts as a site-specific termination factor. The Alc sites occur frequently in E. coli DNA, resulting in early cessation of elongation in several tested transcription units. Alc-dependent termination requires unimpeded propagation of the elongating complex as it approaches the Alc site. Temporary halting of RNA polymerase within 10-15 bp before the Alc site prevents termination. Bacteriophage T4 transcription is protected from the action of Alc by overall substitution of cytosine with 5-hydroxymethyl cytosine in T4 DNA. In vitro methylation of CpG sequences in the vicinity of an Alc site abolishes the effect of Alc. Thus, Alc-dependent termination involves local sensing of the state of cytosine modification and a short-term ''memory'' of recent pausing.	EVERGREEN STATE COLL,OLYMPIA,WA 98505		KASHLEV, M (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016, USA.			Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD VD, 1978, NUCLEIC ACIDS RES, V10, P3549; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; CHAN CL, 1993, IN PRESS TRANSCRIPTI; DRIVDAHL RH, 1990, J BACTERIOL, V172, P2716, DOI 10.1128/jb.172.5.2716-2727.1990; FREIDMAN DJ, 1983, LAMBDA, V2; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KNAUS R, 1988, EMBO J, V7, P2919, DOI 10.1002/j.1460-2075.1988.tb03150.x; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUTTER E, 1984, GENETICS, V108, P291; KUTTER E, 1975, J MOL BIOL, V99, P591, DOI 10.1016/S0022-2836(75)80174-4; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEHMAN IR, 1960, J BIOL CHEM, V235, P3254; MUSTAEV A, 1993, IN PRESS J BIOL CHEM; SAGITOV V, 1993, J BIOL CHEM, V268, P2195; SNYDER L, 1976, P NATL ACAD SCI USA, V73, P3098, DOI 10.1073/pnas.73.9.3098; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	20	42	44	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					147	154		10.1016/S0092-8674(05)80091-1	http://dx.doi.org/10.1016/S0092-8674(05)80091-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402894				2022-12-28	WOS:A1993MB66700015
J	BEARDON, PHG; MCGILCHRIST, MM; MCKENDRICK, AD; MCDEVITT, DG; MACDONALD, TM				BEARDON, PHG; MCGILCHRIST, MM; MCKENDRICK, AD; MCDEVITT, DG; MACDONALD, TM			PRIMARY NONCOMPLIANCE WITH PRESCRIBED MEDICATION IN PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article							NONCOMPLIANCE	Objective-To determine the rate of patients not redeeming their prescriptions (primary non-compliance) and assess the factors influencing this. Design-Observational study comparing copies of prescriptions written by general practitioners with those dispensed by pharmacists and subsequent case record review. Setting-A large rural general practice in Tayside. Subjects-All 4854 patients who received prescriptions (20 921) written between january 1989 and March 1989. Main outcome measures-The rate of non-redemption of prescriptions. Results-Seven hundred and two patients (14.5%) did not redeem 1072 (5.2%) prescriptions during the study period, amounting to 11.5% of men and 16.3% of women. Non-redemption was highest in women aged 16-29 (27.6% of women) and men aged 40-49 (18.3% of men). Of prescriptions issued to women for oral contraceptives 24.8% were not redeemed during the study period. In those who redeemed prescriptions 17% were not exempt from prescription charges compared with 33% of patients who failed to redeem them. The non-redemption rate was highest for prescriptions issued at the weekends, although this was a small proportion of all prescribing. Prescriptions issued by trainee general practitioners were also less likely to be redeemed. Conclusions-Non-redemption varies with age, sex, general practitioner, exemption status, and with day of the week the prescription was written. Observational studies of drug exposure can be more accurately estimated from dispensing rather than prescribing data.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PHARMACOL & CLIN PHARMACOL,MED MONITORING UNIT,DUNDEE DD1 9SY,SCOTLAND; CARNOUSTIE HLTH CTR,TAYSIDE DD7 7RB,ENGLAND	University of Dundee				MacDonald, Thomas/0000-0001-5189-6669				BEGG D, 1984, J ROY COLL GEN PRACT, V34, P272; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; FEELY M, 1989, GERIATRIC MED    JUN, P14; GRAHAM D J, 1988, American Journal of Preventive Medicine, V4, P15; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; RASHID A, 1982, BRIT MED J, V284, P24, DOI 10.1136/bmj.284.6308.24; WATERS WHR, 1976, BRIT MED J, V1, P1062, DOI 10.1136/bmj.1.6017.1062; WISEMAN IC, 1991, S AFR MED J, V79, P155; WONNACOTT TH, 1977, INTRO STATISTICS, P223	9	264	273	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					846	848		10.1136/bmj.307.6908.846	http://dx.doi.org/10.1136/bmj.307.6908.846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401129	Bronze, Green Published			2022-12-28	WOS:A1993MA29300024
J	DRISCOLL, PA; ROSS, R; NICHOLSON, DA				DRISCOLL, PA; ROSS, R; NICHOLSON, DA			ABC OF EMERGENCY RADIOLOGY - CERVICAL-SPINE .2.	BRITISH MEDICAL JOURNAL			English	Article											DRISCOLL, PA (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					855	862		10.1136/bmj.307.6908.855	http://dx.doi.org/10.1136/bmj.307.6908.855			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401132	Bronze, Green Published			2022-12-28	WOS:A1993MA29300027
J	PLEASURE, IT; BLACK, MM; KEEN, JH				PLEASURE, IT; BLACK, MM; KEEN, JH			VALOSIN-CONTAINING PROTEIN, VCP, IS A UBIQUITOUS CLATHRIN-BINDING PROTEIN	NATURE			English	Article							YEAST; MEMBER; FAMILY; SECRETION; CDNA	CLATHRIN is the structural protein of coated membranes involved in receptor-mediated endocytosis and aspects of Golgi sorting in eukaryotic cells. We have now detected a stoichiometric complex of clathrin with a novel protein of M(r) approximately 100,000 (100K) in lysates of different mammalian cells. Formation of the complex, which also includes the 70K heat-shock protein Hsc70, occurs within 15 min of synthesis. The 100K protein has been identified as valosin-containing protein (VCP; ref. 1), an early substrate for tyrosine phosphorylation on T-cell receptor activation2. Further, VCP is the mammalian homologue of yeast Cdc48p (ref. 3) and is a member of a larger gene family that includes putative ATP-binding proteins involved in vesicle transport and fusion4,5, 26S proteasome function6, regulation of the expression of human immunodeficiency virus7,8, and assembly of peroxisomes9. The association with clathrin and the morphological and catalytic similarity to the chaperonin proteins indicate that VCP may modulate protein-protein interactions in membrane transport processes.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,233 S 10TH ST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLACK MM, 1991, J NEUROSCI, V11, P163; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; MILARSKI KL, 1989, J CELL BIOL, V108, P413, DOI 10.1083/jcb.108.2.413; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	19	117	119	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					459	462		10.1038/365459a0	http://dx.doi.org/10.1038/365459a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413590				2022-12-28	WOS:A1993LZ63300062
J	SEEMAN, P; GUAN, HC; VANTOL, HHM				SEEMAN, P; GUAN, HC; VANTOL, HHM			DOPAMINE D4 RECEPTORS ELEVATED IN SCHIZOPHRENIA	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN-BRAIN; ANTIPSYCHOTIC-DRUGS; HIGH-AFFINITY; BINDING; NEUROLEPTICS; D2-RECEPTORS; POPULATION; NUCLEOTIDE; CONVERSION	ALTHOUGH the biological basis of schizophrenia is not known, possible causes include genetic defects, viruses1, amines2, brain structure and metabolism3-5, neuroreceptors6-8, and G proteins9. The hypothesis of dopamine overactivity in schizophrenia is based on the fact that neuroleptics block dopamine D2 receptors in direct relation to their clinical antipsychotic potencies10,11. Moreover, dopamine D2 or D2-like receptors are elevated in postmortem schizophrenia brain tissue8,12,13. This elevation, however, is only found in vivo using [C-11]methylspiperone14 but not [C-11]raclopride15. The dopamine D4 receptor gene16 has not yet been excluded in schizophrenia because the 21 gene variants17 of D4 have not yet been tested. Because the link between D1 and D2 receptors is reduced in schizophrenia tissue9, we tested whether one component of this link was sensitive to guanine nucleotide. We report here that the binding of [H-3]raclopride to D2 receptors in schizophrenia was not sensitive to guanine nucleotide. This finding permitted analysis of data12,18 on the binding of [H-3]emonapride to the D2, D3 and D4 receptors. We conclude that the combined density of D2 and D3 receptors (labelled by [H-3]raclopride16,19) is increased by only 10% in schizophrenia brain, as found by Farde et al.15, but that it is the density of dopamine D4 receptors which is sixfold elevated in schizophrenia. These findings resolve the apparent discrepancy, mentioned above, wherein the density of [C-11]methylspiperone-labelled sites14 (D2, D3 and D4), but not that of [C-11]raclopride-labelled sites15 (D2 and D3), was found elevated in the schizophrenia striatum.	UNIV TORONTO,DEPT PSYCHIAT,TORONTO M5S 1A8,ONTARIO,CANADA; CLARKE INST PSYCHIAT,MOLEC NEUROBIOL LAB,TORONTO M5T 1R8,ONTARIO,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	SEEMAN, P (corresponding author), UNIV TORONTO,DEPT PHARMACOL,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA.							ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; BATTAGLIA G, 1984, J NEUROCHEM, V43, P1213, DOI 10.1111/j.1471-4159.1984.tb05375.x; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; CARTER GI, 1987, J NEUROL NEUROSUR PS, V50, P247, DOI 10.1136/jnnp.50.3.247; CROW TJ, 1980, ENZYMES NEUROTRANSMI, P559; EZRINWATERS C, 1981, J CLIN PSYCHIAT, V42, P16; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; GEORGE SR, 1985, J NEUROCHEM, V44, P1168, DOI 10.1111/j.1471-4159.1985.tb08740.x; HALL H, 1992, NEUROSCI LETT, V136, P79, DOI 10.1016/0304-3940(92)90652-N; LAZARENO S, 1983, J RECEPTOR RES, V3, P163, DOI 10.3109/10799898309041931; LEE T, 1978, NATURE, V274, P897, DOI 10.1038/274897a0; LICHTER JB, 1992, NATURE, V360, P424, DOI 10.1038/360424b0; MELTZER HY, 1991, SCHIZOPHRENIA BULL, V17, P263, DOI 10.1093/schbul/17.2.263; SEEMAN P, 1984, J NEUROCHEM, V43, P221, DOI 10.1111/j.1471-4159.1984.tb06700.x; SEEMAN P, 1992, EUR J PHARM-MOLEC PH, V227, P139, DOI 10.1016/0922-4106(92)90121-B; SEEMAN P, 1988, ISI ATLAS-PHARMACOL, V2, P161; SEEMAN P, 1989, P NATL ACAD SCI USA, V86, P10156, DOI 10.1073/pnas.86.24.10156; SEEMAN P, 1975, P NATL ACAD SCI USA, V72, P4376, DOI 10.1073/pnas.72.11.4376; SEEMAN P, 1991, EUR J PHARMACOL, V203, P105, DOI 10.1016/0014-2999(91)90796-S; SEEMAN P, 1974, FED PROC, V33, P246; SEEMAN P, 1989, SYNAPSE, V3, P96, DOI 10.1002/syn.890030113; SEEMAN P, 1985, BIOCHEM PHARMACOL, V34, P151, DOI 10.1016/0006-2952(85)90116-9; SEEMAN P, 1987, NEUROPSYCHOPHARMACOL, V1, P5, DOI 10.1016/0893-133X(87)90004-2; SEEMAN P, 1993, SYNAPSE, V14, P247, DOI 10.1002/syn.890140402; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SPOKES EGS, 1980, J NEUROL SCI, V48, P303, DOI 10.1016/0022-510X(80)90103-3; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; VANTOL HHM, 1992, NATURE, V358, P149; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495; WREGGETT KA, 1984, MOL PHARMACOL, V25, P10	32	616	642	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					441	445		10.1038/365441a0	http://dx.doi.org/10.1038/365441a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413587				2022-12-28	WOS:A1993LZ63300056
J	DRAMAIX, M; HENNART, P; BRASSEUR, D; BAHWERE, P; MUDJENE, O; TONGLET, R; DONNEN, P; SMETS, R				DRAMAIX, M; HENNART, P; BRASSEUR, D; BAHWERE, P; MUDJENE, O; TONGLET, R; DONNEN, P; SMETS, R			SERUM-ALBUMIN CONCENTRATION, ARM CIRCUMFERENCE, AND EDEMA AND SUBSEQUENT RISK OF DYING IN CHILDREN IN CENTRAL-AFRICA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL-STATUS; MALNUTRITION; SURVIVAL; DIARRHEA; INDEXES; DEATH	Objective-To measure the prognostic value of Clinical, anthropometric, and biological indicators of protein energy malnutrition in hospitalised children. Design-Hospital based follow up study from admission to discharge or death of a cohort of children. Setting-Paediatric hospital in Zaire. Subjects-1129 children consecutively admitted between August 1986 and October 1988. Main outcome measures-Height, weight, arm circumference, skinfold thicknesses, serum albumin concentration, and mortality. Results-Mortality was higher in wasted children and in those with a mid-upper arm circumference <125 mm, a serum albumin concentration <16 g/l, and oedema. After multivariate analysis, serum albumin concentration was the best predictor of subsequent risk of dying. Mid-upper arm circumference and oedema, however, still contributed considerably to evaluation of mortality. Conclusions-In this specific environment of central Africa an isolated clinical sign such as oedema is not enough to detect children with a high risk of dying among those admitted to paediatric wards with severe protein energy malnutrition. Measurement of additional indicators such as arm circumference and serum albumin concentration seems to be of crucial importance.	FREE UNIV BRUSSELS, SCH PUBL HLTH, EPIDEMIOL & SOCIAL MED LAB, ROUTE LENNIX 808, B-1070 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, CUMUBAC MED TEAM, B-1050 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, QUEEN FABIOLA CHILDRENS HOSP, B-1050 BRUSSELS, BELGIUM; NAT SCI RES CTR, LWIRO, DEM REP CONGO	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel								Alleyne GAO, 1977, PROTEIN ENERGY MALNU; [Anonymous], 1970, LANCET, V2, P302; ARMITAGE P, 1987, STATISTICAL METHODS, P205; BEAU JP, 1987, J TROP PEDIATRICS, V33, P4, DOI 10.1093/tropej/33.1.4; BRIEND A, 1986, BRIT MED J, V293, P373, DOI 10.1136/bmj.293.6543.373; BRIEND A, 1988, Indian Pediatrics, V25, P930; BRIEND A, 1989, EUR J CLIN NUTR, V43, P715; COWARD WA, 1972, BRIT J NUTR, V28, P433, DOI 10.1079/BJN19720053; Dixon W. J., 1990, BMDP STATISTICAL SOF; GOLDEN MHN, 1982, AM J CLIN NUTR, V35, P1159, DOI 10.1093/ajcn/35.5.1159; GOLDEN MHN, 1980, LANCET, V1, P114, DOI 10.1016/S0140-6736(80)90603-0; Gomez Federico, 1956, J Trop Pediatr (Lond), V2, P77; HAY RW, 1975, LANCET, V2, P427; HENNART P, 1984, CHILDREN TROPICS, V149, P38; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JELIFFE DB, 1966, WHO MONOGR, V53, P194; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P12; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P103; MCFARLANE H, 1970, BMJ-BRIT MED J, V4, P268, DOI 10.1136/bmj.4.5730.268; MCLAREN DS, 1982, TXB PAEDIATRIC NUTRI; NORUSSIS MJ, 1990, JSPSS STATISTICAL DA; SACHDEV HPS, 1991, J PEDIATR GASTR NUTR, V12, P76, DOI 10.1097/00005176-199101000-00016; SONNET J, 1952, Rev Belg Pathol Med Exp, V22, P226; TOLBOOM JJM, 1986, TROP GEOGR MED, V38, P351; TROWBRIDGE FL, 1982, AM J CLIN NUTR, V36, P691, DOI 10.1093/ajcn/36.4.691; VANROOSMALENWIEBENGA MW, 1986, J TROP PEDIATRICS, V32, P240, DOI 10.1093/tropej/32.5.240; WATERLOW JC, 1972, BRIT MED J, V3, P566, DOI 10.1136/bmj.3.5826.566; WATRLOW JC, 1992, PROTEIN ENERGY MALNU; 1977, VITAL HLTH STATISTIC, V2	29	24	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1993	307	6906					710	713		10.1136/bmj.307.6906.710	http://dx.doi.org/10.1136/bmj.307.6906.710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401093	Green Published, Bronze			2022-12-28	WOS:A1993LY29200020
J	SHAUKAT, N; DEBONO, DP; CRUICKSHANK, JK				SHAUKAT, N; DEBONO, DP; CRUICKSHANK, JK			CLINICAL-FEATURES, RISK-FACTORS, AND REFERRAL DELAY IN BRITISH PATIENTS OF INDIAN AND EUROPEAN ORIGIN WITH ANGINA MATCHED FOR AGE AND EXTENT OF CORONARY ATHEROMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,DEPT CARDIOL,LEICESTER LE3 9QP,ENGLAND; UNIV MANCHESTER,SCH MED,CLIN EPIDEMIOL UNIT,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Leicester; University of Manchester			G, G/A-3459-2012					BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; HUGHES LO, 1990, ATHEROSCLEROSIS, V83, P15, DOI 10.1016/0021-9150(90)90125-3; HUGHES LO, 1989, BRIT MED J, V299, P537, DOI 10.1136/bmj.299.6698.537; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; SHAUKAT N, 1993, ACCESS HLTH CARE PEO, P133	5	51	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					717	718		10.1136/bmj.307.6906.717	http://dx.doi.org/10.1136/bmj.307.6906.717			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401095	Bronze, Green Published			2022-12-28	WOS:A1993LY29200022
J	VERONESI, U; LUINI, A; DELVECCHIO, M; GRECO, M; GALIMBERTI, V; MERSON, M; RILKE, F; SACCHINI, V; SACCOZZI, R; SAVIO, T; ZUCALI, R; ZURRIDA, S; SALVADORI, B				VERONESI, U; LUINI, A; DELVECCHIO, M; GRECO, M; GALIMBERTI, V; MERSON, M; RILKE, F; SACCHINI, V; SACCOZZI, R; SAVIO, T; ZUCALI, R; ZURRIDA, S; SALVADORI, B			RADIOTHERAPY AFTER BREAST-PRESERVING SURGERY IN WOMEN WITH LOCALIZED CANCER OF THE BREAST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY RADIATION-THERAPY; PROGNOSTIC-SIGNIFICANCE; CONSERVATIVE TREATMENT; AXILLARY DISSECTION; PATHOLOGIC FEATURES; QUADRANTECTOMY; IRRADIATION; MASTECTOMY; RECURRENCE; RELAPSE	Background and Methods. Conservative surgery and radiotherapy have become well-established treatments for breast cancer, and many trials in progress are attempting to define the most acceptable type of procedure. Between 1987 and 1989 we randomly assigned 567 women with small breast cancers (<2.5 cm in diameter) to quadrantectomy followed by radiotherapy or to quadrantectomy without radiotherapy. All patients underwent total axillary dissection. The median follow-up period was 39 months (range, 28 to 54). Results. The incidence of local recurrence was 8.8 percent among the patients treated with quadrantectomy without radiotherapy, as compared with 0.3 percent among those treated with postsurgical radiotherapy (P = 0.001). However, there was a substantial effect of age: patients more than 55 years old who did not receive radiotherapy had a low rate of local recurrence (3.8 percent). The four-year overall survival was similar in the two treatment groups. Conclusions. Administering radiotherapy after quadrantectomy reduces the risk of local recurrence in women with small cancers of the breast, but radiotherapy may not be necessary in elderly women.			VERONESI, U (corresponding author), IST NAZL STUDIO & CURA TUMORI,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		GALIMBERTI, Viviana Enrica/AAS-3963-2020	GALIMBERTI, Viviana Enrica/0000-0002-5036-7439				CHAUVET B, 1990, INT J RADIAT ONCOL, V19, P1125, DOI 10.1016/0360-3016(90)90215-6; CHU AM, 1984, AM J CLIN ONCOL-CANC, V7, P221, DOI 10.1097/00000421-198406000-00006; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1991, NCI MONOGRAPHS, V11, P7; FOURQUET A, 1989, INT J RADIAT ONCOL, V17, P719, DOI 10.1016/0360-3016(89)90057-6; HARRIS JR, 1985, ANN SURG, V201, P164, DOI 10.1097/00000658-198502000-00005; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Ribeiro G G, 1990, Clin Oncol (R Coll Radiol), V2, P27, DOI 10.1016/S0936-6555(05)80215-8; ROSE MA, 1989, INT J RADIAT ONCOL, V17, P711, DOI 10.1016/0360-3016(89)90056-4; Sarrazin D, 1983, CONSERVATIVE MANAGEM, P101; SCHNITT SJ, 1985, INT J RADIAT ONCOL, V11, P1277, DOI 10.1016/0360-3016(85)90242-1; SOLIN LJ, 1991, INT J RADIAT ONCOL, V21, P279, DOI 10.1016/0360-3016(91)90772-V; STEWART HJ, 1989, LANCET, V2, P168; VANDONGEN J, 1992, NCI MONOGRAPHS, V11, P15; VERONESI U, 1990, ANN SURG, V211, P250; VERONESI U, 1990, EUR J CANCER, V26, P671, DOI 10.1016/0277-5379(90)90114-9; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; 1990, J NATL CANCER I, V82, P277	19	576	594	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1587	1591		10.1056/NEJM199306033282202	http://dx.doi.org/10.1056/NEJM199306033282202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8387637	Green Submitted			2022-12-28	WOS:A1993LE28900002
J	KAMEL, OW; VANDERIJN, M; WEISS, LM; DELZOPPO, GJ; HENCH, PK; ROBBINS, BA; MONTGOMERY, PG; WARNKE, RA; DORFMAN, RF				KAMEL, OW; VANDERIJN, M; WEISS, LM; DELZOPPO, GJ; HENCH, PK; ROBBINS, BA; MONTGOMERY, PG; WARNKE, RA; DORFMAN, RF			REVERSIBLE LYMPHOMAS ASSOCIATED WITH EPSTEIN-BARR-VIRUS OCCURRING DURING METHOTREXATE THERAPY FOR RHEUMATOID-ARTHRITIS AND DERMATOMYOSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							LOW-DOSE METHOTREXATE; HODGKINS-DISEASE; TRANSPLANT RECIPIENTS; IMMUNE SYSTEM; NEOPLASMS; CANCER; CELLS; IMMUNOSUPPRESSION; DISORDERS; FREQUENCY		CITY HOPE NATL MED CTR, DEPT PATHOL, DUARTE, CA 91010 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS CLIN, DIV HEMATOL MED ONCOL, LA JOLLA, CA 92037 USA; SCRIPPS CLIN, DIV RHEUMATOL, LA JOLLA, CA 92037 USA; SCRIPPS CLIN, DEPT PATHOL, LA JOLLA, CA 92037 USA; MTN STATES TUMOR INST, DIV HEMATOL ONCOL, BOISE, ID USA	City of Hope; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	KAMEL, OW (corresponding author), STANFORD UNIV, MED CTR, DEPT PATHOL, 300 PASTEUR DR, STANFORD, CA 94305 USA.			van de Rijn, Matt/0000-0002-1909-9739	PHS HHS [33119, 50341, 34233] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAILIN PL, 1975, JAMA-J AM MED ASSOC, V232, P359, DOI 10.1001/jama.232.4.359; BINDL JM, 1986, AM J CLIN PATHOL, V85, P490, DOI 10.1093/ajcp/85.4.490; CASTOR CW, 1985, AM J MED, V78, P33, DOI 10.1016/0002-9343(85)90243-8; CHITTAL SM, 1988, AM J SURG PATHOL, V12, P9, DOI 10.1097/00000478-198801000-00002; DEPPER JM, 1981, J IMMUNOL, V127, P1899; DOYLE TJ, 1983, CANCER, V51, P245, DOI 10.1002/1097-0142(19830115)51:2<245::AID-CNCR2820510213>3.0.CO;2-W; ELLMAN MH, 1991, J RHEUMATOL, V18, P1741; HAKULINEN T, 1985, AM J MED, V78, P29, DOI 10.1016/0002-9343(85)90242-6; HAZLEMAN B, 1985, AM J MED, V78, P39, DOI 10.1016/0002-9343(85)90244-X; KHAN G, 1992, AM J PATHOL, V140, P757; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NALESNIK MA, 1988, CURR PROB SURG, V25, P365; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENN I, 1981, TRANSPLANT P, V13, P736; PRIOR P, 1985, AM J MED, V78, P15, DOI 10.1016/0002-9343(85)90240-2; SHIROKY JB, 1991, J RHEUMATOL, V18, P1172; STARZL TE, 1984, LANCET, V1, P583; SYMMONS DPM, 1985, AM J MED, V78, P22, DOI 10.1016/0002-9343(85)90241-4; TOSATO G, 1984, J CLIN INVEST, V73, P1789, DOI 10.1172/JCI111388; UCCINI S, 1990, INT J CANCER, V46, P581, DOI 10.1002/ijc.2910460405; VAUGHAN JH, 1985, AM J MED, V78, P6, DOI 10.1016/0002-9343(85)90238-4; WEINSTEIN A, 1985, AM J MED, V79, P331, DOI 10.1016/0002-9343(85)90312-2; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WEISS LM, 1991, AM J PATHOL, V139, P1259; ZIJLMANS JMJM, 1992, NEW ENGL J MED, V326, P1363	29	370	379	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1317	1321		10.1056/NEJM199305063281806	http://dx.doi.org/10.1056/NEJM199305063281806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	8385742				2022-12-28	WOS:A1993KZ64000006
J	NIENABER, CA; VONKODOLITSCH, Y; NICOLAS, V; SIGLOW, V; PIEPHO, A; BROCKHOFF, C; KOSCHYK, DH; SPIELMANN, RP				NIENABER, CA; VONKODOLITSCH, Y; NICOLAS, V; SIGLOW, V; PIEPHO, A; BROCKHOFF, C; KOSCHYK, DH; SPIELMANN, RP			THE DIAGNOSIS OF THORACIC AORTIC DISSECTION BY NONINVASIVE IMAGING PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; DIGITAL SUBTRACTION ANGIOGRAPHY; FEATURES AFFECTING PROGNOSIS; COMPUTED-TOMOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; DOPPLER ECHOCARDIOGRAPHY; ANEURYSM; RECOGNITION; INSUFFICIENCY; ACCURACY	Background and Methods. This study was designed to assess the safety and reliability of new noninvasive imaging methods as compared with aortography in the diagnosis of dissection of the thoracic aorta. One hundred ten patients with clinically suspected aortic dissection followed a diagnostic protocol that included transthoracic and transesophageal color-flow Doppler echocardiography (TTE and TEE), contrast-enhanced x-ray computed tomography (CT), and magnetic resonance imaging (MRI). Imaging results were compared in a blinded fashion and validated independently against intraoperative findings in 62 patients, autopsy findings in 7, and the results of contrast angiography in 64. Results. The sensitivities of MRI, TEE and x-ray CT for detecting dissection were similar, at 98.3, 97.7, and 93.8 percent, respectively; TTE had a sensitivity of only 59.3 percent (P<0.005). The specificities of both TTE (83.0 percent) and TEE (76.9 percent) were lower than those of x-ray CT (87.1 percent) and MRI (97.8 percent; P<0.05), mainly as a result of false positive findings in the ascending aorta. MRI and x-ray CT were more sensitive than TTE in detecting the formation of thrombus in the entire thoracic aorta (P<0.05), but were not superior to TEE in this regard. CT was not effective in detecting an entry site or aortic regurgitation, but MRI and TEE accurately identified both. Two patients died during or soon after CT and TEE, and three died between retrograde angiography and surgery. Conclusions. A noninvasive diagnostic strategy using MRI in all hemodynamically stable patients and TEE in patients who are too unstable to be moved should be considered the optimal approach to detecting dissection of the thoracic aorta. Comprehensive and detailed evaluation can thus be reduced to a single noninvasive diagnostic test in the investigation of suspected dissection of the thoracic aorta.	UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT DIAGNOST RADIOL,W-2000 HAMBURG 20,GERMANY; UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT THORAC SURG,W-2000 HAMBURG 20,GERMANY; UNIV KIEL,DEPT RADIOL,W-2300 KIEL 1,GERMANY	University of Hamburg; University of Hamburg; University of Kiel	NIENABER, CA (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT INTERNAL MED 2,DIV CARDIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							AMPARO EG, 1985, RADIOLOGY, V155, P399, DOI 10.1148/radiology.155.2.3983390; ANAGNOSTOPOULOS CE, 1972, AM J CARDIOL, V30, P263, DOI 10.1016/0002-9149(72)90070-7; BALLAL RS, 1991, CIRCULATION, V84, P1903, DOI 10.1161/01.CIR.84.5.1903; BORNER N, 1984, AM J CARDIOL, V54, P1157, DOI 10.1016/S0002-9149(84)80175-7; BRENOT P, 1984, ANN RADIOL, V27, P5; CHEITLIN MD, 1990, DILEMMAS CARDIOLOGY, P293; Daily P O, 1970, Ann Thorac Surg, V10, P237; DANZA FM, 1984, RADIOLOGY, V152, P827; DEBAKEY ME, 1982, SURGERY, V92, P1118; DESANCTIS RW, 1987, NEW ENGL J MED, V317, P1060, DOI 10.1056/NEJM198710223171705; DINSMORE RE, 1972, RADIOLOGY, V105, P567, DOI 10.1148/105.3.567; DINSMORE RE, 1986, AM J ROENTGENOL, V146, P309, DOI 10.2214/ajr.146.2.309; DINSMORE RE, 1966, NEW ENGL J MED, V275, P1152, DOI 10.1056/NEJM196611242752102; DINSMORE RE, 1986, AM J ROENTGENOL, V146, P1286, DOI 10.2214/ajr.146.6.1286; DOROGHAZI RM, 1984, J AM COLL CARDIOL, V3, P1026, DOI 10.1016/S0735-1097(84)80363-0; EAGLE KA, 1989, CURR PROB CARDIOLOGY, V14, P225, DOI 10.1016/S0146-2806(89)80010-6; EAGLE KA, 1986, AM J CARDIOL, V57, P322, DOI 10.1016/0002-9149(86)90912-4; ERBEL R, 1989, LANCET, V1, P457; GEISINGER MA, 1985, RADIOLOGY, V155, P407, DOI 10.1148/radiology.155.2.3983391; GODWIN JD, 1982, J COMPUT ASSIST TOMO, V6, P750, DOI 10.1097/00004728-198208000-00015; GODWIN JD, 1980, RADIOLOGY, V136, P125, DOI 10.1148/radiology.136.1.7384486; GOLDMAN AP, 1986, AM HEART J, V111, P970, DOI 10.1016/0002-8703(86)90648-4; GUTHANER DF, 1983, AM J ROENTGENOL, V141, P157, DOI 10.2214/ajr.141.1.157; HANRATH P, 1981, DEUT MED WOCHENSCHR, V106, P523, DOI 10.1055/s-2008-1070348; HANSMANN A, 1990, COR VASA, V4, P173; HART WL, 1963, CIRCULATION, V27, P1140, DOI 10.1161/01.CIR.27.6.1140; HASHIMOTO S, 1989, J AM COLL CARDIOL, V14, P1253, DOI 10.1016/0735-1097(89)90424-5; HAVERICH A, 1985, CIRCULATION, V72, P22; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; ILICETO S, 1984, EUR HEART J, V5, P545, DOI 10.1093/oxfordjournals.eurheartj.a061704; ILICETO S, 1987, CIRCULATION, V75, P748, DOI 10.1161/01.CIR.75.4.748; JEX RK, 1987, J THORAC CARDIOV SUR, V93, P375; KASPER W, 1978, AM J CARDIOL, V42, P291, DOI 10.1016/0002-9149(78)90913-X; KERSTINGSOMMERHOFF BA, 1988, RADIOLOGY, V166, P651, DOI 10.1148/radiology.166.3.3340758; Laas J, 1987, Eur J Cardiothorac Surg, V1, P169, DOI 10.1016/1010-7940(87)90035-2; LEVINSON DC, 1950, CIRCULATION, V1, P360, DOI 10.1161/01.CIR.1.3.360; MATHEW T, 1984, AM J CARDIOL, V54, P379, DOI 10.1016/0002-9149(84)90201-7; Miller D C, 1980, World J Surg, V4, P571; MILLER DC, 1979, J THORAC CARDIOV SUR, V78, P365; MINTZ GS, 1979, AM J CARDIOL, V44, P232, DOI 10.1016/0002-9149(79)90310-2; MONCADA R, 1981, LANCET, V1, P238; MUGGE A, 1990, AM J CARDIOL, V65, P527, DOI 10.1016/0002-9149(90)90827-N; NANDA NC, 1990, ECHOCARDIOGR-J CARD, V7, P771, DOI 10.1111/j.1540-8175.1990.tb00429.x; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; PAULIN S, 1987, AM J ROENTGENOL, V148, P665, DOI 10.2214/ajr.148.4.665; SCHIEBLER M, 1987, J COMPUT ASSIST TOMO, V11, P627, DOI 10.1097/00004728-198707000-00015; SCHOPP D, 1989, RADIOLOGE, V29, P237; SECHTEM U, 1988, RADIOLOGY, V167, P425, DOI 10.1148/radiology.167.2.3357951; SHUFORD WH, 1969, NEW ENGL J MED, V280, P225, DOI 10.1056/NEJM196901302800501; SILVEY SV, 1991, AM J CARDIOL, V68, P286, DOI 10.1016/0002-9149(91)90769-H; SINGH H, 1986, BRIT HEART J, V56, P171; SLATER EE, 1976, AM J MED, V60, P625, DOI 10.1016/0002-9343(76)90496-4; SPIELMANN RP, 1990, FORTSCHR RONTG NEUEN, V152, P316; SUCHATO C, 1980, J COMPUT ASSIST TOMO, V4, P115, DOI 10.1097/00004728-198002000-00022; SUTTON MSJ, 1981, J CARDIOVASC SURG, V22, P195; THORSEN MK, 1983, RADIOLOGY, V148, P773, DOI 10.1148/radiology.148.3.6878699; VASILE N, 1986, J COMPUT ASSIST TOMO, V10, P211, DOI 10.1097/00004728-198603000-00008; VICTOR MF, 1981, AM J CARDIOL, V48, P1155, DOI 10.1016/0002-9149(81)90334-9; VONSCHULTHESS GK, 1987, RADIOLOGY, V164, P549, DOI 10.1148/radiology.164.2.3602400; WHITE RD, 1986, AM J CARDIOL, V57, P282, DOI 10.1016/0002-9149(86)90906-9; WOLFE WG, 1983, ANN SURG, V197, P738, DOI 10.1097/00000658-198306000-00013; 1975, DISCRETE MULTIVARIAT, P257	62	614	640	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					1	9		10.1056/NEJM199301073280101	http://dx.doi.org/10.1056/NEJM199301073280101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8416265				2022-12-28	WOS:A1993KF50700001
J	GERBER, GS; THOMPSON, IM; THISTED, R; CHODAK, GW				GERBER, GS; THOMPSON, IM; THISTED, R; CHODAK, GW			DISEASE-SPECIFIC SURVIVAL FOLLOWING ROUTINE PROSTATE-CANCER SCREENING BY DIGITAL RECTAL EXAMINATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADENOCARCINOMA; DIAGNOSIS; ANTIGEN	Objective.-To assess prostate cancer mortality in men undergoing routine screening by routine digital rectal examination. Design.-Cohort study with a median follow-up period of 75 months. Setting.-Population consisted of volunteers at a university clinic and men in an institutional health maintenance clinic. Patients.-Fifty-six men with a mean age of 65 years (range, 52 to 79 years) diagnosed with prostate cancer. Interventions.-Patients treated initially by observation, external or interstitial radiotherapy, radical prostatectomy, hormone therapy, or combination. Main Outcome Measures.-Kaplan-Meier analysis of time to local progression, distant metastases, death from all causes, and death from prostate cancer. Mantel-Haenszel log-rank statistic was used to compare outcome in men diagnosed on initial examination with those diagnosed on subsequent examinations. Results.-Clinically localized prostate cancer was diagnosed in 73% during an initial examination and in 33% (6/18) during subsequent examinations. Five- and 10-year disease-specific survival was 97% and 86%, respectively, for men diagnosed during the first rectal examination compared with only 81% and 57%, respectively, for men diagnosed on subsequent rectal examinations (P=.02). Conclusion.-Routine screening for prostate cancer by annual digital rectal examination alone may be insufficiently frequent and/or sensitive to prevent significant mortality from this disease.	UNIV CHICAGO HOSP & CLIN,DEPT SURG,DIV UROL,CHICAGO,IL 60637; UNIV CHICAGO HOSP & CLIN,DEPT STAT,CHICAGO,IL 60637; UNIV CHICAGO HOSP & CLIN,DEPT ANESTHESIA & CRIT CARE,CHICAGO,IL 60637; BROOKE ARMY MED CTR,DEPT SURG,UROL SERV,FT SAM HOUSTON,TX 78234	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; San Antonio Military Medical Center; United States Department of Defense; United States Army			Thisted, Ronald A/B-1985-2008					AUBERT R, 1992, MMWR, V41, P401; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1989, J UROLOGY, V141, P1136, DOI 10.1016/S0022-5347(17)41192-X; Cooner W H, 1987, Ala Med, V56, P13; GILBERTSON JA, 1976, JAMA-J AM MED ASSOC, V215, P81; GUINAN P, 1980, NEW ENGL J MED, V303, P499, DOI 10.1056/NEJM198008283030906; JENSON CB, 1960, JAMA-J AM MED ASSOC, V174, P1783, DOI 10.1001/jama.1960.03030140005002; LEE F, 1988, RADIOLOGY, V168, P389, DOI 10.1148/radiology.168.2.3293108; MURPHY GP, 1982, J UROLOGY, V127, P928, DOI 10.1016/S0022-5347(17)54135-X; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERBERG E, 1987, CA-CANCER J CLIN, V37, P2; STAMEY TA, 1988, J UROLOGY, V139, P1235; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; THOMPSON IM, 1987, J UROLOGY, V137, P424, DOI 10.1016/S0022-5347(17)44055-9	16	68	69	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					61	64		10.1001/jama.269.1.61	http://dx.doi.org/10.1001/jama.269.1.61			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416407				2022-12-28	WOS:A1993KF02600028
J	FREY, SJ; DOUGHERTY, D				FREY, SJ; DOUGHERTY, D			AN INCONSISTENT PICTURE - A COMPILATION OF ANALYSES OF ECONOMIC-IMPACTS OF COMPETING APPROACHES TO HEALTH-CARE REFORM BY EXPERTS AND STAKEHOLDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											FREY, SJ (corresponding author), US OFF TECHNOL ASSESSMENT,HLTH PROGRAM,WASHINGTON,DC 20510, USA.							1993, OTAH540 OFF TECHN AS	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2030	2030						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MD882	8411562				2022-12-28	WOS:A1993MD88200004
J	ROSSDEGNAN, D; SOUMERAI, SB; FORTESS, EE; GURWITZ, JH				ROSSDEGNAN, D; SOUMERAI, SB; FORTESS, EE; GURWITZ, JH			EXAMINING PRODUCT RISK IN CONTEXT - MARKET WITHDRAWAL OF ZOMEPIRAC AS A CASE-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARE; PROPOXYPHENE; MORTALITY; PAYMENT; THERAPY	Objective.-To examine changes in the prescribing of analgesics after the market entry and subsequent withdrawal of zomepirac sodium, a nonsteroidal anti-inflammatory drug (NSAID), following repeated reports of zomepirac-related deaths. Design.-To evaluate this natural quasi experiment, we conducted time-series analyses to compare prescribing in two cohorts of primary care physicians from July 1980 through September 1983. Setting.-Study physicians provided outpatient pharmaceutical care to patients enrolled in the New Jersey Medicaid program. Participants.-We identified 260 primary care physicians who provided 10 or more prescriptions for zomepirac (zomepirac prescribers) and 308 who provided 10 or more prescriptions for NSAIDs other than zomepirac (other-NSAID prescribers) in Medicaid during the study period. Main Outcome Measures.-Monthly rates of prescribing for zomepirac and several categories of substitute analgesics among Medicaid patients seen by study physicians. Main Results.-Zomepirac accounted for a stable 11.0% of analgesic prescribing among the zomepirac-prescriber cohort; label changes and manufacturer product-risk warnings 11 months before the product's withdrawal from the market had no impact on use. After market entry, zomepirac prescribers reduced use of other NSAIDs and propoxyphene (hydrochloride or napsylate) in comparison with other-NSAID prescribers (-8.1% and -2.80% of total analgesic prescribing, respectively; P<.001). After the product's withdrawal from the market, zomepirac prescribers showed significant increases in relative prescribing of other NSAIDs (+6.8%; P<.001), propoxyphene (+2.1%; P<.05), and analgesics containing barbiturates (+2.7%; P<.001). Conclusions.-The sudden withdrawal of zomepirac from the market resulted in substitutions not only of other NSAIDs, but also of alternative analgesics that carry risks of habituation and adverse effects. Apparent gains in patient safety resulting from market withdrawal of medications must be evaluated in comparison with risks of medications likely to be substituted.	HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,DRUG POLICY RES GRP,BOSTON,MA 02115; SUFFOLK UNIV,DEPT PUBL MANAGEMENT HLTH ADM CONCENTRAT,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Suffolk University; Harvard University; Brigham & Women's Hospital					AHRQ HHS [HS 05554] Funding Source: Medline; NIA NIH HHS [KO8 AG00510] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1982, SAS USERS GUIDE; BAUM C, 1985, ARTHRITIS RHEUM, V28, P686, DOI 10.1002/art.1780280613; BAUM C, 1983, DRUG USE US 1982 4TH, P25; BRAHAMS D, 1991, LANCET, V338, P938, DOI 10.1016/0140-6736(91)91792-S; CORRE KA, 1988, ANN EMERG MED, V17, P145, DOI 10.1016/S0196-0644(88)80300-7; EKEBERG O, 1987, ACTA MED SCAND, V221, P483; FERRANDO C, 1987, DRUG INTEL CLIN PHAR, V21, P653, DOI 10.1177/1060028087021007-819; GILLINGS D, 1981, AM J PUBLIC HEALTH, V71, P38, DOI 10.2105/AJPH.71.1.38; GORTMAKER SL, 1987, HEALTH SERV RES, V22, P91; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; KOCH H, 1984, NCHS ADV DATA, V96, P1; MARSHALL E, 1985, SCIENCE, V229, P1071, DOI 10.1126/science.4035348; RALL T, 1990, GOODMAN GILMANS PHAR, P358; RAO P, 1971, APPLIED ECONOMETRICS; ROSS SR, 1982, ANN ALLERGY, V48, P233; SAMUEL SA, 1981, NEW ENGL J MED, V304, P978; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Shochet RB, 1988, J INTENSIVE CARE MED, V3, P246; SHORR RI, 1992, J GERONTOL, V47, pM111, DOI 10.1093/geronj/47.4.M111; SMITH VT, 1982, JAMA-J AM MED ASSOC, V247, P1172; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; STROM BL, 1987, ARTHRITIS RHEUM, V30, P1142, DOI 10.1002/art.1780301009; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEISER B, 1988, WASHINGTON POST 1026, pA1; 1981, SCRIP WORLD PHARM NE, V590, P10; 1986, DRUG INFORMATION 86; 1983, WKLY PHARM REP, V32, P2; 1983, WASHINGTON POST 0927, pD12; STATISTICAL SERIES G; 1983, AMA DRUG EVALUATION, P98; 1980, SCRIP WORLD PHARM NE, V539, P13; 1981, SCRIP WORLD PHARM NE, V591, P9; 1983, DRUG FACTS COMP; STATISTICAL SERIES 1	39	72	73	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1937	1942		10.1001/jama.270.16.1937	http://dx.doi.org/10.1001/jama.270.16.1937			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC513	8411550	Green Submitted			2022-12-28	WOS:A1993MC51300024
J	BERNHAGEN, J; CALANDRA, T; MITCHELL, RA; MARTIN, SB; TRACEY, KJ; VOELTER, W; MANOGUE, KR; CERAMI, A; BUCALA, R				BERNHAGEN, J; CALANDRA, T; MITCHELL, RA; MARTIN, SB; TRACEY, KJ; VOELTER, W; MANOGUE, KR; CERAMI, A; BUCALA, R			MIF IS A PITUITARY-DERIVED CYTOKINE THAT POTENTIATES LETHAL ENDOTOXEMIA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MIGRATION-INHIBITORY FACTOR; ACTIVATES HUMAN MACROPHAGES; BINDING-PROTEIN; LIPOPOLYSACCHARIDE; CACHECTIN; INTERLEUKIN-1; HYPOTHALAMUS; CELLS; GENES	CYTOKINES are critical in the often fatal cascade of events that cause septic shock1-3. One regulatory system that is likely to be important in controlling inflammatory responses is the neuroendocrine axis. The pituitary, for example, is ideally situated to integrate central and peripheral stimuli4, and initiates the increase in systemic glucocorticoids that accompanies host stress responses6-8. To assess further the contribution of the pituitary to systemic inflammatory processes, we examined the secretory profile of cultured pituitary cells and whole pituitaries in vivo after stimulation with bacterial lipopolysaccharide (LPS). Here we identify macrophage migration inhibitory factor (MIF)9-11 as a major secreted protein released by anterior pituitary cells in response to LPS stimulation. Serum analysis of control, hypophysectomized and T-cell-deficient (nude) mice suggests that pituitary-derived MIF contributes to circulating MIF present in the post-acute phase of endotoxaemia. Recombinant murine MIF greatly enhances lethality when co-injected with LPS and anti-MIF antibody confers full protection against lethal endotoxaemia. We conclude that MIF plays a central role in the toxic response to endotoxaemia and possibly spetic shock.	PICOWER INST MED RES,350 COMMUNITY DR,MANHASSET,NY 11030; UNIV TUBINGEN,INST PHYSIOL CHEM,W-7400 TUBINGEN 1,GERMANY; CORNELL UNIV,MED CTR,NEW YORK HOSP,COLL MED,DIV NEUROSURG,NEW YORK,NY 10021; N SHORE UNIV HOSP,CORNELL UNIV MED COLL,COLL MED,DEPT SURG,MANHASSET,NY 11030	Northwell Health; Eberhard Karls University of Tubingen; Cornell University; NewYork-Presbyterian Hospital; Cornell University; Northwell Health; North Shore University Hospital			Calandra, Thierry/D-9017-2015	Calandra, Thierry/0000-0003-3051-1285; Tracey, Kevin J/0000-0003-1884-6314				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CUNHA FQ, 1993, J IMMUNOL, V150, P1908; DAVID JR, 1966, P NATL ACAD SCI USA, V65, P72; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; FRAKER DL, 1988, J EXP MED, V168, P95, DOI 10.1084/jem.168.1.95; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HEUMANN D, 1991, J INFECT DIS, V163, P762, DOI 10.1093/infdis/163.4.762; KOENIG JI, 1990, ENDOCRINOLOGY, V126, P3053, DOI 10.1210/endo-126-6-3053; KRIEG M, 1990, TESTOSTERONE ACTION, P219; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; MAKARA GB, 1971, ENDOCRINOLOGY, V88, P412, DOI 10.1210/endo-88-2-412; POZZI LAM, 1992, CELL IMMUNOL, V145, P372, DOI 10.1016/0008-8749(92)90339-Q; Reichlin S., 1992, WILLIAMS TXB ENDOCRI, P135; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SILVERSTEIN R, 1991, J EXP MED, V173, P357, DOI 10.1084/jem.173.2.357; THORNER MO, 1992, WILLIAMS TXB ENDOCRI, P221; Tracey K J, 1990, Adv Surg, V23, P21; TRACEY KJ, 1989, LANCET, V1, P1122; WEISER WY, 1992, P NATL ACAD SCI USA, V89, P8049, DOI 10.1073/pnas.89.17.8049; WEISER WY, 1991, J IMMUNOL, V147, P2006; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YASUDA N, 1978, ENDOCRINOLOGY, V102, P947, DOI 10.1210/endo-102-3-947	27	891	947	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					756	759		10.1038/365756a0	http://dx.doi.org/10.1038/365756a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413654				2022-12-28	WOS:A1993MC81200064
J	FUNAHASHI, S; CHAFEE, MV; GOLDMANRAKIC, PS				FUNAHASHI, S; CHAFEE, MV; GOLDMANRAKIC, PS			PREFRONTAL NEURONAL-ACTIVITY IN RHESUS-MONKEYS PERFORMING A DELAYED ANTI-SACCADE TASK	NATURE			English	Article							POSTERIOR PARIETAL CORTEX; SUPERIOR COLLICULUS; EYE-MOVEMENTS; FRONTAL-LOBE; PROJECTIONS; RESPONSES; MACAQUE; AREAS; GOAL	PATIENTS with damage to the dorsolateral prefrontal cortex are impaired on cognitive tasks such as the Wisconsin Card Sort Test1, the Stroop Test2 and an anti-saccade paradigm3, in which sensory-guided habitual responses must be suppressed in favour of conceptually or memory-guided responses. We report here recordings from prefrontal neurons in rhesus monkeys trained to perform a delayed anti-saccade task based on tests that have been used with humans3. Activity in the same prefrontal neurons was recorded across conditions when saccades were made toward a remembered target, and also when this prepotent response was suppressed and a saccade in the opposite direction required. Our findings show that most prefrontal neurons code the location of the visual stimulus in working memory, and that this memory can be engaged to suppress as well as prescribe a response. These results establish, in a subset of prefrontal neurons, the iconic nature of the memory code, and suggest a role for visual memory in response suppression.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510	Yale University								ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P164, DOI 10.1152/jn.1990.64.1.164; Baddeley A., 1974, PSYCHOL LEARNING MOT, V8; BARBAS H, 1987, J COMP NEUROL, V256, P211, DOI 10.1002/cne.902560203; BARBAS H, 1981, J COMP NEUROL, V200, P407, DOI 10.1002/cne.902000309; BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; FRIES W, 1984, J COMP NEUROL, V230, P55, DOI 10.1002/cne.902300106; FUKUSHIMA J, 1988, BIOL PSYCHIAT, V23, P670, DOI 10.1016/0006-3223(88)90050-9; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1991, J NEUROPHYSIOL, V65, P1464, DOI 10.1152/jn.1991.65.6.1464; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDMAN PS, 1976, BRAIN RES, V116, P145, DOI 10.1016/0006-8993(76)90256-0; GUITTON D, 1985, EXP BRAIN RES, V58, P455; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; McGuire PK, 1991, CEREB CORTEX, V1, P390, DOI 10.1093/cercor/1.5.390; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NIKI H, 1976, BRAIN RES, V105, P79, DOI 10.1016/0006-8993(76)90924-0; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; SELEMON LD, 1985, J NEUROSCI, V5, P776; THAKER G, 1989, PSYCHOPHARMACOL BULL, V25, P491	23	519	526	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					753	756		10.1038/365753a0	http://dx.doi.org/10.1038/365753a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413653				2022-12-28	WOS:A1993MC81200063
J	BEGUN, DJ; AQUADRO, CF				BEGUN, DJ; AQUADRO, CF			AFRICAN AND NORTH-AMERICAN POPULATIONS OF DROSOPHILA-MELANOGASTER ARE VERY DIFFERENT AT THE DNA LEVEL	NATURE			English	Article							RESTRICTION-MAP VARIATION; NATURAL-POPULATIONS; PHENOTYPIC VARIATION; GENETIC-VARIATION; GENIC VARIATION; LOCUS REGION; POLYMORPHISM; ENDONUCLEASES; PATTERNS; FLOW	UNDERSTANDING genetic evolution within species requires an accurate description of variation within and between populations and the ability to distinguish between the potential causes of an observed distribution of variation. In the cosmopolitan species Drosophila melanogaster, previous studies suggested that gene flow within and between continents is extensive1 and that most of the nuclear gene variation is found within, rather than among, populations2,3. Here we present evidence that a population from Zimbabwe is more than twice as variable as those from the United States of America at the DNA sequence level, that most variants are not shared between the two geographic regions, and that there are nearly fixed differences between the Zimbabwe and USA samples in genomic regions experiencing low recombination rates. It appears that there is an unappreciated degree of population structure in D. melanogaster and that equilibrium models of molecular evolution are inappropriate for this species.			BEGUN, DJ (corresponding author), CORNELL UNIV, GENET & DEV SECT, BIOTECHNOL BLDG, ITHACA, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036431] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM036431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; CHARLESWORTH B, 1993, GENETICS, V134, P1289; DAVID JR, 1988, TRENDS GENET, V4, P106, DOI 10.1016/0168-9525(88)90098-4; EANES WF, 1989, MOL BIOL EVOL, V6, P384; EANES WF, 1989, MOL BIOL EVOL, V6, P492; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1992, MOL BIOL EVOL, V9, P138; HUDSON RR, 1987, GENETICS, V116, P153; HUDSON RR, 1992, GENETICS, V132, P583; HUDSON RR, 1982, GENETICS, V100, P711; KAPLAN NL, 1989, GENETICS, V123, P887; KREITMAN M, 1986, P NATL ACAD SCI USA, V83, P3562, DOI 10.1073/pnas.83.10.3562; KREITMAN M, 1983, NATURE, V304, P412, DOI 10.1038/304412a0; KREITMAN M, 1991, GENETICS, V127, P565; LANGLEY CH, 1993, P NATL ACAD SCI USA, V90, P1800, DOI 10.1073/pnas.90.5.1800; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARTINCAMPOS JM, 1992, GENETICS, V130, P805; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; MIYASHITA N, 1988, GENETICS, V120, P199; MIYASHITA NT, 1990, GENETICS, V125, P407; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; SINGH RS, 1987, GENETICS, V117, P255; SINGH RS, 1987, GENETICS, V115, P313; SINGH RS, 1982, GENETICS, V101, P235; STEPHAN W, 1992, GENETICS, V132, P1039, DOI 10.1093/genetics/132.4.1039; TAJIMA F, 1989, GENETICS, V123, P585	26	261	262	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1993	365	6446					548	550		10.1038/365548a0	http://dx.doi.org/10.1038/365548a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413609				2022-12-28	WOS:A1993MA66100054
J	DAY, ML; PICKERING, SJ; JOHNSON, MH; COOK, DI				DAY, ML; PICKERING, SJ; JOHNSON, MH; COOK, DI			CELL-CYCLE CONTROL OF A LARGE-CONDUCTANCE K+-CHANNEL IN MOUSE EARLY EMBRYOS	NATURE			English	Article							POTASSIUM CHANNELS; IMPROVED CULTURE; CALCIUM CURRENT; LYMPHOCYTE-T; PROLIFERATION; CLEAVAGE; PROTEINS; INVITRO	THERE have been few investigations into the role of ion channels in mammalian early embryonic development1-4, despite studies showing that changes in ion channel activity accompany the early embryonic development of non-mammalian species5-7 and the proliferation of mammalian cells8-12. Here we report that a large-conductance, voltage-activated K+ channel is active in unfertilized mouse oocytes but is rarely observed in later embryos. The channel activity is linked to the cell cycle, being active throughout M and G1 phases, and switching off during the G1-to-S transition. These changes in channel activity are accompanied by corresponding shifts in membrane potential. Inactivation of the channel during S/G2 can be prevented by exposing the oocytes to dibutyryl cyclic AMP or forskolin, an activator of adenylyl cyclase. Inhibition of protein synthesis with puromycin did not prevent inactivation of the channel at the end of G1 or its subsequent reactivation at the end of G2, indicating that the channel activity is not regulated by mitosis-promoting factor or cyclins.	UNIV SYDNEY, DEPT PHYSIOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV CAMBRIDGE, DEPT ANAT, CAMBRIDGE CB2 3DY, ENGLAND	University of Sydney; University of Cambridge				Day, Margot/0000-0002-8689-7458; johnson, martin/0000-0002-5906-5883				AMIGORENA S, 1990, J IMMUNOL, V144, P2038; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; BOLTON VN, 1984, J EMBRYOL EXP MORPH, V79, P139; BOUNTRA C, 1987, Q J EXP PHYSIOL CMS, V72, P483, DOI 10.1113/expphysiol.1987.sp003090; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; CHIU SY, 1989, J PHYSIOL-LONDON, V408, P199, DOI 10.1113/jphysiol.1989.sp017455; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DEUTSCH C, 1990, PROG CLIN BIOL RES, V334, P251; GRANDIN N, 1991, J CELL BIOL, V112, P711, DOI 10.1083/jcb.112.4.711; HOWLETT SK, 1985, J EMBRYOL EXP MORPH, V87, P175; HOWLETT SK, 1986, CELL, V45, P387, DOI 10.1016/0092-8674(86)90324-7; KLINE D, 1991, DEV BIOL MEMBRANE TR, V39, P89; LEE SJ, 1987, IN VITRO FERT EMBRYO, V4, P331; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MEDINA I, 1991, P ROY SOC B-BIOL SCI, V245, P159, DOI 10.1098/rspb.1991.0103; MEDINA IR, 1988, PROC R SOC SER B-BIO, V235, P95, DOI 10.1098/rspb.1988.0064; MITANI S, 1985, J PHYSIOL-LONDON, V363, P71, DOI 10.1113/jphysiol.1985.sp015696; MOODY WJ, 1991, J NEUROBIOL, V22, P674, DOI 10.1002/neu.480220703; NASRESFAHANI M, 1990, HUM REPROD, V5, P997, DOI 10.1093/oxfordjournals.humrep.a137235; PERES A, 1987, J PHYSIOL-LONDON, V391, P573, DOI 10.1113/jphysiol.1987.sp016757; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; ROBINSON DH, 1991, DEV BIOL MEMBRANE TR, V39, P121; SABATH DE, 1986, P NATL ACAD SCI USA, V83, P4739, DOI 10.1073/pnas.83.13.4739; SMITH RKW, 1986, J REPROD FERTIL, V76, P393, DOI 10.1530/jrf.0.0760393; WAKSMUNDZKA M, 1984, J EMBRYOL EXP MORPH, V79, P77; WEGMAN EA, 1991, PFLUG ARCH EUR J PHY, V417, P562, DOI 10.1007/BF00372952; WHITAKER M, 1990, DEVELOPMENT, V108, P525; YOSHIDA S, 1990, PFLUG ARCH EUR J PHY, V415, P516, DOI 10.1007/BF00373637	30	119	122	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1993	365	6446					560	562		10.1038/365560a0	http://dx.doi.org/10.1038/365560a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413614				2022-12-28	WOS:A1993MA66100059
J	ROBINSON, R				ROBINSON, R			ECONOMIC-EVALUATION AND HEALTH-CARE .4. COST-UTILITY ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							QALYS; PROFILE	Decisions have to be made about allocating health resources. Currently the best economic evaluation method for doing this is cost-utility analysis. This compares the costs of different procedures with their outcomes measured in ''utility based'' units-that is, units that relate to a person's level of wellbeing. The most commonly used unit is the quality adjusted life year (QALY). QALYs are calculated by estimating the total life years gained from a procedure and weighting each year to reflect the quality of life in that year. To compare outcomes of different programmes the Rosser index is one measure that is widely used to assign quality of life scores to patients. Combined with a measure of life years gained from a procedure, this enables QALYs to be calculated and procedures ranked according to cost per QALY gained. In this article Ray Robinson explains the measures used and discusses how QALY league tables can be used to guide decisions on resource allocation.			ROBINSON, R (corresponding author), UNIV SOUTHAMPTON,INST HLTH POLICY STUDIES,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND.							BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; BROOME J, 1987, P ROYAL I PHILOS C P; BUSH JW, 1984, ASSESSMENT QUALITY L; BUXTON MJ, 1985, DHSS12 RES REP; CARRHILL RA, 1989, SOC SCI MED, V29, P469, DOI 10.1016/0277-9536(89)90296-7; CARRHILL RA, 1991, INT J HEALTH SERV, V21, P351, DOI 10.2190/HPLM-EGXV-BWKY-5XBN; Cullis J G, 1993, RATIONING RATIONALIT; CULYER AJ, 1992, 99 U YORK CTR HLTH E; Gerard K, 1993, Health Econ, V2, P59, DOI 10.1002/hec.4730020108; GERARD K, 1991, 1191 U AB HLTH EC RE; GUDES C, 1988, 38 U YORK CTR HLTH E; Gudex C, 1990, Health Trends, V22, P103; Hunt SM, 1986, MEASURING HLTH STATU; JENKINSON C, 1988, SOC SCI MED, V27, P1411, DOI 10.1016/0277-9536(88)90207-9; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; MAYS N, 1990, INT J TECHNOL ASSESS, V6, P631; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; OBRIEN BJ, 1988, J EPIDEMIOL COMMUN H, V42, P232, DOI 10.1136/jech.42.3.232; ROSSER R, 1982, VALUE LIFE SOC; Teeling-Smith G, 1988, MEASURING HLTH PRACT; WAGSTAFF A, 1991, J HEALTH ECON, V10, P21, DOI 10.1016/0167-6296(91)90015-F; Wiener JM, 1992, RATIONING AM MED CAR; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; WILLIAMS A, 1987, STRATEGY SCREENING R	26	162	167	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					859	862		10.1136/bmj.307.6908.859	http://dx.doi.org/10.1136/bmj.307.6908.859			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MA293	8401133	Green Published, Bronze			2022-12-28	WOS:A1993MA29300028
J	GOLDSMITH, PC; LESLIE, TA; SAMS, V; BRYCESON, ADB; ALLASONJONES, E; DOWD, PM				GOLDSMITH, PC; LESLIE, TA; SAMS, V; BRYCESON, ADB; ALLASONJONES, E; DOWD, PM			LESSON OF THE WEEK - LESIONS OF SCHISTOSOMIASIS MIMICKING WARTS ON THE VULVA	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL, SCH MED, DEPT HISTOPATHOL, LONDON WC1E 6AU, ENGLAND; HOSP TROP DIS, LONDON NW1 0PE, ENGLAND; UNIV COLL HOSP LONDON, DEPT GENITOURINARY MED, LONDON WC1E 6AU, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University College London Hospitals NHS Foundation Trust; University of London; University College London	DOWD, PM (corresponding author), UCL, MIDDLESEX HOSP, SCH MED, DEPT DERMATOL, LONDON W1N 8AA, ENGLAND.							ADEYEMIDORO FAB, 1979, BRIT J VENER DIS, V55, P446; CAHILL KM, 1964, AM J TROP MED HYG, V13, P800, DOI 10.4269/ajtmh.1964.13.800; DAVIS A, 1979, B WORLD HEALTH ORGAN, V57, P773; EL-MOFTY A M, 1964, Dermatol Trop Ecol Geogr, V30, P157, DOI 10.1111/j.1365-4362.1964.tb06096.x; ELZAWAHRY M, 1965, BRIT J DERMATOL, V77, P344, DOI 10.1111/j.1365-2133.1965.tb14659.x; FINDLAY GH, 1971, BRIT J DERMATOL, V85, P98, DOI 10.1111/j.1365-2133.1971.tb14120.x; LESLIE TA, 1993, J ROY SOC MED, V86, P51; MCKEE PH, 1983, CLIN EXP DERMATOL, V8, P189, DOI 10.1111/j.1365-2230.1983.tb01764.x; SAXE N, 1975, S AFR MED J, V49, P57	9	24	24	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1993	307	6903					556	557		10.1136/bmj.307.6903.556	http://dx.doi.org/10.1136/bmj.307.6903.556			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400980	Green Published, Bronze			2022-12-28	WOS:A1993LV18000029
J	PEREZMORGA, DL; ENGLUND, PT				PEREZMORGA, DL; ENGLUND, PT			THE ATTACHMENT OF MINICIRCLES TO KINETOPLAST DNA NETWORKS DURING REPLICATION	CELL			English	Article							CRITHIDIA-FASCICULATA; 2 SITES; TRYPANOSOMES; LOCALIZATION	Kinetoplast DNA (kDNA), the trypanosomatid mitochondrial DNA, is a network containing several thousand interlocked minicircles. During kDNA synthesis, minicircles dissociate from the network, and after replication their progeny reattach to the network periphery. Using electron microscopy autoradiography, we found that newly synthesized H-3-labeled minicircles, after short labeling periods, are concentrated in two peripheral zones on opposite sides of the network. These must be minicircle attachment sites, adjacent to the two diametrically opposed complexes of replication proteins observed previously. From the pattern of radiolabeling during longer pulses, we reached the unexpected conclusion that minicircle attachment around the entire network periphery may be due to a relative movement of the kinetoplast and the two complexes. The kinetoplast probably rotates between two fixed complexes.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				Perez-Morga, David/0000-0002-7168-1865	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-27608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BOUTEILLE M, 1976, J MICROSC BIOL CELL, V27, P121; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; HAJDUK SL, 1984, CELL, V36, P483, DOI 10.1016/0092-8674(84)90241-1; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; PEREZMORGA DL, 1993, NUCLEIC ACIDS RES, V21, P1327, DOI 10.1093/nar/21.5.1327; RAUCH CA, 1993, EMBO J, V12, P403, DOI 10.1002/j.1460-2075.1993.tb05672.x; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; Steinert M., 1976, P193; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X	19	81	81	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					703	711		10.1016/0092-8674(93)90517-T	http://dx.doi.org/10.1016/0092-8674(93)90517-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395351				2022-12-28	WOS:A1993LU59200013
J	HIRSCH, MS; DAQUILA, RT				HIRSCH, MS; DAQUILA, RT			THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AIDS-RELATED COMPLEX; RECOMBINANT SOLUBLE CD4; COLONY-STIMULATING FACTOR; REVERSE-TRANSCRIPTASE INHIBITORS; SYNTHETIC HIV-1 PROTEASE; PLACEBO-CONTROLLED TRIAL; TERM ZIDOVUDINE THERAPY; HERPES-SIMPLEX VIRUS; PHASE-I TRIAL; INTERFERON-ALPHA				HIRSCH, MS (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MED, INFECT DIS UNIT, BOSTON, MA 02114 USA.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ASHORN P, 1992, J ACQ IMMUN DEF SYND, V5, P70; BALIS FM, 1992, J INFECT DIS, V165, P99, DOI 10.1093/infdis/165.1.99; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BOUCHER CAB, 1992, AIDS, V6, P259; BRODER S, 1990, AM J MED, V88, pS2, DOI 10.1016/0002-9343(90)90413-8; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; CHATIS PA, 1989, NEW ENGL J MED, V320, P297, DOI 10.1056/NEJM198902023200507; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CLARK AGB, 1992, J ACQ IMMUN DEF SYND, V5, P52; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; CONNOLLY KJ, 1991, AM J MED, V91, P471, DOI 10.1016/0002-9343(91)90182-W; CONNOLLY KJ, 1992, ANTIMICROB AGENTS CH, V36, P245, DOI 10.1128/AAC.36.2.245; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COOPER DA, 1992, 8TH INT C AIDS 3RD S, V2, pB210; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DAVEY RT, 1991, J INFECT DIS, V164, P43, DOI 10.1093/infdis/164.1.43; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DUDLEY MN, 1992, J INFECT DIS, V166, P480, DOI 10.1093/infdis/166.3.480; DURAND E, 1991, NEW ENGL J MED, V324, P1062; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; FISCHL M, 1989, Journal of the American Medical Association, V262, P2405, DOI 10.1001/jama.262.17.2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1991, J ACQ IMMUN DEF SYND, V4, P1; FISCHL MA, 1993, ANN INTERN MED, V118, P762, DOI 10.7326/0003-4819-118-10-199305150-00002; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GROOPMAN JE, 1990, SEMIN HEMATOL, V27, P8; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HENDERSON DK, 1989, J INFECT DIS, V160, P321, DOI 10.1093/infdis/160.2.321; HO DD, 1985, LANCET, V1, P602; HODGES TL, 1991, ANTIMICROB AGENTS CH, V35, P2580, DOI 10.1128/AAC.35.12.2580; HORWITZ JP, 1964, J ORG CHEM, V29, P2076, DOI 10.1021/jo01030a546; HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; JONES PD, 1991, LANCET, V338, P884, DOI 10.1016/0140-6736(91)91535-3; JOSHI S, 1991, J VIROL, V65, P5524, DOI 10.1128/JVI.65.10.5524-5530.1991; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KONG XB, 1992, ANTIMICROB AGENTS CH, V36, P808, DOI 10.1128/AAC.36.4.808; KOVACS JA, 1989, ANN INTERN MED, V111, P280, DOI 10.7326/0003-4819-111-4-280; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LAND S, 1991, LANCET, V338, P830, DOI 10.1016/0140-6736(91)90727-7; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MAZZULLI T, 1992, COMBINATION THERAPY, P385; MCKINNEY RE, 1990, J PEDIATR-US, V116, P640, DOI 10.1016/S0022-3476(05)81619-1; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MILES SA, 1991, BLOOD, V77, P2109; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OSTERTAG W, 1974, P NATL ACAD SCI USA, V71, P4980, DOI 10.1073/pnas.71.12.4980; PALASANTHIRAN P, 1990, J PAEDIATR CHILD H, V26, P257, DOI 10.1111/j.1440-1754.1990.tb01067.x; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PIZZO PA, 1990, AM J MED, V88, pS16, DOI 10.1016/0002-9343(90)90416-B; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; RAGNI MV, 1992, J ACQ IMMUN DEF SYND, V5, P120; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1991, J INFECT DIS, V164, P1075, DOI 10.1093/infdis/164.6.1075; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1990, REV INFECT DIS, V12, pS507; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; RICHMAN DD, 1992, 8TH INT C AIDS 3RD S, V2, pB183; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; ROOKE R, 1991, ANTIMICROB AGENTS CH, V35, P988, DOI 10.1128/AAC.35.5.988; ROSEN CA, 1992, AIDS RES HUM RETROV, V8, P175, DOI 10.1089/aid.1992.8.175; SANDSTROM EG, 1985, LANCET, V1, P1480; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SKOWRON G, 1993, ANN INTERN MED, V118, P321, DOI 10.7326/0003-4819-118-5-199303010-00001; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TAN CK, 1991, BIOCHEMISTRY-US, V30, P4831, DOI 10.1021/bi00234a001; TILL MA, 1990, J ACQ IMMUN DEF SYND, V3, P609; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; VALENTINE F, 1992, 8TH INT C AIDS 3RD W, V1; VANLEEUWEN R, 1992, AIDS, V6, P1471, DOI 10.1097/00002030-199212000-00008; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VITTECOQ D, 1992, J INFECT DIS, V165, P364, DOI 10.1093/infdis/165.2.364; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WELLS DE, 1991, J VIROL, V65, P6325, DOI 10.1128/JVI.65.11.6325-6330.1991; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMAMOTO JK, 1986, J INTERFERON RES, V6, P143, DOI 10.1089/jir.1986.6.143; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1992, 8TH INT C AIDS 3RD S, V1; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748; 1992, 1992 AIDS CLIN TRIAL; 1992, NEW ENGL J MED, V326, P213; 1993, 1993 COMM PROGR CLIN	133	156	167	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1993	328	23					1686	1695						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF054	8387640				2022-12-28	WOS:A1993LF05400007
J	STOABIRKETVEDT, G				STOABIRKETVEDT, G			EFFECT OF CIMETIDINE SUSPENSION ON APPETITE AND WEIGHT IN OVERWEIGHT SUBJECTS	BRITISH MEDICAL JOURNAL			English	Article							OBESITY; OCTAPEPTIDE; FOOD	Objective-To investigate the weight reducing effect of cimetidine, comparing it with placebo. Design-Block randomised parallel group double blind study using suspensions with identical appearance and taste. Setting-Primary care practice. Subjects-55 women and 5 men aged 18-59, body mass index 25-37 kg/m2, completed the study according to the protocol. Interventions-Cimetidine suspension 200 mg or placebo 30 minutes was given before the three main meals for eight weeks. Subjects followed a diet restricted to 5 MJ/day supplemented with 9 g fibre per day. Main outcome measures-Weight reduction; abdominal and hip circumferences and systolic and diastolic blood pressures were also recorded. Results-Subjects given cimetidine lost a mean of 7.3 (95% confidence interval 6.5 to 8.3) kg more than subjects given placebo (p < 0.001); body mass index decreased 3.33 (SD 0.76) and 0.77 (0.43), respectively (p < 0.001). Abdominal and hip circumference was decreased more in the cimetidine group (8.6 (3.9) cm and 7.8 (3.1) cm) than in the placebo group (2.2 (1.5) cm and 2.1 (1.5) cm). Mean reductions in systolic and diastolic blood pressure were greater in the cimetidine group than the placebo group (mean 5.8 v 0.4 and 6.5 v 0.4, p < 0.001). Conclusion-Intake of cimetidine suspension 30 minutes before meals in overweight subjects may lead to reduced hunger, less food intake, and subsequent weight loss. This effect may be due to the suppression of gastric acid secretion. Cimetidine suspension may be a valuable adjunct in treating obesity.			STOABIRKETVEDT, G (corresponding author), DOVRE MED CTR,KYRRE GREPPSVEI 31,N-1472 FJELLHAMAR,NORWAY.							ANAGNOSTIDES A, 1984, GASTROENTEROLOGY, V87, P109; BOZHURT T, 1990, INT J PANCRAT, V6, P281; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MUURAHAINEN NE, 1983, SOC NEUR ABSTR, V9, P183; PENICK SB, 1963, AM J CLIN NUTR, V13, P110, DOI 10.1093/ajcn/13.2.110; PENICK SB, 1961, NEW ENGL J MED, V264, P893, DOI 10.1056/NEJM196105042641801; PISUNYER X, 1982, PHYSIOL BEHAV, V29, P627, DOI 10.1016/0031-9384(82)90230-X; SCHULMAN JL, 1957, J APPL PHYSIOL, V11, P419, DOI 10.1152/jappl.1957.11.3.419; SIMOPOULOS AP, 1987, ANN NY ACAD SCI, V499, P4, DOI 10.1111/j.1749-6632.1987.tb36193.x; SIMOPOULOS AP, 1984, ANN INTERN MED, V100, P285, DOI 10.7326/0003-4819-100-2-285; STACHER G, 1982, PEPTIDES, V3, P133, DOI 10.1016/0196-9781(82)90041-9; WALAN A, 1985, SCAND J GASTROENTERO, V20, P24, DOI 10.3109/00365528509093753; WING RR, 1979, INT J OBESITY, V3, P261	14	25	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1091	1093		10.1136/bmj.306.6885.1091	http://dx.doi.org/10.1136/bmj.306.6885.1091			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8388285	Bronze, Green Published			2022-12-28	WOS:A1993KZ56500018
J	GLASER, JB; GREIFINGER, RB				GLASER, JB; GREIFINGER, RB			CORRECTIONAL HEALTH-CARE - A PUBLIC-HEALTH OPPORTUNITY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PRISONERS; COMMUNICABLE DISEASES; COMMUNICABLE DISEASE CONTROL; PUBLIC POLICY; PUBLIC HEALTH	HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B; PRISON-INMATES; TENNESSEE PRISONERS; URBAN ADOLESCENTS; HIV-1 INFECTION; TUBERCULOSIS; PREVALENCE; ANTIBODY; POPULATION	The approximately 1.2 million inmates in U.S. correctional institutions have a high prevalence of communicable diseases, such as human immunodeficiency virus (HIV) infection, tuberculosis, hepatitis B virus infection, and gonorrhea. Before their incarceration, most inmates had limited access to health care, which, together with poor compliance because of lifestyle, made them difficult to identify and treat in the general community. Because of the high yearly turnover (approximately 800% and 50% in jails and prisons, respectively), the criminal justice system can play an important public health role both during incarceration and in the immediate postrelease period. A public policy agenda for criminal justice should include an epidemiologic orientation, as well as resources for education, counseling, early detection, and treatment. Taking advantage of the period of confinement would serve both the individual and society by controlling communicable diseases in large urban communities.	NEW YORK STATE DEPT CORRECT SERV, ALBANY, NY USA		GLASER, JB (corresponding author), STATEN ISL UNIV HOSP, DIV INFECT DIS, 475 SEAVIEW AVE, STATEN ISL, NY 10305 USA.							ALCABES P, 1989, AM REV RESPIR DIS, V140, P1194, DOI 10.1164/ajrccm/140.5.1194; ALEXANDERRODRIGUEZ T, 1987, PEDIATRICS, V80, P561; ANDA RF, 1985, AM J PUBLIC HEALTH, V75, P1182, DOI 10.2105/AJPH.75.10.1182; Anno B., 1991, PRISON HLTH CARE GUI; ANNO BJ, 1984, J PRISON JAIL HLTH, V4, P77; [Anonymous], 1990, JAMA, V263, P987; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BAKER CJ, 1988, 4 INT C AIDS STOCKH; BELL TA, 1985, SEX TRANSM DIS, V12, P140, DOI 10.1097/00007435-198507000-00009; BRAUN MM, 1987, JAMA-J AM MED ASSOC, V257, P1471, DOI 10.1001/jama.257.11.1471; CELENTANO D, 1990, J PRISON JAIL HLTH, V9, P45; CHISOLM SA, 1988, AM J INFECT CONTROL, V16, P107, DOI 10.1016/0196-6553(88)90047-8; COHEN D, 1992, AM J PUBLIC HEALTH, V82, P552, DOI 10.2105/AJPH.82.4.552; DECKER MD, 1985, J INFECT DIS, V152, P214, DOI 10.1093/infdis/152.1.214; DECKER MD, 1984, J INFECT DIS, V150, P450, DOI 10.1093/infdis/150.3.450; DECKER MD, 1985, AM J PUBLIC HEALTH, V75, P1134, DOI 10.2105/AJPH.75.10.1134; DUBLER NN, 1989, MILBANK Q, V67, P171, DOI 10.2307/3350137; DUBLER NN, 1988, J PRISON JAIL HLTH, V7, P3; ELLERBECK EF, 1989, SEX TRANSM DIS, V16, P165, DOI 10.1097/00007435-198910000-00001; FELDMAN YM, 1982, B NY ACAD MED, V58, P559; GLASER JB, 1992, J ACQ IMMUN DEF SYND, V5, P430; GLASER JB, 1991, J ACQ IMMUN DEF SYND, V4, P540; GLASER JB, 1988, 4 INT C AIDS STOCKH; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HAMMETT TM, 1989, 1988 UPDATE AIDS COR, P7; HARDING TW, 1987, LANCET, V2, P1260; HEIN K, 1977, J PEDIATR-US, V91, P123, DOI 10.1016/S0022-3476(77)80462-9; HEIN K, 1980, PEDIATRICS, V66, P239; HEIN K, 1977, J PEDIATR-US, V90, P634, DOI 10.1016/S0022-3476(77)80388-0; HERNANDEZ V, 1991, 7 INT C AIDS FLOR; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; HULL HF, 1985, AM J PUBLIC HEALTH, V75, P1213, DOI 10.2105/AJPH.75.10.1213; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; KELLEY PW, 1986, JAMA-J AM MED ASSOC, V256, P2198, DOI 10.1001/jama.1986.03380160056015; Martin J W, 1988, Pa Med, V91, P42; MARTIN JW, 1988, PA MED, V91, P42; MIKI J, 1991, 7 INT C AIDS FLOR; MORAN JS, 1990, JAMA-J AM MED ASSOC, V263, P987; MORSE DL, 1990, NEW YORK STATE J MED, V90, P133; Neaigus A, 1990, AIDS Educ Prev, V2, P253; NOONE S, 1988, 4 INT C AIDS STOCKH; NOVICK LF, 1977, MED CARE, V15, P205, DOI 10.1097/00005650-197703000-00002; Prout Curtis, 1988, CARE PUNISHMENT DILE; RABA JM, 1983, J PRISON JAIL HLTH, V3, P6; SALIVE ME, 1990, PUBLIC HEALTH REP, V105, P307; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMITH P, 1989, 5 INT C AIDS MONTR; SPENCER SS, 1989, AM J PUBLIC HEALTH, V79, P507, DOI 10.2105/AJPH.79.4.507; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; STEINWALD C, 1973, REPORT 1972 AMA MED; TRUMAN BI, 1988, 4 INT C AIDS STOCKH; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; VLAHOV D, 1990, J ACQ IMMUN DEF SYND, V3, P531; VLAHOV D, 1989, J ACQ IMMUN DEF SYND, V2, P283; VOWELS JMH, 1989, 5 INT C AIDS MONTR; WEINER J, 1992, ANN INTERN MED, V117, P71, DOI 10.7326/0003-4819-117-1-71; WEISFUSE IB, 1991, AIDS, V5, P1133, DOI 10.1097/00002030-199109000-00013; 1991, MEDIAN TIME SERVED 1; 1991, MMWR, V40, P27; 1991, AIDS NEW YORK STATE; 1991, REPORT HIV DISEASE C; 1990, MMWR, V39, P273; 1991, BUREAU JUSTICE STATI; 1990, 1988 TEX COMM ALC DR; 1987, STANDARDS HLTH SERVI; 1991, MMWR, V40, P23; 1991, MMWR, V40, P585; 1989, MMWR S4, V38, P1; 1985, ANN INTERN MED, V103, P391; 1991, CORRECTIONS YB 1991; 1986, MMWR, V35, P195; 1988, MMWR, V37, P755; 1992, MMWR, V41, P507; 1989, MMWR, V38, P313; 1986, ACQUIRED IMMUNE DEFI; 1985, MMWR, V34, P615	76	227	236	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					139	145		10.7326/0003-4819-118-2-199301150-00010	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416310				2022-12-28	WOS:A1993KF91800010
J	LI, FP; DECKER, HJH; ZBAR, B; STANTON, VP; KOVACS, G; SEIZINGER, BR; ABURATANI, H; SANDBERG, AA; BERG, S; HOSOE, S; BROWN, RS				LI, FP; DECKER, HJH; ZBAR, B; STANTON, VP; KOVACS, G; SEIZINGER, BR; ABURATANI, H; SANDBERG, AA; BERG, S; HOSOE, S; BROWN, RS			CLINICAL AND GENETIC-STUDIES OF RENAL-CELL CARCINOMAS IN A FAMILY WITH A CONSTITUTIONAL CHROMOSOME-3,8 TRANSLOCATION - GENETICS OF FAMILIAL RENAL-CARCINOMA	ANNALS OF INTERNAL MEDICINE			English	Article						CARCINOMA, RENAL CELL; NEOPLASTIC SYNDROMES, HEREDITARY; KIDNEY NEOPLASMS; CHROMOSOMES, HUMAN, PAIR-3; CHROMOSOMES, HUMAN, PAIR-8	VONHIPPEL-LINDAU DISEASE; GRADIENT GEL-ELECTROPHORESIS; TUMOR SUPPRESSOR GENES; SHORT ARM; HEREDITARY; DELETION; 3P; HETEROZYGOSITY; LOCALIZATION; INVOLVEMENT	Objective: To describe the clinical course and genetic studies of renal carcinoma in members of a family with the constitutional chromosome translocation, t(3;8) (p14;q24). Design: A follow-up study that updates our 1979 report of renal carcinoma in 1 0 of these relatives. Setting: A cancer center and university hospital. Patients: Members of the family, including five carriers of the 3;8 translocation who were in remission of renal cancer. Measurements: Clinical follow-up of the family and genetic analyses of the renal cancer specimens of three patients. Results: Renal carcinoma recurred in all five patients in the family at 1 to 16 years of follow-up. Three patients have died of renal cancer, and two are in a second remission. The renal cancers from three family members consistently reveal loss of the entire derivative chromosome 8, which bears the chromosome 3p segment spanning band p14 to the telomere. In contrast, no genetic change was detected in the derivative chromosome 3 or in normal chromosomes 3 and 8. Conclusions: This family illustrates the importance of clinical follow-up of patients with a hereditary cancer that can develop at multiple foci and recur over time. The inherited 3;8 translocation and loss of the translocated distal chromosome 3p in tumor specimens of family members may help localize the gene or genes involved in the pathogenesis of both familial and sporadic renal carcinoma.	NCI, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; MIT, CAMBRIDGE, MA 02139 USA; SW BIOMED RES INST, SCOTTSDALE, AZ USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	LI, FP (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, 44 BINNEY ST, MAYER 3A27, BOSTON, MA 02115 USA.			Stanton, Vincent/0000-0002-2205-6000	NATIONAL CANCER INSTITUTE [R01CA049455] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49455] Funding Source: Medline; NHGRI NIH HHS [HG00299] Funding Source: Medline; NHLBI NIH HHS [HL41484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGLARD P, 1991, CANCER RES, V51, P1071; AURON PE, 1988, BIOTECHNIQUES, V6, P347; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BOLDOG F, 1991, GENE CHROMOSOME CANC, V3, P403, DOI 10.1002/gcc.2870030513; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DECKER HJH, 1989, CANCER GENET CYTOGEN, V39, P289, DOI 10.1016/0165-4608(89)90194-5; EGGERS PW, 1990, AM J KIDNEY DIS, V15, P414, DOI 10.1016/S0272-6386(12)70359-1; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; HENCO K, 1990, NUCLEIC ACIDS RES, V18, P6733, DOI 10.1093/nar/18.22.6733; Kantor A F, 1985, Natl Cancer Inst Monogr, V68, P149; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; KOVACS G, 1988, HUM GENET, V78, P148, DOI 10.1007/BF00278186; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; KOVACS G, 1989, INT J CANCER, V43, P422, DOI 10.1002/ijc.2910430313; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LI FP, 1988, CANCER RES, V48, P5358; MAHER ER, 1991, BRIT J CANCER, V63, P176, DOI 10.1038/bjc.1991.43; MORITA R, 1991, CANCER RES, V51, P820; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHEFFIELD VC, 1990, PCR PROTOCOLS GUIDE, P206; SHIMIZU M, 1990, ONCOGENE, V5, P185; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; VANDERHOUT AH, 1991, CANCER GENET CYTOGEN, V51, P121, DOI 10.1016/0165-4608(91)90017-O; WALTER TA, 1989, CANCER GENET CYTOGEN, V43, P15, DOI 10.1016/0165-4608(89)90123-4; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WRIGHT LF, 1991, AM J KIDNEY DIS, V17, P25, DOI 10.1016/S0272-6386(12)80245-9; YAMAKAWA K, 1991, CANCER RES, V51, P4707; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	34	75	75	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					106	111		10.7326/0003-4819-118-2-199301150-00005	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416305				2022-12-28	WOS:A1993KF91800005
J	SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS				SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS			EFFECT OF FECAL OCCULT BLOOD TESTING ON MORTALITY FROM COLORECTAL-CANCER - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						OCCULT BLOOD; COLORECTAL NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; ADENOCARCINOMA; MORTALITY	CONTROLLED TRIAL; FOLLOW-UP; SENSITIVITY; EFFICACY; DEFINITION; PATTERNS	Objective: To estimate by case-control methods the effect of screening using the fecal occult blood test (FOBT) on mortality from colorectal cancer and to examine the relation of that effect to the interval since the most recent screening test. Design: A case-control study. Setting: The Kaiser Permanente Medical Care Program of Northern California. Patients: A total of 485 persons who developed fatal colorectal cancer after 50 years of age and 727 age- and sex-matched controls. Measurements: History of screening FOBTs during the 5 years before case diagnosis. Results: After adjustment for potentially confounding factors, an odds ratio of 0.69 (95% CI, 0.52 to 0.91) was observed for exposure to at least one screening FOBT during the 5-year interval. The odds ratio was lowest for the first year after the most recent FOBT and rose to 1.00 three years after the last screening examination. False-negative results among cases in the 1 to 2 years before diagnosis contributed substantially to lowering the estimate of efficacy. Conclusions: These data suggest that a program of annual or biennial screening using FOBTs might lower population risk for mortality from colorectal cancer sufficiently to have important public health implications. However, the confidence intervals around our odds ratio estimates were wide. We therefore believe that additional data will be needed before making recommendations that FOBT screening be expanded.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98125 USA	University of Washington; University of Washington Seattle	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3451 PIEDMONT AVE, OAKLAND, CA 94611 USA.				NCI NIH HHS [R01 CA 46569, R35 CA 49761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046569, R35CA049761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLQUIST DA, 1989, CANCER, V63, P1826; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; CARLSSON U, 1986, DIS COLON RECTUM, V29, P553, DOI 10.1007/BF02554252; CLARKE EA, 1979, LANCET, V2, P1; CROWLEY ML, 1983, J CLIN GASTROENTEROL, V5, P127, DOI 10.1097/00004836-198304000-00007; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; HARDCASTLE JD, 1989, LANCET, V1, P1160; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MORRISON AS, 1982, AM J EPIDEMIOL, V115, P6; MORRISON AS, 1985, SCREENING CHRONIC DI, P108; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; VERBEEK ALM, 1984, LANCET, V1, P1222; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; WINAWER SJ, 1985, SCREENING CANCER, P347; 1990, CLIN EFFICACY ASSESS; 1989, SUMMARY CURRENT GUID; 1987, WORKING GUIDELINES E	27	215	217	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					1	6		10.7326/0003-4819-118-1-199301010-00001	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416152				2022-12-28	WOS:A1993KE60500001
J	SHAFER, MA; SCHACHTER, J; MONCADA, J; KEOGH, J; PANTELL, R; GOURLAY, L; EYRE, S; BOYER, CB				SHAFER, MA; SCHACHTER, J; MONCADA, J; KEOGH, J; PANTELL, R; GOURLAY, L; EYRE, S; BOYER, CB			EVALUATION OF URINE-BASED SCREENING STRATEGIES TO DETECT CHLAMYDIA-TRACHOMATIS AMONG SEXUALLY ACTIVE ASYMPTOMATIC YOUNG MALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; ENZYME-IMMUNOASSAY; NEISSERIA-GONORRHOEAE; GENITAL SPECIMENS; ADOLESCENT MALES; MEN; URETHRITIS; ANTIGENS; INFECTIONS; DIAGNOSIS	Objective.-To evaluate the performances of diagnostic screening tests alone or in combination to detect asymptomatic chlamydial urethral infection in young males. Design.-Comparisons of the performance profiles of the following chlamydia screening strategies were done: urethral culture; identification of polymorphonucleocytes (PMNs) on spun first-void urine (FVU); urinary leukocyte esterase test (LET) on unspun FVU; chlamydial enzyme immunoassay (EIA) applied to FVU sediment; combining LET on unspun FVU followed by EIA with or without direct fluorescent antibody (DFA) confirmation on FVU sediment; and combining PMNs on spun FVU followed by EIA with or without DFA confirmation. Setting.-General clinics at a youth detention center, university-based teen clinic, college health service, and a military screening clinic. Patients.-A total of 618 males aged 12 to 35 years (mean, 17 years) were recruited as a convenience sample; site participation rates ranged from 50% to 80%. Eligible subjects were sexually active, denied symptoms of urethritis, and had taken no antibiotics in the prior 2 weeks. Main Outcome Measures.-Sensitivity, specificity, and positive and negative predictive values of each test strategy's ability to detect Chlamydia trachomatis infection, and cost to confirm each positive case. Results.-With a 7% prevalence of chlamydial infection, tissue culture had a sensitivity of only 61%. However, two strategies yielded significantly better performance profiles compared with the others: EIA confirmed by DFA test with a sensitivity of 84%, a specificity of 100%, and a cost to identify each positive case of $434; and PMNs followed by EIA confirmed by DFA test with a sensitivity of 78%, a specificity of 100%, and a cost to identify each positive case of $199. The LET followed by EIA-DFA had a similar performance profile to the PMN test strategies. Conclusions.-A combination of a nonspecific screening of FVU for PMNs or LET followed by specific testing with EIA with DFA confirmation has superior clinical and cost-effective performance for detecting asymptomatic C trachomatis urethritis in young males compared with other strategies. However, an evaluation of the medical, fiscal, and psychological benefits and risks associated with a specific screening strategy for sexually transmitted diseases must be made before adopting a specific strategy for a particular population.	MED INTELLIGENCE,CAMBRIDGE,MA; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SHAFER, MA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,DIV ADOLESCENT MED,400 PARNASSUS AVE,ROOM AC-01,BOX 0374,SAN FRANCISCO,CA 94143, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028481] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28481] Funding Source: Medline; NICHD NIH HHS [R01-HD-24801] Funding Source: Medline; PHS HHS [CCR902728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADGER H, 1984, LANCET, V2, P944; BOWIE WR, 1990, SEXUALLY TRANSMITTED, P627; Cates Jr, 1990, Adolesc Med, V1, P409; CHERNESKY M, 1990, J INFECT DIS, V161, P124; CHERNESKY MA, 1986, J INFECT DIS, V154, P141, DOI 10.1093/infdis/154.1.141; CLARK A, 1992, J CLIN MICROBIOL, V30, P2762, DOI 10.1128/JCM.30.11.2762-2764.1992; FERRIS DG, 1991, J FAM PRACTICE, V33, P73; GAYDOS CA, 1990, J CLIN MICROBIOL, V28, P1541, DOI 10.1128/JCM.28.7.1541-1544.1990; JASCHEK O, 1993, J CLIN MICROBIOL, V31, P1209; JENSEN IP, 1992, SEX TRANSM DIS, V19, P165, DOI 10.1097/00007435-199205000-00011; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; LOEFFELHOLZ MJ, 1992, J CLIN MICROBIOL, V30, P2847, DOI 10.1128/JCM.30.11.2847-2851.1992; MONCADA J, 1992, J DIAGN MICROBIOL IN, V15, P663; OBRIEN SF, 1988, AM J PUBLIC HEALTH, V78, P1583, DOI 10.2105/AJPH.78.12.1583; PODGARE J, 1982, J INFECT DIS, V148, P828; RIPA KT, 1977, J CLIN MICROBIOL, V6, P328; SCHWEBKE JR, 1991, J CLIN MICROBIOL, V29, P2446, DOI 10.1128/JCM.29.11.2446-2449.1991; SELLORS J, 1991, J CLIN MICROBIOL, V29, P407, DOI 10.1128/JCM.29.2.407-409.1991; SHAFER MA, 1989, JAMA-J AM MED ASSOC, V262, P2562, DOI 10.1001/jama.262.18.2562; SHAFER MA, 1987, J INFECT DIS, V156, P223, DOI 10.1093/infdis/156.1.223; STAMM WE, 1984, ANN INTERN MED, V100, P47, DOI 10.7326/0003-4819-100-1-47; WERNER MJ, 1991, J ADOLESCENT HEALTH, V12, P326, DOI 10.1016/0197-0070(91)90008-A; WU CH, 1992, SEX TRANSM DIS, V19, P193, DOI 10.1097/00007435-199207000-00002	23	63	63	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2065	2070		10.1001/jama.270.17.2065	http://dx.doi.org/10.1001/jama.270.17.2065			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411573				2022-12-28	WOS:A1993MD88200025
J	MILLER, FW				MILLER, FW			MYOSITIS-SPECIFIC AUTOANTIBODIES - TOUCHSTONES FOR UNDERSTANDING THE INFLAMMATORY MYOPATHIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSFER RNA-SYNTHETASE; SIGNAL RECOGNITION PARTICLE; DERMATOMYOSITIS; POLYMYOSITIS; DISEASE; PICORNAVIRUS; ANTIBODIES; ANTI-JO-1				MILLER, FW (corresponding author), US FDA,CTR BIOL EVALUAT & RES,MOLEC IMMUNOL LAB,N29,ROOM 507,HFM-521,BETHESDA,MD 20892, USA.		Miller, Frederick/D-2431-2019	Miller, Frederick/0000-0003-2831-9593				[Anonymous], 1887, Z KLIN MED, V12, P533; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOWLES NE, 1987, LANCET, V1, P1004; CHOU SM, 1970, NEUROLOGY, V20, P205, DOI 10.1212/WNL.20.3.205; CHRISTENSEN ML, 1986, ARTHRITIS RHEUM, V29, P1365, DOI 10.1002/art.1780291109; Cronin M E, 1988, In Vivo, V2, P25; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; ENGEL AG, 1990, RES P ARNMD, V68, P141; ENGEL AG, 1986, HUM PATHOL, V17, P704, DOI 10.1016/S0046-8177(86)80180-0; ENZ LA, 1992, ARTHRITIS RHEUM, V35, pS52; Franks AG, 1988, J MUSCULOSKELETAL ME, V5, P39; GURLEY R C, 1991, Arthritis and Rheumatism, V34, pS137; JOFFE MM, 1993, AM J MED, V94, P379, DOI 10.1016/0002-9343(93)90148-I; LEFF RL, 1991, ARTHRITIS RHEUM, V34, P1391; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; LOVE LA, 1992, ARTHRITIS RHEUM, V35, pS40; MILLER F W, 1991, Current Opinion in Rheumatology, V3, P902, DOI 10.1097/00002281-199112000-00002; MILLER FW, 1990, J CLIN INVEST, V85, P468, DOI 10.1172/JCI114461; MILLER FW, 1990, P NATL ACAD SCI USA, V87, P9933, DOI 10.1073/pnas.87.24.9933; MILLER FW, 1990, CLIN EXP IMMUNOL, V81, P373; ODDIS CV, 1989, DRUGS, V37, P382, DOI 10.2165/00003495-198937030-00007; PLOTZ PH, 1992, JAMA-J AM MED ASSOC, V268, P2074, DOI 10.1001/jama.268.15.2074; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; PLOTZ PH, 1988, MT SINAI J MED, V55, P501; ROSENBERG NL, 1989, ANN NEUROL, V26, P204, DOI 10.1002/ana.410260204; TARGOFF I N, 1990, Comprehensive Therapy, V16, P16; TARGOFF IN, 1992, ARTHRITIS RHEUM, V35, P821, DOI 10.1002/art.1780350718; TARGOFF IN, 1990, AM J MED, V88, P241, DOI 10.1016/0002-9343(90)90149-8; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TARGOFF IN, 1990, ARTHRITIS RHEUM, V33, P1361, DOI 10.1002/art.1780330908	30	83	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1846	1849		10.1001/jama.270.15.1846	http://dx.doi.org/10.1001/jama.270.15.1846			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411528				2022-12-28	WOS:A1993MB46400029
J	JAMES, RH; RABEY, PG				JAMES, RH; RABEY, PG			ILLEGIBILITY OF DRUG AMPOULE LABELS	BRITISH MEDICAL JOURNAL			English	Article											JAMES, RH (corresponding author), LEICESTER ROYAL INFIRM,DEPT ANAESTHESIA,LEICESTER LE1 5WW,ENGLAND.							ANANTHANARAYAN C, 1991, REGION ANESTH, V16, P189; FERNER RE, 1992, J MED DEFENCE UNION, P60; HILL G, 1990, J MED DEFENCE UN SPR, P10; 1979, DANGEROUS MISTAKES D; 1989, ASTM D426789 AM SOC	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					658	659		10.1136/bmj.307.6905.658	http://dx.doi.org/10.1136/bmj.307.6905.658			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401052	Bronze, Green Published			2022-12-28	WOS:A1993LX47000018
J	SPENGLER, D; WAEBER, C; PANTALONI, C; HOLSBOER, F; BOCKAERT, J; SEEBURG, PH; JOURNOT, L				SPENGLER, D; WAEBER, C; PANTALONI, C; HOLSBOER, F; BOCKAERT, J; SEEBURG, PH; JOURNOT, L			DIFFERENTIAL SIGNAL-TRANSDUCTION BY 5 SPLICE VARIANTS OF THE PACAP RECEPTOR	NATURE			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; METABOTROPIC GLUTAMATE RECEPTORS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; SYMPATHETIC NEUROBLASTS; CALCIUM RELEASE; BINDING-SITES; RAT-BRAIN; EXPRESSION; PEPTIDE	THE two forms of pituitary adenylyl cyclase-activating polypeptide (PACAP-27 and -38) are neuropeptides of the secretin/glucagon/vasoactive intestinal polypeptide/growth-hormone-releasing hormone family and regulate hormone release from the pituitary and adrenal gland1-3. They may also be involved in spermatogenesis4, and PACAP-38 potently stimulates neuritogenesis and survival of cultured rat sympathetic neuroblast5,6 and promotes neurite outgrowth of PC-12 cells7. The PACAP type-I receptor (found in hypothalamus, brain stem, pituitary, adrenal gland and testes), specific for PACAP, is positively coupled to adenylyl cyclase and phospholipase C. The recently cloned type II receptor does not discriminate between PACAP and vasoactive intestinal polypeptide and is coupled to only adenylyl cyclase8. Here we have used a new expression cloning strategy, based on the induction of a reporter gene by cyclic AMP, to isolate a complementary DNA encoding the type-I PACAP receptor. On transfection of this cDNA, both PACAP-27 and -38 stimulate adenylyl cyclase with similar EC50 values (50% effective concentration, 0.1-0.4 nM), whereas only PACAP-38 stimulates phospholipase C with high potency (EC50 = 15 nM). Four other splice variants were isolated with insertions at the C-terminal end of the third intracellular loop. Expression of these cDNAs revealed altered patterns of adenylyl cyclase and phospholipase C stimulation, suggesting a novel mechanism for fine tuning of signal transduction.	CCIPE,CNRS,UPR 9023,RUE CARDONILLE,F-34094 MONTPELLIER 05,FRANCE; UNIV HEIDELBERG,ZMBH,MOLEC NEUROENDOCRINOL LAB,W-6900 HEIDELBERG 1,GERMANY; MAX PLANCK INST PSYCHIAT,INST CLIN,DEPT NEUROENDOCRINOL,W-8000 MUNICH 40,GERMANY	Centre National de la Recherche Scientifique (CNRS); Ruprecht Karls University Heidelberg; Max Planck Society			Waeber, Christian/A-8333-2009; Waeber, Christian/B-3171-2016; Journot, Laurent/T-9652-2018	Waeber, Christian/0000-0001-6078-0027; Waeber, Christian/0000-0001-6078-0027; Journot, Laurent/0000-0003-3499-8887				ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; CAUVIN A, 1991, REGUL PEPTIDES, V35, P161, DOI 10.1016/0167-0115(91)90478-Y; COLSON P, 1992, AM J PHYSIOL, V263, pE1054; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; GAYLINN BD, 1993, MOL ENDOCRINOL, V7, P77, DOI 10.1210/me.7.1.77; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GOTTSCHALL PE, 1991, FASEB J, V5, P194, DOI 10.1096/fasebj.5.2.1848519; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KOCH B, 1992, REGUL PEPTIDES, V38, P45, DOI 10.1016/0167-0115(92)90071-2; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MENGOD G, 1991, MOL BRAIN RES, V10, P185, DOI 10.1016/0169-328X(91)90110-J; MINKES RK, 1992, AM J PHYSIOL, V263, pH1659, DOI 10.1152/ajpheart.1992.263.6.H1659; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SPENGLER D, 1992, MOL ENDOCRINOL, V6, P1931, DOI 10.1210/me.6.11.1931; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W	33	1128	1139	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					170	175						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8396727				2022-12-28	WOS:A1993LW44200051
J	GALLOE, AM; RASMUSSEN, HS; JORGENSEN, LN; AURUP, P; BALSLOV, S; CINTIN, C; GRAUDAL, N; MCNAIR, P				GALLOE, AM; RASMUSSEN, HS; JORGENSEN, LN; AURUP, P; BALSLOV, S; CINTIN, C; GRAUDAL, N; MCNAIR, P			INFLUENCE OF ORAL MAGNESIUM SUPPLEMENTATION ON CARDIAC EVENTS AMONG SURVIVORS OF AN ACUTE MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; INTRAVENOUS-MAGNESIUM; VASCULAR DISEASES; SERUM MAGNESIUM; HYPOMAGNESEMIA; DEFICIENCY	Objective-To investigate the effect of long term oral magnesium treatment on incidence of cardiac events among survivors of an acute myocardial infarction. Design-Double blind, placebo controlled parallel study in which patients were randomised to treatment or placebo. Setting-Two coronary care units and corresponding outpatient clinics. Subjects-468 survivors of an acute myocardial infarction (289 men and 178 women) aged 31-92. Interventions-One tablet of 15 mmol magnesium hydroxide or placebo daily for one year. Main outcome measures-Incidences of reinfarction, sudden death, and coronary artery bypass grafting in one year. Results-There was no significant difference between treatment and placebo groups in the incidence of each of the three cardiac events, but when the events were combined and drop outs were excluded from calculations there was a significantly higher incidence of events in the treatment group (56/167 v 33/153; relative risk 1.55 (95% confidence interval 1.07 to 2.25); p = 0.02). When the timing of events was incorporated by means of a Kaplan-Meier plot the treatment group showed a significantly higher incidence of events whether drop outs were included or excluded (p < 0.025). Conclusion-Long term oral treatment with 15 mmol magnesium daily does not reduce the incidence of cardiac events in survivors of an acute myocardial infarction and, indeed, seems to increase the risk of developing a cardiac event. Consequently, this treatment cannot be recommended as secondary prophylaxis for such patients.	BISPEBJERG HOSP,DEPT MED P,DK-2400 COPENHAGEN,DENMARK; HVIDOVRE UNIV HOSP,DEPT MED A,DK-2650 HVIDOVRE,DENMARK; HVIDOVRE UNIV HOSP,DEPT CLIN CHEM,DK-2650 HVIDOVRE,DENMARK	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; University of Copenhagen								ABRAHAM AS, 1977, NEW ENGL J MED, V296, P862, DOI 10.1056/NEJM197704142961509; ALTURA BM, 1981, FED PROC, V40, P2672; ALTURA BM, 1981, ARTERY, V9, P212; DYCKNER T, 1984, DRUGS, V28, P161, DOI 10.2165/00003495-198400281-00016; FLINK EB, 1981, ARCH INTERN MED, V141, P441, DOI 10.1001/archinte.141.4.441; GANON WF, 1977, REV MED PHYSL, P232; LIM P, 1972, BMJ-BRIT MED J, V3, P620, DOI 10.1136/bmj.3.5827.620; MATTHEWS DE, 1988, USING UNDERSTANDING, V79, P178; Morton B C, 1984, Magnesium, V3, P346; PETERSEN B, 1978, DAN MED BULL, V25, P116; RASMUSSEN HS, 1986, ARCH INTERN MED, V146, P872, DOI 10.1001/archinte.146.5.872; RASMUSSEN HS, 1986, LANCET, V1, P234; RASMUSSEN HS, 1988, CLIN CARDIOL, V11, P377, DOI 10.1002/clc.4960110604; RASMUSSEN HS, 1988, ARCH INTERN MED, V148, P329, DOI 10.1001/archinte.148.2.329; RASMUSSEN HS, 1986, LANCET, V1, P551; RECTOR WG, 1981, AM J MED SCI, V281, P25, DOI 10.1097/00000441-198101000-00004; RUDNICKI M, 1991, MINER ELECTROL METAB, V17, P399; RYZEN E, 1986, AM HEART J, V111, P475, DOI 10.1016/0002-8703(86)90051-7; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V	20	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					585	587		10.1136/bmj.307.6904.585	http://dx.doi.org/10.1136/bmj.307.6904.585			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401013	Green Published, Bronze			2022-12-28	WOS:A1993LW14900013
J	SLOAN, DSG				SLOAN, DSG			TRAVEL MEDICINE AND GENERAL-PRACTICE - A SUITABLE CASE FOR AUDIT	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-A; NEED IMMUNOGLOBULIN; PRACTITIONERS	Travel medicine becomes more important with the continual expansion of international travel and the increased popularity of exotic holiday destinations. In the United Kingdom general practitioners provide the bulk of travel health advice and immunisation and there is growing interest in providing these services. While their armamentarium has been expanded with attractive but expensive new vaccines, the need for health service advice has never been more vital, with the risks of HIV infection and drug resistant malaria. Advantages of a general practice based travel medicine service include maintaining continuity of care for the patient, but a disadvantage might be that the general practitioner sees too few patients to acquire enough skill in the subject. Furthermore, there may be a conflict of interest between time devoted to the ''vaccination ritual'' and giving health advice. Overall there seems to be a case for both audit and support by the health authorities.	ARGYLL & CLYDE HLTH BOARD,PAISLEY,SCOTLAND									ABELSMITH B, 1976, VALUE MONEY HLTH SER, P61; BARLOW D, 1992, PHLS MICROBIOLOGY DI, V9, P129; BLACK ME, 1992, LANCET, V340, P244, DOI 10.1016/0140-6736(92)90516-6; BLACKBURN J, 1992, PULSE, V552, P49; Brook M G, 1993, Commun Dis Rep CDR Rev, V3, pR28; COSSAR J H, 1989, World Health Statistics Quarterly, V42, P61; COSSAR JH, 1987, BRIT MED J, V294, P1503, DOI 10.1136/bmj.294.6586.1503; Cossar Jonathan H., 1992, Health Bulletin (Edinburgh), V50, P428; DAWOOD R, 1992, TRAVELLERS HLTH; INGRAM M, 1992, GENERAL PRACTIT 0403, P34; KINGMAN S, 1992, BRIT MED J, V305, P1314; KUDESIA G, 1987, BRIT MED J, V295, P118, DOI 10.1136/bmj.295.6590.118-b; Lea G, 1992, Commun Dis Rep CDR Rev, V2, pR82; LEA G, 1992, PHLS MICROBIOLOGY DI, V9, P132; MOTT A, 1990, BRIT MED J, V300, P25, DOI 10.1136/bmj.300.6716.25; NOONE A, 1992, BRIT MED J, V305, P1431, DOI 10.1136/bmj.305.6866.1431; PHILLIPSHOWARD PA, 1988, TRAVEL MED INT, V6, P51; PORTER JDH, 1992, BRIT MED J, V304, P1323, DOI 10.1136/bmj.304.6838.1323; TURNER AC, 1991, TRAVELLERS HLTH GUID; USHERWOOD V, 1989, J ROY COLL GEN PRACT, V39, P148; WALKER E, 1989, ABC HLTH TRAVEL; 1993, BRIT NATIONAL FORMUL, V25, P458; 1992, STATEMENT FEES ALLOW, P57; 1992, WKLY EPIDEMIOL RES, V67, P349; 1992, PUBLIC HLTH NEWS, V3, P127; 1992, IMMUNISATOIN INFECTI; 1992, MONTHLY INDEX MED SP, V19, P58; 1992, GENERAL PRACTIT 1030, P57; 1992, COMMUNICABLE DISEASE, V2, P141; 1993, HLTH ADVICE TRAVELLE; 1992, LANCET, V340, P341; 1993, INT TRAVEL HLTH 1992; 1992, GENERAL PRACTIT 1023, P79; 1990, IMMUNISATOIN INFECTI	34	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					615	617		10.1136/bmj.307.6904.615	http://dx.doi.org/10.1136/bmj.307.6904.615			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401022	Green Published, Bronze			2022-12-28	WOS:A1993LW14900025
J	KASISKE, BL; KALIL, RSN; MA, JZ; LIAO, MJ; KEANE, WF				KASISKE, BL; KALIL, RSN; MA, JZ; LIAO, MJ; KEANE, WF			EFFECT OF ANTIHYPERTENSIVE THERAPY ON THE KIDNEY IN PATIENTS WITH DIABETES - A METAREGRESSION ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review						DIABETES-MELLITUS; PROTEINURIA; GLOMERULAR FILTRATION RATE; DIABETIC NEPHROPATHY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS	CONVERTING-ENZYME-INHIBITION; INSULIN-DEPENDENT DIABETICS; ADRENOCEPTOR-BLOCKING-DRUGS; ARTERIAL BLOOD-PRESSURE; HYPERTENSIVE PATIENTS; GLUCOSE-TOLERANCE; ALBUMIN EXCRETION; METABOLIC CONTROL; RENAL-FUNCTION; TREATING HYPERTENSION	Objective: To assess the relative effect of different antihypertensive agents on proteinuria and renal function in patients with diabetes. Data Sources: We used MEDLINE and bibliographies in recent articles to identify studies of the effects of antihypertensive agents on renal function in patients with diabetes. Study Selection: We selected 100 controlled and uncontrolled studies that provided data on renal function, proteinuria, or both, before and after treatment with an antihypertensive agent. Data Extraction: Data on blood pressure, renal function, proteinuria, patient characteristics (for example, age, sex, and type of diabetes), and study design (for example, random allocation and the use of a placebo) were extracted from selected studies. Data Synthesis: Multiple linear regression analysis indicated that angiotensin-converting enzyme (ACE) inhibitors decreased proteinuria independent of changes in blood pressure, treatment duration, and the type of diabetes or stage of nephropathy, as well as study design (P < 0.0001). Reductions in proteinuria from other antihypertensive agents could be entirely explained by changes in blood pressure. Blood pressure reduction in itself was associated with a relative increase in glomerular filtration rate (regression coefficient [+/SE], 3.70 +/- .92 mL/min for each reduction of 10 mm Hg in mean arterial pressure; P = 0.0002); however, compared with other agents, ACE inhibitors had an additional favorable effect on glomerular filtration rate that was independent of blood pressure changes (3.41 +/- 1.71 mL/min; P = 0.05). Conclusion: Angiotensin-converting enzyme inhibitors can decrease proteinuria and preserve glomerular filtration rate in patients with diabetes. These effects occur independent of changes in systemic blood pressure.			KASISKE, BL (corresponding author), HENNEPIN CTY MED CTR, DEPT MED, DIV NEPHROL, 701 PK AVE, MINNEAPOLIS, MN 55415 USA.							ABUROMEH SH, 1989, CLIN NEPHROL, V31, P18; ANDERSON S, 1989, KIDNEY INT, V36, P526, DOI 10.1038/ki.1989.227; ANDERSON S, 1991, CLIN RES, V39, pA247; ANDREN L, 1988, AM J CARDIOL, V62, pG114; ARANDA P, 1988, POSTGRAD MED J, V64, P87; ARROYO JA, 1991, DIABETES, V40, pA441; BABA T, 1989, DIABETOLOGIA, V32, P40; BAKRIS GL, 1990, ANN INTERN MED, V112, P707, DOI 10.7326/0003-4819-112-9-707; BANK N, 1987, KIDNEY INT, V31, P898, DOI 10.1038/ki.1987.83; BENFIELD GFA, 1982, BRIT J CLIN PHARMACO, V13, P219, DOI 10.1111/j.1365-2125.1982.tb01360.x; Bhandarkar S D, 1978, J Postgrad Med, V24, P182; BILO HJG, 1988, DIABETES RES CLIN EX, V9, P21; BJORCK S, 1986, BMJ-BRIT MED J, V293, P471, DOI 10.1136/bmj.293.6545.471; BJORCK S, 1990, BMJ-BRIT MED J, V300, P904, DOI 10.1136/bmj.300.6729.904; BOULTON AJ, 1991, DIABETES, V40, pA508; BRICHARD SM, 1989, DIABETES METAB, V15, P388; CAPEWELL S, 1989, DIABETIC MED, V6, P809, DOI 10.1111/j.1464-5491.1989.tb01284.x; CAPPUCCIO FP, 1989, J HYPERTENS, V7, P941, DOI 10.1097/00004872-198912000-00003; CASADO S, 1988, POSTGRAD MED J, V64, P85; CASTRIGNANO R, 1988, AM HEART J, V116, P1778, DOI 10.1016/0002-8703(88)90229-3; CHAZAN BI, 1991, BR J CLIN PRACT, P393; CHELLINGSWORTH MC, 1989, J HUM HYPERTENS, V3, P35; CHRISTENSEN CK, 1985, HYPERTENSION, V7, P109; COOK J, 1990, J PEDIATR-US, V117, P39, DOI 10.1016/S0022-3476(05)82441-2; COOPER ME, 1990, DIABETES, V39, P1575, DOI 10.2337/diabetes.39.12.1575; COOPER ME, 1989, DIABETOLOGIA, V32, P326, DOI 10.1007/BF00265552; CORCORAN JS, 1987, DIABETIC MED, V4, P164, DOI 10.1111/j.1464-5491.1987.tb00855.x; COVES MJ, 1989, J MED, V20, P291; CRUICKSHANK JK, 1988, BRIT MED J, V297, P1155, DOI 10.1136/bmj.297.6657.1155; DANGELO A, 1986, POSTGRAD MED J, V62, P69; DELLAMAS LG, 1991, EUR J CLIN PHARMACOL, V41, P405, DOI 10.1007/BF00626360; DEMARIE BK, 1990, ANN INTERN MED, V113, P987, DOI 10.7326/0003-4819-113-12-987; DERSIMONIAN R, 1983, HARVARD EDUC REV, V53, P1; DOMINGUEZ JR, 1986, POSTGRAD MED J, V62, P66; DOYLE AE, 1991, BRIT MED J, V302, P210; DRUMMOND K, 1989, DIABETOLOGIA, V32, P255, DOI 10.1007/BF00285294; DUNN BR, 1986, J HYPERTENS, V4, pS251; DVORAK I, 1987, Cor et Vasa, V29, P30; ELVING LD, 1989, J CLIN PHARMACOL, V29, P316, DOI 10.1002/j.1552-4604.1989.tb03334.x; ESCOBARJIMINEZ F, 1988, POSTGRAD MED J, V64, P65; ETO M, 1988, CURR THER RES CLIN E, V43, P427; FERDER L, 1991, AM J HYPERTENS, V4, pA87; FOGARI R, 1990, CURR THER RES CLIN E, V47, P879; FRIEDMAN PJ, 1986, LANCET, V2, P1042; FUJIHARA CK, 1990, KIDNEY INT, V37, P506; GALL M, 1990, DIABETES S1, V39, pA124; GAMBARO G, 1985, J HYPERTENS, V3, pS149; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GROOP L, 1982, ACTA MED SCAND, V211, P7; GUTHRIE GP, 1983, CLIN PHARMACOL THER, V34, P713, DOI 10.1038/clpt.1983.239; HARROWER ADB, 1985, HYPERTENSION, V7, P161; HASSLACHER C, 1985, HYPERTENSION, V7, P74; HAUGERKLEVENE JH, 1985, EUR J CLIN PHARMACOL, V29, P391, DOI 10.1007/BF00613450; HAY U, 1988, POSTGRAD MED J, V64, P88; HOLDAAS H, 1991, J INTERN MED, V229, P163, DOI 10.1111/j.1365-2796.1991.tb00325.x; HOLLAENDER E, 1988, Therapia Hungarica, V36, P191; HOMMEL E, 1986, DIABETOLOGIA, V29, P211, DOI 10.1007/BF00454877; HOMMEL E, 1986, BMJ-BRIT MED J, V293, P467, DOI 10.1136/bmj.293.6545.467; INSUA A, 1988, POSTGRAD MED J, V64, P59; JACKSON B, 1987, J CARDIOVASC PHARM, V10, pS167, DOI 10.1097/00005344-198710100-00057; JANKA HU, 1989, J HYPERTENS, V7, pS316, DOI 10.1097/00004872-198900076-00154; KISCH ES, 1987, ISRAEL J MED SCI, V23, P833; KOLENDORF K, 1982, ACTA MED SCAND, V211, P175; Lanza G, 1985, Minerva Med, V76, P183; LEVY P, 1989, AM J MED, V86, P59, DOI 10.1016/0002-9343(89)90132-0; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARTELLO MA, 1991, DIABETES, V40, pA506; MARUYAMA H, 1991, AM HEART J, V121, P1302, DOI 10.1016/0002-8703(91)90437-M; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATTHEWS DM, 1987, J HUM HYPERTENS, V1, P19; MATTHEWS DM, 1986, POSTGRAD MED J, V62, P73; MBANYA JC, 1987, DIABETOLOGIA, V30, pA556; MICOSSI P, 1984, HORM METAB RES, V16, P59, DOI 10.1055/s-2007-1014697; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; MORELLI E, 1990, DIABETES, V39, P76, DOI 10.2337/diabetes.39.1.76; NORGAARD K, 1990, DIABETOLOGIA, V33, P407, DOI 10.1007/BF00404089; NORUSIS MJ, 1988, STATISTICAL PACKAGE; PAOLISSO G, 1990, DIABETES METAB, V16, P264; PARVING HH, 1985, HYPERTENSION, V7, P114; PARVING HH, 1991, DIABETES CARE, V14, P260, DOI 10.2337/diacare.14.3.260; PARVING HH, 1986, DIABETIC MED, V3, P312, DOI 10.1111/j.1464-5491.1986.tb00770.x; PARVING HH, 1989, BMJ-BRIT MED J, V299, P533, DOI 10.1136/bmj.299.6698.533; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PARVING HH, 1981, DIABETES CARE, V4, P459, DOI 10.2337/diacare.4.4.459; PARVING HH, 1986, POSTGRAD MED J, V62, P65; PASSA P, 1987, DIABETES CARE, V10, P200, DOI 10.2337/diacare.10.2.200; PEDERSEN MM, 1988, DIABETIC MED, V5, P562, DOI 10.1111/j.1464-5491.1988.tb01052.x; PRINCE MJ, 1988, ARCH INTERN MED, V148, P2363, DOI 10.1001/archinte.148.11.2363; RABKIN R, 1984, KIDNEY INT, V25, P205; RAGGI U, 1985, HYPERTENSION, V7, P157; REAMS GP, 1991, CLIN RES, V39, pA247; RETT K, 1988, POSTGRAD MED J, V64, P69; RIOBO P, 1988, POSTGRAD MED J, V64, P63; ROMERO R, 1988, MED CLIN-BARCELONA, V90, P494; ROUX P, 1981, POSTGRAD MED J, V57, P70; RUDBERG S, 1990, DIABETOLOGIA, V33, P470, DOI 10.1007/BF00405108; SCHMITZ PG, IN PRESS AM J PHYSL; SLOMOWITZ LA, 1990, AM J NEPHROL, V10, P457, DOI 10.1159/000168169; STORNELLO M, 1989, J HYPERTENS, V7, pS314, DOI 10.1097/00004872-198900076-00153; STORNELLO M, 1989, J HYPERTENS, V7, pS65, DOI 10.1097/00004872-198909007-00016; STORNELLO M, 1989, J CARDIOVASC PHARM, V14, P851, DOI 10.1097/00005344-198912000-00009; STORNELLO M, 1988, J HYPERTENS, V6, pS464, DOI 10.1097/00004872-198812040-00146; STORNELLO M, 1991, NEPHRON, V58, P52, DOI 10.1159/000186378; STORNELLO M, 1989, J NEPHROL S1, V2, P24; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; UEDA Y, 1990, NEPHRON, V55, P85; VALVO E, 1988, AM J MED, V85, P344, DOI 10.1016/0002-9343(88)90584-0; WALLIN JD, 1985, J CLIN HYPERTENS, V4, P315; WEBER MA, 1984, J CARDIOVASC PHARM, V6, pS823, DOI 10.1097/00005344-198400065-00019; WHITCROFT IA, 1990, HORM METAB RES, V22, P42; WIEGMANN TB, 1992, DIABETES, V41, P62, DOI 10.2337/diabetes.41.1.62; WINOCOUR PH, 1987, BRIT MED J, V295, P391, DOI 10.1136/bmj.295.6594.391; WRIGHT AD, 1979, BRIT MED J, V1, P159, DOI 10.1136/bmj.1.6157.159; YOSHIDA K, 1990, P INT C NEPHROLOGY T, pA160; ZANDER E, 1990, EXP CLIN ENDOCRINOL, V95, P70, DOI 10.1055/s-0029-1210936; ZANELLA MT, 1987, HYPERTENSION, V9, P543; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; 1990, USRDS1990 NIH NAT I	120	575	579	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					129	138		10.7326/0003-4819-118-2-199301150-00009	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416309				2022-12-28	WOS:A1993KF91800009
J	GALETTO, G; LEVINE, A				GALETTO, G; LEVINE, A			AIDS-ASSOCIATED PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; RADIATION-THERAPY; CHEMOTHERAPY; RISK		NIAID,DIV AIDS,AIDS CLIN TRIALS GRP,ONCOL CORE COMM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	GALETTO, G (corresponding author), UNIV SO CALIF,SCH MED,1441 EASTLAKE AVE,LOS ANGELES,CA 90033, USA.							BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; CORN BW, 1992, P ASCO, V11, P44; DEANGELIS LM, 1990, NEUROLOGY, V40, P80, DOI 10.1212/WNL.40.1.80; EBY NL, 1988, CANCER, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO;2-M; FORMENTI SC, 1989, CANCER, V63, P1101, DOI 10.1002/1097-0142(19890315)63:6<1101::AID-CNCR2820630611>3.0.CO;2-R; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; LEVINE AM, 1991, JAMA-J AM MED ASSOC, V266, P84, DOI 10.1001/jama.266.1.84; LEVY RM, 1992, NEUROSURGERY, V30, P186, DOI 10.1227/00006123-199202000-00006; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; SHETTER AG, 1977, SURG NEUROL, V8, P341; SOCIE G, 1990, CANCER, V65, P322, DOI 10.1002/1097-0142(19900115)65:2<322::AID-CNCR2820650223>3.0.CO;2-D	14	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					92	93		10.1001/jama.269.1.92	http://dx.doi.org/10.1001/jama.269.1.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416414				2022-12-28	WOS:A1993KF02600035
J	CLOZEL, M; BREU, V; BURRI, K; CASSAL, JM; FISCHLI, W; GRAY, GA; HIRTH, G; LOFFLER, BM; MULLER, M; NEIDHART, W; RAMUZ, H				CLOZEL, M; BREU, V; BURRI, K; CASSAL, JM; FISCHLI, W; GRAY, GA; HIRTH, G; LOFFLER, BM; MULLER, M; NEIDHART, W; RAMUZ, H			PATHOPHYSIOLOGICAL ROLE OF ENDOTHELIN REVEALED BY THE 1ST ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST	NATURE			English	Article							SUBARACHNOID HEMORRHAGE; CORONARY-ARTERY; SMOOTH-MUSCLE; BLOOD-FLOW; RATS; CELLS; VASODILATION; MECHANISM; CLONING; SUBTYPE	SINCE its discovery1, endothelin-1 has attracted considerable scientific interest because of its extremely potent and long-lasting vaso-constrictor effect and its binding to G-protein-coupled receptors2. Plasma concentrations of endothelin-1 are low3 and its release by endothelial cells is polarized towards the basolateral side4,5, suggesting that it is a paracrine factor and not a hormone. Consequently, the effect of injected endothelin-1 may not reflect the effect of endogenous endothelin-1. In contrast, blockade of the action of endogenous endothelin-1 using receptor antagonists should be a valuable means of investigating its physiological and pathological effects. We report here evidence for the pathophysiological role of endothelin-1 as brought by the first synthetic orally active non-peptide antagonist of endothelin receptors, Ro 46-2005.			CLOZEL, M (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND.		Gray, Gillian A/B-4058-2014	Gray, Gillian A/0000-0003-3104-3305				ANDO K, 1989, FEBS LETT, V245, P164, DOI 10.1016/0014-5793(89)80213-3; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; CLOZEL JP, 1993, HYPERTENSION, V11, P75; CLOZEL M, 1989, J HYPERTENS, V7, P913, DOI 10.1097/00004872-198911000-00011; CLOZEL M, 1991, J CARDIOVASC PHARM, V17, pS313, DOI 10.1097/00005344-199100177-00089; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; CLOZEL M, 1993, LIFE SCI, V52, P825, DOI 10.1016/0024-3205(93)90081-D; DOHI Y, 1991, HYPERTENSION, V18, P543, DOI 10.1161/01.HYP.18.4.543; EMORI T, 1990, FEBS LETT, V263, P261, DOI 10.1016/0014-5793(90)81388-5; FISCHLI W, 1989, LIFE SCI, V44, P1429, DOI 10.1016/0024-3205(89)90321-4; HARRISON VJ, 1992, BRIT J PHARMACOL, V105, P511, DOI 10.1111/j.1476-5381.1992.tb09009.x; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; KASUYA Y, 1992, BRIT J PHARMACOL, V107, P456, DOI 10.1111/j.1476-5381.1992.tb12767.x; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; MCMURDO L, 1993, BRIT J PHARMACOL, V108, P557, DOI 10.1111/j.1476-5381.1993.tb12840.x; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; MINO N, 1992, EUR J PHARMACOL, V221, P77; MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; SUZUKI R, 1992, J NEUROSURG, V77, P96, DOI 10.3171/jns.1992.77.1.0096; TAKAYANAGI R, 1991, FEBS LETT, V282, P103, DOI 10.1016/0014-5793(91)80454-B; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; WEBB ML, 1992, BIOCHEM BIOPH RES CO, V185, P887, DOI 10.1016/0006-291X(92)91710-8; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIMOTO S, 1991, J CARDIOVASC PHARM, V17, pS260, DOI 10.1097/00005344-199100177-00074	31	499	536	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					759	761		10.1038/365759a0	http://dx.doi.org/10.1038/365759a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413655				2022-12-28	WOS:A1993MC81200065
J	PALLEROS, DR; REID, KL; SHI, L; WELCH, WJ; FINK, AL				PALLEROS, DR; REID, KL; SHI, L; WELCH, WJ; FINK, AL			ATP-INDUCED PROTEIN HSP70 COMPLEX DISSOCIATION REQUIRES K+ BUT NOT ATP HYDROLYSIS	NATURE			English	Article							HEAT-SHOCK PROTEINS; UNFOLDED PROTEINS; DNAK; CHAPERONE; BINDING; GROEL	THE molecular chaperone proteins, particularly Hsp60 and Hsp70, have been implicated in essential cell functions under both normal and stress conditions (reviewed in refs 1-5). Members of the family of heat-shock proteins of M(r) 70K, Hsp70, bind to unfolded proteins and short peptides6-13. Addition of Mg-ATP results in the dissociation of the substrate polypeptides from the chaperone7-11, but as ATP-gammaS (an ATP analogue that is only slowly hydrolysable) cannot substitute for ATP in this reaction7,9,11, it has been concluded that ATP hydrolysis is necessary to dissociate Hsp70-substrate protein complexes. By independently measuring the rates of ATP hydrolysis and substrate protein dissociation, we show here that Mg-ATP binding but not Mg-ATP hydrolysis is essential for substrate dissociation. We also show that there is an absolute requirement for K+ for the effect of Mg-ATP: only the combination of K+ and Mg-ATP will cause the conformational change in Hsp70 that is necessary for substrate dissociation. Moreover, in the absence of K+, Mg-ATP favours complex formation. We consider these results in terms of a G-protein-like model.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California Santa Cruz; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANG D, 1991, J BIOL CHEM, V266, P24233; ANTONINO LC, 1991, P NATL ACAD SCI USA, V88, P7715, DOI 10.1073/pnas.88.17.7715; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; ELLIS RJ, 1991, SEMIN CELL BIOL, V1, P1; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1992, NATURE, V355, P35; HARTL FU, 1992, REV BIOPHYS BIOMED S, V21, P293; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID SL, 1985, J BIOL CHEM, V260, P57	20	372	376	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					664	666		10.1038/365664a0	http://dx.doi.org/10.1038/365664a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413631				2022-12-28	WOS:A1993MB84600064
J	RONCO, JJ; FENWICK, JC; TWEEDDALE, MG; WIGGS, BR; PHANG, PT; COOPER, DJ; CUNNINGHAM, KF; RUSSELL, JA; WALLEY, KR				RONCO, JJ; FENWICK, JC; TWEEDDALE, MG; WIGGS, BR; PHANG, PT; COOPER, DJ; CUNNINGHAM, KF; RUSSELL, JA; WALLEY, KR			IDENTIFICATION OF THE CRITICAL OXYGEN DELIVERY FOR ANAEROBIC METABOLISM IN CRITICALLY ILL SEPTIC AND NONSEPTIC HUMANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; PATHOLOGICAL SUPPLY DEPENDENCE; GLUCOSE TRANSPORTER; SKELETAL-MUSCLE; CRITICAL-LEVEL; O-2 UPTAKE; CONSUMPTION; SEPSIS; SHOCK; SURVIVORS	Objectives.-To determine the critical oxygen delivery threshold for anaerobic metabolism and to compare its value between septic and nonseptic critically ill patients. Design.-Cohort analytic study, consecutive sample. Setting.-Two tertiary care medical and surgical intensive care units in university hospitals. Patients.-Nine septic and nine nonseptic critically ill humans. A diagnosis of sepsis was established by the presence of sepsis syndrome, positive cultures obtained within 48 hours of study, and autopsy evidence of a source of infection. Methods and Interventions.-The O2 consumption (determined by indirect calorimetry), O2 delivery (calculated from the Fick equation), and concentration of arterial plasma lactate were simultaneously determined at 5- to 20-minute intervals while life support was discontinued. Main Outcome Measures.-Critical O2 delivery, critical O2 extraction ratio, and maximal O2 extraction ratio. Results.-In all septic and eight nonseptic patients, O2 delivery and O2 consumption displayed a biphasic relationship over the range of O2 delivery studied. There were no differences in critical O2 delivery threshold (3.8+/-1.5 vs 4.5+/-1.3 mL.min-1.kg-1; P>.28), Critical O2 extraction ratio (0.61+/-0.05 vs 0.59+/-0.16; P>.64), and maximal O2 extraction ratio (0.74+/-0.08 vs 0.80+/-0.11; P>.29) between septic and nonseptic patients. These data have greater than 90% power to detect a difference of 2 mL.min-1.kg-1 in the critical O2 delivery and 0.1 in the critical and maximal O2 extraction ratios between the septic and nonseptic groups. Conclusions.-The critical O2 delivery for anaerobic metabolism was identified from the biphasic relationship between O2 delivery and O2 consumption in individual humans. The critical O2 delivery is considerably lower than previously reported in humans with the use of pooled group data. Sepsis does not alter the critical O2 delivery for anaerobic metabolism or tissue O2 extraction ability. Interventions to increase O2 delivery to supranormal levels in critically ill humans in the hope of increasing O2 consumption may be inappropriate.	UNIV BRITISH COLUMBIA,ST PAULS HOSP,VANCOUVER V6T 1W5,BC,CANADA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	RONCO, JJ (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,PROGRAM CRIT CARE MED,INTENS CARE UNIT ADM,LSP 2,VANCOUVER V5Z 1M9,BC,CANADA.		Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051				BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; CURTIS SE, 1992, AM REV RESPIR DIS, V145, P348, DOI 10.1164/ajrccm/145.2_Pt_1.348; DANEK SJ, 1980, AM REV RESPIR DIS, V122, P387; DANTZKER DR, 1991, AM REV RESPIR DIS, V143, P675, DOI 10.1164/ajrccm/143.3.675; FENWICK JC, 1990, J CRIT CARE, V5, P81, DOI 10.1016/0883-9441(90)90052-B; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HARGROVE DM, 1988, AM J PHYSIOL, V254, pE16; HAUPT MT, 1985, AM REV RESPIR DIS, V131, P912; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOMATSU T, 1987, CRIT CARE MED, V15, P194, DOI 10.1097/00003246-198703000-00002; KRUSE JA, 1987, AM J MED, V83, P77, DOI 10.1016/0002-9343(87)90500-6; MOHSENIFAR Z, 1983, CHEST, V84, P267, DOI 10.1378/chest.84.3.267; NELSON DP, 1987, J APPL PHYSIOL, V63, P1487, DOI 10.1152/jappl.1987.63.4.1487; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1991, J CRIT CARE, V6, P36, DOI 10.1016/0883-9441(91)90031-N; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; RUSSELL JA, 1990, AM REV RESPIR DIS, V141, P659, DOI 10.1164/ajrccm/141.3.659; SAMSEL RW, 1988, J APPL PHYSIOL, V65, P1377, DOI 10.1152/jappl.1988.65.3.1377; SCHUMACKER PT, 1989, J APPL PHYSIOL, V67, P1234, DOI 10.1152/jappl.1989.67.3.1234; SHIBUTANI K, 1983, CRIT CARE MED, V11, P640, DOI 10.1097/00003246-198308000-00010; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; VARY TC, 1986, AM J PHYSIOL, V250, pE634, DOI 10.1152/ajpendo.1986.250.6.E634; VERMEIJ CG, 1991, CHEST, V99, P1438, DOI 10.1378/chest.99.6.1438; VINCENT JL, 1990, AM REV RESPIR DIS, V142, P2, DOI 10.1164/ajrccm/142.1.2; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; WOLL PJ, 1979, EUR J CLIN INVEST, V9, P397, DOI 10.1111/j.1365-2362.1979.tb00903.x; Zar JH., 1999, BIOSTAT ANAL; ZELLER WP, 1991, BIOCHEM BIOPH RES CO, V176, P535, DOI 10.1016/0006-291X(91)90958-A	32	218	226	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1724	1730		10.1001/jama.270.14.1724	http://dx.doi.org/10.1001/jama.270.14.1724			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411504				2022-12-28	WOS:A1993MA29400030
J	DALY, E; GRAY, A; BARLOW, D; MCPHERSON, K; ROCHE, M; VESSEY, M				DALY, E; GRAY, A; BARLOW, D; MCPHERSON, K; ROCHE, M; VESSEY, M			MEASURING THE IMPACT OF MENOPAUSAL SYMPTOMS ON QUALITY-OF-LIFE	BRITISH MEDICAL JOURNAL			English	Article							HORMONE REPLACEMENT THERAPY; HEALTH-CARE; OF-LIFE; GENERAL-PRACTICE; ESTROGEN; QALYS; WOMEN	Objective-To examine the impact of menopausal symptoms on the overall quality of life of women. Design-Data collection with a questionnaire administered by an interviewer, incorporating two different quality of life measurement techniques (time trade off and rating scale). Setting-Specialist menopause clinic and two general practices in Oxford. Subjects-63 women aged 45-60 years recruited opportunistically during a clinic or appointment with a general practitioner; no exclusion criteria. Results-Subjects gave very low quality of life ratings for health states with menopausal symptoms. The time trade off method of measuring preferences for these health states (on a scale from 0 to 1, where preference for full health is given as 1) yielded utility values of 0.64 for severe menopausal symptoms and 0.85 for mild symptoms. The rating scale measurement technique yielded even lower values: utilities of 0.30 and 0.65 were obtained for severe and mild symptoms respectively. Kappa scores indicated that the two methods produced results that were poorly related but not contradictory. Comparison of quality of life ratings before and after treatment with hormone replacement therapy showed significant improvements: with the rating scale measurement technique mean increases in utility values after the relief of severe and mild menopausal symptoms were 0.56 and 0.18 respectively. Conclusions-Quality of life may be severely compromised in women with menopausal symptoms, and perceived improvements in quality of life in users of hormone replacement therapy seem to be substantial. This emphasises the need to include quality of life measurements when assessing outcomes of hormone replacement therapy. Several limitations may exist with widely applied measurement techniques, calling for the development of appropriate and well validated instruments for measuring quality of life associated with reduced health states.	UNIV OXFORD WOLFSON COLL,CTR SOCIOLEGAL STUDIES,OXFORD OX2 6UD,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; OXFORD AREA HLTH AUTHOR,OXFORD OX3 7LG,ENGLAND	University of Oxford; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	DALY, E (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.		Barlow, David/F-8738-2011					[Anonymous], 1991, LANCET, V338, P350; AVIS NE, 1991, MATURITAS, V13, P65, DOI 10.1016/0378-5122(91)90286-Y; BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; BUNGAY GT, 1980, BRIT MED J, V2, P181; BUXTON M, 1987, ALTERNATIVE METHODS; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; COAST J, 1992, BMJ-BRIT MED J, V305, P87, DOI 10.1136/bmj.305.6845.87; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; CUBBON J, 1991, J MED ETHICS, V17, P181, DOI 10.1136/jme.17.4.181; DALY E, 1992, BRIT MED BULL, V48, P368, DOI 10.1093/oxfordjournals.bmb.a072552; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; Fletcher Astrid, 1992, British Medical Journal, V305, P1145; GREENBLATT RB, 1950, J CLIN ENDOCRINOL, V10, P1547, DOI 10.1210/jcem-10-12-1547; Gudex C, 1988, QALY TOOLKIT; HARRIS J, 1991, J MED ETHICS, V17, P185, DOI 10.1136/jme.17.4.185; HOLLAND G, 1985, TECHNIQUES HLTH STAT; HUNT K, 1988, J ROY COLL GEN PRACT, V38, P398; HUNT K, 1991, CURR OBSTET GYNAECOL, V1, P21; KANIS JA, 1992, OSTEOPOROSIS INT, V2, P161, DOI 10.1007/BF01623919; MCKINLAY SM, 1974, BRIT J PREV SOC MED, V28, P108; MCTURK L, 1991, BRIT MED J, V302, P1601, DOI 10.1136/bmj.302.6792.1601-b; RICHARDSON J, 1992, RES HLTH CARE DESIGN; ROBERTS PJ, 1991, BRIT J GEN PRACT, V41, P421; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SACKETT DL, 1978, J CHRON DIS, V31, P679; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1205, DOI 10.1136/bmj.305.6863.1205; THOMSON J, 1977, BRIT MED J, V2, P1317, DOI 10.1136/bmj.2.6098.1317; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; WADE DT, 1991, BRIT MED J, V303, P1136; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; Willard A, 1988, MAPPING MORAL DOMAIN, P225; WREN BG, 1990, MATURITAS, V13, P17	35	217	221	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					836	840		10.1136/bmj.307.6908.836	http://dx.doi.org/10.1136/bmj.307.6908.836			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401125	Green Published, Bronze			2022-12-28	WOS:A1993MA29300020
J	MULLAART, E; DEVOS, GJ; MEERMAN, GJT; UITTERLINDEN, AG; VIJG, J				MULLAART, E; DEVOS, GJ; MEERMAN, GJT; UITTERLINDEN, AG; VIJG, J			PARALLEL GENOME ANALYSIS BY 2-DIMENSIONAL DNA TYPING	NATURE			English	Article							ELECTROPHORESIS; PROTEINS		UNIV GRONINGEN,DEPT MED GENET,9713 AW GRONINGEN,NETHERLANDS	University of Groningen	MULLAART, E (corresponding author), INGENY BV,POB 685,2300 AR LEIDEN,NETHERLANDS.							FISCHER SG, 1979, CELL, V16, P191, DOI 10.1016/0092-8674(79)90200-9; HOVIG E, 1993, GENOMICS, V17, P66, DOI 10.1006/geno.1993.1284; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; MEERMAN GJT, IN PRESS AM J HUM GE; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHAAP GH, 1983, CYTOMETRY, V3, P408, DOI 10.1002/cyto.990030604; SCHEELE GA, 1975, J BIOL CHEM, V250, P5375; UITTERLINDEN AG, 1989, P NATL ACAD SCI USA, V86, P2742, DOI 10.1073/pnas.86.8.2742; UITTERLINDEN AG, 1993, 2 DIMENSIONAL DNA TY; VERWEST AM, IN PRESS BR J CANCER	10	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					469	471		10.1038/365469a0	http://dx.doi.org/10.1038/365469a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413593				2022-12-28	WOS:A1993LZ63300068
J	HUI, CH; CHAN, LC				HUI, CH; CHAN, LC			AGRANULOCYTOSIS ASSOCIATED WITH CEPHALOSPORIN	BRITISH MEDICAL JOURNAL			English	Letter											HUI, CH (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,HONG KONG,HONG KONG.							MURPHY MF, 1985, BRIT J HAEMATOL, V59, P9, DOI 10.1111/j.1365-2141.1985.tb02957.x; NEFTEL KA, 1985, J INFECT DIS, V152, P90, DOI 10.1093/infdis/152.1.90; 1985, LANCET, V2, P814; 1989, ARCH INTERN MED, V149, P1036	4	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					484	484		10.1136/bmj.307.6902.484-a	http://dx.doi.org/10.1136/bmj.307.6902.484-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400935	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1993LU59000026
J	OBRIEN, MD; GILMOURWHITE, S				OBRIEN, MD; GILMOURWHITE, S			EPILEPSY AND PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							ANTIEPILEPTIC DRUGS; FOLIC-ACID; RISK				OBRIEN, MD (corresponding author), GUYS HOSP,LONDON SE1 9RT,ENGLAND.							ALMUSAED AA, 1992, J ROY SOC MED, V85, P19; ANNEGERS JF, 1988, EPILEPSIA, V29, P451, DOI 10.1111/j.1528-1157.1988.tb03745.x; BIALE Y, 1984, EUR J OBSTET GYN R B, V18, P211, DOI 10.1016/0028-2243(84)90119-9; BUEHLER BA, 1990, NEW ENGL J MED, V322, P1567, DOI 10.1056/NEJM199005313222204; DANAHAERI J, 1982, BRIT MED J, V284, P85, DOI 10.1136/bmj.284.6309.85-a; DELGARDOESCUETA AV, 1992, NEUROLOGY S5, V42; GAILY E, 1988, J PEDIATR-US, V113, P677; GAUTRAY JP, 1978, FERTIL STERIL, V29, P275; GUILLEBAUD J, 1991, PILL; HARPER PS, 1988, PRACTICAL GENETIC CO, P158; LINDHOUT D, 1986, LANCET, V1, P1392; MANDELBROT L, 1988, THROMB HAEMOSTASIS, V60, P39; NAKANE Y, 1980, EPILEPSIA, V21, P663, DOI 10.1111/j.1528-1157.1980.tb04320.x; ORME M, 1991, WOMEN EPILEPSY, P145; PERUCCA E, 1983, CLIN PHARM OBSTETRIC, P264; 1988, DRUHGS HUMAN LACTATI, P329; 1991, LANCET, V338, P131	17	17	17	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					492	495		10.1136/bmj.307.6902.492	http://dx.doi.org/10.1136/bmj.307.6902.492			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400940	Bronze, Green Published			2022-12-28	WOS:A1993LU59000031
J	GIRARD, S; CLAPHAM, D				GIRARD, S; CLAPHAM, D			ACCELERATION OF INTRACELLULAR CALCIUM WAVES IN XENOPUS-OOCYTES BY CALCIUM INFLUX	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; LAEVIS OOCYTES; ENDOPLASMIC-RETICULUM; 2ND MESSENGERS; CA-2+; RELEASE; CELLS; RECEPTORS; 1,4,5-TRISPHOSPHOROTHIOATE; OSCILLATIONS	Many cell membrane receptors stimulate the phosphoinositide (PI) cycle, which produces complex intracellular calcium signals that regulate diverse processes such as secretion and transcription. A major messenger of this cycle, inositol 1,4,5-trisphosphate (IP3), stimulates its receptor channel on the endoplasmic reticulum to release calcium into the cytosol. Activation of the PI cycle also induces calcium influx, which refills the intracellular calcium stores. Confocal microscopy was used to show that receptor-activated calcium influx, enhanced by hyperpolarization, modulates the frequency and velocity of IP3-dependent calcium waves in Xenopus laevis oocytes. These results demonstrate that transmembrane voltage and calcium influx pathways may regulate spatial and temporal patterns of IP3-dependent calcium release.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BEMENT WM, 1990, J ELECTRON MICR TECH, V16, P202, DOI 10.1002/jemt.1060160303; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DELISLE S, 1992, AM J PHYSIOL, V262, pC1456, DOI 10.1152/ajpcell.1992.262.6.C1456; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FERGUSON JE, 1990, BIOCHEM BIOPH RES CO, V172, P229, DOI 10.1016/S0006-291X(05)80198-6; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIIRARD S, IN PRESS METHODS CEL; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LUPUMEIRI M, 1990, FEBS LETT, V262, P165, DOI 10.1016/0014-5793(90)80180-Q; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; POTTER BVL, 1990, DUPONT BIOTECH UPDAT, V5, P1; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; TAYLOR CW, 1988, BIOCHEM BIOPH RES CO, V150, P626, DOI 10.1016/0006-291X(88)90438-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1991, NEW BIOL, V3, P3	42	152	152	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1993	260	5105					229	232		10.1126/science.8385801	http://dx.doi.org/10.1126/science.8385801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8385801				2022-12-28	WOS:A1993KW45200043
J	BAHN, RS; HEUFELDER, AE				BAHN, RS; HEUFELDER, AE			MECHANISMS OF DISEASE - PATHOGENESIS OF GRAVES OPHTHALMOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							THYROID-ASSOCIATED OPHTHALMOPATHY; HUMAN RETROOCULAR FIBROBLASTS; LINKED IMMUNOSORBENT-ASSAY; HEAT-SHOCK PROTEINS; EYE MUSCLE; CULTURED FIBROBLASTS; INTERFERON-GAMMA; IMMUNOGLOBULINS; ANTIBODIES; TISSUE		UNIV MUNICH,MED KLIN,W-8000 MUNICH 2,GERMANY	University of Munich	BAHN, RS (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,DIV ENDOCRINOL,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NEI NIH HHS [EY08819] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008819] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMANN A, 1987, J CLIN ENDOCR METAB, V64, P454, DOI 10.1210/jcem-64-3-454; ATKINSON S, 1984, LANCET, V2, P374; BAHN RS, 1990, J CLIN ENDOCR METAB, V71, P559, DOI 10.1210/jcem-71-3-559; BAHN RS, 1987, J CLIN ENDOCR METAB, V65, P665, DOI 10.1210/jcem-65-4-665; BAHN RS, 1989, J CLIN ENDOCR METAB, V69, P622, DOI 10.1210/jcem-69-3-622; CAMPBELL RJ, 1984, EYE ORBIT THYROID DI, P25; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DONG Q, 1991, J CLIN ENDOCR METAB, V72, P1375, DOI 10.1210/jcem-72-6-1375; FELICIELLO A, 1993, LANCET, V342, P337, DOI 10.1016/0140-6736(93)91475-2; FRECKER M, 1986, CLIN ENDOCRINOL, V25, P479, DOI 10.1111/j.1365-2265.1986.tb03599.x; HANSSON HA, 1986, LANCET, V1, P218; HEUFELDER AE, 1991, J CLIN ENDOCR METAB, V73, P739, DOI 10.1210/jcem-73-4-739; HEUFELDER AE, 1992, EUR J CLIN INVEST, V22, P529, DOI 10.1111/j.1365-2362.1992.tb01501.x; HEUFELDER AE, 1991, J CLIN ENDOCR METAB, V73, P307, DOI 10.1210/jcem-73-2-307; HEUFELDER AE, 1993, CLIN EXP IMMUNOL, V91, P381; HEUFELDER AE, 1993, EUR J CLIN INVEST, V23, P10, DOI 10.1111/j.1365-2362.1993.tb00712.x; HEUFELDER AE, 1992, J CLIN ENDOCR METAB, V74, P724, DOI 10.1210/jc.74.4.724; HEUFELDER AE, 1992, J CLIN ENDOCR METAB, V74, P732, DOI 10.1210/jc.74.4.732; HEUFELDER AE, IN PRESS THYROID; HEUFELDER AE, IN PRESS INVEST OPHT; HUFNAGEL TJ, 1984, OPHTHALMOLOGY, V91, P1411; IMAI Y, 1992, ACTA ENDOCRINOL-COP, V126, P541, DOI 10.1530/acta.0.1260541; KADLUBOWSKI M, 1986, J CLIN ENDOCR METAB, V63, P990, DOI 10.1210/jcem-63-4-990; KAHALY G, 1990, CLIN ENDOCRINOL, V33, P35, DOI 10.1111/j.1365-2265.1990.tb00463.x; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; KENDLER DL, 1991, CLIN ENDOCRINOL, V35, P539, DOI 10.1111/j.1365-2265.1991.tb00941.x; KOORNNEEF L, 1908, EYE, V2, P130; KORDUCKI JM, 1992, INVEST OPHTH VIS SCI, V33, P2037; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MAROCCI C, 1989, ACTA ENDOCRINOL-COP, V120, P473; MCKENZIE JM, 1978, CLIN ENDOCRINOL META, V7, P31, DOI 10.1016/S0300-595X(78)80034-6; MILLER A, 1986, ACTA ENDOCRINOL-COP, V113, P514, DOI 10.1530/acta.0.1130514; MUNRO RE, 1973, J CLIN ENDOCR METAB, V37, P286, DOI 10.1210/jcem-37-2-286; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; PRUMMEL MF, 1989, ACTA ENDOCRINOL-COP, V121, P185; PURMMEL MF, 1992, CLIN EXP IMMUNOL, V88, P405; PURMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479; ROSEN CE, 1992, OPHTHALMOLOGY, V99, P146; ROSS PV, 1993, J CLIN ENDOCR METAB, V77, P433, DOI 10.1210/jc.77.2.433; ROTELLA CM, 1986, J CLIN ENDOCR METAB, V62, P357, DOI 10.1210/jcem-62-2-357; SALVI M, 1988, FEBS LETT, V232, P135, DOI 10.1016/0014-5793(88)80402-2; SALVI M, 1990, J CLIN ENDOCR METAB, V70, P89, DOI 10.1210/jcem-70-1-89; Salvi M, 1991, Thyroid, V1, P207, DOI 10.1089/thy.1991.1.207; SCHIFFERDECKER E, 1989, ACTA ENDOCRINOL-COP, V121, P643, DOI 10.1530/acta.0.1210643; SHILLINGLAW J, 1968, J CLIN ENDOCR METAB, V28, P1069, DOI 10.1210/jcem-28-7-1069; SHINE B, 1990, LANCET, V335, P1261, DOI 10.1016/0140-6736(90)91315-2; SISSON JC, 1971, EXP EYE RES, V12, P285, DOI 10.1016/0014-4835(71)90151-5; SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; SMITH TJ, 1991, J CLIN ENDOCR METAB, V72, P1169, DOI 10.1210/jcem-72-5-1169; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TALLSTEDT L, 1988, INVEST OPHTH VIS SCI, V29, P175; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1373; TENG CS, 1977, BRIT MED J, V1, P273, DOI 10.1136/bmj.1.6056.273; WALL JR, 1979, J ENDOCRINOL INVEST, V2, P375, DOI 10.1007/BF03349336; WEETMAN AP, 1992, AUTOIMMUNITY, V12, P215, DOI 10.3109/08916939209148462; WEETMAN AP, 1989, CLIN EXP IMMUNOL, V75, P222; WEETMAN AP, 1991, LANCET, V338, P25, DOI 10.1016/0140-6736(91)90013-F; WEETMAN AP, 1989, J ROY SOC MED, V82, P153, DOI 10.1177/014107688908200313; WEIGHTMAN D, 1989, J ENDOCRINOL, V122, P201, DOI 10.1677/joe.0.1220201; WENZEL BE, 1990, AUTOIMMUNITY, V7, P295, DOI 10.3109/08916939009087589; WERNER SC, 1974, NEW ENGL J MED, V290, P1447, DOI 10.1056/NEJM197406272902602; WORTSMAN J, 1981, ARCH DERMATOL, V117, P635, DOI 10.1001/archderm.117.10.635	63	407	429	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1468	1475						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413459				2022-12-28	WOS:A1993MF29200007
J	BURROWS, RF; KELTON, JG				BURROWS, RF; KELTON, JG			FETAL THROMBOCYTOPENIA AND ITS RELATION TO MATERNAL THROMBOCYTOPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL THROMBOCYTOPENIA; PURPURA; PREGNANCY; MANAGEMENT; WOMEN	Background. Neonates with severe thrombocytopenia can have bleeding leading to death or lifelong residual defects. The predictors, frequency, and consequences of fetal thrombocytopenia are not known, nor is it known if there are maternal clinical features that could predict fetal thrombocytopenia. Methods. We conducted a seven-year cross-sectional study in which platelet counts were determined in newborns' umbilical-cord blood and blood obtained from their mothers at consecutive deliveries in one obstetrical unit. The relations of the umbilical-cord platelet count to maternal risk factors were determined. Results. Platelet counts were determined in blood samples from 15,471 mothers and 15,932 newborn infants. The cord-blood platelet count was less than 50,000 per cubic millimeter in 19 infants (0.12 percent; 95 percent confidence interval, 0.07 to 0.19 percent), whereas the platelet count was less than 150,000 per cubic millimeter in 6.6 percent of the mothers (95 percent confidence interval, 6.2 to 7.0 percent). One infant among those born to 756 mothers with incidental thrombocytopenia, 5 infants among those born to 1414 mothers with hypertension, and 4 infants among those born to 46 mothers with idiopathic thrombocytopenic purpura had cord-blood platelet counts between 20,000 and 50,000 per cubic millimeter. Only 6 infants (0.04 percent; 95 percent confidence interval, 0.01 to 0.08 percent) had cord-blood platelet counts of less than 20,000 per cubic millimeter; all their mothers were among the 18 whose 19 fetuses were at risk for neonatal alloimmune thrombocytopenia. Two of these infants had in utero intracranial hemorrhage. In addition, 3 infants born to these 18 women had cord-blood platelet counts between 20,000 and 50,000 per cubic millimeter; there was 1 stillbirth due to intracranial hemorrhage. Conclusions. Moderate-to-severe fetal thrombocytopenia is a rare event. The only severely affected neonates with morbidity or mortality due to this condition are those born to mothers with antiplatelet alloantibodies.	CANADIAN RED CROSS,BLOOD TRANSFUS SERV,HAMILTON CTR,HAMILTON,ON,CANADA; MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University	BURROWS, RF (corresponding author), MCMASTER UNIV,MED CTR,DEPT OBSTET & GYNECOL,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							ANDREW M, 1987, J PEDIATR-US, V110, P457, DOI 10.1016/S0022-3476(87)80517-6; BLANCHETTE VS, 1988, CURR STUD HEMATOL BL, V54, P112; BURROWS RF, 1990, AM J OBSTET GYNECOL, V163, P1147, DOI 10.1016/0002-9378(90)90675-W; BURROWS RF, 1990, AM J OBSTET GYNECOL, V162, P731, DOI 10.1016/0002-9378(90)90996-K; BURROWS RF, 1988, NEW ENGL J MED, V319, P142, DOI 10.1056/NEJM198807213190304; BURROWS RF, 1990, OBSTET GYNECOL, V76, P234; BUSEL JB, 1991, HEMATOLOGY BASIC PRI, P1485; CHRISTIAENS GCML, 1990, BRIT J OBSTET GYNAEC, V97, P893, DOI 10.1111/j.1471-0528.1990.tb02443.x; CINES DB, 1984, MED GRAND ROUNDS, V3, P344; COOK RL, 1991, OBSTET GYNECOL, V78, P578; HATHAWAY WE, 1978, PERINATAL COAGULATIO, P115; KELTON JG, 1983, ANN INTERN MED, V99, P796, DOI 10.7326/0003-4819-99-6-796; MCCRAE KR, 1992, BLOOD, V80, P2697; MOUTET A, 1990, ARCH INTERN MED, V150, P2141, DOI 10.1001/archinte.150.10.2141; MUELLERECKHARDT C, 1989, LANCET, V1, P363; PEARSON HA, 1964, BLOOD, V23, P154, DOI 10.1182/blood.V23.2.154.154; SAMUELS P, 1990, NEW ENGL J MED, V323, P229, DOI 10.1056/NEJM199007263230404; SHULMAN NR, 1964, PROG HEMATOL, V4, P222; Taaning E, 1990, Obstet Gynecol Surv, V45, P521, DOI 10.1097/00006254-199008000-00004; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	20	323	339	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1463	1466		10.1056/NEJM199311113292005	http://dx.doi.org/10.1056/NEJM199311113292005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413457	Bronze			2022-12-28	WOS:A1993MF29200005
J	SUNG, P; BAILLY, V; WEBER, C; THOMPSON, LH; PRAKASH, L; PRAKASH, S				SUNG, P; BAILLY, V; WEBER, C; THOMPSON, LH; PRAKASH, L; PRAKASH, S			HUMAN XERODERMA-PIGMENTOSUM GROUP-D GENE ENCODES A DNA HELICASE	NATURE			English	Article								XERODERMA pigmentosum (XP), a genetically heterogeneous human disease, results from a defect in nucleotide excision repair of ultraviolet-damaged DNA. XP patients are extremely sensitive to sunlight and suffer from a high incidence of skin cancers. Cell fusion studies have identified seven XP complementation groups, A-G1-3. Group D is of particular interest as mutations in this gene can also cause Cockayne's syndrome and trichothiodystrophy4. The XPD gene was initially named ERCC2 (excision repair cross complementing) as it was cloned using human DNA to complement the ultraviolet sensitivity of a rodent cell line5. We have purified the XPD protein to near homogeneity and show that it possesses single-stranded DNA-dependent ATPase and DNA helicase activities. We tested whether XPD can substitute for its yeast counterpart RAD3, which is essential for excision repair and for cell viability6. Expression of the XPD gene in Saccharomyces cerevisiae can complement the lethality defect of a mutation in the RAD3 gene6, suggesting that XPD is an essential gene in humans.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642; LAWRENCE LIVERMORE NATL LAB,BIOL & TECHNOL RES PROGRAM,LIVERMORE,CA 94550	University of Rochester; University of Rochester; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DEWEERDK.EA, 1972, NATURE-NEW BIOL, V238, P80, DOI 10.1038/newbio238080a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; JOHNSON RT, 1992, MUTAT RES, V273, P97, DOI 10.1016/0921-8777(92)90072-B; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; Prakash S, 1990, EUKARYOTIC NUCLEUS, P275; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; VERMEULEN W, 1991, MUTAT RES, V255, P201, DOI 10.1016/0921-8777(91)90054-S; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	17	289	299	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					852	855		10.1038/365852a0	http://dx.doi.org/10.1038/365852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413672				2022-12-28	WOS:A1993MD95100055
J	KOLLEF, MH				KOLLEF, MH			VENTILATOR-ASSOCIATED PNEUMONIA - A MULTIVARIATE-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNIT; CONTINUOUS MECHANICAL VENTILATION; HOSPITAL-ACQUIRED PNEUMONIA; NOSOCOMIAL PNEUMONIA; SELECTIVE DECONTAMINATION; DIGESTIVE-TRACT; RISK-FACTORS; FAILURE; ASPIRATION; PROGNOSIS	Objectives.-To identify factors associated with the development of ventilator-associated pneumonia (VAP) and to examine the incidence of VAP in different intensive care unit (ICU) populations. Design.-An inception cohort study. Setting.-Barnes Hospital, St Louis, Mo, an academic tertiary care center. Patients or Other Participants.-A total of 277 consecutive patients required mechanical ventilation for longer than 24 hours from a medical ICU (75 patients), surgical ICU (100 patients), or cardiothoracic ICU (102 patients). Interventions.-Prospective patient surveillance and data collection. Main Outcome Measures.-Ventilator-associated pneumonia and ICU mortality. Results.-Ventilator-associated pneumonia occurred in 43 patients (15.5%). Stepwise logistic regression analysis identified four factors to be independently associated with VAP (P<.05): an organ system failure index of 3 or greater (adjusted odds ratio [AOR]=10.2; 95% confidence interval [CI], 4.5 to 23; P<.001); patient age of 60 years or older (AOR=5.1; 95% CI, 1.9 to 14.1; P=.002); prior administration of antibiotics (AOR=3.1; 95% CI, 1.4 to 6.9; P=.004); and supine head positioning during the first 24 hours of mechanical ventilation (AOR=2.9; 95% Cl, 1.3 to 6.8; P=.013). Ventilator-associated pneumonia occurred more often in cardiothoracic patients (21.6%) compared with medical patients (9.3%) (P=.03). Patients with VAP also had a higher mortality (37.2%) than those without; VAP (8.5%) (P<.001). An organ system failure index of 3 or greater (AOR=16.1; 95% CI, 6.1 to 42; P<.001), a premorbid lifestyle score of 2 or greater (AOR=3.1; 95% CI, 1.3 to 7.3; P=.012), and supine head positioning during the first 24 hours of mechanical ventilation (AOR=3.1; 95% CI, 1.2 to 7.8; P=.016) were independently associated with mortality. Conclusions.-These data suggest potential interventions that might affect the incidence of VAP or outcome associated with VAP. Additionally, they indicate that different ICU populations may have different incidences of VAP.			KOLLEF, MH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV PULM & CRIT CARE,BOX 8052,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							BARTLETT JG, 1986, ARCH INTERN MED, V146, P868, DOI 10.1001/archinte.146.5.868; BARTLETT RH, 1986, CHEST, V89, P684, DOI 10.1378/chest.89.5.684; BEALE R, 1993, CRIT CARE MED, V21, pS1, DOI 10.1097/00003246-199302001-00001; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONTEN MJM, 1993, NEW ENGL J MED, V328, P209, DOI 10.1056/NEJM199301213280311; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUNAGAN WC, 1991, REV INFECT DIS, V13, P405; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, AM REV RESPIR DIS, V147, pA105; FIDDIANGREEN RG, 1991, CRIT CARE MED, V19, P763; FIDDIANGREEN RG, 1993, CRIT CARE MED, V21, pS103, DOI 10.1097/00003246-199302001-00017; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GRAYBILL JR, 1973, AM REV RESPIR DIS, V108, P1130; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; Horan T C, 1986, MMWR CDC Surveill Summ, V35, p17SS; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; HUDSON L D, 1989, American Review of Respiratory Disease, V140, pS19; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOLLEF MH, IN PRESS CHEST; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MENZIES R, 1989, CHEST, V95, P398, DOI 10.1378/chest.95.2.398; MONTECALVO MA, 1992, CRIT CARE MED, V20, P1377, DOI 10.1097/00003246-199210000-00004; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; STEVENS RM, 1974, ARCH INTERN MED, V134, P106, DOI 10.1001/archinte.134.1.106; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; 1992, NEW ENGL J MED, V327, P234; 1990, SAS STAT USERS GUIDE, P1	39	492	514	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1965	1970		10.1001/jama.270.16.1965	http://dx.doi.org/10.1001/jama.270.16.1965			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8411554				2022-12-28	WOS:A1993MC51300029
J	GROSOF, DH; SHAPLEY, RM; HAWKEN, MJ				GROSOF, DH; SHAPLEY, RM; HAWKEN, MJ			MACAQUE-V1 NEURONS CAN SIGNAL ILLUSORY CONTOURS	NATURE			English	Article							MONKEY VISUAL-CORTEX; SUBJECTIVE CONTOURS; PERCEPTION; SENSITIVITY; ORGANIZATION; MECHANISMS; ELEMENTS; CONTRAST; MOTION; CUES	WE describe here a new view of primary visual cortex (V1) based on measurements of neural responses in V1 to patterns called 'illusory contours' (Fig. 1a, b). Detection of an object's boundary contours is a fundamental visual task. Boundary contours are defined by discontinuities not only in luminance and colour, but also in texture1-3, disparity4 and motion5-7. Two theoretical approaches can account for illusory contour perception. The cognitive approach emphasizes top-down processes8,9. An alternative emphasizes bottom-up processing. This latter view is supported by (1) stimulus constraints for illusory contour perception10-14 and (2) the discovery by von der Heydt and Peterhans15-17 of neurons in extrastriate visual area V2 (but not in V1) of macaque monkeys that respond to illusory contours. Using stimuli different from those used previously15,16, we found illusory contour responses in about half the neurons studied in V1 of macaque monkeys. Therefore, there are neurons as early as V1 with the computational power to detect illusory contours and to help distinguish figure from ground.	NYU,CTR NEURAL SCI,4 WASHINGTON PL,NEW YORK,NY 10003	New York University								BECK J, 1983, BIOL CYBERN, V48, P125, DOI 10.1007/BF00344396; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GREGORY RL, 1977, PERCEPTION, V6, P113, DOI 10.1068/p060113; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; HAWKEN MJ, 1988, J NEUROSCI, V8, P3541; HOCHSTEIN S, 1976, J PHYSIOL-LONDON, V262, P237, DOI 10.1113/jphysiol.1976.sp011594; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Julesz B., 1962, IRE T INFORM THEOR, V8, P84, DOI [10.1109/TIT.1962.1057698, DOI 10.1109/TIT.1962.1057698]; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; MERRILL EG, 1972, MED BIOL ENG, V10, P662, DOI 10.1007/BF02476084; MILKMAN N, 1980, BEHAV RES METH INSTR, V12, P283, DOI 10.3758/BF03201667; NAKAYAMA K, 1985, PERCEPTION, V14, P225, DOI 10.1068/p140225; NAKAYAMA K, 1981, VISION RES, V21, P427, DOI 10.1016/0042-6989(81)90089-4; PARADISO MA, 1989, VISION RES, V29, P1205, DOI 10.1016/0042-6989(89)90066-7; PETERHANS E, 1989, J NEUROSCI, V9, P1749; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SHAPLEY R, 1985, PERCEPT PSYCHOPHYS, V37, P84, DOI 10.3758/BF03207143; SHAPLEY R, 1988, PERCEPTION ILLUSORY, P109; SMITH AT, 1979, PERCEPT PSYCHOPHYS, V25, P95, DOI 10.3758/BF03198792; SMITH AT, 1977, PERCEPTION, V6, P441, DOI 10.1068/p060441; SPITZER H, 1985, J NEUROPHYSIOL, V53, P1266, DOI 10.1152/jn.1985.53.5.1266; TAKAHASHI S, 1992, VISION RES, V32, P1709, DOI 10.1016/0042-6989(92)90163-D; VANDOORN AJ, 1982, EXP BRAIN RES, V45, P179, DOI 10.1007/BF00235777; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	27	305	308	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					550	552		10.1038/365550a0	http://dx.doi.org/10.1038/365550a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA661	8413610				2022-12-28	WOS:A1993MA66100055
J	OLIVERA, A; SPIEGEL, S				OLIVERA, A; SPIEGEL, S			SPHINGOSINE-1-PHOSPHATE AS 2ND MESSENGER IN CELL-PROLIFERATION INDUCED BY PDGF AND FCS MITOGENS	NATURE			English	Article							PROTEIN-KINASE-C; ENDOGENOUS GANGLIOSIDE; SIGNAL TRANSDUCTION; PHOSPHATIDIC-ACID; FREE SPHINGOSINE; ACTIVATION; HYDROLYSIS; RECEPTOR; LIVER	GROWTH signalling networks that use glycerophospholipid metabolites as second messengers have been well characterized1,2, but less is known of the second messengers derived from sphingolipids3,4, another major class of membrane lipids. A tantalizing fink between sphingolipids and cellular proliferation has emerged from the discovery that the sphingolipid metabolites sphingosine and sphingosine-1-phosphate stimulate growth of quiescent Swiss 3T3 fibroblasts by a pathway that is independent of protein kinase C5,6. Sphingosine-1-phosphate is rapidly produced from sphingosine and may mediate its biological effects6. Furthermore, sphingosine-1-phosphate triggers the dual signal transduction pathways of calcium mobilization6,7 and activation of phospholipase D8, prominent events in the control of cellular proliferation. Here we report that activation of sphingosine kinase and the formation of sphingosine-1-phosphate are important in the signal transduction pathways activated by the potent mitogens platelet-derived growth factor (PDGF) and fetal calf serum (FCS).	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Georgetown University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Christie W.W., 2003, LIPID ANAL; DESAI NN, 1992, J BIOL CHEM, V267, P23122; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MERRILL AH, 1988, BIOCHEMISTRY-US, V227, P340; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SPIEGEL S, 1989, J BIOL CHEM, V264, P6766; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILSON E, 1988, J BIOL CHEM, V263, P9304; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	29	802	835	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					557	560		10.1038/365557a0	http://dx.doi.org/10.1038/365557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413613				2022-12-28	WOS:A1993MA66100058
J	FARRER, M; GAME, FL; ALBERS, CJ; NEIL, HAW; WINOCOUR, PH; LAKER, MF; ADAMS, PC; ALBERTI, KGMM				FARRER, M; GAME, FL; ALBERS, CJ; NEIL, HAW; WINOCOUR, PH; LAKER, MF; ADAMS, PC; ALBERTI, KGMM			ASSOCIATION BETWEEN IMPAIRED GLUCOSE-TOLERANCE AND CIRCULATING CONCENTRATION OF LP(A) LIPOPROTEIN IN RELATION TO CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; MIDDLE-AGED MEN; GLYCOPROTEIN PHENOTYPES; MYOCARDIAL-INFARCTION; GEL-ELECTROPHORESIS; INSULIN ACTION; PIMA-INDIANS; PLASMA; POPULATION; APOLIPOPROTEIN-(A)	Objective-To examine whether impaired glucose tolerance and raised Lp(a) lipoprotein concentrations are associated in subjects with coronary artery disease. Design-Study of two subject populations, one with and one without symptomatic coronary artery disease. Case-control analysis of patients with impaired glucose tolerance and normal glucose tolerance performed in each subject population independently. Setting-A general practice and a hospital ward in Newcastle upon Tyne. Subjects-517 apparently healthy subjects, 13 with impaired glucose tolerance, and 245 patients who had undergone coronary artery bypass graft surgery 12 months before, 51 with impaired glucose tolerance. Main outcome measures-Serum Lp(a) lipoprotein concentration, plasma glucose concentration before and after oral challenge with 75 g glucose monohydrate, and Lp(a) lipoprotein isoforms. Results-In both the asymptomatic subjects and the subjects with coronary artery disease there was no significant difference between subjects with impaired glucose tolerance and subjects with normal glucose tolerance who were matched for age, sex, and body mass index in serum Lp(a) lipoprotein concentrations (geometric mean 61 (geometric SD 4) mg/l v 83 (5) mg/l for asymptomatic subjects, 175 (3) v 197 (2) for subjects with heart disease), nor was there any difference in the proportion of subjects who had Lp(a) lipoprotein concentrations >300 mg/l (31% v 23% for asymptomatic subjects, 37% v 37% for subjects with heart disease). For both subject groups there was no significant correlation between Lp(a) lipoprotein concentration and plasma glucose concentration after a glucose tolerance test, nor did Lp(a) lipoprotein concentration vary by quintile of glucose concentration after the test. Examination of Lp(a) lipoprotein isoforms in the subjects with coronary artery disease revealed an inverse relation between isoform size and plasma Lp(a) lipoprotein concentration, but there was no evidence that impaired glucose tolerance was associated with particular Lp(a) lipoprotein isoforms. Conclusion-Raised Lp(a) lipoprotein concentrations are not responsible for the association between impaired glucose tolerance and coronary artery disease.	ROYAL VICTORIA INFIRM,DEPT CARDIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT CLIN BIOCHEM,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; University of Oxford; Newcastle University - UK				Game, Frances/0000-0002-5294-4789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMS ME, 1969, BRIT MED J, V1, P599, DOI 10.1136/bmj.1.5644.599; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BERG K, 1974, CLIN GENET, V6, P230; BOERWINKLE E, 1989, HUM GENET, V82, P73, DOI 10.1007/BF00288277; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; CAPALDO B, 1983, DIABETES CARE, V6, P575, DOI 10.2337/diacare.6.6.575; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAVIES M, 1992, BRIT MED J, V304, P1610, DOI 10.1136/bmj.304.6842.1610; DURRINGTON PN, 1988, LANCET, V1, P1070; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FARRER M, 1992, CLIN CHIM ACTA, V207, P215, DOI 10.1016/0009-8981(92)90120-F; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FULLER JH, 1980, LANCET, V1, P1374; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; HOWARD BV, 1984, ARTERIOSCLEROSIS, V4, P462, DOI 10.1161/01.ATV.4.5.462; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P59; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; MANN JI, 1988, BMJ, V296, P1701; MODAN M, 1988, ARTERIOSCLEROSIS, V8, P227, DOI 10.1161/01.ATV.8.3.227; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; ORAHILLY SP, 1986, LANCET, V2, P360; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCHAEFER EJ, 1992, CIRCULATION, V86, P812; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHARP CL, 1964, P ROY SOC MED, V57, P193, DOI 10.1177/003591576405700319; STAMLER R, 1979, J CHRON DIS, V32, P683, DOI 10.1016/0021-9681(79)90047-X; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VACCARO O, 1984, ARTERIOSCLEROSIS, V4, P592, DOI 10.1161/01.ATV.4.6.592; WINOCOUR PH, 1992, ATHEROSCLEROSIS, V93, P71, DOI 10.1016/0021-9150(92)90201-Q; ZAVARONI I, 1987, AM J MED, V83, P609, DOI 10.1016/0002-9343(87)90887-4	35	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					832	836		10.1136/bmj.307.6908.832	http://dx.doi.org/10.1136/bmj.307.6908.832			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401124	Bronze, Green Published			2022-12-28	WOS:A1993MA29300019
J	MOORE, MJ; SHARP, PA				MOORE, MJ; SHARP, PA			EVIDENCE FOR 2 ACTIVE-SITES IN THE SPLICEOSOME PROVIDED BY STEREOCHEMISTRY OF PREMESSENGER RNA SPLICING	NATURE			English	Article							SMALL NUCLEAR-RNA; TETRAHYMENA RIBOZYME; MUTATIONAL ANALYSIS; BINDING-SITE; YEAST; STEP; SUBSTITUTION; POLYMERASE; ADENOSINE; CLEAVAGE	EXCISION of introns from nuclear precursors to messenger RNAs (pre-mRNAs) by the spliceosome requires two distinct phosphodiester transfer (transesterification) reactions: exchange of a 3'-5' for a 2'-5' bond in the first step (lariat formation) and exchange of one 3'-5' phosphodiester for another in the second step (exon ligation)1-3. We report here determination of the stereochemical course of each step using splicing substrates that contained a chiral phosphorothioate. This has provided strong evidence that both steps occur as single 'in-line' SN2 nucleophilic displacement reactions, analogous to the mechanism of group I self-splicing introns4,5. Additionally, because both steps are strongly inhibited by the R(P) phosphorothioate diastereomer, but not by S(P), the spliceosome probably shifts between two active sites in catalysis of the two steps. Chemical and stereochemical similarities suggest that the catalytic site for the second step of spliceosomal processing is related to that of group I self-splicing introns.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	MOORE, MJ (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BRYANT FR, 1979, BIOCHEMISTRY-US, V18, P2825, DOI 10.1021/bi00580a022; BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; MASCHHOFF KL, 1992, NUCLEIC ACIDS RES, V20, P1949, DOI 10.1093/nar/20.8.1949; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOORE MJ, 1983, RNA WORLD, P303; NELSON PS, 1984, J ORG CHEM, V49, P2314, DOI 10.1021/jo00187a003; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; REILLY JD, 1989, METHOD ENZYMOL, V180, P177; RUBY SW, 1991, TRENDS GENET, V7, P79; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972; 1987, APPLIED BIOSYSTEMS M, V44, P1	36	188	195	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1993	365	6444					364	368		10.1038/365364a0	http://dx.doi.org/10.1038/365364a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8397340				2022-12-28	WOS:A1993LY49600060
J	RYDER, REJ				RYDER, REJ			NATURAL FAMILY-PLANNING - EFFECTIVE BIRTH-CONTROL SUPPORTED BY THE CATHOLIC-CHURCH	BRITISH MEDICAL JOURNAL			English	Article							OVULATION; SYMPTOMS; EFFICACY; MUCUS	During 20-22 September Manchester is to host the 1993 follow up to last year's ''earth summit'' in Rio de janeiro. At that summit the threat posed by world overpopulation received considerable attention. Catholicism was perceived as opposed to birth control and therefore as a particular threat. This was based on the notion that the only method of birth control approved by the church-natural family planning-is unreliable, unacceptable, and ineffective. In the 20 years since E L Billings and colleagues first described the cervical mucus symptoms associated with ovulation natural family planning has incorporated these symptoms and advanced considerably. Ultrasonography shows that the symptoms identify ovulation precisely. According to the World Health Organisation, 93%. of women everywhere can identify the symptoms, which distinguish adequately between the fertile and infertile phases of the menstrual cycle. Most pregnancies during trials of natural family planning occur after intercourse at times recognised by couples as fertile. Thus pregnancy rates have depended on the motivation of couples. Increasingly studies show that rates equivalent to those with other contraceptive methods are readily achieved in the developed and developing worlds. Indeed, a study of 19843 poor women in India had a pregnancy rate approaching zero. Natural family planning is cheap, effective, without side effects, and may be particularly acceptable to and efficacious among people in areas of poverty.			RYDER, REJ (corresponding author), DUDLEY RD GEN HOSP,DEPT ENDOCRINOL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.		Ryder, Robert Elford/AAC-9014-2022	Ryder, Robert Elford/0000-0003-4424-355X				[Anonymous], 1981, FERTIL STERIL, V36, P591; [Anonymous], 1987, FERTIL STERIL, V47, P765; BALL M, 1976, European Journal of Obstetrics and Gynecology and Reproductive Biology, V6, P63, DOI 10.1016/0028-2243(76)90004-6; Barbato M, 1988, Int J Fertil, V33 Suppl, P48; BILLINGS EL, 1972, LANCET, V1, P282, DOI 10.1016/s0140-6736(72)90291-7; BILLINGS JJ, 1976, LANCET, V2, P969; BILLINGS JJ, 1976, LANCET, V2, P579; BONNYMAN J, 1982, Australian Radiation Laboratory Technical Report Series ARL-TR, P1; BROMWICH P D, 1985, British Journal of Sexual Medicine, V12, P124; CLUBB EM, 1990, NATURAL FAMILY PLANN, P130; DEPARES J, 1986, BRIT MED J, V292, P1562, DOI 10.1136/bmj.292.6535.1562; DORAIRAJ K, 1991, AM J OBSTET GYNECOL, V165, P2066, DOI 10.1016/S0002-9378(11)90584-5; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; FLYNN AM, 1976, BRIT J OBSTET GYNAEC, V83, P656, DOI 10.1111/j.1471-0528.1976.tb00906.x; FLYNN AM, 1991, MATERNAL CHILD HLTH, V16, P148; FRANCE JT, 1982, RECENT ADV OBSTETRIC, P215; FRANCIOLI P, 1987, SCHWEIZ MED WSCHR, P27; FRANKHERRMANN P, 1991, AM J OBSTET GYNECOL, V165, P2052, DOI 10.1016/S0002-9378(11)90580-8; Ghosh AK, 1982, J OBSTET GYNAECOL, V32, P443; GODLEE F, 1992, BRIT MED J, V304, P1525; KAMBIC RT, 1991, AM J OBSTET GYNECOL, V165, P2078; KELLY J, 1992, J TROP PEDIATRICS, V38, P206, DOI 10.1093/tropej/38.4.206; LAING JE, 1984, STUD FAMILY PLANN, V15, P49, DOI 10.2307/1966046; MARSHALL J, 1968, LANCET, V2, P8; MARSHALL J, 1976, LANCET, V2, P1085; MARSHALL J, 1976, LANCET, V2, P685; MARSHALL J, 1976, LANCET, V2, P282; MILLS A, 1984, CLIN OBSTET GYNAECOL, V11, P641; Parenteau-Carreau S, 1976, VIIE MED CANADA FRAN, V4, P145; Perez A, 1983, Rev Chil Obstet Ginecol, V48, P97; POOLE J, 1992, LANCET, V339, P1340; REID KM, 1985, HDB FAMILY PLANNING, P25; RICE FJ, 1981, INT J FERTIL, V26, P222; ROETZER J, 1981, INT REV NATURAL FAMI, V5, P200; RYDER REJ, 1985, CLIN SCI, V69, pP17, DOI 10.1042/cs069017Pa; VESSEY M, 1982, LANCET, V1, P841; WEISSMANN MC, 1972, LANCET, V2, P813; 1993, FERTIL STERIL, V40, P773; 1981, FERTIL STERIL, V36, P152; 1984, FERTIL STERIL, V41, P593	40	52	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					723	726		10.1136/bmj.307.6906.723	http://dx.doi.org/10.1136/bmj.307.6906.723			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401097	Bronze, Green Published			2022-12-28	WOS:A1993LY29200024
J	PEARSON, MG; SPENCE, DPS; RYLAND, I; HARRISON, BDW				PEARSON, MG; SPENCE, DPS; RYLAND, I; HARRISON, BDW			VALUE OF PULSUS PARADOXUS IN ASSESSING ACUTE SEVERE ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									W NORWICH HOSP,NORWICH,ENGLAND		PEARSON, MG (corresponding author), FAZAKERLEY DIST GEN HOSP,AINTREE CHEST CTR,LIVERPOOL L9 7AL,ENGLAND.							British Thoracic Society (BTS), 1993, THORAX, V48, pS1; COCHRANE GM, 1990, RESPIRATORY MED, P614; EDELSON JD, 1985, ARCH INTERN MED, V145, P321, DOI 10.1001/archinte.145.2.321; KNOWLES GK, 1973, LANCET, V2, P1356; 1990, BMJ, V301, P797	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					659	659		10.1136/bmj.307.6905.659	http://dx.doi.org/10.1136/bmj.307.6905.659			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401053	Bronze, Green Published			2022-12-28	WOS:A1993LX47000019
J	WAKEFORD, R; FOULKES, J; MCMANUS, C; SOUTHGATE, L				WAKEFORD, R; FOULKES, J; MCMANUS, C; SOUTHGATE, L			MRCGP PASS RATE BY MEDICAL-SCHOOL AND REGION OF POSTGRADUATE TRAINING	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,LOCAL EXAMINAT SYNDICATE,CAMBRIDGE CB1 2EU,ENGLAND; ST MARYS HOSP,SCH MED,LONDON W2 1PG,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,LONDON EC1M 6BQ,ENGLAND	University of Cambridge; Imperial College London; University of London; Queen Mary University London	WAKEFORD, R (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CAMBRIDGE CB2 2SP,ENGLAND.							CAMPBELL LM, IN PRESS BR J GEN PR; REES L, 1993, BRIT MED J, V306, P258, DOI 10.1136/bmj.306.6872.258; 1992, MEMBERS REFERENCE BO, P48	3	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					542	543		10.1136/bmj.307.6903.542-a	http://dx.doi.org/10.1136/bmj.307.6903.542-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400976	Green Published, Bronze			2022-12-28	WOS:A1993LV18000020
J	THORN, P; LAWRIE, AM; SMITH, PM; GALLACHER, DV; PETERSEN, OH				THORN, P; LAWRIE, AM; SMITH, PM; GALLACHER, DV; PETERSEN, OH			LOCAL AND GLOBAL CYTOSOLIC CA2+ OSCILLATIONS IN EXOCRINE CELLS EVOKED BY AGONISTS AND INOSITOL TRISPHOSPHATE	CELL			English	Article							PANCREATIC ACINAR-CELLS; CALCIUM RELEASE; 1,4,5-TRISPHOSPHATE RECEPTOR; CHOLECYSTOKININ RECEPTORS; DIFFERENT PATTERNS; CHANNELS; RAT; ACTIVATION; SIGNALS; ACETYLCHOLINE	Submaximal stimulation with agonists generating inositol 1,4,5-trisphosphate (IP3) evokes cytosolic Ca2+ oscillations in many different cell types. In general, each Ca2+ rise is initiated from a specific region near the plasma membrane and then spreads as a wave throughout the cell. We now demonstrate that low (physiological) agonist concentrations evoke local cytosolic Ca2+ spikes in the secretory pole of single mouse pancreatic acinar cells that are particularly sensitive to blockade by the IP3 receptor antagonist heparin. These spikes can occur alone or repetitively or can precede longer lasting Ca2+ signals that spread throughout the cell. Intracellular IP3 application mimics these agonist actions. The short-lasting local Ca2+ spikes provide an economical signaling mechanism and are of physiological significance since they activate Ca2+-dependent Cl- and cation currents important for control of fluid secretion.			THORN, P (corresponding author), UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,CROWN ST,LIVERPOOL L69 3BX,ENGLAND.		Thorn, Peter/F-7030-2010; Petersen, Ole H/E-8708-2010	Thorn, Peter/0000-0002-3228-770X; Petersen, Ole/0000-0002-6998-0380				ALBRITTON NL, 1992, SCIENCE, V258, P1812; AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; DELISLE S, 1992, J BIOL CHEM, V267, P7963; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FORSTER ER, 1992, EXP PHYSIOL, V77, P693, DOI 10.1113/expphysiol.1992.sp003635; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; INAGAKI N, 1991, P NATL ACAD SCI USA, V88, P4215, DOI 10.1073/pnas.88.10.4215; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MARTY A, 1991, J MEMBRANE BIOL, V124, P189, DOI 10.1007/BF01994353; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NOBLE NJ, 1992, BIOORG MED CHEM LETT, V2, P471, DOI 10.1016/S0960-894X(00)80172-9; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN CCH, 1991, FEBS LETT, V293, P179, DOI 10.1016/0014-5793(91)81181-7; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; SCHNEFEL S, 1988, FEBS LETT, V230, P125, DOI 10.1016/0014-5793(88)80655-0; SMITH PM, 1992, J PHYSIOL-LONDON, V446, pP72; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; STREB H, 1985, J BIOL CHEM, V260, P7309; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THELER JM, 1992, J BIOL CHEM, V267, P18110; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TONES MA, 1989, FEBS LETT, V252, P105, DOI 10.1016/0014-5793(89)80898-1; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	51	440	441	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					661	668		10.1016/0092-8674(93)90513-P	http://dx.doi.org/10.1016/0092-8674(93)90513-P			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395347				2022-12-28	WOS:A1993LU59200009
J	ROTHE, J; LESSLAUER, W; LOTSCHER, H; LANG, Y; KOEBEL, P; KONTGEN, F; ALTHAGE, A; ZINKERNAGEL, R; STEINMETZ, M; BLUETHMANN, H				ROTHE, J; LESSLAUER, W; LOTSCHER, H; LANG, Y; KOEBEL, P; KONTGEN, F; ALTHAGE, A; ZINKERNAGEL, R; STEINMETZ, M; BLUETHMANN, H			MICE LACKING THE TUMOR-NECROSIS-FACTOR RECEPTOR-1 ARE RESISTANT TO TNF-MEDIATED TOXICITY BUT HIGHLY SUSCEPTIBLE TO INFECTION BY LISTERIA-MONOCYTOGENES	NATURE			English	Article							VIRUS-REPLICATION; GAMMA INTERFERON; FACTOR-ALPHA; MOUSE; EXPRESSION; CLONING; INTERLEUKIN-1; ENDOTOXIN; CACHECTIN; INVIVO	TUMOUR necrosis factor (TNF), jointly referring to TNFalpha and TNFbeta, is a central mediator of immune and inflammatory responses; its activities are mediated by two distinct receptors, TNFR1 (p55) and TNFR2 (p75) (reviewed in refs 1-3). The cytoplasmic domains of the TNFRs are unrelated, suggesting that they link to different intracellular signalling pathways4. Although most TNF responses have been assigned to one or the other of the TNF receptors (mostly TNFR1), there is no generally accepted model for the physiological role of the two receptor types. To investigate the role of TNFR1 in beneficial and detrimental activities of TNF, we generated TNFR1-deficient mice by gene targeting. We report here that mice homozygous for a disrupted Tnfr1 allele (Tnfr1(0)) are resistant to the lethal effect of low doses of lipopolysaccharide after sensitization with D-galactosamine, but remain sensitive to high doses of lipopolysaccharide. The increased susceptibility of Tnfr1(0)/Tnfr1(0) mutant mice to infection with the facultative intracellular bacterium Listeria monocytogenes indicates an essential role of TNF in nonspecific immunity.	F HOFFMANN LA ROCHE & CO LTD, DEPT BIOL, PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; UNIV ZURICH, INST EXPTL IMMUNOL, CH-8057 ZURICH, SWITZERLAND	Roche Holding; University of Zurich								ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AGGARWAL BB, 1992, TUMOUR NECROSIS FACT; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1992, TUMOUR NECROSIS FACT; Blanden R V, 1972, Scand J Immunol, V1, P379, DOI 10.1111/j.1365-3083.1972.tb03304.x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; FEDUCHI E, 1989, J VIROL, V63, P1354, DOI 10.1128/JVI.63.3.1354-1359.1989; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GEHR G, 1992, J IMMUNOL, V149, P911; HAUSER T, 1990, MED MICROBIOL IMMUN, V179, P95; HAVELL EA, 1987, J IMMUNOL, V139, P4225; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KONTGEN F, IN PRESS INT IMMUN; LEIST TP, 1989, J VIROL, V63, P2813, DOI 10.1128/JVI.63.6.2813-2819.1989; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; NAKANE A, 1988, INFECT IMMUN, V56, P2563, DOI 10.1128/IAI.56.10.2563-2569.1988; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, MOL IMMUNOL, V30, P165, DOI 10.1016/0161-5890(93)90088-S; ROTHE JG, 1991, IMMUNOGENETICS, V34, P338, DOI 10.1007/BF00211997; SHALABY MR, 1989, CLIN IMMUNOL IMMUNOP, V53, P488, DOI 10.1016/0090-1229(89)90010-X; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; ZINKERNAGEL RM, 1988, J EXP MED, V168, P1187, DOI 10.1084/jem.168.3.1187	32	1140	1171	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	1993	364	6440					798	802		10.1038/364798a0	http://dx.doi.org/10.1038/364798a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8395024				2022-12-28	WOS:A1993LU58100055
J	KAKU, DA; GIFFARD, RG; CHOI, DW				KAKU, DA; GIFFARD, RG; CHOI, DW			NEUROPROTECTIVE EFFECTS OF GLUTAMATE ANTAGONISTS AND EXTRACELLULAR ACIDITY	SCIENCE			English	Article							DEPRIVATION NEURONAL INJURY; D-ASPARTATE ANTAGONIST; ISCHEMIC BRAIN-DAMAGE; GLUCOSE DEPRIVATION; HIPPOCAMPAL-NEURONS; CORTICAL CULTURES; CEREBRAL HYPOXIA; CALCIUM-BINDING; AMINO-ACIDS; PH CHANGES	Glutamate antagonists protect neurons from hypoxic injury both in vivo and in vitro, but in vitro studies have not been done under the acidic conditions typical of hypoxia-ischemia in vivo. Consistent with glutamate receptor antagonism, extracellular acidity reduced neuronal death in murine cortical cultures that were deprived of oxygen and glucose. Under these acid conditions, N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate-kainate antagonists further reduced neuronal death, such that some neurons tolerated prolonged oxygen and glucose deprivation almost as well as did astrocytes. Neuroprotection induced by this combination exceeded that induced by glutamate antagonists alone, suggesting that extracellular acidity has beneficial effects beyond the attenuation of ionotropic glutamate receptor activation.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305	Washington University (WUSTL); Stanford University				Giffard, Rona/0000-0003-2173-4436	NINDS NIH HHS [NS 26907, NS 01425] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026907, K08NS001425] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; BING OHL, 1973, SCIENCE, V180, P1297, DOI 10.1126/science.180.4092.1297; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUCHAN AM, 1992, ARCH NEUROL-CHICAGO, V49, P420, DOI 10.1001/archneur.1992.00530280114032; BURNIER M, 1988, AM J PHYSIOL, V254, pC839, DOI 10.1152/ajpcell.1988.254.6.C839; CHESNAIS JM, 1975, J MOL CELL CARDIOL, V7, P627, DOI 10.1016/0022-2828(75)90140-6; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J PHARMACOL EXP THER, V242, P713; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1987, J NEUROSCI, V7, P357; CHURCH J, 1985, EUR J PHARMACOL, V111, P185, DOI 10.1016/0014-2999(85)90755-1; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1987, NEUROSCI LETT, V80, P11, DOI 10.1016/0304-3940(87)90486-1; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KAKU D A, 1991, Society for Neuroscience Abstracts, V17, P1266; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KIM D, 1987, AM J PHYSIOL, V253, pC137, DOI 10.1152/ajpcell.1987.253.1.C137; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; LANGER GA, 1985, CIRC RES, V57, P374, DOI 10.1161/01.RES.57.3.374; LEHMANN J, 1988, EUR J PHARMACOL, V154, P89, DOI 10.1016/0014-2999(88)90368-8; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MONYER H, 1988, BRAIN RES, V446, P144, DOI 10.1016/0006-8993(88)91304-2; MONYER H, 1989, BRAIN RES, V483, P347, DOI 10.1016/0006-8993(89)90179-0; NAKAMARU Y, 1972, J GEN PHYSIOL, V59, P22, DOI 10.1085/jgp.59.1.22; NORENBERG MD, 1987, J NEUROPATH EXP NEUR, V46, P154, DOI 10.1097/00005072-198703000-00004; PENTTILA A, 1976, LIFE SCI, V18, P1419, DOI 10.1016/0024-3205(76)90359-3; PENTTILA A, 1974, SCIENCE, V185, P277, DOI 10.1126/science.185.4147.277; PHILIPSON KD, 1982, CIRC RES, V50, P287, DOI 10.1161/01.RES.50.2.287; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN S, 1988, J PHARMACOL EXP THER, V246, P137; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHURR A, 1988, BRAIN RES, V438, P311, DOI 10.1016/0006-8993(88)91354-6; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	46	180	183	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1516	1518		10.1126/science.8389056	http://dx.doi.org/10.1126/science.8389056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8389056				2022-12-28	WOS:A1993LF05800040
J	CONKLIN, BR; FARFEL, Z; LUSTIG, KD; JULIUS, D; BOURNE, HR				CONKLIN, BR; FARFEL, Z; LUSTIG, KD; JULIUS, D; BOURNE, HR			SUBSTITUTION OF 3 AMINO-ACIDS SWITCHES RECEPTOR SPECIFICITY OF G(Q)ALPHA TO THAT OF G(I)ALPHA	NATURE			English	Article							G-PROTEINS; ADRENERGIC-RECEPTOR; ADENYLYL CYCLASE; ALPHA-SUBUNITS; INHIBITION; RHODOPSIN; CLONING; SITE; GENE; IDENTIFICATION	AGONIST-BOUND receptors activate heterotrimeric (alphabetagamma) G proteins by catalysing replacement of GDP bound to the alpha-subunit by GTP1-5. Mutations in the C terminus of the alpha-subunit6,7, its covalent modification by pertussis toxin-catalysed ribosylation of ADP8, peptide-specific antibodies directed against it9-11, and peptides mimicking C-terminal sequences12, all inhibit receptor-mediated activation of G proteins. The logical prediction-that specific amino-acid residues at the C-termini of alpha-subunits can determine the abilities of individual G proteins to discriminate among specific subsets of receptors-has so far not been tested experimentally. Different hormone receptors specifically activate G(q) or G(i), whose alpha-subunits (alpha(q) or alpha(i)) stimulate phosphatidylinositol-specific phospholipase C or inhibit adenylyl cyclase, respectively1-5. Here we replace C-terminal amino acids of alpha(q) with the corresponding residues of alpha(i2) to create alpha(q)/alpha(i2) chimaeras that can mediate stimulation of phospholipase C by receptors otherwise coupled exclusively to G(i). A minimum of three alpha(i2) amino acids, including a glycine three residues from the C terminus, suffices to switch the receptor specificity of the alpha(q)/alpha(i2) chimaeras. We propose that a C-terminal turn, centred on this glycine, plays an important part in specifying receptor interactions of G proteins in the G(i)/G(o)/G(z) family.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, S1212 BOX 0450, SAN FRANCISCO, CA 94143 USA; TEL AVIV UNIV, CHAIM SHEBA MED CTR, DEPT MED E, IL-52621 TEL AVIV, ISRAEL; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Chaim Sheba Medical Center; Tel Aviv University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; AVIGAN J, 1992, BIOCHEMISTRY-US, V31, P7736, DOI 10.1021/bi00148a039; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; WEST RE, 1985, J BIOL CHEM, V260, P4428; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	37	596	647	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1993	363	6426					274	276		10.1038/363274a0	http://dx.doi.org/10.1038/363274a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8387644				2022-12-28	WOS:A1993LC86600056
J	MCGLADEMCCULLOH, E; YAMAMOTO, H; TAN, SE; BRICKEY, DA; SODERLING, TR				MCGLADEMCCULLOH, E; YAMAMOTO, H; TAN, SE; BRICKEY, DA; SODERLING, TR			PHOSPHORYLATION AND REGULATION OF GLUTAMATE RECEPTORS BY CALCIUM CALMODULIN-DEPENDENT PROTEIN KINASE-II	NATURE			English	Article							POSTSYNAPTIC DENSITY PROTEIN; MOLECULAR-CLONING; SUBUNIT; EXPRESSION; BRAIN; BINDING; KAINATE; SYSTEM; AMPA	THE major postsynaptic density (PSD) protein1,2 at glutaminergic synapses is calcium/calmodulin-dependent protein kinase II (CaM-K II), but its function in the PSD is not known. We have examined glutamate receptors (GluRs) as substrates for CaM-K II because (1) they are colocalized in the PSD3, (2) cloned GluRs4-7 contain consensus phosphorylation sites for protein kinases including CaM-K II, and (3) several GluRs are regulated by other protein kinases8-12. Regulation of GluRs, which are involved in excitatory synaptic transmission and in mechanisms of learning and memory13, by CaM-K II is of interest because of the postulated role of CaM-K II in synaptic plasticity14,15 and its known involvement in induction of long-term potentiation16. Furthermore, mice lacking the major neural isoform of CaM-K II exhibit deficits in models of learning and memory that require hippocampal input17,18. We report here that CaM-K II phosphorylates GluR in several in vitro systems, including the PSD, and that activated CaM-K II enhances kainate-induced ion current three- to fourfold in cultured hippocampal neurons. These results are consistent with a role for PSD CaM-K II in strengthening postsynaptic GluR responses in synaptic plasticity.	OREGON HLTH SCI UNIV,VOLLUM INST,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201	Oregon Health & Science University								BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KNAPP AG, 1990, P NATL ACAD SCI USA, V87, P767, DOI 10.1073/pnas.87.2.767; LESTER RAJ, 1989, MOL PHARMACOL, V35, P565; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; SIEKEVITZ P, 1985, P NATL ACAD SCI USA, V82, P3494, DOI 10.1073/pnas.82.10.3494; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SUMMNERS MD, 1988, TEXAS AGR EXPT STATI, V1555; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG LY, 1992, NEUR ABSTR, V18, P653; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WESTBROOK GL, 1989, SEMINARS NEUROSCIENC, V1, P103; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x	30	347	348	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					640	642		10.1038/362640a0	http://dx.doi.org/10.1038/362640a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8385275				2022-12-28	WOS:A1993KX43800051
J	HAAS, JS; UDVARHELYI, IS; MORRIS, CN; EPSTEIN, AM				HAAS, JS; UDVARHELYI, IS; MORRIS, CN; EPSTEIN, AM			THE EFFECT OF PROVIDING HEALTH COVERAGE TO POOR UNINSURED PREGNANT-WOMEN IN MASSACHUSETTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; EXPANSION	Objectives.-There has been substantial policy interest in whether the provision of health coverage to poor uninsured pregnant women affects access to prenatal care and birth outcomes. We therefore examined whether the statewide provision of health coverage to uninsured low-income pregnant women affects access to prenatal care and infant birth outcomes. Design.-Natural experiment. Patients.-All inhospital, single-gestation live births in 1984 (N=57257) and 1987 (N=64 346). Intervention.-In 1985, Massachusetts instituted Healthy Start, a program providing health coverage to uninsured pregnant women with incomes below 185% of the federal poverty level. Main Outcome Measures.-Rates of satisfactory prenatal care, care initiated before the third trimester, and adverse infant outcome for uninsured women and for two concurrent control groups, women with Medicaid, and women with private insurance. We calculated the difference in rates between the uninsured and each concurrent control. To assess the effect of the program, we examined the change in these interpayer differences in rates between 1984 and 1987. Main Results.-Between 1984 and 1987, the rate of satisfactory prenatal care declined from 96.4% to 93.8% for all women in Massachusetts (P<.001). There was no statewide change in the overall incidence of adverse birth outcome (6.6% in both years). In 1984, uninsured women were less likely than privately insured women to receive satisfactory prenatal care (90.5% and 98.1 %, respectively; interpayer difference, -7.6%) and to initiate care before the third trimester (94.2% and 99.1 %; interpayer difference, -4.9%), and were more likely to suffer an adverse birth outcome (7.1 % and 5.8%; interpayer difference, 1.3%). Between 1984 and 1987, there were no statistically significant changes in the interpayer differences in rates for any of the outcome measures relative to either control group. Conclusions.-Our findings suggest that access to prenatal care may have declined for all women in Massachusetts between 1984 and 1987. In the setting of this statewide decline in access, the expansion of health coverage to uninsured low-income pregnant women was not associated with an improvement in access to prenatal care or birth outcomes.	HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B,1ST FLOOR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, HLTH SERV & POLICY RES SECT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health				HAAS, JENNIFER/0000-0001-7227-851X				ALEXANDER GR, 1991, AM J PUBLIC HEALTH, V81, P1013, DOI 10.2105/AJPH.81.8.1013; AZZARA CV, 1988, HLTH START PROGRAM E; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; GOLD LB, 1987, BLESSED EVENTS BOTTO; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GUYER B, 1990, CHILDREN CHANGING HL, P297; HILL IT, 1989, COORDINATING PRENATA; Kessner DM, 1973, CONTRASTS HLTH STATU; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MILLER CL, 1989, AM J PUBLIC HEALTH, V79, P62, DOI 10.2105/AJPH.79.1.62; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; ROSENBAUM S, 1988, MED CARE, V26, P315, DOI 10.1097/00005650-198804000-00002; ROSENBAUM S, 1991, HLTH AM CHILDREN; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; TAFFEL S, 1980, VITAL HLTH STATIS 21, V37; TORRES A, 1989, FAM PLANN PERSPECT, V21, P19, DOI 10.2307/2135414; WEGMAN ME, 1990, PEDIATRICS, V86, P835; 1987, GAOHRD87137 US GEN A; 1980, PHS801260 US DEP HLT; 1988, OBSTETRIC GYNECOLOGI	20	98	98	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					87	91		10.1001/jama.269.1.87	http://dx.doi.org/10.1001/jama.269.1.87			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416413				2022-12-28	WOS:A1993KF02600034
J	HENSEL, WA				HENSEL, WA			GIVEN THE CHOICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					50	50						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416405				2022-12-28	WOS:A1993KF02600025
J	AUCOUTURIER, P; KHAMLICHI, AA; TOUCHARD, G; JUSTRABO, E; COGNE, M; CHAUFFERT, B; MARTIN, F; PREUDHOMME, JL				AUCOUTURIER, P; KHAMLICHI, AA; TOUCHARD, G; JUSTRABO, E; COGNE, M; CHAUFFERT, B; MARTIN, F; PREUDHOMME, JL			HEAVY-CHAIN DEPOSITION DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							IMMUNOGLOBULINS		FAC SCI POITIERS,F-86022 POITIERS,FRANCE; UNIV HOSP POITIERS,DEPT NEPHROL,POITIERS,FRANCE; UNIV HOSP DIJON,DEPT PATHOL,DIJON,FRANCE; UNIV HOSP DIJON,HUMAN & EXPTL DIGEST CANC UNIT,INSERM,U252,DIJON,FRANCE	Universite de Poitiers; CHU Poitiers; Universite de Poitiers; CHU Dijon Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	AUCOUTURIER, P (corresponding author), CHU POITIERS,CNRS,IMMUNOL & MOLEC INTERACT LAB,UNITE RECH ASSOCIEE 1172,BP 577,F-86021 POITIERS,FRANCE.		cogné, michel/D-7370-2015	cogné, michel/0000-0002-8519-4427; Khamlichi, Ahmed Amine/0000-0002-6523-2035				BRIAULT S, 1988, CLIN EXP IMMUNOL, V74, P182; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; COGNE M, 1992, BLOOD, V79, P2181; EULITZ M, 1990, P NATL ACAD SCI USA, V87, P6542, DOI 10.1073/pnas.87.17.6542; KABAT EA, 1991, DHHS NIH913242 PUBL, V1, P324; KELLY PJ, 1992, J IMMUNOL, V148, P1294; PREUDHOMME JL, 1980, CLIN EXP IMMUNOL, V42, P545; RADL J, 1990, IMMUNOL TODAY, V11, P234, DOI 10.1016/0167-5699(90)90096-R; RANDALL RE, 1976, AM J MED, V60, P293, DOI 10.1016/0002-9343(76)90440-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	10	90	96	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1389	1393		10.1056/NEJM199311043291905	http://dx.doi.org/10.1056/NEJM199311043291905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413435	Green Submitted, Bronze			2022-12-28	WOS:A1993MD94900005
J	BREWER, TF; WILSON, ME; GONZALEZ, E; FELSENSTEIN, D				BREWER, TF; WILSON, ME; GONZALEZ, E; FELSENSTEIN, D			BACON THERAPY AND FURUNCULAR MYIASIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DERMATOBIA-HOMINIS; CUTANEOUS MYIASIS; TUMBU FLY; LARVAE	Objective.-To evaluate a simple, noninvasive method for removing fly larvae from patients with furuncular myiasis. Design.-Case series. Setting.-Ambulatory office of a tertiary care center. Patients.-Three patients who presented with Dermatobia hominis infestation. Intervention.-The patients with D hominis infestation were treated with the application of bacon fat over the larval apertures. Main Outcome Measure.-Removal of intact larvae. Results.-Within 3 hours of the application of bacon, the larvae had migrated sufficiently far out of the skin to be removed with tweezers. Ten larvae were removed with this method. There were no treatment failures or complications. Conclusions.-Furuncular myiasis will be seen more frequently in temperate areas as individuals travel to endemic areas. We describe the clinical characteristics of myiasis and a simple method of treatment that permits rapid diagnosis and cure.	MASSACHUSETTS GEN HOSP, DEPT DERMATOL, BOSTON, MA 02114 USA; MT AUBURN HOSP, DIV INFECT DIS, CAMBRIDGE, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Mount Auburn Hospital	BREWER, TF (corresponding author), MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, GRAY 5, BOSTON, MA 02114 USA.							BAKOS L, 1979, BRIT J DERMATOL, V100, P223, DOI 10.1111/j.1365-2133.1979.tb05565.x; Beaver PC, 1984, CLIN PARASITOLOGY, P685; CHOPRA A, 1985, LANCET, V1, P1165; DAVIS E, 1982, HOSP PRACT, V17, P115; DONDERO TJ, 1979, SOUTHERN MED J, V72, P1508, DOI 10.1097/00007611-197912000-00005; EVERETT ED, 1977, ARCH DERMATOL, V113, P1122, DOI 10.1001/archderm.113.8.1122b; FARRELL LD, 1987, AM FAM PHYSICIAN, V35, P127; FILE TM, 1985, ARCH DERMATOL, V121, P1195, DOI 10.1001/archderm.121.9.1195; HUBLER WR, 1974, ARCH DERMATOL, V110, P109, DOI 10.1001/archderm.110.1.109; IANNINI PB, 1975, JAMA-J AM MED ASSOC, V233, P1375, DOI 10.1001/jama.233.13.1375; JAMES AS, 1992, ARCH EMERG MED, V9, P58; KLEEMAN FJ, 1983, NEW ENGL J MED, V308, P847; NUNZI E, 1986, ARCH DERMATOL, V122, P140, DOI 10.1001/archderm.122.2.140; PALLAI L, 1992, AM J MED SCI, V303, P245, DOI 10.1097/00000441-199204000-00007; PAMPIGLIONE S, 1992, BRIT J DERMATOL, V126, P418, DOI 10.1111/j.1365-2133.1992.tb00698.x; ROBERTS LW, 1982, J MED ENTOMOL, V19, P350, DOI 10.1093/jmedent/19.3.350; ROSSI MA, 1973, AM J TROP MED HYG, V22, P267, DOI 10.4269/ajtmh.1973.22.267; RUCH DM, 1967, ARCH DERMATOL, V96, P677, DOI 10.1001/archderm.96.6.677; RYAN ME, 1984, PEDIATR INFECT DIS J, V3, P135, DOI 10.1097/00006454-198403000-00012; SCHEMBRE DB, 1990, CAN J SURG, V33, P145; SWEET RD, 1962, BRIT J DERMATOL, V74, P141, DOI 10.1111/j.1365-2133.1962.tb13477.x; WILDY GS, 1982, LANCET, V1, P1130; WIRTZ RA, 1991, HUNTERS TROPICAL MED, P900; 1972, BMJ, V1, P58	24	80	83	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2087	2088		10.1001/jama.270.17.2087	http://dx.doi.org/10.1001/jama.270.17.2087			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411575				2022-12-28	WOS:A1993MD88200029
J	ATTALI, B; GUILLEMARE, E; LESAGE, F; HONORE, E; ROMEY, G; LAZDUNSKI, M; BARHANIN, J				ATTALI, B; GUILLEMARE, E; LESAGE, F; HONORE, E; ROMEY, G; LAZDUNSKI, M; BARHANIN, J			THE PROTEIN ISK IS A DUAL ACTIVATOR OF K+ AND CL- CHANNELS	NATURE			English	Article								THE protein IsK (M(r) 14,500) is present in epithelial cells1, heart2,3, uterus4 and lymphocytes5 and induces slowly activating K+ currents when expressed in Xenopus oocytes1. The finding that mutations of its single transmembrane segment altered channel gating6 or selectivity7 has suggested that IsK is a channel-forming protein. But IsK does not exhibit the K+ channel hallmarks8 (a conserved K+ selective pore (H5) flanked by either six9-11 or two 12,13 membrane-spanning regions). Here we report that IsK expression in Xenopus oocytes also induces a Cl- selective current very similar to the Cl- current produced by phospholemman expression14 and wit h biophysical, pharmacological and regulation characteristics very different from those of the IsK-induced K+ channel activity. IsK mutagenesis identifies amino- and carboxy-terminal domains as critical for the induction of Cl- and K+ channel activities, respectively. Our data lead to a model in which the IsK protein (now called IsK, Cl) acts as a potent activator of endogenous and otherwise silent K+ or Cl- channels.	SOPHIA ANTIPOLIS,CNRS,INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; HONORE, Eric/0000-0002-8007-0919				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ATTALI B, 1992, J BIOL CHEM, V267, P8650; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; BUSCH AE, 1992, BIOCHEM BIOPH RES CO, V184, P804, DOI 10.1016/0006-291X(92)90661-4; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HONORE E, 1992, BIOCHEM BIOPH RES CO, V184, P1135, DOI 10.1016/S0006-291X(05)80001-4; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754	22	126	128	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					850	852		10.1038/365850a0	http://dx.doi.org/10.1038/365850a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413671				2022-12-28	WOS:A1993MD95100054
J	MAMMANO, F; ASHMORE, JF				MAMMANO, F; ASHMORE, JF			REVERSE TRANSDUCTION MEASURED IN THE ISOLATED COCHLEA BY LASER MICHELSON INTERFEROMETRY	NATURE			English	Article								IT is thought that the sensitivity of mammalian hearing depends on amplification of the incoming sound within the cochlea by a select population of sensory cells, the outer hair cells. It has been suggested that these cells sense displacements and feedback forces which enhance the basilar membrane motion by reducing the inherent damping of the cochlear partition1-7. In support of this hypothesis, outer hair cells show membrane-potential-induced length changes1-3 at acoustic rates. This process has been termed 'reverse transduction'. For amplification, the forces should be large enough to move the basilar membrane. Using a displacement-sensitive interferometer8, we tested this hypothesis in an isolated cochlea while stimulating the outer hair cells with current passed across the partition. We show here that the cochlear partition distorts under the action of electrically driven hair cell length changes and produces place-specific vibration of the basilar membrane of a magnitude comparable to that observed near auditory threshold (about 1 nm). Such measurements supply direct evidence that cochlear amplification arises from the properties of the outer hair cell population.	SCH MED SCI,DEPT PHYSIOL,UNIV WALK,BRISTOL BS8 1TD,ENGLAND	University of Bristol			Mammano, Fabio/I-5064-2012; Mammano, Fabio/AAM-3902-2020	Mammano, Fabio/0000-0003-3751-1691; Mammano, Fabio/0000-0003-3751-1691	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1986, NATURE, V322, P368, DOI 10.1038/322368a0; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1984, HEARING RES, V14, P281, DOI 10.1016/0378-5955(84)90055-8; DALLOS P, 1988, AUDITORY FUNCTION NE, P153; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; DAVIS H, 1958, Laryngoscope, V68, P359; EVANS B N, 1988, Society for Neuroscience Abstracts, V14, P800; Evans E F, 1981, Ciba Found Symp, V85, P108; GREENWOOD DD, 1990, J ACOUST SOC AM, V87, P2592, DOI 10.1121/1.399052; HUBBARD A, 1993, SCIENCE, V259, P68, DOI 10.1126/science.8418496; HUBBARD AE, 1983, SCIENCE, V222, P510, DOI 10.1126/science.6623090; KOLSTON PJ, 1989, J ACOUST SOC AM, V86, P133, DOI 10.1121/1.398332; MAMMANO F, 1993, J ACOUST SOC AM, V93, P3320, DOI 10.1121/1.405716; MAMMANO F, 1992, J PHYSIOL-LONDON, V452, pP169; MCFADDEN D, 1984, J ACOUST SOC AM, V76, P443, DOI 10.1121/1.391585; NEELY ST, 1986, J ACOUST SOC AM, V79, P1472, DOI 10.1121/1.393674; NUTTALL AL, 1991, HEARING RES, V51, P203, DOI 10.1016/0378-5955(91)90037-A; REUTER G, 1992, HEARING RES, V60, P236, DOI 10.1016/0378-5955(92)90025-I; REUTER G, 1990, HEARING RES, V43, P219, DOI 10.1016/0378-5955(90)90230-M; RUGGERO MA, 1991, J NEUROSCI, V11, P1057; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; STYPULKOWSKI PH, 1990, HEARING RES, V46, P113, DOI 10.1016/0378-5955(90)90144-E; ULFENDAHL M, 1989, HEARING RES, V40, P55, DOI 10.1016/0378-5955(89)90099-3	28	170	175	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					838	841		10.1038/365838a0	http://dx.doi.org/10.1038/365838a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413667				2022-12-28	WOS:A1993MD95100050
J	KUHN, R; LOHLER, J; RENNICK, D; RAJEWSKY, K; MULLER, W				KUHN, R; LOHLER, J; RENNICK, D; RAJEWSKY, K; MULLER, W			INTERLEUKIN-10-DEFICIENT MICE DEVELOP CHRONIC ENTEROCOLITIS	CELL			English	Article							INHIBITS CYTOKINE PRODUCTION; CELL STIMULATORY FACTOR; T-CELLS; MONOCLONAL-ANTIBODY; B-CELLS; ACTIVATED MACROPHAGES; TARGETED DISRUPTION; INTERFERON-GAMMA; DOWN-REGULATION; STEM-CELLS	Interleukin-10 (IL-10) affects the growth and differentiation of many hemopoietic cells in vitro; in particular, it is a potent suppressor of macrophage and T cell functions. In IL-10-deficient mice, generated by gene targeting, lymphocyte development and antibody responses are normal, but most animals are growth retarded and anemic and suffer from chronic enterocolitis. Alterations in intestine include extensive mucosal hyperplasia, inflammatory reactions, and aberrant expression of major histocompatibility complex class II molecules on epithelia. In contrast, mutants kept under specific pathogen-free conditions develop only a local inflammation limited to the proximal colon. These results indicate that the bowel inflammation in the mutants originates from uncontrolled immune responses stimulated by enteric antigens and that IL-10 is an essential immunoregulator in the intestinal tract.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY; DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, PALO ALTO, CA 94304 USA	Heinrich Pette Institute; University of Hamburg; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	KUHN, R (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Kühn, Ralf/U-1278-2017; Muller, Werner/B-9044-2008	Kühn, Ralf/0000-0003-1694-9803; Muller, Werner/0000-0002-1297-9725				BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BOLLI, 1991, PRAKTISCHE BLUTZELLD; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Grutzmann R., 1981, THESIS U COLOGNE COL; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; ISHIDA H, 1992, J EXP MED, V175, P1213, DOI 10.1084/jem.175.5.1213; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KASSAI T, 1982, HDB NIPPOSTRONGYLUS; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; KIM JM, 1992, J IMMUNOL, V148, P3618; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MALEFYT RD, 1992, CURR OPIN IMMUNOL, V4, P314, DOI 10.1016/0952-7915(92)90082-P; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MEANS RT, 1992, J AM SOC HEMATOL, V80, P1639; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; MOSMANN TR, 1990, J IMMUNOL, V145, P2938; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OGARRA A, 1992, EUR J IMMUNOL, V22, P711, DOI 10.1002/eji.1830220314; RIZZO LV, 1992, J IMMUNOL, V22, P711; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SARTOR RB, 1990, CAN J GASTROENTEROL, V4, P271; SCHMITZ J, 1993, EUR J IMMUNOL, V23, P191, DOI 10.1002/eji.1830230130; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHER A, 1991, J IMMUNOL, V147, P2713; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x	54	3516	3611	3	153	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					263	274		10.1016/0092-8674(93)80068-P	http://dx.doi.org/10.1016/0092-8674(93)80068-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402911				2022-12-28	WOS:A1993MD88500008
J	STONE, BL; THUMMEL, CS				STONE, BL; THUMMEL, CS			THE DROSOPHILA 78C EARLY-LATE PUFF CONTAINS E78, AN ECDYSONE-INDUCIBLE GENE THAT ENCODES A NOVEL MEMBER OF THE NUCLEAR HORMONE-RECEPTOR SUPERFAMILY	CELL			English	Article							RETINOIC ACID RECEPTOR; POLYTENE CHROMOSOMES; DNA-BINDING; SALIVARY-GLANDS; HEPATOCELLULAR-CARCINOMA; MELANOGASTER; PROTEIN; TRANSCRIPTION; ACTIVATION; EXPRESSION	We report the molecular definition of an early late puff locus, at position 78C, that is inducible by ecdysone at the onset of Drosophila metamorphosis. This puff contains a single ecdysone-inducible gene consisting of two nested transcription units, E78A and E78B. E78A mRNA is expressed during a brief interval in mid-pupal development and encodes a novel member of the nuclear hormone receptor superfamily. E78B encodes a truncated receptor isoform that lacks the DNA-binding domain and is predominantly expressed at puparium formation and immediately following E78A in pupae. E78B is directly inducible by ecdysone in late third instar larvae and depends on ecdysone-induced protein synthesis for its maximal level of expression. These observations indicate that E78 represents a distinct subset of early ecdysone-inducible regulatory genes.			STONE, BL (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112, USA.				NIGMS NIH HHS [GM40905] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040905] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES AJ, 1992, TRENDS GENET, V8, P132, DOI 10.1016/0168-9525(92)90079-J; ANDRES AJ, 1992, DEVELOPMENT, V116, P865; ANDRES AJ, 1993, IN PRESS DEV BIOL; ASHBURNER M, 1972, CHROMOSOMA, V38, P255, DOI 10.1007/BF00290925; ASHBURNER M, 1967, CHROMOSOMA, V21, P398, DOI 10.1007/BF00336950; ASHBURNER M, 1976, DEV BIOL, V54, P241, DOI 10.1016/0012-1606(76)90302-X; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; ASHBURNER M, 1973, DEV BIOL, V35, P47, DOI 10.1016/0012-1606(73)90006-7; AYER S, 1993, NUCLEIC ACIDS RES, V21, P1619, DOI 10.1093/nar/21.7.1619; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER HJ, 1959, CHROMOSOMA, V10, P654, DOI 10.1007/BF00396591; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BOYD L, 1991, DEVELOPMENT, V112, P981; BOYD L, 1993, IN PRESS P NATL ACAD; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; Bridges PN, 1941, J HERED, V32, P64, DOI 10.1093/oxfordjournals.jhered.a104998; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHAO AT, 1986, EMBO J, V5, P143, DOI 10.1002/j.1460-2075.1986.tb04188.x; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DIBELLO PR, 1991, GENETICS, V129, P385; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GOLDBERG M, 1981, THESIS STANFORD U ST; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUAY PS, 1991, GENETICS, V129, P169; HANDLER AM, 1982, DEV BIOL, V93, P73, DOI 10.1016/0012-1606(82)90240-8; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HILL RJ, 1993, INSECT BIOCHEM MOLEC, V23, P99, DOI 10.1016/0965-1748(93)90087-9; HUET F, 1993, DEVELOPMENT, V118, P613; IRVINE KD, 1991, DEVELOPMENT, V111, P407; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KARIM FD, 1993, DEVELOPMENT, V118, P977; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1993, IN PRESS P NATL ACAD; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OHNO CK, 1993, MECH DEVELOP, V40, P13, DOI 10.1016/0925-4773(93)90084-B; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PAK MD, 1987, J LIQ CHROMATOGR, V10, P2591, DOI 10.1080/01483918708066815; PALLI SR, 1992, DEV BIOL, V150, P306, DOI 10.1016/0012-1606(92)90244-B; Parkhurst Susan M., 1992, Current Biology, V2, P629, DOI 10.1016/0960-9822(92)90097-T; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; RESTIFO LL, 1986, J MOL BIOL, V188, P517, DOI 10.1016/S0022-2836(86)80002-X; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; Richards Geoff, 1992, Current Biology, V2, P657, DOI 10.1016/0960-9822(92)90123-R; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; Sambrook J, 1989, MOL CLONING LABORATO; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SEGRAVES WA, 1988, THESIS STANFORD U ST; SEMESHIN VF, 1985, CHROMOSOMA, V91, P210, DOI 10.1007/BF00328218; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SLITER TJ, 1992, GENETICS, V130, P555; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANDOREN M, 1991, DEVELOPMENT, V113, P245; WALKER VK, 1981, CELL, V26, P269, DOI 10.1016/0092-8674(81)90309-3; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	86	91	94	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					307	320		10.1016/0092-8674(93)80072-M	http://dx.doi.org/10.1016/0092-8674(93)80072-M			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402914				2022-12-28	WOS:A1993MD88500012
J	LEBWOHL, M				LEBWOHL, M			IMAGES IN CLINICAL MEDICINE - PSEUDOXANTHOMA ELASTICUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											LEBWOHL, M (corresponding author), MT SINAI MED CTR,NEW YORK,NY 10029, USA.								0	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1240	1240						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8413391				2022-12-28	WOS:A1993MB98800006
J	MORGENSTERN, L				MORGENSTERN, L			THE REST OF HIM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1816	1816		10.1001/jama.270.15.1816	http://dx.doi.org/10.1001/jama.270.15.1816			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411524				2022-12-28	WOS:A1993MB46400023
J	ESTEVEZ, M; ATTISANO, L; WRANA, JL; ALBERT, PS; MASSAGUE, J; RIDDLE, DL				ESTEVEZ, M; ATTISANO, L; WRANA, JL; ALBERT, PS; MASSAGUE, J; RIDDLE, DL			THE DAF-4 GENE ENCODES A BONE MORPHOGENETIC PROTEIN-RECEPTOR CONTROLLING C-ELEGANS DAUER LARVA DEVELOPMENT	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSFORMING GROWTH-FACTOR; SERINE THREONINE KINASE; VENTRALIZING FACTOR; MESSENGER-RNA; FAMILY; DIFFERENTIATION; TEMPERATURE; EXPRESSION; PHEROMONE	THE bone morphogenetic protein (BMP) family is a conserved group of signalling molecules within the transforming growth factor-beta (TGF-beta) superfamily1,2. This group, including the Drosophila decapentaplegic (dpp) protein and the mammalian BMPs, mediates cellular interactions and tissue differentiation during development3,4 . Here we show that a homologue of human BMPs controls a developmental switch in the life cycle of the free-living soil nematode Caenorhabditis elegans. Starvation and overcrowding induce C elegans to form a developmentally arrested, third-stage dauer larva5. The daf-4 gene, which acts to inhibit dauer larva formation and promote growth, encodes a receptor protein kinase similar to the daf-1, activin and TGF-beta receptor serine/threonine kinases. When expressed in monkey COS cells, the daf-4 receptor binds human BMP-2 and BMP-4. The daf-4 receptor is the first to be identified for any growth factor in the BMP family.	UNIV MISSOURI,DIV BIOL SCI,COLUMBIA,MO 65211; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	University of Missouri System; University of Missouri Columbia; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	ESTEVEZ, M (corresponding author), UNIV MISSOURI,MOLEC BIOL PROGRAM,311 TUCKER HALL,COLUMBIA,MO 65211, USA.		Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DALE L, 1992, DEVELOPMENT, V115, P573; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES D, 1986, J BIOL CHEM, V261, P2006; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1069; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MATTHEWS LS, 1991, CELL, V65, P973; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Sulston J., 1988, NEMATODE CAENORHABDI, P587; TRENT C, 1983, GENETICS, V104, P619; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681	31	333	357	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					644	649		10.1038/365644a0	http://dx.doi.org/10.1038/365644a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413626				2022-12-28	WOS:A1993MB84600058
J	LARDER, BA; KOHLI, A; KELLAM, P; KEMP, SD; KRONICK, M; HENFREY, RD				LARDER, BA; KOHLI, A; KELLAM, P; KEMP, SD; KRONICK, M; HENFREY, RD			QUANTITATIVE DETECTION OF HIV-1 DRUG-RESISTANCE MUTATIONS BY AUTOMATED DNA-SEQUENCING	NATURE			English	Article							TRANSCRIPTASE		APPL BIOSYST 850,FOSTER CITY,CA 94404; APPL BIOSYST LTD,WARRINGTON WA3 7PB,CHESHIRE,ENGLAND	Thermo Fisher Scientific; Applied Biosystems; Thermo Fisher Scientific; Applied Biosystems	LARDER, BA (corresponding author), WELLCOME FDN LTD,ANTIVIRAL THERAPEUT RES UNIT,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.		Larder, Brendan/AAB-3106-2020	Kohli, Arinder/0000-0003-3199-3554; Kellam, Paul/0000-0003-3166-4734				LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	7	168	171	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					671	673		10.1038/365671a0	http://dx.doi.org/10.1038/365671a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413632				2022-12-28	WOS:A1993MB84600066
J	YAN, RT; MALONEY, PC				YAN, RT; MALONEY, PC			IDENTIFICATION OF A RESIDUE IN THE TRANSLOCATION PATHWAY OF A MEMBRANE CARRIER	CELL			English	Article							MITOCHONDRIAL ASPARTATE GLUTAMATE; SUGAR PHOSPHATE-TRANSPORT; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; LAC PERMEASE; CYSTEINE RESIDUES; ANION-EXCHANGE; SH-REAGENTS; MUTANTS; DNA	Preliminary work using directed mutagenesis proved that cysteine is not required for operation of UhpT, the anion exchange protein responsible for glucose 6-phosphate transport by E. coll. We then made a detailed study of C143 and C265, because these cysteines impart sensitivity to p-chloromercuribenzosulfonate (PCMBS), a sulfhydral agent resembling glucose 6-phosphate in size, shape, and charge. We showed that C143 was exposed to the cytoplasm, as expected from hydropathy analysis, but we found no sidedness for C265. Rather, C265 was accessible to PCMBS from both membrane surfaces. And since the attack at C265 was blocked by glucose 6-phosphate, position 265 must lie directly on the pathway taken by the substrate as it moves through this membrane carrier.			YAN, RT (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21209, USA.				NIGMS NIH HHS [GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, R01GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, P NATL ACAD SCI USA, V83, P280, DOI 10.1073/pnas.83.2.280; AQUILA H, 1987, FEBS LETT, V212, P109; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; FOX CF, 1965, P NATL ACAD SCI USA, V54, P891, DOI 10.1073/pnas.54.3.891; Frederick M., 1989, CURRENT PROTOCOLS MO; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; HOCHHAUSER SJ, 1978, J BACTERIOL, V134, P157, DOI 10.1128/JB.134.1.157-166.1978; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JI, 1992, J BIOL CHEM, V267, P20758; LINDENTHAL S, 1991, P NATL ACAD SCI USA, V88, P6540, DOI 10.1073/pnas.88.15.6540; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MALONEY PC, 1990, RES MICROBIOL, V141, P374, DOI 10.1016/0923-2508(90)90015-I; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P162, DOI 10.1016/0006-291X(85)91002-2; MITCHELL P, 1953, J GEN MICROBIOL, V9, P273, DOI 10.1099/00221287-9-2-273; MITCHELL P, 1990, RES MICROBIOL, V141, P286, DOI 10.1016/0923-2508(90)90002-8; RAO US, 1990, J BIOL CHEM, V265, P7227; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SAIER MH, 1993, TRENDS BIOCHEM SCI, V18, P13; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR HK, 1986, J BIOL CHEM, V261, P8914; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WIDDAS WF, 1952, J PHYSIOL-LONDON, V118, P23, DOI 10.1113/jphysiol.1952.sp004770; WIDDAS WF, 1988, BIOCHIM BIOPHYS ACTA, V947, P385, DOI 10.1016/0304-4157(88)90001-9; YAMOTO I, 1988, J BIOL CHEM, V263, P16055	39	72	73	16	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					37	44		10.1016/S0092-8674(05)80082-0	http://dx.doi.org/10.1016/S0092-8674(05)80082-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402899				2022-12-28	WOS:A1993MB66700006
J	DENARIE, J; CULLIMORE, J				DENARIE, J; CULLIMORE, J			LIPO-OLIGOSACCHARIDE NODULATION FACTORS - A MINIREVIEW NEW CLASS OF SIGNALING MOLECULES MEDIATING RECOGNITION AND MORPHOGENESIS	CELL			English	Review							SYMBIOTIC HOST-SPECIFICITY; RHIZOBIUM-MELILOTI; ROOT NODULE; PLANT; ALFALFA; LIPOOLIGOSACCHARIDES; FAMILY; MOIETY				DENARIE, J (corresponding author), INRA,CNRS,BIOL MOLEC RELAT PLANTES MICROORGANISMS LAB,F-31326 CASTANET TOLOSAN,FRANCE.			Cullimore, Julie/0000-0001-8804-4849				DEJONG AJ, 1993, PLANT CELL, V5, P615, DOI 10.2307/3869804; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; EHRHARDT DW, 1992, SCIENCE, V256, P998, DOI 10.1126/science.10744524; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; HORVATH B, 1993, PLANT J, V4, P727, DOI 10.1046/j.1365-313X.1993.04040727.x; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; NAP JP, 1990, SCIENCE, V250, P948, DOI 10.1126/science.250.4983.948; NICOLAOU KC, 1992, J AM CHEM SOC, V114, P8701, DOI 10.1021/ja00048a054; PALACIOS R, 1993, NEW HORIZONS NITROGE; PICHON M, 1992, PLANT CELL, V4, P1199, DOI 10.1105/tpc.4.10.1199; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; RYAN CA, 1991, ANNU REV PLANT PHYS, V42, P651, DOI 10.1146/annurev.pp.42.060191.003251; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VANBRUSSEL AAN, 1992, SCIENCE, V257, P70, DOI 10.1126/science.257.5066.70	20	250	257	3	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					951	954		10.1016/0092-8674(93)90717-5	http://dx.doi.org/10.1016/0092-8674(93)90717-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402884				2022-12-28	WOS:A1993LY49300002
J	MILLER, C				MILLER, C			POTASSIUM SELECTIVITY IN PROTEINS - OXYGEN CAGE OR IN THE F-ACE	SCIENCE			English	Editorial Material							MOLECULAR RECOGNITION; ION; CHANNELS; BINDING; MEDIA		BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University	MILLER, C (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.							BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Dobler M., 1981, IONOPHORES THEIR STR; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; EISENMAN G, 1962, Biophys J, V2, P259; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1991, IONIC CHANNELS EXCIT; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; RENNER M, 1993, P NATL ACAD SCI USA, V90, P6493, DOI 10.1073/pnas.90.14.6493; SHEPODD TJ, 1988, J AM CHEM SOC, V110, P1983, DOI 10.1021/ja00214a063; SNYDER EE, 1990, BIOCHEMISTRY-US, V29, P3937, DOI 10.1021/bi00468a021; STAUFFER DA, 1988, TETRAHEDRON LETT, V29, P6039, DOI 10.1016/S0040-4039(00)82259-5; SUNNER J, 1981, J PHYS CHEM-US, V85, P1814, DOI 10.1021/j150613a011; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040	16	54	54	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1692	1693		10.1126/science.8397443	http://dx.doi.org/10.1126/science.8397443			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8397443				2022-12-28	WOS:A1993LY58400014
J	PLASTERK, RHA				PLASTERK, RHA			MOLECULAR MECHANISMS OF TRANSPOSITION AND ITS CONTROL	CELL			English	Review							TRANSPOSABLE ELEMENT; CAENORHABDITIS-ELEGANS; P-ELEMENTS; DROSOPHILA; DNA; RECOMBINATION; MU; IDENTIFICATION; PROTEINS; ORIGIN				PLASTERK, RHA (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.							AARTS MGM, 1993, NATURE, V363, P715, DOI 10.1038/363715a0; [Anonymous], 1988, NEW PHILOS BIOL OBSE; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, IN PRESS CELL, V74; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BUCHETON A, 1992, GENETICA, V86, P175, DOI 10.1007/BF00133719; CURCIO MJ, 1992, MOL CELL BIOL, V12, P2813, DOI 10.1128/MCB.12.6.2813; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DOMBROMSKI BA, 1993, IN PRESS P NATL ACAD; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1992, BIOESSAYS, V14, P681, DOI 10.1002/bies.950141007; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GARCIAFERNANDEZ J, 1993, NATURE, V364, P109, DOI 10.1038/364109a0; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; HANIFORD DB, 1991, CELL, V64, P171; HEINKOFF S, 1992, NEW BIOL, V4, P382; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; KIDWELL MG, 1992, GENETICA, V86, P275, DOI 10.1007/BF00133726; LASKI FA, 1989, GENE DEV, V3, P720, DOI 10.1101/gad.3.5.720; LEMAITRE B, 1993, IN PRESS GENETICS; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MORENO MA, 1992, GENETICS, V131, P939; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; RIO DC, 1988, P NATL ACAD SCI USA, V85, P8929, DOI 10.1073/pnas.85.23.8929; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; ROBERTSON HM, 1993, IN PRESS INSECT MOL; RONSSERAY S, 1993, IN PRESS MOL GEN GEN; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUSHFORTH AM, 1993, MOL CELL BIOL, V13, P902, DOI 10.1128/MCB.13.2.902; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; TAUSTA SL, 1989, CELL, V59, P1019, DOI 10.1016/0092-8674(89)90758-7; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; ZHANG P, 1993, GENETICS, V133, P361; ZWAAL RR, 1993, IN PRESS P NATL ACAD, V90	41	34	36	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					781	786		10.1016/0092-8674(93)90458-3	http://dx.doi.org/10.1016/0092-8674(93)90458-3			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8397072				2022-12-28	WOS:A1993LX29200004
J	TEAHON, K; BATEMAN, DN				TEAHON, K; BATEMAN, DN			A SURVEY OF INTRAVENOUS DRUG ADMINISTRATION BY PREREGISTRATION HOUSE OFFICERS	BRITISH MEDICAL JOURNAL			English	Article							WORKLOAD				TEAHON, K (corresponding author), REG DRUG & THERAPEUT CTR,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 4LP,ENGLAND.			Bateman, David Nicholas/0000-0002-8971-862X				BAIN PG, 1990, BRIT MED J, V300, P1463; CUNNINGHAM S, 1990, BRIT MED J, V300, P1342; DYER C, 1991, BRIT MED J, V303, P1218, DOI 10.1136/bmj.303.6812.1218; LESLIE PJ, 1990, BRIT MED J, V300, P1038, DOI 10.1136/bmj.300.6731.1038; TOMFORD JW, 1984, ARCH INTERN MED, V144, P1191, DOI 10.1001/archinte.144.6.1191	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					605	606		10.1136/bmj.307.6904.605	http://dx.doi.org/10.1136/bmj.307.6904.605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401018	Bronze, Green Published			2022-12-28	WOS:A1993LW14900019
J	AERDTS, SJA; CLASENER, HAL; BLAIR, PHB; ROWLANDS, BJ; BRUNBUISSON, C; LEGRAND, P; CERRA, FB; DUNN, D; COCKERILL, FR; THOMPSON, RL; FERRER, M; TORRES, A; GASTINNE, H; WOLFF, M; GAUSSORGUES, P; GODARD, J; MOTIN, J; HAMMOND, JMJ; POTGIETER, PD; HUNEFELD, G; JACOBS, S; FOWERAKER, JE; KERVER, AJH; ROMMERS, JH; KORINEK, AM; LAISNE, MJ; MARTINEZPELLUZ, A; RODRIGUEZROLDAN, J; PALOMAR, M; ALVAREZ, F; PUGIN, J; SUTER, PM; ROCHA, LA; VILLANUEVA, R; ROLANDO, N; WILLIAMS, R; SANCHEZGARCIA, M; CAMBRONEROGALACHE, JA; TETTEROO, GWM; BRUINING, HA; ULRICH, C; DEWEERD, JEH; UNERTL, K; PETER, K; VERHAEGEN, J; VERWAEST, L; WINTER, R; HUMPHREYS, H				AERDTS, SJA; CLASENER, HAL; BLAIR, PHB; ROWLANDS, BJ; BRUNBUISSON, C; LEGRAND, P; CERRA, FB; DUNN, D; COCKERILL, FR; THOMPSON, RL; FERRER, M; TORRES, A; GASTINNE, H; WOLFF, M; GAUSSORGUES, P; GODARD, J; MOTIN, J; HAMMOND, JMJ; POTGIETER, PD; HUNEFELD, G; JACOBS, S; FOWERAKER, JE; KERVER, AJH; ROMMERS, JH; KORINEK, AM; LAISNE, MJ; MARTINEZPELLUZ, A; RODRIGUEZROLDAN, J; PALOMAR, M; ALVAREZ, F; PUGIN, J; SUTER, PM; ROCHA, LA; VILLANUEVA, R; ROLANDO, N; WILLIAMS, R; SANCHEZGARCIA, M; CAMBRONEROGALACHE, JA; TETTEROO, GWM; BRUINING, HA; ULRICH, C; DEWEERD, JEH; UNERTL, K; PETER, K; VERHAEGEN, J; VERWAEST, L; WINTER, R; HUMPHREYS, H			METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT	BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE UNIT; CRITICALLY ILL PATIENTS; DOUBLE-BLIND; VENTILATED PATIENTS; CLINICAL-TRIALS; INTESTINAL DECONTAMINATION; NOSOCOMIAL INFECTION; PREVENTION; COLONIZATION; PROPHYLAXIS	Objective-To determine the clinical benefits of selective decontamination of the digestive tract in patients treated in intensive care units. Design-Meta-analysis of 22 randomised trials that compared different combinations of oral non-absorbable antibiotics, with or without a systemic component, with no treatment in controls. Subjects-4142 patients seen in general and specialised intensive care units around the world. 2047 received some form of antibiotic treatment, the remainder no prophylaxis. Data analysis-Each trial was reviewed through direct contact with study investigators. Data collected were: the randomisation procedure, number of patients, number excluded from the analysis, and numbers of respiratory tract infections and deaths. Data were combined according to an intention to treat analysis with the Mantel-Haenszel-Peto method. Main outcome measures-Respiratory tract infections and total mortality. Results-Selective decontamination of the digestive tract significantly reduced respiratory tract infections (odds ratio 0.37; 95% confidence interval 0.31 to 0.43). The value of the common odds ratio for total mortality (0.90; 0.79 to 1.04) suggested at best a moderate treatment effect, reaching statistical significance only when the subgroup of trials of topical and systemic treatment combined was considered separately (odds ratio 0.80; 0.67 to 0.97). No firm conclusions could be drawn owing to large variations in patient mix and severity within and between trials. Conclusions-The findings strongly indicate that selective decontamination significantly reduces infection related morbidity in patients receiving intensive care. They also highlight why definite conclusions about the effect of prophylaxis on mortality cannot be drawn despite the large number of trials available. Based on the most favourable results obtained by pooling data from trials in which combined topical and systemic treatment was used it may be estimated that 6 (range 5-9) and 23 (13-139) patients would need to be treated to prevent one respiratory tract infection and one death respectively.	SOPHIA HOSP,ZWOLLE,NETHERLANDS; ROYAL VICTORIA HOSP,BELFAST BT12 6BA,NORTH IRELAND; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; HOSP CLIN BARCELONA,BARCELONA 36,SPAIN; HOP CROIX ROUSSE,LYON,FRANCE; HOP EDOUARD HERRIOT,F-69374 LYON 08,FRANCE; GROOTE SCHUUR HOSP,CAPE TOWN 7925,SOUTH AFRICA; EVANGEL KRANKENHAUS,GOTTINGEN,GERMANY; UNIV HOSP WALES,CARDIFF,WALES; ST FRANCISKUS HOSP,ROTTERDAM,NETHERLANDS; HOP PITIE SALPETRIER,PARIS,FRANCE; GEN HOSP,MURCIA,SPAIN; HOSP VALLE DE HEBRON,BARCELONA,SPAIN; UNIV GENEVA,HOP CANTONAL,CH-1211 GENEVA 4,SWITZERLAND; HOSP JUAN CANALEJO,LA CORUNA,SPAIN; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND; HOSP PPE AUSTRIAS,ALCALA DE HENARES,SPAIN; UNIV HOSP DIJKZIGT,ROTTERDAM,NETHERLANDS; WESTEINDE ZIEKENHUIS,THE HAGUE,NETHERLANDS; KLINIKUM GROSSHADERN,MUNICH,GERMANY; UNIV HOSP LOUVAIN,LOUVAIN,BELGIUM; UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; Mayo Clinic; University of Barcelona; Hospital Clinic de Barcelona; CHU Lyon; CHU Lyon; University of Cape Town; Cardiff University; Franciscus Gasthuis; Hospital Universitari Vall d'Hebron; University of Geneva; Complejo Hospitalario Universitario A Coruna; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Prince of Asturias University Hospital; Erasmus University Rotterdam; Erasmus MC; University of Munich; Universite Catholique Louvain; Universite Catholique Louvain Hospital; University of Nottingham			Humphreys, Hilary/C-9918-2012	Ferrer, Miguel/0000-0001-8171-6673				AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; BEGG CB, 1985, STAT MED, V4, P1, DOI 10.1002/sim.4780040103; BLAIR P, 1991, SURGERY, V110, P303; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, P254, DOI 10.1016/0197-2456(89)90067-6; BRAZZI L, 1992, REANIMATION URGENCES, V1, P501; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CERRA FB, 1992, ARCH SURG-CHICAGO, V127, P163; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FERRER M, 1992, American Review of Respiratory Disease, V145, pA112; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Gaussorgues P., 1991, REANIMATION SOINS IN, V7, P169; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; Hunefeld G, 1989, Anaesthesiol Reanim, V14, P131; Jacobs S., 1992, CLIN INTENSIVE CARE, V3, P52; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KORINEK AM, IN PRESS CRIT CARE M; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LIBERATI A, 1992, REANIMATION URGENCES, V1, P521; McGlynn E A, 1990, Int J Technol Assess Health Care, V6, P450; PALOMAR M, 1992, MED INTENSIVA, V16, P81; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1016/0270-9139(93)90076-Y; SANCHEZ M, 1992, 32ND P INT C ANT AG; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VANSAENE HF, 1992, CRIT CARE MED, V20, P691, DOI 10.1097/00003246-199205000-00024; VANSAENE HKF, 1993, J HOSP INFECT, V24, P158, DOI 10.1016/0195-6701(93)90079-F; VELLEMAN PF, 1981, AM STAT, V35, P234, DOI 10.2307/2683296; VERHAEGEN J, 1992, THESIS U LOUVAIN BEL; WEBB CH, 1992, J HOSP INFECT, V22, P1, DOI 10.1016/0195-6701(92)90125-6; WINTER R, 1992, J ANTIMICROB CHEMOTH, V30, P73, DOI 10.1093/jac/30.1.73; 1988, BMJ, V296, P320; 1992, INTENS CARE MED, V18, P182	41	153	155	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					525	532						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400971				2022-12-28	WOS:A1993LV18000014
J	KREIDBERG, JA; SARIOLA, H; LORING, JM; MAEDA, M; PELLETIER, J; HOUSMAN, D; JAENISCH, R				KREIDBERG, JA; SARIOLA, H; LORING, JM; MAEDA, M; PELLETIER, J; HOUSMAN, D; JAENISCH, R			WT-1 IS REQUIRED FOR EARLY KIDNEY DEVELOPMENT	CELL			English	Article							WILMS-TUMOR GENE; ZINC-FINGER GENE; WT1 GENE; EMBRYONIC KIDNEY; GROWTH-FACTOR; UROGENITAL DEVELOPMENT; ORGAN-CULTURE; WAGR SYNDROME; LOCUS; MUTATIONS	In humans, germline mutations of the WT-1 tumor suppressor gene are associated with both Wilms' tumors and urogenital malformations. To develop a model system for the molecular analysis of urogenital development, we introduced a mutation into the murine WT-1 tumor suppressor gene by gene targeting in embryonic stem cells. The mutation resulted in embryonic lethality in homozygotes, and examination of mutant embryos revealed a failure of kidney and gonad development. Specifically, at day 11 of gestation, the cells of the metanephric blastema underwent apoptosis, the ureteric bud failed to grow out from the Wolffian duct, and the inductive events that lead to formation of the metanephric kidney did not occur. In addition, the mutation caused abnormal development of the mesothelium, heart, and lungs. Our results establish a crucial role for WT-1 in early urogenital development.	UNIV HELSINKI,DEPT PATHOL,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,SF-00100 HELSINKI 10,FINLAND; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3A 2T5,QUEBEC,CANADA; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Helsinki; University of Helsinki; McGill University; McGill University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	KREIDBERG, JA (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NCI NIH HHS [5-R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BAIRD PN, 1992, ONCOGENE, V7, P2141; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COWELL JK, 1991, ONCOGENE, V6, P595; CROISILLE Y, 1976, TESTS TERATOGENICITY, P149; DAVIS LM, 1991, GENOMICS, V10, P588, DOI 10.1016/0888-7543(91)90440-P; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GLASER T, 1989, GENOMICS, V5, P880, DOI 10.1016/0888-7543(89)90130-4; GROBSTEIN C, 1953, SCIENCE, V118, P52, DOI 10.1126/science.118.3054.52; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1988, ANTIBODIES LABORATOR; HUFF V, 1991, AM J HUM GENET, V48, P997; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KLEINEBRECHT J, 1982, ANAT ANZEIGER, V152, P313; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MORRIS JF, 1991, ONCOGENE, V6, P2339; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J, 1989, MOL CLONING LABORATO; SAXEN L, 1976, NATURE, V259, P662, DOI 10.1038/259662a0; SAXEN L, 1987, DIFFERENTIATION, V36, P2, DOI 10.1111/j.1432-0436.1987.tb00176.x; Saxen L., 1987, ORGANOGENESIS KIDNEY; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4	52	1557	1602	1	60	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					679	691		10.1016/0092-8674(93)90515-R	http://dx.doi.org/10.1016/0092-8674(93)90515-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395349				2022-12-28	WOS:A1993LU59200011
J	CHEN, P; JOHNSON, P; SOMMER, T; JENTSCH, S; HOCHSTRASSER, M				CHEN, P; JOHNSON, P; SOMMER, T; JENTSCH, S; HOCHSTRASSER, M			MULTIPLE UBIQUITIN-CONJUGATING ENZYMES PARTICIPATE IN THE IN-VIVO DEGRADATION OF THE YEAST MAT-ALPHA-2 REPRESSOR	CELL			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATOR; PROTEIN-DEGRADATION; BETA-GALACTOSIDASE; GENE; RAD6; BIOGENESIS; ENCODES	Attachment of ubiquitin to proteins is catalyzed by a family of ubiquitin-conjugating (UBC) enzymes. Although these enzymes are essential for many cellular processes, their molecular functions remain unclear because no physiological target has been identified for any of them. Here we show that four UBC proteins (UBC4, UBC5, UBC6, and UBC7) target the yeast MATalpha2 transcriptional regulator for intracellular degradation by two distinct ubiquitination pathways. UBC6 and UBC7 define one of the pathways and can physically associate. The UBC6/UBC7-containing complex targets the Deg1 degradation signal of alpha2, a conclusion underscored by the finding that UBC6 is encoded by DOA2, a gene previously implicated in Deg1-mediated degradation. These data reveal an unexpected overlap in substrate specificity among diverse UBC enzymes and suggest a combinatorial mechanism of substrate selection in which UBC enzymes partition into multiple ubiquitination complexes.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,W-7400 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society	CHEN, P (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637, USA.			Hochstrasser, Mark/0000-0002-1131-5484	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046904, T32GM007183, R01GM046904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07183-18, GM46904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BELL JB, 1991, J BIOL CHEM, V266, P12662; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COOK WJ, 1992, J BIOL CHEM, V267, P15116; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1991, GENETIC ENG, P307; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; MYLIN LM, 1990, METHOD ENZYMOL, V185, P297; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; PRAKASH L, 1989, GENOME, V31, P597, DOI 10.1139/g89-111; QIN S, 1991, J BIOL CHEM, V266, P15549; RONNE H, 1988, P NATL ACAD SCI USA, V85, P2696, DOI 10.1073/pnas.85.8.2696; ROSE M, 1981, P NATL ACAD SCI-BIOL, V78, P2460, DOI 10.1073/pnas.78.4.2460; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sherman F., 1986, METHODS YEAST GENETI; SILICIANO PG, 1986, P NATL ACAD SCI USA, V83, P2320, DOI 10.1073/pnas.83.8.2320; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Stryer L., 1988, BIOCHEMISTRY-US; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VASSAL A, 1992, BIOCHIM BIOPHYS ACTA, V1132, P211, DOI 10.1016/0167-4781(92)90015-R; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	45	290	299	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					357	369		10.1016/0092-8674(93)90426-Q	http://dx.doi.org/10.1016/0092-8674(93)90426-Q			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8393731				2022-12-28	WOS:A1993LP72600016
J	LEE, HC; AARHUS, R; WALSETH, TF				LEE, HC; AARHUS, R; WALSETH, TF			CALCIUM MOBILIZATION BY DUAL RECEPTORS DURING FERTILIZATION OF SEA-URCHIN EGGS	SCIENCE			English	Article							CYCLIC ADP-RIBOSE; RELEASE; METABOLITE; NAD+; TISSUES; ENZYME	Fertilization is accompanied by a transient increase in the concentration of intracellular Ca2+, which serves as a signal for initiating development. Some of the Ca2+ appears to be released from intracellular stores by the binding of inositol trisphosphate (IP3) to its receptor. However, in sea urchin eggs, other mechanisms appear to participate. Cyclic adenosine diphosphate-ribose (cADPR), a naturally occurring metabolite of nicotinamide adenine dinucleotide, is as potent as IP3 in mobilizing Ca2+ in sea urchin eggs. Experiments with antagonists of the cADPR and IP3 receptors revealed that both Ca2+ mobilizing systems were activated during fertilization. Blockage of either of the systems alone was not sufficient to prevent the sperm-induced Ca2+ transient. This study provides direct evidence for a physiological role of cADPR in the Ca2+ signaling process.	UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CROSSLEY I, 1991, CELL REGUL, V2, P121, DOI 10.1091/mbc.2.2.121; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DUPONT G, 1990, CELL REGUL, V1, P853, DOI 10.1091/mbc.1.11.853; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; Epel D, 1980, Ann N Y Acad Sci, V339, P74, DOI 10.1111/j.1749-6632.1980.tb15970.x; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TURNER PR, 1984, NATUE, V310, P464; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WALSETH TF, IN PRESS BIOCH BIOPH; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER MJ, 1982, Q REV BIOPHYS, V15, P593, DOI 10.1017/S0033583500003760	25	284	287	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					352	355		10.1126/science.8392749	http://dx.doi.org/10.1126/science.8392749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8392749				2022-12-28	WOS:A1993LM67800036
J	DAVODEAU, F; PEYRAT, MA; HOUDE, I; HALLET, MM; DELIBERO, G; VIE, H; BONNEVILLE, M				DAVODEAU, F; PEYRAT, MA; HOUDE, I; HALLET, MM; DELIBERO, G; VIE, H; BONNEVILLE, M			SURFACE EXPRESSION OF 2 DISTINCT FUNCTIONAL ANTIGEN RECEPTORS ON HUMAN-GAMMA-DELTA T-CELLS	SCIENCE			English	Article							PERIPHERAL-BLOOD; LYMPHOCYTES-T; GENES; REARRANGEMENT; REGION; POLYMORPHISM; DIVERSITY; SUBSETS; BEARING	Lymphocytes recognize antigens with highly variable heterodimeric surface receptors. Although four distinct antigen receptors could in principle be produced by any lymphocyte, only one functional combination of receptor chains has thus far been found expressed on their surface. Examination of human gammadelta T cells revealed a population that violated this rule by expressing on their surface two distinct functional gammadelta T cell receptors (TCRs) that used different TCRgamma gene alleles. Thus, current models for T cell clonal selection may need modification and a possible escape mechanism for autoreactive TCRs is suggested.	INST BIOL,INSERM,U211,F-44035 NANTES,FRANCE; INST EXPTL IMMUNOL,DEPT RES,CH-4031 BASEL,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm)			Davodeau, Francois/M-1888-2015; François, Davodeau/GLU-4061-2022; Vie, Henri/L-2651-2015	François, Davodeau/0000-0001-8181-0192; 				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORST J, 1989, EUR J IMMUNOL, V19, P1559, DOI 10.1002/eji.1830190907; DAVODEAU F, IN PRESS J BIOL CHEM; DAVODEAU F, UNPUB; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; EZQUERRA A, 1992, EUR J IMMUNOL, V22, P491, DOI 10.1002/eji.1830220230; FERRINI S, 1989, EUR J IMMUNOL, V19, P57, DOI 10.1002/eji.1830190110; HEILIG JS, 1987, P NATL ACAD SCI USA, V84, P8070, DOI 10.1073/pnas.84.22.8070; JITSUKAWA S, 1987, J EXP MED, V166, P1192, DOI 10.1084/jem.166.4.1192; KABELITZ D, 1992, CRIT REV IMMUNOL, V11, P251; KONING F, 1988, J IMMUNOL, V141, P2057; LEFRANC MP, 1985, NATURE, V316, P464, DOI 10.1038/316464a0; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; LEFRANC MP, 1986, NATURE, V319, P420, DOI 10.1038/319420a0; LEFRANC MP, 1986, P NATL ACAD SCI USA, V83, P9596, DOI 10.1073/pnas.83.24.9596; LEFRANC MP, 1990, RES IMMUNOL, V141, P267; LITTMAN DR, 1987, NATURE, V326, P85, DOI 10.1038/326085a0; MAEDA K, 1987, P NATL ACAD SCI USA, V84, P6536, DOI 10.1073/pnas.84.18.6536; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; TAKIHARA Y, 1989, J EXP MED, V169, P393, DOI 10.1084/jem.169.2.393; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VIE H, 1989, BLOOD, V74, P285; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0	28	69	69	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1800	1802		10.1126/science.8390096	http://dx.doi.org/10.1126/science.8390096			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8390096				2022-12-28	WOS:A1993LH20500048
J	LEE, MS; KLIEWER, SA; PROVENCAL, J; WRIGHT, PE; EVANS, RM				LEE, MS; KLIEWER, SA; PROVENCAL, J; WRIGHT, PE; EVANS, RM			STRUCTURE OF THE RETINOID-X RECEPTOR-ALPHA DNA-BINDING DOMAIN - A HELIX REQUIRED FOR HOMODIMERIC DNA-BINDING	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; GLUCOCORTICOID RECEPTOR; PROTEINS; SPECTROSCOPY; ELEMENTS; ACIDS; NMR	The three-dimensional solution structure of the DNA binding domain (DBD) of the retinoid X receptor alpha (RXRalpha) was determined by nuclear magnetic resonance spectroscopy. The two zinc fingers of the RXR DBD fold to form a single structural domain that consists of two perpendicularly oriented helices and that resembles the corresponding regions of the glucocorticoid and estrogen receptors (GR and ER, respectively). However, in contrast to the DBDs of the GR and ER, the RXR DBD contains an additional helix immediately after the second zinc finger. This third helix mediates both protein-protein and protein-DNA interactions required for cooperative, dimeric binding of the RXR DBD to DNA. Identification of the third helix in the RXR DBD thus defines a structural feature required for selective dimerization of the RXR on hormone response elements composed of half-sites (5'-AGGTCA-3') arranged as tandem repeats.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Wright, Peter/0000-0002-1368-0223				BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BAX A, 1987, J AM CHEM SOC, V109, P7188; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAVEL T, 1984, B MATH BIOL, V46, P673, DOI 10.1007/BF02459510; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATAHIRA M, 1992, BIOCHEMISTRY-US, V31, P6474, DOI 10.1021/bi00143a017; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lee M., UNPUB; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAO T, UNPUB; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	40	253	256	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1117	1121		10.1126/science.8388124	http://dx.doi.org/10.1126/science.8388124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8388124				2022-12-28	WOS:A1993LC94200027
J	LAUBE, BL; GEORGOPOULOS, A; ADAMS, GK				LAUBE, BL; GEORGOPOULOS, A; ADAMS, GK			PRELIMINARY-STUDY OF THE EFFICACY OF INSULIN AEROSOL DELIVERED BY ORAL INHALATION IN DIABETIC-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABSORPTION	Objective.-To maximize deposition of an aerosolized dose of insulin (mean+/-SD=0.99+/-0.06 U/kg of body weight) in the lungs of subjects with non-insulin-dependent diabetes mellitus (NIDDM), and investigate its efficacy in normalizing plasma glucose levels during the fasting state. Design.-Nonrandomized, placebo-controlled trial. Setting.-A primary care facility. Patients or Other Participants.-Six nonobese, nonsmoking volunteers with NIDDM. No subjects withdrew from the study. Intervention.-Aerosolized insulin was administered by oral inhalation after a 12-hour period of fasting. Aerosol was generated by a raindrop nebulizer from regular 500 U/mL pork insulin. During inhalation, inspiratory flow was regulated at 17 L/min. Plasma samples were collected after inhalation and analyzed for insulin and glucose levels. Main Outcome Measures.-Plasma insulin and glucose levels. Results.-Deposition of the aerosol was maximized within the lungs, with 79% +/-17% of the inhaled dose depositing below the larynx. Geometric mean fasting plasma insulin level was 71 pmol/L (11.8 muU/mL), rising to 269 pmol/L (44.8 muU/mL) after insulin inhalation. Average time to peak insulin level was 40+/-34 minutes. The mean fasting plasma glucose level (12.63+/-2.59 mmol/L [225.5+/-46.3 mg/dL]) was reduced to within the normal range in five subjects and was almost normal in the sixth subject (5.52+/-0.89 mmol/L [98.6+/-15.9 mg/dL]). Average maximum decrease in plasma glucose from baseline was 55%+/-10% (n=6) vs 13%-9% after placebo aerosol inhalation (n=3). No side effects were reported following insulin or placebo aerosol inhalation. Conclusions.-These preliminary results indicate that a dose of approximately 1.0 U of aerosolized insulin per kilogram of body weight, delivered by oral inhalation and deposited predominantly within the lungs, is well tolerated and can effectively normalize plasma glucose levels in patients with NIDDM.	JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV ALLERGY & CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	LAUBE, BL (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV RADIAT HLTH SCI,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NCRR NIH HHS [5MO IRR00722] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMER L-O, 1988, Diabetes Research and Clinical Practice, V5, pS163; CRESIA DA, 1988, FASEB J, V2, pA537; ELLIOTT RB, 1987, AUST PAEDIATR J, V23, P293; GALLOWAY JA, 1981, DIABETES CARE, V4, P366, DOI 10.2337/diacare.4.3.366; LAUBE BL, 1984, AEROSOL SCI TECH, V3, P97, DOI 10.1080/02786828408958997; LIN MS, 1974, RADIOLOGY, V112, P443, DOI 10.1148/112.2.443; MACEY DJ, 1982, J NUCL MED, V23, P731; MOSES AC, 1983, DIABETES, V32, P1040, DOI 10.2337/diabetes.32.11.1040; RUFFIN RE, 1978, THORAX, V33, P689, DOI 10.1136/thx.33.6.689; SALZMAN R, 1985, NEW ENGL J MED, V312, P1078, DOI 10.1056/NEJM198504253121702; WASNICH RD, 1976, J NUCL MED, V17, P707; WIGLEY FM, 1971, DIABETES, V20, P552, DOI 10.2337/diab.20.8.552	12	93	123	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2106	2109		10.1001/jama.269.16.2106	http://dx.doi.org/10.1001/jama.269.16.2106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8385716				2022-12-28	WOS:A1993KY36600032
J	DURAND, ML; CALDERWOOD, SB; WEBER, DJ; MILLER, SI; SOUTHWICK, FS; CAVINESS, VS; SWARTZ, MN				DURAND, ML; CALDERWOOD, SB; WEBER, DJ; MILLER, SI; SOUTHWICK, FS; CAVINESS, VS; SWARTZ, MN			ACUTE BACTERIAL-MENINGITIS IN ADULTS - A REVIEW OF 493 EPISODES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE CHILDHOOD MENINGITIS; LUMBAR PUNCTURE; COMPUTED-TOMOGRAPHY; PURULENT-MENINGITIS; UNITED-STATES; COUNTY; SURVEILLANCE; PROGNOSIS; LISTERIA; CITY	Background and Methods. To characterize acute bacterial meningitis in adults, we reviewed the charts of all persons 16 years of age or older in whom acute bacterial meningitis was diagnosed at Massachusetts General Hospital from 1962 through 1988. We included patients who were admitted after initial treatment at other hospitals. Results. During the 27-year period, 445 adults were treated for 493 episodes of acute bacterial meningitis, of which 197 (40 percent) were nosocomial. Gram-negative bacilli (other than Haemophilus influenzae) caused 33 percent of the nosocomial episodes but only 3 percent of the community-acquired episodes. In the 296 episodes of community-acquired meningitis, the most common pathogens were Streptococcus pneumoniae (37 percent), Neisseria meningitidis (13 percent), and Listeria monocytogenes (10 percent); these organisms accounted for only 8 percent of the nosocomial episodes. Only 19 of the 493 episodes of meningitis (4 percent) were due to H. influenzae. Nine percent of all patients had recurrent meningitis; many had a cerebrospinal fluid leak. Seizures occurred in 23 percent of patients with community-acquired meningitis, and 28 percent had focal central nervous system findings. Risk factors for death among those with single episodes of community-acquired meningitis included older age (greater-than-or-equal-to 60 years), obtunded mental state on admission, and seizures within the first 24 hours. Among those with single episodes, the in-hospital mortality rate was 25 percent for community-acquired and 35 percent for nosocomial meningitis. The overall case fatality rate was 25 percent and did not vary significantly over the 27 years. Conclusions. In our large urban hospital, a major proportion of cases of acute bacterial meningitis in adults were nosocomial. Recurrent episodes of meningitis were frequent. The overall mortality rate remained high.	MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	DURAND, ML (corresponding author), MASSACHUSETTS GEN HOSP, FAC INFECT DIS, FRUIT ST, BOSTON, MA 02114 USA.							ADDY DP, 1987, ARCH DIS CHILD, V62, P873, DOI 10.1136/adc.62.9.873; ADDY DP, 1987, ARCH DIS CHILD, V62, P1293; BODINO J, 1982, AM J DIS CHILD, V136, P495, DOI 10.1001/archpedi.1982.03970420019003; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; BOHR V, 1983, J INFECTION, V7, P102, DOI 10.1016/S0163-4453(83)90443-7; BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; CABRAL DA, 1987, J PEDIATR-US, V111, P201, DOI 10.1016/S0022-3476(87)80067-7; CARPENTER R R, 1962, Am J Med, V33, P262, DOI 10.1016/0002-9343(62)90024-4; CHERUBIN CE, 1981, AM J MED, V71, P199, DOI 10.1016/0002-9343(81)90106-6; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DODGE PR, 1965, NEW ENGL J MED, V272, P1003, DOI 10.1056/NEJM196505132721906; FEIGIN RD, 1987, TXB PEDIATRIC INFECT, V1, P439; FINLAND M, 1977, J INFECT DIS, V136, P400, DOI 10.1093/infdis/136.3.400; FRASER DW, 1973, J INFECT DIS, V128, P300, DOI 10.1093/infdis/128.3.300; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GEISELER PJ, 1980, REV INFECT DIS, V2, P725; Genton B, 1988, Rev Med Suisse Romande, V108, P795; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; GORSE GJ, 1985, ARCH INTERN MED, V145, P957, DOI 10.1001/archinte.1985.00360050227058; HAND WL, 1970, ANN INTERN MED, V73, P862, DOI 10.7326/0003-4819-73-5-862; HARPER JR, 1985, BRIT MED J, V291, P651, DOI 10.1136/bmj.291.6496.651; Harris L F, 1988, Ala Med, V58, P20; HO JL, 1986, ARCH INTERN MED, V146, P520, DOI 10.1001/archinte.146.3.520; HODGES GR, 1975, AM J MED SCI, V270, P427, DOI 10.1097/00000441-197511000-00003; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; KAPLAN SL, 1985, BACTERIAL MENINGITIS, V3, P83; KARANDANIS D, 1976, SOUTHERN MED J, V69, P449, DOI 10.1097/00007611-197604000-00021; KLINE MW, 1989, PEDIATR INFECT DIS J, V8, P630, DOI 10.1097/00006454-198909000-00013; KLINE MW, 1988, PEDIATR INFECT DIS J, V7, P855; LEVIN S, 1972, AM J MED SCI, V264, P319, DOI 10.1097/00000441-197210000-00010; LORBER J, 1980, LANCET, V1, P785; Magnussen C R, 1980, N Y State J Med, V80, P901; MCGEE ZA, 1990, PRINCIPLES PRACTICE, P741; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; RISCHBIETH R. H., 1960, Medical Journal of Australia, V1, P578; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SILBERSTEIN P, 1986, MED J AUSTRALIA, V144, P110, DOI 10.5694/j.1326-5377.1986.tb113682.x; SLACK J, 1980, LANCET, V2, P474; SNYDER RD, 1984, NEUROPEDIATRICS, V15, P136, DOI 10.1055/s-2008-1052356; SNYDER RD, 1981, J NEUROL NEUROSUR PS, V44, P581, DOI 10.1136/jnnp.44.7.581; SPENDER Q, 1985, BRIT MED J, V291, P898, DOI 10.1136/bmj.291.6499.898; STEPHENSON JBP, 1985, BRIT MED J, V291, P1123, DOI 10.1136/bmj.291.6502.1123-b; STOVRING J, 1980, J PEDIATR-US, V96, P820, DOI 10.1016/S0022-3476(80)80549-X; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; TUNKEL AR, 1990, ANN INTERN MED, V112, P610, DOI 10.7326/0003-4819-112-8-610; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS CP, 1964, PEDIATRICS, V34, P220; 1992, MED LETT DRUGS THER, V34, P49	52	955	985	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					21	28		10.1056/NEJM199301073280104	http://dx.doi.org/10.1056/NEJM199301073280104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8416268	Green Published			2022-12-28	WOS:A1993KF50700004
J	THEODOROPOULOS, DS; KRASNEWICH, D; KAISERKUPFER, MI; GAHL, WA				THEODOROPOULOS, DS; KRASNEWICH, D; KAISERKUPFER, MI; GAHL, WA			CLASSIC NEPHROPATHIC CYSTINOSIS AS AN ADULT DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NERVOUS-SYSTEM INVOLVEMENT; AGE 10 YEARS; CYSTEAMINE; COMPLICATIONS; INSUFFICIENCY; CHILDREN; PATIENT	Objective.-To delineate the clinical characteristics of infantile nephropathic cystinosis in adult patients who have undergone renal transplantation. Design.-Case series. Setting.-Clinical research unit. Patients.-All 36 adult patients with nephropathic cystinosis referred to the National Institutes of Health. Outcome Measures.-Longevity, growth, renal allograft survival, visual acuity, endocrine insufficiency, myopathy and swallowing dysfunction, cerebral calcifications, and occupational status. Results.-Of the 36 patients, seven were dead, five with functioning allografts. The 1-year and 5-year graft survival rates for 30 cadaveric allografts were 90% and 75%, respectively. The patients' mean height and weight were severely retarded. Five patients were legally blind, and three others had severely impaired vision in one eye. Thirty-one (86%) of 36 patients required thyroid hormone replacement therapy. One third had a distal myopathy, and 21 had moderate to severe swallowing abnormalities. Eight patients had cerebral calcifications on computed tomographic scan. Despite these complications, the sighted patients engaged in a normal variety of occupations. Only 11 patients were receiving adequate cystine-depleting therapy with cysteamine (mercaptamine) or phosphocysteamine. Conclusions.-Adult patients with nephropathic cystinosis suffer serious complications of the disease.	NIH, CTR CLIN, INTERINST MED GENET PROGRAM, BETHESDA, MD 20892 USA; NICHHD, HUMAN GENET BRANCH, HUMAN BIOCHEM GENET SECT, BETHESDA, MD 20892 USA; NEI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								CHAN AM, 1970, AM J MED, V48, P678, DOI 10.1016/S0002-9343(70)80002-X; FINK JK, 1989, ARCH NEUROL-CHICAGO, V46, P543, DOI 10.1001/archneur.1989.00520410077027; FIVUSH B, 1988, J PEDIATR-US, V112, P49, DOI 10.1016/S0022-3476(88)80119-7; FIVUSH B, 1987, AM J DIS CHILD, V141, P1087, DOI 10.1001/archpedi.1987.04460100065027; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1986, J PEDIATR-US, V109, P605, DOI 10.1016/S0022-3476(86)80221-9; GAHL WA, 1990, PEDIATR NEPHROL, V4, P129, DOI 10.1007/BF00858823; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1987, PEDIATR NEPHROL, V1, P260, DOI 10.1007/BF00849221; GAHL WA, 1988, NEW ENGL J MED, V319, P1461, DOI 10.1056/NEJM198812013192206; GAHL WA, 1992, BIOCHEM MED METAB B, V48, P275, DOI 10.1016/0885-4505(92)90074-9; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1989, METABOLIC BASIS INHE, P2619; GRETZ N, 1982, P EUR DIAL TRANS, V19, P582; JONAS AJ, 1987, AM J MED, V83, P966, DOI 10.1016/0002-9343(87)90661-9; KAISERKUPFER MI, 1987, NEW ENGL J MED, V316, P775, DOI 10.1056/NEJM198703263161304; KAISERKUPFER MI, 1990, ARCH OPHTHALMOL-CHIC, V108, P689, DOI 10.1001/archopht.1990.01070070075038; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P706, DOI 10.1001/archopht.1986.01050170096030; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRASNEWICH DM, 1991, ENDOCRINOLOGIST, V1, P111; MARKELLO TC, 1993, NEW ENGL J MED, V328, P1157, DOI 10.1056/NEJM199304223281604; OSHIMA RG, 1974, J BIOL CHEM, V249, P6033; SMOLIN LA, 1988, PEDIATR RES, V23, P616, DOI 10.1203/00006450-198806000-00018; SONIES BC, 1990, NEW ENGL J MED, V323, P565, DOI 10.1056/NEJM199008303230903; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; THOROGOOD J, 1992, TRANSPLANTATION, V54, P152, DOI 10.1097/00007890-199207000-00027; VOGEL DG, 1990, J NEUROPATH EXP NEUR, V49, P591, DOI 10.1097/00005072-199011000-00005	28	70	74	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2200	2204		10.1001/jama.270.18.2200	http://dx.doi.org/10.1001/jama.270.18.2200			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411603				2022-12-28	WOS:A1993ME81600031
J	HULL, R; RASKOB, G; PINEO, G; ROSENBLOOM, D; EVANS, W; MALLORY, T; ANQUIST, K; SMITH, F; HUGHES, G; GREEN, D; ELLIOTT, CG; PANJU, A; BRANT, R				HULL, R; RASKOB, G; PINEO, G; ROSENBLOOM, D; EVANS, W; MALLORY, T; ANQUIST, K; SMITH, F; HUGHES, G; GREEN, D; ELLIOTT, CG; PANJU, A; BRANT, R			A COMPARISON OF SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN WITH WARFARIN SODIUM FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER HIP OR KNEE IMPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTOPERATIVE VENOUS THROMBOSIS; LOW-DOSE HEPARIN; UNFRACTIONATED HEPARIN; PULMONARY-EMBOLISM; STANDARD HEPARIN; RANDOMIZED TRIAL; ROENTGENOGRAPHIC PHLEBOGRAPHY; IMPEDANCE PLETHYSMOGRAPHY; KABI 2165; SURGERY	Background. Deep-vein thrombosis is a potentially life-threatening complication of total hip or knee replacement. There are few data on the effectiveness and safety of warfarin as compared with low-molecular-weight heparin as prophylaxis against this problem. Methods. We therefore performed a randomized, double-blind trial in 1436 patients to evaluate the effectiveness and safety of low-molecular-weight heparin (given subcutaneously once daily) as compared with adjusted-dose warfarin to prevent venous thrombosis after hip or knee replacement. Treatment with the drugs was started postoperatively. The primary end point was deep-vein thrombosis as detected by contrast venography (performed a mean of 9.4 days after surgery in each group). Results. Among the 1207 patients with interpretable venograms, 231 of 617 patients (37.4 percent) in the warfarin group and 185 of 590 patients (31.4 percent) in the low-molecular-weight-heparin group had deep-vein thrombosis (P = 0.03). The reduction in risk with low-molecular-weight heparin as compared with warfarin was 16 percent, and the absolute difference in the incidence of venous thrombosis was 6 percent in favor of low-molecular-weight heparin (95 percent confidence interval, 0.8 to 11.4 percent). The incidence of major bleeding was 1.2 percent (9 of 721 patients) in the warfarin group and 2.8 percent (20 of 715 patients) in the low-molecular-weight-heparin group (P = 0.04), and the absolute difference was 1.5 percent in favor of warfarin (95 percent confidence interval, 0.1 to 3.0 percent). Conclusions. Our data demonstrate that the small reduction in the incidence of venous thrombosis with low-molecular-weight heparin, as compared with warfarin, was offset by an increase in bleeding complications. Although the use of low-molecular-weight heparin is simpler, because it is administered subcutaneously without the need for monitoring, it may be more costly than warfarin. Warfarin is inexpensive, but the overall cost of its use is increased by the need to monitor the intensity of anticoagulation. At this time it is unclear which of these approaches is the most cost effective.	OHIO STATE UNIV, COLUMBUS, OH 43210 USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; LATTER DAY ST HOSP, SALT LAKE CITY, UT 84143 USA; CHEDOKE MCMASTER HOSP, HAMILTON L8N 3Z5, ONTARIO, CANADA	University System of Ohio; Ohio State University; Northwestern University; McMaster University	HULL, R (corresponding author), UNIV CALGARY, FAC MED, DEPT MED, CLIN TRIALS UNIT, 3330 HOSP DR NW, CALGARY T2N 4N1, AB, CANADA.			Brant, Rollin/0000-0002-8026-2451				AIACH M, 1983, THROMB RES, V31, P611, DOI 10.1016/0049-3848(83)90458-9; ANDERSON FA, 1991, ANN INTERN MED, V115, P591, DOI 10.7326/0003-4819-591; Armitage P, 1987, STAT METHODS MED RES, P93; BARA L, 1985, THROMB RES, V39, P631, DOI 10.1016/0049-3848(85)90244-0; BERGQVIST D, 1988, BRIT J SURG, V75, P888, DOI 10.1002/bjs.1800750920; BERGQVIST D, 1983, THROMB RES, V32, P381, DOI 10.1016/0049-3848(83)90091-9; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BOOKSTEIN JJ, 1974, RADIOLOGY, V110, P25, DOI 10.1148/110.1.25; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; BRATT G, 1986, THROMB RES, V42, P613, DOI 10.1016/0049-3848(86)90340-3; CAEN JP, 1988, THROMB HAEMOSTASIS, V59, P216; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COMEROTA AJ, 1988, J VASC SURG, V7, P40, DOI 10.1067/mva.1988.avs0070040; COVENTRY MB, 1973, J BONE JOINT SURG AM, VA 55, P1487, DOI 10.2106/00004623-197355070-00016; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DECHAVANNE M, 1989, HAEMOSTASIS, V19, P5; ENCKE A, 1988, BRIT J SURG, V75, P1058; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; FRYDMAN AM, 1988, J CLIN PHARMACOL, V28, P609, DOI 10.1002/j.1552-4604.1988.tb03184.x; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HARRIS WH, 1990, NEW ENGL J MED, V323, P801, DOI 10.1056/NEJM199009203231206; HARRIS WH, 1976, J BONE JOINT SURG AM, V58, P939, DOI 10.2106/00004623-197658070-00008; HARRIS WH, 1977, NEW ENGL J MED, V297, P1246, DOI 10.1056/NEJM197712082972302; HEIT J, 1991, BLOOD S187A, V78; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HULL R, 1979, THROMB RES, V16, P37, DOI 10.1016/0049-3848(79)90267-6; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; JOHNSON R, 1977, CLIN ORTHOP RELAT R, V127, P123; JOHNSON R, 1978, CLIN ORTHOP RELAT R, V132, P24; KAEMPFFE FA, 1991, CLIN ORTHOP RELAT R, P89; KAKKAR VV, 1985, BRIT J SURG, V72, P786, DOI 10.1002/bjs.1800721006; LECLERC JR, 1992, THROMB HAEMOSTASIS, V67, P417; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LEYVRAZ PF, 1991, BRIT MED J, V303, P1243; MATZSCH T, 1987, THROMB HAEMOSTASIS, V57, P97; MCKENNA R, 1980, BRIT MED J, V280, P514, DOI 10.1136/bmj.280.6213.514; NILLIUS AS, 1979, BRIT J SURG, V66, P324, DOI 10.1002/bjs.1800660508; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; Paiement G, 1987, J Arthroplasty, V2, P23, DOI 10.1016/S0883-5403(87)80027-X; PAIEMENT GD, 1987, CLIN ORTHOP RELAT R, V223, P188; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SALZMAN EW, 1986, NEW ENGL J MED, V315, P957, DOI 10.1056/NEJM198610093151509; SAMAMA M, 1988, BRIT J SURG, V75, P128, DOI 10.1002/bjs.1800750213; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; STRINGER MD, 1989, J BONE JOINT SURG BR, V71, P492, DOI 10.1302/0301-620X.71B3.2785998; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; VERSTRAETE M, 1990, DRUGS, V40, P498, DOI 10.2165/00003495-199040040-00003; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WOOLSON ST, 1991, J BONE JOINT SURG AM, V73A, P507, DOI 10.2106/00004623-199173040-00005	59	385	392	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1370	1376		10.1056/NEJM199311043291902	http://dx.doi.org/10.1056/NEJM199311043291902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413432	Bronze			2022-12-28	WOS:A1993MD94900002
J	LETVIN, NL				LETVIN, NL			VACCINES AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS - PROGRESS AND PROSPECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CYTOTOXIC LYMPHOCYTES-T; LYMPHADENOPATHY-ASSOCIATED VIRUS; ENVELOPE GLYCOPROTEIN GP120; HIV-INFECTION; NEUTRALIZING ANTIBODIES; CEREBROSPINAL-FLUID; CONFERS PROTECTION; RHESUS-MONKEYS; SIV VACCINE; AIDS				LETVIN, NL (corresponding author), HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,1 PINE HILL DR,POB 9102,SOUTHBOROUGH,MA 01772, USA.				NCI NIH HHS [CA50139] Funding Source: Medline; NIAID NIH HHS [AI20729] Funding Source: Medline; NIDDK NIH HHS [DK43351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020729, R37AI020729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; BERMAN PW, 1988, P NATL ACAD SCI USA, V85, P5200, DOI 10.1073/pnas.85.14.5200; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; EIMINI EA, 1992, NATURE, V355, P728; FAST PE, 1992, AIDS SUPPL, pS147; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HART MK, 1990, J IMMUNOL, V145, P2677; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HU SL, 1992, SCIENCE, V255, P459; JASSOY C, 1992, J IMMUNOL, V149, P3113; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KANG CY, 1991, P NATL ACAD SCI USA, V88, P6171, DOI 10.1073/pnas.88.14.6171; KARON JM, 1993, MMWR-MORBID MORTAL W, V41, P1; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; LAROSA GJ, 1991, SCIENCE, V251, P811, DOI 10.1126/science.1990444; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LETVIN NL, 1990, IMMUNOL TODAY, V11, P322, DOI 10.1016/0167-5699(90)90127-U; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MARTHAS ML, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P117; MEIGNAN M, 1990, AM REV RESPIR DIS, V141, P1241, DOI 10.1164/ajrccm/141.5_Pt_1.1241; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; MYERS G, 1992, HUMAN RETROVIRUSES A; PERRYMAN LE, 1988, J VIROL, V62, P3073, DOI 10.1128/JVI.62.8.3073-3076.1988; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POSNER MR, 1991, J IMMUNOL, V146, P4325; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; RUSCHE JR, 1989, P NATL ACAD SCI USA, V86, P1667; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P8697, DOI 10.1073/pnas.85.22.8697; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SETHI KK, 1988, NATURE, V335, P178, DOI 10.1038/335178a0; SHEN L, 1991, SCIENCE, V252, P440, DOI 10.1126/science.1708168; SMITH FB, 1988, ARCH PATHOL LAB MED, V112, P742; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Weiss R, 1985, RNA TUMOR VIRUSES; YAMAMOTO H, 1992, J IMMUNOL, V149, P728; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993	53	55	66	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1400	1405						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413438				2022-12-28	WOS:A1993MD94900008
J	THIBAULT, GE				THIBAULT, GE			THE HEART OF THE MATTER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							OSTEOGENESIS IMPERFECTA; AORTIC REGURGITATION; VALVE REPLACEMENT; ANEURYSM; DISEASE; SINUS				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKY,BOSTON,MA 02132, USA.							Bennett J M, 1987, Eur J Cardiothorac Surg, V1, P46, DOI 10.1016/S1010-7940(87)80013-1; Browell J N Jr, 1966, Henry Ford Hosp Med J, V14, P245; CAREY MC, 1968, Q J MED, V37, P437; CRISCITIELLO MG, 1965, CIRCULATION, V31, P255, DOI 10.1161/01.CIR.31.2.255; FEIGENBAUM H, 1992, HEART DISEASE TXB CA, P64; HEPPNER RL, 1973, AM J CARDIOL, V31, P654, DOI 10.1016/0002-9149(73)90338-X; JEYAMALAR R, 1989, SMJ Singapore Medical Journal, V30, P316; KOENTGES D, 1986, ACTA CARDIOL, V41, P147; MCKUSICK VA, 1972, HERITABLE DISORDERS, P390; MELAMED R, 1976, ISRAEL J MED SCI, V12, P1325; OHTEKI H, 1991, THORAC CARDIOV SURG, V39, P294, DOI 10.1055/s-2007-1019989; PASSMORE JM, 1987, J AM COLL CARDIOL, V9, P960, DOI 10.1016/S0735-1097(87)80255-3; ROGERSON ME, 1986, BRIT HEART J, V56, P187; STEIN D, 1977, AM HEART J, V94, P637, DOI 10.1016/S0002-8703(77)80135-X; WATERS DD, 1977, CHEST, V72, P363, DOI 10.1378/chest.72.3.363; WEISINGER B, 1975, BRIT HEART J, V37, P475; WOOD SJ, 1973, BRIT HEART J, V35, P103	17	10	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1406	1410		10.1056/NEJM199311043291909	http://dx.doi.org/10.1056/NEJM199311043291909			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413439				2022-12-28	WOS:A1993MD94900009
J	FEDSON, DS; WAJDA, A; NICOL, JP; HAMMOND, GW; KAISER, DL; ROOS, LL				FEDSON, DS; WAJDA, A; NICOL, JP; HAMMOND, GW; KAISER, DL; ROOS, LL			CLINICAL EFFECTIVENESS OF INFLUENZA VACCINATION IN MANITOBA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RESPIRATORY-DISEASE; PROTECTIVE EFFICACY; ADMINISTRATIVE DATA; EXCESS MORTALITY; UNITED-STATES; PNEUMONIA; EPIDEMICS; POPULATION; REDUCTION; HOSPITALIZATIONS	Objective.-To assess the clinical effectiveness of influenza vaccination in preventing influenza-associated hospitalization and death. Design.-Case-control study. Setting and Patients.-Noninstitutionalized persons aged 45 years or older living in Manitoba, on December 1, 1982, and December 1, 1985. Methods.-Linked records of the Manitoba population registry, hospital-discharge abstracts, physician claims for ambulatory-patient visits and influenza vaccination, and vital statistics were used. A matched-set analysis estimated the clinical effectiveness of influenza vaccination in preventing hospital admissions and deaths from influenza-associated conditions during influenza A (H3N2) outbreak periods in 1982 to 1983 (12 weeks) and 1985 to 1986 (10 weeks). The analysis adjusted for hospital discharge and ambulatory care for high-risk conditions within the previous 15 months and 3 months, respectively. Results.-Influenza vaccination prevented 32% to 39% of hospital admissions with pneumonia and influenza and 15% to 34% of admissions with all respiratory conditions. Vaccination was 43% to 65% effective in preventing hospital deaths with these conditions (all listed diagnoses) and 27% to 30% effective in preventing deaths from all causes. Conclusion.-Influenza vaccination has substantial clinical effectiveness in preventing hospital admission and death from influenza-associated conditions in noninstitutionalized individuals.	MANITOBA CTR HLTH POLICY & EVALUAT,WINNIPEG,MB,CANADA; UNIV MANITOBA,DEPT MED MICROBIOL & INFECT DIS,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT COMMUNITY HLTH SCI,WINNIPEG R3T 2N2,MANITOBA,CANADA; CADHAM PROV LAB,WINNIPEG,MB,CANADA	University of Manitoba; University of Manitoba	FEDSON, DS (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT MED,BOX 494,CHARLOTTESVILLE,VA 22908, USA.			Roos, Leslie L./0000-0002-4215-8346	NATIONAL INSTITUTE ON AGING [R01AG009145] Funding Source: NIH RePORTER; NIA NIH HHS [5-R01AG09145] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BARKER WH, 1981, AM J PUBLIC HEALTH, V71, P643, DOI 10.2105/AJPH.71.6.643; BARKER WH, 1986, OPTIONS CONTROL INFL, P169; BLACKWELDER WC, 1982, AM REV RESPIR DIS, V125, P5111; Cohen M M, 1993, Ann Epidemiol, V3, P93; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; EDMONDSON WP, 1971, AM J EPIDEMIOL, V93, P480, DOI 10.1093/oxfordjournals.aje.a121282; FEDSON DS, 1992, ANN INTERN MED, V116, P550, DOI 10.7326/0003-4819-116-7-550; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GHENDON Y, 1991, B WORLD HEALTH ORGAN, V69, P509; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; IEZZONI LI, 1992, 920056 AG HLTH CAR P, P83; LAMONTAGNE JR, 1983, REV INFECT DIS, V5, P723; LIU KJ, 1987, AM J PUBLIC HEALTH, V77, P712; MARRIE TJ, 1987, MED CARE, V25, P20, DOI 10.1097/00005650-198701000-00003; MAZUMDAR S, 1986, AM J PUBLIC HEALTH, V76, P803, DOI 10.2105/AJPH.76.7.803; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; ROMANO PS, 1992, 920056 AG HLTH CAR P, P57; ROOS LL, 1987, J CHRON DIS, V40, P41, DOI 10.1016/0021-9681(87)90095-6; ROOS LL, 1991, J CLIN EPIDEMIOL, V44, P881, DOI 10.1016/0895-4356(91)90050-J; ROOS LL, 1990, MED INN CR, V1, P47; ROOS LL, 1993, MED CARE, V31, P201, DOI 10.1097/00005650-199303000-00002; ROOS LL, 1992, 920056 AG HLTH CAR P, P119; ROOS NP, 1989, SOC SCI MED, V28, P109, DOI 10.1016/0277-9536(89)90137-8; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; SAITZ EW, 1978, JAMA-J AM MED ASSOC, V239, P2372, DOI 10.1001/jama.239.22.2372; SCHOENBA.SC, 1969, B WORLD HEALTH ORGAN, V41, P531; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; STUART WH, 1969, J AMER MED ASSOC, V209, P232, DOI 10.1001/jama.209.2.232; 1986, SUGI SUPPLEMENTAL LI, P307; 1989, INT CLASSIFICATION D; 1993, AB933 DEP HLTH HUM S; 1980, RELIABILITY NATIONAL	46	240	245	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1956	1961		10.1001/jama.270.16.1956	http://dx.doi.org/10.1001/jama.270.16.1956			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC513	8411553				2022-12-28	WOS:A1993MC51300027
J	HECKERLING, PS; WIENER, SL; WOLFKIEL, CJ; KUSHNER, MS; DODIN, EM; JELNIN, V; FUSMAN, B; CHOMKA, EV				HECKERLING, PS; WIENER, SL; WOLFKIEL, CJ; KUSHNER, MS; DODIN, EM; JELNIN, V; FUSMAN, B; CHOMKA, EV			ACCURACY AND REPRODUCIBILITY OF PRECORDIAL PERCUSSION AND PALPATION FOR DETECTING INCREASED LEFT-VENTRICULAR END-DIASTOLIC VOLUME AND MASS - A COMPARISON OF PHYSICAL FINDINGS AND ULTRAFAST COMPUTED-TOMOGRAPHY OF THE HEART	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERFORMANCE; PRECISION; MORTALITY	Objective.-To assess the accuracy and reproducibility of indirect definitive precordial percussion in detecting increased left ventricular end-diastolic volume (LVEDV), left ventricular mass (LVM), and left ventricular end-diastolic wall thickness ( LVEDWT), and to compare it with palpation of the apical impulse. Design.-Descriptive study. Setting.-Hospitals and clinics of a university medical center. Patients.-Convenience sample of 103 patients (62 men and 41 women) referred for ultrafast computed tomography (CT) of the heart. Interventions.-Percussion dullness distance from the midsternal line in the left fourth through sixth intercostal spaces, distance of the apical impulse from the mid-sternal line, and apical impulse diameter in the left lateral decubitus position were measured on all patients. Measurements of LVEDV, LVM, and LVEDWT were taken using ultrafast CT of the heart. Investigators performing the physical diagnostic maneuvers were blinded to the clinical history and CT results, and investigators performing the CT scans were blinded to physical findings. Results.-Percussion dullness distance in the left fifth intercostal space was the best discriminator of LVEDV (receiver operating characteristic [ROC] area, 0.680; 95% confidence interval [CI], 0.547 to 0.813), and dullness distance in the left sixth intercostal space was the best discriminator of LVM and LVEDWT (ROC areas, 0.831, 95% CI, 0.674 to 0.988; and 0.849, 95% CI, 0.651 to 0.999, respectively). A percussion dullness distance of greater than 10.5 cm in the left fifth intercostal space detected increased LVEDV or LVM with a sensitivity of 91.3% (95% CI, 70.5% to 98.5%) and a specificity of 30.3% (95% CI, 19.9% to 43.0%). There was moderate concordance between investigators for percussion dullness distance (kappa, 0.57; 95% CI, 0.18 to 0.96). In patients in whom an impulse was palpated, an apical impulse diameter of greater than 3.0 cm in the left lateral decubitus detected increased LVEDV or LVM with a sensitivity of 100% (95% CI, 77.1% to 100%) and a specificity of 40% (95% CI, 23.2% to 59.3%). However, an impulse was palpable in only 53% of cases and showed only slight interobserver reproducibility (kappa, 0.18; 95% CI, 0.0 to 0.58). Conclusion.-Indirect definitive percussion of the precordium is a sensitive and moderately reproducible maneuver for excluding cardiomegaly due to increased LVEDV or LVM. Although measurement of apical impulse diameter was also sensitive in excluding cardiomegaly, lack of a palpable impulse in many patients and low precision between physicians may limit its utility in clinical practice.	UNIV ILLINOIS, DEPT MED, CARDIOL SECT, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	HECKERLING, PS (corresponding author), UNIV ILLINOIS, DEPT MED, GEN INTERNAL MED SECT, BOX 6998 M-C 787, CHICAGO, IL 60680 USA.							CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CHOMKA E V, 1987, American Journal of Noninvasive Cardiology, V1, P140; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DEGOWIN EL, 1969, BEDSIDE DIAGNOSTIC E, P330; DIETHELM L, 1989, RADIOLOGY, V171, P213, DOI 10.1148/radiology.171.1.2522665; DIXON WJ, 1988, BMDP STATISTICAL SOF, V1, P357; DORFMAN DD, 1969, J MATH PSYCHOL, V6, P487, DOI 10.1016/0022-2496(69)90019-4; DUBOIS D, 1916, P SOC EXP BIOL MED, V13, P77; EILEN SD, 1983, ANN INTERN MED, V99, P628, DOI 10.7326/0003-4819-99-5-628; ERTL G, 1991, AM J CARDIOL, V68, pD116; Fleiss JL., 1981, STAT METHODS RATES P, P14; Green D. M., 1966, SIGNAL DETECTION THE, P45; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HECKERLING PS, 1988, J GEN INTERN MED, V3, P604, DOI 10.1007/BF02596109; HECKERLING PS, 1991, AM J MED, V91, P328, DOI 10.1016/0002-9343(91)90149-R; KENNEDY JW, 1966, CIRCULATION, V34, P272; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; KOMAJDA M, 1990, EUR HEART J, V11, P824, DOI 10.1093/oxfordjournals.eurheartj.a059803; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAZNER P, 1986, J AM COLL CARDIOL, V8, P682; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; MATTLEMAN SJ, 1983, J AM COLL CARDIOL, V1, P417, DOI 10.1016/S0735-1097(83)80068-0; ONEILL TW, 1989, LANCET, V1, P410; PIETRAS RJ, 1991, INVEST RADIOL, V26, P28, DOI 10.1097/00004424-199101000-00006; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REITER SJ, 1986, CIRCULATION, V74, P890, DOI 10.1161/01.CIR.74.4.890; ROIG E, 1991, J AM COLL CARDIOL, V18, P990, DOI 10.1016/0735-1097(91)90758-2; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P54; SPITERI MA, 1988, LANCET, V1, P873; THOMPSON WD, 1988, J CLIN EPIDEMIOL, V41, P949, DOI 10.1016/0895-4356(88)90031-5; WACHSPRESS JD, 1988, CATHETER CARDIO DIAG, V15, P277, DOI 10.1002/ccd.1810150414; WIENER SL, 1990, CLIN RES, V38, pA735	37	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1943	1948		10.1001/jama.270.16.1943	http://dx.doi.org/10.1001/jama.270.16.1943			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8411551				2022-12-28	WOS:A1993MC51300025
J	TURNER, BM				TURNER, BM			DECODING THE NUCLEOSOME	CELL			English	Review							TUMOR VIRUS PROMOTER; HISTONE ACETYLATION; TERMINAL MUTATIONS; TRANSCRIPTION; REPRESSION; DOMAINS; INVIVO; GAL4				TURNER, BM (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; COVAULT J, 1980, J BIOL CHEM, V255, P9110; DIMITROV S, 1993, IN PRESS DEV BIOL; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KORNBERG RD, 1981, SCI AM, V244, P48, DOI 10.1038/scientificamerican0281-52; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; KURODA MI, 1993, SEM DEV BIOL, V4, P107; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; NORTON VG, 1990, J BIOL CHEM, V265, P19848; PALMER MJ, 1993, GENETICS, V134, P545; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; ROBERGE M, 1991, FEBS LETT, V288, P215, DOI 10.1016/0014-5793(91)81037-9; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SOMMERVILLE J, 1993, J CELL BIOL, V120, P277, DOI 10.1083/jcb.120.2.277; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TURNER BM, 1991, J CELL SCI, V99, P13; TURNER BM, 1992, CELL, V69, P376; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735	31	299	314	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					5	8		10.1016/S0092-8674(05)80078-9	http://dx.doi.org/10.1016/S0092-8674(05)80078-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402900				2022-12-28	WOS:A1993MB66700002
J	KEAVENEY, M; BERKENSTAM, A; FEIGENBUTZ, M; VRIEND, G; STUNNENBERG, HG				KEAVENEY, M; BERKENSTAM, A; FEIGENBUTZ, M; VRIEND, G; STUNNENBERG, HG			RESIDUES IN THE TATA-BINDING PROTEIN REQUIRED TO MEDIATE A TRANSCRIPTIONAL RESPONSE TO RETINOIC ACID IN EC CELLS	NATURE			English	Article							ACTIVATION DOMAIN; STEM-CELLS; GENE; E1A; COACTIVATORS; SPECIFICITY; PROMOTER; RECEPTOR; INVIVO; YEAST	THE eukaryotic TATA-binding protein TBP, which is required for transcription by RNA polymerase II, is tightly associated with a particular set of factors in the TFIID complex1-5, and as such provides a target for transcriptional regulation exerted by upstream factors. An embryonic carcinoma (EC) cell-specific activity like that of the viral factor E1A has been implicated in the mediation of transactivation from the retinoic acid receptor to human TBP, but yeast TBP cannot perform this function6. Using TBP mutants with an altered TATA-box-binding specificity7, we show here that yeast TBP can mediate transcriptional activation in mammalian cells and that its inability to convey retinoic acid-dependent transactivation in EC cells is due to specific residues in its core region. These residues preclude a functional association with the cellular E1A-like activity. TBP is thus a target for retinoic acid-dependent transactivation in EC cells by providing a surface for interaction with the EC cell-specific E1A-like activity.	EMBL,GENE EXPRESS PROGRAM,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY; EMBL,BIOL STRUCT PROGRAM,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)			Vriend, G./H-8112-2014; Vriend, Gert/D-6730-2011; Berkenstam, Anders/E-7136-2012; Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576				BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	31	59	59	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					562	566		10.1038/365562a0	http://dx.doi.org/10.1038/365562a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413615				2022-12-28	WOS:A1993MA66100060
J	ZAPP, ML; STERN, S; GREEN, MR				ZAPP, ML; STERN, S; GREEN, MR			SMALL MOLECULES THAT SELECTIVELY BLOCK RNA-BINDING OF HIV-1 REV PROTEIN INHIBIT REV FUNCTION AND VIRAL PRODUCTION	CELL			English	Article							CHRONICALLY INFECTED-CELLS; TRANS-ACTIVATOR GENE; ARGININE-RICH MOTIF; MESSENGER-RNA; VIRUS-REPLICATION; SPLICING INVITRO; HTLV-III; EXPRESSION; TRANSCRIPTION; RECOGNITION	Replication of RNA viruses, such as the human immunodeficiency virus (HIV), is dependent upon multiple specific interactions between viral RNAs and viral and cellular proteins. A small molecule that interferes specifically with one or more of these RNA-protein interactions could be an efficacious antiviral agent. Here we show that certain aminoglycoside antibiotics, in particular neomycin B, can block binding of the HIV Rev protein to its viral RNA recognition element. Inhibition appears to be highly selective, resulting from competitive binding of the drug to a small viral RNA region within the Rev-binding site. We further demonstrate that neomycin B can specifically antagonize Rev f unction in vitro and in vivo and can inhibit production of HIV. Our results establish the feasibility for developing antiviral drugs that act by selectively blocking RNA-protein interactions.			ZAPP, ML (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BEVEC D, 1992, P NATL ACAD SCI USA, V89, P9870, DOI 10.1073/pnas.89.20.9870; BOTTO RE, 1983, J AM CHEM SOC, V105, P1021, DOI 10.1021/ja00342a062; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; CUNDLIFFE E, 1987, BIOCHIMIE, V69, P863, DOI 10.1016/0300-9084(87)90213-6; CUNDLIFFE E, 1990, RIBOSOME, P479; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Green MR, 1993, AIDS RES REV, V3, P41; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANESSIAN S, 1970, CARBOHYDRATES      A, V2, P139; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; KARLOWSKY JA, 1992, CLIN INFECT DIS, V15, P654, DOI 10.1093/clind/15.4.654; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MICHAEL NL, 1991, J VIROL, V65, P1291, DOI 10.1128/JVI.65.3.1291-1303.1991; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MOORE MJ, 1992, RNA WORLD, P1; NIWA M, 1991, GENE EXPRESSION, V1, P5; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; PRICE KE, 1977, STRUCTURE ACTIVITY R, P239; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; Umezewa S., 1982, AMINOGLYCOSIDE ANTIB, P37; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; VONAHSEN U, 1993, SCIENCE, V260, P1500, DOI 10.1126/science.8502993; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	62	374	395	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					969	978		10.1016/0092-8674(93)90720-B	http://dx.doi.org/10.1016/0092-8674(93)90720-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402886				2022-12-28	WOS:A1993LY49300005
J	LIN, SC; LIN, CJR; GUKOVSKY, I; LUSIS, AJ; SAWCHENKO, PE; ROSENFELD, MG				LIN, SC; LIN, CJR; GUKOVSKY, I; LUSIS, AJ; SAWCHENKO, PE; ROSENFELD, MG			MOLECULAR-BASIS OF THE LITTLE MOUSE PHENOTYPE AND IMPLICATIONS FOR CELL-TYPE-SPECIFIC GROWTH	NATURE			English	Article							HORMONE-RELEASING-FACTOR; ANTERIOR-PITUITARY CELLS; PANCREATIC-ISLET TUMOR; TRANSGENIC MICE; MESSENGER-RNA; DWARF MICE; THYROID-CELLS; CYCLIC-AMP; PROTEIN; GENE	The molecular basis for the little (lit) mouse phenotype, characterized by a hypoplastic anterior pituitary gland, is the mutation of a single nucleotide that alters Asp 60 to Gly in the growth hormone releasing factor receptor. Detailed analysis of the lit mouse anterior pituitary reveals spatially distinct proliferative zones of growth hormone-producing stem cells and mature somatotrophs, each regulated by a different trophic factor. This sequential growth factor requirement for a specific cell type may exemplify a common strategy for regulating cellular proliferation in other mammalian organs.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; SALK INST BIOL STUDIES, NEURONAL STRUCT & FUNCT LAB, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Salk Institute	LIN, SC (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.		Lin, SC/G-4666-2010					AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; AYLINN BD, 1993, MOL ENDOCRINOL, V7, P77; BARINAGA M, 1983, NATURE, V306, P84, DOI 10.1038/306084a0; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BORRELLI E, 1989, NATURE, V339, P538, DOI 10.1038/339538a0; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CARBAJOPEREZ E, 1990, CELL TISSUE RES, V261, P333, DOI 10.1007/BF00318674; CHENG TC, 1983, ENDOCRINOLOGY, V113, P1669, DOI 10.1210/endo-113-5-1669; DIETRICH W, 1992, GENETICS, V3, P425; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; ELLIOTT RW, 1992, MAMM GENOME, V3, pS81, DOI 10.1007/BF00648424; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; FRAWLEY LS, 1991, ENDOCR REV, V12, P337, DOI 10.1210/edrv-12-4-337; FROHMAN MA, 1989, MOL ENDOCRINOL, V3, P1529, DOI 10.1210/mend-3-10-1529; GICK GG, 1984, P NATL ACAD SCI-BIOL, V81, P1553, DOI 10.1073/pnas.81.5.1553; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; HEN R, 1989, P NATL ACAD SCI USA, V86, P4785, DOI 10.1073/pnas.86.12.4785; IKEDA H, 1991, CELL TISSUE RES, V263, P41, DOI 10.1007/BF00318398; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; ISHIHARA T, 1992, NEURON, V8, P815; JANSSON JO, 1986, SCIENCE, V232, P511, DOI 10.1126/science.3008329; JAPPNER H, 1991, SCIENCE, V254, P1024; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVINE MA, 1988, P NATL ACAD SCI USA, V85, P617, DOI 10.1073/pnas.85.2.617; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RIVIER J, 1982, NATURE, V300, P276, DOI 10.1038/300276a0; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROUSE M, 1982, CELL TISSUE RES, V223, P415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; SEIFERT H, 1985, NATURE, V313, P487, DOI 10.1038/313487a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SLABAUGH MB, 1981, ENDOCRINOLOGY, V109, P1040, DOI 10.1210/endo-109-4-1040; Sneil GD, 1929, P NATL ACAD SCI USA, V15, P733, DOI 10.1073/pnas.15.9.733; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; TSANG BK, 1980, J CELL PHYSIOL, V102, P19, DOI 10.1002/jcp.1041020104; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WARDEN CH, IN PRESS J CLIN INVE; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WILSON DB, 1986, ANAT EMBRYOL, V174, P277, DOI 10.1007/BF00824343	54	416	421	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1993	364	6434					208	213		10.1038/364208a0	http://dx.doi.org/10.1038/364208a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8391647				2022-12-28	WOS:A1993LM68300047
J	CULVER, GM; MCCRAITH, SM; ZILLMANN, M; KIERZEK, R; MICHAUD, N; LAREAU, RD; TURNER, DH; PHIZICKY, EM				CULVER, GM; MCCRAITH, SM; ZILLMANN, M; KIERZEK, R; MICHAUD, N; LAREAU, RD; TURNER, DH; PHIZICKY, EM			AN NAD DERIVATIVE PRODUCED DURING TRANSFER-RNA SPLICING - ADP-RIBOSE 1''-2'' CYCLIC PHOSPHATE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; PURIFICATION; NUCLEOTIDES; METABOLITE; SUBSTRATE; MECHANISM; LIGASE; ENZYME	Transfer RNA (tRNA) splicing is essential in Saccharomyces cerevisiae as well as in humans, and many of its features are the same in both. In yeast, the final step of this process is removal of the 2' phosphate generated at the splice junction during ligation. A nicotinamide adenine dinucleotide (NAD)-dependent phosphotransferase catalyzes removal of the 2' phosphate and produces a small molecule. It is shown here that this small molecule is an NAD derivative: adenosine diphosphate (ADP)-ribose 1''-2'' cyclic phosphate. Evidence is also presented that this molecule is produced in Xenopus laevis oocytes as a result of dephosphorylation of ligated tRNA.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,601 ELMWOOD AVE,ROCHESTER,NY 14642; POLISH ACAD SCI,INST BIOORGAN CHEM,PL-60704 POZNAN,POLAND; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627	University of Rochester; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; University of Rochester; University of Rochester			Schroeder, Susan/D-3946-2011	Kierzek, Ryszard/0000-0002-7644-0016	NIDCR NIH HHS [DE07202-02] Funding Source: Medline; NIGMS NIH HHS [GM 22939, GM 25349] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349, R01GM022939] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BARTON RA, 1977, J CHROMATOGR, V130, P145, DOI 10.1016/S0021-9673(00)89790-3; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, pCH1; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; CULVER GM, UNPUB; FERNLEY HN, 1971, ENZYMES, V4, pCH18; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HOPPER AK, 1992, MOL CELLULAR BIOL YE, P99; KALCKAR HM, 1947, J BIOL CHEM, V167, P477; KIERZEK R, UNPUB; KNAPP G, 1979, CELL, V18, P37, DOI 10.1016/0092-8674(79)90351-9; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LEE HC, 1989, J BIOL CHEM, V264, P1608; LITTLE JW, 1972, ANAL BIOCHEM, V48, P217, DOI 10.1016/0003-2697(72)90184-4; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; NEU HC, 1964, J BIOL CHEM, V239, P2927; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4597; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; REED TW, 1971, ENZYMES, V4, pCH17; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; RUSHIZKY GW, 1963, J BIOL CHEM, V238, P371; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; SZEKELY E, 1988, J BIOL CHEM, V263, P13839; TYC K, 1987, J BIOL CHEM, V262, P12994; UCHIDA T, 1967, J BIOCHEM-TOKYO, V61, P44, DOI 10.1093/oxfordjournals.jbchem.a128519; VONTOL H, 1988, NUCLEIC ACIDS RES, V16, P1951; WALDRON C, 1975, J BACTERIOL, V122, P855, DOI 10.1128/JB.122.3.855-865.1975; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZILLMANN M, 1992, J BIOL CHEM, V267, P10289	39	79	81	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					206	208		10.1126/science.8392224	http://dx.doi.org/10.1126/science.8392224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8392224				2022-12-28	WOS:A1993LL59600039
J	DAVIS, S; ALDRICH, TH; STAHL, N; PAN, L; TAGA, T; KISHIMOTO, T; IP, NY; YANCOPOULOS, GD				DAVIS, S; ALDRICH, TH; STAHL, N; PAN, L; TAGA, T; KISHIMOTO, T; IP, NY; YANCOPOULOS, GD			LIFR-BETA AND GP-130 AS HETERODIMERIZING SIGNAL TRANSDUCERS OF THE TRIPARTITE CNTF RECEPTOR	SCIENCE			English	Article							LEUKEMIA-INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; INTERLEUKIN-6; EXPRESSION; CLONING; GP130; CHAIN	The ciliary neurotrophic factor (CNTF) receptor complex is shown here to include the CNTF binding protein (CNTFRalpha) as well as the components of the leukemia inhibitory factor (LIF) receptor, LIFRbeta (the LIF binding protein) and gp130 [the signal transducer of interleukin-6 (IL-6)]. Thus, the conversion of a bipartite LIF receptor into a tripartite CNTF receptor apparently occurs by the addition of the specificity-conferring element CNTFRalpha. Both CNTF and LIF trigger the association of initially separate receptor components, which in turn results in tyrosine phosphorylation of receptor subunits. Unlike the IL-6 receptor complex in which homodimerization of gp130 appears to be critical for signal initiation, signaling by the CNTF and LIF receptor complexes depends on the heterodimerization of gp130 with LIFRbeta. Ligand-induced dimerization of signal-transducing receptor components, also seen with receptor tyrosine kinases, may provide a general mechanism for the transmission of a signal across the cell membrane.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,FUKUSHIMA KU,OSAKA 553,JAPAN	Osaka University; Osaka University	DAVIS, S (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Kishimoto, Tadamitsu/C-8470-2009					BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, UNPUB; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, UNPUB; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	31	623	660	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1805	1808		10.1126/science.8390097	http://dx.doi.org/10.1126/science.8390097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8390097				2022-12-28	WOS:A1993LH20500050
J	FFRENCHCONSTANT, RH; ROCHELEAU, TA; STEICHEN, JC; CHALMERS, AE				FFRENCHCONSTANT, RH; ROCHELEAU, TA; STEICHEN, JC; CHALMERS, AE			A POINT MUTATION IN A DROSOPHILA GABA RECEPTOR CONFERS INSECTICIDE RESISTANCE	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; ALPHA-SUBUNIT; PICROTOXININ; SEQUENCE; CHANNELS; DIELDRIN; CLONING; REGION; FORM; CDNA	VERTEBRATES and invertebrates both have GABA (gamma-aminobutyric acid) as a major inhibitory neurotransmitter1,2. GABA(A) receptors in vertebrates assemble as heteromultimers to form an integral chloride ion channel3. These receptors are targets for drugs and pesticides4 and are also implicated in seizure-related diseases5,6. Picrotoxinin (PTX) and cyclodiene insecticides are GABA(A) receptor antagonists which competitively displace each other from the same binding site7. Insects8 and vertebrates9 showing resistance to cyclodienes also show cross-resistance to PTX. Previously, we used a field-isolated Drosophila mutant Rdl (Resistant to dieldrin)10 insensitive to PTX and cyclodienes to clone a putative GABA receptor11. Here we report the functional expression and novel pharmacology of this GABA receptor and examine the functionality of a resistance-associated point mutation (alanine to serine) within the second membrane-spanning domain, the region thought to line the chloride ion channel pore. This substitution is found globally in Drosophila populations12. This mutation not only identifies a single amino acid conferring high levels of resistance to the important GABA receptor antagonist PTX but also, by conferring resistance to cyclodienes, may account for over 60% of reported cases of insecticide resistance13.	RHONE POULENC AG CO,RES TRIANGLE PK,NC 27709		FFRENCHCONSTANT, RH (corresponding author), UNIV WISCONSIN,DEPT ENTOMOL,RUSSELL LABS 237,1630 LINDEN DR,MADISON,WI 53706, USA.			ffrench-Constant, Richard/0000-0001-5385-9888				BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BLOOMQUIST JR, 1991, PESTIC SCI, V32, P463, DOI 10.1002/ps.2780320408; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; ELDEFRAWI AT, 1987, FASEB J, V1, P262, DOI 10.1096/fasebj.1.4.2443413; FEIGENSPAN A, 1993, NATURE, V361, P159, DOI 10.1038/361159a0; FFRENCHCONSTANT R, IN PRESS P NATN ACAD; FFRENCHCONSTANT RH, 1991, GENET RES, V57, P17, DOI 10.1017/S0016672300028986; FFRENCHCONSTANT RH, 1990, J ECON ENTOMOL, V83, P1733, DOI 10.1093/jee/83.5.1733; FFRENCHCONSTANT RH, 1992, J NEUROCHEM, V59, P1562, DOI 10.1111/j.1471-4159.1992.tb08475.x; FFRENCHCONSTANT RH, 1991, P NATL ACAD SCI USA, V88, P7209, DOI 10.1073/pnas.88.16.7209; GEORGHIOU GP, 1986, PEST RESISTANCE PEST; HARVEY RJ, 1991, EMBO J, V10, P3239, DOI 10.1002/j.1460-2075.1991.tb04887.x; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KADOUS AA, 1983, PESTIC BIOCHEM PHYS, V19, P157, DOI 10.1016/0048-3575(83)90135-9; KUFFLER SW, 1965, J NEUROPHYSIOL, V21, P589; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LUMMIS SCR, 1990, COMP BIOCHEM PHYS C, V95, P1, DOI 10.1016/0742-8413(90)90073-I; MATSUMURA F, 1983, J ENVIRON SCI HEAL B, V18, P1, DOI 10.1080/03601238309372355; MEDLRUM BS, 1989, BR J CLIN PHARM, V27, pS3; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QIAN HH, 1993, NATURE, V361, P162, DOI 10.1038/361162a0; ROUSH RT, 1987, ANNU REV ENTOMOL, V32, P361, DOI 10.1146/annurev.en.32.010187.002045; SATELLE DB, 1992, TRANSMITTER AMINO AC, P273; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; USHERWOOD PN, 1965, J NEUROPHYSIOL, V28, P497, DOI 10.1152/jn.1965.28.3.497; WAGSTAFF J, 1991, AM J HUM GENET, V49, P330; YARBROUGH JD, 1986, EXPERIENTIA, V42, P851, DOI 10.1007/BF01941551	32	461	489	2	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					449	451		10.1038/363449a0	http://dx.doi.org/10.1038/363449a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8389005				2022-12-28	WOS:A1993LE93800058
J	MALLICK, CA; DUDLEY, EC; VINEY, JL; OWEN, MJ; HAYDAY, AC				MALLICK, CA; DUDLEY, EC; VINEY, JL; OWEN, MJ; HAYDAY, AC			REARRANGEMENT AND DIVERSITY OF T-CELL RECEPTOR BETA-CHAIN GENES IN THYMOCYTES - A CRITICAL ROLE FOR THE BETA-CHAIN IN DEVELOPMENT	CELL			English	Article							TRANSGENIC MICE; LYMPHOCYTES-B; PRE-B; EXPRESSION; DNA; ORGANIZATION; REPERTOIRE; SEGMENTS; LAMBDA-5; THYMUS	Thymocytes from mice congenitally deficient for TCR alpha chain synthesis were examined for the status of their TCR beta chain genes, by DNA sequencing and by a novel technique that analyzes populations of gene rearrangements. TCR beta chain genes were predominantly productively rearranged, in contrast with the statistical prediction for a quasi-random rearrangement process. Therefore, productive TCR beta chain gene rearrangement appears to be a critical step in thymocyte maturation, independent of TCR alpha chain expression. Moreover, the beta chain gene rearrangements in TCRalpha-/- mice are typical of those found in the thymus and periphery of normal mice. Thus, the extent of junctional diversity is a property of TCR genes that is imposed prior to selection on the mature alphabeta TCR.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	MALLICK, CA (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.		Yang, Chen/G-1379-2010		NIGMS NIH HHS [GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BEHKLE MA, 1985, SCIENCE, V229, P566; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; CANDEIAS S, 1991, J EXP MED, V174, P989, DOI 10.1084/jem.174.5.989; CHIEN Y, 1984, NATURE, V312, P31, DOI 10.1038/312031a0; CHOU HS, 1987, SCIENCE, V238, P545, DOI 10.1126/science.2821625; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; Kisielow P, 1990, Semin Immunol, V2, P35; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; Maniatis T., 1982, MOL CLONING; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOLLAY R, 1978, NATURE, V276, P79, DOI 10.1038/276079a0; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0	34	183	186	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					513	519		10.1016/0092-8674(93)90138-G	http://dx.doi.org/10.1016/0092-8674(93)90138-G			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387894	hybrid			2022-12-28	WOS:A1993LA74300012
J	TINETTI, ME; LIU, WL; CLAUS, EB				TINETTI, ME; LIU, WL; CLAUS, EB			PREDICTORS AND PROGNOSIS OF INABILITY TO GET UP AFTER FALLS AMONG ELDERLY PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; FUNCTIONAL STATUS; OLD-PEOPLE; COMMUNITY; INTERVENTIONS; HOME	Objective.-To identify the predictors and prognosis associated with inability to get up after failing. Design.-Cohort study with a mean 21-month follow-up. Setting.-General community. Subjects.-1103 New Haven, Conn, residents aged 72 years and older who were able to follow simple commands and walk unassisted. Main Outcome Measures.-Self-reported inability to get up without help after falls not resulting in serious injury; activity restriction and hospitalization after a fall; death; and placement in a nursing home. Results.-Inability to get up without help was reported after 220 of 596 non-injurious falls. Of 313 noninjured fallers, 148 (47%) reported inability to get up after at least one fall. Compared with nonfallers, the risk factors independently associated with inability to get up included the following: an age of at least 80 years (adjusted relative risk [RR], 1.6; 95% confidence interval [CI], 1.2 to 2.1); depression (RR, 1.5; CI, 1.1 to 2.0); and poor balance and gait (RR, 2.0; CI, 1.5 to 2.7). Previous stroke (RR, 1.6; CI, 1.0 to 2.4) and sedative use (RR, 1.5; CI, 0.9 to 2.2) did not achieve significance. Among fallers, older age and poor balance and gait were associated marginally with inability to get up. Compared with fallers who were able to get up, fallers who were unable to get up were more likely to suffer lasting decline in activities of daily living (35% vs 26%). Fallers who were unable to get up were more likely to die, to be hospitalized, and to suffer a decline in activities of daily living for at least 3 days, and were less likely to be placed in a nursing home than were fallers who were able to get up, but these trends were not statistically significant. Conclusions.-The risk factors for inability to get up were similar to those for falling, although certain factors imparted a particular risk of inability to get up without help. The frequency of inability to get up and the short- and long-term morbidity associated with this inability suggest the need for preventive and treatment efforts.	YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510	Yale University	TINETTI, ME (corresponding author), YALE UNIV,SCH MED,DEPT MED,333 CEDAR ST,POB 3333,NEW HAVEN,CT 06510, USA.				NIA NIH HHS [R01AG07449] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007449] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; CORNONIHUNTLEY J, 1986, NIH862443 US DEP HLT; Cumming Robert G., 1990, Annals of Epidemiology, V1, P49; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRISSO JA, 1992, J AM GERIATR SOC, V40, P673; HINDMARSH JJ, 1989, ARCH INTERN MED, V149, P2217, DOI 10.1001/archinte.149.10.2217; Hoppenfeld S., 1976, PHYS EXAMINATION SPI, P1; HOSMER DW, 1989, APPL LOGISTIC REGRES, P216; KIEL DP, 1991, MED CARE, V29, P221; MALLINSON WJW, 1985, AGE AGEING, V14, P174, DOI 10.1093/ageing/14.3.174; MARCUS EL, 1992, J AM GERIATR SOC, V40, P454, DOI 10.1111/j.1532-5415.1992.tb02010.x; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Prudham D, 1981, Age Ageing, V10, P141; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RISCH HA, 1988, AM J EPIDEMIOL, V128, P420, DOI 10.1093/oxfordjournals.aje.a114982; SATTIN RW, 1992, ANNU REV PUBL HEALTH, V13, P489, DOI 10.1146/annurev.pu.13.050192.002421; SHELDON JH, 1960, BRIT MED J, V2, P1685, DOI 10.1136/bmj.2.5214.1685; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; VELLAS B, 1987, AGE AGEING, V16, P189, DOI 10.1093/ageing/16.3.189; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WALKER JE, 1991, AM J OCCUP THER, V45, P119, DOI 10.5014/ajot.45.2.119; WILD D, 1981, BRIT MED J, V282, P266, DOI 10.1136/bmj.282.6260.266; 1987, PF3986 CONS AFF PROG; 1987, DAN MED B S4, V34, P1; 1991, PHS9150213 US DEP HL	33	316	318	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					65	70		10.1001/jama.269.1.65	http://dx.doi.org/10.1001/jama.269.1.65			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KF026	8416408				2022-12-28	WOS:A1993KF02600029
J	MEYER, KC; MCMANUS, EJ; MAKI, DG				MEYER, KC; MCMANUS, EJ; MAKI, DG			OVERWHELMING PULMONARY BLASTOMYCOSIS ASSOCIATED WITH THE ADULT-RESPIRATORY-DISTRESS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NORTH-AMERICAN BLASTOMYCOSIS; WISCONSIN; DERMATITIDIS; EPIDEMIC; COCCIDIOIDOMYCOSIS; TUBERCULOSIS; DIAGNOSIS; OUTBREAK; PATIENT	Background and Methods. Few cases of overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome have been reported. We describe 10 patients with this condition who were treated at one center in Wisconsin. Results. All 10 patients presented with fever, cough, and dyspnea; radiographic evidence of diffuse pulmonary infiltrates; and marked impairment of oxygenation. The mean alveolar-arterial oxygen gradient was 616 mm Hg. Six of the patients had no underlying disease associated with altered immunity, and two had no recent exposure to environmental reservoirs of Blastomyces dermatitidis. In all 10 patients, large numbers of broad-based budding yeasts were seen on microscopical examination of tracheal secretions. All patients were treated with intravenous amphotericin B (0.7 to 1.0 mg per kilogram per day). Of the five survivors, four received full doses of amphotericin B in the first 24 hours, and four required mechanical ventilatory support for 7 to 151 days. Long-term follow-up of three survivors showed good recovery of pulmonary function. Conclusions. Overwhelming infection with B. dermatitidis can cause diffuse pneumonitis and the adult respiratory distress syndrome, even in immunocompetent hosts. With prompt diagnosis by microscopical examination of tracheal secretions, intensive therapy with amphotericin B, and ventilatory support, good recovery of pulmonary function is possible.	UNIV WISCONSIN,SCH MED,DEPT MED,PULM & CRIT CARE MED SECT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT MED,INFECT DIS SECT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,CTR TRAUMA & LIFE SUPPORT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								ARMSTRONG CW, 1987, J INFECT DIS, V155, P568, DOI 10.1093/infdis/155.3.568; ARVANITAKIS C, 1972, AM REV RESPIR DIS, V105, P827; ATKINSON JB, 1983, HUM PATHOL, V14, P186, DOI 10.1016/S0046-8177(83)80250-0; BRADSHER RW, 1992, CLIN INFECT DIS, V14, pS82, DOI 10.1093/clinids/14.Supplement_1.S82; BRADSHER RW, 1985, ANN INTERN MED, V103, P872, DOI 10.7326/0003-4819-103-6-872; BRONNIMANN DA, 1987, ANN INTERN MED, V106, P372, DOI 10.7326/0003-4819-106-3-372; BROWN LR, 1991, MAYO CLIN PROC, V66, P29, DOI 10.1016/S0025-6196(12)61172-0; CALLAWAY JJ, 1986, MAYO CLIN PROC, V61, P75, DOI 10.1016/S0025-6196(12)61402-5; COCKERILL FR, 1984, CHEST, V86, P688, DOI 10.1378/chest.86.5.688; CUSH R, 1976, CHEST, V69, P345, DOI 10.1378/chest.69.3.345; DERESINSKI SC, 1975, MEDICINE, V54, P377, DOI 10.1097/00005792-197509000-00002; DYER RA, 1984, THORAX, V39, P383, DOI 10.1136/thx.39.5.383; EHNI W, 1989, AM J MED, V86, P831, DOI 10.1016/0002-9343(89)90483-X; EVANS ME, 1982, AM REV RESPIR DIS, V126, P1099; FURCOLOW ML, 1970, AM J EPIDEMIOL, V92, P121, DOI 10.1093/oxfordjournals.aje.a121184; GRIFFITH JE, 1979, CHEST, V75, P630, DOI 10.1378/chest.75.5.630; KITCHEN MS, 1977, AM REV RESPIR DIS, V115, P1063; KLEIN BS, 1987, AM REV RESPIR DIS, V136, P1333, DOI 10.1164/ajrccm/136.6.1333; KLEIN BS, 1986, NEW ENGL J MED, V314, P529, DOI 10.1056/NEJM198602273140901; KLEIN BS, 1985, AM J EPIDEMIOL, V122, P897, DOI 10.1093/oxfordjournals.aje.a114173; LASKEY W, 1978, ANN INTERN MED, V88, P50, DOI 10.7326/0003-4819-88-1-50; LOCKRIDGE RS, 1979, SOUTHERN MED J, V72, P235, DOI 10.1097/00007611-197902000-00031; LOWRY PW, 1989, AM J EPIDEMIOL, V130, P151, DOI 10.1093/oxfordjournals.aje.a115307; MACDONALD D, 1990, CHEST, V98, P1527, DOI 10.1378/chest.98.6.1527; MARINI JJ, 1990, CLIN CHEST MED, V11, P673; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; ONAL E, 1976, AM REV RESPIR DIS, V113, P83; ONWUBALILI JK, 1986, Q J MED, V59, P599; PALMER PE, 1968, NEW ENGL J MED, V279, P979, DOI 10.1056/NEJM196810312791806; PAPPAS PG, 1992, ANN INTERN MED, V116, P847, DOI 10.7326/0003-4819-116-10-847; RECHT LD, 1982, AM REV RESPIR DIS, V125, P359; SANDERS JS, 1977, CHEST, V72, P193, DOI 10.1378/chest.72.2.193; SAROSI GA, 1979, AM REV RESPIR DIS, V120, P911; SHOEMAKER WC, 1989, CHEST, V96, P120, DOI 10.1378/chest.96.1.120; SKILLRUD DM, 1985, MAYO CLIN PROC, V60, P266, DOI 10.1016/S0025-6196(12)60320-6; Thiele J S, 1984, J La State Med Soc, V136, P38; TOSH FE, 1974, AM REV RESPIR DIS, V109, P525; WYNNE JW, 1974, CHEST, V66, P158, DOI 10.1378/chest.66.2.158	39	96	96	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1231	1236		10.1056/NEJM199310213291704	http://dx.doi.org/10.1056/NEJM199310213291704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8413389				2022-12-28	WOS:A1993MB98800004
J	SCHULTZ, JR; VERSTUYFT, JG; GONG, EL; NICHOLS, AV; RUBIN, EM				SCHULTZ, JR; VERSTUYFT, JG; GONG, EL; NICHOLS, AV; RUBIN, EM			PROTEIN-COMPOSITION DETERMINES THE ANTI-ATHEROGENIC PROPERTIES OF HDL IN TRANSGENIC MICE	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CORONARY-ARTERY DISEASE; CHOLESTEROL EFFLUX; PARTICLES; ATHEROSCLEROSIS; SIZE; SUSCEPTIBILITY; EXPRESSION; CELLS	HIGH-DENSITY lipoprotein (HDL) contains two major proteins, apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), comprising about 70% and 20% of the total HDL protein mass, respectively. HDL exists in human plasma in two main forms, one containing apoA-I with apoA-II (AI/AII-HDL) and another containing apoA-I without apoA-II (AI-HDL). A strong inverse relationship exists between total plasma HDL concentration and atherosclerosis, but the results of studies examining the relationship between AI-HDL and AI/AII-HDL and atherosclerosis have been conflicting1-9. To determine whether these two HDL populations have different effects on atherogenesis, human apoA-I (AI) and human apoA-I and apoA-II (AI/AII) transgenic mice were produced in an atherosclerosis-susceptible strain10-12. Following an atherogenic diet, despite similar total cholesterol and HDL cholesterol concentrations, the area of atherogenic lesions in the AI/AII mice was 15-fold greater than in the AI animals. These studies show that the protein composition of HDL significantly affects its role in atherogenesis and that AI-HDL is more anti-atherogenic than AI/AII-HDL.	LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory								BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; CIVEIRA F, 1992, ATHEROSCLEROSIS, V92, P165, DOI 10.1016/0021-9150(92)90275-L; COSTEBUREL M, 1990, CLIN CHEM, V36, P1889; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GENEST JJ, 1990, CIRCULATION, V82, P621; GLOMSET JA, 1968, J LIPID RES, V9, P155; IZZO C, 1981, CLIN CHEM, V27, P371; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; KNOTT TJ, 1984, BIOCHEM BIOPH RES CO, V120, P734, DOI 10.1016/S0006-291X(84)80168-0; LEBOEUF RC, 1990, J LIPID RES, V31, P91; LUC G, 1991, METABOLISM, V40, P1238, DOI 10.1016/0026-0495(91)90022-O; LUSSIERCACAN S, 1989, ATHEROSCLEROSIS, V78, P167, DOI 10.1016/0021-9150(89)90221-9; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P375; STEWARTPHILLIPS JL, 1991, ATHEROSCLEROSIS, V90, P211, DOI 10.1016/0021-9150(91)90117-L; VALIMAKI M, 1991, METABOLISM, V40, P1168, DOI 10.1016/0026-0495(91)90211-E	30	256	269	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					762	764		10.1038/365762a0	http://dx.doi.org/10.1038/365762a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413656				2022-12-28	WOS:A1993MC81200066
J	SIBAI, BM; CARITIS, SN; THOM, E; KLEBANOFF, M; MCNELLIS, D; ROCCO, L; PAUL, RH; ROMERO, R; WITTER, F; ROSEN, M; DEPP, R				SIBAI, BM; CARITIS, SN; THOM, E; KLEBANOFF, M; MCNELLIS, D; ROCCO, L; PAUL, RH; ROMERO, R; WITTER, F; ROSEN, M; DEPP, R			PREVENTION OF PREECLAMPSIA WITH LOW-DOSE ASPIRIN IN HEALTHY, NULLIPAROUS PREGNANT-WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL GROWTH-RETARDATION; INDUCED HYPERTENSION; CLINICAL-TRIALS; PRE-ECLAMPSIA; THERAPY; RISK	Background. Although low-dose aspirin has been reported to reduce the incidence of preeclampsia among women at high risk for this complication, its efficacy and safety in healthy, nulliparous pregnant women are not known. Methods. We studied 3135 normotensive nulliparous women who were 13 to 26 weeks pregnant to determine whether treatment with aspirin reduced the incidence of preeclampsia. Of this group, 1570 women received 60 mg of aspirin per day and 1565 received placebo for the remainder of their pregnancies. We also evaluated the effect of aspirin on maternal and neonatal morbidity. Results. Of the original group of 3135 women, 2985 (95 percent) were followed throughout pregnancy and the immediate puerperium. The incidence of preeclampsia was lower in the aspirin group (69 of 1485 women [4.6 percent]) than in the placebo group (94 of 1500 women [6.3 percent]) (relative risk, 0.7; 95 percent confidence interval, 0.6 to 1.0; P = 0.05), whereas the incidence of gestational hypertension was 6.7 and 5.9 percent, respectively. There were no significant differences in the infants' birth weight or in the incidence of fetal growth retardation, post-partum hemorrhage, or neonatal bleeding problems between the two groups. Subgroup analysis showed that preeclampsia occurred primarily in women whose initial systolic blood pressure was 120 to 134 mm Hg (incidence among such women, 5.6 percent in the aspirin group vs. 11.9 percent in the placebo group; P = 0.01). The incidence of abruptio placentae was greater among the women who received aspirin (11 women, vs. 2 in the placebo group; P = 0.01). Conclusions. Low-dose aspirin decreases the incidence of preeclampsia among nulliparous women, primarily through its effect in those who have elevated systolic blood pressure initially. This treatment does not decrease perinatal morbidity but increases the risk of abruptio placentae.			SIBAI, BM (corresponding author), DEPT OBSTET & GYNECOL,853 JEFFERSON SUITE E102,MEMPHIS,TN 38103, USA.		Romero, Roberto/A-5268-2019	Romero, Roberto/0000-0002-4448-5121; caritis, steve/0000-0002-2169-0712	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021410] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021366, U01HD021410, U10HD021434, U01HD021366, U01HD021434] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 21434, HD 21366, HD 21410] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS WW, 1992, J REPROD MED, V37, P73; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; BREMER HA, 1992, FETAL MATERN MED REV, V4, P37; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; COLLINS R, 1989, EFFECTIVE CARE PREGN, V1, P512; DEKKER GA, 1993, AM J OBSTET GYNECOL, V168, P214, DOI 10.1016/S0002-9378(12)90917-5; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OBRIEN WF, 1993, AM J OBSTET GYNECOL, V168, P1164, DOI 10.1016/0002-9378(93)90362-M; ODENDAAL HJ, 1990, OBSTET GYNECOL, V76, P1070; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P777, DOI 10.1016/0002-9378(90)91009-2; SIBAI BM, 1989, OBSTET GYNECOL, V74, P551; SIBAI BM, 1991, OBSTETRICS NORMAL PR, P993; TRUDINGER BJ, 1988, AM J OBSTET GYNECOL, V159, P681, DOI 10.1016/S0002-9378(88)80034-6; UZAN S, 1991, LANCET, V337, P1427, DOI 10.1016/0140-6736(91)93124-R; WALLENBURG HCS, 1987, AM J OBSTET GYNECOL, V157, P1230, DOI 10.1016/S0002-9378(87)80300-9; WALLENBURG HCS, 1986, LANCET, V1, P1; 1993, LANCET, V341, P396; 1990, AM J OBSTET GYNECOL, V163, P1689	25	419	427	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1213	1218		10.1056/NEJM199310213291701	http://dx.doi.org/10.1056/NEJM199310213291701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8413387	Bronze			2022-12-28	WOS:A1993MB98800001
J	FRASURESMITH, N; LESPERANCE, F; TALAJIC, M				FRASURESMITH, N; LESPERANCE, F; TALAJIC, M			DEPRESSION FOLLOWING MYOCARDIAL-INFARCTION - IMPACT ON 6-MONTH SURVIVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; HEART-RATE VARIABILITY; AFFECTIVE-DISORDERS; MORTALITY; VARIABLES; SEROTONIN; PLATELETS; THERAPY	Objective.-To determine if the diagnosis of major depression in patients hospitalized following myocardial infarction (MI) would have an independent impact on cardiac mortality over the first 6 months after discharge. Design.-Prospective evaluation of the impact of depression assessed using a modified version of the National Institute of Mental Health Diagnostic Interview Schedule for major depressive episode. Cox proportional hazards regression was used to evaluate the independent impact of depression after control for significant clinical predictors in the data set. Setting.-A large, university-affiliated hospital specializing in cardiac care, located in Montreal, Quebec. Patients.-All consenting patients (N=222) who met established criteria for MI between August 1991 and July 1992 and who survived to be discharged from the hospital. Patients were interviewed between 5 and 15 days following the MI and were followed up for 6 months. There were no age limits (range, 24 to 88 years; mean, 60 years). The sample was 78% male. Primary Outcome Measure.-Survival status at 6 months. Results.-By 6 months, 12 patients had died. All deaths were due to cardiac causes. Depression was a significant predictor of mortality (hazard ratio, 5.74; 95% confidence interval, 4.61 to 6.87; P=.0006). The impact of depression remained after control for left ventricular dysfunction (Killip class) and previous MI, the multivariate significant predictors of mortality in the data set (adjusted hazard ratio, 4.29; 95% confidence interval, 3.14 to 5.44; P=.013). Conclusion.-Major depression in patients hospitalized following an MI is an independent risk factor for mortality at 6 months. Its impact is at least equivalent to that of left ventricular dysfunction (Killip class) and history of previous MI. Additional study is needed to determine whether treatment of depression can influence post-MI survival and to assess possible underlying mechanisms.	MCGILL UNIV,DEPT PSYCHIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; UNIV MONTREAL,DEPT PSYCHIAT,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA	McGill University; Universite de Montreal; Universite de Montreal	FRASURESMITH, N (corresponding author), MONTREAL HEART INST,RES CTR,5000 BELANGER E,MONTREAL H1T 1C8,QUEBEC,CANADA.		Lesperance, Francois/C-4716-2015	Lesperance, Francois/0000-0003-4604-2823; Talajic, Mario/0000-0001-8469-4748				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; BEACH ML, 1989, CONTROL CLIN TRIALS, V10, pS161; Beck A.T., 1987, BECK DEPRESSION INVE; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BLUMENTHAL JA, 1982, PSYCHOSOM MED, V44, P519, DOI 10.1097/00006842-198212000-00003; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; CARNEY RM, 1988, J PSYCHOSOM RES, V32, P159, DOI 10.1016/0022-3999(88)90050-5; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; COX DR, 1972, J R STAT SOC B, V34, P187; DALACK GW, 1990, J CLIN PSYCHIAT, V51, P4; Dixon W. J., 1990, BMDP STATISTICAL SOF; FIELDING R, 1991, SOC SCI MED, V32, P1017, DOI 10.1016/0277-9536(91)90159-A; FRASURESMITH N, 1991, AM J CARDIOL, V67, P121, DOI 10.1016/0002-9149(91)90432-K; GORKIN L, IN PRESS CONTROLLED; HAGA DA, 1991, PSYCHOL BULL, V110, P215; HOUSE A, 1988, J PSYCHOSOM RES, V32, P345, DOI 10.1016/0022-3999(88)90017-7; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KUSUMI I, 1991, BIOL PSYCHIAT, V30, P310, DOI 10.1016/0006-3223(91)90114-2; LADWIG KH, 1991, EUR HEART J, V12, P959; MCGEE HM, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283-a; MELTZER HY, 1991, 5 HYDROXYTRYPTAMINE, P50; Meltzer HY., 1987, PSYCHOPHARMACOLOGY 3, VVol. 1, P513; MIKUNI M, 1992, PSYCHOPHARMACOLOGY, V106, P311, DOI 10.1007/BF02245410; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; PENKOFER S, 1991, CIRCULATION S2, V84, P59; PEREZSTABLE EJ, 1990, ARCH INTERN MED, V150, P1083, DOI 10.1001/archinte.150.5.1083; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; RICHARDSON JL, 1987, HEALTH PSYCHOL, V6, P183, DOI 10.1037/0278-6133.6.3.183; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROOSE SP, 1992, J CLIN PSYCHIAT, V53, P25; ROOSE SP, 1991, J CLIN PSYCHIAT, V52, P34; RUBERMAN W, 1984, NEW ENGL J MED, V311, P522; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; STOKES JP, 1989, ANXIETY DEPRESSION D, P253; VANHOUTTE PM, 1991, J CARDIOVASC PHARM, V17, pS6; Yamaguchi K., 1991, EVENT HIST ANAL; ZUNG W W K, 1990, Journal of Clinical Psychiatry, V51, P77; 1987, DIAGNOSTIC STATISTIC; 1991, NEW ENGL J MED, V325, P293; 1982, JAMA-J AM MED ASSOC, V247, P1707	41	1511	1544	0	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1819	1825		10.1001/jama.270.15.1819	http://dx.doi.org/10.1001/jama.270.15.1819			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MB464	8411525				2022-12-28	WOS:A1993MB46400024
J	CHENEY, RE; OSHEA, MK; HEUSER, JE; COELHO, MV; WOLENSKI, JS; ESPREAFICO, EM; FORSCHER, P; LARSON, RE; MOOSEKER, MS				CHENEY, RE; OSHEA, MK; HEUSER, JE; COELHO, MV; WOLENSKI, JS; ESPREAFICO, EM; FORSCHER, P; LARSON, RE; MOOSEKER, MS			BRAIN MYOSIN-V IS A 2-HEADED UNCONVENTIONAL MYOSIN WITH MOTOR-ACTIVITY	CELL			English	Article							CALMODULIN-BINDING PROTEINS; PROTEOLYTIC FRAGMENTS; INVITRO MOTILITY; ACTIN-FILAMENTS; CHICKEN BRAIN; LIGHT-CHAINS; MUSCLE; COMPLEX; CALCIUM; PURIFICATION	Chicken myosin-V is a member of a recently recognized class of myosins distinct from both the myosins-I and the myosins-II. We report here the purification, electron microscopic visualization, and motor properties of a protein of this class. Myosin-V molecules consist of two heads attached to an approximately 30 nm stalk that ends in a globular region of unknown function. Myosin-V binds to and decorates F-actin, has actin-activated magnesium-ATPase activity, and is a barbed-end-directed motor capable of moving actin filaments at rates of up to 400 nm/s. Myosin-V does not form filaments. Each myosin-V heavy chain is associated with approximately four calmodulin light chains as well as two less abundant proteins of 23 and 17 kd.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL, ST LOUIS, MO 63110 USA; UNIV SAO PAULO, SCH MED RIBEIRAO PRETO, DEPT BIOCHEM, BR-14049 RIBEIRAO PRETO, SP, BRAZIL	Washington University (WUSTL); Universidade de Sao Paulo	CHENEY, RE (corresponding author), YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA.		Heuser, John/H-5940-2012; Espreafico, Enilza/AAW-4658-2021; Espreafico, Enilza/O-3053-2016	Espreafico, Enilza/0000-0002-7552-4234; Espreafico, Enilza/0000-0002-7552-4234; Cheney, Richard/0000-0001-6565-7888	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025387, R01DK025387, R56DK025387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25387] Funding Source: Medline; NIGMS NIH HHS [GM-29647] Funding Source: Medline; NINDS NIH HHS [NS-28695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANSON LW, 1992, CELL MOTIL CYTOSKEL, V22, P274, DOI 10.1002/cm.970220407; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; KENDRICKJONES J, 1981, J MUSCLE RES CELL M, V2, P347, DOI 10.1007/BF00711965; KIELLEY WW, 1960, BIOCHIM BIOPHYS ACTA, V41, P401; KNIGHT AE, 1993, J MOL BIOL, V231, P148, DOI 10.1006/jmbi.1993.1266; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LARSON RE, 1990, J NEUROCHEM, V54, P1288, DOI 10.1111/j.1471-4159.1990.tb01961.x; LARSON RE, 1988, BRAZ J MED BIOL RES, V21, P213; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; MERCER JA, 1991, NATURE, V352, P547, DOI 10.1038/352547b0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOOSEKER MS, 1991, CURR TOP MEMBR, V38, P31; PLANCKE YD, 1983, MOL CELL BIOL, V3, P1412, DOI 10.1128/MCB.3.8.1412; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SCOPES RK, 1987, PROTEIN PURFICATION; SHEETZ MP, 1986, METHOD ENZYMOL, V134, P531; SILVERS WK, 1979, COAT COLORS MICE, P83; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; TAKIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P671, DOI 10.1093/oxfordjournals.jbchem.a123106; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; WOLENSKI JS, 1993, IN PRESS J EXP ZOOL	45	386	391	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					13	23		10.1016/0092-8674(93)90675-G	http://dx.doi.org/10.1016/0092-8674(93)90675-G			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402892	hybrid			2022-12-28	WOS:A1993MB66700004
J	PENDERGAST, AM; QUILLIAM, LA; CRIPE, LD; BASSING, CH; DAI, ZH; LI, NX; BATZER, A; RABUN, KM; DER, CJ; SCHLESSINGER, J; GISHIZKY, ML				PENDERGAST, AM; QUILLIAM, LA; CRIPE, LD; BASSING, CH; DAI, ZH; LI, NX; BATZER, A; RABUN, KM; DER, CJ; SCHLESSINGER, J; GISHIZKY, ML			BCR-ABL-INDUCED ONCOGENESIS IS MEDIATED BY DIRECT INTERACTION WITH THE SH2 DOMAIN OF THE GRB-2 ADAPTER PROTEIN	CELL			English	Article							MITOGENIC SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; RAS PROTEINS; GENE-PRODUCT; SEVENLESS GENE; C-ABL; GROWTH; CELLS	BCR-ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph1)-positive human leukemias. Sequences within the first exon of BCR are required to activate the transforming potential of BCR-ABL. The SH2/SH3 domain-containing GRB-2 protein links tyrosine kinases to Ras signaling. We demonstrate that BCR-ABL exists in a complex with GRB-2 in vivo. Binding of GRB-2 to BCR-ABL is mediated by the direct interaction of the GRB-2 SH2 domain with a phosphorylated tyrosine, Y177, within the BCR first exon. The BCR-ABL-GRB-2 interaction is required for activation of the Ras signaling pathway. Mutation of Y177 to phenylalanine (Y177F) abolishes GRB-2 binding and abrogates BCR-ABL-induced Ras activation. The BCR-ABL (Y177F) mutant is unable to transform primary bone marrow cultures and is impaired in its ability to transform Rat1 fibroblasts. These findings implicate activation of Ras function as an important component in BCR-ABL-mediated transformation and demonstrate that GRB-2 not only functions in normal development and mitogenesis but also plays a role in oncogenesis.	UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; DUKE UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, DURHAM, NC 27710 USA; NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; SUGEN INC, REDWOOD CITY, CA 94063 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; New York University	PENDERGAST, AM (corresponding author), DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA.		Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015	Pendergast, Ann Marie/0000-0002-1250-6880; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978] Funding Source: Medline; NIDDK NIH HHS [DK01965] Funding Source: Medline; NIGMS NIH HHS [GM07184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HAUSER CA, 1993, IN PRESS METH ENZYMO; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU JX, 1993, ONCOGENE, V8, P101; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIMMONS MS, 1989, ONCOGENE, V4, P559; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	64	620	641	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					175	185		10.1016/S0092-8674(05)80094-7	http://dx.doi.org/10.1016/S0092-8674(05)80094-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402896	hybrid			2022-12-28	WOS:A1993MB66700018
J	MORRIS, M				MORRIS, M			TELLING TAILS EXPLAIN THE DISCREPANCY IN SEXUAL PARTNER REPORTS	NATURE			English	Article							HIV TRANSMISSION; LIFE-STYLES	AN anomaly often noted in surveys of sexual behaviour is that the number of female sexual partners reported by men exceeds the number of male partners reported by women1-3. This discrepancy is sometimes interpreted as evidence that surveys produce unreliable data due to sex-linked response and sampling bias. We report here that among the 90% of respondents reporting fewer than 20 lifetime partners, however, the ratio of male to female reports drops from 3.2:1 to 1.2:1. The anomaly thus appears to be driven by the upper tail of the contact distribution, an example of the general principle of outlier influence in data analysis. The implication is that sexual behaviour surveys provide reliable data in the main, and that simple improvements can increase precision in the upper tail to make these data more useful for modelling the spread of AIDS and other sexually transmitted diseases.	COLUMBIA UNIV,DEPT SOCIOL,NEW YORK,NY 10027	Columbia University	MORRIS, M (corresponding author), UNIV CAMBRIDGE,ISAAC NEWTON INST MATH SCI,20 CLARKSON RD,CAMBRIDGE CB3 0EH,ENGLAND.		Morris, Martina/I-7510-2012					ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; BLOWER SM, 1992, J ACQ IMMUN DEF SYND, V5, P633; BLYTHE SP, 1990, NATURE, V344, P202, DOI 10.1038/344202a0; BURT RS, 1984, SOC NETWORKS, V6, P293, DOI 10.1016/0378-8733(84)90007-8; HETHCOTE H, 1984, TRANSMISSION DYNAMIC; Hethcote HW, 1992, MODELING HIV TRANSMI; JACQUEZ JA, 1993, EPIDEMIC MODELS THEI; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; JOHNSON AM, 1990, NATURE, V343, P109, DOI 10.1038/343109a0; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MORRIS M, 1991, MATH BIOSCI, V107, P349, DOI 10.1016/0025-5564(91)90014-A; MORRIS M, 1993, SOC METH RES, V22, P97; NORC, 2021, GEN SOC SERV; POTTERAT JJ, 1990, J SEX RES, V27, P233, DOI 10.1080/00224499009551554; RODRIGUEZ G, 1981, POP STUD-J DEMOG, V35, P321, DOI 10.1080/00324728.1981.10404970; Smith T. W., 1992, J OFF STAT, V8, P309; SMITH TW, 1991, NORC68 GEN SOC SURV; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; 1992, NATURE, V360, P407	19	110	110	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					437	440		10.1038/365437a0	http://dx.doi.org/10.1038/365437a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413586				2022-12-28	WOS:A1993LZ63300055
J	AMON, A; TYERS, M; FUTCHER, B; NASMYTH, K				AMON, A; TYERS, M; FUTCHER, B; NASMYTH, K			MECHANISMS THAT HELP THE YEAST-CELL CYCLE CLOCK TICK - G2 CYCLINS TRANSCRIPTIONALLY ACTIVATE G2 CYCLINS AND REPRESS G1 CYCLINS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PROTEIN-KINASE; DNA-SYNTHESIS; S-PHASE; POSITIVE FEEDBACK; GENE-EXPRESSION; HO GENE; COMPLEX; MITOSIS	In budding yeast, G1 cyclins such as CLN1 and CLN2 are expressed in G1 and S phases, while mitotic cyclins such as CLB1 and CLB2 are expressed in G2 and M phases. We find that the CLBs play a central role in the transition from CLNs to CLBs: the CLBs stimulate their own expression while repressing that of CLNs. This negative regulation of CLNs may occur via the transcription factor SW14, because CLBs are necessary for G2 repression of SCB-regulated genes like CLN1 and CLN2 but not for repression of MCB-regulated genes like DNA polymerase and CLBS. Furthermore, SW14 associates with CLB2 protein and is a substrate for the CLB2-associated CDC28 kinase in vitro.			AMON, A (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Tyers, Michael/ABE-3194-2021	Amon, Angelika/0000-0001-9837-0314; Nasmyth, Kim/0000-0001-7030-4403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039978, R01GM045410] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39978, GM45410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; Kaufman T C, 1990, Adv Genet, V27, P309; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; Maniatis T., 1982, MOL CLONING; MCKINNEY J, 1992, Current Biology, V2, P421, DOI 10.1016/0960-9822(92)90322-2; MOLL T, 1992, J CELL SCI S, V16, P87; MORTIMER RK, 1969, YEASTS, V1, P385; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PINES J, 1990, New Biologist, V2, P389; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Rubin G M, 1975, Methods Cell Biol, V12, P45; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOCKANATHAN S, 1991, THESIS U CAMBRIDGE C; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	56	310	314	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					993	1007		10.1016/0092-8674(93)90722-3	http://dx.doi.org/10.1016/0092-8674(93)90722-3			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402888				2022-12-28	WOS:A1993LY49300007
J	KENDRICK, T; SIBBALD, B; ADDINGTONHALL, J; BRENNEMAN, D; FREELING, P				KENDRICK, T; SIBBALD, B; ADDINGTONHALL, J; BRENNEMAN, D; FREELING, P			DISTRIBUTION OF MENTAL-HEALTH PROFESSIONALS WORKING ON SITE IN ENGLISH AND WELSH GENERAL PRACTICES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC CLINICS; CARE; SERVICES	Objective-To describe the nature and distribution of mental health professionals working on site in general practices. Design-Postal questionnaire and telephone interview survey. Setting-English and Welsh general practices. Subjects-1880 general practitioners, of whom 1542 (82%) responded. Main outcome measures-Prevalence, types, and distribution of mental health professionals working on site among general practices. Factors predicting the presence of mental health professionals on site. Results-The number of practices reporting the presence on site of each type of professional were 528 for community psychiatric nurses; 266 for practice counsellors; 177 for clinical psychologists; 132 for psychiatrists; 96 for psychiatric social workers; and 45 for psychotherapists. Mental health professionals tended to cluster together in practices more often than expected by chance alone. Practice characteristics which independently predicted the presence of a mental health professional on site were having four or more partners; being a training practice; and running stress, bereavement, or other mental health clinics. The proportions of practices with mental health professionals on site varied significantly among health regions. There was no association between the presence of mental health professionals on site and the location of practices, the social class mix of patients, or the estimated percentage of elderly patients or patients of non-European origin. Conclusions-Mental health professionals tend to cluster together, with a preponderance in larger training practices. Specialist mental health care provision within general practices is unevenly distributed. Further research is needed to determine whether this uneven distribution reflects differences in need or inequalities in the provision of mental health services.	ST GEORGE HOSP, SCH MED, DIV GEN PRACTICE & PRIMARY CARE, LONDON SW17 0RE, ENGLAND	St Georges University London	KENDRICK, T (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND.		Kendrick, Tony/H-8558-2014	Kendrick, Tony/0000-0003-1618-9381				GOLDBERG D, 1991, EVALUATION COMPREHEN, P115; HALL J, 1986, B BRIT PSYCHOL SOC, V39, P126; JARMAN B, 1992, BRIT MED J, V305, P1130, DOI 10.1136/bmj.305.6862.1130; SIBBALD B, 1993, BMJ-BRIT MED J, V306, P29, DOI 10.1136/bmj.306.6869.29; STRATHDEE G, 1984, J ROY COLL GEN PRACT, V34, P615; THOMAS RVR, 1992, BRIT J GEN PRACT, V42, P358; TYRER P, 1984, BRIT J PSYCHIAT, V145, P15, DOI 10.1192/bjp.145.1.15; TYRER P, 1984, BRIT J PSYCHIAT, V145, P9, DOI 10.1192/bjp.145.1.9; WHITE E, 1991, 3RD QUINQUENNIAL NAT; WILLIAMS P, 1989, BRIT J PSYCHIAT, V154, P67, DOI 10.1192/bjp.154.1.67; WOOFF K, 1988, BRIT J PSYCHIAT, V153, P30, DOI 10.1192/bjp.153.1.30	11	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1993	307	6903					544	546		10.1136/bmj.307.6903.544	http://dx.doi.org/10.1136/bmj.307.6903.544			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400977	Green Published, Bronze			2022-12-28	WOS:A1993LV18000023
J	BAKER, TA; MIZUUCHI, M; SAVILAHTI, H; MIZUUCHI, K				BAKER, TA; MIZUUCHI, M; SAVILAHTI, H; MIZUUCHI, K			DIVISION-OF-LABOR AMONG MONOMERS WITHIN THE MU-TRANSPOSASE TETRAMER	CELL			English	Article							DNA STRAND-TRANSFER; P ELEMENT TRANSPOSITION; BACTERIOPHAGE-MU; B-PROTEIN; PHAGE-MU; INVITRO TRANSPOSITION; A-PROTEIN; CLEAVAGE; SITE; ENDS	A single tetramer of Mu transposase (MuA) pairs the recombination sites, cleaves the donor DNA, and joins these ends to a target DNA by strand transfer. Analysis of C-terminal deletion derivatives of MuA reveals that a 30 amino acid region between residues 575 and 605 is critical for these three steps. Although inactive on its own, a deletion protein lacking this region assembles with the wild-type protein. These mixed tetramers carry out donor cleavage but do not promote strand transfer, even when the donor cleavage stage is by-passed. These data suggest that the active center of the transposase is composed of the C-terminus of four MuA monomers; one dimer carries out donor cleavage while all four monomers contribute to strand transfer.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Savilahti, Harri/0000-0002-6246-2572				ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BETERMIER M, 1990, MOL MICROBIOL, V3, P1159; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DESMET L, 1989, MOL MICROBIOL, V3, P1145, DOI 10.1111/j.1365-2958.1989.tb00265.x; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ENGELMAN A, 1993, IN PRESS EMBO J, V12; HANIFORD DB, 1991, CELL, V64, P171; JONES KS, 1992, J BIOL CHEM, V267, P16037; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; RIO DC, 1991, TRENDS GENET, V7, P282, DOI 10.1016/0168-9525(91)90176-Q; STUDIER TA, 1990, METHOD ENZYMOL, V185, P60; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WIEGAND TW, 1992, J BACTERIOL, V174, P1229, DOI 10.1128/jb.174.4.1229-1239.1992; ZOU A, 1991, J BIOL CHEM, V266, P20476	40	98	100	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					723	733		10.1016/0092-8674(93)90519-V	http://dx.doi.org/10.1016/0092-8674(93)90519-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395353				2022-12-28	WOS:A1993LU59200015
J	KASAI, H; LI, YX; MIYASHITA, Y				KASAI, H; LI, YX; MIYASHITA, Y			SUBCELLULAR-DISTRIBUTION OF CA2+ RELEASE CHANNELS UNDERLYING CA2+ WAVES AND OSCILLATIONS IN EXOCRINE PANCREAS	CELL			English	Article							ACINAR-CELLS; INOSITOL TRISPHOSPHATE; CALCIUM-CONCENTRATION; ENDOPLASMIC-RETICULUM; CA-2+; RECEPTOR; LOCALIZATION; STIMULATION; SECRETION; MECHANISM	Agonists trigger Ca2+ waves and oscillations in exocrine gland cells. Our confocal Ca2+ imaging revealed three distinct phases during the Ca2+ waves in the rat pancreatic acinar cell. Rises in Ca2+ concentration were initiated at a small trigger zone, or T zone, in the granular area; then, Ca2+ waves rapidly spread within the area and, at high agonist concentrations, propagated slowly toward the basal pole. Injection of inositol 1,4,5-trisphosphate (IP3) or Ca2+ from patch pipettes demonstrated the presence of high sensitivity IP3 receptors at the T zone, Ca2+-induced Ca2+ release channels in the granular area, and low sensitivity IP3 receptors in the basal area. The IP3 receptors at the T zone appeared to generate autonomous Ca2+ spikes and to initiate patterned Ca2+ oscillations. Thus, heterogeneous cytosolic localization of Ca2+ release channels plays a key role in Ca2+ waves and oscillations.			KASAI, H (corresponding author), UNIV TOKYO, FAC MED, DEPT PHYSIOL, BUNKYO KU, TOKYO 113, JAPAN.		Miyashita, Yasushi/B-7171-2019	Miyashita, Yasushi/0000-0003-3496-8637; Kasai, Haruo/0000-0003-2327-9027				AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kern HF, 1986, EXOCRINE PANCREAS BI, P9; LASKEY RE, 1992, P NATL ACAD SCI USA, V89, P1690, DOI 10.1073/pnas.89.5.1690; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; MARUYAMA Y, 1993, J PHYSIOL-LONDON, V463, P729, DOI 10.1113/jphysiol.1993.sp019619; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIYAZAKI S, 1988, DEV GROWTH DIFFER, V30, P603; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SITSAPESAN R, 1990, J PHYSIOL-LONDON, V423, P425, DOI 10.1113/jphysiol.1990.sp018031; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145	43	344	345	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					669	677		10.1016/0092-8674(93)90514-Q	http://dx.doi.org/10.1016/0092-8674(93)90514-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395348				2022-12-28	WOS:A1993LU59200010
J	MCLAUGHLIN, PJ; GOOCH, JT; MANNHERZ, HG; WEEDS, AG				MCLAUGHLIN, PJ; GOOCH, JT; MANNHERZ, HG; WEEDS, AG			STRUCTURE OF GELSOLIN SEGMENT-1-ACTIN COMPLEX AND THE MECHANISM OF FILAMENT SEVERING	NATURE			English	Article							ACTIN-BINDING PROTEINS; HUMAN ANNEXIN-V; F-ACTIN; PLASMA GELSOLIN; SITES; SEQUENCE; DOMAINS; ACID; CRYSTALLIZATION; IDENTIFICATION	The structure of the segment 1 domain of gelsolin, a protein that fragments actin filaments in cells, is reported in complex with actin. Segment 1 binds monomer using an apolar patch rimmed by hydrogen bonds in a cleft between actin domains. On the actin filament model it binds tangentially, disrupting only those contacts between adjacent subunits in one helical strand. The segment 1 fold is general for all segments of the gelsolin family because the conserved residues form the core of the structure. It also provides a basis for understanding the origin of an amyloidosis caused by a gelsolin variant.	UNIV MARBURG,INST CYTOBIOL & CYTOPATHOL,W-3550 MARBURG,GERMANY	Philipps University Marburg	MCLAUGHLIN, PJ (corresponding author), MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.		Mannherz, Hans Georg/HHM-2867-2022	Mannherz, Hans Georg/0000-0001-8158-5722				AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BREMER A, 1991, J CELL BIOL, V115, P689, DOI 10.1083/jcb.115.3.689; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELACHAPELLE A, 1992, NAT GENET, V2, P157, DOI 10.1038/ng1092-157; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; DOI Y, 1984, J BIOL CHEM, V259, P1868; DOI Y, 1992, BIOCHEMISTRY-US, V31, P10061, DOI 10.1021/bi00156a028; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MANNHERZ HG, 1992, J MOL BIOL, V226, P899, DOI 10.1016/0022-2836(92)90641-V; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MCLAUGHLIN PJ, 1992, FEBS LETT, V302, P253, DOI 10.1016/0014-5793(92)80453-N; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TELLAM RL, 1989, TRENDS BIOCHEM SCI, V14, P130, DOI 10.1016/0968-0004(89)90142-4; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; VANDEKERCKHOVE J, 1984, J MOL BIOL, V179, P391, DOI 10.1016/0022-2836(84)90072-X; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YIN HL, 1988, BIOESSAYS, V7; YU FX, 1992, J BIOL CHEM, V267, P14616; [No title captured]	46	524	536	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					685	692		10.1038/364685a0	http://dx.doi.org/10.1038/364685a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8395021				2022-12-28	WOS:A1993LT67700047
J	NABESHIMA, Y; HANAOKA, K; HAYASAKA, M; ESUMI, E; LI, SW; NONAKA, I; NABESHIMA, Y				NABESHIMA, Y; HANAOKA, K; HAYASAKA, M; ESUMI, E; LI, SW; NONAKA, I; NABESHIMA, Y			MYOGENIN GENE DISRUPTION RESULTS IN PERINATAL LETHALITY BECAUSE OF SEVERE MUSCLE DEFECT	NATURE			English	Article							MYOD; FIBROBLASTS; EXPRESSION; MYOBLASTS; INACTIVATION; SOMITES; FAMILY; MYF-5; MRF4	MYOGENIN is a member of the basic helix-loop-helix (bHLH) gene family and converts multipotential mesodermal cells to myoblasts1-4. The four members of the myoD family show unique spatio-temporal expression patterns5 and therefore may have different functions during myogenesis. Here we inactivate the myogenin gene in order to understand its role in myogenesis. Homozygous mutations are lethal perinatally owing to the resulting major defects in skeletal muscle. The extent of disorganization of muscle tissue differs in three regions. In the latero-ventral body wall, most cells, including myogenic cells, disappear and there is rapid accretion of fluid. In the limbs, cells of the myogenic lineage exist, but they are severely disrupted, and some of them are mono-nucleate with properties of myoblasts. In contrast, there are many axial, intercostal and back muscle fibres to be seen, although fibres are mainly disorganized and Z-lines are not present in most myofibrils. These findings are evidence that myogenin is crucial for muscle development in utero and demonstrate that other members of the myogenic gene family cannot compensate for the defect.	NATL INST NEUROSCI,DEPT ANIM MODEL HUMAN DIS,KODAIRA,TOKYO 187,JAPAN; NATL INST NEUROSCI,DEPT ULTRASTRUCT RES,KODAIRA,TOKYO 157,JAPAN; JICHI MED SCH,DEPT NEUROL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Jichi Medical University	NABESHIMA, Y (corresponding author), NATL INST NEUROSCI,DEPT MOLEC GENET,NCNP 4-1-1,OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN.							ABE H, 1989, DEV BIOL, V118, P42; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CUSELLADEANGELIS MG, 1992, J CELL BIOL, V116, P1243, DOI 10.1083/jcb.116.5.1243; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDE DA, 1986, SOMITES DEV EMBRYOS, P209; FUJISAWASEHARA A, 1992, J BIOL CHEM, V267, P10031; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KIM DW, 1990, GENE, V9, P217; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILAIRE J, 1976, Archives de Biologie, V87, P315; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; OLSEN EN, 1992, DEV BIOL, V154, P261; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SAWAI S, 1991, NEW BIOL, V3, P861; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	26	732	755	3	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					532	535		10.1038/364532a0	http://dx.doi.org/10.1038/364532a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393146				2022-12-28	WOS:A1993LQ66700056
J	CONE, RW; HACKMAN, RC; HUANG, MLW; BOWDEN, RA; MEYERS, JD; METCALF, M; ZEH, J; ASHLEY, R; COREY, L				CONE, RW; HACKMAN, RC; HUANG, MLW; BOWDEN, RA; MEYERS, JD; METCALF, M; ZEH, J; ASHLEY, R; COREY, L			HUMAN HERPESVIRUS-6 IN LUNG-TISSUE FROM PATIENTS WITH PNEUMONITIS AFTER BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; CYTOMEGALO-VIRUS INFECTION; INTERSTITIAL PNEUMONITIS; EXANTHEM-SUBITUM; RAPID DIAGNOSIS; RISK-FACTORS; HHV-6; DNA; AMPLIFICATION; HEPATITIS	Background. Human herpesvirus 6 (HHV-6) is a recently described herpesvirus that is epidemiologically and biologically similar to cytomegalovirus. It is the cause of exanthem subitum (roseola) in children. Methods. To evaluate the possible role of HHV-6 infection in pneumonitis in immunocompromised patients, we used quantitative HHV-6 polymerase chain reactions to study lung-biopsy specimens from 15 patients with pneumonitis after bone marrow transplantation and lung tissue from 15 immunocompetent subjects without pneumonitis and 6 fetuses. Results. HHV-6 DNA was detected in lung tissue from all 15 patients, from 14 seropositive control subjects, and from none of the 7 seronegative control subjects. Six patients had levels of HHV-6 DNA in lung tissue that were 10 to 500 times higher than those in any of the other patients or control subjects. Increased levels of HHV-6 DNA correlated with a decreased risk of death from pneumonitis (P = 0.015), an increased severity of graft-versus-host disease (P = 0.023), and the presence of idiopathic pneumonitis (P = 0.037). Levels of HHV-6 DNA correlated directly with the changes in HHV-6 antibody titers in the interval between the pretransplantation period and the open-lung biopsy (P = 0.002). Low levels of HHV-6 antibody at the time of the open-lung biopsy were also associated with the diagnosis of idiopathic pneumonitis (P = 0.002). Conclusions. The concentrations of HHV-6 genome in lung tissue and their relation to changes in serologic titers support an association between HHV-6 infection and idiopathic pneumonitis in immunocompromised hosts.	UNIV WASHINGTON, DEPT LAB MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT STAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DEPT PATHOL, SEATTLE, WA 98104 USA; FRED HUTCHINSON CANC RES CTR, DEPT INFECT DIS, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NCI NIH HHS [CA 15704, CA 18029] Funding Source: Medline; NIAID NIH HHS [1 R29 AI30648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; ASANO Y, 1991, NEW ENGL J MED, V324, P634; ASHLEY R, 1988, 13TH INT HERP WORKSH; BIBERFELD P, 1988, J VIROL METHODS, V21, P49, DOI 10.1016/0166-0934(88)90051-1; BROWN MB, 1974, J AM STAT ASSOC, V69, P364, DOI 10.2307/2285659; BUCHWALD D, 1990, J CLIN IMMUNOL, V10, P335, DOI 10.1007/BF00917479; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CONE RW, 1990, LANCET, V336, P686, DOI 10.1016/0140-6736(90)92180-P; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; CONE RW, 1993, J CLIN MICROBIOL, V31, P1262, DOI 10.1128/JCM.31.5.1262-1267.1993; DUBEDAT S, 1989, LANCET, V2, P1463; FOX JD, 1990, LANCET, V336, P590, DOI 10.1016/0140-6736(90)93392-3; GLEAVES CA, 1987, AM J CLIN PATHOL, V88, P354, DOI 10.1093/ajcp/88.3.354; GOPAL MR, 1990, LANCET, V335, P1598, DOI 10.1016/0140-6736(90)91433-B; HACKMAN RC, 1985, J INFECT DIS, V151, P325, DOI 10.1093/infdis/151.2.325; KONDO K, 1990, J CLIN MICROBIOL, V28, P970, DOI 10.1128/JCM.28.5.970-974.1990; LARCHER C, 1988, LANCET, V2, P963; LAWRENCE GL, 1990, J VIROL, V64, P287, DOI 10.1128/JVI.64.1.287-299.1990; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; OKUNO T, 1990, TRANSPLANTATION, V49, P519, DOI 10.1097/00007890-199003000-00009; PIETROBONI GR, 1988, LANCET, V1, P1059; PIETROBONI GR, 1988, J CLIN PATHOL, V41, P1310, DOI 10.1136/jcp.41.12.1310; PIETROBONI GR, 1988, LANCET, V1, P1235; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; QAVI HB, 1989, CURR EYE RES, V8, P379, DOI 10.3109/02713688908996385; RAMSEY PG, 1982, ANN INTERN MED, V97, P813, DOI 10.7326/0003-4819-97-6-813; WEINER RS, 1986, ANN INTERN MED, V104, P168, DOI 10.7326/0003-4819-104-2-168; YAMANISHI K, 1988, LANCET, V1, P1065; YOSHIYAMA H, 1990, PEDIATR INFECT DIS J, V9, P71; Zar JH., 1999, BIOSTAT ANAL	33	248	253	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					156	161		10.1056/NEJM199307153290302	http://dx.doi.org/10.1056/NEJM199307153290302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL460	8390614				2022-12-28	WOS:A1993LL46000002
J	NEUHAUS, G; BOWLER, C; KERN, R; CHUA, NH				NEUHAUS, G; BOWLER, C; KERN, R; CHUA, NH			CALCIUM/CALMODULIN-DEPENDENT AND CALCIUM/CALMODULIN-INDEPENDENT PHYTOCHROME SIGNAL-TRANSDUCTION PATHWAYS	CELL			English	Article							CHLOROPLAST GENE-EXPRESSION; PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; G-PROTEINS; MOLECULAR ANALYSIS; AUREA MUTANT; TOMATO; MEMBRANES; CONTAINS; CALCIUM	Phytochrome is a well-characterized plant photoreceptor, able to modulate many morphological, physiological, and biochemical events through as yet undefined mechanisms. By developing single-cell assays to visualize phytochrome responses, we have studied the effects of microinjecting putative signaling intermediates into phytochrome-deficient tomato cells. We demonstrate that phytochrome phototransduction initially involves the activation of one or more G proteins that are coupled to at least two different pathways; one pathway requires calcium and activated calmodulin and can stimulate expression of a photoregulated cab-GUS reporter gene together with the synthesis and assembly of some, but not all, of the photosynthetic complexes. The other pathway, controlling anthocyanin biosynthesis, does not require calcium. Furthermore, our results reveal that phytochrome signaling is cell autonomous and is not likely to require any light-activated steps downstream of the G protein.	SWISS FED INST TECHNOL,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	NEUHAUS, G (corresponding author), ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021, USA.		Bowler, Chris/AAC-6256-2019	Bowler, Chris/0000-0003-3835-6187	PHS HHS [44640] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BOSSEN ME, 1991, J PLANT PHYSIOL, V137, P706, DOI 10.1016/S0176-1617(11)81226-5; CHAI YG, 1987, ANAL BIOCHEM, V163, P322, DOI 10.1016/0003-2697(87)90231-4; CHORY J, 1992, DEVELOPMENT, V115, P337; DANON L, 1991, EMBO J, V13, P3993; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; ENYEDI AJ, 1992, CELL, V70, P879, DOI 10.1016/0092-8674(92)90239-9; ERICKSON JM, 1986, EMBO J, V5, P1745, DOI 10.1002/j.1460-2075.1986.tb04422.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GILROY S, 1991, PLANT CELL, V3, P333, DOI 10.1105/tpc.3.4.333; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; GRIFFITHS WT, 1978, BIOCHEM J, V174, P681, DOI 10.1042/bj1740681; GRUISSEM W, 1989, CELL, V56, P161, DOI 10.1016/0092-8674(89)90889-1; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JEFFERSON RA, 1987, EMBO J, V6, P3901; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIERMAYER O, 1968, PLANTA, V83, P223, DOI 10.1007/BF00385332; KIERMAYER O, 1970, PROTOPLASMA, V69, P97, DOI 10.1007/BF01276654; Koornneef M., 1981, Induced mutations -- a tool in plant research. Proceedings of an international symposium. Vienna, 9-13 March 1981, P227; KOORNNEEF M, 1985, J PLANT PHYSIOL, V120, P153, DOI 10.1016/S0176-1617(85)80019-5; LAM E, 1989, MOL CELL BIOL, V9, P4819, DOI 10.1128/MCB.9.11.4819; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MISHKIND ML, 1983, PLANT PHYSIOL, V72, P847, DOI 10.1104/pp.72.3.847; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NAGY F, 1987, EMBO J, V6, P2537, DOI 10.1002/j.1460-2075.1987.tb02541.x; NEBENFUHR A, 1991, PLANTA, V185, P65, DOI 10.1007/BF00194516; NEUHAUS G, 1986, EMBO J, V5, P1437, DOI 10.1002/j.1460-2075.1986.tb04380.x; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; PARKS BM, 1987, PLANT MOL BIOL, V9, P97, DOI 10.1007/BF00015642; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; ROCHAIX JD, 1988, TRENDS BIOCHEM SCI, V13, P56, DOI 10.1016/0968-0004(88)90029-1; ROMERO LC, 1991, FEBS LETT, V282, P341, DOI 10.1016/0014-5793(91)80509-2; SCHROEDER JI, 1991, PLANT CELL, V3, P555, DOI 10.2307/3869184; SEXTON TB, 1990, EMBO J, V9, P4485, DOI 10.1002/j.1460-2075.1990.tb07899.x; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHARROCK RA, 1988, MOL GEN GENET, V213, P9, DOI 10.1007/BF00333391; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOHN G, 1991, J HISTOCHEM CYTOCHEM, V39, P921, DOI 10.1177/39.7.1865109; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; THORNE SW, 1971, BIOCHIM BIOPHYS ACTA, V226, P113, DOI 10.1016/0005-2728(71)90183-6; TRETYN A, 1991, PHOTOCHEM PHOTOBIOL, V54, P1135, DOI 10.1111/j.1751-1097.1991.tb02136.x; WARPEHA KMF, 1992, PHOTOCHEM PHOTOBIOL, V55, P595, DOI 10.1111/j.1751-1097.1992.tb04282.x; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925	51	432	448	1	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					937	952		10.1016/0092-8674(93)90272-R	http://dx.doi.org/10.1016/0092-8674(93)90272-R			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8388782	Bronze			2022-12-28	WOS:A1993LF06100010
J	CHEN, RH; EBNER, R; DERYNCK, R				CHEN, RH; EBNER, R; DERYNCK, R			INACTIVATION OF THE TYPE-II RECEPTOR REVEALS 2 RECEPTOR PATHWAYS FOR THE DIVERSE TGF-BETA ACTIVITIES	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; EXPRESSION; INHIBITION; CELLS; PURIFICATION	Transforming growth factor-beta (TGF-beta) is a multifunctional protein that regulates cell proliferation and differentiation and extracellular matrix production. Although two receptor types, the type I and type II receptors, have been implicated in TGF-beta-induced signaling, it is unclear how the many activities of TGF-beta are mediated through these receptors. With the use of cells overexpressing truncated type II receptors as dominant negative mutants to selectively block type II receptor signaling, the existence of two receptor pathways was shown. The type II receptors, possibly in conjunction with type I receptors, mediate the induction of growth inhibition and hypophosphorylation of the retinoblastoma gene product pRB. The type I receptors are responsible for effects on extracellular matrix, such as the induction of fibronectin and plasminogen activator inhibitor I, and for increased JunB expression. Selective inactivation of the type II receptors alters the TGF-beta response in a similar manner to the functional inactivation of pRB, suggesting a role for pRB in the type II, but not the type I, receptor pathway.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Chen R., UNPUB; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIKE B, 1986, J BIOL CHEM, V261, P3426; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	28	392	403	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1335	1338		10.1126/science.8388126	http://dx.doi.org/10.1126/science.8388126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8388126				2022-12-28	WOS:A1993LE02500046
J	MACK, DH; VARTIKAR, J; PIPAS, JM; LAIMINS, LA				MACK, DH; VARTIKAR, J; PIPAS, JM; LAIMINS, LA			SPECIFIC REPRESSION OF TATA-MEDIATED BUT NOT INITIATOR-MEDIATED TRANSCRIPTION BY WILD-TYPE-P53	NATURE			English	Article							MAMMALIAN-CELLS; P53; PROMOTER; ACTIVATION; ANTIGEN; PROTEIN	THE p53 protein is apparently central to the development of human cancers because both alleles are often found to be mutated in different tumour types1. In addition, wild-type p53 can inhibit transformation by viral and cellular oncogenes in vitro, so p53 has been classified as a tumour suppressor2. Investigations of the normal function of p53 have indicated that at least one of its functions could involve the activation of gene expression through the binding of specific DNA-regulatory sequences3,4. Also, overexpression of p53 can mediate growth arrest5 and repress transcription from a variety of promoters6,7. We demonstrate here both in vivo and in vitro that expression of wild-type p53 specifically represses the activity of promoters whose initiation is dependent on the presence of a TATA box. Promoters whose accurate transcription is directed by a pyrimidine-rich initiator element, however, are immune to the effects of p53. Furthermore, we observe that repression is mediated by an interaction of p53 with basal transcription factor(s). Thus, p53 appears to repress the activity of certain promoters through direct communication with TATA box-dependent basal transcription machinery.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; INOSTROZA JA, 1992, CELL, V70, P477; KASTAN MB, 1991, CANCER RES, V51, P6304; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	26	345	351	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					281	283		10.1038/363281a0	http://dx.doi.org/10.1038/363281a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8387645				2022-12-28	WOS:A1993LC86600058
J	YANOVSKI, JA; CUTLER, GB; CHROUSOS, GP; NIEMAN, LK				YANOVSKI, JA; CUTLER, GB; CHROUSOS, GP; NIEMAN, LK			CORTICOTROPIN-RELEASING HORMONE STIMULATION FOLLOWING LOW-DOSE DEXAMETHASONE ADMINISTRATION - A NEW TEST TO DISTINGUISH CUSHINGS-SYNDROME FROM PSEUDO-CUSHINGS STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PITUITARY-ADRENAL AXIS; DIFFERENTIAL-DIAGNOSIS; SUPPRESSION TEST; CORTISOL; DISEASE; DEPRESSION; RESPONSES; CLEARANCE; ACTH; CRF	Objective.-The biochemical and phenotypic presentation of mild hypercortisolism in Cushing's syndrome is often indistinguishable from that seen in pseudo-Cushing's states such as depression. Both dexamethasone suppression and corticotropin-releasing hormone (CRH) stimulation tests have been used individually to distinguish these conditions, but neither approach has achieved a diagnostic accuracy greater than 85%. Therefore, we sought to develop a combined dexamethasone-CRH test that would take advantage of the altered sensitivity of patients with Cushing's syndrome to both dexamethasone and CRH and would achieve greater accuracy in the diagnosis of Cushing's syndrome. Design.-Prospective cohort study. Setting.-Tertiary care research hospital. Patients.-A total of 58 adults referred for evaluation of mild hypercortisolism (urine free cortisol level < 1000 nmol/d). The diagnosis of Cushing's syndrome was confirmed at surgery in 39 patients. The diagnosis of a pseudo-Cushing's state was made in 19 patients on the basis of extended follow-up (mean, 28 months) without progression of cushingoid features. Intervention.-The low-dose dexamethasone suppression test, the CRH stimulation test, and the CRH stimulation test started 2 hours after completion of low-dose dexamethasone suppression (the dexamethasone-CRH test) were performed in all patients. Main Outcome Measures.-Sensitivity, specificity, and accuracy of the three procedures for diagnosis of Cushing's syndrome were calculated from plasma corticotropin, plasma cortisol, urine free cortisol, and urine 17-hydroxycorticosteroid values. Results.-The low-dose dexamethasone suppression test had 74% specificity, 69% sensitivity, and 71% diagnostic accuracy, using the standard criterion (1 7-hydroxycorticosteroid excretion level > 11.0 mumol/d on the second day of dexamethasone administration). With a urine free cortisol criterion for Cushing's syndrome of greater than 100 nmol/d, the low-dose dexamethasone suppression test had 100% specificity, 56% sensitivity, and 71% diagnostic accuracy. The CRH stimulation test without dexamethasone pretreatment had 1 00% specificity, 640/. sensitivity, and 76% diagnostic accuracy. The diagnostic accuracy of the dexamethasone-CRH test for Cushing's syndrome was significantly greater than the accuracy of either the low-dose dexamethasone test or the CRH test alone (P<.01). A plasma cortisol concentration greater than 38 nmol/L measured 15 minutes after the administration of CRH correctly identified all cases of Cushing's syndrome and all cases of pseudo-Cushing's states (100% specificity sensitivity, and diagnostic accuracy). Conclusion.-The dexamethasone-CRH test is a more accurate test to distinguish Cushing's syndrome from pseudo-Cushing's states in patients with mild hypercortisolism.			YANOVSKI, JA (corresponding author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,ROOM 10N262,BETHESDA,MD 20892, USA.			Yanovski, Jack/0000-0001-8542-1637				ANDREIS PG, 1992, ENDOCRINOLOGY, V131, P69, DOI 10.1210/en.131.1.69; ASHCRAFT MW, 1982, ANN INTERN MED, V97, P21, DOI 10.7326/0003-4819-97-1-21; BESSER GM, 1972, CLINICS ENDOCRINOLOG, V1, P451; BROWN RD, 1973, J CLIN ENDOCR METAB, V36, P445; BURKE CW, 1973, Q J MED, V42, P175; BUTLER PWP, 1968, LANCET, V1, P1234; CARO JF, 1978, J CLIN ENDOCR METAB, V47, P667, DOI 10.1210/jcem-47-3-667; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; EDDY RL, 1973, AM J MED, V55, P621, DOI 10.1016/0002-9343(73)90184-8; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; GAMBARDELLA S, 1989, J ENDOCRINOL INVEST, V12, P163, DOI 10.1007/BF03349953; GOLD EM, 1979, ANN INTERN MED, V90, P829, DOI 10.7326/0003-4819-90-5-829; GOLD PW, 1986, NEW ENGL J MED, V314, P1335, DOI 10.1056/NEJM198605223142102; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GROSSMAN AB, 1988, CLIN ENDOCRINOL, V29, P167, DOI 10.1111/j.1365-2265.1988.tb00258.x; HANKIN ME, 1977, CLIN ENDOCRINOL, V6, P185, DOI 10.1111/j.1365-2265.1977.tb03314.x; Heuser I J, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p159A; HOLSBOERTRACHSLER E, 1991, PSYCHIAT RES, V38, P163, DOI 10.1016/0165-1781(91)90041-M; KAPCALA LP, 1984, ARCH INTERN MED, V144, P636, DOI 10.1001/archinte.144.3.636; KENNEDY L, 1984, BRIT MED J, V289, P1188, DOI 10.1136/bmj.289.6453.1188; KRIEGER DT, 1977, J CLIN ENDOCR METAB, V44, P361, DOI 10.1210/jcem-44-2-361; LAMBERTS SWJ, 1979, JAMA-J AM MED ASSOC, V242, P1640, DOI 10.1001/jama.242.15.1640; Laue L, 1991, Adv Pediatr, V38, P287; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LYTRAS N, 1984, CLIN ENDOCRINOL, V20, P71, DOI 10.1111/j.1365-2265.1984.tb00061.x; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MULLER OA, 1986, PSYCHONEUROENDOCRINO, V11, P49, DOI 10.1016/0306-4530(86)90031-4; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; PLOTZ CM, 1952, AM J MED, V13, P597, DOI 10.1016/0002-9343(52)90027-2; REINCKE M, 1991, ENDOCR SOC ABSTR, V73, P250; RUPPRECHT R, 1989, J CLIN ENDOCR METAB, V69, P600, DOI 10.1210/jcem-69-3-600; SCHTEINGART DE, 1963, METABOLISM, V12, P484; SCHTEINGART DE, 1989, ENDOCRIN METAB CLIN, V18, P311, DOI 10.1016/S0889-8529(18)30373-6; SMITH SR, 1975, J CLIN ENDOCR METAB, V40, P43, DOI 10.1210/jcem-40-1-43; STREETEN DH, 1969, J CLIN ENDOCR METAB, V29, P1191, DOI 10.1210/jcem-29-9-1191; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; WALLACE EZ, 1980, J CLIN ENDOCR METAB, V50, P46, DOI 10.1210/jcem-50-1-46; WAND GS, 1991, J CLIN ENDOCR METAB, V72, P1290, DOI 10.1210/jcem-72-6-1290; WATSON AC, 1988, CLIN ENDOCRINOL, V28, P471, DOI 10.1111/j.1365-2265.1988.tb03681.x; WERNER S, 1992, J CLIN ENDOCR METAB, V75, P1005, DOI 10.1210/jc.75.4.1005; 1987, DIAGNOSTIC STATISTIC	41	207	212	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2232	2238		10.1001/jama.269.17.2232	http://dx.doi.org/10.1001/jama.269.17.2232			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8386285				2022-12-28	WOS:A1993KZ40600031
J	RAINIER, S; JOHNSON, LA; DOBRY, CJ; PING, AJ; GRUNDY, PE; FEINBERG, AP				RAINIER, S; JOHNSON, LA; DOBRY, CJ; PING, AJ; GRUNDY, PE; FEINBERG, AP			RELAXATION OF IMPRINTED GENES IN HUMAN CANCER	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; WILMS-TUMOR; H19 GENE; HETEROZYGOSITY; CHROMOSOME-11; HYPOMETHYLATION; CARCINOMA; DISOMY; 11P; RNA	GENOMIC imprinting, or parental allele-specific expression of genes, has been demonstrated at the molecular level in insects and mice1,2 but not in man. Imprinting as a potential mechanism of human disease is suggested by paternal uniparental disomy of 11p15 in Beckwith-Wiedemann syndrome3 and by maternal uniparental disomy of 15q11-12 in Prader-Willi syndrome4. Beckwith-Wiedemann syndrome is characterized by multiorgan overgrowth and predisposition to embryonal tumours such as Wilms' tumour of the kidneys. A loss of heterozygosity of 11p15 is also frequently found in a wide variety of tumours, including Wilms' tumour and lung, bladder, ovarian, liver and breast cancers6-11; 11p15 also directly suppresses tumour growth in vitro 12 . Two genes in this band, H19 and insulin-like growth factor-11 (IGF2) undergo reciprocal imprinting in the mouse., with maternal expression of H19 (ref. 13) and paternal expression of IGF2 (ref. 14). Here we find that both of these genes show monoallelic expression in human tissues and, as in mouse, H19 is expressed from the maternal allele and IGF2 from the paternal allele. In contrast, 69% of Wilms' tumours not undergoing loss of heterozygosity at 11p showed biallelic expression of one or both genes, suggesting that relaxation or loss of imprinting could represent a new epigenetic mutational mechanism in carcinogenesis.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,4520 MSRB 1,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; CROSS CANC INST,DEPT PEDIAT,EDMONTON T6G 1Z2,ALBERTA,CANADA; UNIV ALBERTA,EDMONTON T6G 1Z2,AB,CANADA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Alberta; University of Alberta			Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Beckers J. M., 1990, ESO Messenger, P1; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVISSON MT, 1991, CYTOGENET CELL GENET, V58, P1152, DOI 10.1159/000133726; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUJIMORI M, 1991, CANCER RES, V51, P89; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; HAIG D, 1991, CELL, V64, P1045; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOLLIDAY R, 1990, DEVELOPMENT, P125; HOOVERS JMN, 1992, LANCET, V339, P1228, DOI 10.1016/0140-6736(92)91164-4; JONES PA, 1986, CANCER RES, V46, P461; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KOI M, IN PRESS SCIENCE; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1991, MOL GENETICS WILMS T; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; PETTENATI MJ, 1986, HUM GENET, V74, P143, DOI 10.1007/BF00282078; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHULDINER AR, 1991, BIOTECHNIQUES, V11, P760; SKINNER MA, 1990, CANCER RES, V50, P2303; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; WADEY RB, 1990, ONCOGENE, V5, P901; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807; WILLISON K, 1991, TRENDS GENET, V7, P107, DOI 10.1016/0168-9525(91)90441-R; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	39	742	762	0	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					747	749		10.1038/362747a0	http://dx.doi.org/10.1038/362747a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8385745	Green Published			2022-12-28	WOS:A1993KY45000055
J	GROOP, LC; KANKURI, M; SCHALINJANTTI, C; EKSTRAND, A; NIKULAIJAS, P; WIDEN, E; KUISMANEN, E; ERIKSSON, J; FRANSSILAKALLUNKI, A; SALORANTA, C; KOSKIMIES, S				GROOP, LC; KANKURI, M; SCHALINJANTTI, C; EKSTRAND, A; NIKULAIJAS, P; WIDEN, E; KUISMANEN, E; ERIKSSON, J; FRANSSILAKALLUNKI, A; SALORANTA, C; KOSKIMIES, S			ASSOCIATION BETWEEN POLYMORPHISM OF THE GLYCOGEN-SYNTHASE GENE AND NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE; RESISTANCE; DEFECTS; NIDDM; DNA	Background. The storage of glucose as glycogen in skeletal muscle is frequently impaired in patients with non-insulin-dependent diabetes mellitus (NIDDM) and their nondiabetic relatives. Despite an intensive search for candidate genes associated with NIDDM, no data have been available on the gene coding for the key enzyme of this pathway, glycogen synthase. Methods and Results. Using a human complementary DNA probe, the restriction enzyme XbaI, and Southern blot analysis, we identified two polymorphic alleles, A1 and A2, in the glycogen synthase gene. The gene was localized to chromosome 19. The A1A2 or A2A2 genotype was found in 30 percent of 107 patients with NIDDM but in only 8 percent of 164 nondiabetic subjects without a family history of NIDDM (P<0.001). The diabetic patients with the A2 allele had a stronger family history of N IDDM (P = 0.019), a higher prevalence of hypertension (P = 0.008), ard a more severe defect in insulin-stimulated glucose storage (P = 0.001) than the diabetic patients with the A1 allele. The concentration of the glycogen synthase protein in biopsy specimens of skeletal muscle from the patients with the A2 allele was normal, however, suggesting that expression of the gene was unaltered. The XbaI polymorphism was due to a change of a single base in an intron. Conclusions. The XbaI polymorphism of the glycogen synthase gene identifies a subgroup of patients with NIDDM characterized by a strong family history of NIDDM, a high prevalence of hypertension, and marked insulin resistance.	UNIV HELSINKI,DEPT MED 4,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,DEPT BIOCHEM,SF-00100 HELSINKI 10,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki								BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; ERIKSSON J, 1992, DIABETOLOGIA, V35, P143, DOI 10.1007/BF00402546; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; K÷bberling J., 1982, GENETICS DIABETES ME, P201; PERMUTT MA, 1991, BAILLIERE CLIN ENDOC, V5, P495, DOI 10.1016/S0950-351X(05)80144-2; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VANDENPLAS S, 1984, J MED GENET, V21, P164, DOI 10.1136/jmg.21.3.164; VESTERGAARD H, 1991, DIABETES, V40, P1740, DOI 10.2337/diabetes.40.12.1740	17	176	181	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					10	14		10.1056/NEJM199301073280102	http://dx.doi.org/10.1056/NEJM199301073280102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8416266				2022-12-28	WOS:A1993KF50700002
J	MARZUK, PM; TARDIFF, K; HIRSCH, CS; LEON, AC; STAJIC, M; HARTWELL, N; PORTERA, L				MARZUK, PM; TARDIFF, K; HIRSCH, CS; LEON, AC; STAJIC, M; HARTWELL, N; PORTERA, L			INCREASE IN SUICIDE BY ASPHYXIATION IN NEW-YORK-CITY AFTER THE PUBLICATION OF FINAL EXIT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							TELEVISION-NEWS STORIES		OFF CHIEF MED EXAMINER,NEW YORK,NY 10016		MARZUK, PM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PSYCHIAT,1300 YORK AVE,NEW YORK,NY 10021, USA.				NIDA NIH HHS [DA-06534] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALTMAN LK, 1991, NY TIMES        0724, pA10; CARD JJ, 1974, OMEGA-J DEATH DYING, V5, P37, DOI 10.2190/K59M-Y0KN-PAKV-JFUV; COX M, 1991, WALL STREET J   0527, pB1; Gould M.S., 1990, SUICIDE LIFE CYCLE R, P517; Humphry Derek, 1991, FINAL EXIT PRACTICAL; KESSLER RC, 1989, J NERV MENT DIS, V177, P551, DOI 10.1097/00005053-198909000-00006; LAVIN MR, 1992, NEW ENGL J MED, V326, P890; MARZUK PM, 1992, ARCH GEN PSYCHIAT, V49, P451; MEHTA CR, 1990, STATABLE ELECTORNIC; OLKIN I, 1980, PROBABILITY MODELS A, P253; PHILLIPS DP, 1986, NEW ENGL J MED, V315, P685, DOI 10.1056/NEJM198609113151106; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; RODIN G, 1986, AM J PSYCHIAT, V143, P696; SACKS MH, 1992, AM J PSYCHIAT, V149, P842; WEISSMAN MM, 1974, ARCH GEN PSYCHIAT, V30, P737; 1991, DHHS PHS911101 NAT C, V2	16	56	57	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1508	1510		10.1056/NEJM199311113292022	http://dx.doi.org/10.1056/NEJM199311113292022			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MF292	8413474				2022-12-28	WOS:A1993MF29200035
J	AREVALO, JH; TAUSSIG, MJ; WILSON, IA				AREVALO, JH; TAUSSIG, MJ; WILSON, IA			MOLECULAR-BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY	NATURE			English	Article								TWO major unanswered questions concerning the specificity of antibodies are: how do structurally different antigens bind with high affinity to the same antibody, and what are the limits of the antibody combining site complementarity and flexibility that contribute to such crossreactivity? We report here a comparative analysis of the X-ray structures of five conformationally different steroids in complex with the Fab' fragment of an anti-progesterone antibody DB3 at 2.7 angstrom. This antibody is unable to complement completely the shape of the hydrophobic antigen so that crossreactivity occurs with other ligands without major structural rearrangements of the binding site. Antigen specificity can be explained through conserved interactions of DB3 with the steroid D-ring, whereas some of the crossreactivity is realized through different binding orientations of the steroid skeleton that place the A-ring into alternative pockets on the antibody surface. The restricted gene usage of the VGAM3.8 family in the generation of anti-progesterone monoclonal antibodies1,2 may be explained by the specific interaction Of V(H) hallmark residues with the steroid D-ring. This first detailed structure of steroid interactions with a protein could be applied to the understanding of general mechanisms of steroid recognition as well as in the design of specific binding sites for small hydrophobic ligands.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; AFRC, BABRAHAM INST, DEPT IMMUNOL, STRUCT STUDIES LAB, CAMBRIDGE CB2 4AT, ENGLAND	Scripps Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BOHACEK RS, 1992, J MED CHEM, V35, P1671, DOI 10.1021/jm00088a002; BRUNGER AT, 1990, XPLOR VERSION 21; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DEVERSON E, 1987, EUR J IMMUNOL, V17, P9, DOI 10.1002/eji.1830170103; Duax W. L., 1975, ATLAS STEROID STRUCT, V1; ELLIS ST, 1988, J ENDOCRINOL, V118, P69, DOI 10.1677/joe.0.1180069; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GRIFFIN JF, 1984, ATLAS STEROID STRUCT, V2; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kabat EA, 1991, SEQUENCES PROTEINS I; Landsteiner K., 1962, SPECIFICITY SEROLOGI; LASCOMBE MB, 1992, P NATL ACAD SCI USA, V89, P9429, DOI 10.1073/pnas.89.20.9429; LEE B, 1971, J MOL BIOL, V55, P376; LUUTHE V, 1991, BIOCHEMISTRY-US, V30, P8861; MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4; PARHAMISEREN B, 1993, J IMMUNOL, V150, P1829; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SIMS MJ, 1992, J IMMUNOL, V149, P1642; STANFIELD RL, IN PRESS STRUCTURE; STRICKLER RC, 1980, BIOCHEMISTRY-US, V19, P4950, DOI 10.1021/bi00563a002; STURA EA, 1987, IMMUNOLOGY, V62, P511; TAUSSIG MJ, 1991, IMMUNOLOGY, V72, P471; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; WRIGHT LJ, 1982, NATURE, V295, P415, DOI 10.1038/295415a0	34	154	157	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					859	863		10.1038/365859a0	http://dx.doi.org/10.1038/365859a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413674				2022-12-28	WOS:A1993MD95100057
J	FREEMAN, HJ; KWAN, WCP				FREEMAN, HJ; KWAN, WCP			NON-CORTICOSTEROID-ASSOCIATED OSTEONECROSIS OF THE FEMORAL HEADS IN 2 PATIENTS WITH INFLAMMATORY BOWEL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CROHNS-DISEASE; NECROSIS		UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA	University of British Columbia	FREEMAN, HJ (corresponding author), UNIV HOSP BRITISH COLUMBIA, DEPT MED GASTROENTEROL, ACU F-137, UBC SITE, 2211 WESBROOK MALL, VANCOUVER V6T 1W5, BC, CANADA.							BROM B, 1971, GASTROENTEROLOGY, V60, P1106; CRUESS RL, 1981, CAN J SURG, V24, P567; CULP RW, 1989, J HAND SURG-AM, V14, P294, DOI 10.1016/0363-5023(89)90024-5; FISHER DE, 1971, J BONE JOINT SURG AM, VA 53, P859, DOI 10.2106/00004623-197153050-00002; FREEMAN HJ, 1990, CAN J GASTROENTEROL, V4, P26; KAWAI K, 1980, CLIN ORTHOP RELAT R, P273; KWAN WCP, 1991, CAN J GASTROENTEROL, V5, P59; MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473; PEREIRA GR, 1980, PEDIATRICS, V66, P26; Pietrogrande V, 1957, ORTHOP TRAUM APPAR M, V25, P791; SHAPIRO SC, 1985, J PEDIATR GASTR NUTR, V4, P502, DOI 10.1097/00005176-198506000-00031; Simmonds SD, 1987, GASTROENTEROLOGY, V92, P112, DOI 10.1016/0016-5085(87)90846-8; SWEETNAM DR, 1960, BRIT MED J, V1, P1392, DOI 10.1136/bmj.1.5183.1392; VAKIL N, 1989, GASTROENTEROLOGY, V96, P62, DOI 10.1016/0016-5085(89)90764-6	14	37	37	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1314	1316		10.1056/NEJM199310283291805	http://dx.doi.org/10.1056/NEJM199310283291805			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413411				2022-12-28	WOS:A1993MD55700005
J	GOODWIN, EB; OKKEMA, PG; EVANS, TC; KIMBLE, J				GOODWIN, EB; OKKEMA, PG; EVANS, TC; KIMBLE, J			TRANSLATIONAL REGULATION OF TRA-2 BY ITS 3' UNTRANSLATED REGION CONTROLS SEXUAL IDENTITY IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EMBRYONIC CELL LINEAGES; DETERMINING GENE; GERM-LINE; 3'-UNTRANSLATED REGION; DNA-POLYMERASE; MESSENGER-RNA; FEM GENES; SPERMATOGENESIS; HERMAPHRODITE	C. elegans hermaphrodites make sperm and then oocytes in an otherwise female animal. Gain-of-function mutations in the sex-determining gene tra-2 (tra-2(gf)) transform hermaphrodites into females (spermless hermaphrodites). The tra-2(gf) mutations map to a perfect direct repeat in the 3' untranslated region; each repeat is called a direct repeat element (DRE). Three experiments demonstrate that DREs repress tra-2 at the translational level. First, tra-2(gf) mRNAs are associated with larger polysomes than are their wild-type counterparts. Second, translation of a reporter RNA is inhibited by DREs. Third, disruption of DREs does not increase tra-2 mRNA levels. An RNA binding activity specifically associates with the DREs. We propose that tra-2 translation is inhibited by association of an RNA binding-factor with the DREs and that this translational control is essential for development of C. elegans as a hermaphrodite/male species.	CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science	GOODWIN, EB (corresponding author), UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA.							Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARTON MK, 1990, GENETICS, V125, P29; BARTON MK, 1987, GENETICS, V115, P107; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; DONIACH T, 1986, GENETICS, V114, P53; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GRAHAM PL, 1993, GENETICS, V133, P919; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN J, 1986, GENETICS, V114, P15; HODGKIN JA, 1977, GENETICS, V86, P275; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KLASS M, 1976, DEV BIOL, V52, P1, DOI 10.1016/0012-1606(76)90002-6; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LHERNAULT SW, 1988, GENETICS, V120, P435; MADL JE, 1979, GENETICS, V93, P393; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER DM, 1986, P NATL ACAD SCI USA, V83, P2305, DOI 10.1073/pnas.83.8.2305; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NELSON GA, 1978, DEV BIOL, V66, P386, DOI 10.1016/0012-1606(78)90247-6; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEDL T, 1989, GENETICS, V123, P755; SCHEDL T, 1988, GENETICS, V119, P43; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; STANDART N, 1990, GENE DEV, V4, P2157, DOI 10.1101/gad.4.12a.2157; STANDART N, 1993, SEMIN DEV BIOL, V3, P367; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRENT C, 1988, GENETICS, V120, P145; Villeneuve A.M., 1990, Advances in Genetics, V27, P117; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813	48	171	186	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					329	339		10.1016/0092-8674(93)80074-O	http://dx.doi.org/10.1016/0092-8674(93)80074-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402916				2022-12-28	WOS:A1993MD88500014
J	BUTLER, JC; BREIMAN, RF; CAMPBELL, JF; LIPMAN, HB; BROOME, CV; FACKLAM, RR				BUTLER, JC; BREIMAN, RF; CAMPBELL, JF; LIPMAN, HB; BROOME, CV; FACKLAM, RR			PNEUMOCOCCAL POLYSACCHARIDE VACCINE EFFICACY - AN EVALUATION OF CURRENT RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; PROTECTIVE EFFICACY; ANTIBODY-RESPONSES; HIGH-RISK; DISEASE; REVACCINATION; IMMUNIZATION; EPIDEMIOLOGY	Objective.-To determine pneumococcal polysaccharide vaccine efficacy in selected populations at risk for serious pneumococcal infection for whom vaccination is currently recommended and to assess duration of protection after vaccination. Design.-Vaccine efficacy was estimated using indirect cohort analysis to compare the proportion of pneumococcal infections caused by serotypes included in the vaccines of vaccinated and unvaccinated persons who were identified during 14 years of national surveillance. Setting.-Hospital laboratories in the United States that submitted pneumococcal isolates to the Centers for Disease Control and Prevention between May 1978 and April 1992. Participants.-A total of 2837 persons older than 5 years who had pneumococcus isolated from blood or cerebrospinal fluid. Results.-Overall efficacy for preventing infection caused by serotypes included in the vaccine was 57% (95% confidence interval [CI], 45% to 66%). Efficacy among persons with diabetes mellitus was 84% (95% CI, 50% to 95%); with coronary vascular disease, 73% (95% CI, 23% to 90%); with congestive heart failure, 69% (95% CI, 17% to 88%); with chronic pulmonary diseases, 65% (95% CI, 26% to 83%); and with anatomic asplenia, 77% (95% CI, 14% to 95%). Efficacy was not documented for patients with alcoholism or cirrhosis, sickle cell disease, chronic renal failure, lymphoma, leukemia, or multiple myeloma, although sample sizes were small for these groups. Efficacy for immunocompetent persons older than 65 years was 75% (95% CI, 57% to 85%). Efficacy did not decline with increasing interval after vaccination: 5 to 8 years after vaccination it was 71% (95% CI, 24% to 89%), and 9 years or more after vaccination it was 80% (95% CI, 16% to 95%). Conclusions.-Intensified efforts to improve pneumococcal vaccine coverage among certain populations for whom vaccination is currently recommended is indicated, but universal revaccination is not warranted at this time.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA; CTR DIS CONTROL & PREVENT,OFF DIRECTOR,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	BUTLER, JC (corresponding author), CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,RESP DIS BRANCH,MS C-09,1600 CLIFTON RD,ATLANTA,GA 30333, USA.							APPLEBAUM PC, 1992, CLIN INFECT DIS, V15, P77; AUSTRIAN R, 1984, NEW ENGL J MED, V310, P651, DOI 10.1056/NEJM198403083101010; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; Austrian R, 1976, Trans Assoc Am Physicians, V89, P184; BOLAN G, 1986, ANN INTERN MED, V104, P1, DOI 10.7326/0003-4819-104-1-1; BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010; BROOME CV, 1981, REV INFECT DIS, V3, P277; BROOME CV, 1980, NEW ENGL J MED, V303, P549, DOI 10.1056/NEJM198009043031003; BRUYN GAW, 1992, CLIN INFECT DIS, V14, P251, DOI 10.1093/clinids/14.1.251; BUTLER JC, 1993, 33RD INT C ANT AG CH; CANO FR, 1983, P SOC EXP BIOL MED, V173, P57; CARLSON AJ, 1979, P SOC EXP BIOL MED, V161, P558; CLEMENS JD, 1984, REV INFECT DIS, V6, P589; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FEDSON DS, 1988, VACCINES, P271; FLEISS JL, 1981, STATISTICAL METHODS, P71; HILLEMAN MR, 1981, REV INFECT DIS S, V3, P531; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KRAUS C, 1985, MED MICROBIOL IMMUN, V174, P51, DOI 10.1007/BF02123671; LAMOTHE F, 1984, CAN MED ASSOC J, V130, P737; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LINNEMANN CC, 1986, ARCH INTERN MED, V146, P1554, DOI 10.1001/archinte.146.8.1554; LINNEMANN CC, 1981, ARCH INTERN MED, V146, P1554; MINOR DR, 1979, ANN INTERN MED, V90, P887, DOI 10.7326/0003-4819-90-6-887; MUFSON MA, 1983, P SOC EXP BIOL MED, V173, P270, DOI 10.3181/00379727-173-41643; MUFSON MA, 1987, AM J MED SCI, V293, P279, DOI 10.1097/00000441-198705000-00001; MUFSON MA, 1985, J INFECT DIS, V151, P749, DOI 10.1093/infdis/151.4.749; MUFSON MA, 1991, VACCINE, V9, P403, DOI 10.1016/0264-410X(91)90126-Q; MUFSON MA, 1984, P SOC EXP BIOL MED, V177, P220, DOI 10.3181/00379727-177-41934; MUFSON MA, 1990, PRINCIPLES PRACTICE, P1539; MUSHER DM, 1990, J INFECT DIS, V161, P736, DOI 10.1093/infdis/161.4.736; MUSHER DM, 1990, AM J MED SCI, V300, P45, DOI 10.1097/00000441-199007000-00011; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; OVERTURF GD, 1982, AM J PEDIAT HEMATOL, V4, P19; OXTOBY MJ, 1986, ANN INTERN MED, V104, P587, DOI 10.7326/0003-4819-104-4-587_3; PENN RL, 1982, INFECT IMMUN, V36, P1261, DOI 10.1128/IAI.36.3.1261-1262.1982; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; REYNOLDS HY, 1991, PHYSIOL REV, V71, P1117, DOI 10.1152/physrev.1991.71.4.1117; RIGAUPEREZ JG, 1983, PEDIATR INFECT DIS J, V2, P199, DOI 10.1097/00006454-198305000-00005; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCHMID GP, 1981, J INFECT DIS, V143, P590, DOI 10.1093/infdis/143.4.590; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; SHAPIRO ED, 1987, NEW ENGL J MED, V316, P1272; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SMIT P, 1977, JAMA-J AM MED ASSOC, V238, P2613, DOI 10.1001/jama.238.24.2613; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; VELLA PP, 1980, P SOC EXP BIOL MED, V164, P435; WEINTRUB PS, 1984, J PEDIATR-US, V105, P261, DOI 10.1016/S0022-3476(84)80124-9; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1984, MMWR MORB MORTAL WKL, V33, P273; 1989, MMWR MORB MORTAL WKL, V38, P64; 1991, MMWR MORB MORTAL WKL, V40, P42	60	516	547	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1826	1831		10.1001/jama.270.15.1826	http://dx.doi.org/10.1001/jama.270.15.1826			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411526				2022-12-28	WOS:A1993MB46400025
J	COON, WW				COON, WW			VENA-CAVAL FILTERS AND ANTICOAGULANTS FOR PULMONARY EMBOLI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											COON, WW (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1867	1868						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411533				2022-12-28	WOS:A1993MB46400035
J	MCCORMICK, D; HODGSON, J				MCCORMICK, D; HODGSON, J			A WINDOW OF OPPORTUNITY	NATURE			English	Article																		BURRILL G, 1992, BIOTECH 93 ACCELERAT; MCCORMICK DK, 1993, BIO-TECHNOL, V11, P994, DOI 10.1038/nbt0993-994; SPALDING BJ, 1993, BIO-TECHNOL, V11, P768	3	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					676	678		10.1038/365676a0	http://dx.doi.org/10.1038/365676a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413633				2022-12-28	WOS:A1993MB84600067
J	STEIMLE, V; OTTEN, LA; ZUFFEREY, M; MACH, B				STEIMLE, V; OTTEN, LA; ZUFFEREY, M; MACH, B			COMPLEMENTATION CLONING OF AN MHC CLASS-II TRANSACTIVATOR MUTATED IN HEREDITARY MHC CLASS-II DEFICIENCY (OR BARE LYMPHOCYTE SYNDROME)	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL LINES; PROMOTER-BINDING-PROTEIN; HLA-DRA GENE; TRANSCRIPTIONAL REGULATION; MAMMALIAN-CELLS; WILD-TYPE; EXPRESSION; DEFECT; DNA	Hereditary major histocompatibility complex (MHC) class II deficiency (or bare lymphocyte syndrome) is a form of severe primary immunodeficiency with a total lack of MHC class II expression. It is due to a defect in the regulation of MHC class II genes. A novel gene was isolated by complementation cloning, using an MHC class II-negative mutant cell line. This gene (CIITA) functions as a transactivator of MHC class II gene expression and restores expression of all MHC class II isotypes in mutant cells. In addition, CIITA fully corrects the MHC class II regulatory defect of cells from patients with bare lymphocyte syndrome. In this disease we have identified a splicing mutation that results in a 24 amino acid deletion in CIITA, resulting in loss of function of the transactivator. Hence, the CIITA gene is essential for MHC class II gene expression and has been shown to be responsible for hereditary MHC class II deficiency.			STEIMLE, V (corresponding author), UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,JEANTET LAB MOLEC GENET,CH-1211 GENEVA 4,SWITZERLAND.							ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACCOLLA RS, 1986, J EXP MED, V164, P369, DOI 10.1084/jem.164.1.369; ACCOLLA RS, 1991, INT J CANCER S, V6, P20; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PW, 1987, CANCER RES, V47, P740; [Anonymous], 1985, DNA REPAIR; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BENACERRAF B, 1981, SCIENCE, V212, P1229, DOI 10.1126/science.6165083; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CALMAN AF, 1987, J IMMUNOL, V139, P2489; CARREL S, 1976, CANCER RES, V36, P3978; CASPER JT, 1990, J PEDIATR-US, V116, P262, DOI 10.1016/S0022-3476(05)82885-9; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; DEPREVAL C, 1985, NATURE, V318, P219; GIORDANO TJ, 1990, GENE, V88, P285, DOI 10.1016/0378-1119(90)90045-S; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GONCZY P, 1989, MOL CELL BIOL, V9, P296; Griscelli C, 1989, Immunodefic Rev, V1, P135; GRISCELLI C, 1980, PRIMARY IMMUNODEFICI, P499; GROSS N, 1987, INT J CANCER, V39, P521, DOI 10.1002/ijc.2910390420; GUARDIOLA J, 1986, P NATL ACAD SCI USA, V83, P7415, DOI 10.1073/pnas.83.19.7415; HADAM MR, 1984, HISTOCOMPATIBILITY T, P645; HASEGAWA SL, 1993, J IMMUNOL, V150, P1781; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; HUME CR, 1989, HUM IMMUNOL, V25, P1, DOI 10.1016/0198-8859(89)90065-7; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KOCH W, 1988, J EXP MED, V167, P1781, DOI 10.1084/jem.167.6.1781; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAWCZAK M, 1992, HUM GENET, V90, P41; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LISOWSKAGROSPIERRE B, 1985, J CLIN INVEST, V76, P381, DOI 10.1172/JCI111974; LONG EO, 1984, IMMUNOGENETICS, V19, P349, DOI 10.1007/BF00345408; MACH B, 1986, COLD SPRING HARB SYM, V51, P67, DOI 10.1101/SQB.1986.051.01.009; MACH B, 1993, HLA SYSTEM CLIN TRAN, P82; MACH B, 1990, MOL BIOL HLA CLASS 2, P201; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MANNHALTER JW, 1991, IMMUNOL INVEST, V20, P151, DOI 10.3109/08820139109050783; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SLOAN JH, 1988, P NATL ACAD SCI USA, V85, P8186, DOI 10.1073/pnas.85.21.8186; SPICKOFSKY N, 1990, DNA PROT ENG TECH, V2, P14; STIMAC E, 1991, J IMMUNOL, V146, P4398; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; ZIEGLER A, 1986, IMMUNOBIOLOGY, V171, P77, DOI 10.1016/S0171-2985(86)80019-5	66	759	787	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					135	146		10.1016/0092-8674(93)90685-J	http://dx.doi.org/10.1016/0092-8674(93)90685-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402893				2022-12-28	WOS:A1993MB66700014
J	YOKOYAMA, C; WANG, XD; BRIGGS, MR; ADMON, A; WU, J; HUA, XX; GOLDSTEIN, JL; BROWN, MS				YOKOYAMA, C; WANG, XD; BRIGGS, MR; ADMON, A; WU, J; HUA, XX; GOLDSTEIN, JL; BROWN, MS			SREBP-1, A BASIC-HELIX-LOOP-HELIX-LEUCINE ZIPPER PROTEIN THAT CONTROLS TRANSCRIPTION OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR GENE	CELL			English	Article							STEROL REGULATORY ELEMENT; DNA-BINDING; ACTIVATES TRANSCRIPTION; CLONING; EXPRESSION; REDUCTASE; PROMOTER; DOMAIN; IDENTIFICATION; SEQUENCE	Sterol regulatory element 1 (SRE-1), a decamer (5'-ATC-ACCCCAC-3') flanking the low density lipoprotein (LDL) receptor gene, activates transcription in sterol-depleted cells and is silenced by sterols. We report the cDNA cloning of human SREBP-1, a protein that binds SRE-1, activates transcription, and thereby mediates the final regulatory step in LDL metabolism. SREBP-1 contains a basic-helix-loop-helix-leucine zipper (bHLH-ZIP) motif, but it differs from other bHLH-ZIP proteins in its larger size (I 147 amino acids) and target sequence. Instead of an inverted repeat (CANNTG), the target for all known bHLH-ZIP proteins, SRE-1 contains a direct repeat of CAC. Overexpression of SREBP-1 activates transcription of reporter genes containing SRE-1 in the absence (15-fold) and presence (90-fold) of sterols, abolishing sterol regulation. We suggest that SREBP-1 is regulated by an unknown factor that is overwhelmed when SREBP-1 is overexpressed. Understanding the regulation of SREBP-1 may be crucial for understanding the control of plasma cholesterol in humans.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	YOKOYAMA, C (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Admon, Arie/0000-0003-0504-3950; Wang, Xiaodong/0000-0001-9885-356X	NHLBI NIH HHS [5F32HL07833, HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007833, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FARMER K, 1992, J BIOL CHEM, V267, P5631; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STONE KL, 1989, PRACTICAL GUIDE PROT, P33; WANG XD, 1993, J BIOL CHEM, V268, P14497; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	34	780	822	3	52	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					187	197		10.1016/S0092-8674(05)80095-9	http://dx.doi.org/10.1016/S0092-8674(05)80095-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402897				2022-12-28	WOS:A1993MB66700019
J	WINSLOW, JT; HASTINGS, N; CARTER, CS; HARBAUGH, CR; INSEL, TR				WINSLOW, JT; HASTINGS, N; CARTER, CS; HARBAUGH, CR; INSEL, TR			A ROLE FOR CENTRAL VASOPRESSIN IN PAIR BONDING IN MONOGAMOUS PRAIRIE VOLES	NATURE			English	Article							NEUROHYPOPHYSEAL PEPTIDES; MICROTUS-OCHROGASTER; SEXUAL-BEHAVIOR; MALE-RATS; OXYTOCIN; RECEPTOR; ANTAGONISTS; SYSTEM	MONOGAMOUS social organization is characterized by selective affiliation with a partner, high levels of paternal behaviour and, in many species, intense aggression towards strangers for defence of territory, nest and mate1,2. Although much has been written about the evolutionary causes of monogamy, little is known about the proximate mechanisms for pair bonding in monogamous mammals2,3. The prairie vole, Microtus ochrogaster, is a monogamous, biparental rodent which exhibits long-term pair bonds characterized by selective affiliation (partner preference) and aggression4,5. Here we describe the rapid development of both selective aggression and partner preferences following mating in the male of this species. We hypothesized that either arginine-vasopressin (AVP) or oxytocin (OT), two nine-amino-acid neuropeptides with diverse forebrain projections, could mediate the development of selective aggression and affiliation. This hypothesis was based on the following observations: (1) monogamous and polygamous voles differ specifically in the distribution of forebrain AVP and OT receptors6,7; (2) AVP innervation in the prairie vole brain is sexually dimorphic and important for paternal behaviour8; (3) central AVP pathways have been previously implicated in territorial displays and social memory9,10; and (4) central OT pathways have been previously implicated in affiliative behaviours11. We now demonstrate that central AVP is both necessary and sufficient for selective aggression and partner preference formation, two critical features of pair bonding in the monogamous prairie vole.	NIMH,NEUROPHYSIOL LAB,POB 608,POOLESVILLE,MD 20837; UNIV MARYLAND,DEPT ZOOL,COLL PK,MD 20742	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University System of Maryland; University of Maryland College Park								BAMSHAD M, 1993, J NEUROENDOCRINOL, V5, P247, DOI 10.1111/j.1365-2826.1993.tb00480.x; BAMSHAD M, 1992, SOC NEUR ABSTR, V18; CAMPAAN JC, 1993, BRAIN RES B, V30, P1; CARTER CS, 1986, ADV STUD BEHAV, P109; CLUTTONBROCK TH, 1989, PROC R SOC SER B-BIO, V236, P339, DOI 10.1098/rspb.1989.0027; DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192; DEWIED D, 1991, P NATL ACAD SCI USA, V88, P1494, DOI 10.1073/pnas.88.4.1494; DEWSBURY DA, 1988, AM ZOOL NEBR S MOT, P1; ELANDS J, 1987, EUR J PHARMACOL, V147, P197; FERRIS CF, 1984, SCIENCE, V224, P521, DOI 10.1126/science.6538700; FERRIS CF, 1988, EUR J PHARMACOL, V154, P153, DOI 10.1016/0014-2999(88)90092-1; GETZ LL, 1981, BEHAV ECOL SOCIOBIOL, V8, P189, DOI 10.1007/BF00299829; HUGHES AM, 1987, BRAIN RES, V414, P133, DOI 10.1016/0006-8993(87)91333-3; INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981; INSEL TR, 1992, PSYCHONEUROENDOCRINO, V17, P3, DOI 10.1016/0306-4530(92)90073-G; INSEL TR, 1993, REGUL PEPTIDES, V45, P127, DOI 10.1016/0167-0115(93)90194-D; JANNETT F J JR, 1980, Biologist (Charleston), V62, P3; JONES PM, 1982, NEUROENDOCRINOLOGY, V34, P297, DOI 10.1159/000123316; KLEIMAN DG, 1977, Q REV BIOL, V52, P39, DOI 10.1086/409721; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; Miczek K. A., 1987, EXPT PSYCHOPHARMACOL, P27; MURPHY MR, 1987, J CLIN ENDOCR METAB, V65, P738, DOI 10.1210/jcem-65-4-738; PIERCE JD, 1991, AGGRESSIVE BEHAV, V17, P337, DOI 10.1002/1098-2337(1991)17:6<337::AID-AB2480170605>3.0.CO;2-F; POPICK FE, 1975, LIFE SCI, V18, P197; ROCHE KE, 1979, SCIENCE, V204, P1343, DOI 10.1126/science.221973; WILLIAMS JR, 1992, HORM BEHAV, V26, P339, DOI 10.1016/0018-506X(92)90004-F; WITT DM, 1991, ENDOCRINOLOGY, V128, P3269, DOI 10.1210/endo-128-6-3269	27	692	705	1	145	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					545	548		10.1038/365545a0	http://dx.doi.org/10.1038/365545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413608				2022-12-28	WOS:A1993MA66100053
J	EWEN, ME; SLUSS, HK; WHITEHOUSE, LL; LIVINGSTON, DM				EWEN, ME; SLUSS, HK; WHITEHOUSE, LL; LIVINGSTON, DM			TGF-BETA INHIBITION OF CDK4 SYNTHESIS IS LINKED TO CELL-CYCLE ARREST	CELL			English	Article							RETINOBLASTOMA GENE-PRODUCT; SV40 LARGE-T; GROWTH-FACTOR-BETA; SUSCEPTIBILITY GENE; PROTEIN-KINASE; FACTOR-BINDING; G1 PHASE; EXPRESSION; PHOSPHORYLATION; SUPPRESSION	Transforming growth factor beta1 (TGFbeta1) causes G1 growth arrest and the accumulation of unphosphorylated retinoblastoma protein (Rb) in responsive cells. Cdk4 (cyclin-dependent kinase), a major catalytic subunit of the mammalian D-type G1 cyclins, can phosphorylate Rb in vitro, and at least one D-type cyclin, D2, directs the phosphorylation of Rb in vivo. Here we show that TGFbetga1 induces suppression of cdk4 synthesis in G1 in mink lung epithelial cells. Constitutive cdk4 synthesis in these cells led to TGFbeta1 resistance. It also resulted in growth in low serum medium when these cells were released from contact inhibition. Cdk2 activity was also suppressed by TGFbeta1 action, but its constitutive expression failed to override a TGFbeta1-induced G1 block. Hence, the TGFbeta1 block is primarily mediated by cdk4 modulation. Further evidence suggests that TGFbeta1-induced down-modulation of cdk4 leads to inhibition of cdk2 activation and that both events might contribute to TGFbeta1 growth suppression.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	EWEN, ME (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULBECCO R, 1970, NATURE, V227, P802, DOI 10.1038/227802a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, J VIROL, V52, P4565; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KATO JY, 1993, OGENES DEV, V7, P331; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	56	535	541	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1009	1020		10.1016/0092-8674(93)90723-4	http://dx.doi.org/10.1016/0092-8674(93)90723-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402878				2022-12-28	WOS:A1993LY49300008
J	NOURI, FM; LINCOLN, NB				NOURI, FM; LINCOLN, NB			PREDICTING DRIVING PERFORMANCE AFTER STROKE	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP NOTTINGHAM,STROKE RES UNIT,NOTTINGHAM NG5 1PB,ENGLAND	Canterbury Christ Church University; Nottingham University Hospital NHS Trust; Nottingham City Hospital			Lincoln, Nadina B/B-9149-2009					[Anonymous], 1990, LANCET, V336, P781; BULL JP, 1992, J ROY SOC MED, V85, P188; Nouri F M, 1987, Int Disabil Stud, V9, P110; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]	4	58	58	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					482	483		10.1136/bmj.307.6902.482	http://dx.doi.org/10.1136/bmj.307.6902.482			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400933	Bronze, Green Published			2022-12-28	WOS:A1993LU59000023
J	GEHRING, K; LEROY, JL; GUERON, M				GEHRING, K; LEROY, JL; GUERON, M			A TETRAMERIC DNA-STRUCTURE WITH PROTONATED CYTOSINE.CYTOSINE BASE-PAIRS	NATURE			English	Article							ACID	OLIGOMERS containing tracts of-cytidine form hemiprotonated base pairs at acid pH and have been considered to be double-stranded. We have solved the structure of the DNA oligomer 5'-d(TCCCCC) at acid pH and find that it is a four-stranded complex in which two base-paired parallel-stranded duplexes are intimately associated, with their base pairs fully intercalated. The relative orientation of the duplexes is antiparallel, so that each base pair is face-to-face with its neighbours. The NMR spectrum displays only six spin systems, showing that the structure is highly symmetrical on the NMR timescale; the four strands are equivalent. A model derived by energy minimization and constrained molecular dynamics shows excellent compatibility with the observed nuclear Overhauser effects (NOEs) particularly for the very unusual inter-residue sugar-sugar NOEs H1'-H1', H1'-H2'' and H1'-H4'. These NOEs are probably diagnostic for such tetrameric structures.	CNRS, URA D1254, F-91128 PALAISEAU, FRANCE; ECOLE POLYTECH, BIOPHYS GRP, F-91128 PALAISEAU, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris			Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; AHMED S, 1992, NUCLEIC ACIDS RES, V20, P507, DOI 10.1093/nar/20.3.507; AKRINIMISKI EO, 1963, BIOCHEMISTRY-US, V2, P340; ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; ARNOTT S, 1976, J MOL BIOL, V106, P735, DOI 10.1016/0022-2836(76)90262-X; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1990, X PLOR VERSION 2 1 M; HARTMAN KA, 1965, J AM CHEM SOC, V87, P2033, DOI 10.1021/ja01087a031; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KELLOGG GW, 1992, J MAGN RESON, V98, P176, DOI 10.1016/0022-2364(92)90122-N; KISTENMACHER TJ, 1978, BIOPOLYMERS, V17, P2581, DOI 10.1002/bip.1978.360171106; KOCHOYAN M, 1990, BIOCHEMISTRY-US, V29, P4799, DOI 10.1021/bi00472a008; LANGRIDGE R, 1963, NATURE, V198, P725, DOI 10.1038/198725a0; LEROY JL, IN PRESS BIOCHEMISTR; LEROY JL, 1992, 15 INT C MAGN RES BI; LEROY JL, 1990, 14 INT C MAGN RES BI; LUO J, 1992, FEBS LETT, V306, P223, DOI 10.1016/0014-5793(92)81005-7; LYAMICHEV VI, 1989, NATURE, V339, P634, DOI 10.1038/339634a0; MARSH RE, 1962, ACTA CRYSTALLOGR, V15, P310, DOI 10.1107/S0365110X62000791; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WESTHOF E, 1980, P NATL ACAD SCI-BIOL, V77, P1852, DOI 10.1073/pnas.77.4.1852; WESTHOF E, 1992, NATURE, V358, P459, DOI 10.1038/358459b0; WESTHOF E, 1980, J MOL BIOL, V142, P331, DOI 10.1016/0022-2836(80)90276-4; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P211; 1989, EMBO J, V8, P1	28	918	939	11	222	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1993	363	6429					561	565		10.1038/363561a0	http://dx.doi.org/10.1038/363561a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8389423				2022-12-28	WOS:A1993LF93900056
J	LUGINBUHL, LM; ORAV, EJ; MCINTOSH, K; LIPSHULTZ, SE				LUGINBUHL, LM; ORAV, EJ; MCINTOSH, K; LIPSHULTZ, SE			CARDIAC MORBIDITY AND RELATED MORTALITY IN CHILDREN WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; EPSTEIN-BARR-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; VENTRICULAR-TACHYCARDIA; AUTONOMIC NEUROPATHY; PENTAMIDINE THERAPY; RAPID DETECTION; SYNDROME AIDS; DE-POINTES	Objective.-Dysrhythmias, hemodynamic instability, congestive heart failure, and sudden death are serious complications of human immunodeficiency virus (HIV) infection that, to our knowledge, have not been studied systematically. We sought to determine the cumulative incidence and clinical predictors of these adverse events in a cohort of HIV-infected children Design.-Historical cohort study. Setting.-University-affiliated, primary and tertiary care pediatric hospital and ambulatory care center. Participants.-Eighty-one HIV-infected children who had one or more cardiac evaluations between 1984 and 1991 form the study cohort. The initial cardiac evaluation occurred at a median age of 1.5 years, and children were followed up to a median age of 3.6 years. Main Outcome Measures.-Mortality (related to cardiac dysfunction as well as noncardiac causes), tachycardia, bradycardia, hypertension, hypotension, marked sinus arrhythmia, cardiac arrest, and chronic congestive heart failure. Results.-Hemodynamic abnormalities and dysrhythmias occurred frequently. Eight unexpected cardiorespiratory arrests occurred in seven children (9%). Chronic congestive heart failure was noted in 10% of patients. Thirty children died, 10 with significant cardiac dysfunction. As HIV-infected children progressed from acquired immunodeficiency syndrome (AIDS)-related complex to AIDS, significant cardiac problems were more likely to occur. Both nonneurologic AIDS and encephalopathy were strongly associated with most severe cardiac outcomes. However, encephalopathy was the strongest correlate of cardiorespiratory arrest (P=.002). Epstein-Barr virus coinfection was the strongest correlate of chronic congestive heart failure (P<.001). Conclusions.-Cardiac morbidity and mortality are more common with advanced HIV infection. The presence of encephalopathy or Epstein-Barr virus coinfection identifies HIV-infected children at especially high risk for adverse cardiac outcomes.	CHILDRENS HOSP MED CTR, DEPT CARDIOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DIV INFECT DIS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [1NO1HR96041] Funding Source: Medline; NIAID NIH HHS [UO1AI25934, R01AI28076] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR096041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025934, R01AI028076] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACIERNO LJ, 1989, J AM COLL CARDIOL, V13, P1144, DOI 10.1016/0735-1097(89)90277-5; ANDERSON DW, 1988, J AM COLL CARDIOL, V11, P792, DOI 10.1016/0735-1097(88)90213-6; ANDERSON DW, 1990, HUM PATHOL, V21, P253, DOI 10.1016/0046-8177(90)90224-S; ANDIMAN WA, 1985, LANCET, V2, P1390; [Anonymous], 1987, PEDIATRICS, V79, P1; BHARATI S, 1989, CHEST, V96, P406, DOI 10.1378/chest.96.2.406; BRADY M T, 1988, Pediatric Pathology, V8, P205; BUTLER T, 1981, J INFECTION, V3, P172, DOI 10.1016/S0163-4453(81)91411-0; CALABRESE LH, 1987, ANN INTERN MED, V107, P691, DOI 10.7326/0003-4819-107-5-691; CAPPEL R, 1978, ARCH VIROL, V58, P253, DOI 10.1007/BF01317608; CENACCHI G, 1990, MICROBIOLOGICA, V13, P145; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; COHEN JA, 1989, NEUROLOGY, V39, P1111, DOI 10.1212/WNL.39.8.1111; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P2149, DOI 10.1001/jama.263.16.2149; CRADDOCK C, 1987, LANCET, V2, P16; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; De Castro S., 1993, Journal of the American College of Cardiology, V21, p280A; FISH M, 1958, ARCH INTERN MED, V101, P636, DOI 10.1001/archinte.1958.00260150124016; FLEISHER G, 1979, J INFECT DIS, V139, P553, DOI 10.1093/infdis/139.5.553; FLOMENBAUM M, 1989, J ACQ IMMUN DEF SYND, V2, P129; FREEMAN R, 1990, NEUROLOGY, V40, P575, DOI 10.1212/WNL.40.4.575; FRISHMAN W, 1977, CHEST, V72, P535, DOI 10.1378/chest.72.4.535; Garson AJ, 1983, ELECTROCARDIOGRAM IN; GLEAVES CA, 1984, J CLIN MICROBIOL, V19, P917, DOI 10.1128/JCM.19.6.917-919.1984; GOLDBLUM N, 1990, DEV BIOLOGICALS, V72, P309; GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S; HSIA J, 1992, CIRCULATION, V86, P795; JACOB AJ, 1991, BRIT HEART J, V66, P1, DOI 10.1136/hrt.66.1.1; JOSHI VV, 1988, HUM PATHOL, V19, P69, DOI 10.1016/S0046-8177(88)80318-6; KAPLAN LD, 1991, AIDS UPDATES, V4, P1; KAUL S, 1991, AM HEART J, V122, P535, DOI 10.1016/0002-8703(91)91013-D; KAVANAUGH-MCHUGH A L, 1992, Pediatric Research, V31, p166A; KELLY JW, 1992, CLIN INFECT DIS, V14, P1034, DOI 10.1093/clinids/14.5.1034; KOVACS A, 1992, Pediatric Research, V31, p167A; LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635; LENNETTE ET, 1988, LABORATORY DIAGNOSIS, V2, P230; Lewis W, 1992, Cardiovasc Pathol, V1, P53, DOI 10.1016/1054-8807(92)90007-B; LIPSHULTZ SE, 1990, AM J CARDIOL, V66, P246, DOI 10.1016/0002-9149(90)90603-X; LIPSHULTZ SE, 1992, NEW ENGL J MED, V327, P1260, DOI 10.1056/NEJM199210293271802; LIPSHULTZ SE, 1989, AM J CARDIOL, V63, P1489, DOI 10.1016/0002-9149(89)90014-3; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA183; LIPSHULTZ SE, 1991, CIRCULATION, V84, P660; MALLON R, 1990, J VIROL, V64, P6282, DOI 10.1128/JVI.64.12.6282-6285.1990; MILLER R, 1973, CHEST, V63, P102, DOI 10.1378/chest.63.1.102; MOISEEV VS, 1990, TERAPEVT ARKH, V62, P77; Ogurtsov P P, 1988, Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR, V11, P18; REILLY JM, 1988, AM J CARDIOL, V62, P789, DOI 10.1016/0002-9149(88)91223-4; RUTTIMANN S, 1991, ARCH INTERN MED, V151, P2441, DOI 10.1001/archinte.151.12.2441; SCOTT G, 1990, AIDS, V4, P1279, DOI 10.1097/00002030-199012000-00017; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; STEIN KM, 1990, AM J CARDIOL, V66, P888, DOI 10.1016/0002-9149(90)90380-J; STEIN KM, 1991, AM J CARDIOL, V68, P1091, DOI 10.1016/0002-9149(91)90502-C; STEWART JM, 1989, AM HEART J, V117, P140, DOI 10.1016/0002-8703(89)90668-6; TYSON AA, 1989, SOUTHERN MED J, V82, P1184, DOI 10.1097/00007611-198909000-00033; VILLA A, 1992, AIDS, V6, P85, DOI 10.1097/00002030-199201000-00011; Villa A, 1990, Acta Neurol (Napoli), V12, P14; WEBSTER BH, 1957, AM J MED SCI, V234, P62, DOI 10.1097/00000441-195707000-00008; WELBY SB, 1991, J INFECTION, V23, P123, DOI 10.1016/0163-4453(91)91958-Z; WHARTON JM, 1987, AM J MED, V83, P571, DOI 10.1016/0002-9343(87)90774-1; WU AYY, 1990, MODERN PATHOL, V3, P625; WU TC, 1992, AIDS, V6, P777, DOI 10.1097/00002030-199208000-00002; 1987, MMWR MORB MORTAL WKL, V36, P225	64	82	84	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2869	2875		10.1001/jama.269.22.2869	http://dx.doi.org/10.1001/jama.269.22.2869			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8388521				2022-12-28	WOS:A1993LE93600023
J	GOODWIN, RG; ALDERSON, MR; SMITH, CA; ARMITAGE, RJ; VANDENBOS, T; JERZY, R; TOUGH, TW; SCHOENBORN, MA; DAVISSMITH, T; HENNEN, K; FALK, B; COSMAN, D; BAKER, E; SUTHERLAND, GR; GRABSTEIN, KH; FARRAH, T; GIRI, JG; PATRICIABECKMANN, M				GOODWIN, RG; ALDERSON, MR; SMITH, CA; ARMITAGE, RJ; VANDENBOS, T; JERZY, R; TOUGH, TW; SCHOENBORN, MA; DAVISSMITH, T; HENNEN, K; FALK, B; COSMAN, D; BAKER, E; SUTHERLAND, GR; GRABSTEIN, KH; FARRAH, T; GIRI, JG; PATRICIABECKMANN, M			MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A LIGAND FOR CD27 DEFINES A NEW FAMILY OF CYTOKINES WITH HOMOLOGY TO TUMOR-NECROSIS-FACTOR	CELL			English	Article							NERVE GROWTH-FACTOR; T-CELL ACTIVATION; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGEN; CLONING; CDNA; SEQUENCES; PROTEINS	CD27 is a surface antigen found on T and B cells that has homology to a family of molecules including the receptors for tumor necrosis factor (TNF) and nerve growth factor. A cDNA encoding a ligand for CD27 was isolated by a direct-expression cloning strategy using a fusion protein composed of the extracellular domain of CD27 linked to the constant domain of a human immunoglobulin G1 molecule as a probe. The predicted protein product is a type II transmembrane protein whose gene maps to 19p13 and that shows homology to TNF and the ligand for CD40. Biological characterization indicates that the cloned ligand induces the proliferation of costimulated T cells and enhances the generation of cytolytic T cells.	ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA		GOODWIN, RG (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.		Sutherland, Grant Robert/D-2606-2012					ALDERSON MR, 1990, J EXP MED, V172, P577, DOI 10.1084/jem.172.2.577; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIGLER RD, 1988, J IMMUNOL, V141, P21; BROWNING JL, 1991, J IMMUNOL, V147, P1230; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CARRIER A, 1992, GENE, V116, P173, DOI 10.1016/0378-1119(92)90513-O; DEJONG R, 1991, J IMMUNOL, V146, P2488; DOWER SK, 1984, J IMMUNOL, V132, P751; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES EY, 1990, PROG CLIN BIOL RES, V349, P321; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MAURER D, 1990, EUR J IMMUNOL, V20, P2679, DOI 10.1002/eji.1830201223; MAURER D, 1992, J IMMUNOL, V148, P3700; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUGITA K, 1991, J IMMUNOL, V147, P1477; URDAL DL, 1988, J BIOL CHEM, V263, P2870; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P811; VANLIER RAW, 1987, J IMMUNOL, V139, P1589	40	289	348	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					447	456		10.1016/0092-8674(93)90133-B	http://dx.doi.org/10.1016/0092-8674(93)90133-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387892				2022-12-28	WOS:A1993LA74300007
J	KAWAMURA, S				KAWAMURA, S			RHODOPSIN PHOSPHORYLATION AS A MECHANISM OF CYCLIC-GMP PHOSPHODIESTERASE REGULATION BY S-MODULIN	NATURE			English	Article							ROD OUTER SEGMENTS; LIGHT-ACTIVATED PHOSPHODIESTERASE; RETINAL RODS; GUANYLATE-CYCLASE; FREE CALCIUM; ADAPTATION; ATP; MEMBRANES; KINETICS; CASCADE	DURING light-adaptation by the vertebrate eye, the rods are desensitized and the light response is accelerated1,2. When light is absorbed by the rods, a phosphodiesterase is activated that hydrolyses cyclic GMP3,4. A light-induced decrease in cytoplasmic Ca2+ concentration5-7 is part of this light-adaptation process8,9. The protein S-modulin (M(r) 26,000) is known to increase the fraction of light-activated cyclic GMP-phosphodiesterase (PDE) at high Ca2+ concentrations in frog rod photoreceptors10. Here I present evidence that S-modulin lengthens the lifetime of active PDE (PDE*) at high Ca2+ Concentrations. These S-modulin effects are observed in the physiological range of Ca2+ concentration (30 nM to 1 muM; half-maximum effects at 200-400 nM). At the high Ca2+ concentrations at which S-modulin prolongs the lifetime of PDE*, S-modulin inhibits rhodopsin phosphorylation (half-maximum effect at approximately 100 nM Ca2+). ATP is necessary for the S-modulin effects on PDE activation. I therefore conclude that the Ca2+-dependent regulation of PDE by S-modulin is mediated by rhodopsin phosphorylation. This regulation seems to be the principal mechanism of light adaptation in vertebrate photoreceptors.			KAWAMURA, S (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINANO MACHI 35,SHINJUKU KU,TOKYO 160,JAPAN.							BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAWAMURA S, 1986, BIOCHIM BIOPHYS ACTA, V870, P256, DOI 10.1016/0167-4838(86)90230-X; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KAWAMURA S, 1983, BIOCHIM BIOPHYS ACTA, V732, P276, DOI 10.1016/0005-2736(83)90212-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; RATTO GM, 1988, J NEUROSCI, V8, P3240; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YEE R, 1978, J BIOL CHEM, V253, P8902	23	340	346	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					855	857		10.1038/362855a0	http://dx.doi.org/10.1038/362855a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8386803				2022-12-28	WOS:A1993KZ56300062
J	RIBEIRO, JMC; HAZZARD, JMH; NUSSENZVEIG, RH; CHAMPAGNE, DE; WALKER, FA				RIBEIRO, JMC; HAZZARD, JMH; NUSSENZVEIG, RH; CHAMPAGNE, DE; WALKER, FA			REVERSIBLE BINDING OF NITRIC-OXIDE BY A SALIVARY HEME PROTEIN FROM A BLOODSUCKING INSECT	SCIENCE			English	Article							HUMAN-HEMOGLOBIN; LIGAND-BINDING; COMPLEXES; RESONANCE	The bloodsucking bug Rhodnius prolixus has a salivary vasodilator, previously characterized as a nitrovasodilator, with salivary smooth muscle-relaxing and antiplatelet activity. Rhodnius salivary glands are bright red owing to the abundance of heme proteins. Electron paramagnetic resonance and optical spectroscopic experiments indicated that the salivary vasodilator is a nitrosylheme protein with an Fe(III) heme that binds nitric oxide (NO) reversibly. Dilution of the protein in neutral pH promoted NO release. This protein thus appears to be the NO carrier that helps R. prolixus to feed on blood.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,DEPT CHEM,TUCSON,AZ 85721	University of Arizona; University of Arizona	RIBEIRO, JMC (corresponding author), UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721, USA.		Walker, Frances A/O-4395-2016	Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018694, R37AI018694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK031038, R01DK031038] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18694] Funding Source: Medline; NIDDK NIH HHS [DK-31038] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONINI E, 1966, J BIOL CHEM, V241, P3236; BRUNORI M, 1974, P NATL ACAD SCI USA, V71, P2470, DOI 10.1073/pnas.71.6.2470; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHAMPAGNE DE, UNPUB; DOLPHIN D, 1979, PORPHYRINS, V4, pCH6; EBEL RE, 1975, FEBS LETT, V55, P198, DOI 10.1016/0014-5793(75)80991-4; HILLE R, 1979, J BIOL CHEM, V254, P2110; HORI H, 1990, J BIOL CHEM, V265, P15028; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; RADOMSKI MW, 1991, PHILOS T ROY SOC B, V334, P129, DOI 10.1098/rstb.1991.0102; RIBEIRO JMC, 1990, BRIT J PHARMACOL, V101, P932, DOI 10.1111/j.1476-5381.1990.tb14183.x; ROMBERG RW, 1979, BIOCHEMISTRY-US, V18, P5387, DOI 10.1021/bi00591a020; SCHOLLER DM, 1979, J BIOL CHEM, V254, P4072; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; TODD P, 1969, ANAL BIOCHEM, V28, P369, DOI 10.1016/0003-2697(69)90192-4; WIGGLESWORTH VB, 1942, P ROYAL SOC LOND B, V131, P313; YASHIMURA T, 1983, J INORG BIOCHEM, V18, P263	20	284	295	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					539	541		10.1126/science.8386393	http://dx.doi.org/10.1126/science.8386393			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8386393				2022-12-28	WOS:A1993KY50400033
J	EDWARDS, KM; DECKER, MD; GRAHAM, BS; MEZZATESTA, J; SCOTT, J; HACKELL, J				EDWARDS, KM; DECKER, MD; GRAHAM, BS; MEZZATESTA, J; SCOTT, J; HACKELL, J			ADULT IMMUNIZATION WITH ACELLULAR PERTUSSIS-VACCINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPONENT DTP VACCINE; ADVERSE REACTIONS; TETANUS TOXOIDS; IMMUNE-RESPONSE; HOSPITAL STAFF; WHOOPING-COUGH; DIPHTHERIA; CHILDREN; ANTIBODY; INFECTION	Objective.-To evaluate the safety and immunogenicity in adults of several different concentrations of an acellular pertussis vaccine. Design.-Double-blind, randomized, placebo-controlled trial. Setting.-Medical center immunization clinic. Participants.-One hundred eighteen healthy adult volunteers. Interventions.-Participants received standard adult tetanus-diphtheria vaccine alone or combined with full-strength, half-strength, or quarter-strength concentrations of a currently licensed acellular pertussis vaccine used for booster doses in young children. Full-strength vaccine contained 40 mug of pertussis proteins, consisting of 86% filamentous hemagglutinin, 8% pertussis toxin, 4% 69-kd outer-membrane protein, and 2% agglutinogens. Main Outcome Measures.-Local and systemic reactions were assessed for 14 days after vaccination. Serum samples for antibody assay were obtained before, 1 month after, and 1 year after immunization. Results.-Adverse reactions were few and minor and did not differ in frequency or severity among the four study groups. The groups receiving acellular pertussis vaccine showed strong antibody responses to pertussis antigens, which did not significantly differ by concentration of vaccine. After 1 year, levels of antibody to pertussis had declined by approximately 50% but remained substantially higher than preimmunization levels. The four groups did not differ in antibody responses to tetanus or diphtheria toxoids. Conclusions.-Routine reimmunization of adults with a vaccine containing acellular pertussis antigens in addition to diphtheria and tetanus toxoids can substantially enhance pertussis antibody levels without an increase in adverse reactions or diminution in response to the diphtheria and tetanus components. Such a program might materially reduce respiratory illness among both adults and children.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,DIV INFECT DIS,NASHVILLE,TN 37232; AMER CYANAMID CO,LEDERLE LABS,PEARL RIVER,NY 10965	Vanderbilt University; Vanderbilt University; Vanderbilt University			Graham, Barney S./AAC-5898-2019	Graham, Barney S./0000-0001-8112-0853; Decker, Michael/0000-0003-1008-7472	NCRR NIH HHS [5MO-IRR90095] Funding Source: Medline; NIAID NIH HHS [N01-AI-02645] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI002645] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; ARMITAGE P, 1971, STATISTICAL METHODS, P442; BIELLIK RJ, 1988, J INFECT DIS, V175, P1134; BLUMBERG DA, 1990, J PEDIATR-US, V117, P46, DOI 10.1016/S0022-3476(05)82442-4; CADOZ M, 1986, SAFETY IMMUNOGENICIT, P131; CHERRY JD, 1989, WESTERN J MED, V150, P319; CHRISTIE CDC, 1989, AM J DIS CHILD, V143, P1199, DOI 10.1001/archpedi.1989.02150220097027; COLTON T, 1974, STAT MED, P131; EDWARDS KM, 1990, PEDIATR CLIN N AM, V37, P549; EDWARDS KM, 1986, AM J DIS CHILD, V140, P867, DOI 10.1001/archpedi.1986.02140230037024; GRANSTROM M, 1985, J INFECT DIS, V151, P646, DOI 10.1093/infdis/151.4.646; GRANSTROM M, 1987, EUR J CLIN MICROBIOL, V6, P18, DOI 10.1007/BF02097184; HERWALDLT LA, 1991, ARCH INTERN MED, V115, P1510; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; KURT TL, 1972, J AMER MED ASSOC, V221, P264, DOI 10.1001/jama.221.3.264; LAMBERT HJ, 1965, PUBLIC HEALTH REP, V80, P365, DOI 10.2307/4592424; LEWIS K, 1986, AM J DIS CHILD, V140, P872, DOI 10.1001/archpedi.1986.02140230042025; LINNEMANN CC, 1977, ANNU REV MED, V28, P179, DOI 10.1146/annurev.me.28.020177.001143; LINNEMANN CC, 1975, LANCET, V2, P540; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MERTSOLA J, 1983, J PEDIATR-US, V103, P359, DOI 10.1016/S0022-3476(83)80403-X; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; MIYAMURA K, 1974, J BIOL STAND, V2, P189, DOI 10.1016/0092-1157(74)90015-8; MORSE SI, 1968, ANN INTERN MED, V68, P953, DOI 10.7326/0003-4819-68-4-953; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; MORTIMER EA, 1990, AM J DIS CHILD, V144, P899, DOI 10.1001/archpedi.1990.02150320063029; MORTIMER EA, 1988, VACCINES, P74; NELSON JD, 1978, AM J DIS CHILD, V132, P371, DOI 10.1001/archpedi.1978.02120290043006; PICHICHERO ME, 1987, PEDIATR INFECT DIS J, V6, P352, DOI 10.1097/00006454-198704000-00004; ROBERTSON PW, 1987, MED J AUSTRALIA, V146, P522, DOI 10.5694/j.1326-5377.1987.tb120392.x; RUTTER DA, 1988, VACCINE, V6, P29, DOI 10.1016/0264-410X(88)90010-2; RUUSKANEN O, 1991, VACCINE, V9, P117, DOI 10.1016/0264-410X(91)90267-A; SEKURA RD, 1988, J PEDIATR-US, V113, P806, DOI 10.1016/S0022-3476(88)80005-2; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; TROLLFORS B, 1981, BRIT MED J, V283, P696, DOI 10.1136/bmj.283.6293.696; VANSAVAGE J, 1990, J INFECT DIS, V161, P487, DOI 10.1093/infdis/161.3.487; WHITE C, 1973, SEROLOGIC EPIDEMIOLO, P19; 1981, LANCET, V1, P955; 1986, SEP TRANSCR WORKSH A; 1953, MINIMUM REQUIREMENTS	41	102	105	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					53	56		10.1001/jama.269.1.53	http://dx.doi.org/10.1001/jama.269.1.53			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416406				2022-12-28	WOS:A1993KF02600026
J	KORETZ, RL				KORETZ, RL			MALIGNANT POLYPS - ARE THEY SHEEP IN WOLVES CLOTHING	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						COLONIC POLYPS; COLONIC NEOPLASMS; ADENOMA; AUTOPSY; COLONOSCOPY	COLORECTAL-CANCER; OCCULT BLOOD; LARGE-INTESTINE; CONTROLLED TRIAL; LARGE BOWEL; COLONIC POLYPS; COLONOSCOPY; RISK; DIVERTICULOSIS; NECROPSY	One of the arguments supporting the concept that benign adenomatous polyps of the colon degenerate into cancer is the observation of malignancy in polypoid growths known to have been present for years. Although a latent phase-the duration of time between the initial development of a malignancy and the subsequent occurrence of a clinical problem-must exist, this argument implies that this time span is not many years. If both the prevalence of malignant polyps and the incidence of consequent symptomatic colon cancer were known, the average latent phase could be calculated. In order to estimate this prevalence, I used autopsy data; the estimate was validated using independent data from three colonoscopic screening studies. The annual incidence of all colon cancer in the United States is approximately 150 000 cases. I estimate that 725 000 people in the United States harbor at least one malignant polyp. Even if all 150 000 cases of colon cancer were associated with symptoms and began as malignant polyps, the average latent phase is 4.8 years. Because some colon cancers are removed while the patient is still asymptomatic (discovered on screening examination) and because at least some colon cancers arise de novo from the mucosa, the average latent phase must be even longer. These estimates suggest that it cannot be assumed that the histologic finding of cancer in a polyp that has been observed for many years represents ''malignant degeneration'' of a previously benign neoplasm; such a malignancy may have had that histologic characteristic from the start. Further, histologically ominous lesions (malignant polyps) may often have prolonged benign clinical courses.			KORETZ, RL (corresponding author), OLIVE VIEW MED CTR, DEPT MED, 14445 OLIVE VIEW DR, SYLMAR, CA 91342 USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ALSTEAD E M, 1990, Gastroenterology, V98, pA269; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; BALDRIDGE M, 1987, STATISTICAL ABSTRACT; BELLENCANI S, 1990, Gastroenterology, V98, pA273; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; BUNTAIN WL, 1972, SURG GYNECOL OBSTETR, V134, P499; BUSSEY HJR, 1985, BRIT J SURG, V72, pS29, DOI 10.1002/bjs.1800721318; CARLSSON G, 1987, ARCH SURG-CHICAGO, V122, P1261; CHAPMAN I, 1963, ANN SURG, V157, P223, DOI 10.1097/00000658-196302000-00007; COLARIAN J, 1990, Gastroenterology, V98, pA276; COLVERT JR, 1948, AM J MED SCI, V215, P24, DOI 10.1097/00000441-194801000-00004; DISARIO JA, 1991, AM J GASTROENTEROL, V86, P941; EIDE TJ, 1978, CANCER, V42, P2839, DOI 10.1002/1097-0142(197812)42:6<2839::AID-CNCR2820420645>3.0.CO;2-Y; ENQUIST IF, 1952, SURGERY, V32, P696; GABRIELSSON N, 1978, ACTA RADIOL DIAGN, V19, P479, DOI 10.1177/028418517801900309; GILBERTS.VA, 1974, CANCER, V34, P936, DOI 10.1002/1097-0142(197409)34:3+<936::AID-CNCR2820340722>3.0.CO;2-5; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; GILBERTSON VA, 1963, SURG GYNECOL OBSTET, V116, P413; GILLESPIE PE, 1979, GUT, V20, P240, DOI 10.1136/gut.20.3.240; HARDCASTLE JD, 1989, LANCET, V1, P1160; HELWIG EB, 1947, SURG GYNECOL OBSTET, V84, P36; Hughes L E, 1968, Aust N Z J Surg, V38, P30; IKEGAMI M, 1987, ACTA PATHOL JAPON, V37, P21; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; KURAMOTO S, 1988, CANCER, V61, P829, DOI 10.1002/1097-0142(19880215)61:4<829::AID-CNCR2820610431>3.0.CO;2-P; KURZON RM, 1974, AM J CLIN PATHOL, V62, P447; LAWRENCE JC, 1936, AM J SURG, V32, P499; Lee Y S, 1987, Ann Acad Med Singap, V16, P412; LESCHER TC, 1967, DIS COLON RECTUM, V10, P118, DOI 10.1007/BF02617358; LEUCHTENBERGER C, 1954, LAB INVEST, V3, P132; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; LOFTI AM, 1986, MAYO CLIN P, V61, P337; MOERTEL CG, 1966, MAYO CLIN PROC, V41, P368; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; PAGTALUN.RJ, 1965, SURG GYNECOL OBSTETR, V120, P1259; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; RIDER JA, 1954, AM J MED, V16, P555, DOI 10.1016/0002-9343(54)90372-1; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SATO E, 1976, CANCER, V37, P1316, DOI 10.1002/1097-0142(197603)37:3<1316::AID-CNCR2820370312>3.0.CO;2-#; SCARBOROUGH R A, 1960, Dis Colon Rectum, V3, P336, DOI 10.1007/BF02623800; SHINYA H, 1979, ANN SURG, V190, P679, DOI 10.1097/00000658-197912000-00001; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; SPRATT JS, 1962, JAMA-J AM MED ASSOC, V179, P337, DOI 10.1001/jama.1962.03050050027005; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; Stewart MJ, 1931, LANCET, V2, P669; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; SWINTON N W, 1947, Lahey Clin Bull, V5, P84; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBB WA, 1985, ANN SURG, V201, P626, DOI 10.1097/00000658-198505000-00012; WELCH CE, 1952, NEW ENGL J MED, V247, P959, DOI 10.1056/NEJM195212182472501; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; WILSON GS, 1955, AM J SURG, V90, P834, DOI 10.1016/0002-9610(55)90707-8; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WYCHULIS AR, 1967, SURG GYNECOL OBSTETR, V124, P87; 1988, ANN CANCER STATISTIC; 1988, GASTROENTEROLOGY OBS, V7, P7; 1988, GASTROENTEROLOGY OBS, V7, P1	62	68	71	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					63	68		10.7326/0003-4819-118-1-199301010-00011	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416159				2022-12-28	WOS:A1993KE60500010
J	SWACKHAMER, K				SWACKHAMER, K			CHINA TALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2105	2105						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411580				2022-12-28	WOS:A1993MD88200035
J	DAVIES, L; SATRE, M; MARTIN, JB; GROSS, JD				DAVIES, L; SATRE, M; MARTIN, JB; GROSS, JD			THE TARGET OF AMMONIA ACTION IN DICTYOSTELIUM	CELL			English	Article							NUCLEAR MAGNETIC-RESONANCE; INTRACELLULAR PH; CELL-DIFFERENTIATION; CAMP ACCUMULATION; DISCOIDEUM; INHIBITION; AMEBAS; ACIDIFICATION; MOBILIZATION; ALKYLAMINES	The weak base ammonia is implicated in a number of key processes in Dictyostelium development, notably aggregation and culmination. To determine its intracellular site of action, we compared its biological potency with that of other weak bases. All the bases inhibited these developmental processes effectively, but differed manyfold in potency in accordance with their activity in dissipating pH gradients, as measured by in vivo P-31 NMR with pH-sensitive phosphonate probes. These results indicate that weak bases influence development by raising the pH of an intracellular acidic compartment.	CEN, DEPT BIOL MOLEC & STRUCT, BIOL CELLULAIRE LAB, CNRS, F-38041 GRENOBLE, FRANCE; CEN, RESONANCE MAGNET BIOL & MED LAB, F-38041 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS)	DAVIES, L (corresponding author), UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND.			Davies, Lynne/0000-0003-2066-7008	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; BARON Z, 1985, BIOCHIM BIOPHYS ACTA, V813, P207, DOI 10.1016/0005-2736(85)90235-4; BONNER JT, 1985, J EMBRYOL EXP MORPH, V87, P207; BONNER JT, 1966, BIOL BULL-US, V130, P28, DOI 10.2307/1539950; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BRENOT F, 1992, BIOCHIMIE, V74, P883, DOI 10.1016/0300-9084(92)90072-M; CAPPUCCINELLI P, 1976, EXP CELL RES, V103, P387, DOI 10.1016/0014-4827(76)90274-3; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FEIT IN, 1988, DEV GENET, V9, P639, DOI 10.1002/dvg.1020090440; GREGG JH, 1954, BIOL BULL, V107, P226, DOI 10.2307/1538609; GROSS JD, 1988, DIFFERENTIATION, V38, P91, DOI 10.1111/j.1432-0436.1988.tb00202.x; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; KAY RR, 1986, J CELL SCI, V83, P165; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; LONSKI J, 1976, DEV BIOL, V51, P158, DOI 10.1016/0012-1606(76)90131-7; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; NISSANI E, 1989, BIOCHIM BIOPHYS ACTA, V978, P293, DOI 10.1016/0005-2736(89)90127-2; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; PELORGEAS S, 1992, BIOCHEM PHARMACOL, V44, P2157, DOI 10.1016/0006-2952(92)90342-G; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; ROONEY EK, 1992, P NATL ACAD SCI USA, V89, P8025, DOI 10.1073/pnas.89.17.8025; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SATRE M, 1989, BIOCHIMIE, V71, P941, DOI 10.1016/0300-9084(89)90076-X; SATRE M, 1985, BIOCHEM BIOPH RES CO, V132, P140, DOI 10.1016/0006-291X(85)90999-4; SCHINDLER J, 1977, J MOL BIOL, V116, P161, DOI 10.1016/0022-2836(77)90124-3; SCHINDLER J, 1979, DEV GENET, V1, P13, DOI 10.1002/dvg.1020010104; SCHULDINER S, 1972, EUR J BIOCHEM, V25, P64, DOI 10.1111/j.1432-1033.1972.tb01667.x; Sussman M., 1966, METHOD CELL PHYSIOL, V2, P397; WEEKS G, 1991, BIOCHEM CELL BIOL, V69, P608, DOI 10.1139/o91-090; WILLIAMS GB, 1984, DEV BIOL, V105, P377, DOI 10.1016/0012-1606(84)90294-X; Williams JG, 1991, CURR OPIN GENET DEV, V1, P358, DOI 10.1016/S0959-437X(05)80300-4	37	63	63	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					321	327		10.1016/0092-8674(93)80073-N	http://dx.doi.org/10.1016/0092-8674(93)80073-N			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402915				2022-12-28	WOS:A1993MD88500013
J	MCPHERSON, CE; SHIM, EY; FRIEDMAN, DS; ZARET, KS				MCPHERSON, CE; SHIM, EY; FRIEDMAN, DS; ZARET, KS			AN ACTIVE TISSUE-SPECIFIC ENHANCER AND BOUND TRANSCRIPTION FACTORS EXISTING IN A PRECISELY POSITIONED NUCLEOSOMAL ARRAY	CELL			English	Article							TUMOR VIRUS PROMOTER; YEAST ALPHA-2 REPRESSOR; FORK HEAD DOMAIN; GLUCOCORTICOID RECEPTOR; GENE FAMILY; ALBUMIN ENHANCER; NUCLEAR-PROTEIN; DNA; CHROMATIN; MOUSE	Nucleosomes positioned over promoters are usually inhibitory to protein binding and activity. We analyzed at the nucleotide level of resolution the nucleosomal organization of a distal, liver-specific enhancer in various mouse tissues and found that the enhancer exists in an array of three precisely positioned nucleosomes only in liver chromatin, where the enhancer is active. In vivo footprinting reveals that essential transcription factor-binding sites are occupied on apparent nucleosome surfaces, in one case leading to a perturbed nucleosomal structure. A similar nucleosomal array is generated with an in vitro chromatin assembly system in which nucleosome positioning is dependent upon binding to the enhancer of proteins related to hepatocyte nuclear factor 3. We suggest that certain transcription factors can organize nucleosomal structures that define an active enhancer element.			MCPHERSON, CE (corresponding author), BROWN UNIV, BIOCHEM SECT, PROVIDENCE, RI 02912 USA.				NIGMS NIH HHS [GM36477] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036477, R37GM036477] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HU JM, 1992, CELL GROWTH DIFFER, V3, P577; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEVITT M, 1978, P NATL ACAD SCI USA, V75, P640, DOI 10.1073/pnas.75.2.640; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PERLMANN T, 1992, P NATL ACAD SCI USA, V89, P3884, DOI 10.1073/pnas.89.9.3884; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POWELL DJ, 1984, MOL BIOL, V170, P21; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEN R, 1989, IMMUNOGLOBULIN GENES, P327; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WOLFFE A P, 1991, Current Biology, V1, P366, DOI 10.1016/0960-9822(91)90195-3; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	64	298	299	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					387	398		10.1016/0092-8674(93)80079-T	http://dx.doi.org/10.1016/0092-8674(93)80079-T			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402920				2022-12-28	WOS:A1993MD88500019
J	BEATH, SV; BROOK, GD; KELLY, DA; CASH, AJ; MCMASTER, P; MAYER, AD; BUCKELS, JAC				BEATH, SV; BROOK, GD; KELLY, DA; CASH, AJ; MCMASTER, P; MAYER, AD; BUCKELS, JAC			SUCCESSFUL LIVER-TRANSPLANTATION IN BABIES UNDER 1 YEAR	BRITISH MEDICAL JOURNAL			English	Article							HEPATIC TRANSPLANTATION; NUTRITIONAL-STATUS; BILIARY ATRESIA; MUSCLE AREAS; CHILDREN; PEDIATRICS; SURVIVAL; INFANCY; GROWTH; AGE	Objective-To review the outcome of liver transplantation in babies aged less than 1 year. Design-Prospective evaluation of survival, clinical complications, and nutritional and developmental status before and one year after liver transplantation. Setting-The Children's Hospital and Queen Elizabeth Hospital, Birmingham. Subjects-All 25 babies who received liver transplantation from january 1989 to December 1992 were included. Median age was 9 months and median weight was 7.0 kg. Seven babies were assessed but were not given transplants because they died while on the waiting list (two) or had severe extrahepatic disease (five). Results-24 babies had severe decompensated liver disease and 20 were severely malnourished despite nutritional support. Six babies received a whole liver graft and 19 received a reduction hepatectomy. Postoperative complications included primary nonfunction of the transplanted liver (one baby), hepatic artery thrombosis (two), biliary obstruction (seven), acute and chronic rejection (six), and sepsis (18). Three babies required a second transplant; all survived. Three babies, two of whom presented with fulminant hepatic failure, died. The overall actuarial survival rate (4 months to 4 years) is 88%. Review at 12 months showed a dramatic improvement in growth (p<0.001) and normal psychosocial development with good quality of life. Conclusion-The improvement in survival rates and quality of life in this group of very sick babies is related not only to the development of reduction hepatectomy but also to advances in medical and nursing expertise. Early referral for liver transplantation is justified even if babies are critically ill.	CHILDRENS HOSP,LIVER UNIT,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								BADGER IL, 1992, BRIT J SURG, V79, P47, DOI 10.1002/bjs.1800790115; Brooke O. G., 1986, Energy and protein needs during infancy, P3; BUCKELS JAC, 1989, TRANSPLANT P, V21, P2460; CHIN SE, 1991, J PAEDIATR CHILD H, V27, P380, DOI 10.1111/j.1440-1754.1991.tb00424.x; CHIYENDE J, 1992, ARCH DIS CHILD, V67, P1124, DOI 10.1136/adc.67.9.1124; ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0; FRISANCHO AR, 1981, AM J CLIN NUTR, V34, P2540, DOI 10.1093/ajcn/34.11.2540; HARRIS G, 1992, MONOGRAPHS CLIN PEDI, P61; HOUSSIN D, 1992, SURGERY, V111, P532; JORDAN MD, 1987, CDC ANTHROPOMETRIC S; KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7; KAUFMAN SS, 1987, J PEDIATR-US, V110, P679, DOI 10.1016/S0022-3476(87)80002-1; LYNCH SV, 1992, TRANSPLANT P, V24, P186; MALATACK JJ, 1987, J PEDIATR-US, V111, P479, DOI 10.1016/S0022-3476(87)80105-1; MIYAWAKI T, 1981, IMMUNOL REV, V57, P61, DOI 10.1111/j.1600-065X.1981.tb00442.x; MORGAN GE, 1992, CLIN ANAESTHESIOLOGY, P630; MOUKARZEL AA, 1990, TRANSPLANT P, V22, P1560; OTTE JB, 1990, ANN SURG, V211, P146, DOI 10.1097/00000658-199002000-00006; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P222; RYCKMAN FC, 1991, J PEDIATR SURG, V26, P422, DOI 10.1016/0022-3468(91)90989-7; SALT A, 1992, BMJ-BRIT MED J, V304, P416, DOI 10.1136/bmj.304.6824.416; SANN L, 1988, ARCH DIS CHILD, V63, P256, DOI 10.1136/adc.63.3.256; SMITH D E, 1989, Journal of Human Nutrition and Dietetics, V2, P217, DOI 10.1111/j.1365-277X.1989.tb00025.x; SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1; STEWART SM, 1989, J PEDIATR-US, V114, P574, DOI 10.1016/S0022-3476(89)80696-1; WHITINGTON PF, 1991, J PEDIATR-US, V118, P169, DOI 10.1016/S0022-3476(05)80478-0; 1986, GRIFFITHS MENTAL DEV	27	61	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					825	828		10.1136/bmj.307.6908.825	http://dx.doi.org/10.1136/bmj.307.6908.825			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401122	Green Published, Bronze			2022-12-28	WOS:A1993MA29300017
J	KERR, LD; RANSONE, LJ; WAMSLEY, P; SCHMITT, MJ; BOYER, TG; ZHOU, Q; BERK, AJ; VERMA, IM				KERR, LD; RANSONE, LJ; WAMSLEY, P; SCHMITT, MJ; BOYER, TG; ZHOU, Q; BERK, AJ; VERMA, IM			ASSOCIATION BETWEEN PROTO-ONCOPROTEIN REL AND TATA-BINDING PROTEIN MEDIATES TRANSCRIPTIONAL ACTIVATION BY NF-KAPPA-B	NATURE			English	Article							RNA POLYMERASE-II; DNA-BINDING; C-REL; BASIC REPEAT; P65 SUBUNIT; GENE; BOX; DOMAIN; YEAST; INVITRO	The c-Rel protein is able to associate in vitro and in vivo with the TATA-binding protein (TBP) of the TFIID complex. Coexpression of TBP with c-Rel augments transactivation from the kappaB site in Drosophila Schneider cells. DNA-binding mutants of TBP not only fall to cooperate, but they repress transactivation by c-Rel. There may be a direct communication between kappaB enhancer binding proteins and basal transcription factors which leads to enhanced transcription.	SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92138; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Salk Institute; University of California System; University of California Los Angeles			BERK, ARNOLD/AAF-7052-2020					BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Coulombe Benoit, 1992, Gene Expression, V2, P99; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1992, CANCER SURV, V15, P69; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENBLATT J, 1992, NATURE, V360, P16, DOI 10.1038/360016a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1988, CELL, V54, P655; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; IP YT, 1991, CELL, V64, P439; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V6, P557; NILOLOV DB, 1992, NATURE, V360, P40; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAN D, 1991, DEVELOPMENT, V5, P1892; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHU H, 1991, NEW BIOL, V3, P455	50	154	157	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					412	419		10.1038/365412a0	http://dx.doi.org/10.1038/365412a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413585				2022-12-28	WOS:A1993LZ63300047
J	STEHLE, JH; FOULKES, NS; MOLINA, CA; SIMONNEAUX, V; PEVET, P; SASSONECORSI, P				STEHLE, JH; FOULKES, NS; MOLINA, CA; SIMONNEAUX, V; PEVET, P; SASSONECORSI, P			ADRENERGIC SIGNALS DIRECT RHYTHMIC EXPRESSION OF TRANSCRIPTIONAL REPRESSOR CREM IN THE PINEAL-GLAND	NATURE			English	Article							MELATONIN; GENE; RAT; ANTAGONIST; ACTIVATOR; RECEPTOR; HAMSTER	Transcription factor CREM appears to play a key physiological and developmental role within the hypothalamic-pituitary-gonadal axis. This axis is modulated by the pineal hormone melatonin, whose production is in turn driven by the endogenous clock. There is striking circadian fluctuation of a novel CREM isoform, ICER, which is expressed at high levels during the night. ICER is generated from an alternative, intronic promoter and functions as a powerful repressor of cyclic AMP-induced transcription. Rhythmic adrenergic signals originated by the clock direct ICER expression by stimulation of the cAMP signal transduction pathway.	FAC MED STRASBOURG, CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE; UNIV STRASBOURG 1, CNRS, URA 1332, F-67070 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891				ASCHOFF J, 1981, HDB BEHAV NEUROBIOLO, V4, P1; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BROWNSTEIN M, 1974, SCIENCE, V184, P163, DOI 10.1126/science.184.4133.163; CARTER DS, 1983, ENDOCRINOLOGY, V113, P1261, DOI 10.1210/endo-113-4-1261; CRAFT CM, 1984, NEUROENDOCRINOLOGY, V38, P193, DOI 10.1159/000123890; Darwin C, 1880, POWER MOVEMENT PLANT; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMANN K, 1981, HDB BEHAVIOURAL NEUR, V4, P449; ILLNEROVA H, 1979, J NEUROCHEM, V32, P673, DOI 10.1111/j.1471-4159.1979.tb00407.x; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1985, PHOTOPERIODISM MELAT; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MEIJER GH, 1991, SUPRACHIASMATIC NUCL; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MOLINA CA, IN PRESS CELL; MOORE RY, 1983, FED PROC, V42, P2783; PERLOW MJ, 1980, BRAIN RES, V182, P211, DOI 10.1016/0006-8993(80)90848-3; PEVET P, 1988, REPROD NUTR DEV, V28, P443, DOI 10.1051/rnd:19880310; REITER RJ, 1991, TRENDS ENDOCRIN MET, V2, P13, DOI 10.1016/1043-2760(91)90055-R; ROMERO JA, 1974, SCIENCE, V184, P1091, DOI 10.1126/science.184.4141.1091; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; SIMONNEAUX V, 1989, J PINEAL RES, V7, P63, DOI 10.1111/j.1600-079X.1989.tb00443.x; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDGEN D, 1985, NATURE, V314, P359; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; TAMARKIN L, 1985, SCIENCE, V227, P714, DOI 10.1126/science.3881822; TAMARKIN L, 1979, ENDOCRINOLOGY, V104, P385, DOI 10.1210/endo-104-2-385; VANECEK J, 1985, ENDOCRINOLOGY, V116, P2167, DOI 10.1210/endo-116-6-2167; VULLIAMY TJ, 1988, P NATL ACAD SCI USA, V85, P5171, DOI 10.1073/pnas.85.14.5171; WILLIAMS JG, 1987, NUCL ACID HYBRIDISAT, P139; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; [No title captured]	48	377	378	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1993	365	6444					314	320		10.1038/365314a0	http://dx.doi.org/10.1038/365314a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8397338				2022-12-28	WOS:A1993LY49600043
J	EVANS, EGV; DODMAN, B; WILLIAMSON, DM; BROWN, GJ; BOWEN, RG				EVANS, EGV; DODMAN, B; WILLIAMSON, DM; BROWN, GJ; BOWEN, RG			COMPARISON OF TERBINAFINE AND CLOTRIMAZOLE IN TREATING TINEA-PEDIS	BRITISH MEDICAL JOURNAL			English	Article							TOPICAL TERBINAFINE; 1-PERCENT CREAM; EFFICACY; TOLERABILITY; INVITRO; CRURIS	Objective-To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. Design-Multicentre, double blind parallel group study. Setting-32 general practices and one hospital. Patients-256 patients with mycologically confirmed tinea pedis. Of the 211 patients evaluable, 107 were randomised to terbinafine (75 male, 32 female; mean (range) age 40 (12-81) years) and 104 to clotrimazole (79 male, 25 female; mean (range) age 36 (12-71) years). Interventions-Terbinafine 1% cream applied twice daily for one week and inert cream applied twice daily for the next three weeks. Clotrimazole 1% cream applied twice daily for four weeks. Main outcome measures-Mycological cure (negative results on microscopy and culture) and effective treatment (mycological cure plus no or minimal signs and symptoms) measured at weeks 1, 2, 3, 4, and 6. Results-At week four rates of mycological cure were 93.5% for terbinafine and 73.1% for clotrimazole (p=0.0001); and at week six 97.2% for terbinafine and 83.7% for clotrimazole (p=0.001). Rates of effective treatment at week 4 were 89.7% for terbinafine and 58.7% for clotrimazole (p=0.0001); and 89.7% for terbinafine and 73.1% for clotrimazole (p=0.002) at week 6. Conclusion-These results indicate that a one week course of terbinafine 1% cream is more effective in the treatment of tinea pedis than a four week course of clotrimazole 1% cream, both in terms of mycological cure and effective treatment.	GEN INFIRM,LEEDS LS2 9JT,ENGLAND; ACKTON HOSP,PONTEFRACT WF7 6HT,W YORKSHIRE,ENGLAND; UNIV BIRMINGHAM,CTR HLTH,BIRMINGHAM B15 2SE,ENGLAND	Leeds General Infirmary; University of Birmingham	EVANS, EGV (corresponding author), UNIV LEEDS,DEPT MICROBIOL,PHLS,MYCOL REFERENCE LAB,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							BERMAN B, 1992, J AM ACAD DERMATOL, V26, P956, DOI 10.1016/0190-9622(92)70141-2; CLAYTON YM, 1989, CLIN EXP DERMATOL, V14, P101, DOI 10.1111/j.1365-2230.1989.tb00901.x; EANS EGV, 1992, BRIT J DERMATOL, V127, P21; Evans E., 1991, J DERMATOL TREAT, V2, P95, DOI [10.3109/09546639109092729, DOI 10.3109/09546639109092729]; Evans EGV, 1992, J DERMATOL TREAT, V3, P181; GREER DL, 1990, J AM ACAD DERMATOL, V23, P800, DOI 10.1016/0190-9622(90)70292-P; HILL S, 1992, BRIT J DERMATOL, V127, P396, DOI 10.1111/j.1365-2133.1992.tb00461.x; MILLIKAN LE, 1990, J AM ACAD DERMATOL, V23, P795, DOI 10.1016/0190-9622(90)70291-O; PETRANYI G, 1987, ANTIMICROB AGENTS CH, V31, P1365, DOI 10.1128/AAC.31.9.1365; SUD IJ, 1981, J INVEST DERMATOL, V76, P438, DOI 10.1111/1523-1747.ep12521036; VILLARS V, 1989, CLIN EXP DERMATOL, V14, P124, DOI 10.1111/j.1365-2230.1989.tb00908.x	11	40	43	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					645	647		10.1136/bmj.307.6905.645	http://dx.doi.org/10.1136/bmj.307.6905.645			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401048	Bronze, Green Published			2022-12-28	WOS:A1993LX47000014
J	FOREMAN, DM; FARSIDES, C				FOREMAN, DM; FARSIDES, C			ETHICAL USE OF COVERT VIDEOING TECHNIQUES IN DETECTING MUNCHAUSEN-SYNDROME BY PROXY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILD-ABUSE; SURVEILLANCE	Munchausen syndrome by proxy is an especially malignant form of child abuse in which the carer (usually the mother) fabricates or exacerbates illness in the child to obtain medical attention. It can result in serious illness and even death of the child and it is difficult to detect. Some investigators have used video to monitor the carer's interaction with the child without obtaining consent-covert videoing. The technique presents several ethical problems, including exposure of the child to further abuse and a breach of trust between carer, child, and the professionals. Although covert videoing can be justified in restricted circumstances, new abuse procedures under the Children Act now seem to make its use unethical in most cases. Sufficient evidence should mostly be obtained from separation of the child and carer or videoing with consent to enable action to be taken to protect the child under an assessment order. If the new statutory instruments prove ineffective in Munchausen syndrome by proxy covert videoing may need to be re-evaluated.	KEELE UNIV, DEPT PHILOSOPHY, STOKE ON TRENT ST4 7QB, ENGLAND	Keele University	FOREMAN, DM (corresponding author), KEELE UNIV, DEPT PSYCHIAT, STOKE ON TRENT ST4 7QB, ENGLAND.							[Anonymous], 1989, CHILDREN ACT; ASHER R, 1951, LANCET, V260, P339; BAUMAN WA, 1981, J PEDIATR-US, V99, P588, DOI 10.1016/S0022-3476(81)80264-8; BHUGRA D, 1988, ACTA PSYCHIAT SCAND, V77, P497, DOI 10.1111/j.1600-0447.1988.tb05160.x; BOOLS CN, 1992, ARCH DIS CHILD, V67, P77, DOI 10.1136/adc.67.1.77; CAMPBELL AV, 1975, MORAL DILEMMAS MED; CLARK GD, 1984, PEDIATRICS, V74, P1100; EMINSON DM, 1992, ARCH DIS CHILD, V67, P1510, DOI 10.1136/adc.67.12.1510; EPSTEIN MA, 1987, PEDIATRICS, V80, P220; GODDING V, 1991, ARCH DIS CHILD, V66, P956, DOI 10.1136/adc.66.8.956; LANMAN JT, 1954, JAMA-J AM MED ASSOC, V155, P223, DOI 10.1001/jama.1954.03690210001001; LEONARD KF, 1992, POSTGRAD MED, V91, P197; MASON J, 1991, LAW MED ETHICS, P242; MEADOW R, 1982, ARCH DIS CHILD, V57, P92, DOI 10.1136/adc.57.2.92; MEADOW R, 1977, LANCET, V2, P343; ROSEN CL, 1986, J PEDIATR-US, V109, P1065, DOI 10.1016/S0022-3476(86)80301-8; ROSEN CL, 1983, PEDIATRICS, V71, P715; ROSENBERG DA, 1987, CHILD ABUSE NEGLECT, V11, P547, DOI 10.1016/0145-2134(87)90081-0; SAMUELS MP, 1992, BRIT J HOSP MED, V47, P759; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; Schultz L., 1989, ISSUES CHILD ABUSE A, V1, P29; SIGAL M, 1989, COMPR PSYCHIAT, V30, P527, DOI 10.1016/0010-440X(89)90083-7; SOUTHALL DP, 1987, BRIT MED J, V294, P1637, DOI 10.1136/bmj.294.6588.1637; SUGAR JA, 1991, J AM ACAD CHILD PSY, V30, P1015, DOI 10.1097/00004583-199111000-00023; TURK L, 1990, COMPREHENSIVE PEDIAT, V13, P279; WILLIAMS C, 1988, LANCET, V1, P780; 1992, TIMES           0312, P20; 1974, REPORT COMMITTEE INQ, P61; 1992, MEMORANDUM GOOD PRAC	29	39	39	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	1993	307	6904					611	613		10.1136/bmj.307.6904.611	http://dx.doi.org/10.1136/bmj.307.6904.611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401021	Green Published, Bronze			2022-12-28	WOS:A1993LW14900023
J	JEWSON, N; MASON, D; BOURKE, H; BRACEBRIDGE, C; BROSNAN, F; MILTON, K				JEWSON, N; MASON, D; BOURKE, H; BRACEBRIDGE, C; BROSNAN, F; MILTON, K			CHANGES IN ETHNIC-MINORITY MEMBERSHIP OF HEALTH AUTHORITIES 1989-92	BRITISH MEDICAL JOURNAL			English	Article											JEWSON, N (corresponding author), UNIV LEICESTER,ETHN RES CTR,LEICESTER LE1 7RH,ENGLAND.							CIARNCROSS L, 1993, HLTH SERVICE J, V102, P20; 1990, ETHNIC MINORITY HLTH; 1989, CMND555; 1991, GUIDANCE MEMBERSHIP	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					604	605		10.1136/bmj.307.6904.604	http://dx.doi.org/10.1136/bmj.307.6904.604			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401017	Bronze, Green Published			2022-12-28	WOS:A1993LW14900018
J	DALY, AK; THOMAS, DJ; COOPER, J; PEARSON, WR; NEAL, DE; IDLE, JR				DALY, AK; THOMAS, DJ; COOPER, J; PEARSON, WR; NEAL, DE; IDLE, JR			HOMOZYGOUS DELETION OF GENE FOR GLUTATHIONE S-TRANSFERASE-M1 IN BLADDER-CANCER	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV VIRGINIA,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	Newcastle University - UK; University of Virginia	DALY, AK (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,PHARMACOGENET RES UNIT,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Pearson, William/K-4908-2019; Daly, Ann/H-3144-2011; Idle, Jeff/B-1152-2012	Pearson, William/0000-0002-0727-3680; Daly, Ann/0000-0002-7321-0629; Idle, Jeff/0000-0002-6143-1520; Neal, David/0000-0002-6033-5086				BOARD P, 1990, PHARMACOL THERAPEUT, V48, P357, DOI 10.1016/0163-7258(90)90054-6; MILLER AB, 1977, CANCER RES, V37, P2939; PEARSON WR, 1993, AM J HUM GENET, V53, P220; Roots I, 1992, PHARMACOGENETICS DRU, P815; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33	5	79	80	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					481	482		10.1136/bmj.307.6902.481	http://dx.doi.org/10.1136/bmj.307.6902.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400932	Green Published, Bronze			2022-12-28	WOS:A1993LU59000022
J	TOTH, PT; BINDOKAS, VP; BLEAKMAN, D; COLMERS, WF; MILLER, RJ				TOTH, PT; BINDOKAS, VP; BLEAKMAN, D; COLMERS, WF; MILLER, RJ			MECHANISM OF PRESYNAPTIC INHIBITION BY NEUROPEPTIDE-Y AT SYMPATHETIC-NERVE TERMINALS	NATURE			English	Article							CALCIUM CHANNELS; SYNAPTIC FUNCTIONS; NEURONS; RELEASE; MODULATION; MICROCULTURES; NOREPINEPHRINE; ACETYLCHOLINE; RECEPTOR; CELLS	CALCIUM influx through voltage-sensitive Ca2+ channels is the normal physiological stimulus for the activity-dependent release of neurotransmitters at synaptic contacts. It has been postulated that presynaptic inhibition of transmitter release is due to a reduction in Ca2+ influx at the nerve terminal, which could result from the direct inhibition of Ca2+ channels. Neuropeptide Y and noradrenaline act as cotransmitters at many sympathetic synapses. Both of these substances produce presynaptic inhibition and can inhibit Ca2+ currents in the soma of sympathetic neurons1-5. Here we provide direct evidence that presynaptic inhibition produced by neuropeptide Y at sympathetic nerve terminals is associated with a reduction in Ca2+ influx and that this is due to the selective inhibition of neuronal N-type Ca2+ channels.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637; UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Chicago; University of Alberta			Colmers, William/C-3106-2013	Colmers, William/0000-0001-7902-3560; Toth, Peter/0000-0003-2168-0124				BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DALHOF K, 1985, N-S ARCH PHARMACOL, V328, P327; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; ELLIS JL, 1990, BRIT J PHARMACOL, V100, P457, DOI 10.1111/j.1476-5381.1990.tb15828.x; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V456, P107, DOI 10.1113/jphysiol.1992.sp019329; FOUCART S, 1993, J PHARMACOL EXP THER, V265, P903; FURSHPAN EJ, 1986, J NEUROSCI, V6, P1061; HAASS M, 1989, N-S ARCH PHARMACOL, V339, P71; Higgins D., 1991, CULTURING NERVE CELL, P177; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; KLAPSTEIN GJ, 1992, BRIT J PHARMACOL, V105, P470, DOI 10.1111/j.1476-5381.1992.tb14277.x; LANDIS SC, 1976, P NATL ACAD SCI USA, V73, P4220, DOI 10.1073/pnas.73.11.4220; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; Marubio L. M., 1992, Society for Neuroscience Abstracts, V18, P1138; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; POTTER DD, 1986, J NEUROSCI, V6, P1080; SCHOFIELD GG, 1990, EUR J PHARMACOL, V180, P37, DOI 10.1016/0014-2999(90)90590-3; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SUETAKE K, 1981, BRAIN RES, V205, P436, DOI 10.1016/0006-8993(81)90357-7; Toth P. T., 1992, Society for Neuroscience Abstracts, V18, P1353; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; WILEY JW, 1990, J NEUROPHYSIOL, V63, P1499, DOI 10.1152/jn.1990.63.6.1499; ZIDICHOUSKI JA, 1990, NEUROSCI LETT, V117, P123, DOI 10.1016/0304-3940(90)90130-2	25	142	143	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					635	639		10.1038/364635a0	http://dx.doi.org/10.1038/364635a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8394510				2022-12-28	WOS:A1993LR77100055
J	WITCHER, DR; DEWAARD, M; SAKAMOTO, J; FRANZINIARMSTRONG, C; PRAGNELL, M; KAHL, SD; CAMPBELL, KP				WITCHER, DR; DEWAARD, M; SAKAMOTO, J; FRANZINIARMSTRONG, C; PRAGNELL, M; KAHL, SD; CAMPBELL, KP			SUBUNIT IDENTIFICATION AND RECONSTITUTION OF THE N-TYPE CA2+ CHANNEL COMPLEX PURIFIED FROM BRAIN	SCIENCE			English	Article							SENSITIVE CALCIUM-CHANNEL; CONOTOXIN GVIA RECEPTOR; OMEGA-CONOTOXIN; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; TRANSMITTER RELEASE; VERTEBRATE CELLS; DYSTROPHIN; PROTEIN; ALPHA-2-SUBUNIT	Calcium channels play an important role in regulating various neuronal processes, including synaptic transmission and cellular plasticity. The N-type calcium channels, which are sensitive to omega-conotoxin, are involved in the control of transmitter release from neurons. A functional N-type calcium channel complex was purified from rabbit brain. The channel consists of a 230-kilodalton subunit (alpha1B) that is tightly associated with a 160-kilodalton subunit (alpha2delta), a 57-kilodalton subunit (beta3), and a 95-kilodalton glycoprotein subunit. The complex formed a functional calcium channel with the same pharmacological properties and conductance as those of the native omega-conotoxin-sensitive calcium channel in neurons.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; UNIV PENN,DEPT ANAT,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Pennsylvania			De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889; Kahl, Steven/0000-0001-7085-9556				ABE T, 1986, NEUROSCI LETT, V71, P203, DOI 10.1016/0304-3940(86)90559-8; AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; COHEN MW, 1991, J NEUROSCI, V11, P1032; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; FUKUNAGA H, 1982, MUSCLE NERVE, V5, P687; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAY SD, 1991, J BIOL CHEM, V266, P3287; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PLUMMER MR, 1989, NEURON, V2, P453; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SHER E, 1989, LANCET, V2, P640; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	36	195	197	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					486	489		10.1126/science.8392754	http://dx.doi.org/10.1126/science.8392754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392754				2022-12-28	WOS:A1993LN62300041
J	BALTENSPERGER, K; KOZMA, LM; CHERNIACK, AD; KLARLUND, JK; CHAWLA, A; BANERJEE, U; CZECH, MP				BALTENSPERGER, K; KOZMA, LM; CHERNIACK, AD; KLARLUND, JK; CHAWLA, A; BANERJEE, U; CZECH, MP			BINDING OF THE RAS ACTIVATOR SON OF SEVENLESS TO INSULIN-RECEPTOR SUBSTRATE-1 SIGNALING COMPLEXES	SCIENCE			English	Article							TYROSINE KINASE; PROTEIN; STIMULATION; ONCOGENES; TRANSDUCTION; EXPRESSION; P21RAS; CELLS; GAP	Signal transmission by insulin involves tyrosine phosphorylation of a major insulin receptor substrate (IRS-1) and exchange of Ras-bound guanosine diphosphate for guanosine triphosphate. Proteins containing Src homology 2 and 3 (SH2 and SH3) domains, such as the p85 regulatory subunit of phosphatidylinositol-3 kinase and growth factor receptor-bound protein 2 (GRB2), bind tyrosine phosphate sites on IRS-1 through their SH2 regions. Such complexes in COS cells were found to contain the heterologously expressed putative guanine nucleotide exchange factor encoded by the Drosophila son of sevenless gene (dSos). Thus, GRB2, p85, or other proteins with SH2-SH3 adapter sequences may link Sos proteins to IRS-1 signaling complexes as part of the mechanism by which insulin activates Ras.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles	BALTENSPERGER, K (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, UNPUB; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; KOZMA LM, UNPUB; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TOBE K, 1993, J BIOL CHEM, V268, P11167; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	47	292	294	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1950	1952		10.1126/science.8391166	http://dx.doi.org/10.1126/science.8391166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8391166				2022-12-28	WOS:A1993LJ34900045
J	AARTS, MGM; DIRKSE, WG; STIEKEMA, WJ; PEREIRA, A				AARTS, MGM; DIRKSE, WG; STIEKEMA, WJ; PEREIRA, A			TRANSPOSON TAGGING OF A MALE-STERILITY GENE IN ARABIDOPSIS	NATURE			English	Article							TRANSGENIC TOBACCO; SPM ELEMENT; MAIZE; CELLS	TRANSFORMATION of the well-studied maize transposable elements into other plant species1 should enable transposon tagging methodology2 to be used for the isolation of interesting genes in the heterologous host. Here we describe the isolation of a transposon-tagged male sterile mutant in Arabidopsis thaliana using the maize Enhancer-Inhibitor3,4 transposable element system introduced into Arabidopsis. The mutant lacks pollen, preventing normal self-fertilization, a characteristic important for production of hybrid seed in many crop plants. We have identified an Enhancer-transposase-mediated Inhibitor element insertion responsible for the male sterile phenotype, and isolated the corresponding gene named MALE STERILITY 2. Critical evidence that the Inhibitor-element-containing gene is involved in the male sterile phenotype is provided by the DNA sequences of new excision-derived alleles from independent stable fertile and male sterile progeny of the original mutant.	DLO,CTR PLANT BREEDING & REPROD RES,DEPT MOLEC BIOL,POB 16,6700 AA WAGENINGEN,NETHERLANDS				Pereira, Andy/AAF-4781-2020; Aarts, Mark/O-1706-2019; Aarts, Mark G.M./G-8929-2013	Pereira, Andy/0000-0003-1378-4273; Aarts, Mark/0000-0001-5257-0740; Aarts, Mark G.M./0000-0001-5257-0740				BAKER B, 1986, P NATL ACAD SCI USA, V83, P4844, DOI 10.1073/pnas.83.13.4844; BEDINGER P, 1992, PLANT CELL, V4, P879, DOI 10.1105/tpc.4.8.879; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREY M, 1989, MOL GEN GENET, V217, P172, DOI 10.1007/BF00330958; HANSON MR, 1991, ANNU REV GENET, V25, P461, DOI 10.1146/annurev.ge.25.120191.002333; Kaul, 1988, MALE STERILITY HIGHE; MASSON P, 1989, P NATL ACAD SCI USA, V86, P2219, DOI 10.1073/pnas.86.7.2219; McClintock B., 1954, CARNEGIE I WASH YB, V53, P254; OCHMAN H, 1988, GENETICS, V120, P621; PEREIRA A, 1989, EMBO J, V8, P1315, DOI 10.1002/j.1460-2075.1989.tb03511.x; PEREIRA A, 1985, EMBO J, V4, P17, DOI 10.1002/j.1460-2075.1985.tb02311.x; PETERSON PA, 1953, GENETICS, V38, P682; SCHWARZSOMMER Z, 1985, EMBO J, V4, P591, DOI 10.1002/j.1460-2075.1985.tb03671.x; SCHWARZSOMMER Z, 1985, EMBO J, V4, P2439, DOI 10.1002/j.1460-2075.1985.tb03953.x; SCOTT R, 1991, PLANT SCI, V80, P167, DOI 10.1016/0168-9452(91)90281-C; SPENCER DF, 1992, PLANT MOL BIOL, V20, P347, DOI 10.1007/BF00014506; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANDENELZEN PJM, 1985, PLANT MOL BIOL, V5, P299, DOI 10.1007/BF00020627; VANDERVEEN JH, 1968, EUPHYTICA, V17, P371, DOI 10.1007/BF00056238; WALBOT V, 1992, ANNU REV PLANT PHYS, V43, P49, DOI 10.1146/annurev.pp.43.060192.000405; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	22	155	197	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					715	717		10.1038/363715a0	http://dx.doi.org/10.1038/363715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8390620				2022-12-28	WOS:A1993LJ33900054
J	CONKLIN, BR; BOURNE, HR				CONKLIN, BR; BOURNE, HR			STRUCTURAL ELEMENTS OF G-ALPHA-SUBUNITS THAT INTERACT WITH G-BETA-GAMMA, RECEPTORS, AND EFFECTORS	CELL			English	Review							NUCLEOTIDE-BINDING PROTEIN; MUSCARINIC K+-CHANNEL; ROD OUTER SEGMENTS; CARBOXYL TERMINUS; ADENYLATE-CYCLASE; RAS P21; TRIPHOSPHATE CONFORMATION; MEMBRANE ATTACHMENT; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURE		UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CONKLIN, BR (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.		Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASEY P, 1992, NATURE, V359, P671, DOI 10.1038/359671a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, IN PRESS NATURE; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DERETIC D, 1987, J BIOL CHEM, V262, P10839; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; EASON MG, 1992, J BIOL CHEM, V267, P15795; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GRAF R, 1992, J BIOL CHEM, V267, P24307; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; HAMM HE, 1990, ADV SEC MESS PHOSPH, V24, P76; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HUFF RM, 1985, J BIOL CHEM, V260, P864; HWANG YW, 1992, J BIOL CHEM, V267, P22198; ITOH H, 1991, J BIOL CHEM, V266, P16226; JOHNSON GL, 1991, J CELL BIOCHEM, V47, P136, DOI 10.1002/jcb.240470207; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, BIOCHEM BIOPH RES CO, V164, P46, DOI 10.1016/0006-291X(89)91680-X; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMRCKA AV, 1993, IN PRESS J BIOL CHEM; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TSAI SC, 1984, J BIOL CHEM, V259, P5320; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	98	406	412	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					631	641		10.1016/0092-8674(93)90245-L	http://dx.doi.org/10.1016/0092-8674(93)90245-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8388779				2022-12-28	WOS:A1993LD83000004
J	LOHNES, D; KASTNER, P; DIERICH, A; MARK, M; LEMEUR, M; CHAMBON, P				LOHNES, D; KASTNER, P; DIERICH, A; MARK, M; LEMEUR, M; CHAMBON, P			FUNCTION OF RETINOIC ACID RECEPTOR-GAMMA IN THE MOUSE	CELL			English	Article							DIFFERENTIAL PATTERN; NUCLEAR RECEPTORS; BINDING-PROTEINS; EXPRESSION; TRANSCRIPTION; PROMOTER; ISOFORMS; EMBRYOS; ALPHA; GENES	Null mutant mice for retinoic acid receptor gamma2 (RARgamma2) or all RARgamma isoforms were generated. RARgamma2 mutants appeared normal, whereas RARgamma mutants exhibited growth deficiency, early lethality, and male sterility due to squamous metaplasia of the seminal vesicles and prostate. These defects were previously observed in vitamin A-deficient animals and could be prevented by RA administration, demonstrating that RARgamma mediates some of the retinoid signal in vivo. Congenital defects included Harderian gland agenesis, tracheal cartilage malformations, and homeotic transformations along the rostral axial skeleton, establishing a direct link between RA and patterning of the axial skeleton. We also show that in utero RA-induced lumbosacral truncations are mediated by RARgamma. The observed RARgamma null phenotype suggests a high degree of functional redundancy among the RARs. The variable penetrance of some of the observed defects is discussed in light of this redundancy and stochastic variation of gene activity.			LOHNES, D (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE.							ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BROOKFIELD J, 1992, EVOL GENET, V2, P553; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLON RA, 1992, DEVELOPMENT, V116, P357; DE LUCA LM, 1991, FASEB J, V5, P2924; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Hamilton HL, 1952, INTRO EMBRYOLOGY; HOWELL JMG, 1963, J REPROD FERTIL, V5, P159, DOI 10.1530/jrf.0.0050159; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1993, IN PRESS VITAMIN HLT; KESSEL M, 1992, DEVELOPMENT, V115, P487; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMURA M, 1962, GENETICS, V47, P713; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KO MSH, 1992, BIOESSAYS, V14, P341, DOI 10.1002/bies.950140510; Kraft J, 1992, RETINOIDS NORMAL DEV, P267; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAUDET V, 1992, Current Biology, V2, P293; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; LIVREA MA, 1993, RETINOIDS; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MOHANTYHEJMADI P, 1992, NATURE, V355, P352, DOI 10.1038/355352a0; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGPAL S, 1993, IN PRESS EMBO J; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; POPPERL H, 1993, MOL CELL BIOL, V13, P257; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sambrook J, 1989, MOL CLONING LABORATO; SHARMA RP, 1993, RETINOIDS, P569; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017; UNDERWOOD BA, 1984, RETINOIDS, V1, P282; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WEBSTER WS, 1986, J CRAN GENET DEV BIO, V6, P211; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yu Victor C., 1992, Current Opinion in Biotechnology, V3, P597, DOI 10.1016/0958-1669(92)90002-Z; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	84	528	542	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					643	658		10.1016/0092-8674(93)90246-M	http://dx.doi.org/10.1016/0092-8674(93)90246-M			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8388780				2022-12-28	WOS:A1993LD83000005
J	HEALY, DL; BURGER, HG; MAMERS, P; JOBLING, T; BANGAH, M; QUINN, M; GRANT, P; DAY, AJ; ROME, R; CAMPBELL, JJ				HEALY, DL; BURGER, HG; MAMERS, P; JOBLING, T; BANGAH, M; QUINN, M; GRANT, P; DAY, AJ; ROME, R; CAMPBELL, JJ			ELEVATED SERUM INHIBIN CONCENTRATIONS IN POSTMENOPAUSAL WOMEN WITH OVARIAN-TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER	Background. Inhibin is an ovarian hormone that inhibits the secretion of follicle-stimulating hormone (FSH) by the anterior pituitary gland. Women with granulosa-cell tumors of the ovary have elevated serum inhibin concentrations, but whether the concentrations are increased in women with other ovarian tumors is unknown. Methods. We measured serum inhibin and FSH concentrations before surgery in 212 postmenopausal women with suspected ovarian cancer and after surgery in 210 of them. Results. Eighteen of the 22 women (82 percent) with mucinous carcinomas (mucinous cystadenocarcinomas and mucinous borderline cystic tumors) of the ovary had elevated serum inhibin concentrations, whereas only 9 of the 53 women (17 percent) with serous carcinomas (serous cystadenocarcinomas and serous borderline cystic tumors) had elevated levels. Serum inhibin concentrations were also elevated in 2 of 12 women (17 percent) with clear-cell carcinomas, 4 of 26 women (15 percent) with undifferentiated carcinomas, 3 of 3 women (100 percent) with granulosa-cell tumors, and 5 of 27 women (19 percent) with other ovarian cancers. The serum concentrations of inhibin were increased in 2 of 28 women (7 percent) with nonovarian pelvic cancers and 11 of 41 women (27 percent) with benign ovarian diseases. All women but one with initially elevated serum inhibin concentrations had low values one week after surgery. Serum inhibin concentrations correlated negatively with serum FSH concentrations (P = 0.05) in women with granulosa-cell tumors but not in women with other tumors, suggesting that the inhibin secreted by tumors in the latter group has decreased biologic activity. Conclusions. Serum inhibin concentrations are elevated in most postmenopausal women with mucinous carcinomas of the ovary and in some women with other types of epithelial ovarian tumors. The concentrations fall after tumor removal.	MONASH UNIV,DEPT OBSTET & GYNECOL,MELBOURNE,VIC 3004,AUSTRALIA; MERCY HOSP WOMEN,MELBOURNE,AUSTRALIA; PRINCE HENRY INST MED RES,MELBOURNE,AUSTRALIA; ROYAL WOMENS HOSP,MELBOURNE,AUSTRALIA; PETER MACCALLUM INST,MELBOURNE,AUSTRALIA	Monash University; Prince Henry's Institute of Medical Research; Peter Maccallum Cancer Center				Burger, Henry/0000-0002-5333-6144; Quinn, Michael/0000-0003-0694-3870				BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; KAUPPILA A, 1992, GYNECOL ENDOCRINOL, V6, P271, DOI 10.3109/09513599209024990; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; LONGCOPE C, 1986, MATURITAS, V8, P189, DOI 10.1016/0378-5122(86)90025-3; MCLACHLAN RI, 1987, J CLIN ENDOCR METAB, V65, P954, DOI 10.1210/jcem-65-5-954; Montag T W, 1990, Obstet Gynecol Surv, V45, P94, DOI 10.1097/00006254-199002000-00003; OKAMOTO SH, 1987, BRIT MED J, V294, P667, DOI 10.1136/bmj.294.6573.667; PIVER MS, 1983, CURRENT REV OBSTETRI, V4, P1; SEROV SF, 1973, HISTOLOGICAL TYPING, P37; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; WESTHOFF C, 1991, AM J OBSTET GYNECOL, V165, P502, DOI 10.1016/0002-9378(91)90275-V	12	202	210	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1539	1542		10.1056/NEJM199311183292104	http://dx.doi.org/10.1056/NEJM199311183292104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8413476				2022-12-28	WOS:A1993MG18800004
J	ROBERTSON, D; HOLLISTER, AS; BIAGGIONI, I; NETTERVILLE, JL; MOSQUEDAGARCIA, R; ROBERTSON, RM				ROBERTSON, D; HOLLISTER, AS; BIAGGIONI, I; NETTERVILLE, JL; MOSQUEDAGARCIA, R; ROBERTSON, RM			THE DIAGNOSIS AND TREATMENT OF BAROREFLEX FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINOAORTIC BARORECEPTOR DENERVATION; NEUROGENIC HYPERTENSION; CAROTID ENDARTERECTOMY; ORTHOSTATIC HYPOTENSION; BLOOD-PRESSURE; HUMANS; DYSFUNCTION	Background. Baroreflexes originate in the great vessels of the neck and thorax and prevent arterial pressure from rising or failing excessively. Methods. This study was undertaken to clarify the cause, clinical spectrum, and therapy of this disorder. We studied 11 patients with baroreflex failure presenting as severe, labile hypertension and hypotension, often with headache, diaphoresis, and emotional instability, and characterized by the failure of exogenous vasoactive substances to alter heart rate. Each underwent hemodynamic monitoring and biochemical, physiologic, and pharmacologic testing. Results. The patients' maximal systolic blood pressures ranged from 164 to 280 mm Hg, and their minimal systolic pressures ranged from 58 to 96 mm Hg. Plasma norepinephrine and epinephrine concentrations were sometimes many times normal during blood-pressure surges. All the patients had excessive pressor and tachycardic responses to the mental-arithmetic and cold pressor tests and marked hypersensitivity to clonidine. The underlying causes of baroreflex failure included the familial paraganglioma syndrome, neck surgery or radiation therapy for pharyngeal carcinoma, bilateral lesions of the nucleus tractus solitarii, and surgical section of the glossopharyngeal nerves; in two patients the cause was unknown. Therapy with clonidine reduced the frequency of attacks by 81 percent and attenuated the elevated blood pressure and heart rate in the attacks that occurred. Conclusions. The syndrome of baroreflex failure should be considered in patients with otherwise unexplained labile hypertension. Clonidine attenuates the pressor and tachycardic surges in baroreflex failure.	VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT NEUROL,NASHVILLE,TN 37232; VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT OTOLARYNGOL,NASHVILLE,TN 37232; UNIV COLORADO,HLTH SCI CTR,DIV CLIN PHARMACOL,DENVER,CO 80262	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ROBERTSON, D (corresponding author), VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT MED,AA3228 MCN,NASHVILLE,TN 37232, USA.			Netterville, James/0000-0002-7282-8769	NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [HL44589, HL37961] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044589, R01HL037961] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOUD FM, 1979, J PHYSIOL-LONDON, V286, P173, DOI 10.1113/jphysiol.1979.sp012612; AKSAMIT TR, 1987, HYPERTENSION, V9, P309, DOI 10.1161/01.HYP.9.3.309; ATUK NO, 1972, NEW ENGL J MED, V287, P1356; BOVE EL, 1979, SURGERY, V85, P633; BRAVO EL, 1981, NEW ENGL J MED, V305, P623, DOI 10.1056/NEJM198109103051107; BRAVO EL, 1990, HYPERTENSION S1, V15, P128; BRODAL A, 1957, HJERNENERVENE, P1; CHAMONTIN B, 1989, ARCH MAL COEUR VAISS, V82, P1143; COWLEY AW, 1973, CIRC RES, V32, P564, DOI 10.1161/01.RES.32.5.564; DOBA N, 1974, CIRC RES, V34, P293, DOI 10.1161/01.RES.34.3.293; Eckberg D, 1992, HUMAN BAROREFLEXES H; FAGIUS J, 1985, BRAIN, V108, P423, DOI 10.1093/brain/108.2.423; FERGUSON DW, 1985, J CLIN INVEST, V76, P2265, DOI 10.1172/JCI112236; FORD FR, 1957, J HOPKINS MED J, V100, P14; FUNCKBRENTANO C, 1987, BRIT HEART J, V57, P487; GUZ A, 1966, CLIN SCI, V30, P161; HOLTON P, 1965, J PHYSIOL-LONDON, V181, P365, DOI 10.1113/jphysiol.1965.sp007767; HSU CY, 1984, AM J MED, V76, pA49, DOI 10.1016/0002-9343(84)90839-8; JANNETTA PJ, 1985, ANN SURG, V201, P391, DOI 10.1097/00000658-198503000-00023; KEZDI P, 1953, ARCH INTERN MED, V91, P26, DOI 10.1001/archinte.1953.00240130034003; KUCHEL O, 1987, J HYPERTENS, V5, P277, DOI 10.1097/00004872-198706000-00003; LAMPEN HEINRICH, 1949, ZEITSCHR KREISLAUFFORSCH, V38, P726; Langford HG, 1987, J HYPERTENS       S5, V5, pS467; Magnus O, 1977, Prog Brain Res, V47, P199; Manger WM, 1977, PHEOCHROMOCYTOMA; Page IH, 1935, AM J MED SCI, V190, P9, DOI 10.1097/00000441-193507000-00002; PAGE IH, 1987, HYPERTENSION MECH, P707; PERSSON PB, 1991, BAROREFLEXES INTEGRA; REIS DJ, 1972, NEW ENGL J MED, V287, P1355; ROBERTSON D, 1983, AM J MED, V74, P193, DOI 10.1016/0002-9343(83)90607-1; ROBERTSON D, 1984, AM J MED, V76, pA58, DOI 10.1016/0002-9343(84)90844-1; ROBERTSON D, 1979, CIRCULATION, V59, P637, DOI 10.1161/01.CIR.59.4.637; Robertson D, 1981, CLIN DIAGNOSTIC MANU, P86; ROBERTSON D, 1992, CLIN PHARM, P84; SANDERS JS, 1989, CIRCULATION, V79, P83, DOI 10.1161/01.CIR.79.1.83; TOWNE JB, 1980, SURGERY, V88, P575; VANBAARS FM, 1981, ACTA OTO-LARYNGOL, V91, P589, DOI 10.3109/00016488109138545; WADE JG, 1970, NEW ENGL J MED, V282, P823, DOI 10.1056/NEJM197004092821501; [No title captured]	39	223	230	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1449	1455		10.1056/NEJM199311113292003	http://dx.doi.org/10.1056/NEJM199311113292003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413455				2022-12-28	WOS:A1993MF29200003
J	BREO, DL				BREO, DL			KICKING BUTTS - AMA, JOE CAMEL, AND THE BLACK-FLAG WAR ON TOBACCO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	9	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1978	1984		10.1001/jama.270.16.1978	http://dx.doi.org/10.1001/jama.270.16.1978			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC513	8411558				2022-12-28	WOS:A1993MC51300033
J	MODELL, M				MODELL, M			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - A GENERAL-PRACTITIONERS PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article							REPRODUCTIVE-BEHAVIOR; PRENATAL-DIAGNOSIS; CONSEQUENCES; COMMUNITY; ATTITUDES; FAMILIES; RISK	The identification of the gene for cystic fibrosis has led to the possibility of population based screening for carriers of cystic fibrosis to identify couples at risk of having an affected child. Pilot studies have shown that screening is feasible and does not cause untoward anxiety, though the uptake of testing varies considerably with the setting and method of invitation. Screening offered at times when individuals (and health professionals) perceive it as directly relevant will probably gradually become established in the United Kingdom. This review examines the role of general practice in genetic carrier screening as exemplified by cystic fibrosis. General practice has a pivotal role from the beginning in providing individuals and couples with information, facilitating testing of patients' relatives and of carriers identified by screening elsewhere (such as antenatal clinics), and offering testing in the context of reproduction. Screening for the cystic fibrosis gene will probably be followed by other genetic screening programmes.			MODELL, M (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BORGO G, 1992, PRENATAL DIAG, V12, P821, DOI 10.1002/pd.1970121008; BOUE J, 1991, PRENATAL DIAG, V11, P209, DOI 10.1002/pd.1970110402; BURN J, 1993, BRIT MED J, V306, P1558, DOI 10.1136/bmj.306.6892.1558; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; HARRIS HJ, 1992, LANCET, V339, P1539, DOI 10.1016/0140-6736(92)91303-P; HARRIS R, 1992, J ROY COLL PHYS LOND, V26, P437; KABACK M, 1984, CYSTIC FIBROSIS HORI, P15; MAGNAY D, 1992, J ROY COLL PHYS LOND, V26, P69; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL B, 1980, BMJ-BRIT MED J, V280, P1347, DOI 10.1136/bmj.280.6228.1347; MODELL B, 1991, WHO EUROPEAN SERIES, V38; Modell M., 1992, HLTH BABY CONGENITAL; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; SUPER M, 1992, LANCET, V340, P490, DOI 10.1016/0140-6736(92)91816-Q; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WALTERS S, 1993, BRIT MED J, V306, P549, DOI 10.1136/bmj.306.6877.549; WATSON EK, 1992, LANCET, V340, P217, DOI 10.1016/0140-6736(92)90477-K; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; WILLIAMSON R, 1993, NAT GENET, V3, P195, DOI 10.1038/ng0393-195; 1989, REPORT PRENATAL DIAG	23	19	19	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					849	852		10.1136/bmj.307.6908.849	http://dx.doi.org/10.1136/bmj.307.6908.849			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401130	Bronze, Green Published			2022-12-28	WOS:A1993MA29300025
J	GACZYNSKA, M; ROCK, KL; GOLDBERG, AL				GACZYNSKA, M; ROCK, KL; GOLDBERG, AL			GAMMA-INTERFERON AND EXPRESSION OF MHC GENES REGULATE PEPTIDE HYDROLYSIS BY PROTEASOMES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ANTIGEN PRESENTATION; LYMPHOCYTE-T; LINKED LMP; PROTEINASE; UBIQUITIN; SUBUNITS	THE presentation of intracellular proteins to the immune system requires their degradation to small peptides1,2 that then become associated with major histocompatibility complex (MHC) class I molecules3,4. The generation of these peptides may involve the 20S or 26S proteasome particles, which contain multiple proteolytic activities5-14 including distinct sites that preferentially cleave small peptides on the carboxyl side of hydrophobic, basic or acidic residues6,13,14. Degradation of most cell proteins requires their conjugation to ubiquitin before hydrolysis by the 26S proteasome6,13-16. This large complex contains the 20S proteasome as its proteolytic core6,14,16-18. This ubiquitin-dependent proteolytic pathway is implicated in MHC class I presentation11,12. Gamma-interferon (gamma-IFN, a stimulator of antigen presentation1, induces a subclass of proteasomes that contain two MHC-encoded subunits, LMP2 and 7 (refs 5-10). Here we show that gamma-interferon alters the peptidase activities of the 20S and 26S proteasomes without affecting the rates of breakdown of proteins or of ubiquitinated proteins. By enhancing the expression of MHC genes, gamma-IFN increases the proteasomes' capacity to cleave small peptides after hydrophobic and basic residues but reduces cleavage after acidic residues. Moreover, proteasomes of mutants lacking LMP subunits show decreased rates of cleavage after hydrophobic and basic residues. Thus, gamma-IFN and expression of these MHC genes should favour the production by proteasomes of the types of peptides found on MHC class I molecules, which terminate almost exclusively with hydrophobic or basic residues19.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	GACZYNSKA, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.							AHN JY, 1991, J BIOL CHEM, V266, P15746; ARMON T, 1990, J BIOL CHEM, V265, P20723; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; Falk K, 1993, Semin Immunol, V5, P81, DOI 10.1006/smim.1993.1012; FINLEY D, 1991, REV CELL BIOL, V7, P25; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PARHAM P, 1992, NATURE, V360, P300, DOI 10.1038/360300a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V218, P1; SCHERRER K, 1990, MOL BIOL REP, V14, P1, DOI 10.1007/BF00422709; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	28	535	546	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					264	267		10.1038/365264a0	http://dx.doi.org/10.1038/365264a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396732				2022-12-28	WOS:A1993LX47100058
J	LENNANE, KJ				LENNANE, KJ			WHISTLEBLOWING - A HEALTH ISSUE	BRITISH MEDICAL JOURNAL			English	Article							NHS	Objective-To examine the response of organisations to ''whistleblowing'' and the effects on individual whistleblowers. Design-Questionnaire survey of whistleblowers who contacted Whistleblowers Australia after its publicity campaign. Setting-Australia. Subjects-25 men and 10 women from various occupations who had exposed corruption or danger to the public, or both, from a few months to over 20 years before. Results-All subjects in this non-random sample had suffered adverse consequences. For 29 victimisation had started immediately after their first, internal, complaint. Only 17 approached the media. Victimisation at work was extensive: dismissal (eight subjects), demotion (10), and resignation or early retirement because of ill health related to victimisation (10) were common. Only 10 had a full time job. Long term relationships broke up in seven cases, and 60 of the 77 children of 30 subjects were adversely affected. Twenty nine subjects had a mean of 5.3 stress related symptoms initially, with a mean of 3.6 still present. Fifteen were prescribed long term treatment with drugs which they had not been prescribed before. Seventeen had considered suicide. Income had been reduced by three quarters or more for 14 subjects. Total financial loss was estimated in hundreds of thousands of Australian dollars in 17. Whistleblowers received little or no help from statutory authorities and only a modest amount from workmates. In most cases the corruption and malpractice continued unchanged. Conclusion-Although whistleblowing is important in protecting society, the typical organisational response causes severe and longlasting health, financial, and personal problems for whistleblowers and their families.										Anderson S L, 1990, Nurs Forum, V25, P5, DOI 10.1111/j.1744-6198.1990.tb00852.x; DYER C, 1992, BRIT MED J, V305, P1177; DYER C, 1992, BRIT MED J, V304, P203; ESSEX C, 1993, BRIT MED J, V306, P291; EWING D, 1980, ORG SHOCK, P328; Hoffman W, 1984, BUSINESS ETHICS READ, P249; KORYAGIN A, 1989, BRIT J PSYCHIAT, V154, P336, DOI 10.1192/bjp.154.3.336; LAMPERT N, 1985, WHISTLEBLOWING SOVIE; MACMILLAN J, 1989, 4TH P INT ANT C CANB, P91; Martin B., 1986, INTELLECTUAL SUPPRES, P79; MCMILLAN J, 1990, CORRUPTION REFORM FI; MILGRAM S., 1974, OBEDIENCE AUTHORITY; Myers I.B., 1980, GIFTS DIFFERING; SMITH R, 1992, BRIT MED J, V305, P1308, DOI 10.1136/bmj.305.6865.1308; WARDEN J, 1992, BRIT MED J, V305, P1180; 1992, AUSTR MED       1005, P5; 1989, NURSING, V19, P47; 1993, BMJ, V306, P541	18	49	49	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					667	670		10.1136/bmj.307.6905.667	http://dx.doi.org/10.1136/bmj.307.6905.667			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401056	Green Published, Bronze			2022-12-28	WOS:A1993LX47000023
J	MAYOU, R; BRYANT, B; DUTHIE, R				MAYOU, R; BRYANT, B; DUTHIE, R			PSYCHIATRIC CONSEQUENCES OF ROAD TRAFFIC ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC EVENTS; URBAN-POPULATION; YOUNG-ADULTS; INJURY	Objective-To determine the psychiatric consequences of being a road traffic accident victim. Design-Follow up study of road accident victims for up to one year. Setting-Emergency department of the John Radcliffe Hospital, Oxford. Subjects-188 consecutive road accident victims aged 18-70 with multiple injuries (motorcycle or car) or whiplash neck injury, who had not been unconscious for more than 15 minutes, and who lived in the catchment area. Main outcome measures-Present state examination ''caseness''; post-traumatic stress disorder and travel anxiety; effects on driving and on being a passenger. Results-Acute, moderately severe emotional distress was common. Almost one fifth of subjects, however, suffered from an acute stress syndrome characterised by mood disturbance and horrific memories of the accident. Anxiety and depression usually improved over the 12 months, though one tenth of patients had mood disorders at one year. In addition, specific post-traumatic symptoms were common. Post-traumatic stress disorder occurred during follow up in one tenth of patients, and phobic travel anxiety as a driver or passenger was more common and frequently disabling. Emotional disorder was associated with having pre-accident psychological or social problems and, in patients with multiple injuries, continuing medical complications. Post-traumatic syndromes were not associated with a neurotic predisposition but were strongly associated with horrific memories of the accident. They did not occur in subjects who had been briefly unconscious and were amnesic for the accident. Mental state at three months was highly predictive of mental state at one year. Conclusions-Psychiatric symptoms and disorder are frequent after major and less severe road accident injury. Post-traumatic symptoms are common and disabling. Early information and advice might reduce psychological distress and travel anxiety and contribute to road safety and assessing ''nervous shock.''	NUFFIELD ORTHOPAED CTR,NUFFIELD DEPT ORTHOPAED SURG,OXFORD OX3 7LD,ENGLAND	Nuffield Orthopaedic Centre	MAYOU, R (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							[Anonymous], 1992, ICD 10 CLASSIFICATIO; Beck AT, 1978, DEPRESSION INVENTORY; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BRESLAU N, 1992, AM J PSYCHIAT, V149, P671; CORNES P, 1992, INJURY, V23, P256, DOI 10.1016/S0020-1383(05)80011-7; DAVIDSON JRT, 1991, J ABNORM PSYCHOL, V100, P346, DOI 10.1037/0021-843X.100.3.346; DAVIDSON JRT, 1992, POST TRAUMATIC STRES; Eysenck HJ, 1992, MANUAL EYSENCK PERSO; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; KRZANOWSKI WJ, 1988, PRINCIPLES MULTIVARA; KUCH K, 1985, CAN J PSYCHIAT, V30, P426, DOI 10.1177/070674378503000610; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; MALT U, 1982, BEDRE FORE VAR STUDI; MAYOU R, 1991, INJURY, V22, P365, DOI 10.1016/0020-1383(91)90095-V; NEWMAN PK, 1990, BMJ-BRIT MED J, V301, P395, DOI 10.1136/bmj.301.6749.395; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; RAFFLE PAB, 1991, J ROY SOC MED, V84, P390, DOI 10.1177/014107689108400703; Spielberger C. D., 1970, SELF EVALUATION QUES; TUNBRIDGE RJ, 1988, 136 TRANSP ROAD RES; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090; 1991, DSM 4 OPTIONS BOOK; 1987, DIAGNOSTIC STATISTIC	24	432	437	0	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					647	651		10.1136/bmj.307.6905.647	http://dx.doi.org/10.1136/bmj.307.6905.647			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LX470	8401049	Bronze, Green Published			2022-12-28	WOS:A1993LX47000015
J	LOVAT, LB; SCOTT, J; HODGSON, HJF; SHARPE, J; WAXMAN, J; BLOOM, SR				LOVAT, LB; SCOTT, J; HODGSON, HJF; SHARPE, J; WAXMAN, J; BLOOM, SR			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - A CASE OF CHYLOUS ASCITES	BRITISH MEDICAL JOURNAL			English	Discussion							MANAGEMENT				LOVAT, LB (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0NN,ENGLAND.		Lovat, Laurence/C-1986-2009	Lovat, Laurence/0000-0003-4542-3915				Aliaga L, 1990, An Med Interna, V7, P419; BIGLER D, 1981, Ugeskrift for Laeger, V143, P551; CHENG WSC, 1989, J GASTROEN HEPATOL, V4, P95, DOI 10.1111/j.1440-1746.1989.tb00811.x; DUMONT AE, 1989, LYMPHOLOGY, V22, P199; KELLEY ML, 1960, GASTROENTEROLOGY, V39, P161; MARTENSEN RM, 1988, AM J MED SCI, V296, P272; NIX J T, 1957, Am J Gastroenterol, V28, P40; PRESS OW, 1982, ANN INTERN MED, V96, P358, DOI 10.7326/0003-4819-96-3-358; SHERRY S, 1959, AM J MED, V26, P919; SILK YN, 1991, SURGERY, V110, P561; TAN WC, 1989, GUT, V30, P1622, DOI 10.1136/gut.30.11.1622; VARMA JS, 1985, SCOT MED J, V30, P111, DOI 10.1177/003693308503000208; 1986, NEW ENGL J MED, V314, P1369	13	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					495	497		10.1136/bmj.307.6902.495	http://dx.doi.org/10.1136/bmj.307.6902.495			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400941	Green Published, Bronze			2022-12-28	WOS:A1993LU59000032
J	HOLLOWAY, SL; GLOTZER, M; KING, RW; MURRAY, AW				HOLLOWAY, SL; GLOTZER, M; KING, RW; MURRAY, AW			ANAPHASE IS INITIATED BY PROTEOLYSIS RATHER THAN BY THE INACTIVATION OF MATURATION-PROMOTING FACTOR	CELL			English	Article							DNA TOPOISOMERASE-II; PROTO-ONCOGENE PRODUCT; XENOPUS EGGS; SACCHAROMYCES-CEREVISIAE; MICROTUBULE DYNAMICS; MULTIUBIQUITIN CHAIN; MITOTIC SPINDLE; CELL-CYCLE; M-PHASE; MITOSIS	We have used frog egg extracts that assemble mitotic spindles to identify the event that triggers sister chromatid separation. Adding a nondegradable form of cyclin B prevents maturation-promoting factor (MPF) inactivation but does not block sister chromatid separation, showing that MPF inactivation is not needed to initiate anaphase. In contrast, adding an N-terminal fragment of cyclin, which acts as a specific competitor for cyclin degradation, produces a dose-dependent delay in MPF inactivation and sister chromatid separation. Methylated ubiquitin, which inhibits ubiquitin-mediated proteolysis, also delays sister chromatid separation, suggesting that ubiquitin-mediated proteolysis is necessary to initiate anaphase. The N-terminal cyclin fragment inhibits chromosome separation even in extracts that contain only nondegradable forms of cyclin, suggesting that proteins other than the known cyclins must be degraded to dissolve the linkage between sister chromatids.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	HOLLOWAY, SL (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA.			King, Randall/0000-0001-7882-8180				ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN GL, 1984, J BIOL CHEM, V259, P3560; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HARLOW E, 1988, ANTIBODIES; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MURRAY A, 1993, CELL CYCLE; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER CW, 1990, METHOD ENZYMOL, V182, P721; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VANDERVELDEN HMW, 1993, MOL CELL BIOL, V13, P1480, DOI 10.1128/MCB.13.3.1480; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0	40	520	534	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1393	1402		10.1016/0092-8674(93)90364-V	http://dx.doi.org/10.1016/0092-8674(93)90364-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391932	Bronze			2022-12-28	WOS:A1993LL20900013
J	JI, H; MOORE, DP; BLOMBERG, MA; BRAITERMAN, LT; VOYTAS, DF; NATSOULIS, G; BOEKE, JD				JI, H; MOORE, DP; BLOMBERG, MA; BRAITERMAN, LT; VOYTAS, DF; NATSOULIS, G; BOEKE, JD			HOTSPOTS FOR UNSELECTED TY1 TRANSPOSITION EVENTS ON YEAST CHROMOSOME-III ARE NEAR TRANSFER-RNA GENES AND LTR SEQUENCES	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPOSABLE ELEMENTS; REPETITIVE ELEMENT; SIGMA-ELEMENTS; PHYSICAL MAP; COPY NUMBER; INTEGRATION; INSERTION; INVITRO; EXPRESSION	A collection of yeast strains bearing single marked Ty1 insertions on chromosome III was generated. Over 100 such insertions were physically mapped by pulsed-field gel electrophoresis. These insertions are very nonrandomly distributed. Thirty-two such insertions were cloned by the inverted PCR technique, and the flanking DNA sequences were determined. The sequenced insertions all fell within a few very limited regions of chromosome III. Most of these regions contained tRNA coding regions and/or LTRs of pre-existing transposable elements. Open reading frames were disrupted at a far lower frequency than expected for random transposition. The results suggest that the Ty1 integration machinery can detect regions of the genome that may represent ''safe havens'' for insertion. These regions of the genome do not contain any special DNA sequences, nor do they behave as particularly good targets for Ty1 integration in vitro, suggesting that the targeted regions have special properties allowing specific recognition in vivo.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University				Voytas, Daniel/0000-0002-4944-1224	NIGMS NIH HHS [GM36481, T32GM07445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445, R01GM036481] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1991, GENETICS, V129, P1043; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; BRODEUR GM, 1983, P NATL ACAD SCI-BIOL, V80, P3292, DOI 10.1073/pnas.80.11.3292; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BYSTROM AS, 1989, MOL GEN GENET, V216, P276, DOI 10.1007/BF00334366; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHALKER DL, 1990, GENETICS, V126, P837; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DUTCHER SK, 1981, MOL CELL BIOL, V1, P246; EIBEL H, 1984, NATURE, V307, P386, DOI 10.1038/307386a0; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EIGEL A, 1982, EMBO J, V1, P1245, DOI 10.1002/j.1460-2075.1982.tb00020.x; Elder R T, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 2, P581; ERREDE B, 1980, CELL, V22, P427, DOI 10.1016/0092-8674(80)90353-0; GABER RF, 1982, GENE, V19, P163, DOI 10.1016/0378-1119(82)90002-6; GARFINKEL DJ, 1988, GENETICS, V120, P95; GENBAUFFE FS, 1984, J BIOL CHEM, V259, P518; HALLING SM, 1982, CELL, V28, P155, DOI 10.1016/0092-8674(82)90385-3; KANG XL, 1992, GENETICS, V130, P285; KITAMURA UY, 1992, P NATL ACAD SCI USA, V89, P5532; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; LINK AJ, 1991, GENETICS, V127, P681; MCCORMICK M K, 1990, Technique (Philadelphia), V2, P65; NATSOULIS G, 1989, GENETICS, V123, P269; NELBOCK P, 1985, BIOL CHEM H-S, V366, P1041, DOI 10.1515/bchm3.1985.366.2.1041; NEWLON CS, 1991, GENETICS, V129, P343; OCHMAN H, 1988, GENETICS, V120, P621; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; RILES L, 1993, IN PRESS GENETICS, V134; Rose MD., 1990, METHODS YEAST GENETI; SANDMEYER SB, 1982, P NATL ACAD SCI-BIOL, V79, P7674, DOI 10.1073/pnas.79.24.7674; SANDMEYER SB, 1988, NUCLEIC ACIDS RES, V16, P1499, DOI 10.1093/nar/16.4.1499; SCHERER S, 1982, NATURE, V298, P815, DOI 10.1038/298815a0; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SIMCHEN G, 1984, P NATL ACAD SCI-BIOL, V81, P2431, DOI 10.1073/pnas.81.8.2431; STUCKA R, 1987, CURR GENET, V12, P323, DOI 10.1007/BF00405754; STUCKA R, 1989, NUCLEIC ACIDS RES, V17, P4993, DOI 10.1093/nar/17.13.4993; Varmus H., 1989, MOBILE DNA; VOYTAS DF, 1992, NATURE, V358, P717, DOI 10.1038/358717a0; WARMINGTON JR, 1986, NUCLEIC ACIDS RES, V14, P3475, DOI 10.1093/nar/14.8.3475; WARMINGTON JR, 1987, NUCLEIC ACIDS RES, V15, P8963, DOI 10.1093/nar/15.21.8963; WARMINGTON JR, 1985, NUCLEIC ACIDS RES, V13, P6679, DOI 10.1093/nar/13.18.6679; WILKE CM, 1989, GENETICS, V123, P655; XU H, 1991, MOL CELL BIOL, V11, P2736, DOI 10.1128/MCB.11.5.2736; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504	55	178	183	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					1007	1018		10.1016/0092-8674(93)90278-X	http://dx.doi.org/10.1016/0092-8674(93)90278-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8388781	Bronze			2022-12-28	WOS:A1993LF06100016
J	SCHU, PV; TAKEGAWA, K; FRY, MJ; STACK, JH; WATERFIELD, MD; EMR, SD				SCHU, PV; TAKEGAWA, K; FRY, MJ; STACK, JH; WATERFIELD, MD; EMR, SD			PHOSPHATIDYLINOSITOL 3-KINASE ENCODED BY YEAST VPS34 GENE ESSENTIAL FOR PROTEIN SORTING	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; KINASE; VACUOLE; 3-PHOSPHATE; BIOGENESIS; DOMAINS	The VPS34 gene product (Vps34p) is required for protein sorting to the lysosome-like vacuole of the yeast Saccharomyces cerevisiae. Vps34p shares significant sequence similarity with the catalytic subunit of bovine phosphatidylinositol (PI) 3-kinase [the 110-kilodalton (p110) subunit of PI 3-kinase], which is known to interact with activated cell surface receptor tyrosine kinases. Yeast strains deleted for the VPS34 gene or carrying vps34 point mutations lacked detectable PI 3-kinase activity and exhibited severe defects in vacuolar protein sorting. Overexpression of Vps34p resulted in an increase in PI 3-kinase activity, and this activity was specifically precipitated with antisera to Vps34p. VPS34 encodes a yeast PI 3-kinase, and this enzyme appears to regulate intracellular protein trafficking decisions.	UNIV CALIF SAN DIEGO,SCH MED,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; HOWARD HUGHES MED INST,LA JOLLA,CA 92093; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of California System; University of California San Diego; Howard Hughes Medical Institute; Ludwig Institute for Cancer Research				Fry, Michael/0000-0001-8518-1370				AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL T, 1985, P NATL ACAD SCI USA, V82, P5463; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LIPS DL, 1989, J BIOL CHEM, V264, P17809; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Sherman F, 1979, METHODS YEAST GENETI; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STACK JH, IN PRESS EMBO J; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946	36	772	805	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					88	91		10.1126/science.8385367	http://dx.doi.org/10.1126/science.8385367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8385367				2022-12-28	WOS:A1993KV42300034
J	MCGINNIS, JM; FOEGE, WH				MCGINNIS, JM; FOEGE, WH			ACTUAL CAUSES OF DEATH IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHYSICAL-ACTIVITY; RISK-FACTORS; SOCIOECONOMIC-STATUS; PRIMARY PREVENTION; MATERNAL SMOKING; CANCER INCIDENCE; CHRONIC DISEASES; DAILY MORTALITY; HEART-DISEASE; AIR-POLLUTION	Objective.-To identify and quantify the major external (nongenetic) factors that contribute to death in the United States. Data Sources.-Articles published between 1977 and 1993 were identified through MEDLINE searches, reference citations, and expert consultation. Government reports and compilations of vital statistics and surveillance data were also obtained. Study Selection.-Sources selected were those that were often cited and those that indicated a quantitative assessment of the relative contributions of various factors to mortality and morbidity. Data Extraction.-Data used were those for which specific methodological assumptions were stated. A table quantifying the contributions of leading factors was constructed using actual counts, generally accepted estimates, and calculated estimates that were developed by summing various individual estimates and correcting to avoid double counting. For the factors of greatest complexity and uncertainty (diet and activity patterns and toxic agents), a conservative approach was taken by choosing the lower boundaries of the various estimates. Data Synthesis.-The most prominent contributors to mortality in the United States in 1990 were tobacco (an estimated 400 000 deaths), diet and activity patterns (300 000), alcohol (100 000), microbial agents (90 000), toxic agents (60 000), firearms (35 000), sexual behavior (30 000), motor vehicles (25 000), and illicit use of drugs (20 000). Socioeconomic status and access to medical care are also important contributors, but difficult to quantify independent of the other factors cited. Because the studies reviewed used different approaches to derive estimates, the stated numbers should be viewed as first approximations. Conclusions.-Approximately half of all deaths that occurred in 1990 could be attributed to the factors identified. Although no attempt was made to further quantify the impact of these factors on morbidity and quality of life, the public health burden they impose is considerable and offers guidance for shaping health policy priorities.	CARTER PRESIDENTIAL CTR, ATLANTA, GA USA		MCGINNIS, JM (corresponding author), US DEPT HHS, 330 C ST SW, ROOM 2132, WASHINGTON, DC 20201 USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; Amler RW, 1987, AM J PREV MED, V3, P181; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; Bennett J. V., 1987, AM J PREV MED; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; Burner S T, 1992, Health Care Financ Rev, V14, P1; CAMPBELL BJ, 1987, J TRAUMA, V27, P733, DOI 10.1097/00005373-198707000-00007; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEVITA VT, 1989, CANCER PRINCIPLES PR, V1; DIBISCEGLIE AM, 1990, ETIOLOGY PATHOLOGY T; DOLL R, 1992, CANCER RES, V52, pS2024; Doll R, 1981, THE CAUSES OF CANCER; Estimated national spending on prevention-United States, 1988, MMWR MORB MORTAL WKL, V41, P529; FARER LS, 1987, AM J PREV MED S, V3, P115; FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V264, P2210, DOI 10.1001/jama.1990.03450170058012; FINGERHUT LA, 1989, ADV DATA VITAL HLTH, V178; FOEGE WH, 1987, AM J PREV MED S, V3, P3; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GORI GB, 1978, SCIENCE, V200, P1124, DOI 10.1126/science.653358; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; HAMMOND EC, 1980, PREV MED, V9, P206, DOI 10.1016/0091-7435(80)90077-8; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HENSHAW SK, 1989, FAM PLANN PERSPECT, V21, P85, DOI 10.2307/2135559; HERMAN WH, 1987, AM J PREV MED S, V3, P72; HIGGINSON J, 1979, JNCI-J NATL CANCER I, V63, P1291; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; Johannes RS, 1987, AM J PREV MED S, V3, P83; Kaplan G.A., 1987, AM J PREVENTIVE ME S, V3, P125; KLEINMAN JC, 1988, AM J EPIDEMIOL, V127, P274, DOI 10.1093/oxfordjournals.aje.a114803; KLEINMAN JC, 1985, AM J EPIDEMIOL, V121, P843, DOI 10.1093/oxfordjournals.aje.a114055; LANDRIGAN PJ, 1989, ANN NY ACAD SCI, V572, P27; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LUBIN JH, 1989, HEALTH PHYS, V57, P417, DOI 10.1097/00004032-198909000-00008; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MCCOY GF, 1989, INJURY, V20, P65, DOI 10.1016/0020-1383(89)90141-1; Milio N., 1981, PROMOTING HLTH PUBLI; NELSON JH, 1989, CA-CANCER J CLIN, V39, P157, DOI 10.3322/canjclin.39.3.157; NEWBERNE PM, 1978, B NEW YORK ACAD MED, V54, P385; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; PAFFENBARGER RS, 1986, ACTA MED SCAND, P85; PAFFENBARGER RS, 1990, EXERCISE FITNESS HLT; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PERERA FP, 1991, SCIENCE, V252, P903, DOI 10.1126/science.252.5008.903; POLLOCK DA, 1991, JAMA-J AM MED ASSOC, V266, P2233, DOI 10.1001/jama.266.16.2233; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211, DOI 10.1080/00039896.1992.9938351; POWELL KE, 1989, AM J CLIN NUTR, V49, P999, DOI 10.1093/ajcn/49.5.999; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; PUSKIN JS, 1989, JAPCA J AIR WASTE MA, V39, P915, DOI 10.1080/08940630.1989.10466577; ROTHENBERG R, 1987, AM J PREV MED S, V3, P30; SALONEN JT, 1982, J EPIDEMIOL COMMUN H, V36, P294, DOI 10.1136/jech.36.4.294; SCHOENBORN CA, 1991, ADV DATA VITAL HLTH, V205; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12, DOI 10.1093/oxfordjournals.aje.a116195; SHULTZ JM, 1991, PUBLIC HEALTH REP, V106, P326; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; SMITH ESO, 1977, CAN MED ASSOC J, V117, P507; SMITH GS, 1987, AM J PREV MED S, V3, P143; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P2268, DOI 10.1001/jama.266.16.2268; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; SWANSON GM, 1988, CANCER-AM CANCER SOC, V62, P1725, DOI 10.1002/1097-0142(19881015)62:1+<1725::AID-CNCR2820621310>3.0.CO;2-E; TERRIS M, 1990, J PUBLIC HLTH POLICY, V2, P151; TYROLER H A, 1989, Hypertension (Dallas), V13, pI94; WALLACE LA, 1985, EPA PROJECT SUMMARY; WASHINGTON AE, 1986, JAMA-J AM MED ASSOC, V255, P1735, DOI 10.1001/jama.255.13.1735; WEBSTER DW, 1991, ISSUES SCI TECHNOL, V7, P73; WEST LJ, 1984, ANN INTERN MED, V100, P405, DOI 10.7326/0003-4819-100-3-405; WHITE CC, 1987, AM J PREV MED, V3, P304; WICHMANN HE, 1989, ENVIRON HEALTH PERSP, V79, P89, DOI 10.2307/3430534; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; WYNDER EL, 1977, JNCI-J NATL CANCER I, V58, P825, DOI 10.1093/jnci/58.4.825; 1990, MMWR MORB MORTAL WKL, V39, P173; 1990, IN PRESS VITAL STATI, V2; 1992, TROUBLING TRENDS PER; 1986, REPORT SECRETORYS TA; 1992, DIVISION STD HIV PRE; 1993, MONTHLY VITAL STATIS, V41; 1993, HIV AIDS SURVEILLANC; 1993, MMWR MORB MORTAL WKL, V42, P645; 1990, ADM901656 US DEP HLT; 1990, ANN DATA 1989 DATA 1, V9; 1988, PHS8850210 US DEP HL; 1988, USE CONTROLLED SUBST; 1992, US EPA600690006F PUB; 1992, EBRI123 EMPL BEN RES; 1991, DRUG ABUSE DRUG ABUS; 1993, PHS931232 US DEP HLT; 1991, SEXUALLY TRANSMITTED; 1987, AM J PREV MED S, V3, P130; 1985, MMWR MORB MORTALWKLY, V34, P313; 1993, CANCER FACTS FIGURES; 1988, DHHS992699 US DEP HL; 1989, CDC898411 US DEP HLT	99	2029	2076	2	160	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2207	2212		10.1001/jama.270.18.2207	http://dx.doi.org/10.1001/jama.270.18.2207			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411605				2022-12-28	WOS:A1993ME81600033
J	HEIJBOER, H; BULLER, HR; LENSING, AWA; TURPIE, AGG; COLLY, LP; TENCATE, JW				HEIJBOER, H; BULLER, HR; LENSING, AWA; TURPIE, AGG; COLLY, LP; TENCATE, JW			A COMPARISON OF REAL-TIME COMPRESSION ULTRASONOGRAPHY WITH IMPEDANCE PLETHYSMOGRAPHY FOR THE DIAGNOSIS OF DEEP-VEIN THROMBOSIS IN SYMPTOMATIC OUTPATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-MODE ULTRASONOGRAPHY; VENOUS-THROMBOSIS; CLINICAL VALIDITY; MANAGEMENT; VENOGRAPHY; TESTS	Background. Impedance plethysmography performed serially over a one-week period has been shown to be an effective diagnostic strategy for patients with clinically suspected acute deep-vein thrombosis. Compression ultrasonography has a high sensitivity and specificity for the detection of proximal-vein thrombosis. The clinical value of repeated ultrasonography in the management of symptomatic deep-vein thrombosis is unknown. Methods. We conducted a randomized trial in 985 consecutive outpatients with clinically suspected deep-vein thrombosis to compare the diagnostic value of serial impedance plethysmography (494 patients) and serial compression ultrasonography (491 patients). We compared the positive predictive values of both tests for the diagnosis of venous thrombosis, using contrast venography as a reference. The frequencies of venous thromboembolism during a six-month follow-up period were also compared in patients with repeatedly normal results in order to evaluate the safety of withholding anticoagulant therapy from such patients. Results. The positive predictive value of an abnormal ultrasonogram was 94 percent (95 percent confidence interval, 87 to 98 percent), whereas the predictive value of impedance plethysmography was 83 percent (95 percent confidence interval, 75 to 90 percent) (P = 0.02). In patients with repeatedly normal results, the incidence of venous thromboembolism during the six-month follow-up period was 1.5 percent (95 percent confidence interval, 0.5 to 3.3 percent) for serial compression ultrasonography, as compared with 2.5 percent (95 percent confidence interval, 1.2 to 4.6 percent) for serial impedance plethysmography. Conclusions. In making the diagnosis of deep-vein thrombosis in symptomatic outpatients, serial compression ultrasonography is preferable to impedance plethysmography, in view of its superior performance in detecting venous thrombosis.	UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLAMMAT RES,1105 AZ AMSTERDAM,NETHERLANDS; HAMILTON GEN HOSP,HAMILTON CIVIC HOSP GEN DIV,MCMASTER CLIN,HAMILTON L8L 2X2,ONTARIO,CANADA	University of Amsterdam; Academic Medical Center Amsterdam; McMaster University								BULLER HR, 1991, THROMB HAEMOSTASIS, V66, P133; CRANLEY JJ, 1976, ARCH SURG-CHICAGO, V111, P34; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; CRONAN JJ, 1988, RADIOLOGY, V168, P101, DOI 10.1148/radiology.168.1.2967984; DAUZAT MM, 1986, J ULTRAS MED, V5, P625; HEIJBOER H, 1992, THROMB HAEMOSTASIS, V67, P510; HIRSH J, 1991, THROMB HAEMOSTASIS, V65, P221; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, NEW ENGL J MED, V304, P1561, DOI 10.1056/NEJM198106253042602; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; HULL RD, 1987, HEMOSTASIS THROMBOSI, P1220; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; VACCARO JP, 1990, RADIOLOGY, V175, P645, DOI 10.1148/radiology.175.3.2188294; WHEELER HB, 1982, ARCH SURG-CHICAGO, V117, P1206	22	298	300	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1365	1369		10.1056/NEJM199311043291901	http://dx.doi.org/10.1056/NEJM199311043291901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413431				2022-12-28	WOS:A1993MD94900001
J	KERBER, RA; TILL, JE; SIMON, SL; LYON, JL; THOMAS, DC; PRESTONMARTIN, S; RALLISON, ML; LLOYD, RD; STEVENS, W				KERBER, RA; TILL, JE; SIMON, SL; LYON, JL; THOMAS, DC; PRESTONMARTIN, S; RALLISON, ML; LLOYD, RD; STEVENS, W			A COHORT STUDY OF THYROID-DISEASE IN RELATION TO FALLOUT FROM NUCLEAR-WEAPONS TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEVADA TEST SITE; RETROSPECTIVE COHORT; RADIOACTIVE FALLOUT; RADIATION; CANCER; NODULARITY; CHILDHOOD; CHILDREN; EXPOSURE; IRRADIATION	Objective.-To estimate individual radiation doses and current thyroid disease status for a previously identified cohort of 4818 schoolchildren potentially exposed to fallout from detonations of nuclear devices at the Nevada Test Site between 1951 and 1958. Design.-Cohort analytic study. Setting.-Communities in southwestern Utah, southeastern Nevada, and southeastern Arizona. Participants.-Individuals who were still residing in the three-state area (n=3122) were reexamined in 1985 and 1986, and information on the subjects' and their mothers' milk and vegetable consumption during the fallout period was obtained by telephone interview (n=3545). After exclusions to eliminate missing data and confounding factors, 2473 subjects were available for analysis. Main Outcome Measures.-Individual radiation doses to the thyroid were estimated by combining consumption data with radionuclide deposition rates provided by the US Department of Energy and a survey of milk producers. Relative risk models adjusted for age, sex, and state were fitted using maximum likelihood to period prevalence data for thyroid carcinomas, neoplasms, and nodules. Results.-Doses ranged from 0 mGy to 4600 mGy, and averaged 170 mGy in Utah. There was a statistically significant excess of thyroid neoplasms (benign and malignant; n=19), with an increase in excess relative risk of 0.7% per milligray. A relative risk- for thyroid neoplasms of 3.4 was observed among 169 subjects exposed to doses greater than 400 mGy. Positive but nonsignificant dose-response slopes were found for carcinomas and nodules. Conclusions.-Exposure to Nevada Test Site-generated radioiodines was associated with an excess of thyroid neoplasms. The conclusions are limited by the small number of exposed individuals and the low incidence of thyroid neoplasms.	RADIOL ASSESSMENTS CORP, NEESES, SC USA; UNIV UTAH, DEPT PEDIAT, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT RADIOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT ANAT, SALT LAKE CITY, UT 84132 USA; UNIV SO CALIF, DEPT PREVENT MED, LOS ANGELES, CA 90089 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Southern California	KERBER, RA (corresponding author), UNIV UTAH, DEPT FAMILY & PREVENT MED, SALT LAKE CITY, UT 84132 USA.		Kerber, Richard/B-8038-2009		NCI NIH HHS [N01-CO-23917] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO023917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS WH, 1992, J RADIOAN NUCL CH AR, V156, P269, DOI 10.1007/BF02038344; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BECK HL, 1990, NVO320 US DEP EN REP; HAMILTON PM, 1989, FDA898276 US DEP HLT; HAMILTON TE, 1987, JAMA-J AM MED ASSOC, V258, P629, DOI 10.1001/jama.258.5.629; HICKS HG, 1982, HEALTH PHYS, V42, P585, DOI 10.1097/00004032-198205000-00003; HOLM LE, 1988, JNCI-J NATL CANCER I, V80, P1132, DOI 10.1093/jnci/80.14.1132; HOLM LE, 1980, J NATL CANCER I, V64, P1055; HOLM LE, 1984, RAD CARCINOGENESIS E; KOPECKY KJ, 1987, J STAT COMP SIMULAT, V27, P339; LAIRD NM, 1987, RISK ANAL, V7, P299, DOI 10.1111/j.1539-6924.1987.tb00465.x; LEE W, 1982, RADIAT RES, V92, P307, DOI 10.2307/3576007; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAYS CW, 1966, SCI CITIZEN, V8, P3; MCTIERNAN AM, 1984, AM J EPIDEMIOL, V120, P423, DOI 10.1093/oxfordjournals.aje.a113907; POTTERN LM, 1990, J CLIN EPIDEMIOL, V43, P449, DOI 10.1016/0895-4356(90)90133-A; PRESTON DL, 1990, EPI CURE GENERALIZED; PRESTONMARTIN S, 1987, BRIT J CANCER, V55, P191, DOI 10.1038/bjc.1987.36; RALLISON ML, 1974, AM J MED, V56, P457, DOI 10.1016/0002-9343(74)90476-8; RALLISON ML, 1975, J PEDIATR-US, V86, P675, DOI 10.1016/S0022-3476(75)80350-7; RALLISON ML, 1990, HEALTH PHYS, V59, P739, DOI 10.1097/00004032-199011000-00021; RALLISON ML, 1975, JAMA-J AM MED ASSOC, V233, P1069, DOI 10.1001/jama.233.10.1069; ROBBINS J, 1989, RAD THYROID, P11; RON E, 1989, RADIAT RES, V120, P516, DOI 10.2307/3577801; SHORE RE, 1985, J NATL CANCER I, V74, P1177; SHORE RE, 1986, RAD CARCINOGENESIS, P93; SIMON SL, 1990, HEALTH PHYS, V59, P669, DOI 10.1097/00004032-199011000-00017; STEVENS W, 1990, JAMA-J AM MED ASSOC, V264, P585, DOI 10.1001/jama.264.5.585; THOMAS DC, IN PRESS BIOMETRICS; THOMPSON CB, TOWN DATABASE ESTIMA; WEISS ES, 1971, AM J PUBLIC HEALTH N, V61, P241, DOI 10.2105/AJPH.61.2.241; [No title captured]; 80 NAT COUNC RAD PRO	33	111	116	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2076	2082						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411574				2022-12-28	WOS:A1993MD88200027
J	SUCHYNA, TM; XU, LX; GAO, F; FOURTNER, CR; NICHOLSON, BJ				SUCHYNA, TM; XU, LX; GAO, F; FOURTNER, CR; NICHOLSON, BJ			IDENTIFICATION OF A PROLINE RESIDUE AS A TRANSDUCTION ELEMENT INVOLVED IN VOLTAGE GATING OF GAP-JUNCTIONS	NATURE			English	Article								GAP junction channels are structurally distinct from other ion channels in that they comprise two hemichannels which interact head-to-head to form an aqueous channel between cells. Intercellular voltage differences together with increased intracellular concentrations of H+ and Ca2+ cause closure of these normally patent channels1. The relative sensitivity to voltage varies with the subunit (connexin) composition of the channels2. The third of four transmembrane-spanning regions (M3) in connexins has been proposed to form the channel lining3, and a global 'tilting' of the hemichannel subunits has been correlated with channel closure4. But specific components involved in transduction of channel gating events have not been identified in either gap junctions or other ion channel classes (however, see model in ref. 5). We have examined a strictly conserved proline centrally located in M2 of connexin proteins. Mutation of this proline (Pro 87) in connexin 26 causes a reversal in the voltage-gating response when the mutant hemichannel is paired with wild-type connexin 26 in the Xenopus oocyte system. This suggests that the unique properties associated with this residue are critical to the transduction of voltage gating in these channels.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo				Nicholson, Bruce/0000-0003-1649-7173				BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BENNETT MVL, 1988, GAP JUNCTIONS, P287; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CONNOLLY JG, 1989, COMP BIOCHEM PHYS A, V93, P221, DOI 10.1016/0300-9629(89)90210-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FIMMEL AL, 1983, BIOCHEM J, V213, P451, DOI 10.1042/bj2130451; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GUY RH, 1990, TRENDS NEUROSCI, V13, P201; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MOGI T, 1989, J BIOL CHEM, V264, P14192; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; VEENSTRA RD, 1990, AM J PHYSIOL, V258, pC662, DOI 10.1152/ajpcell.1990.258.4.C662; VERSELIS VK, 1992, 22ND NEUR ANN M AN; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; YUN RH, 1991, PROTEINS, V10, P219, DOI 10.1002/prot.340100306	26	136	139	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					847	849		10.1038/365847a0	http://dx.doi.org/10.1038/365847a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413670				2022-12-28	WOS:A1993MD95100053
J	DILL, M; WOLF, R; HEISENBERG, M				DILL, M; WOLF, R; HEISENBERG, M			VISUAL-PATTERN RECOGNITION IN DROSOPHILA INVOLVES RETINOTOPIC MATCHING	NATURE			English	Article							BEES; DISCRIMINATION; ORIENTATION	HONEYBEES remember the shapes of flowers and are guided by visual landmarks on their foraging trips1,2. How insects recognize visual patterns is poorly understood. Experiments suggest that they try to match retinotopically the incoming visual pattern with a previously stored memory image2-7. But bees can be conditioned to individual pattern parameters such as orientation of contours, colour or size2,8-11. These and other results are difficult to reconcile with simple template matching. In such investigations, freely moving animals are observed; their behaviour and visual input, therefore, are not well known. Mostly, processing strategies are inferred from stimulus design. We have studied visual pattern recognition with tethered flies (Drosophila melanogaster) in a flight simulator and report here that flies store visual images at, or together with, fixed retinal positions and can retrieve them from there only5. Position invariance, an acknowledged property of human pattern recognition, may no exist as a primary mechanism in insects.	THEODOR BOVERI INST BIOWISSENSCH, BIOZENTRUM, LEHRSTUHL GENET, HUBLAND, D-97074 WURZBURG, GERMANY									BUCHNER E, 1976, BIOL CYBERN, V24, P85, DOI 10.1007/BF00360648; CARTWRIGHT BA, 1983, J COMP PHYSIOL, V151, P521, DOI 10.1007/BF00605469; CARTWRIGHT BA, 1982, NATURE, V295, P560, DOI 10.1038/295560a0; COLLETT TS, 1992, PHILOS T R SOC B, V337, P295, DOI 10.1098/rstb.1992.0107; CRONLYDILLON JR, 1966, EXP NEUROL, V15, P455, DOI 10.1016/0014-4886(66)90142-7; GOTZ KG, 1965, KYBERNETIK, V2, P215, DOI 10.1007/BF00306417; GOULD JL, 1985, SCIENCE, V227, P1492, DOI 10.1126/science.227.4693.1492; HEISENBERG M, 1988, J COMP PHYSIOL A, V163, P373, DOI 10.1007/BF00604013; HEISENBERG M, 1993, VISUAL MOTION ITS RO, P265; HORRIDGE GA, 1992, PHILOS T R SOC B, V337, P49, DOI 10.1098/rstb.1992.0082; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; MYERS RE, 1955, J COMP PHYSIOL PSYCH, V48, P470, DOI 10.1037/h0044224; OCARROLL D, 1993, NATURE, V362, P541, DOI 10.1038/362541a0; RAMACHANDRAN VS, 1976, NATURE, V262, P382, DOI 10.1038/262382a0; RONACHER B, 1979, BIOL CYBERN, V32, P63, DOI 10.1007/BF00337437; SRINIVASAN MV, 1993, NATURE, V362, P539, DOI 10.1038/362539a0; TINBERGEN N, 1932, Z VERGL PHYSIOL, V15, P305; VANHATEREN JH, 1990, J COMP PHYSIOL A, V167, P649, DOI 10.1007/BF00192658; WEHNER R, 1972, J COMP PHYSIOL PSYCH, V77, P256, DOI 10.1007/BF00696429; WEHNER R, 1981, HDB SENSORY PHYSL, V7; WOLF R, 1991, J COMP PHYSIOL A, V169, P699; ZHANG SW, 1992, P ROY SOC B-BIOL SCI, V248, P55, DOI 10.1098/rspb.1992.0042	22	104	105	0	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 21	1993	365	6448					751	753		10.1038/365751a0	http://dx.doi.org/10.1038/365751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413652				2022-12-28	WOS:A1993MC81200062
J	KIM, YC; GEIGER, JH; HAHN, S; SIGLER, PB				KIM, YC; GEIGER, JH; HAHN, S; SIGLER, PB			CRYSTAL-STRUCTURE OF A YEAST TBP TATA-BOX COMPLEX	NATURE			English	Article							TRANSCRIPTION FACTOR; BINDING-PROTEIN; DNA; DOMAIN; INVIVO; SPECIFICITY; INITIATION; RESOLUTION; REFINEMENT; HYDRATION	The 2.5 angstrom crystal structure of a TATA-box complex with yeast TBP shows that the eight base pairs of the TATA box bind to the concave surface of TBP by bending towards the major groove with unprecedented severity. This produces a wide open, underwound, shallow minor groove which forms a primarily hydrophobic interface with the entire under-surface of the TBP saddle. The severe bend and a positive writhe radically alter the trajectory of the flanking B-form DNA.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Howard Hughes Medical Institute; Yale University; Fred Hutchinson Cancer Center				Geiger, James/0000-0002-9443-4488; Kim, Youngchang/0000-0002-1610-4889				ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1993, XPLOR VERSION 31 MAN; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CONNER BN, 1982, NATURE, V295, P294, DOI 10.1038/295294a0; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; EISENSTEIN M, 1990, NUCLEIC ACIDS RES, V18, P3185, DOI 10.1093/nar/18.11.3185; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAWLEY DK, 1991, CELL, V67, P1231; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LORCH Y, 1993, MOL CELL BIOL, V13, P1872, DOI 10.1128/MCB.13.3.1872; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Patel D J, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P197; POON D, 1993, J BIOL CHEM, V268, P5005; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHAKKED Z, 1983, J MOL BIOL, V166, P183, DOI 10.1016/S0022-2836(83)80005-9; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	47	957	969	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					512	520		10.1038/365512a0	http://dx.doi.org/10.1038/365512a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413604				2022-12-28	WOS:A1993MA66100044
J	MERINO, A; MADDEN, KR; LANE, WS; CHAMPOUX, JJ; REINBERG, D				MERINO, A; MADDEN, KR; LANE, WS; CHAMPOUX, JJ; REINBERG, D			DNA TOPOISOMERASE-I IS INVOLVED IN BOTH REPRESSION AND ACTIVATION OF TRANSCRIPTION	NATURE			English	Article							RNA POLYMERASE-II; BINDING; CLONING; PROTEIN; YEAST; GENE; COMPLEX; PURIFICATION; COACTIVATORS; INITIATION	Reconstituted transcription reactions containing the seven general transcription factors, in addition to RNA polymerase II, respond poorly to transcriptional activators. Two factors, Dr2 and ACF, necessary for high levels of transcription in response to an activator have been identified. ACF can enhance basal and activated transcription. Dr2 represses basal transcription, but this can be overcome by transcriptional activators or TFIIA. Dr2 is human DNA topoisomerase I. The DNA relaxation activity of topoisomerase I is dispensable for transcriptional repreSSion. The effect of Dr2 is specific for TATA-box-containing promoters and is mediated by the TATA-binding protein.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Washington; University of Washington Seattle; Harvard University				Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHODER M, 1991, GENE DEV, V5, P2315, DOI 10.1101/gad.5.12a.2315; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; ENG W, 1989, J BIOL CHEM, V164, P13373; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE PL, 1993, P NATL ACAD SCI USA, V90, P6656; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MADDEN KR, 1992, CANCER RES, V52, P525; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1989, J BIOL CHEM, V264, P21266; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STEWART AF, 1990, CELL, V60, P141; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; ZAWEL L, 1993, NUCLEIC ACID RES MOL, V44, P67; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	47	337	340	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					227	232		10.1038/365227a0	http://dx.doi.org/10.1038/365227a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396729				2022-12-28	WOS:A1993LX47100045
J	YAWO, H; CHUHMA, N				YAWO, H; CHUHMA, N			PREFERENTIAL INHIBITION OF OMEGA-CONOTOXIN-SENSITIVE PRESYNAPTIC CA2+ CHANNELS BY ADENOSINE AUTORECEPTORS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSMITTER RELEASE; CALCIUM CURRENTS; CELLS; RECEPTOR; RAT; HIPPOCAMPUS; BRADYKININ; NEURONS; ABSENCE	ADENOSINE is a potent modulator of transmitter release at a variety of synapses. The adenosine A1 receptor is assumed to reside in presynaptic terminals and to function as a negative autoreceptor1. How adenosine reduces transmitter release is uncertain2; it may reduce the calcium influx during nerve terminal depolarization by either activating K+ currents3,4 or inhibiting Ca2+, currents5,6, although other mechanisms have been proposed7-9. We have directly measured intracellular Ca2+ concentrations of giant presynaptic terminals in the chick ciliary ganglion. We report here that adenosine inhibited the nerve-evoked Ca2+ influx in the terminal by activating A1 receptors. Reduced Ca2+ influx was due largely to inhibition of omega-conotoxin GVIA-sensitive Ca2+ channels in the presynaptic terminal.			YAWO, H (corresponding author), KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 60601,JAPAN.		Yawo, Hiromu/I-4871-2015	Yawo, Hiromu/0000-0002-4299-3288; Chuhma, Nao/0000-0002-6846-3461				BENNETT MR, 1991, J PHYSIOL-LONDON, V440, P513, DOI 10.1113/jphysiol.1991.sp018722; BRANISTEANU DD, 1979, N-S ARCH PHARMACOL, V308, P273, DOI 10.1007/BF00501393; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; GERBER U, 1989, J PHYSIOL-LONDON, V417, P567, DOI 10.1113/jphysiol.1989.sp017819; GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILTON BR, 1991, J PHYSIOL-LONDON, V432, P327, DOI 10.1113/jphysiol.1991.sp018387; Haugland R.P., 1992, HDB FLUORESCENT PROB; KWAN CY, 1990, J BIOL CHEM, V265, P678; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V435, P373, DOI 10.1113/jphysiol.1991.sp018515; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SHIMAHARA T, 1990, BRAIN RES, V524, P219, DOI 10.1016/0006-8993(90)90694-7; SILINSKY EM, 1992, J PHYSIOL-LONDON, V457, P315, DOI 10.1113/jphysiol.1992.sp019380; SILINSKY EM, 1986, TRENDS PHARMACOL SCI, V7, P180, DOI 10.1016/0165-6147(86)90309-3; SYNDER SH, 1985, ANNU REV NEUROSCI, V8, P103; TRUSSELL LO, 1985, P NATL ACAD SCI USA, V82, P4857, DOI 10.1073/pnas.82.14.4857; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; YAWO H, 1989, J PHYSIOL-LONDON, V417, P307, DOI 10.1113/jphysiol.1989.sp017803	22	145	149	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					256	258		10.1038/365256a0	http://dx.doi.org/10.1038/365256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396730				2022-12-28	WOS:A1993LX47100055
J	PEZZELLA, F; TURLEY, H; KUZU, I; TUNGEKAR, MF; DUNNILL, MS; PIERCE, CB; HARRIS, A; GATTER, KC; MASON, DY				PEZZELLA, F; TURLEY, H; KUZU, I; TUNGEKAR, MF; DUNNILL, MS; PIERCE, CB; HARRIS, A; GATTER, KC; MASON, DY			BCL-2 PROTEIN IN NON-SMALL-CELL LUNG-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN FOLLICULAR LYMPHOMA; 14-18 TRANSLOCATION; B-CELLS; EXPRESSION; GENE; SURVIVAL; DEATH; CLONING; CANCER	Background. The proto-oncogene bcl-2 encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied bcl-2 expression in patients with non-small-cell lung carcinoma and correlated this phenomenon with survival. Methods. Immunochemical analysis with a monoclonal antibody specific for bcl-2 was used to detect the protein in tumor samples from 122 patients undergoing surgery for squamous-cell carcinoma (80 patients) or adenocarcinoma (42 patients). The possibility that bcl-2 expression correlated with survival was investigated with use of the log-rank test, hazard ratios, and their confidence intervals. Results. We detected bcl-2 protein in 25 percent of squamous-cell carcinomas (20 of 80) and 12 percent of adenocarcinomas (5 of 42). In adjacent normal respiratory epithelium, bcl-2 was expressed only in basal cells. Survival at five years was higher among patients with bcl-2-positive tumors, both in the group as a whole (P<0.1) and in the group with squamous-cell carcinoma (P<0.02). Patients 60 years of age or older who had bcl-2-positive tumors had the best prognoses, both in the group as a whole (P<0.02) and in the group with squamous-cell carcinoma (P<0.01). Conclusions. The proto-oncogene bcl-2 is abnormally expressed in some lung carcinomas, and its expression may have prognostic importance.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,CTR DATA,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; University of Oxford	PEZZELLA, F (corresponding author), JOHN RADCLIFFE HOSP,LEUKAEMIA RES FUND,IMMUNODIAGNOST UNIT,LEVEL 1,MATERN BLOCK,OXFORD OX3 9DU,ENGLAND.		Harris, Adrian L/ABA-3343-2020; KUZU, ISINSU/AAM-8967-2020	Harris, Adrian L/0000-0003-1376-8409; KUZU, ISINSU/0000-0001-5519-1009				AISENBERG AC, 1988, BLOOD, V71, P969; Altman D. G., 1991, PRACTICAL STAT MED R, DOI [10.1201/9780429258589, DOI 10.1201/9780429258589]; Armitage P., 1987, STAT METHODS MED RES, Vsecond, P186, DOI [DOI 10.1002/9780470773666, 10.1002/9780470773666]; BAILAR JC, 1992, MED USES STATISTICS; CARR DT, 1983, LUNG CANCER CLIN DIA, P201; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORSMEYER SJ, 1992, BLOOD, V80, P879; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; LEE JS, 1992, NEW ENGL J MED, V327, P47, DOI 10.1056/NEJM199207023270110; MACHIN D, 1989, STATISTICS CONFIDENC, P64; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCVIE JG, 1990, MANUAL CLIN ONCOLOGY, P217; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PEZZELLA F, 1990, LANCET, V336, P1510, DOI 10.1016/0140-6736(90)93216-C; PEZZELLA F, 1990, BRIT J HAEMATOL, V76, P58, DOI 10.1111/j.1365-2141.1990.tb07836.x; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	28	660	674	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					690	694		10.1056/NEJM199309023291003	http://dx.doi.org/10.1056/NEJM199309023291003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8393963				2022-12-28	WOS:A1993LU58300003
J	LIPTON, SA; CHOI, YB; PAN, ZH; LEI, SZZ; CHEN, HSV; SUCHER, NJ; LOSCALZO, J; SINGEL, DJ; STAMLER, JS				LIPTON, SA; CHOI, YB; PAN, ZH; LEI, SZZ; CHEN, HSV; SUCHER, NJ; LOSCALZO, J; SINGEL, DJ; STAMLER, JS			A REDOX-BASED MECHANISM FOR THE NEUROPROTECTIVE AND NEURODESTRUCTIVE EFFECTS OF NITRIC-OXIDE AND RELATED NITROSO-COMPOUNDS	NATURE			English	Article							RECEPTOR-CHANNEL COMPLEX; NMDA RECEPTOR; GLUTAMATE NEUROTOXICITY; SUPEROXIDE-DISMUTASE; MODULATORY SITE; NEURONAL INJURY; NERVOUS-SYSTEM; PEROXYNITRITE; INHIBITION; OXIDATION	CONGENERS of nitrogen monoxide (NO) are neuroprotective and neurodestructive1-7. To address this apparent paradox, we considered the effects on neurons of compounds characterized by alternative redox states of NO: nitric oxide (NO.) and nitrosonium ion (NO+)8. Nitric oxide, generated from NO. donors or synthesized endogenously after NMDA (N-methyl-D-aspartate) receptor activation, can lead to neurotoxicity3,4. Here, we report that NO.-mediated neurotoxicity is engendered, at least in part, by reaction with superoxide anion (O2.-), apparently leading to formation of peroxynitrite (ONOO-), and not by NO. alone. In contrast, the neuroprotective effects of NO result from downregulation of NMDA-receptor activity by reaction with thiol group(s) of the receptor's redox modulatory site1. This reaction is not mediated by NO. itself, but occurs under conditions supporting S-nitrosylation of NMDA receptor thiol (reaction or transfer of NO+). Moreover, the redox versatility of NO allows for its interconversion from neuroprotective to neurotoxic species by a change in the ambient redox milieu. The details of this complex redox chemistry of NO may provide a mechanism for harnessing neuroprotective effects and avoiding neurotoxicity in the central nervous system.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT NEUROL,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02215; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RESP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BROCKTON W ROXBURY VET ADM MED CTR,CARDIOL SECT,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University	LIPTON, SA (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,CELLULAR & MOLEC NEUROSCI LAB,300 LONGWOOD AVE,ENDERS BLDG,BOSTON,MA 02115, USA.		Loscalzo, Joseph/ABD-8980-2021	Sucher, Nikolaus/0000-0001-6233-1612; Lipton, Stuart/0000-0002-3490-1259; Stamler, Jonathan/0000-0002-6866-1572				BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HOYT KR, 1992, BRAIN RES, V592, P310, DOI 10.1016/0006-8993(92)91690-G; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KINOUCH H, 1991, P NATL ACAD SCI USA, V89, P11158; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; LIU TH, 1989, AM J PHYSIOL, V256, P589; MANCHESTER KS, 1993, NEUROLOGY, V43, pA365; MARKS GS, 1992, CAN J PHYSIOL PHARM, V70, P308, DOI 10.1139/y92-039; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONCADA C, 1992, NEUROREPORT, V3, P530; NOACK E, 1991, BASIC RES CARDIOL, V86, P37; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OLNEY JW, 1990, SCIENCE, V248, P596, DOI 10.1126/science.2185543; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; WALLIS RA, 1992, NEUROREPORT, V3, P645, DOI 10.1097/00001756-199207000-00026; ZUMFT WG, 1982, BIOCHIM BIOPHYS ACTA, V681, P459, DOI 10.1016/0005-2728(82)90188-8	34	2250	2332	1	96	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					626	632		10.1038/364626a0	http://dx.doi.org/10.1038/364626a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8394509				2022-12-28	WOS:A1993LR77100053
J	GALIONE, A; MCDOUGALL, A; BUSA, WB; WILLMOTT, N; GILLOT, I; WHITAKER, M				GALIONE, A; MCDOUGALL, A; BUSA, WB; WILLMOTT, N; GILLOT, I; WHITAKER, M			REDUNDANT MECHANISMS OF CALCIUM-INDUCED CALCIUM-RELEASE UNDERLYING CALCIUM WAVES DURING FERTILIZATION OF SEA-URCHIN EGGS	SCIENCE			English	Article							CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; HAMSTER EGGS; OSCILLATIONS	Propagating Ca2+ waves are a characteristic feature of Ca2+-linked signal transduction pathways. Intracellular Ca2+ waves are formed by regenerative stimulation of Ca2+ release from intracellular stores by Ca2+ itself. Mechanisms that rely on either inositol trisphosphate or ryanodine receptor channels have been proposed to account for Ca2+ waves in various cell types. Both channel types contributed to the Ca2+ wave during fertilization of sea urchin eggs. Alternative mechanisms of Ca2+ release imply redundancy but may also allow for modulation and diversity in the generation of Ca2+ waves.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	Johns Hopkins University; University of London; University College London	GALIONE, A (corresponding author), UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND.		Galione, Antony/E-5884-2011; McDougall, Alex/J-1930-2014	McDougall, Alex/0000-0003-0324-3836; Galione, Antony/0000-0002-4132-7646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CROSSLEY I, 1988, BIOCHEM J, V252, P257, DOI 10.1042/bj2520257; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DELISLE S, 1992, J BIOL CHEM, V267, P7963; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, UNPUB; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; JACOB R, 1990, CELL CALCIUM, V11, P241, DOI 10.1016/0143-4160(90)90075-6; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KLINE D, 1988, SCIENCE, V241, P464, DOI 10.1126/science.3134693; KUBOTA HY, 1987, DEV BIOL, V119, P126; LEICHLEITER JD, 1992, CELL, V69, P283; McDougall Alex, 1993, Zygote, V1, P35; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; PALADE P, 1983, J BIOL CHEM, V258, P8098; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; ROONEY TA, 1991, PHARMACOL THERAPEUT, V49, P223, DOI 10.1016/0163-7258(91)90056-R; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SARDET C, 1992, DEV GROWTH DIFFER, V34, P37; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SPEKSNIJDER JE, 1990, DEV BIOL, V142, P246, DOI 10.1016/0012-1606(90)90168-I; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WHITAKER M, 1993, DEVELOPMENT, V117, P1	40	289	291	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					348	352		10.1126/science.8392748	http://dx.doi.org/10.1126/science.8392748			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8392748	Green Submitted			2022-12-28	WOS:A1993LM67800035
J	VISCOLI, CM; HORWITZ, RI; SINGER, BH				VISCOLI, CM; HORWITZ, RI; SINGER, BH			BETA-BLOCKERS AFTER MYOCARDIAL-INFARCTION - INFLUENCE OF 1ST-YEAR CLINICAL COURSE ON LONG-TERM EFFECTIVENESS	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; ADRENERGIC BETA-RECEPTOR BLOCKADERS; PROPRANOLOL; ARRHYTHMIA; HEART FAILURE, CONGESTIVE	INTRINSIC SYMPATHOMIMETIC ACTIVITY; ADRENERGIC-BLOCKADE; BLOCKING-DRUGS; TRIALS; RISK	Objective: To develop a strategy for evaluating drug efficacy over time that accounts for heterogeneous clinical courses evolving after initiation of therapy and to demonstrate its use in assessing the long-term therapeutic benefit of propranolol after myocardial infarction. Design: Analysis of data from the Beta-Blocker in Heart Attack Trial (BHAT), a randomized, double-blind, placebo-controlled trial that enrolled patients from 1978 to 1980 and followed participants for vital status to April 1982. Setting: Thirty-one clinical centers in the United States and Canada. Patients: Eligible patients included 3297 men and women 30 to 69 years of age who survived 1 year after trial entry. Intervention: Patients were classified as being on treatment at 12 months after randomization if they were receiving beta-blocker therapy at the 12-month visit and off treatment if they were not receiving beta-blocker therapy at that time. Outcome Measure: Vital status evaluated at 720 days of follow-up. Results: A total of 2914 patients (88%) was classified as being at lower risk (strata I and II). For these patients, survival curves by treatment at 12 months were virtually indistinguishable. Among the 383 patients categorized as being at high risk on the basis of recurrent ischemic events, arrhythmias, congestive heart failure, or severe comorbidity during the first 12 months, the use of beta-blockers was associated with a 43% proportional decline in the subsequent risk for death (P = 0.01 by log-rank test). Conclusions: In patients who survived to 1 year with low- to moderate-risk clinical courses, beta-blocker therapy did not have long-term beneficial effect. In contrast, among patients who had a high-risk clinical course during the first year, beta-blockers significantly reduced mortality in the follow-up period.	YALE UNIV, SCH MED, ROOM 1E-61, SHM, POB 3333, NEW HAVEN, CT 06510 USA	Yale University					NHLBI NIH HHS [5-T32-HL07428] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHOBANIAN AV, 1987, AM J CARDIOL, V59, pF48, DOI 10.1016/0002-9149(87)90042-7; COOK EF, 1988, AM J EPIDEMIOL, V127, P626, DOI 10.1093/oxfordjournals.aje.a114838; DIBIANCO R, 1987, AM J CARDIOL, V59, pF38, DOI 10.1016/0002-9149(87)90040-3; DIXON WJ, 1988, BMDP STATISTICAL SOF; FEINSTEIN AR, 1990, MEDICINE, V69, P1; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FRISHMAN WH, 1989, MED CLIN N AM, V73, P409, DOI 10.1016/S0025-7125(16)30680-0; FRISHMAN WH, 1987, AM J CARDIOL, V59, pF33, DOI 10.1016/0002-9149(87)90039-7; FRISHMAN WH, 1984, NEW ENGL J MED, V310, P830; GERBER JG, 1985, ANNU REV MED, V36, P145; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GRIGGS TR, 1983, J AM COLL CARDIOL, V1, P1530, DOI 10.1016/S0735-1097(83)80059-X; Helmers C, 1973, Acta Med Scand Suppl, V555, P7; KENDALL MG, 1983, ADV THEORY STATISTIC; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MOSS AJ, 1976, CIRCULATION, V54, P58, DOI 10.1161/01.CIR.54.1.58; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SHULMAN RS, 1983, CIRCULATION, V67, P19; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1984, CONTROLLED CLIN TRIA, V5, P382; 1981, CONTROLLED CLIN TRIA, V2, P275	22	68	69	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					99	105		10.7326/0003-4819-118-2-199301150-00004	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416325				2022-12-28	WOS:A1993KF91800004
J	OATES, E; METHERALL, J				OATES, E; METHERALL, J			SARCOIDOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											OATES, E (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413436				2022-12-28	WOS:A1993MD94900006
J	GENC, M; RUUSUVAARA, L; MARDH, PA				GENC, M; RUUSUVAARA, L; MARDH, PA			AN ECONOMIC-EVALUATION OF SCREENING FOR CHLAMYDIA-TRACHOMATIS IN ADOLESCENT MALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; URINE SEDIMENT; ENZYME-IMMUNOASSAY; DECISION-ANALYSIS; URETHRITIS; INFECTIONS; GONORRHEA; MEN; DIAGNOSIS; ANTIGENS	Objective.-To assess the cost-effectiveness of identifying asymptomatic carriers of Chlamydia trachomatis among adolescent males. Design.-Cost-effectiveness analysis based on cohort analytic studies previously reported and average salaries and costs of medical care in Sweden. Setting.-Adolescent males attending a primary care center for routine health checks. Participants.-Estimates of costs and benefits are based on a cohort of 1 000 adolescent males and their female contacts. Intervention.-Screening with enzyme immunoassay (EIA), either on leukocyte esterase (LE)-positive urine samples (LE-EIA screening) or on all urine samples (EIA screening), was compared with no screening (no treatment or contact tracing). The effects of confirming positive EIA results with a blocking assay and alternative antibiotic regimens on the outcome of the screening strategies were also evaluated. Results.-Compared with no screening, the LE-EIA and EIA screening strategies reduced the overall costs when the prevalence of chlamydial infection in males exceeded 2% and 10%, respectively. Enzyme immunoassay screening achieved an overall cure rate that was 12.2% to 12.6% (95% confidence interval) better, but reduced the incremental savings by at least $2144 per cured male, in comparison with LE-EIA screening. Confirmation of positive EIA results reduced the overall cost of the LE-EIA screening strategy when the prevalence of C trachomatis among males was less than 8%. Compared with a 7-day course of doxycycline, a single oral dose of azithromycin administered under supervision in the clinic improved the cure rates of both EIA and LE-EIA screening strategies by 15.1% to 16.3% and 11.2% to 12.0%, respectively, while reducing the corresponding overall costs by 5% and 9%, respectively, regardless of the prevalence of chlamydial infection in males. Conclusion.-The use of LE-EIA screening combined with treatment of positive cases with azithromycin was the most cost-effective intervention strategy focusing on asymptomatic male carriers of C trachomatis. Positive EIA results should be confirmed when screening low-risk populations.	UNIV UPPSALA, DEPT OBSTET & GYNECOL, ADOLESCENT HLTH CARE UNIT, S-75122 UPPSALA, SWEDEN	Uppsala University	GENC, M (corresponding author), UNIV UPPSALA, CTR STD RES, BOX 552, S-75122 UPPSALA, SWEDEN.							BEGLEY CE, 1989, SEX TRANSM DIS, V16, P63, DOI 10.1097/00007435-198904000-00004; BUHAUG H, 1989, MED CARE, V27, P833, DOI 10.1097/00005650-198908000-00007; CHERNESKY M, 1990, J INFECT DIS, V161, P124; EDGARDH K, 1987, LAKARTIDNINGEN, V84, P1845; ESTANY A, 1989, SEX TRANSM DIS, V16, P21, DOI 10.1097/00007435-198901000-00005; FENG WC, 1977, JAMA-J AM MED ASSOC, V237, P896; GENC M, 1992, APMIS, V100, P645, DOI 10.1111/j.1699-0463.1992.tb03980.x; GODDEERIS JH, 1985, MED CARE, V23, P1242, DOI 10.1097/00005650-198511000-00003; HERRMANN BF, 1991, SEX TRANSM DIS, V18, P233, DOI 10.1097/00007435-199110000-00007; HILLIS SD, 1993, AM J OBSTET GYNECOL, V168, P1503, DOI 10.1016/S0002-9378(11)90790-X; JUDSON FN, 1989, J REP MED, V30, P269; KATZ BP, 1988, SEX TRANSM DIS, V15, P11, DOI 10.1097/00007435-198801000-00003; KAUFMAN RE, 1974, NEW ENGL J MED, V291, P1175, DOI 10.1056/NEJM197411282912208; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; MARDH PA, 1988, P EUROPEAN SOC CHLAM, P3; MARDH PA, 1989, CHLAMYDIA, P127; MARES I, 1992, GENITOURIN MED, V68, P344; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MOORE G, 1973, JAMA-J AM MED ASSOC, V224, P1499, DOI 10.1001/jama.224.11.1499; MUMTAZ G, 1991, INT J STD AIDS, V2, P359, DOI 10.1177/095646249100200510; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; OBRIEN SF, 1988, AM J PUBLIC HEALTH, V78, P1583, DOI 10.2105/AJPH.78.12.1583; PALMER HM, 1991, J CLIN PATHOL, V44, P321, DOI 10.1136/jcp.44.4.321; PAPPIUS EM, 1984, SEX TRANSM DIS, V11, P123, DOI 10.1097/00007435-198407000-00002; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; Rahm V A, 1992, Lakartidningen, V89, P3675; RAHM VA, 1986, J SWED MED ASS, V83, P615; RANDOLPH AG, 1990, AM J PUBLIC HEALTH, V80, P545, DOI 10.2105/AJPH.80.5.545; ROONGPISUTHIPONG A, 1988, SEX TRANSM DIS, V15, P192, DOI 10.1097/00007435-198810000-00003; SADOF MD, 1987, JAMA-J AM MED ASSOC, V258, P1932, DOI 10.1001/jama.258.14.1932; SCHACHTER J, 1986, NEW ENGL J MED, V314, P276, DOI 10.1056/NEJM198601303140503; SELLORS J, 1991, J CLIN MICROBIOL, V29, P407, DOI 10.1128/JCM.29.2.407-409.1991; SESTROM L, 1993, GENITORIN MED, V69, P9; SHAFER MA, 1989, JAMA-J AM MED ASSOC, V262, P2562, DOI 10.1001/jama.262.18.2562; STARY A, 1991, INFECTION, V19, P205, DOI 10.1007/BF01644946; THELIN I, 1982, GENITAL RELATED INFE, P163; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WASHINGTON AE, 1982, JAMA-J AM MED ASSOC, V22, pS157; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; Whatley J D, 1991, Int J STD AIDS, V2, P248; WOODS ER, 1991, J ADOLESCENT HEALTH, V12, P329, DOI 10.1016/0197-0070(91)90009-B; 1992, INCOME ALLOWANCES 19; 1990, GUIDELINES PREVENTIO, P38	44	57	57	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2057	2064		10.1001/jama.270.17.2057	http://dx.doi.org/10.1001/jama.270.17.2057			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411572				2022-12-28	WOS:A1993MD88200024
J	HANCOCK, SL; TUCKER, MA; HOPPE, RT				HANCOCK, SL; TUCKER, MA; HOPPE, RT			FACTORS AFFECTING LATE MORTALITY FROM HEART-DISEASE AFTER TREATMENT OF HODGKINS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIATION-INDUCED PERICARDITIS; MEDIASTINAL IRRADIATION; BREAST-CANCER; CONSTRICTIVE PERICARDITIS; MYOCARDIAL-INFARCTION; CARDIAC DISEASE; RADIOTHERAPY; THERAPY; COMPLICATIONS; ADJUVANT	Objective.-To assess the risk of death from heart disease after Hodgkin's disease therapy. Design.-Retrospective study comparing treated patients with a matched general population. Setting.-Referral center. Patients.-A total of 2232 consecutive Hodgkin's disease patients treated from 1960 through 1991. Follow-up averaged 9.5 years. Main Outcome Measures.-Relative risks (RRs), the ratio of the observed to the expected cases with 95% confidence intervals (CIs), chi tests for trends, and Kaplan-Meier actuarial risks. Results.-Of the 2232 patients, 88 (3.9%) died of heart disease, 55 from acute myocardial infarction and 33 from other cardiac diseases, including congestive heart failure, radiation pericarditis or pancarditis, cardiomyopathy, or valvular heart disease. The RR for cardiac death was 3.1 (CI, 2.4 to 3.7). Mediastinal radiation of 30 Gy or less (n=385 patients) did not increase risk; above 30 Gy (n=1830), RR was 3.5 (CI, 2.7 to 4.3). Blocking to limit cardiac exposure reduced the RR for other cardiac diseases from 5.3 (CI, 3.1 to 7.5) to 1.4 (CI, 0.6 to 2.9), but not acute myocardial infarction (RR, 3.7 vs 3.4). The RRs increased with duration after treatment (trend in acute myocardial infarction, P=.02; in other cardiac diseases, P=.004). The RR for acute myocardial infarction was highest after irradiation before 20 years of age and decreased with increasing age at treatment (P<.0001 for trend). Conclusions.-Mediastinal irradiation for Hodgkin's disease increases the risk of subsequent death from heart disease. Risk increased with high mediastinal doses, minimal protective cardiac blocking, young age at irradiation, and increasing duration of follow-up.	NCI, GENET EPIDEMIOL BRANCH, ROCKVILLE, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HANCOCK, SL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT RADIAT ONCOL, A089, STANFORD, CA 94305 USA.		Tucker, Margaret A/B-4297-2015		NCI NIH HHS [P0: CA-34233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNEST LS, 1983, J THORAC CARDIOV SUR, V85, P257; APPLEFELD MM, 1983, AM J CARDIOL, V51, P1679, DOI 10.1016/0002-9149(83)90209-6; BOICE JD, 1991, NIH913180 PUBL; BOIVIN JF, 1992, CANCER, V69, P1241; BOIVIN JF, 1982, CANCER-AM CANCER SOC, V49, P2470, DOI 10.1002/1097-0142(19820615)49:12<2470::AID-CNCR2820491210>3.0.CO;2-Y; BROSIUS FC, 1981, AM J MED, V70, P519, DOI 10.1016/0002-9343(81)90574-X; CAMERON J, 1987, AM HEART J, V113, P354, DOI 10.1016/0002-8703(87)90278-X; CARLSON RG, 1991, CHEST, V99, P538, DOI 10.1378/chest.99.3.538; CARMEL RJ, 1976, CANCER-AM CANCER SOC, V37, P2813, DOI 10.1002/1097-0142(197606)37:6<2813::AID-CNCR2820370637>3.0.CO;2-S; COHN KE, 1967, MEDICINE, V46, P281, DOI 10.1097/00005792-196705000-00003; COSSET JM, 1991, INT J RADIAT ONCOL, V21, P447, DOI 10.1016/0360-3016(91)90794-5; DONALDSON SS, 1990, SEMIN ONCOL, V17, P736; DONALDSON SS, 1982, CANCER TREAT REP, V66, P977; FOBAIR P, 1986, J CLIN ONCOL, V4, P805, DOI 10.1200/JCO.1986.4.5.805; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GOTTDIENER JS, 1983, NEW ENGL J MED, V308, P569, DOI 10.1056/NEJM198303103081005; GREENWOO.RD, 1974, CIRCULATION, V50, P1033, DOI 10.1161/01.CIR.50.5.1033; HANCOCK EW, 1983, NEW ENGL J MED, V308, P588, DOI 10.1056/NEJM198303103081010; HANCOCK SL, 1993, J CLIN ONCOL, V11, P1208, DOI 10.1200/JCO.1993.11.7.1208; HANCOCK SL, 1988, ANN INTERN MED, V109, P183, DOI 10.7326/0003-4819-109-3-183; HANCOCK SL, 1991, ANN INTERN MED, V114, P810, DOI 10.7326/0003-4819-114-9-810; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; HORNING SJ, 1988, J CLIN ONCOL, V6, P1822, DOI 10.1200/JCO.1988.6.12.1822; JOENSUU H, 1989, CHEST, V95, P388, DOI 10.1378/chest.95.2.388; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN HS, 1980, HODGKINS DISEASE, P366; KAPLAN HS, 1972, HODGKINS DISEASE, P279; LEDERMAN GS, 1987, CANCER-AM CANCER SOC, V60, P772, DOI 10.1002/1097-0142(19870815)60:4<772::AID-CNCR2820600411>3.0.CO;2-A; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MILL WB, 1984, INT J RADIAT ONCOL, V10, P2061, DOI 10.1016/0360-3016(84)90203-7; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MORTON DL, 1973, CHEST, V64, P291, DOI 10.1378/chest.64.3.291; POHJOLASINTONEN S, 1987, CANCER-AM CANCER SOC, V60, P31, DOI 10.1002/1097-0142(19870701)60:1<31::AID-CNCR2820600107>3.0.CO;2-D; ROSENBERG SA, 1991, ANN ONCOL, V2, P29, DOI 10.1093/annonc/2.suppl_2.29; ROSENBERG SA, 1992, EUR J CANCER, V28A, P1379, DOI 10.1016/0959-8049(92)90524-6; RUBIN E, 1963, AM J MED, V34, P71, DOI 10.1016/0002-9343(63)90039-1; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; STEWART JR, 1984, PROG CARDIOVASC DIS, V27, P173; STEWART JR, 1971, RADIOLOGY, V99, P403, DOI 10.1148/99.2.403; STEWART JR, 1967, RADIOLOGY, V89, P302, DOI 10.1148/89.2.302; STRENDER LE, 1986, CANCER, V57, P929, DOI 10.1002/1097-0142(19860301)57:5<929::AID-CNCR2820570509>3.0.CO;2-6; 1993, MMWR MORB MORTAL WKL, V42, P230; 1988, PHS8811502 US DEP HL, P12; 1989, CDC898411 US DEP HLT	44	569	588	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1949	1955		10.1001/jama.270.16.1949	http://dx.doi.org/10.1001/jama.270.16.1949			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8411552				2022-12-28	WOS:A1993MC51300026
J	SADLACK, B; MERZ, H; SCHORLE, H; SCHIMPL, A; FELLER, AC; HORAK, I				SADLACK, B; MERZ, H; SCHORLE, H; SCHIMPL, A; FELLER, AC; HORAK, I			ULCERATIVE COLITIS-LIKE DISEASE IN MICE WITH A DISRUPTED INTERLEUKIN-2 GENE	CELL			English	Article							INFLAMMATORY BOWEL-DISEASE; EMBRYONIC STEM-CELLS; GERM-LINE TRANSMISSION; T-CELLS; INTRAEPITHELIAL LYMPHOCYTES; RECOMBINANT INTERLEUKIN-2; PERIPHERAL-BLOOD; GUT EPITHELIUM; HPRT GENE; EXPRESSION	Mice deficient for interleukin-2 develop normally during the first 3-4 weeks of age. However, later on they become severely compromised, and about 50% of the animals die between 4 and 9 weeks after birth. Of the remaining mice, 100% develop an inflammatory bowel disease with striking clinical and histological similarity to ulcerative colitis in humans. The alterations of the immune system are characterized by a high number of activated T and B cells, elevated immunoglobin secretion, anti-colon antibodies, and aberrant expression of class II major histocompatibility complex molecules. The data provide evidence for a primary role of the immune system in the etiology of ulcerative colitis and strongly suggest that the disease results from an abnormal immune response to a normal antigenic stimulus.	MED UNIV LUBECK, INST PATHOL, D-23562 LUBECK, GERMANY	University of Lubeck	SADLACK, B (corresponding author), UNIV WURZBURG, INST VIROL & IMMUNOBIOL, VERSBACHER STR 7, D-97078 WURZBURG, GERMANY.		Schorle, Hubert/S-1713-2019; Schorle, Hubert/M-5001-2016; Feller, Alfred/E-3853-2010	Schorle, Hubert/0000-0001-8272-0076; 				BLAND P, 1988, IMMUNOL TODAY, V9, P174, DOI 10.1016/0167-5699(88)91293-5; BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562, DOI 10.1016/0016-5085(89)90406-X; BUDD RC, 1987, J IMMUNOL, V138, P3120; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; FUJIHASHI K, 1990, J IMMUNOL, V145, P2010; FUKUSHIMA K, 1991, GASTROENTEROLOGY, V101, P670, DOI 10.1016/0016-5085(91)90524-O; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HIBI T, 1990, GUT, V31, P1371, DOI 10.1136/gut.31.12.1371; HOANG P, 1991, CLIN EXP IMMUNOL, V85, P498; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; KAPLAN G, 1991, J EXP MED, V173, P993, DOI 10.1084/jem.173.4.993; KOBAYASHI K, 1988, J CLIN LAB IMMUNOL, V25, P63; KUSUGAMI K, 1991, GASTROENTEROLOGY, V101, P1594, DOI 10.1016/0016-5085(91)90397-4; LOWES JR, 1990, SPRINGER SEMIN IMMUN, V12, P251; MACDERMOTT RP, 1981, GASTROENTEROLOGY, V81, P844; MAYER L, 1991, GASTROENTEROLOGY, V100, P3, DOI 10.1016/0016-5085(91)90575-6; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; ROSENBERG SA, 1988, IMMUNOL TODAY, V9, P58, DOI 10.1016/0167-5699(88)91261-3; RUDZIK O, 1974, LAB INVEST, V30, P260; SARTOR RB, 1992, INFLAMM BOWEL DIS, P337; SARTOR RB, 1990, CAN J GASTROENTEROL, V4, P271; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOTT MG, 1986, CLIN EXP IMMUNOL, V66, P209; SEDGWICK JD, 1990, FOCUS LABORATORY MET, P103; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZEITZ M, 1988, GASTROENTEROLOGY, V94, P647, DOI 10.1016/0016-5085(88)90235-1; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	42	1495	1545	3	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					253	261		10.1016/0092-8674(93)80067-O	http://dx.doi.org/10.1016/0092-8674(93)80067-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402910				2022-12-28	WOS:A1993MD88500007
J	HALPERN, ME; HO, RK; WALKER, C; KIMMEL, CB				HALPERN, ME; HO, RK; WALKER, C; KIMMEL, CB			INDUCTION OF MUSCLE PIONEERS AND FLOOR PLATE IS DISTINGUISHED BY THE ZEBRAFISH NO TAIL MUTATION	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL-TUBE FORMATION; SPINAL-CORD; EXPRESSION PATTERN; MESODERM INDUCTION; BRACHYDANIO-RERIO; BRACHYURY T; NOTOCHORD; EMBRYOS; TISSUE	Dorsal mesoderm is thought to provide important signals for axis formation and neural differentiation invertebrate embryos. We have examined induction and patterning in a zebrafish mutant, no tail, that lacks a derivative of dorsal mesoderm, the notochord. Despite the absence of a differentiated notochord, development of the central nervous system including floor plate appears normal, likely owing to the presence of notochord precursor cells. In contrast, somites are misshapen, and muscle pioneer cells are absent. Wild-type cells transplanted into mutant hosts can autonomously differentiate into notochord and thereby rescue somitic defects, suggesting that interactions between notochord and paraxial mesoderm are necessary for proper somite patterning. Thus, cells derived from dorsal mesoderm may have multiple signaling functions during zebrafish embryogenesis.			HALPERN, ME (corresponding author), UNIV OREGON, INST NEUROSCI, EUGENE, OR 97403 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021132] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22486] Funding Source: Medline; NINDS NIH HHS [NS21132] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNHARDT RR, 1992, NEURON, V8, P869, DOI 10.1016/0896-6273(92)90201-N; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; Dobrovolskaia-Zavadskaia N, 1927, CR SOC BIOL, V97, P114; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; FELSENFELD AL, 1991, DEV BIOL, V148, P23, DOI 10.1016/0012-1606(91)90314-S; GERHART J, 1991, BOD MAR LAB, P57; GRIFFITH CM, 1992, ANAT EMBRYOL, V185, P101; HANNEMAN E, 1989, J COMP NEUROL, V284, P350, DOI 10.1002/cne.902840303; HATTA K, 1991, DEVELOPMENT, V112, P821; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; Ho R.K., 1992, Seminars in Developmental Biology, V3, P53; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; HUMPHREY CD, 1974, STAIN TECHNOL, V49, P9, DOI 10.3109/10520297409116929; JESSELL TM, 1992, SEMIN NEUROSCI, V4, P317; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1991, CURR TOP DEV BIOL, V25, P77; KIMMEL CB, 1991, DEVELOPMENT, P47; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1985, DEV BIOL, V108, P94, DOI 10.1016/0012-1606(85)90012-0; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; LYONS GE, 1991, DEVELOPMENT, V111, P233; OPPENHEIMER JM, 1959, J EXP ZOOL, V140, P247, DOI 10.1002/jez.1401400205; PAPALOPULU N, 1992, SEMIN NEUROSCI, V4, P295; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PIKE SH, 1992, DEVELOPMENT, V114, P825; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; RASHBASS P, 1991, NATURE, V353, P348, DOI 10.1038/353348a0; RONG PM, 1992, DEVELOPMENT, V115, P657; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SHIH J, 1992, DEVELOPMENT, V116, P915; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; Spemann H., 1938, EMBRYONIC DEV INDUCT; STREISINGER G, 1986, GENETICS, V112, P311; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; THOROGOOD P, 1987, J CELL SCI, P395; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; VANRAAMSDONK W, 1978, ANAT EMBRYOL, V153, P137; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; VANSTRAATEN HWM, 1985, ACTA MORPHOL NEER SC, V23, P91; WALKER C, 1983, GENETICS, V103, P125; WARGA RM, 1990, DEVELOPMENT, V108, P569; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YANAGISAWA KO, 1981, DEV BIOL, V87, P242, DOI 10.1016/0012-1606(81)90147-0; YOUN BW, 1981, DEV BIOL, V83, P339, DOI 10.1016/0012-1606(81)90479-6	54	466	481	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					99	111		10.1016/0092-8674(93)90682-G	http://dx.doi.org/10.1016/0092-8674(93)90682-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402905				2022-12-28	WOS:A1993MB66700011
J	BENNETT, RJ; DUNDERDALE, HJ; WEST, SC				BENNETT, RJ; DUNDERDALE, HJ; WEST, SC			RESOLUTION OF HOLLIDAY JUNCTIONS BY RUVC RESOLVASE - CLEAVAGE SPECIFICITY AND DNA DISTORTION	CELL			English	Article							ESCHERICHIA-COLI RECA; BACTERIOPHAGE-T7 ENDONUCLEASE-I; GENETIC-RECOMBINATION; SACCHAROMYCES-CEREVISIAE; CRUCIFORM DNA; IHF PROTEIN; SITE; MUTANTS; BINDING; LAMBDA	E. coli RuvC protein resolves Holliday junctions during genetic recombination and postreplication repair. Using small synthetic junctions, we show that junction recognition is structure-specific and occurs in the absence of metal cofactors. In the presence of Mg2+, Holliday junctions are resolved by the introduction of symmetrically related nicks at the 3; side of thymine residues. The nicked duplex products are repaired by the action of DNA ligase. Within the RuvC-Holliday junction complex, the DNA is distorted such that 2 of the 4 strands become hypersensitive to hydroxyl radical attack. The ionic requirements of binding, hydroxyl radical sensitivity, and strand cleavage indicate three distinct steps in the mechanism of RuvC-mediated Holliday junction resolution: structure-specific recognition, DNA distortion, and sequence-dependent cleavage.			BENNETT, RJ (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Bennett, Richard/0000-0001-7563-484X; West, Stephen/0000-0001-8848-9418				BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CHEN JW, 1992, GENE, V119, P37; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; DEMASSY B, 1984, COLD SPRING HARB SYM, V49, P715, DOI 10.1101/SQB.1984.049.01.081; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KALLENBACH NR, 1983, NATURE, V305, P829, DOI 10.1038/305829a0; KEMPER B, 1990, STRUCTURE METHODS, V1, P215; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; Lloyd RG, 1992, CURR OPIN GENET DEV, V2, P683, DOI 10.1016/S0959-437X(05)80127-3; MAHAJAN SK, 1988, GENETIC RECOMBINATIO, P87; Maxam A M, 1980, Methods Enzymol, V65, P499; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; POTTMEYER S, 1992, J MOL BIOL, V223, P607, DOI 10.1016/0022-2836(92)90977-R; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; Sambrook J, 1989, MOL CLONING LABORATO; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WEST SC, 1983, CELL, V32, P817, DOI 10.1016/0092-8674(83)90068-5; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	44	154	156	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1021	1031		10.1016/0092-8674(93)90724-5	http://dx.doi.org/10.1016/0092-8674(93)90724-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402879				2022-12-28	WOS:A1993LY49300009
J	MONTMINY, M				MONTMINY, M			TRYING ON A NEW PAIR OF SH2S	SCIENCE			English	Editorial Material							TYROSINE PHOSPHORYLATION; TRANSCRIPTION; BINDING; ACTIVATION				MONTMINY, M (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x	13	44	45	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1694	1695		10.1126/science.8397444	http://dx.doi.org/10.1126/science.8397444			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8397444				2022-12-28	WOS:A1993LY58400015
J	JAIN, JN; MCCAFFREY, PG; MINER, Z; KERPPOLA, TK; LAMBERT, JN; VERDINE, GL; CURRAN, T; RAO, A				JAIN, JN; MCCAFFREY, PG; MINER, Z; KERPPOLA, TK; LAMBERT, JN; VERDINE, GL; CURRAN, T; RAO, A			THE T-CELL TRANSCRIPTION FACTOR NFAT(P) IS A SUBSTRATE FOR CALCINEURIN AND INTERACTS WITH FOS AND JUN	NATURE			English	Article							DNA-BINDING ACTIVITY; CYCLOSPORINE-A; SIGNAL TRANSDUCTION; ACTIVATION; IDENTIFICATION; FK-506; PROTEIN; DOMAINS; ASSOCIATION; ENHANCER	TRANSCRIPTION of lymphokine genes in activated T cells is inhibited by the immunosuppressive agents cyclosporin A and FK506, which act by blocking the phosphatase activity of calcineurin1-3. NFAT, a DNA-binding protein required for interleukin-2 gene transcription, is a potential target for calcineurin, cyclosporin A and FK506(4-11). NFAT contains a subunit (NFAT(p)) which is present in unstimulated T cells and which forms a complex with Fos and Jun proteins in the nucleus of activated T cells9,11. Here we report that NFAT(p) is a DNA-binding phosphoprotein of relative molecular mass approximately 120,000 and is a substrate for calcineurin in vitro. Purified NFAT(p) forms DNA-protein complexes with recombinant Jun homodimers or Jun-Fos heterodimers; the DNA-binding domains of Fos and Jun are essential for the formation of the NFAT(p)-Fos-Jun-DNA complex. The interaction between the lymphoid-specific factor NFAT(p) and the ubiquitous transcription factors Fos and Jun provides a novel mechanism for combinatorial regulation of interleukin-2 gene transcription, which integrates the calcium-dependent and the protein-kinase C-dependent pathways of T-cell activation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Roche Holding; Harvard University			Kerppola, Tom/AFK-6155-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018; Kerppola, Tom/AAG-4457-2022	Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL JP, 1993, P NATL ACAD SCI USA, V90, P2466; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; VAIGEARCHER VE, 1990, J IMMUNOL, V145, P4355; WALSH CT, 1992, J BIOL CHEM, V267, P13115; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	28	696	707	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					352	355		10.1038/365352a0	http://dx.doi.org/10.1038/365352a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8397339				2022-12-28	WOS:A1993LY49600056
J	MCDONAGH, J; CLARKE, F; VEALE, D				MCDONAGH, J; CLARKE, F; VEALE, D			HOW TO DO IT - WRITE A DEPARTMENTAL HANDBOOK FOR JUNIOR STAFF	BRITISH MEDICAL JOURNAL			English	Article									FREEMAN RD HOSP,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital	MCDONAGH, J (corresponding author), ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			McDonagh, janet/0000-0002-4555-7270				BAKER M, 1993, BRIT MED J, V306, P808, DOI 10.1136/bmj.306.6881.808; CHAMBERLAIN DA, 1989, BRIT MED J, V299, P446, DOI 10.1136/bmj.299.6696.446; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; DUNN DC, 1988, SURGICAL DIAGNOSIS M, P83; ENNALS S, 1991, UNDERSTANDING BENEFI; GILL GV, 1989, HOSPITAL UPDATE, V15, P327; MULLEY GP, 1991, MORE EVERYDAY AIDS A; REGNARD CFB, 1986, GUIDE SYMPTOM RELIEF; 1987, PROCEDURES PRACTICE	9	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					553	555		10.1136/bmj.307.6903.553	http://dx.doi.org/10.1136/bmj.307.6903.553			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400979	Bronze, Green Published			2022-12-28	WOS:A1993LV18000027
J	SHAW, AL; ROTHNAGEL, R; CHEN, D; RAMIG, RF; CHIU, W; PRASAD, BVV				SHAW, AL; ROTHNAGEL, R; CHEN, D; RAMIG, RF; CHIU, W; PRASAD, BVV			3-DIMENSIONAL VISUALIZATION OF THE ROTAVIRUS HEMAGGLUTININ STRUCTURE	CELL			English	Article							CELL-ATTACHMENT PROTEIN; CRYOELECTRON MICROSCOPY; ELECTRON-MICROGRAPHS; RHESUS ROTAVIRUS; INFLUENZA-VIRUS; RNA SEGMENT; REOVIRUS; IDENTIFICATION; SIGMA-1; GENE	Three-dimensional structures of a native simian and reassortant rotavirus have been determined by electron cryomicroscopy and computer image processing. The structural features of the native virus confirm that the hemagglutinin spike is a dimer of VP4, substantiated by in vivo radiolabeling studies. Exchange of native VP4 with a bovine strain equivalent results in a poorly infectious reassortant. No VP4 spikes are detected in the three-dimensional reconstruction of the reassortant. The difference map between the two structures reveals a novel large globular domain of VP4 buried within the virion that interacts extensively with the intermediate shell protein, VP6. Our results suggest that assembly of VP4 precedes that of VP7, the major outer shell protein, and that VP4 may play an important role in the receptor recognition and budding process through the rough endoplasmic reticulum during virus maturation.	BAYLOR COLL MED, WM KECK CTR COMPUTAT BIOL, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Baylor College of Medicine	SHAW, AL (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA.			Prasad, B.V.Venkataram/0000-0002-1172-2071	NCRR NIH HHS [RR02250] Funding Source: Medline; NIAID NIH HHS [AI16687] Funding Source: Medline; NIGMS NIH HHS [GM41064] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016687, R22AI016687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041064] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KS, 1993, VIROLOGY, V194, P665, DOI 10.1006/viro.1993.1306; AU KS, 1988, UCLA S MOL CELL BIOL, V90, P257; BAKER TS, 1990, J VIROL, V64, P563, DOI 10.1128/JVI.64.2.563-573.1990; BASS DM, 1991, VIROLOGY, V183, P602, DOI 10.1016/0042-6822(91)90989-O; BASSELDUBY R, 1987, J VIROL, V61, P1834, DOI 10.1128/JVI.61.6.1834-1841.1987; BURNS JW, 1989, VIROLOGY, V169, P427, DOI 10.1016/0042-6822(89)90168-2; CHEN DY, 1992, J VIROL, V66, P432, DOI 10.1128/JVI.66.1.432-439.1992; CHEN DY, 1992, VIROLOGY, V186, P228, DOI 10.1016/0042-6822(92)90077-3; CHEN DY, 1989, P NATL ACAD SCI USA, V86, P3743, DOI 10.1073/pnas.86.10.3743; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ENDRES MJ, 1989, J GEN VIROL, V70, P223, DOI 10.1099/0022-1317-70-1-223; ENDRES MJ, 1991, J VIROL, V65, P5465, DOI 10.1128/JVI.65.10.5465-5470.1991; ERICKSON HP, 1971, PHILOS T ROY SOC B, V261, P105, DOI 10.1098/rstb.1971.0040; ESPEJO RT, 1981, J VIROL, V37, P156, DOI 10.1128/JVI.37.1.156-160.1981; Estes M. K., 1990, VIROLOGY, P1329; ESTES MK, 1983, CURR TOP MICROBIOL, V105, P123; ESTES MK, 1981, J VIROL, V39, P879, DOI 10.1128/JVI.39.3.879-888.1981; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; HALL CE, 1966, INTRO ELECTRON MICRO; HIRST GK, 1962, COLD SPRING HARB SYM, V27, P303, DOI 10.1101/SQB.1962.027.001.028; HOGUE BG, 1989, J GEN VIROL, V70, P345, DOI 10.1099/0022-1317-70-2-345; JENG TW, 1988, J ELECTRON MICR TECH, V8, P343, DOI 10.1002/jemt.1060080402; KALICA AR, 1983, VIROLOGY, V125, P194, DOI 10.1016/0042-6822(83)90073-9; KALJOT KT, 1988, J VIROL, V62, P1136, DOI 10.1128/JVI.62.4.1136-1144.1988; Kapikian AZ, 1990, VIROLOGY, P1353; LABBE M, 1991, J VIROL, V65, P2946; LAVER WG, 1989, VIROLOGY, V171, P291; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; LIU M, 1988, VIROLOGY, V163, P26, DOI 10.1016/0042-6822(88)90230-9; MAASS DR, 1990, J VIROL, V64, P2632, DOI 10.1128/JVI.64.6.2632-2641.1990; MATTION NM, 1991, ARCH VIROL, V120, P109, DOI 10.1007/BF01310953; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; OFFIT PA, 1986, J VIROL, V57, P46, DOI 10.1128/JVI.57.1.46-49.1986; PEREIRA HG, 1984, J GEN VIROL, V65, P815, DOI 10.1099/0022-1317-65-4-815; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PRASAD BVV, 1993, IN PRESS CURR TOPICS; RAMIG RF, 1991, ADV VIRUS RES, V39, P163; RITCHEY MB, 1976, J VIROL, V20, P307, DOI 10.1128/JVI.20.1.307-313.1976; RUGGERI FM, 1991, J VIROL, V65, P2211, DOI 10.1128/JVI.65.5.2211-2219.1991; SMITH MF, 1992, J MOL BIOL, V226, P763, DOI 10.1016/0022-2836(92)90631-S; STIRZAKER SC, 1987, J CELL BIOL, V105, P2897, DOI 10.1083/jcb.105.6.2897; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; WEINER HL, 1978, VIROLOGY, V86, P581, DOI 10.1016/0042-6822(78)90099-5; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; YEAGER M, 1990, J CELL BIOL, V110, P2133, DOI 10.1083/jcb.110.6.2133; YEUNG MC, 1987, VIROLOGY, V156, P377, DOI 10.1016/0042-6822(87)90417-X	54	111	116	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					693	701		10.1016/0092-8674(93)90516-S	http://dx.doi.org/10.1016/0092-8674(93)90516-S			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395350	Green Published, Bronze			2022-12-28	WOS:A1993LU59200012
J	SCULPTOREANU, A; SCHEUER, T; CATTERALL, WA				SCULPTOREANU, A; SCHEUER, T; CATTERALL, WA			VOLTAGE-DEPENDENT POTENTIATION OF L-TYPE CA2+ CHANNELS DUE TO PHOSPHORYLATION BY CAMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							SKELETAL-MUSCLE FIBERS; CALCIUM CHANNELS; CA-2+ CURRENT; CONTRACTION; FROG; TWITCHES; CELLS	THE force of contraction of motor units in skeletal muscle is graded by changing the discharge rate of motor neurons1, and cytosolic calcium transients are similarly increased2. During single twitches, contraction is not dependent on extracellular calcium3, and L-type Ca2+ channels may only function as voltage sensors for initiating Ca2+ release from the sarcoplasmic reticulum4-6. In contrast, forceful tetanic contractions triggered by action potentials at high frequency (20 to 200 Hz) are dependent on extracellular Ca2+ concentration and sensitive to L-type Ca2+ channel antagonists7-9, but the mechanism of regulation of contractile force is unknown. Here we report a large, voltage- and frequency-dependent potentiation of skeletal muscle L-type Ca2+ currents by trains of high-frequency depolarizing prepulses, which is caused by a shift in the voltage-dependence of channel activation to more negative membrane potentials and requires phosphorylation by cyclic AMP-dependent protein kinase in a voltage-dependent manner. This potentiation would substantially increase Ca2+ influx and contractile force in skeletal muscle fibres in response to tetanic stimuli.			SCULPTOREANU, A (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195, USA.							ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; ARTALEJO CR, 1992, NATURE, V358, P63, DOI 10.1038/358063a0; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; DULHUNTY AF, 1988, J PHYSIOL-LONDON, V399, P63; FEDIDA D, 1988, J PHYSIOL-LONDON, V405, P439, DOI 10.1113/jphysiol.1988.sp017341; FELDMEYER D, 1990, J PHYSIOL-LONDON, V425, P347, DOI 10.1113/jphysiol.1990.sp018107; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V416, P210, DOI 10.1007/BF00370245; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KERNELL D, 1983, EXP BRAIN RES, V50, P220; KOTSIAS BA, 1986, AM J PHYSIOL, V250, pC40, DOI 10.1152/ajpcell.1986.250.1.C40; LAWRENCE JC, 1981, J BIOL CHEM, V256, P6223; LEE KS, 1987, P NATL ACAD SCI USA, V84, P3941, DOI 10.1073/pnas.84.11.3941; MILEDI R, 1982, J PHYSIOL-LONDON, V333, P655, DOI 10.1113/jphysiol.1982.sp014474; OZ M, 1991, J PHARMACOL EXP THER, V257, P575; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0	21	228	231	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					240	243		10.1038/364240a0	http://dx.doi.org/10.1038/364240a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8391648				2022-12-28	WOS:A1993LM68300058
J	PFEFFER, K; MATSUYAMA, T; KUNDIG, TM; WAKEHAM, A; KISHIHARA, K; SHAHINIAN, A; WIEGMANN, K; OHASHI, PS; KRONKE, M; MAK, TW				PFEFFER, K; MATSUYAMA, T; KUNDIG, TM; WAKEHAM, A; KISHIHARA, K; SHAHINIAN, A; WIEGMANN, K; OHASHI, PS; KRONKE, M; MAK, TW			MICE DEFICIENT FOR THE 55KD TUMOR-NECROSIS-FACTOR RECEPTOR ARE RESISTANT TO ENDOTOXIC-SHOCK, YET SUCCUMB TO L-MONOCYTOGENES INFECTION	CELL			English	Article							FACTOR TNF RECEPTOR; MOLECULAR-CLONING; FACTOR-ALPHA; STEM-CELLS; T-CELLS; KAPPA-B; ANTIBACTERIAL RESISTANCE; MONOCLONAL-ANTIBODIES; INDUCED HEPATITIS; BINDING PROTEIN	The multiple biological activities of tumor necrosis factor (TNF) are mediated by two distinct cell surface receptors of 55 kd (TNFRp55) and 75 kd (TNFRp75). Using gene targeting, we generated a TNFRp55-deficient mouse strain. Cells from TNFRp55-/- mutant mice lack expression of TNFRp55 but display normal numbers of high affinity TNFRp75 molecules. Thymocyte development and lymphocyte populations are unaltered, and clonal deletion of potentially self-reactive T cells is not impaired. However, TNF signaling is largely abolished, as judged by the failure of TNF to induce NF-kappaB in T lymphocytes from TNFRp55-deficient mice. The loss of TNFRp55 function renders mice resistant to lethal dosages of either lipopolysaccharides or S. aureus enterotoxin B. In contrast, TNFRp55-deficient mice are severely impaired to clear L. monocytogenes and readily succumb to infection. Thus, the 55 kd TNFR plays a decisive role in the host's defense against microorganisms and their pathogenic factors.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; TECH UNIV MUNICH,INST MED MICROBIOL & HYG,W-8000 MUNICH 80,GERMANY	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Technical University of Munich	PFEFFER, K (corresponding author), AMGEN INST,TORONTO M4X 1K9,ON,CANADA.			Pfeffer, Klaus/0000-0002-5652-6330; Ohashi, Pamela S./0000-0003-2915-9317				ABE R, 1992, J IMMUNOL, V149, P3429; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLANCHARD DK, 1989, J LEUKOCYTE BIOL, V45, P538, DOI 10.1002/jlb.45.6.538; BLANCHARD DK, 1992, TUMOR NECROSIS FACTO, P293; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BRADLEY A, 1986, CURR TOP DEV BIOL, V20, P357, DOI 10.1016/S0070-2153(08)60675-4; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CLARK IA, 1992, TUMOR NECROSIS FACTO, P303; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; DINARELLO CA, 1992, INT J TISSUE REACT, V14, P65; DURUM SK, 1985, ANNU REV IMMUNOL, V3, P263; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIROIR BP, 1992, J CLIN INVEST, V90, P693, DOI 10.1172/JCI115939; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GOODING LR, 1992, CELL, V71, P5; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRAU GE, 1992, TUMOR NECROSIS FACTO, P329; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; GRONER B, 1980, J VIROL, V36, P734, DOI 10.1128/JVI.36.3.734-745.1980; HAUSER T, 1990, MED MICROBIOL IMMUN, V179, P95; HAVELL EA, 1989, J IMMUNOL, V143, P2894; HAVELL EA, 1987, J IMMUNOL, V139, P4225; HELLER RA, 1992, CELL, V70, P47; HEPPNER G, 1965, J BACTERIOL, V90, P696, DOI 10.1128/JB.90.3.696-703.1965; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; KATO K, 1989, MED MICROBIOL IMMUN, V178, P337; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NAKANE A, 1988, INFECT IMMUN, V56, P731; NAKANE A, 1992, TUMOR NECROSIS FACTO, P285; NAKANO Y, 1990, J IMMUNOL, V144, P1935; NAUME B, 1991, J IMMUNOL, V146, P3045; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OHSAWA T, 1989, DEV BIOL, V135, P459, DOI 10.1016/0012-1606(89)90194-2; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; ROLL JT, 1990, IMMUNOLOGY, V69, P316; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VOGEL SN, 1992, TUMOR NECROSIS FACTO, P485; WENDEL A, 1987, BIOCHEM PHARMACOL, V36, P2637, DOI 10.1016/0006-2952(87)90544-2; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	73	1541	1594	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					457	467		10.1016/0092-8674(93)90134-C	http://dx.doi.org/10.1016/0092-8674(93)90134-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387893				2022-12-28	WOS:A1993LA74300008
J	NEUGUT, AI; GARBOWSKI, GC; LEE, WC; MURRAY, T; NIEVES, JW; FORDE, KA; TREAT, MR; WAYE, JD; FENOGLIOPREISER, C				NEUGUT, AI; GARBOWSKI, GC; LEE, WC; MURRAY, T; NIEVES, JW; FORDE, KA; TREAT, MR; WAYE, JD; FENOGLIOPREISER, C			DIETARY RISK-FACTORS FOR THE INCIDENCE AND RECURRENCE OF COLORECTAL ADENOMATOUS POLYPS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						COLORECTAL NEOPLASM; POLYPS; COLONOSCOPY; FOOD HABITS; DIET	LARGE-BOWEL CANCER; RANDOMIZED TRIAL; COLON CANCER; VITAMIN-E; ENERGY-INTAKE; RECTUM; EPIDEMIOLOGY; PREVENTION; FIBER; ETIOLOGY	Objective: To investigate the association of dietary factors with the incidence and recurrence of colorectal adenomatous polyps. Design: Two case-control studies. Setting: Three university-based colonoscopy practices in New York City. Patients: For the incidence study, 286 patients with pathologically confirmed incident adenomatous polyps (162 men and 124 women) were compared with 480 controls (210 men and 270 women) with no current or previous neoplasia. For the recurrence study, 186 patients with recurrent polyps (130 men and 56 women) were compared with 330 controls (187 men and 143 women). These patients had a history of polyps but no current neoplasia. Measurements: Structured interviews using the Block food frequency questionnaire were conducted on all participants and were compared over quartiles of crude nutrient intake of total and saturated fat; fiber; protein; carbohydrates; carotene; vitamins A, C, and E; and various food groups. Data were adjusted for age, Quetelet index, and caloric intake by multiple logistic regression for men and women separately. Results: For incident polyps, elevated adjusted odds ratios (high to low quartile) for women were found for saturated fat (odds ratio, 2.3; 95% CI, 0.9 to 5.8) and the ratio of red meat to chicken and fish intake (odds ratio, 1.9; CI, 1.0 to 3.6). Protective associations were observed for fish and chicken (odds ratio, 0.6; CI, 0.3 to 1.2) and vitamin A intake (odds ratio, 0.4; CI, 0.2 to 0.9). Among women, recurrent polyps showed an association with total dietary fat (odds ratio, 4.4; CI, 1.0 to 19.5), saturated fat (odds ratio, 3.8; CI, 1.0 to 14.9; P = 0.15 for the trend), and total fiber (odds ratio, 0.2; CI, 0.1 to 0.5; P = 0.01) and a borderline association with carbohydrates (odds ratio, 0.3; CI, 0.1 to 1.3; P = 0.10). No consistent relations were observed for men, although increased caloric intake increased the risk for incidence and recurrence in both men and women. Conclusions: These findings are consistent with previously described relations between diet and the incidence of colon cancer and suggest that, at least in women, dietary modification may be warranted in patients diagnosed with polyps.	UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	University System of Ohio; University of Cincinnati; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	NEUGUT, AI (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DIV ONCOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Nieves, Jeri/0000-0001-8593-343X	NATIONAL CANCER INSTITUTE [R01CA037196, K07CA001211] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA37196, KO7-CA01211] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; CROWTHER JS, 1976, BRIT J CANCER, V34, P191, DOI 10.1038/bjc.1976.142; DALES LG, 1979, AM J EPIDEMIOL, V109, P132, DOI 10.1093/oxfordjournals.aje.a112668; DAY DW, 1984, SCAND J GASTROENTERO, V19, P99; DIXON WJ, 1985, BMDP STATISTICAL SOF; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HILL MJ, 1978, LANCET, V1, P245, DOI 10.1016/S0140-6736(78)90487-7; HILL MJ, 1974, CANCER, V34, P815, DOI 10.1002/1097-0142(197409)34:3+<815::AID-CNCR2820340705>3.0.CO;2-6; HOFF G, 1986, SCAND J GASTROENTERO, V21, P199, DOI 10.3109/00365528609034647; HOWE GR, 1986, AM J EPIDEMIOL, V124, P157, DOI 10.1093/oxfordjournals.aje.a114365; JOHNSEN CM, 1987, REV ENDOCRINE RELATE, V25, P25; Kune S, 1987, Nutr Cancer, V9, P21; KUSHI LH, 1985, NEW ENGL J MED, V313, P119; LEIGHTON J, 1988, AM J EPIDEMIOL, V128, P891; Lev R, 1990, ADENOMATOUS POLYPS C; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; LYON JL, 1987, JNCI-J NATL CANCER I, V78, P853; MACOUARTMOULIN G, 1987, INT J CANCER, V40, P179, DOI 10.1002/ijc.2910400209; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701; MCKEOWNEYSSEN G, 1991, AM J EPIDEMIOL, V134, P746; MCMICHAEL AJ, 1983, AM J EPIDEMIOL, V118, P620, DOI 10.1093/oxfordjournals.aje.a113672; MILLER AB, 1983, INT J CANCER, V32, P155, DOI 10.1002/ijc.2910320204; NEUGUT AI, 1985, CANCER, V55, P1586, DOI 10.1002/1097-0142(19850401)55:7<1586::AID-CNCR2820550729>3.0.CO;2-I; NEUGUT AI, 1991, J NATL CANCER I, V83, P359, DOI 10.1093/jnci/83.5.359; NEUGUT AI, 1988, AM J GASTROENTEROL, V83, P295; NEUGUT AI, 1988, DIS COLON RECTUM, V31, P430, DOI 10.1007/BF02552611; NEUGUT AI, 1991, FRONT GASTR RES, V18, P157; NOMURA AMY, 1985, CANCER RES, V45, P2369; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; PHILLIPS RL, 1975, CANCER RES, V35, P3513; POTTER JD, 1986, JNCI-J NATL CANCER I, V76, P557, DOI 10.1093/jnci/76.4.557; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STEMMERMANN GN, 1988, AM J CLIN NUTR, V47, P312, DOI 10.1093/ajcn/47.2.312; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; VANDERWERE SDJ, 1982, LANCET, V1, P759; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1984, NEW ENGL J MED, V310, P430, DOI 10.1056/NEJM198402163100705; WYNDER EL, 1974, CANCER, V34, P801, DOI 10.1002/1097-0142(197409)34:3+<801::AID-CNCR2820340703>3.0.CO;2-P	45	121	121	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					91	95		10.7326/0003-4819-118-2-199301150-00002	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416323				2022-12-28	WOS:A1993KF91800002
J	OSHAUGHNESSY, JA; COWAN, KH				OSHAUGHNESSY, JA; COWAN, KH			DOSE-INTENSIVE THERAPY FOR BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; ADJUVANT CHEMOTHERAPY; PROGENITOR CELLS; SOLID TUMORS; STAGE-II; PHASE-II; DOXORUBICIN; CYCLOPHOSPHAMIDE; CARBOPLATIN				OSHAUGHNESSY, JA (corresponding author), NCI,MED BRANCH,MED BREAST CANC SECT,BLDG 10,ROOM 12N226,BETHESDA,MD 20892, USA.							ABRAMS J, 1991, P AM SOC CLIN ONCOL, V10, pA3247; ANG PT, 1989, J CLIN ONCOL, V7, P1677, DOI 10.1200/JCO.1989.7.11.1677; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; ANTMAN KH, 1992, HIGH DOSE CANCER THE, P701; BASTHOLT L, 1992, P AM SOC CLIN ONCOL, V11, pA51; BRONCHUD MH, 1989, BRIT J CANCER, V60, P121, DOI 10.1038/bjc.1989.234; BUDMAN DR, 1992, P AN M AM SOC CLIN, V11, pA29; CARMOPEREIRA J, 1987, BRIT J CANCER, V56, P471, DOI 10.1038/bjc.1987.226; CARMOPEREIRA J, 1992, P AN M AM SOC CLIN, V11, pA121; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; DEMETRI G, 1992, P ASCO, V11, pA255; DEMETRI GD, 1992, P ASCO, V11, pA370; DUNPHY FR, 1992, J NATL CANCER I, V84, P128, DOI 10.1093/jnci/84.2.128; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; ELIAS AD, 1992, BLOOD, V79, P3036; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GALSKI H, 1989, MOL CELL BIOL, V9, P4357, DOI 10.1128/MCB.9.10.4357; GORDON MS, 1992, BLOOD, V80, P302; HOEKMAN K, 1991, J NATL CANCER I, V83, P1546, DOI 10.1093/jnci/83.21.1546; HRYNIUK W, 1986, J CLIN ONCOL, V4, P1162, DOI 10.1200/JCO.1986.4.8.1162; HRYNIUK W, 1984, J CLIN ONCOL, V2, P1281, DOI 10.1200/JCO.1984.2.11.1281; HUDIS C, 1992, P AN M AM SOC CLIN, V11, pA48; JONES RB, 1987, J CLIN ONCOL, V5, P172, DOI 10.1200/JCO.1987.5.2.172; LIND MJ, 1992, P AM ASSOC CANC RES, V33, pA1447; LUIKART SD, 1991, P AN M AM SOC CLIN, V10, P242; NEIDHART JA, 1991, BREAST CANCER RES S, V20, P515; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; PETERS WP, 1992, ANN ONCOL         S1, V3, P164; PETERS WP, 1990, P ASCO, V9, pA31; SAVARESE DMF, 1993, J CLIN ONCOL, V11, P1795, DOI 10.1200/JCO.1993.11.9.1795; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; STEWARD WP, 1993, J CLIN ONCOL, V11, P15, DOI 10.1200/JCO.1993.11.1.15; SUNDERLAND M, 1991, Breast Cancer Research and Treatment, V19, P158; SWAIN S, 1992, P AM ASSOC CANC RES, V33, pA1533; TANNOCK IF, 1988, J CLIN ONCOL, V6, P1377, DOI 10.1200/JCO.1988.6.9.1377; TJULANDIN S, 1992, P AN M AM SOC CLIN, V11, pA125; VENKURIN M, 1992, P AM SOC CLIN ONCOL, V11, pA36; VERFAILLIE C, 1990, J EXP MED, V172, P509, DOI 10.1084/jem.172.2.509; WATANAKE T, 1992, P AM SOC CLIN ONCOL, V11, pA178; WHEELER RH, 1982, CANCER TREAT REP, V66, P493; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824; WILSON WH, 1992, J CLIN ONCOL, V10, P1712, DOI 10.1200/JCO.1992.10.11.1712	42	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2089	2092						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411576				2022-12-28	WOS:A1993MD88200030
J	SCHRENK, F; BROMAGE, TG; BETZLER, CG; RING, U; JUWAYEYI, YM				SCHRENK, F; BROMAGE, TG; BETZLER, CG; RING, U; JUWAYEYI, YM			OLDEST HOMO AND PLIOCENE BIOGEOGRAPHY OF THE MALAWI RIFT	NATURE			English	Article								THE Malawi Rift and Pliocene palaeofaunas, which include a hominid mandible attributed to Homo rudolfensis, provide a biogeographical link between the better known Plio-Pleistocene faunal records of East and Southern Africa. The Malawi Rift is in a latitudinal position suitable for recording any hominid and faunal dispersion towards the Equator that was brought on by increased aridity of the Late Pliocene African landscape. The evidence suggests that Pliocene hominids originated in the eastern African tropical domain and dispersed to southern Africa only during more favourable ecological circumstances.	UNIV FRANKFURT,INST GEOL PALAONTOL,D-60325 FRANKFURT,GERMANY; UNIV MAINZ,INST GEOWISSENSCH,D-55099 MAINZ,GERMANY; DEPT ANTIQUITIES,LILONGWE,MALAWI; CUNY HUNTER COLL,DEPT ANTHROPOL,NEW YORK,NY 10021	Goethe University Frankfurt; Johannes Gutenberg University of Mainz; City University of New York (CUNY) System; Hunter College (CUNY)	SCHRENK, F (corresponding author), HESS LANDESMUSEUM,DEPT PALAEONTOL,FRIEDENSPL 1,D-64283 DARMSTADT,GERMANY.		Klein, Richard G/B-5910-2009; bromage, timothy/H-8621-2015	bromage, timothy/0000-0002-9843-7993; Betzler, Christian/0000-0002-5757-4553				BETZLER C, IN PRESS J HUM EVOL; BONNEFILLE R, 1976, EARLIEST MAN ENV LAK, P421; Bromage T. G., 1987, J HUM EVOL, V15, P497; BROMAGE TG, IN PRESS J HUM EVOL; Brown F.H., 1988, P325; BROWN FH, 1976, EARLIEST MAN ENV LAK, P50; CLARK JD, 1966, AM ANTHROPOL, V68, P46; Clark JD, 1970, QUATERNARIA, V13, P305; CROSSLEY R, 1980, ACCAD NAZ LINCEI, V47, P77; Delson E., 1984, Courier Forschungsinstitut Senckenberg, V69, P199; DIXEY FQ, 1927, J GEOL SOC LONDON, V83, P432; EBINGER CJ, 1989, GEOL SOC AM BULL, V101, P885, DOI 10.1130/0016-7606(1989)101<0885:TDOTWB>2.3.CO;2; HARRIS J, 1991, KOOBI FORA RES PROJE, V3, P215; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; KAUFULU Z, 1981, Annals of the Transvaal Museum, V33, P1; RING U, IN PRESS J HUM EVOL; SCHRENK F, IN PRESS J HUM EVOL; STRECKER MR, 1990, GEOLOGY, V18, P299, DOI 10.1130/0091-7613(1990)018<0299:ROEDIT>2.3.CO;2; TURNER A, 1993, J HUM EVOL, V24, P147, DOI 10.1006/jhev.1993.1011; Vrba E.S., 1988, P405; VRBA ES, 1985, S AFR J SCI, V81, P224; VRBA ES, 1992, J MAMMAL, V73, P1, DOI 10.2307/1381862; VRBA ES, 1982, PRETIRAGE; WOOD B, 1992, NATURE, V355, P678, DOI 10.1038/355678a0; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B., 1991, HOMINID CRANIAL REMA, V4	26	106	108	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					833	836		10.1038/365833a0	http://dx.doi.org/10.1038/365833a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413666				2022-12-28	WOS:A1993MD95100048
J	YOU, GF; SMITH, CP; KANAI, Y; LEE, WS; STELZNER, M; HEDIGER, MA				YOU, GF; SMITH, CP; KANAI, Y; LEE, WS; STELZNER, M; HEDIGER, MA			CLONING AND CHARACTERIZATION OF THE VASOPRESSIN-REGULATED UREA TRANSPORTER	NATURE			English	Article								UREA is the principal end product of nitrogen metabolism in mammals1. Movement of urea across cell membranes was originally thought to occur by lipid-phase permeation, but recent studies have revealed the existence of specialized transporters with a low affinity for urea (K(m) > 200 mM)2. Here we report the isolation of a complementary DNA from rabbit renal medulla that encodes a 397-amino-acid membrane glycoprotein, UT2, with the functional characteristics of the vasopressin-sensitive urea transporter previously described in in vitro-perfused inner medullary collecting ducts3,4. UT2 is not homologous to any known protein and displays a unique pattern of hydrophobicity. Because of the central role of this transporter in fluid balance1,3-7 and nitrogen metabolism8, the study of this protein will provide important insights into the urinary concentrating mechanism and nitrogen balance.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X				BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; CHOU CL, 1989, AM J PHYSIOL, V257, pF359, DOI 10.1152/ajprenal.1989.257.3.F359; CHOU CL, 1990, AM J PHYSIOL, V258, pF486, DOI 10.1152/ajprenal.1990.258.3.F486; EFFROS RM, 1992, AM J PHYSIOL, V263, pL619, DOI 10.1152/ajplung.1992.263.6.L619; EFFROS RM, 1992, FASEB J, V6, pA2073; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; IMAI M, 1984, PFLUG ARCH EUR J PHY, V402, P385, DOI 10.1007/BF00583939; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KAWAMURA S, 1976, J CLIN INVEST, V58, P604, DOI 10.1172/JCI108507; KNEPPER MA, 1990, AM J PHYSIOL, V259, pF393, DOI 10.1152/ajprenal.1990.259.3.F393; KNEPPER MA, 1989, AM J PHYSIOL, V256, pF610, DOI 10.1152/ajprenal.1989.256.4.F610; KNEPPER MA, 1987, KIDNEY INT, V31, P629, DOI 10.1038/ki.1987.44; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGRAN M, 1992, CLIN SCI, V82, P191, DOI 10.1042/cs0820191; MARSH DJ, 1992, HDB PHYSL 8, V2, P1317; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PALLONE TL, IN PRESS J CLIN INVE; SANDS JM, 1990, KIDNEY INT, V38, P695, DOI 10.1038/ki.1990.261; SANDS JM, 1987, J CLIN INVEST, V79, P138, DOI 10.1172/JCI112774; SANDS JM, 1987, AM J PHYSIOL, V253, pF823, DOI 10.1152/ajprenal.1987.253.5.F823; SANDS JM, 1988, VASOPRESSIN CELLULAR, P137; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; TOON MR, 1988, BIOCHIM BIOPHYS ACTA, V940, P266, DOI 10.1016/0005-2736(88)90201-5; UEZONO Y, 1991, RECEPT CHANNELS, V1, P233; ZHANG R, 1990, J MEMBRANE BIOL, V117, P253, DOI 10.1007/BF01868455	33	274	281	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					844	847		10.1038/365844a0	http://dx.doi.org/10.1038/365844a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413669				2022-12-28	WOS:A1993MD95100052
J	CARROLL, JD; FELDMAN, T				CARROLL, JD; FELDMAN, T			PERCUTANEOUS MITRAL BALLOON VALVOTOMY AND THE NEW DEMOGRAPHICS OF MITRAL-STENOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RHEUMATIC-FEVER; FOLLOW-UP; CLOSED COMMISSUROTOMY; RANDOMIZED TRIAL; VALVE DEFORMITY; HEART-DISEASE; INOUE BALLOON; SHORT-TERM; VALVULOPLASTY; CATHETER	Objective.-This review discusses the latest developments in selected clinical features and catheter-based therapy of mitral stenosis. Data Sources.-English-language journal articles and reviews in the clinical and epidemiological literature as related to mitral valve stenosis from 1965 through March 1993, identified by bibliography review and expert consultation. Study Selection.-Selected studies included clinical trials with adequate patient population description and short- and long-term (5 years) follow-up for topics related to mitral valve stenosis in the clinical literature. Data Extraction.-Two reviewers participated in extracting the data with the aim of presenting a balanced and comprehensive review of the subject. Date Synthesis and Conclusions.-The main conclusions are (1) mitral stenosis should no longer be viewed as a largely ''geriatric disease'' in the United States due to a recent inflow many young immigrants from countries where rheumatic fever continues partially or wholly unabated; (2) clinical and anatomical features of mitral stenosis are age-dependent; when clinical presentation occurs at 30 vs 70 years of age, for example, the degree of valve obstruction may be similar but differences exist in the frequency of atrial fibrillation, the magnitude of reduction in cardiac output, the degree of valve deformity and calcification, and the frequency of coexistent coronary artery disease; and (3) mitral stenosis therapy has undergone a reorientation with the introduction of percutaneous mitral balloon valvotomy, which has proven to be safe, cost-effective, and to provide short- and long-term improvements in symptomatic and hemodynamic status in selected patients.			CARROLL, JD (corresponding author), UNIV CHICAGO HOSP & CLIN,CARDIOL SECT,HANS HECHT HEMODYNAM LAB,5841 S MARYLAND AVE,MC 5076,CHICAGO,IL 60637, USA.							ABBO K, 1992, CLIN RES, V40, pA682; AGARWAL BL, 1981, LANCET, V2, P910; ALKASAB S, 1986, AM J CARDIOL, V63, P135; ALZAIBAG M, 1986, LANCET, V1, P757; [Anonymous], 1965, CIRCULATION, V32, P457; ATTUBATO MJ, 1990, CATHETER CARDIO DIAG, V20, P202, DOI 10.1002/ccd.1810200312; BABIC UU, 1986, AM J CARDIOL, V57, P1101, DOI 10.1016/0002-9149(86)90682-X; BASHORE TM, 1991, J AM COLL CARDIOL, V17, P1188, DOI 10.1016/0735-1097(91)90853-2; BERNARD Y, 1991, EUR HEART J, V12, P90, DOI 10.1093/eurheartj/12.suppl_B.90; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1007; CASALE PN, 1989, CLEV CLIN J MED, V56, P597, DOI 10.3949/ccjm.56.6.597; CHEN CR, 1990, AM HEART J, V120, P561, DOI 10.1016/0002-8703(90)90011-L; CHEN TZ, 1992, J AM COLL CARDIOL, V19, pA143; COHEN DJ, 1992, NEW ENGL J MED, V327, P1329, DOI 10.1056/NEJM199211053271901; DODU SRA, 1989, WORLD HEALTH FORUM, V203, P212; ESSOP MR, 1991, CIRCULATION, V84, P1669, DOI 10.1161/01.CIR.84.4.1669; ESTEVES CA, 1991, AM J CARDIOL, V68, P930, DOI 10.1016/0002-9149(91)90411-D; FATKIN D, 1993, J AM COLL CARDIOL, V21, P390, DOI 10.1016/0735-1097(93)90680-Y; FELDMAN T, 1993, CATHETER CARDIO DIAG, V28, P199, DOI 10.1002/ccd.1810280302; FELDMAN T, 1991, AM HEART J, V121, P1628, DOI 10.1016/0002-8703(91)90005-3; FELDMAN T, 1992, CIRCULATION, V85, P180, DOI 10.1161/01.CIR.85.1.180; FELDMAN T, 1992, PRINCIPLES CRITICAL, P343; GANGBAR EW, 1992, CATHETER CARDIO DIAG, V25, P313, DOI 10.1002/ccd.1810250412; HOMER C, 1991, J RHEUMATOL, V18, P2; HUNG JS, 1991, AM J CARDIOL, V67, P854, DOI 10.1016/0002-9149(91)90619-V; HUNG JS, 1989, AM J CARDIOL, V64, P126; INOUE K, 1993, CATHETER CARDIO DIAG, V28, P119, DOI 10.1002/ccd.1810280206; INOUE K, 1984, J THORAC CARDIOV SUR, V87, P394; INOUE K, 1992, PERCUTANEOUS BALLOON, P237; JOHN S, 1983, CIRCULATION, V68, P891, DOI 10.1161/01.CIR.68.5.891; KAWANISHI DT, 1992, J AM COLL CARDIOL, V19, P192, DOI 10.1016/0735-1097(92)90072-U; KHURI SF, 1988, J AM COLL CARDIOL, V12, P8, DOI 10.1016/0735-1097(88)90349-X; Kronzon I, 1989, J Am Soc Echocardiogr, V2, P380; LEVINE MJ, 1989, CIRCULATION, V79, P1061, DOI 10.1161/01.CIR.79.5.1061; LOCK JE, 1985, NEW ENGL J MED, V313, P1515, DOI 10.1056/NEJM198512123132405; MATTINA CJ, 1986, AM J CARDIOL, V57, P802, DOI 10.1016/0002-9149(86)90617-X; MCKAY CR, 1987, JAMA-J AM MED ASSOC, V257, P1753, DOI 10.1001/jama.257.13.1753; MCKAY RG, 1986, J AM COLL CARDIOL, V7, P1410, DOI 10.1016/S0735-1097(86)80164-4; MEDINA A, 1990, AM HEART J, V120, P568, DOI 10.1016/0002-8703(90)90012-M; NOBUYOSHI M, 1989, CIRCULATION, V80, P782, DOI 10.1161/01.CIR.80.4.782; ODIO A, 1986, WESTERN J MED, V144, P179; PALACIOS I, 1987, CIRCULATION, V75, P778, DOI 10.1161/01.CIR.75.4.778; PALACIOS IF, 1986, J AM COLL CARDIOL, V7, P1416, DOI 10.1016/S0735-1097(86)80165-6; PALACIOS IF, 1989, CIRCULATION, V79, P573, DOI 10.1161/01.CIR.79.3.573; PARK SJ, 1991, J AM COLL CARDIOL, V17, pA340; PATEL JJ, 1991, J AM COLL CARDIOL, V18, P1318, DOI 10.1016/0735-1097(91)90555-N; RIBEIRO P A, 1992, Journal of the American College of Cardiology, V19, p143A; RUIZ CE, 1990, AM J CARDIOL, V65, P473, DOI 10.1016/0002-9149(90)90813-G; SHERRID M, 1991, AM J MED, V90, P189; Stollerman G H, 1990, Adv Intern Med, V35, P1; STOLLERMAN GH, 1992, HEART DIS TXB CARDIO, P1721; STRASSER T, 1981, B WORLD HEALTH ORGAN, V59, P285; TURI ZG, 1991, CIRCULATION, V83, P1179, DOI 10.1161/01.CIR.83.4.1179; TUZCU EM, 1992, CIRCULATION, V85, P963, DOI 10.1161/01.CIR.85.3.963; VAHANIAN A, 1989, AM J CARDIOL, V63, P847, DOI 10.1016/0002-9149(89)90055-6; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WALLER BF, 1986, CARDIOVASCULAR CLIN, P3; YOSHIDA K, 1989, CIRCULATION, V80, P1521, DOI 10.1161/01.CIR.80.6.1521; ZABRISKIE JB, 1985, CIRCULATION, V71, P1077, DOI 10.1161/01.CIR.71.6.1077; 1988, WHO TECHNICAL REPORT, V764; 1987, MMWR MORB MORTAL WKL, V36, P108; 1988, MMWR MORB MORTAL WKL, V34, P519; 1991, STATISTICAL YB IMMIG; 1990, WHO CHRON, V34, P336; 1992, CIRCULATION, V85, P2014; 1992, CIRCULATION, V85, P448; 1988, MMWR MORB MORTAL WKL, V37, P101	67	68	72	2	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1731	1736		10.1001/jama.270.14.1731	http://dx.doi.org/10.1001/jama.270.14.1731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411505				2022-12-28	WOS:A1993MA29400031
J	LIU, JP; BAKER, J; PERKINS, AS; ROBERTSON, EJ; EFSTRATIADIS, A				LIU, JP; BAKER, J; PERKINS, AS; ROBERTSON, EJ; EFSTRATIADIS, A			MICE CARRYING NULL MUTATIONS OF THE GENES ENCODING INSULIN-LIKE GROWTH FACTOR-I (IGF-1) AND TYPE-1 IGF RECEPTOR (IGF1R)	CELL			English	Article							HUMAN-FIBROBLASTS; CELLULAR-PATTERN; BINDING-PROTEIN; MESSENGER-RNA; DNA-SYNTHESIS; EXPRESSION; HORMONE; CELLS; PROTOONCOGENE; DETERMINANTS	Newborn mice homozygous for a targeted disruption of insulin-like growth factor gene 1 (Igf-1) exhibit a growth deficiency similar in severity to that previously observed in viable Igf-2 null mutants (60% of normal birthweight). Depending on genetic background, some of the Igf-1(-/-) dwarfs die shortly after birth, while others survive and reach adulthood. In contrast, null mutants for the Igf1r gene die invariably at birth of respiratory failure and exhibit a more severe growth deficiency (45% normal size). In addition to generalized organ hypoplasia in Igf1r(-/-) embryos, including the muscles, and developmental delays in ossification, deviations from normalcy were observed in the central nervous system and epidermis. Igf-1(-/-)/Igf1r(-/-) double mutants did not differ in phenotype from Igf1r(-/-) single mutants, while in Igf-2(-)/Igf1r(-/-) and Igf-1(-/-)/Igf-2(-) double mutants, which are phenotypically identical, the dwarfism was further exacerbated (30% normal size). The roles of the IGFs in mouse embryonic development, as revealed from the phenotypic differences between these mutants, are discussed.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA	Yale University	LIU, JP (corresponding author), COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; [Anonymous], 1991, INSULIN LIKE GROWTH; AYERLELIEVRE C, 1991, DEVELOPMENT, V111, P105; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P131; CONOVER CA, 1986, BIOCHEM BIOPH RES CO, V139, P501, DOI 10.1016/S0006-291X(86)80019-5; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAUGHADAY WH, 1989, PERSPECT BIOL MED, V32, P194; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FURLANETTO RW, 1987, J CLIN ENDOCR METAB, V64, P1142, DOI 10.1210/jcem-64-6-1142; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HAN VKM, 1992, INSULIN LIKE GROWTH, P178; HILLYARD AL, 1993, MOUSE GENOME, V91, P25; HOGAN B, 1986, MANIPULATING MOUSE E; ISAKSSON OGP, 1991, PEDIATR NEPHROL, V5, P451, DOI 10.1007/BF01453680; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KRANE JF, 1991, J INVEST DERMATOL, V96, P419, DOI 10.1111/1523-1747.ep12469799; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEROITH D, 1991, INSULIN LIKE GROWTH; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; MOXHAM C, 1992, INSULIN LIKE GROWTH, P80; NEELY EK, 1991, ACTA PAEDIATR SCAND, P116; NISHIMOTO I, 1991, MODERN CONCEPTS INSU, P517; NISSLEY P, 1991, INSULIN LIKE GROWTH, P111; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OEMAR BS, 1991, J BIOL CHEM, V266, P2369; OKA Y, 1985, J BIOL CHEM, V260, P9435; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEVENS LEROY C., 1958, JOUR HEREDITY, V49, P153; STRECK RD, 1992, DEV BIOL, V151, P586, DOI 10.1016/0012-1606(92)90196-N; STRECK RD, 1992, ENDOCRINOLOGY, V131, P2030, DOI 10.1210/en.131.4.2030; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	58	2391	2452	0	90	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					59	72		10.1016/0092-8674(93)90679-K	http://dx.doi.org/10.1016/0092-8674(93)90679-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402901				2022-12-28	WOS:A1993MB66700008
J	CHAN, A; ROBERTSON, EF; HAAN, EA; KEANE, RJ; RANIERI, E; CARNEY, A				CHAN, A; ROBERTSON, EF; HAAN, EA; KEANE, RJ; RANIERI, E; CARNEY, A			PREVALENCE OF NEURAL-TUBE DEFECTS IN SOUTH-AUSTRALIA, 1966-91 - EFFECTIVENESS AND IMPACT OF PRENATAL-DIAGNOSIS	BRITISH MEDICAL JOURNAL			English	Article							ETIOLOGIC HETEROGENEITY; SPINA-BIFIDA	Objective-To determine trends in total prevalence of neural tube defects in South Australia during 1966-91, the impact of prenatal diagnosis on birth prevalence, and the effectiveness of prenatal screening for neural tube defects in 1986-91. Design-All births and terminations of pregnancy affected by neural tube defects and information on prenatal screening were ascertained from multiple sources including the South Australian perinatal and abortion statistics collections, birth defects register, and state maternal serum a fetoprotein screening programme. Setting-Southern Australia. Subjects-All 1058 births and terminations of pregnancy affected by neural tube defects in 1966-91. Main outcome measures-Total prevalence and birth prevalence of individual and all neural tube defects. The proportion of screened cases detected prenatally. Results-Total prevalence of neural tube defects during 1966-91 was 2.01/1000 births with no upward or downward trend. However, birth prevalence fell significantly (by 5.1% a year), with an 84% reduction from 2.29/1000 births in 1966 to 0.35/1000 in 1991 (relative risk=0.16, 95% confidence interval 0.07 to 0.34). The fall was 96% for anencephaly and 82% for spina bifida. 85% of defects, both open and closed, were detected before 28 weeks' gestation in women screened by serum alpha fetoprotein or mid-trimester ultrasonography, or both, in 1986-91 (99.0% for anencephaly and 75.7% for spina bifida). Conclusions-While the total prevalence of neural tube defects in South Australia remained stable, prenatal diagnosis and termination of pregnancy resulted in an 84% fall in birth prevalence during 1966-91. Screening detected over four fifths of cases in 1986-91.	ADELAIDE CHILDRENS HOSP INC,CTR MED GENET,DEPT CHEM PATHOL,SCREENING PROGRAMM,ADELAIDE,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,CTR MED GENET,DEPT MED GENET,S AUSTRALIAN BIRTH DEFECTS REGISTER,ADELAIDE,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT NEUROSURG,ADELAIDE,AUSTRALIA		CHAN, A (corresponding author), S AUSTRALIAN HLTH COMMISS,EPIDEMIOL BRANCH,PREGNANCY OUTCOME UNIT,POB 6,RUNDLE MALL,ADELAIDE,SA 5000,AUSTRALIA.							BOWER C, 1993, MED J AUSTRALIA, V158, P152, DOI 10.5694/j.1326-5377.1993.tb121690.x; BOWER C, 1984, J EPIDEMIOL COMMUN H, V38, P208, DOI 10.1136/jech.38.3.208; CREASY MR, 1976, J MED GENET, V13, P9, DOI 10.1136/jmg.13.1.9; CUCKLE H, 1987, PRENATAL DIAG, V7, P91, DOI 10.1002/pd.1970070205; CZEIZEL A, 1983, BRIT MED J, V287, P429, DOI 10.1136/bmj.287.6389.429; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Dean A. G., 1990, EPI INFO VERSION 5 W; FERGUSONSMITH MA, 1983, BRIT MED BULL, V39, P365, DOI 10.1093/oxfordjournals.bmb.a071849; GEBSKI V, 1992, STATISTICAL PACKAGE; HOLMES LB, 1976, NEW ENGL J MED, V294, P365, DOI 10.1056/NEJM197602122940704; KALLEN B, 1984, J EPIDEMIOL COMMUN H, V38, P103, DOI 10.1136/jech.38.2.103; KHOURY MJ, 1982, AM J EPIDEMIOL, V115, P538, DOI 10.1093/oxfordjournals.aje.a113335; KIRKE PN, 1984, BRIT MED J, V289, P1621, DOI 10.1136/bmj.289.6458.1621; OWENS JR, 1981, LANCET, V2, P1032; ROMIJN JA, 1983, LANCET, V1, P64; STEIN SC, 1982, PEDIATRICS, V69, P511; 1991, J EPIDEMIOL COMMUNIT, V45, P52; 1991, LANCET, V338, P131; 1992, MMWR, V41, P497; 1988, INT CLEARINGHOUSE BI	20	69	74	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					703	706		10.1136/bmj.307.6906.703	http://dx.doi.org/10.1136/bmj.307.6906.703			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401091	Green Published, Bronze			2022-12-28	WOS:A1993LY29200015
J	VANOS, J; GALDOS, P; LEWIS, G; BOURGEOIS, M; MANN, A				VANOS, J; GALDOS, P; LEWIS, G; BOURGEOIS, M; MANN, A			SCHIZOPHRENIA SANS-FRONTIERES - CONCEPTS OF SCHIZOPHRENIA AMONG FRENCH AND BRITISH PSYCHIATRISTS	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS	Objective-To compare the first admission rates for schizophrenia in England and France, and to compare the concept of schizophrenia held by practising British and French psychiatrists. Design-Comparative study of incidence rates in England and France; and postal questionnaire survey of a sample of about 1 in 30 psychiatrists in the United Kingdom and in l'Aquitaine, France. Subjects-All first admissions for schizophrenia to psychiatric hospitals in England and France 1973-82; 92 psychiatrists in the United Kingdom and 69 in France. Main outcome measures-Age adjusted first admission rates for schizophrenia between 1973-82; and opinions on the aetiology, diagnosis, and management of schizophrenia. Results-First admission rates were much higher in France than in England before the age of 45, but lower after that age. Rates were falling in England over the 10 year period, while they were rising in France. In the questionnaire study English and French psychiatrists showed prominent differences of opinion for 31 out of 38 statements. The French sample did not diagnose schizophrenia after the age of 45 and endorsed psychoanalytical concepts. Conclusions-British and French psychiatrists use different diagnostic criteria and contrasting methods of treatment for schizophrenia. Differences in diagnostic criteria probably contribute towards the disparity in administrative incidence rates and time trends for schizophrenia in the two countries. Doctors in the European Community can now work in any country. Further work is needed to ensure psychiatrists are talking a common language.	INST PSYCHIAT,DEPT EPIDEMIOL & GEN PRACTICE,LONDON SE5 8AF,ENGLAND; CHU BORDEAUX,CTR CARREIRE,F-33076 BORDEAUX,FRANCE	University of London; King's College London; CHU Bordeaux	VANOS, J (corresponding author), INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND.		van Os, Jim/V-8884-2019; van Os, Jim/I-9496-2012; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; Lewis, Glyn/E-9944-2012	van Os, Jim/0000-0002-7245-1586; van Os, Jim/0000-0002-7245-1586; Lewis, Glyn/0000-0001-5205-8245				Bleuler E., 1950, DEMENTIA PRAECOX; Cooper J.E., 1972, MAUDSLEY MONOGRAPH, V20; CROW TJ, 1990, LANCET, V335, P851, DOI 10.1016/0140-6736(90)90963-6; DENIKER P, 1983, DISCOVERIES PHARM, P163; DER G, 1990, LANCET, V335, P513, DOI 10.1016/0140-6736(90)90745-Q; GRAHAM PM, 1990, LANCET, V335, P852; HAFNER H, 1991, EUR ARCH PSY NEUR SC, V240, P373; JOHNSONSABINE EC, 1983, PSYCHOL MED, V13, P771, DOI 10.1017/S0033291700051473; KELLAM AMP, 1989, BRIT J PSYCHIAT, V155, P153, DOI 10.1192/bjp.155.2.153; KENDELL R, 1987, COMPANION PSYCHIATRI, P362; KENDELL RE, 1974, PSYCHOL MED, V4, P187, DOI 10.1017/S0033291700042021; LEMPERIERE T, 1983, PSYCHIATRIE ADULTE; PICHOT P, 1982, PSYCHOL MED, V12, P475, DOI 10.1017/S0033291700055586; PULL M C, 1987, Encephale, V13, P53; STOTER G, 1987, INT J ANDROL, V10, P407, DOI 10.1111/j.1365-2605.1987.tb00211.x; Turkle Sherry, 1992, PSYCHOANALYTIC POLIT; WESSELY S, 1990, BRIT MED J, V301, P362, DOI 10.1136/bmj.301.6748.362; 1969, B I NATIONAL SANTE R, V24, P3; 1990, SPSS PCPLUS STATISTI; 1992, MONDE           0626, P26; 1985, MENTAL HLTH SERVICES	21	33	34	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					489	492		10.1136/bmj.307.6902.489	http://dx.doi.org/10.1136/bmj.307.6902.489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU590	8400939	Green Published, Bronze			2022-12-28	WOS:A1993LU59000030
J	KUPITZ, Y; ATLAS, D				KUPITZ, Y; ATLAS, D			A PUTATIVE ATP-ACTIVATED NA+ CHANNEL INVOLVED IN SPERM-INDUCED FERTILIZATION	SCIENCE			English	Article							ADENOSINE-TRIPHOSPHATE; URECHIS-CAUPO; SMOOTH-MUSCLE; MARINE WORM; SEA-URCHIN; CELLS; EGGS; POLYSPERMY; MECHANISMS; RESPONSES	Extracellular application of adenosine triphosphate (ATP) to defolliculated Xenopus laevis oocytes activated a saturating inward current with a maximal amplitude E(max) of 2.4 +/- 0.2 microamperes and an apparent Michaelis constant of 197.6 micromolar. The current was carried predominantly by sodium ions and potently inhibited by amiloride, guanosine triphosphate (GTP), and its nonhydrolyzable analogs guanosine 5'-[beta,gamma-imido]triphosphate (GppNHp) and guanosine 5'-O-(3-thiotriphosphate). Likewise, in vitro fertilization using mature eggs and Xenopus sperm was inhibited by amiloride, GTP, and GppNHp. Hence, an ATP receptor on the egg membrane may be the recipient target for ATP originating in sperm, suggesting that an ATP-induced increase in sodium permeability mediates the initial sperm to egg signal in the fertilization process.	HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, J PHYSIOL-LONDON, V387, P473, DOI 10.1113/jphysiol.1987.sp016585; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EPEL D, 1990, CELL DIFFER DEV, V29, P1, DOI 10.1016/0922-3371(90)90019-S; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIEL DD, 1988, J GEN PHYSIOL, V91, P1, DOI 10.1085/jgp.91.1.1; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GOULD M, 1987, SCIENCE, V235, P1654, DOI 10.1126/science.3823908; GOULDSOMERO M, 1979, J CELL BIOL, V82, P426, DOI 10.1083/jcb.82.2.426; HAGIWARA S, 1979, ANNU REV BIOPHYS BIO, V8, P385, DOI 10.1146/annurev.bb.08.060179.002125; HUME RI, 1986, J NEUROSCI, V6, P681; JAFFE LA, 1979, J GEN PHYSIOL, V73, P469, DOI 10.1085/jgp.73.4.469; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LONGO FJ, 1986, DEV BIOL, V118, P155, DOI 10.1016/0012-1606(86)90083-7; LOTAN I, 1986, PFLUG ARCH EUR J PHY, V406, P158, DOI 10.1007/BF00586677; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; NEUHAUS R, 1991, J NEUROSCI, V11, P3984; NIEWKOOP PD, 1956, NORMAL TABLE XENOPUS, P244; SCHUEL H, 1981, DEV BIOL, V87, P249, DOI 10.1016/0012-1606(81)90148-2; SELA D, 1991, J BIOL CHEM, V266, P17990; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNEDDON P, 1982, SCIENCE, V218, P693, DOI 10.1126/science.6291151	27	39	39	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					484	486		10.1126/science.8392753	http://dx.doi.org/10.1126/science.8392753			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392753				2022-12-28	WOS:A1993LN62300040
J	CHENG, TC; WALLACE, MC; MERLIE, JP; OLSON, EN				CHENG, TC; WALLACE, MC; MERLIE, JP; OLSON, EN			SEPARABLE REGULATORY ELEMENTS GOVERNING MYOGENIN TRANSCRIPTION IN MOUSE EMBRYOGENESIS	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; GENE-PRODUCTS; MUSCLE; EXPRESSION; PROTEINS; MYOD1; FAMILY; SOMITE; REGION; CELLS	Expression of the myogenic helix-loop-helix (HLH) protein myogenin in muscle cell precursors within somites and limb buds is among the earliest events associated with myogenic lineage determination in vertebrates. Mutations in the myogenin promoter that abolish binding sites for myogenic HLH proteins or myocyte enhancer factor-2 (MEF-2) suppressed transcription of a linked lacZ transgene in subsets of myogenic precursors in mouse embryos. These results suggest that myogenic HLH proteins and MEF-2 participate i n separable regulatory circuits leading to myogenin transcription and provide evidence for positional regulation of myogenic regulators in the embryo.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)								BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG T, UNPUB; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDMONDSON DG, UNPUB; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOGAN B, 1986, MANIPULATING MOUSE E; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THEILER K, 1989, HOUSE MOUSE; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WH, COMMUNICATION; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	33	242	242	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					215	218		10.1126/science.8392225	http://dx.doi.org/10.1126/science.8392225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8392225				2022-12-28	WOS:A1993LL59600042
J	FREY, U; HUANG, YY; KANDEL, ER				FREY, U; HUANG, YY; KANDEL, ER			EFFECTS OF CAMP SIMULATE A LATE-STAGE OF LTP IN HIPPOCAMPAL CA1 NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; REGION INVITRO; DENTATE GYRUS; LATE PHASE; BLOCKS; ANISOMYCIN; RATS; MAINTENANCE; ANTAGONISTS	Hippocampal long-term potentiation (LTP) is thought to serve as an elementary mechanism for the establishment of certain forms of explicit memory in the mammalian brain. As is the case with behavioral memory, LTP in the CA1 region has stages: a short-term early potentiation lasting 1 to 3 hours, which is independent of protein synthesis, precedes a later, longer lasting stage (L-LTP), which requires protein synthesis. Inhibitors of cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) blocked L-LTP, and analogs of cAMP induced a potentiation that blocked naturally induced L-LTP. The action of the cAMP analog was blocked by inhibitors of protein synthesis. Thus, activation of PKA may be a component of the mechanism that generates L-LTP.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM32099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERI A, 1991, BRAIN RES, V546, P69, DOI 10.1016/0006-8993(91)91160-3; BAULAC M, 1986, REV NEUROL-FRANCE, V142, P895; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; ELIOT LS, 1989, P NATL ACAD SCI USA, V86, P9564, DOI 10.1073/pnas.86.23.9564; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1991, NEUROSCI LETT, V129, P111, DOI 10.1016/0304-3940(91)90732-9; FREY U, 1990, BRAIN RES, V522, P69, DOI 10.1016/0006-8993(90)91578-5; FREY U, 1989, BIOMED BIOCHIM ACTA, V48, P473; FREY U, UNPUB; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRECKSCH G, 1980, PHARMACOL BIOCHEM BE, V12, P663, DOI 10.1016/0091-3057(80)90145-8; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; GROVER LM, 1992, NEUROSCIENCE, V49, P7, DOI 10.1016/0306-4522(92)90072-A; HUANG YN, UNPUB; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MATTHIES H, 1989, ANNU REV PSYCHOL, V40, P381, DOI 10.1146/annurev.ps.40.020189.002121; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OTANI S, 1989, NEUROSCI LETT, V106, P175, DOI 10.1016/0304-3940(89)90222-X; REYMANN KG, 1985, BRAIN RES BULL, V15, P249, DOI 10.1016/0361-9230(85)90147-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1981, ANNU REV PHARMACOL, V21, P323, DOI 10.1146/annurev.pa.21.040181.001543; STANTON PK, 1985, BRAIN RES, V358, P343, DOI 10.1016/0006-8993(85)90981-3; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	27	978	1012	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1661	1664		10.1126/science.8389057	http://dx.doi.org/10.1126/science.8389057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8389057				2022-12-28	WOS:A1993LG17600034
J	SOONG, TW; STEA, A; HODSON, CD; DUBEL, SJ; VINCENT, SR; SNUTCH, TP				SOONG, TW; STEA, A; HODSON, CD; DUBEL, SJ; VINCENT, SR; SNUTCH, TP			STRUCTURE AND FUNCTIONAL EXPRESSION OF A MEMBER OF THE LOW-VOLTAGE ACTIVATED CALCIUM-CHANNEL FAMILY	SCIENCE			English	Article							INFERIOR OLIVARY NEURONS; SKELETAL-MUSCLE; BETA-SUBUNIT; IONIC CONDUCTANCES; VERTEBRATE CELLS; SENSORY NEURONS; CA2+ CHANNELS; THRESHOLD; CURRENTS; INVITRO	Oscillatory firing patterns are an intrinsic property of some neurons and have an important function in information processing. In some cells, low voltage-activated calcium channels have been proposed to underlie a depolarizing potential that regulates bursting. The sequence of a rat brain calcium channel alpha1 subunit (rbE-II) was deduced. Although it is structurally related to high voltage-activated calcium channels, the rbE-II channel transiently activated at negative membrane potentials, required a strong hyperpolarization to deinactivate, and was highly sensitive to block by nickel. In situ hybridization showed that rbE-II messenger RNA is expressed in regions throughout the central nervous system. The electrophysiological properties of the rbE-II current are consistent with a type of low voltage-activated calcium channel that,requires membrane hyperpolarization for maximal activity, which suggests that rbE-II may be involved in the modulation of firing patterns.	UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PSYCHIAT,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia			Vincent, Steven R/D-2996-2012; Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Soong, Tuck Wah/0000-0002-0876-0325				ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BEAN BP, 1985, J GEN PHYSIOL, V86, P1, DOI 10.1085/jgp.86.1.1; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BURLHIS TM, 1987, SYNAPSE, V1, P582, DOI 10.1002/syn.890010611; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; COULTER DA, 1989, NEUROSCI LETT, V98, P74, DOI 10.1016/0304-3940(89)90376-5; COULTER DA, 1989, J PHYSIOL-LONDON, V414, P587, DOI 10.1113/jphysiol.1989.sp017705; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FRIEDMAN A, 1987, NEUROSCI LETT, V81, P117, DOI 10.1016/0304-3940(87)90350-8; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LLINAS R, 1984, BRAIN RES, V294, P127, DOI 10.1016/0006-8993(84)91316-7; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; SAYER RJ, 1990, NEUROSCI LETT, V120, P175, DOI 10.1016/0304-3940(90)90031-4; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WEI XY, 1991, J BIOL CHEM, V266, P21943; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WONG RKS, 1978, BRAIN RES, V159, P385, DOI 10.1016/0006-8993(78)90544-9	41	483	505	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1133	1136		10.1126/science.8388125	http://dx.doi.org/10.1126/science.8388125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8388125				2022-12-28	WOS:A1993LC94200032
J	LOGAN, D; ABUGHAZALEH, R; BLAKEMORE, W; CURRY, S; JACKSON, T; KING, A; LEA, S; LEWIS, R; NEWMAN, J; PARRY, N; ROWLANDS, D; STUART, D; FRY, E				LOGAN, D; ABUGHAZALEH, R; BLAKEMORE, W; CURRY, S; JACKSON, T; KING, A; LEA, S; LEWIS, R; NEWMAN, J; PARRY, N; ROWLANDS, D; STUART, D; FRY, E			STRUCTURE OF A MAJOR IMMUNOGENIC SITE ON FOOT-AND-MOUTH-DISEASE VIRUS	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; ANTIGENIC VARIATION; CRYSTAL-STRUCTURE; PROTEIN; RESOLUTION; SEQUENCE; FIBRONECTIN; ANTIBODIES; REFINEMENT; LOCATION	ATTACHMENT of foot-and-mouth disease virus (FMDV) to its cellular receptor involves a long and highly antigenic loop containing the conserved sequence, Arg-Gly-Asp, a motif known to be a recognition element in many integrin-dependent cell adhesion processes1-7. In our original crystal structure of FMDV the Arg-Gly-Asp-containing loop ('the loop'), located between beta-strands G and H of capsid protein VP1, was disordered and hence essentially invisible. We previously surmised that its disorder is enhanced by a disulphide bond linking the base of the loop (Cys 134) to Cys 130 of VP2 (ref. 8). We report here the crystal structure of the virus in which this disulphide is reduced. Reduced virus retains infectivity and serological experiments suggest that some of the loop's internal structure is conserved8. But here its structure has become sufficiently ordered to allow us to describe an unambiguous conformation, which we relate to some key biological properties of the virus.	UNIV OXFORD,MOLEC BIOPHYS LAB,REX RICHARDS BLDG,OXFORD OX1 3QU,ENGLAND; AFRC,INST ANIM HLTH,WOKING GU24 0NF,ENGLAND; WELLCOME RES LABS,DEPT MOLEC SCI,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; GlaxoSmithKline; Wellcome Research Laboratories			Logan, Derek T/A-1114-2011; Logan, Derek/O-2497-2019; Lea, Susan M/B-7678-2009	Logan, Derek T/0000-0002-0098-8560; Logan, Derek/0000-0002-0098-8560; Lea, Susan M/0000-0001-9287-8053; Curry, Stephen/0000-0002-0552-8870; lewis, richard/0000-0003-2641-8643; Stuart, David/0000-0002-3426-4210				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ACHARYA R, 1989, VACCINES 89 MODERN A; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BAXT B, 1990, Virus Genes, V4, P73, DOI 10.1007/BF00308567; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANG KH, 1992, J GEN VIROL, V73, P621, DOI 10.1099/0022-1317-73-3-621; FOX G, 1987, J MOL BIOL, V196, P591, DOI 10.1016/0022-2836(87)90035-0; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; FRY E, 1993, ACTA CRYSTALLOGR A, V49, P45, DOI 10.1107/S0108767392005737; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; HENRICK K, 1987, PROTEIN ENG, V1, P467, DOI 10.1093/protein/1.6.467; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM S, 1989, J MOL BIOL, V210, P91, DOI 10.1016/0022-2836(89)90293-3; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; PFAFF E, 1982, EMBO J, V1, P869, DOI 10.1002/j.1460-2075.1982.tb01262.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; REED J, 1988, EUR J BIOCHEM, V178, P141, DOI 10.1111/j.1432-1033.1988.tb14439.x; ROWLANDS DJ, 1983, NATURE, V306, P694, DOI 10.1038/306694a0; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SILIGARDI G, 1991, EUR J BIOCHEM, V199, P545, DOI 10.1111/j.1432-1033.1991.tb16153.x; STROHMAIER K, 1982, J GEN VIROL, V59, P295, DOI 10.1099/0022-1317-59-2-295; SUROVOI AY, 1989, SOV J BIOORG CHEM, V14, P572; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	36	313	364	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					566	568		10.1038/362566a0	http://dx.doi.org/10.1038/362566a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8385272				2022-12-28	WOS:A1993KW45300062
J	LANGE, PH				LANGE, PH			THE NEXT ERA FOR PROSTATE-CANCER - CONTROLLED CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTIGEN; ADENOCARCINOMA				LANGE, PH (corresponding author), UNIV WASHINGTON,DEPT UROL,MAILSTOP RL-10,SEATTLE,WA 98195, USA.							BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CATALONA W J, 1992, Journal of Urology, V147, p450A; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; GOLDBLOOM R, 1991, CAN MED ASSOC J, V145, P413; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; Lawrence R, 1989, GUIDE CLIN PREVENTIV; METTLIN C, IN PRESS PROSTATE; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V269, P57; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; TERRIS MK, 1991, J NUCL MED, V32, P1713; 1992, 1992 AM UR ASS COMM	13	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					95	96		10.1001/jama.269.1.95	http://dx.doi.org/10.1001/jama.269.1.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416416				2022-12-28	WOS:A1993KF02600037
J	SHALEV, O; LOTMAN, A				SHALEV, O; LOTMAN, A			PSEUDOTHROMBOCYTOPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											SHALEV, O (corresponding author), HADASSAH UNIV HOSP,JERUSALEM,ISRAEL.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1467	1467						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413458				2022-12-28	WOS:A1993MF29200006
J	DOBERSTEIN, SK; BAINES, IC; WIEGAND, G; KORN, ED; POLLARD, TD				DOBERSTEIN, SK; BAINES, IC; WIEGAND, G; KORN, ED; POLLARD, TD			INHIBITION OF CONTRACTILE VACUOLE FUNCTION IN-VIVO BY ANTIBODIES AGAINST MYOSIN-I	NATURE			English	Article								MYOSIN-I is thought to supply the force for movement of cell membranes relative to actin filaments (reviewed in refs 1, 2), but confirmation of this hypothesis has been difficult because of the presence of multiple isoforms of myosin-I and other unconventional myosins in most cells3. We report here the first evidence that a myosin-I isoform is essential for a specific class of intracellular membrane movements in vivo. In Acanthamoeba, the contractile vacuole is an autonomous structure which fuses with the plasma membrane to control the water content of the cell. Because myosin-IC is the only myosin-I isoform concentrated in the contractile vacuole complex4,5 and a protein antigenically related to myosin-IC is located on or near the Dictyostelium (slime mould) contractile vacuole6, we thought this organelle might provide the best opportunity to demonstrate a relationship between myosin-I and membrane motility. Antibodies that inhibit the activity of Acanthamoeba myosin-IC in vitro interfere with expulsion of excess water by the contractile vacuole in vivo, leading to overfilling of this organelle and cell lysis. Myosin-IC may generate the force required to contract the vacuole and may also be involved in transfer of water to the contractile vacuole during refilling.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21225; NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	DOBERSTEIN, SK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21225, USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ALBANESI JP, 1986, J BIOL CHEM, V261, P445; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CLARKE MSF, 1992, J CELL SCI, V102, P533; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FURUKAWA R, 1992, PROTOPLASMA, V169, P18; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; LYNCH TJ, 1990, METHOD ENZYMOL, V196, P12; MARUTA H, 1977, J BIOL CHEM, V252, P8329; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, REV PHYSL, V53, P653; SINARD JH, 1989, CELL MOTIL CYTOSKEL, V12, P42, DOI 10.1002/cm.970120106; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; WIGG D, 1967, J PROTOZOOL, V14, P104, DOI 10.1111/j.1550-7408.1967.tb01453.x; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	27	110	111	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					841	843		10.1038/365841a0	http://dx.doi.org/10.1038/365841a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413668				2022-12-28	WOS:A1993MD95100051
J	HANDYSIDES, S				HANDYSIDES, S			TAKING BABIES TEMPERATURES - SCIENCE VERSUS SOCIAL TABOOS IN BATTLE OVER BABY CHECK	BRITISH MEDICAL JOURNAL			English	Article							FIELD TRIALS; SCORE CARD; INFANTS	Baby Check, a scoring system for assessing the severity of illness in babies under 6 months old, has not met with the success its developers expected. The inclusion of rectal temperature in the assessment was strongly opposed by the Royal College of Midwives, which refused to alter its view despite evidence of the safety and accuracy of rectal thermometry. British parents appear not to like rectal thermometers either. Most other medical bodies have supported Baby Check and the reason for midwives' opposition may have more to do with professional pique at not being consulted than clinical wisdom.										ASHTON RM, 1991, MIDWIVES CHRONICLE, V104, P109; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P111, DOI 10.1136/adc.66.1.111; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; SMY J, 1991, DOCTOR          0620, P24; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P115, DOI 10.1136/adc.66.1.115; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106, DOI 10.1136/adc.66.1.106; 1988, 1ST HOUS COMM SOC SE; 1991, LANCET, V337, P485	11	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					673	675		10.1136/bmj.307.6905.673	http://dx.doi.org/10.1136/bmj.307.6905.673			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401058	Bronze, Green Published			2022-12-28	WOS:A1993LX47000025
J	RAUTAVA, P; HELENIUS, H; LEHTONEN, L				RAUTAVA, P; HELENIUS, H; LEHTONEN, L			PSYCHOSOCIAL PREDISPOSING FACTORS FOR INFANTILE COLIC	BRITISH MEDICAL JOURNAL			English	Article							FINNISH FAMILY COMPETENCE; CHILDBIRTH; KNOWLEDGE; DISTRESS; WOMEN	Objective-To study associations between characteristics of families during the first pregnancy and after childbirth and the development of infantile colic. Design-Randomised, stratified cluster sampling. Follow up from the first visit to a maternity health care clinic during pregnancy to three months after birth with confidential semistructured questionnaires. Setting-Maternity health care clinics in primary health care centres in Finland. Subjects-1443 nulliparous women and 1407 partners. Altogether 1333 women and 1279 men returned the questionnaires. When the infants were 3 months old 1208 women and 1115 men returned questionnaires. Main outcome measures-Marital relationship; personal and social behaviour of parents during the pregnancy and their coping with the pregnancy; mothers' physical health and events, symptoms, and experiences in relation to pregnancy; self confidence and experiences of mothers and fathers in relation to childbirth; and parents' sociodemographic and educational variables. Measure of colic when the infant was 3 months old. Results-Experience of stress and physical symptoms during the pregnancy, dissatisfaction with the sexual relationship, and negative,experiences during childbirth were associated with the development of colic in the baby. None of the sociodemographic factors was associated with colic. Conclusions-Early preventive health work during pregnancy should attempt to improve parents' tolerance of symptoms of stress and ability to cope and increase their confidence in parenting abilities.	UNIV TURKU,DEPT BIOSTAT,SF-20520 TURKU 52,FINLAND	University of Turku	RAUTAVA, P (corresponding author), UNIV TURKU,DEPT PUBL HLTH,LEMMINKAISENKATU 1,SF-20520 TURKU 52,FINLAND.			Lehtonen, Liisa/0000-0001-8925-2594				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; CAREY WB, 1972, J PEDIATR-US, V81, P823, DOI 10.1016/S0022-3476(72)80115-X; CAREY WB, 1968, CLIN PEDIATR, V7, P590, DOI 10.1177/000992286800701007; DIXON WJ, 1990, BMDP STATISTICAL SOF, V1; FORSYTH BWC, 1989, J PEDIATR-US, V115, P521, DOI 10.1016/S0022-3476(89)80274-4; HEWSON P, 1987, CLIN PEDIATR, V26, P69, DOI 10.1177/000992288702600203; HIDE DW, 1982, ARCH DIS CHILD, V57, P559, DOI 10.1136/adc.57.7.559; HILL DJ, 1992, J PEDIATR-US, V121, P755, DOI 10.1016/S0022-3476(05)81911-0; ILLINGWORTH RS, 1985, ARCH DIS CHILD, V60, P981, DOI 10.1136/adc.60.10.981; ILLINGWORTH RS, 1954, ARCH DIS CHILD, V29, P165, DOI 10.1136/adc.29.145.165; LESTER BM, 1990, INF MENTAL HLTH J, V11, P321, DOI 10.1002/1097-0355(199024)11:4<321::AID-IMHJ2280110403>3.0.CO;2-E; MATHESON I, 1989, JAMA-J AM MED ASSOC, V261, P42, DOI 10.1001/jama.1989.03420010052018; MILLER AR, 1991, PEDIATR CLIN N AM, V38, P1407; MILLER JJ, 1989, ARCH DIS CHILD, V64, P725, DOI 10.1136/adc.64.5.725; MOORE DJ, 1988, J PEDIATR-US, V113, P979, DOI 10.1016/S0022-3476(88)80567-5; Neff FC, 1940, J AMER MED ASSOC, V114, P1745; PARADISE JL, 1966, J AMER MED ASSOC, V197, P191, DOI 10.1001/jama.1966.03110030085031; RAUTAVA P, 1989, SOC SCI MED, V29, P1105, DOI 10.1016/0277-9536(89)90023-3; RAUTAVA P, 1989, J EPIDEMIOL COMMUN H, V43, P253, DOI 10.1136/jech.43.3.253; RUBIN SP, 1984, CHILD CARE HLTH DEV, V10, P219, DOI 10.1111/j.1365-2214.1984.tb00181.x; Spock B, 1944, PSYCHOSOM MED, V6, P162, DOI 10.1097/00006842-194404000-00010; STAHLBERG MR, 1984, EUR J PEDIATR, V143, P108; THOMAS DW, 1987, AM J DIS CHILD, V141, P451, DOI 10.1001/archpedi.1987.04460040109028; THOMPSON PE, 1986, COMPREHENSIVE PEDIAT, V9, P273; WESSEL MA, 1954, PEDIATRICS, V14, P421; White PJ, 1929, AM J DIS CHILD, V38, P935; WINNICOT DW, 1991, MATURATIONAL PROCESS; 1987, STATISTICAL YB FINLA, V82	28	77	79	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					600	604		10.1136/bmj.307.6904.600	http://dx.doi.org/10.1136/bmj.307.6904.600			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401016	Green Published, Bronze			2022-12-28	WOS:A1993LW14900017
J	AKASHI, K; EIZURU, Y; SUMIYOSHI, Y; MINEMATSU, T; HARA, S; HARADA, M; KIKUCHI, M; NIHO, Y; MINAMISHIMA, Y				AKASHI, K; EIZURU, Y; SUMIYOSHI, Y; MINEMATSU, T; HARA, S; HARADA, M; KIKUCHI, M; NIHO, Y; MINAMISHIMA, Y			SEVERE INFECTIOUS-MONONUCLEOSIS LIKE SYNDROME AND PRIMARY HUMAN HERPESVIRUS-6 INFECTION IN AN ADULT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							EPSTEIN-BARR-VIRUS; MARROW TRANSPLANTATION; IMMUNOGLOBULIN-G; CYTOMEGALOVIRUS; ANTIBODY; HHV-6; PREVALENCE; SALIVARY; TROPISM; GLANDS		HARASANSHIN GEN HOSP,DEPT DERMATOL,FUKUOKA,JAPAN; MIYAZAKI MED COLL,DEPT MICROBIOL,MIYAZAKI 88916,JAPAN; FUKUOKA UNIV,SCH MED,DEPT PATHOL 1,FUKUOKA 81401,JAPAN; KYUSHU UNIV,DEPT INTERNAL MED 1,FUKUOKA 812,JAPAN	University of Miyazaki; Fukuoka University; Kyushu University	AKASHI, K (corresponding author), HARASANSHIN GEN HOSP,DEPT HEMATOL,1-8 TAIHAKU MACHI,HAKATA KU,FUKUOKA 812,JAPAN.							ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; AKASHI K, 1991, J CELL PHYSIOL, V148, P446, DOI 10.1002/jcp.1041480317; AUBIN JT, 1991, J CLIN MICROBIOL, V29, P367, DOI 10.1128/JCM.29.2.367-372.1991; BRIGGS M, 1988, LANCET, V1, P1058; BROWN NA, 1989, PEDIATR RES, V25, pA174; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; EIZURU Y, 1989, LANCET, V1, P40; EIZURU Y, 1991, MICROBIOL IMMUNOL, V35, P1015, DOI 10.1111/j.1348-0421.1991.tb01623.x; FOX JD, 1990, LANCET, V336, P590, DOI 10.1016/0140-6736(90)93392-3; IRVING WL, 1990, J INFECT DIS, V161, P910, DOI 10.1093/infdis/161.5.910; IRVING WL, 1990, BRIT MED J, V300, P156, DOI 10.1136/bmj.300.6718.156; KAWANO K, 1987, ARCH VIROL, V95, P41, DOI 10.1007/BF01311333; KONDO K, 1991, J GEN VIROL, V72, P1401, DOI 10.1099/0022-1317-72-6-1401; KRUEGER GRF, 1990, LANCET, V336, P1255, DOI 10.1016/0140-6736(90)92874-H; KRUEGER GRF, 1989, PATHOL RES PRACT, V185, P915, DOI 10.1016/S0344-0338(89)80299-7; LARCHER C, 1988, LANCET, V2, P963; LINDE A, 1990, J CLIN MICROBIOL, V28, P211, DOI 10.1128/JCM.28.2.211-215.1990; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; NIEDERMAN JC, 1988, LANCET, V2, P817; OKUNO T, 1990, VIROLOGY, V176, P625, DOI 10.1016/0042-6822(90)90033-N; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; OKUNO T, 1990, TRANSPLANTATION, V49, P519, DOI 10.1097/00007890-199003000-00009; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; YAMANISHI K, 1988, LANCET, V1, P1065; YANAGI K, 1990, J INFECT DIS, V161, P153, DOI 10.1093/infdis/161.1.153-a; YOSHIKAWA T, 1991, BLOOD, V78, P1381	31	125	128	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					168	171		10.1056/NEJM199307153290304	http://dx.doi.org/10.1056/NEJM199307153290304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL460	8390615	Bronze			2022-12-28	WOS:A1993LL46000004
J	TOKARS, JI; MARCUS, R; CULVER, DH; SCHABLE, CA; MCKIBBEN, PS; BANDEA, CI; BELL, DM				TOKARS, JI; MARCUS, R; CULVER, DH; SCHABLE, CA; MCKIBBEN, PS; BANDEA, CI; BELL, DM			SURVEILLANCE OF HIV-INFECTION AND ZIDOVUDINE USE AMONG HEALTH-CARE WORKERS AFTER OCCUPATIONAL EXPOSURE TO HIV-INFECTED BLOOD	ANNALS OF INTERNAL MEDICINE			English	Article						ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; OCCUPATIONAL EXPOSURE; HEALTH PERSONNEL	HUMAN-IMMUNODEFICIENCY-VIRUS; SCID-HU MICE; PROPHYLACTIC ZIDOVUDINE; POSTEXPOSURE CHEMOPROPHYLAXIS; FAILURE; TYPE-1; TRANSMISSION; RESISTANCE; MUTATIONS; RISK	Objective: To study the risk for human immunodeficiency virus (HIV) infection and the patterns of use and associated toxicity of zidovudine among health care workers after an occupational exposure to HIV. Design: An ongoing, prospective surveillance project conducted by the Centers for Disease Control and Prevention. Participants: Exposed workers voluntarily reported by 312 U.S. health care facilities from August 1983 to June 1992. Results: Four of 1103 enrolled workers with percutaneous exposure to HIV-infected blood seroconverted (HIV seroconversion rate, 0.36%; upper limit of the 95% CI, 0.83%); no enrolled workers with mucous membrane (n = 75) or skin (n = 67) contact seroconverted. During October 1988 to June 1992, 31% of 848 enrolled workers used zidovudine after exposure; this proportion increased from 5% during October through December 1988 to 43% during January through June 1992. Despite using zidovudine after exposure, one worker became infected with a strain of HIV that was apparently sensitive to zidovudine. Adverse symptoms, most commonly nausea, malaise or fatigue, and headache, were reported by 75% of workers using zidovudine; 31% of workers did not complete planned courses of zidovudine because of adverse events. Conclusions: The risk for HIV seroconversion after percutaneous exposure to HIV-infected blood is 0.36%, which is similar to previous estimates. Zidovudine is used after exposure by a sizable proportion of health care workers enrolled in the project despite frequent, minor, associated symptoms. Documented failures of postexposure zidovudine prophylaxis, including in one worker enrolled in this study, indicate that if zidovudine is protective, any protection afforded is not absolute. Postexposure zidovudine, if used, requires careful consideration of possible risks and benefits.	CTR DIS CONTROL, HOSP INFECT PROGRAM, MAILSTOP A-07, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Marcus, Ruthanne/0000-0002-9094-0674				BELL DM, 1992, HOSPITAL INFECTIONS, P823; DURAND E, 1991, NEW ENGL J MED, V324, P1062; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; GIOANNINI P, 1988, EUR J EPIDEMIOL, V4, P119, DOI 10.1007/BF00152703; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1991, AM J MED, V91, pS312, DOI 10.1016/0002-9343(91)90388-E; HENDERSON DK, 1989, J INFECT DIS, V160, P321, DOI 10.1093/infdis/160.2.321; JONES PD, 1991, LANCET, V338, P884, DOI 10.1016/0140-6736(91)91535-3; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LAFON SW, 1990, 30TH INT C ANT AG CH, P167; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; LOT F, 1992, B EPIDEMIOL HEBD, V26, P117; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCLURE HM, 1990, ANN NY ACAD SCI, V616, P287; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PURO V, 1992, AIDS, V6, P963, DOI 10.1097/00002030-199209000-00009; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; TAIT DR, 1992, 8TH INT C AIDS AMST; TSAI CC, 1992, 32ND INT C ANT AG CH, P58; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; 1992, MMWR, V41, P823; 1992, MMWR, V41, P575; 1987, MMWR, V36, P285; 1987, MMWR, V36, pS3; 1990, MMWR, V39, P1	31	257	260	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					913	919		10.7326/0003-4819-118-12-199306150-00001	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8387737				2022-12-28	WOS:A1993LF93700001
J	MCDERMOTT, F; GRUN, R; STRINGER, CB; HAWKESWORTH, CJ				MCDERMOTT, F; GRUN, R; STRINGER, CB; HAWKESWORTH, CJ			MASS-SPECTROMETRIC U-SERIES DATES FOR ISRAELI NEANDERTHAL EARLY-MODERN HOMINID SITES	NATURE			English	Article							BURIAL SITE; TABUN CAVE; ESR DATES; KEBARA; QAFZEH; TIME	THE nature of the relationship between Neanderthals and early modern Homo sapiens is controversial, yet it is fundamental to our understanding of early human evolution1,2. The Middle Palaeolithic sites of Israel are critical to this debate, because unlike those of western Europe and Africa they contain both Neanderthal (at Tabun3 and Kebara4 for example) and anatomically modern hominids (as at Skhul5 and Qafzeh6). Here we present new mass spectrometric Th-230/U-234 dates for dental fragments from the Middle Palaeolithic burial sites of Tabun, Qafzeh and Skhul. These data, combined with published ages from electron spin resonance (ESR), provide compelling evidence that the Tabun Neanderthals and Qafzeh early modern Homo sapiens were approximately coeval in the southern Levant some 100 +/- 5 kyr ago, but indicate that some of the Skhul material is younger. The study also shows that combined mass-spectrometric Th-230/U-234 and ESR dating is an invaluable technique for dating archaeological sites beyond the range of radiocarbon dating.	OPEN UNIV, DEPT EARTH SCI, MILTON KEYNES MK7 6AA, BUCKS, ENGLAND; AUSTRALIA NATL UNIV, QUATERNARY DATING RES CTR, CANBERRA 2601, AUSTRALIA; NAT HIST MUSEUM, DEPT PALAEONTOL, LONDON SW7 5BD, ENGLAND	Open University - UK; Australian National University; Natural History Museum London			McDermott, Frank/F-3096-2010; Grun, Rainer/A-1437-2012	McDermott, Frank/0000-0001-7037-7936; Grun, Rainer/0000-0003-1366-3674				AITKEN MJ, 1992, PHILOS T ROY SOC B, V337, P139, DOI 10.1098/rstb.1992.0090; Bar-Yosef O., 1981, PREHISTOIRE LEVANT, P281; BARYOSEF O, 1989, HUMAN REVOLUTION, P589; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; FARRAND WR, 1979, J ARCHAEOL SCI, V6, P369, DOI 10.1016/0305-4403(79)90019-0; Garrod D.A.E., 1937, STONE AGE MOUNT CARM, VI; GRUN R, 1988, NUCL TRACKS RAD MEAS, V14, P237; GRUN R, 1991, ARCHAEOMETRY, V33, P153, DOI 10.1111/j.1475-4754.1991.tb00696.x; GRUN R, 1991, J HUM EVOL, V20, P231, DOI 10.1016/0047-2484(91)90074-6; Jelinek A. J., 1990, EMERGENCE MODERN HUM, P81; Jelinek A. J., 1981, PREHISTOIRE LEVANT C, P265; JELINEK AJ, 1982, SCIENCE, V216, P1369, DOI 10.1126/science.216.4553.1369; JELINEK AJ, IN PRESS EVOLUTION D; JELINEK AJ, 1982, BAR INT SERIES, V151, P57; MASTERS PM, 1982, BRIT ARCHAEOLOGICAL, V151, P43; McCown T, 1939, STONE AGE MOUNT CARM, V2; McCown T. D., 1937, STONE AGE MOUNT CARM, V1, P91; MCKINNEY CR, 1991, THESIS SMU DALLAS; OAKLEY KP, 1975, CATALOGUE FOSSIL HOM, V3; Rae A.M., 1986, APPLIED GEOCHEMISTRY, V1, P419; RAK Y, 1990, AM J PHYS ANTHROPOL, V81, P323, DOI 10.1002/ajpa.1330810302; SCHWARCZ HP, 1989, J ARCHAEOL SCI, V16, P653, DOI 10.1016/0305-4403(89)90029-0; SCHWARCZ HP, 1988, J HUM EVOL, V17, P733, DOI 10.1016/0047-2484(88)90063-2; Stringer C. B., 1981, ASPECTS HUMAN EVOLUT, P129; STRINGER CB, 1989, NATURE, V338, P756, DOI 10.1038/338756a0; STRINGER CB, 1991, NATURE, V351, P701, DOI 10.1038/351701a0; Trinkaus E., 1984, P251; VALLADAS H, 1987, NATURE, V330, P159, DOI 10.1038/330159a0; VALLADAS H, 1988, NATURE, V331, P614, DOI 10.1038/331614a0; Vandermeersch B., 1981, HOMMES FOSSILES QAFZ; WOLPOFF MH, 1992, NATURE, V356, P200, DOI 10.1038/356200b0	31	118	121	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1993	363	6426					252	255		10.1038/363252a0	http://dx.doi.org/10.1038/363252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	LC866	8387643				2022-12-28	WOS:A1993LC86600049
J	SHAKIR, KMM; MICHAELS, RD; HAYS, JH; POTTER, BB				SHAKIR, KMM; MICHAELS, RD; HAYS, JH; POTTER, BB			THE USE OF BILE-ACID SEQUESTRANTS TO LOWER SERUM THYROID-HORMONES IN IATROGENIC HYPERTHYROIDISM	ANNALS OF INTERNAL MEDICINE			English	Note						HYPERTHYROIDISM; MYOCARDIAL INFARCTION; THYROID HORMONES; CHOLESTYRAMINE; LEVOTHYROXINE		Hyperthyroidism occasionally must be rapidly restored to euthyroidism, especially if it is associated with an emergent condition such as myocardial infarction. Several modalities are available to render endogenous hyperthyroid patients to a euthyroid state rapidly. Few therapeutic options, however, are available to rapidly treat hyperthyroidism caused by ingestion of excess thyroid hormones, except perhaps the use of beta-blockers. We observed hypothyroidism develop in two patients taking stable doses of levothyroxine after cholestyramine was added to their drug regimen. This finding led us to treat two patients with iatrogenic hyperthyroidism with cholestyramine. A euthyroid state was achieved in 72 to 96 hours whereas in three similar patients without cholestyramine treatment it had taken almost 8 days for serum thyroid hormone levels to fall into normal range. Our preliminary results suggest that bile acid sequestrants may be useful in treating exogenous thyroid-hormone-induced hyperthyroidism in emergent situations.	UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	SHAKIR, KMM (corresponding author), USN, NATL NAVAL MED CTR, DIV ENDOCRINOL & METAB, BETHESDA, MD 20889 USA.							BERGMAN F, 1966, ACTA ENDOCRINOL-COP, V53, P256, DOI 10.1530/acta.0.0530256; GREER MA, 1991, WERNER INGBARS THYRO, P728; HARMON SM, 1991, ANN INTERN MED, V115, P658, DOI 10.7326/0003-4819-115-8-658_2; HAYNES R C JR, 1990, P1361; LARSEN PR, 1992, WILLIAMS TXB ENDOCRI, P371; NORTHCUTT RC, 1969, J AMER MED ASSOC, V208, P1857	6	32	33	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					112	113		10.7326/0003-4819-118-2-199301150-00006	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416306				2022-12-28	WOS:A1993KF91800006
